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Preface 
Brain tumors are a various group of malignancies that remain refractory to 
conventional treatment approaches, including radiotherapy and cytotoxic 
chemotherapy. Molecular neuro-oncology has now begun to clarify the transformed 
phenotype of brain tumors and identify oncogenic pathways that may be amenable to 
targeted therapy. 
Recently, there has been increasing interest in the use of targeted molecular agents for 
the treatment of malignant brain pediatric and adult tumors. These agents are 
generally well tolerated but have demonstrated only modest activity. 
This book tries to cover the complexity of the rapidly developing area of targeted 
therapies in the field of Central Nervous System (CNS) tumors. 
Brain tumors present a continuous challenge to the physicians regardless of the 
patients’ age. The goal of this book to provide up-to-date information for physicians 
based description of regulatory components and effector pathways of selected CNS 
tumors. This book highlights some importance aspects of selected CNS tumors. 
The editor would like to acknowledge the contribution of the authors and the team of 
the Publishing Process Management at InTech - Open Access Publisher. 
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Genetic and Immunology of Brain Tumors 
Sahika Liva Cengiz and Aynur Emine Cicekcibasi  
Selcuk University/Faculty of Medicine, 
 Turkey  
1. Introduction 
Tumors of the intracranial neoplasms are devastating because they frequently cause 
mortality or morbidity. Current studies have shown that the immune system and genetics 
may play a critical role in development of different kinds of brain tumors. 
New insights into the causes and potential treatment of intracranial neoplasms have come 
from discovering connections with genes that control cell growth, differentation and 
development of brain cancer. Host immune response is one of key points in protection 
against brain tumor development.  
This section will outline what is known about molecular genetics, biology and 
immunogenetics of brain tumors.  
 We will first focus on main oncogenes which are seen in CNS tumors and try to find 
answer how do tumor-brain interactions contribute to development of brain tumor.   
 Finally we will discuss the mechanisms of immune activation and immune escape 
during an anti-tumor specific response, and new concepts for immunogenetic 
therapeutic intervention.. 
Thus, the data of immunogenetic pathways that are differentially involved in tumor 
initiation may represent a novel approach for the treatment of malignant brain tumors. 
2. Genetic and immunology of brain tumors 
Brain tumors are one of the leading cause of cancer mortality and remain difficult to cure 
despite advances in surgery and adjuvant therapy. Recent studies are focused on the 
molecular and cellular analysis of the bulk tumor mass. Glioma is the most common and 
mortal type of brain tumors (Kleihues et al., 2002). They are typically comprised of 
morphologically diverse cells that express a variety of neural lineage markers. Gliomas that 
share similar morphology and phenotype can have a very different prognosis and response 
to treatment. Alterations of multiple genes in the cell cycle and regulatory pathways plays 
an important role in tumorigenesis and causes to formation of subtypes (Singh et al., 2003). 
So researches in gene therapy have been often sice 1912 because no effective therapy is 
achieved until now in spite of traditional treatments including surgery, radiation therapy, 
and chemotherapy (Culver et al., 1992). Formerly, the brain has been regarded as an 
immunologically privileged organ site because it possesses a distinct blood-brain barrier 
(BBB) and lacks discrete lymphatic structures (Yoffey & Courtice, 1970).  Despite these 
factors minimizing central nervous system (CNS) immune function, a highly adapted 
system of immune surveillance presents, and effective immune responses can occur in the 
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CNS. Function of both the complement system (Bernheimer et al., 1988) and the antigen-
antibody system, including functional B cells (Aloisi et al., 1999; Sandberg-Wollheim et al., 
1986) have been found within the CNS. In the case of CNS pathologies resident antigen-
presenting cells (APC) of the CNS, microglia cells, undergo activation and upregulate both 
major histocompatibility complex (MHC) and costimulatory molecules,and also contribute 
to both CD41 and CD81 specific T-cell responses (Aloisi et al., 1998; Brannan & Roberts, 
2004; Hickey & Kimura, 1987; Hickey et al., 1991; Hickey, 2001; Krakowski & Owens, 2000). 
Actually a small number of lymphocytes are found in normal, healthy brain (Hickey & 
Kimura, 1987) however both resident lymphocytes and activated T cells have the capability 
to cross the BBB (Hickey & Kimura, 1987; Hickey et al., 1991; Hickey, 2001). Several 
lymphocytes also infiltrate the CNS in the presence of neoplasms (Han et al., 2010). Thus 
considering these factors new and more effective adjunctive treatments are needed. 
3. Brain tumors and oncogenes 
Oncogenes are functional mutations associated with cancer progression. They are derived 
from normal cellular genes called proto-oncogenes. The oncogenes that promote the tumor 
growth and development affecting mechanisms, such as cell proliferation, invasion, 
angiogenesis, and resistance to apoptosis by produced proteins are associated with the brain 
tumors. The protein synthesis which was gene product may increase or functional changes 
can be seen as a result of oncogenic mutation. 
The oncogenic activation associated with nervous system tumors is in the form of gene 
amplification and the number of cell-specific gene increases. The most common oncogenic 
change is the amplification of the epidermal growth factor receptor (EGFR) gene and the 
mutations of the TP53 gene (Ekstrand et al., 1991; Libermann et al., 1985; Wong et al., 1987). 
The EGFR gene that is activated by growth factors such as EGF, TGF-α is “transmembrane 
tyrosine kinase” codes.  
EGFR gene amplification was observed 40-50% of cases with glioblastoma multiforme, but it 
is rare in the anaplastic malignant astrocitoma (Brady et al., 1992; Ekstrand et al., 1991; 
Humphrey et al., 1990; Wong et al., 1987). This change is predictive for the malignancy 
degree of the astrocitomas (Ng & Lam, 1998). In malignant astrocitomas, the gene 
amplifications such as the MYCN, CDK4, MDM2, CCND1, and MET including the growth 
factors family of tyrosine kinase like EGFR were also determined (Bigner et al., 1987; .Fischer 
et al., 1995; He et al., 1994; Reifenberger et al., 1994).  
However, these amplifications were observed lesser than EGFR. In addition, the most 
common amplification was 10-15% CDK4 in malignant astrocitoma and glioblastoma. Each 
of these genes have been associated with the malignancy degree of glial tumors. The 
oncogenic changes were seen less than 10% in the other CNS tumors except for malignant 
astrocitomas. In medulloblastoma, the CMYC and MYCN amplifications were reported. 
Additionally, the β-catenin and TCF mutations were also detected in rare cases (Raffel et al., 
1990; Wasson et al., 1990; Zurawel et al., 1998). 
4. Gene therapy 
‘Gene therapy’ can be defined as the transfer of genetic material into a patient’s tumor cells 
by using stereotaxic injection. Up to present,various  treatment strategies utilizing gene 
therapy have been used, including gene transfer for modulating the immune system, 
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enzyme prodrug (‘suicide gene’) therapy, oncolytic therapy, replacement/ therapeutic gene 
transfer, and antisense therapy (Bansal& Engelhard, 2000). Many of them have been 
attempted both experimentally and in clinical trials (Iwami et al., 2010; Licht et al., 1996; Lun 
et al., 2010; Pedersini et al., 2010; Schmidt et al., 2011; Steffens et al., 2004; Yawata et al., 
2011). Mainly these approaches are based on previously established anti-neoplastic 
principles, like prodrug activating enzymes, inhibition of tumor neovascularization, and 
enhancement of the normally infirm anti-tumor immune response.  
The strategies of gene therapy can be categorized  as follows (Mut& Ziyal,2010). 
1. Enzyme prodrug: enzyme prodrug (‘suicide gene’) therapy. 
2. Oncolytic therapy, replacement. 
3. Transfer of potentially therapeutic genes such as tumor suprosser  (eg p53)  
4. Antisense therapy.  
5. Kemoprotection: Approaches which use the multidrug-resistance gene to protect bone 
marrow from myelosuppression following chemotherapy. Chemoresistance genes 
especially P-glycoprotein, the product of the multidrug-resistance (MDR1) gene, plays a 
major role in clinical treatment failure. 
6. Gene therapy for boosting the activity of the immune system againts tumor cells 
 
Approaches Administered  Genes 
Enzyme prodrug: enzyme prodrug 
(‘suicide gene’) therapy Suicide genes 
Immuno-gene therapy   Genes  of antigens and citokins  
Peplasman therapy Therapeutic genes 
Kemoprotection therapy  Multi-drug resistance  gene (MDR) 
Antisence therapy  Antisense DNA 
Oncolitic virus therapy  Oncolitic genes  
Table 1. Current treatment strategies used in  gene therapy. (Karaoglan &Turkmen,2010 )  
Immune gene therapy aims to enhance the T cell mediated immune responce againts to 
brain neoplasms by using genetically modified T cell therapy, vaccination therapy and 
cytokine therapy (Iwami et al., 2010). Cytotoxic  therapy  is mainly consist of either 
delivering  of gene or virus therapy  (Aboody et al., 2008; Aghi & Chiocca, 2006; Candolfi et 
al., 2009; Kroeger et al., 2010; Lawler et al., 2006). The most common  studied conditional 
cytotoxic transgene is Herpes Simplex Type 1 thymidine kinase (TK), which converts the 
prodrug ganciclovir (or valacyclovir) into the highly toxic deoxyguanosine triphosphate 
causing early chain termination of nascent DNA strands (Beltinger et al., 1999). The by-
stander effect of the TK approach is related to the passage of phosphorylated ganciclovir to 
neighboring cells through gap junctions, amplifying the cytotoxic effect of TK gene therapy 
(Mesnil & Yamasaki, 2000).  
4.1 Vectors in gene therapy 
Several viral and non-viral vectors have been engineered and used for gene transfer, both 
experimentally and clinically. 
Virotherapy is defined delivery of conditionally replicating viral vectors that solely replicate 
in tumor cells and kill them (Ferguson et al., 2010; Jiang et al., 2009; Markert et al., 2009). 
Viruses used for glioma gene therapy can be classified into 2 categories: replication-
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enzyme prodrug (‘suicide gene’) therapy, oncolytic therapy, replacement/ therapeutic gene 
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causing early chain termination of nascent DNA strands (Beltinger et al., 1999). The by-
stander effect of the TK approach is related to the passage of phosphorylated ganciclovir to 
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imcompetent viruses. In the first one, the vector is derived from a virus from which all or 
most of its genome has been removed, so minimizing the toxicity and retaining the gene 
delivery efficiency. In the second, only select viral genes are deleted or mutated so that 
viruses can replicate in and lyse tumor cells selectively (i.e., oncolytic viral therapy) (Iwami 
et al., 2010). 
4.1.1 Strategies in transgenic viruses (Iwami et al., 2010; Kozarsky & Wilson, 1993; 
Markert et al., 2009) 
1. Scientists add healthy functioning genes to cells that have damage or missing genes in 
order to substitute the bad non-working copy of the gene with a better copy of the 
working gene. The extraction of reproductive   are of virus was done initially. Genes 
have been added to and removed from the viruses so they cannot replicate on their 
own, but they can still break out of the tumor cells and invade nearby dividing cancer 
cells. 
2. Injecting of  the tumor cell with genes that can kill the  tumor cells. For instance, suicide 
genes are inserted into the tumor cells. A pro-drug or an inactive form of a toxic drug is 
administered to the patients, and this drug will kill off any tumor cells with the suicide 
genes in them. This method is called  enzyme prodrug (‘suicide gene’) therapy, Once 
inside the tumor cells, the viruses produce an enzyme that will turn an otherwise 
harmless drug into one that is toxic to the tumor cells. When the patient is treated with 
the drug gancyclovir, the enzyme converts it into something that is toxic to the tumor 
cells, and those cells die. 
3. Researchers can also transfer genetic materials into cancer cells by using ex-vivo 
techniques. Cancer cells are taken out of the body from the patient's blood or bone 
marrow surgically, and the necessary genes are added to them in the laboratory. 
4. Other method that is commonly used in laboratory is the in-vivo techniques. Virus or a 
plasmid is entirely necessary because gene cannot be directly inserted into a cell. The 
gene is inserted into the host's cell by using a vector. A vector acts as a bacteriophage or 
a plasmid (circular, small pieces of DNA) that can transfer genes from one cell to 
another. Vectors from the viruses adenoviruses are often used for gene therapy because 
viruses reproduce by inserting their genetic material into the cells they infect. 
Other transferring therapeutic genes to brain tumor cells are mostly used by HSV, retrovirus 
and adenovirus due to following key points. Application of adenovirus mediated gene 
therapy was successful in liver cell and respiratory epithelium (Kozarsky & Wilson, 1993; 
Kramm et al., 1995). Herpes simplex virus-thymidine kinase (HSV-tk) gene, had a good 
tendency to neuronal cells. Retroviral vectors have long survive in target cells (Kramm et al., 
1995). Oncolytic reovirus and measles viral vectors are under development for GBM 
virotherapy (Kroeger et al., 2010).  
Gene directed prodrug therapy utilizing the herpes simplex virus thymidine kinase gene 
was the first gene therapy experienced clinically (Mesnil & Yamasaki, 2000; Yawata et al., 
2011). The most frequent used paradigm is based on the activation of ganciclovir to a 
cytotoxic compound by a viral enzyme, thymidine kinase, which is expressed by tumor 
cells, after the gene has been introduced by a retroviral vector. This paradigm has proven to 
be a potent therapy with minimal side effects in several rodent brain tumor models, and has 
proceeded to phase 1 clinical trials (Kramm et al., 1995). 
Oncolytic viral therapy: This approach uses replication-competent viruses infect and lyse 
the target cells. An oncolytic vector should conditionally replicate within the target tumor 
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cells with minimal toxicity to the surrounding normal brain tissue. Oncolytic vectors are 
grouped as either mesogenic (moderately pathogenic, capable of producing viable progeny 
and infecting adjacent cells) or lentogenic (attenuated non-pathogenic, produces defective 
progeny and is incapable of spreading between tissues) (Dey et al., 2010). Replicating, 
oncolytic viruses have been developed from several species of viruses. The most common 
vectors are replicating herpes simplex virus (HSV), adenovirus and replication-competent 
retrovirus (RCR). Replicating herpes simplex virus (HSV) vectors have been tested for the 
treatment of malignant glioma (Grandi et al., 2009; Granelli-Piperno et al., 2000; Parker et al., 
2009). The common widely studied oncolytic HSV vector is G207, a genetically engineered 
HSV-1 (Markert et al., 2000). 
Tumor suppressor gene therapy: Mutation or inactivation of the p53 tumor suppressor gene 
is one of the early genetic alterations in the tumor progression of gliomas (Fults et al., 1992; 
von Deimling et al., 1992). Using a gene to encode a tumor-suppressor protein in glioma 
cells that is mutated or absent. Is the fundamental of this approach? TP53 is most common 
studied suppressor gene, whose mutations have been reported in 30-60% of malignant 
gliomas (Louis et al., 2001; Vousden & Lane, 2007). It is demonstrated that the replacement 
of wild-type p53 in tumor cells induced rapid cell death even in cells with the intact 
functional gene (Li et al., 1999; Roth, 2006).  
Antisense therapy: Antisense oligonucleotides are single strands of DNA or RNA that are 
complementary to a chosen sequence. Antisense oligonucleotides specific for insulin-like 
growth factor-1 (IGF-1) or transforming growth factor b2 (TGF-b2) have been used in 
various clinical studies (Tambuyzer et al., 2009; Vauleon et al., 2010).  
5. Non-viral methods  
Non-viral methods provide certain advantages over viral methods, such as simple large 
scale production and low host immunogenicity, however small levels of transfection and 
expression of the gene are a disadvantage of this methods (Iwami et al., 2010).  
1. Injection of naked DNA or naked PCR product,  
2. Physical methods to enhance delivery 
a. Electroporation 
b. Gene gun 
c. Sonoporation 
d. Magnetofection 
3. Chemical methods to enhance delivery 
Synthetic oligonucleotides, lipoplexes and polyplexes, dendrimers 
a. Hybrid methods: Combination of two or more techniques. For example virosomes 
are combine with liposomes using an inactivated HIV or influenza virus. 
Difficulties in gene therapy in brain tumors can be arranged as follows: (Mut & Ziyal, 2010). 
1. Difficulties to recognize tumor cells as target for attack. 
2. In order to inject gene cells into the specific region of the brain, to perform stereotactic 
brain surgery is mandatory. 
3. After the genes are injected into the region, there is the possibility that the viral vectors 
that are used to transfer the genetic material into the cell might infect healthy cells as 
well as brain tumors. 
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4. The new gene might also insert into the wrong location in the DNA, thus leading to 
harmful mutations of the DNA and triggering unwanted reaction by the immune 
system. 
5. The transferred genes can also be overexpressed by producing a lot of missing proteins. 
6. Finally, inflammation of the lining of the brain or infection can occur after the 
treatment. 
7. The negative side, on the other hand, is that the gene therapy will affect the 
development of the fetus in many unexpected ways like causing long-term illness or 
other side effects. The human gene pool can also be permanently affected by these gene 
alterations.  
6. Supressive factors of gliomas on immune system  
Gliomas can abstain immune system at different steps of antigen recognition and immune 
activation (Parney et al., 2000). Many glioma cells express low or defective levels of human 
leukocyte antigens (HLA) and also ave been found deficient in proper antigen presentation 
for cytotoxic and helper T-cell activation (Flügel et al., 1999). Inhibition of antigen 
presentation by microglia and macrophages in the tumor micro environment also causes to 
the tumors’ ability to escape immune detection.  
In gliomas, T cells, specifically the CD41 population, both in peripheral blood and in the 
tumor microenvironment, have depressed function (Roszman & Brooks, 1985; Roszman et 
al., 1985). Innate helper T cells (CD41) reveal weak proliferative responses and dramatically 
lowered synthesis of the TH1 cytokine IL-2 (Das et al., 2008).  
One hypothesis sugested that these are actually resident T cells passively infiltrating the 
tumor across a compromised BBB caused by the tumor; alternatively, they may represent a 
population that once was active but has been subsequently rendered inactive by the host of 
immunosuppressive mechanisms found in the tumor microenvironment (Han et al., 2010).  
Secretion of various immune inhibitory cytokines and molecules by glioma cells also plays 
an important role in glioma-associated immunosuppression. High levels of expression of 
TGF-b2, IL-10 and prostaglandin E2 are present in malignant gliomas (Couldwell et al., 
1992; Nitta et al., 1994). TGF-b2 mRNA is found in samples of glioblastome multiforme 
(GBM) (Bodmer et al., 1989). 
Iatrogenic factors may also cause a systemic immunosuppression in patients with glioma 
(Roszman & Brooks, 1985). Corticosteroids given in the treatment of tumor-associated 
edema may cause inhibition of cytokine production and sequestration of CD41 T cells 
(Barshes et al., 2004). Otherwise recent reports suggest, however, that at therapeutic doses 
corticosteroids may not interfere with immunotherapy (Fenstermaker & Ciesielski, 2004; 
Lesniak et al., 2004). 
Stimulation of microglia in the existence of tumor cells reduces the secretion of 
proinflammatory cytokines, such as tumor necrosis factor (TNF)-a, however also increases 
the secretion of the inhibitory cytokine interleukin (IL)-10 (Dix et al., 1999). 
7. Immunotherapy 
Immunotherapy is one of the new promising therapeutic approaches that can especially 
target tumour cells. Adoptive and active immunotherapies using lymphokine-activated 
killer cells, cytotoxic T cells, tumour-infiltrating lymphocytes, autologous tumour cells, and 
dendritic cells are mainly used in this approach (Prasad et al., 2004). 
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Microglial cells constitute the first step of defense for the brain. They migrate toward 
inflammatory zones and, after activation, possess phagocytic properties and synthesize 
several types of cytokines and chemokines (Tsurushima et al., 1999). They express a number 
of macrophage-associated markers and major histocompatability (MHC) antigens 
suggesting that they may actually function as APCs in the brain thus evidence suggests that 
antigen presentation cells (APCs) are indeed present in the brain (Cash & Rott, 1994).  
To date, it was generally suggested that immune reactions do not occur in the brain because 
of the blood-brain barrier (BBB) and the specific features of the brain such as the absence of 
conventional lymphatic vessels or the low level of circulating T cells. This hypthesiz is not 
true excacly. Cell based Immunotherapies are affective in brain tumors. Immune effector 
cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), 
cytotoxic T lymphocytes (CTL), etc., work together to defend the body against tumor by 
targeting abnormal antigens expressed on the surface of the tumor due to mutation. An 
adaptive immune response implies antigen recognition (Prasad et al., 2004). A variety of 
immunologically based strategies, including passive immunization and adoptive cellular 
immunotherapy (Fujimiya et al., 1999; Inoue et al., 1996; Kruse et al., 1990; Merchant et al., 
1997; Plautz et al., 1997; Plautz et al., 1998) local and systemic delivery of biological response 
modifiers (Dranoff et al., 1993; Färkkilä et al., 1994; Jean et al., 1998; Jean et al., 2004; Lichtor 
et al., 1995; Ohno et al., 2009; Thompson et al., 1996; Yu et al; 1993) and vaccination with 
parental and genetically modified tumor cells (Dranoff et al., 1993; Jean et al., 1998; Lichtor 
et al., 1995; Thompson et al., 1996; Ohno et al., 2009; Yu et al; 1993) have been attempted. 
7.1 Cytokine therapy 
Cytokines are a heterogeneous group of soluble small polypeptides or glycoproteins, which 
have either pro- or anti-inflammatory activity and immunosuppressive activity, depending 
on the microenvironments. The tumor microenvironment consists of a variable combination 
of tumor cells, endothelial cells and infiltrating leukocytes, such as macrophages, 
T-lymphocytes, natural killer (NK) cells, B-cells and antigen-presenting cells (APCs). 
Cytokine production acts as a means of communication in the tumor microenvironment 
(Giezeman-Smits et al., 2000).  Several strategies for delivery of cytokines to the CNS have 
been studied, including injection/infusion of recombinant cytokines, vectors containing 
cytokine encoding genes, cells that secrete cytokines, or cytokines linked to toxins (Das et al., 
2008). 
7.2 Passive immunotherapy 
Passive immunotherapy includes serotherapy and adoptive immunotherapy. Serotherapy 
uses monoclonal antibodies to effect an antitumor response or to achieve very specific 
delivery of toxins, chemotherapy, or radiotherapy to the tumor cells. An important finding 
of its advantage is the identification of ‘‘tumor antigens,’’ specific antigens expressed on 
tumor cell surfaces but not on normal brain parenchyma (Ohno et al., 2009). Targeted 
glioma antigens have included tenascin, EGFR and its mutated form EGFRvIII, chondroitin 
sulfate, vascular endothelial growth factor (VEGF) receptor, neural cell adhesion molecule 
(NCAM), and hepatocyte growth factor/scatter factor (Hopkins et al., 1996). 
 In adoptive immunotherapy, immune cells activated ex vivo are administrated to the 
tumour-bearing patient. The activated cells are either injected directly into the tumour 
cavity or intravenously (Han et al., 2010). The first types of cells used for gliomas were 
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cytokine encoding genes, cells that secrete cytokines, or cytokines linked to toxins (Das et al., 
2008). 
7.2 Passive immunotherapy 
Passive immunotherapy includes serotherapy and adoptive immunotherapy. Serotherapy 
uses monoclonal antibodies to effect an antitumor response or to achieve very specific 
delivery of toxins, chemotherapy, or radiotherapy to the tumor cells. An important finding 
of its advantage is the identification of ‘‘tumor antigens,’’ specific antigens expressed on 
tumor cell surfaces but not on normal brain parenchyma (Ohno et al., 2009). Targeted 
glioma antigens have included tenascin, EGFR and its mutated form EGFRvIII, chondroitin 
sulfate, vascular endothelial growth factor (VEGF) receptor, neural cell adhesion molecule 
(NCAM), and hepatocyte growth factor/scatter factor (Hopkins et al., 1996). 
 In adoptive immunotherapy, immune cells activated ex vivo are administrated to the 
tumour-bearing patient. The activated cells are either injected directly into the tumour 
cavity or intravenously (Han et al., 2010). The first types of cells used for gliomas were 
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lymphocyte-activated killer (LAK) cells (Tsuboi et al., 2003). Cytotoxic T lymphocytes (CTL) 
can also be used. Autologous tumour cells (ATC) are generally used as antigen source 
(Holladay et al., 1996; Tsuboi et al., 2003). Another approach was to collect lymphocytes 
from lymph nodes (Holladay et al., 1996; Plautz et al., 1998; Plautz et al., 2000; Sloan et al., 
2000; Wood et al., 2000).  
Active immunotherapy involves strengthing patients’ immunity in vivo by vaccination 
against tumor antigen. Tumor vaccines for malignant glioma have been the focus of great 
interest currently. Successful development of glioma vaccines, however, requires proper 
presentation of tumor antigens and induction of effective, durable antigen-specific T cell 
immune response.A lot of antigen sources can be used for active immunotherapy such as 
intact tumour cells, tumour protein lysates, tumour-derived mRNA, peptides eluded from 
tumour MHC class I molecules, and synthetic peptides (Ishikawa et al., 2007; Okada et al., 
2007; Sloan et al., 2000; Steiner et al., 2004).  
8. Conclusion  
As brain tumor neoplasms constitute a formidable therapeutic challenge, gene and immuno 
therapy present powerful, novel opportunities for developing adjuvant therapies in brain 
cancer. However, more effective researches for adjuvant treatments of malignant gliomas 
are needed.  
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lymphocyte-activated killer (LAK) cells (Tsuboi et al., 2003). Cytotoxic T lymphocytes (CTL) 
can also be used. Autologous tumour cells (ATC) are generally used as antigen source 
(Holladay et al., 1996; Tsuboi et al., 2003). Another approach was to collect lymphocytes 
from lymph nodes (Holladay et al., 1996; Plautz et al., 1998; Plautz et al., 2000; Sloan et al., 
2000; Wood et al., 2000).  
Active immunotherapy involves strengthing patients’ immunity in vivo by vaccination 
against tumor antigen. Tumor vaccines for malignant glioma have been the focus of great 
interest currently. Successful development of glioma vaccines, however, requires proper 
presentation of tumor antigens and induction of effective, durable antigen-specific T cell 
immune response.A lot of antigen sources can be used for active immunotherapy such as 
intact tumour cells, tumour protein lysates, tumour-derived mRNA, peptides eluded from 
tumour MHC class I molecules, and synthetic peptides (Ishikawa et al., 2007; Okada et al., 
2007; Sloan et al., 2000; Steiner et al., 2004).  
8. Conclusion  
As brain tumor neoplasms constitute a formidable therapeutic challenge, gene and immuno 
therapy present powerful, novel opportunities for developing adjuvant therapies in brain 
cancer. However, more effective researches for adjuvant treatments of malignant gliomas 
are needed.  
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1.1 Brain tumours in children and adults 
Primary Central Nervous System (CNS) tumours are considered to be those that originate in 
the CNS and usually remain there. Primary CNS tumours, despite not leading the cancer 
frequency rates, rank first among cancer types for the average years of life lost (Burnet et al., 
2005). By contrast with other malignancies, where research has lead to the establishment of 
more successful treatment options, the diagnosis of a CNS tumour, particularly the more 
malignant histological types, still has devastating effects on the patients and their relatives, 
not only due to the dismal prognosis of these tumours with extremely high rates of 
mortality, but also to the great morbidity that actual treatment options cause (Laughton et 
al., 2008; Mulhern et al., 2004; Silber et al., 1992).  
The estimated annual worldwide age-standardized incidence of malignant primary CNS 
tumours is 3.5 per 100,000 people, which represents more than 200,000 cases. The rate is 
slightly higher in males (3.9 per 100,000 people per year) than in females (3.1 per 100,000 
people per year) (Ferlay et al., 2008). The frequency of brain tumours is also higher in more 
developed countries (5.2 per 100,000 people per year) compared to less developed countries 
(3.0 per 100,000 people per year), probably due to diagnostic advances, as well as access to 
adequate health care in the developed regions (Ferlay et al., 2008; Wrensch et al., 2005). 
Similarly, estimated annual global age-standardized mortality of malignant primary CNS 
tumours is higher in males (3.0 per 100,000 people) than in females (2.2 per 100,000 people), 
with higher rates also in more developed countries (3.2 per 100,000 people) than in less 
developed regions (2.3 per 100,000 people) (Ferlay et al., 2008). The median age of diagnosis 
for all primary CNS tumours is 57 years, however the histology-specific median age ranges 
from 9 to 70 years ( Central Brain Tumor Registry of the United States [CBTRUS], 2010). 
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1.1 Brain tumours in children and adults 
Primary Central Nervous System (CNS) tumours are considered to be those that originate in 
the CNS and usually remain there. Primary CNS tumours, despite not leading the cancer 
frequency rates, rank first among cancer types for the average years of life lost (Burnet et al., 
2005). By contrast with other malignancies, where research has lead to the establishment of 
more successful treatment options, the diagnosis of a CNS tumour, particularly the more 
malignant histological types, still has devastating effects on the patients and their relatives, 
not only due to the dismal prognosis of these tumours with extremely high rates of 
mortality, but also to the great morbidity that actual treatment options cause (Laughton et 
al., 2008; Mulhern et al., 2004; Silber et al., 1992).  
The estimated annual worldwide age-standardized incidence of malignant primary CNS 
tumours is 3.5 per 100,000 people, which represents more than 200,000 cases. The rate is 
slightly higher in males (3.9 per 100,000 people per year) than in females (3.1 per 100,000 
people per year) (Ferlay et al., 2008). The frequency of brain tumours is also higher in more 
developed countries (5.2 per 100,000 people per year) compared to less developed countries 
(3.0 per 100,000 people per year), probably due to diagnostic advances, as well as access to 
adequate health care in the developed regions (Ferlay et al., 2008; Wrensch et al., 2005). 
Similarly, estimated annual global age-standardized mortality of malignant primary CNS 
tumours is higher in males (3.0 per 100,000 people) than in females (2.2 per 100,000 people), 
with higher rates also in more developed countries (3.2 per 100,000 people) than in less 
developed regions (2.3 per 100,000 people) (Ferlay et al., 2008). The median age of diagnosis 
for all primary CNS tumours is 57 years, however the histology-specific median age ranges 
from 9 to 70 years ( Central Brain Tumor Registry of the United States [CBTRUS], 2010). 
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In children, CNS tumours are the second most frequent malignancy after leukaemia and are 
therefore the most common solid tumours in childhood (Jemal et al., 2009). An estimated 
3,750 new cases of childhood primary non-malignant and malignant CNS tumours are 
expected to be diagnosed in the United States each year. This number reflects an annual 
incidence rate of 4.5 cases per 100,000 people. As in adults, the rate is higher in males (4.7 
cases per 100,000 people) than in females (4.3 cases per 100,000 people) (CBTRUS, 2010). 
Importantly, malignant brain tumours are the leading cause of cancer-related death in the 
childhood (Rickert & Paulus, 2001). 
Pathologically, CNS tumours are generally classified according to the World Health 
Organization (WHO) criteria (Louis et al., 2007). There are a wide range of CNS histological 
entities, classified according to the cell morphology and the degree of malignant behaviour. 
The WHO classification (Louis et al., 2007) includes a grading scheme that is a reference for 
predicting the biological behaviour of the tumour. Grade I tumours generally have a low 
proliferative potential and the possibility of cure after surgical resection, whilst grade IV 
tumours are histologically malignant, mitotically active and necrotic, and are associated 
with rapid disease evolution contributing to the high rates of mortality and morbidity 
among malignant brain tumour patients. The incidence of different histological types of 
brain tumours varies across specific age groups (Maity et al., 2004); accordingly, the regions 
of the brain mostly affected in paediatric and adult tumours are also different. In adults and 
older children, brain tumours are mostly supratentorial (cerebrum), whereas in young 
children they are more commonly infratentorial (cerebellum) (Gottardo & Gajjar, 2008). This 
chapter will focus on malignant CNS tumours, more particularly supratentorial high-grade 
gliomas (WHO grades III and IV) and cerebellar medulloblastomas (grade IV), which are the 
most common malignant CNS tumours of adults and children, respectively. 
Brain tumour aetiology is thought to be multifactorial and is likely to vary by tumour type. 
There is a likely connection between genetics and environment, meaning that particular 
genetic susceptibilities lead to increased vulnerability to environmental factors. The only 
proven exogenous environmental cause of brain tumours, in children or adults, is ionizing 
radiation, often seen in the setting of previous radiation therapy for the treatment of a 
former malignancy (Baldwin & Preston-Martin, 2004; Bondy et al., 2008; Ohgaki & Kleihues, 
2005; Pettorini et al., 2008; Wrensch et al., 2005). Genetic susceptibility to brain tumours 
comes from rare syndromes and polymorphisms, specifically in pathways thought to be 
involved in the process of brain tumour formation. Familial tumour predisposition 
syndromes are associated with germline mutations, typically in tumour suppressor genes, 
which confer an increased susceptibility of individuals to tumour formation from childhood 
until their adult life (Ullrich, 2008). Some of the major syndromes associated with high-
grade gliomas or medulloblastomas (with genes affected by germline mutations) are 
neurofibromatosis type 1 (NF1), Li-Fraumeni syndrome (TP53) and Turcot syndrome (APC 
and MLH1/PMS2/MSH2/MSH6) (complete list in Table 1).  
1.2 High-grade glioma 
The majority of CNS tumours in all age groups are gliomas. The estimated annual incidence 
rate of gliomas in the United States is 6.0 per 100,000 people. Overall, the broad category of 
gliomas accounts for 36% of all CNS tumours and 81% of malignant lesions. In young adults 
(20-34 years), gliomas represent 39% of all CNS tumours and 86% of malignant tumours; in 
adolescents (15-19 years), 45% of all CNS tumours and 81% of malignant; whereas in  
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Table 1. Familial syndromes and genes involved causing increased risk of gliomas and 
medulloblastomas. Adapted from (Louis et al., 2007). 
children less than 15 years the frequency of gliomas is higher (56%), but they only account for 
74% of malignant tumours (CBTRUS, 2010). The incidence rates of gliomas by histology varies 
among age-specific groups; in children and adolescents grade I gliomas are the most common 
tumours, whereas in older patients grade IV gliomas have the highest incidence (CBTRUS, 
2010). The treatment of low-grade gliomas with surgical resection alone allows in most 
instances the possibility of cure. High-grade gliomas by contrast remain a difficult therapeutic 
challenge with a poor prognosis. Conventional treatment includes surgery, radiotherapy and 
chemotherapy, however despite improving survival times and quality of life, current 
therapeutic regimens are still unable to effect a cure. In malignant histologies, tumour cells 
infiltrate into the surrounding brain and are generally not completely removed by surgery, 
which coupled with the fact that these remaining cells are often resistant to radio- and 
chemotherapy are the main reasons for the therapeutic failure in high-grade gliomas (Imbach, 
2006). Similarly in children, surgery plays a major role in the treatment of gliomas, with the 
extent of tumour resection the most important prognostic factor in this age group. For the 
more malignant subtypes, focal radiation is used as first line adjuvant therapy, except in 
infants (Hargrave, 2009; Imbach, 2006). Both in adult and paediatric populations, histological 
type and grade of the tumour, anatomic location, extent of surgical resection, patient’s age, 
whether radiotherapy is applied, and some chemotherapy protocols have been consistently 
considered prognostic factors (Stewart & Cohen, 1998; Wrensch et al., 2005).  
The major subtypes of gliomas are astrocytomas, oligodendrogliomas and the mixed 
lineage, oligoastrocytomas. 
Astrocytoma represents a highly heterogeneous histological group of neoplasms. They 
represent about 75% of all gliomas and can occur in most parts of the brain, and are the most 
frequent gliomas of childhood (CBTRUS, 2010). While malignant astrocytomas comprise 
only 2% of all adult tumours, their malignant nature makes them the fourth greatest cancer-
related death (Davis et al., 1998). The different histological types of astrocytoma, grade I 
pilocytic, grade II diffuse, grade III anaplastic and grade IV glioblastoma vary in frequency, 
age and gender distribution, location within the brain and clinical features. The major 
malignant subtypes, anaplastic astrocytoma and glioblastoma, account respectively for 8% 
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In children, CNS tumours are the second most frequent malignancy after leukaemia and are 
therefore the most common solid tumours in childhood (Jemal et al., 2009). An estimated 
3,750 new cases of childhood primary non-malignant and malignant CNS tumours are 
expected to be diagnosed in the United States each year. This number reflects an annual 
incidence rate of 4.5 cases per 100,000 people. As in adults, the rate is higher in males (4.7 
cases per 100,000 people) than in females (4.3 cases per 100,000 people) (CBTRUS, 2010). 
Importantly, malignant brain tumours are the leading cause of cancer-related death in the 
childhood (Rickert & Paulus, 2001). 
Pathologically, CNS tumours are generally classified according to the World Health 
Organization (WHO) criteria (Louis et al., 2007). There are a wide range of CNS histological 
entities, classified according to the cell morphology and the degree of malignant behaviour. 
The WHO classification (Louis et al., 2007) includes a grading scheme that is a reference for 
predicting the biological behaviour of the tumour. Grade I tumours generally have a low 
proliferative potential and the possibility of cure after surgical resection, whilst grade IV 
tumours are histologically malignant, mitotically active and necrotic, and are associated 
with rapid disease evolution contributing to the high rates of mortality and morbidity 
among malignant brain tumour patients. The incidence of different histological types of 
brain tumours varies across specific age groups (Maity et al., 2004); accordingly, the regions 
of the brain mostly affected in paediatric and adult tumours are also different. In adults and 
older children, brain tumours are mostly supratentorial (cerebrum), whereas in young 
children they are more commonly infratentorial (cerebellum) (Gottardo & Gajjar, 2008). This 
chapter will focus on malignant CNS tumours, more particularly supratentorial high-grade 
gliomas (WHO grades III and IV) and cerebellar medulloblastomas (grade IV), which are the 
most common malignant CNS tumours of adults and children, respectively. 
Brain tumour aetiology is thought to be multifactorial and is likely to vary by tumour type. 
There is a likely connection between genetics and environment, meaning that particular 
genetic susceptibilities lead to increased vulnerability to environmental factors. The only 
proven exogenous environmental cause of brain tumours, in children or adults, is ionizing 
radiation, often seen in the setting of previous radiation therapy for the treatment of a 
former malignancy (Baldwin & Preston-Martin, 2004; Bondy et al., 2008; Ohgaki & Kleihues, 
2005; Pettorini et al., 2008; Wrensch et al., 2005). Genetic susceptibility to brain tumours 
comes from rare syndromes and polymorphisms, specifically in pathways thought to be 
involved in the process of brain tumour formation. Familial tumour predisposition 
syndromes are associated with germline mutations, typically in tumour suppressor genes, 
which confer an increased susceptibility of individuals to tumour formation from childhood 
until their adult life (Ullrich, 2008). Some of the major syndromes associated with high-
grade gliomas or medulloblastomas (with genes affected by germline mutations) are 
neurofibromatosis type 1 (NF1), Li-Fraumeni syndrome (TP53) and Turcot syndrome (APC 
and MLH1/PMS2/MSH2/MSH6) (complete list in Table 1).  
1.2 High-grade glioma 
The majority of CNS tumours in all age groups are gliomas. The estimated annual incidence 
rate of gliomas in the United States is 6.0 per 100,000 people. Overall, the broad category of 
gliomas accounts for 36% of all CNS tumours and 81% of malignant lesions. In young adults 
(20-34 years), gliomas represent 39% of all CNS tumours and 86% of malignant tumours; in 
adolescents (15-19 years), 45% of all CNS tumours and 81% of malignant; whereas in  
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children less than 15 years the frequency of gliomas is higher (56%), but they only account for 
74% of malignant tumours (CBTRUS, 2010). The incidence rates of gliomas by histology varies 
among age-specific groups; in children and adolescents grade I gliomas are the most common 
tumours, whereas in older patients grade IV gliomas have the highest incidence (CBTRUS, 
2010). The treatment of low-grade gliomas with surgical resection alone allows in most 
instances the possibility of cure. High-grade gliomas by contrast remain a difficult therapeutic 
challenge with a poor prognosis. Conventional treatment includes surgery, radiotherapy and 
chemotherapy, however despite improving survival times and quality of life, current 
therapeutic regimens are still unable to effect a cure. In malignant histologies, tumour cells 
infiltrate into the surrounding brain and are generally not completely removed by surgery, 
which coupled with the fact that these remaining cells are often resistant to radio- and 
chemotherapy are the main reasons for the therapeutic failure in high-grade gliomas (Imbach, 
2006). Similarly in children, surgery plays a major role in the treatment of gliomas, with the 
extent of tumour resection the most important prognostic factor in this age group. For the 
more malignant subtypes, focal radiation is used as first line adjuvant therapy, except in 
infants (Hargrave, 2009; Imbach, 2006). Both in adult and paediatric populations, histological 
type and grade of the tumour, anatomic location, extent of surgical resection, patient’s age, 
whether radiotherapy is applied, and some chemotherapy protocols have been consistently 
considered prognostic factors (Stewart & Cohen, 1998; Wrensch et al., 2005).  
The major subtypes of gliomas are astrocytomas, oligodendrogliomas and the mixed 
lineage, oligoastrocytomas. 
Astrocytoma represents a highly heterogeneous histological group of neoplasms. They 
represent about 75% of all gliomas and can occur in most parts of the brain, and are the most 
frequent gliomas of childhood (CBTRUS, 2010). While malignant astrocytomas comprise 
only 2% of all adult tumours, their malignant nature makes them the fourth greatest cancer-
related death (Davis et al., 1998). The different histological types of astrocytoma, grade I 
pilocytic, grade II diffuse, grade III anaplastic and grade IV glioblastoma vary in frequency, 
age and gender distribution, location within the brain and clinical features. The major 
malignant subtypes, anaplastic astrocytoma and glioblastoma, account respectively for 8% 
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and 51% of all gliomas, with glioblastoma representing 80% of malignant tumours 
(CBTRUS, 2010; Imbach, 2006; Louis et al., 2007; Reifenberger et al., 2006; Weingart et al., 
2006). High-grade glioma may arise de novo, and are designated primary tumours, or may be 
considered secondary tumours developing from lower grade lesions. Whereas the great 
majority of adults with diffuse astrocytoma experience malignant transformation to grade 
III and finally to grade IV astrocytoma, the long-term risk of malignant transformation in 
histologically identical neoplasms in children is less than 10% (Broniscer et al., 2007). 
Nevertheless, the majority (about 95%) of glioblastomas are primary tumours, develop very 
rapidly in elderly patients (mean 62 years) after a short clinical history and present a poorer 
prognosis (Louis et al., 2007), whereas secondary glioblastoma mostly develop in younger 
patients below the age of 45 (Louis et al., 2007). Due to its invasive nature, glioblastoma 
cannot be completely resected and despite progress in radio- and chemotherapy, less than 
half of the patients survive more than a year, making glioblastoma the CNS tumour with 
worse prognosis, for both paediatric and adult patients (Louis et al., 2007; Reifenberger et 
al., 2006). 
Oligodendroglioma account for a small subset of all gliomas (about 8%), being 
predominantly tumours of adulthood, with a peak incidence between the fourth and fifth 
decade of life, representing only 1-2% of all CNS tumours in children (CBTRUS, 2010). There 
are two grades of malignancy for oligodendrogliomas, oligodendroglioma (grade II) and 
anaplastic oligodendroglioma (grade III), with grading a significant predictor of survival. 
Precise data on the incidence of oligoastrocytoma are not available, but reported frequencies 
vary from 1-20% of all gliomas, with the higher percentage thought to be overestimated due 
to a consultation bias. These tumours arise preferentially in the cerebral hemispheres and 
mainly occur in the fifth decade of life (Bromberg & van den Bent, 2009; Louis et al., 2007; 
Reifenberger et al., 2006; van den Bent et al., 2008). Similar to oligodendrogliomas, these 
tumours can also be divided in two grades of malignancy. 
1.3 Medulloblastoma 
Medulloblastoma represents a highly malignant, invasive embryonic tumour, and is the 
most common malignant CNS tumour in children, accounting together with other 
embryonic tumours for about 1.5% of all primary CNS tumours (CBTRUS, 2010), 
representing 12-25% of childhood brain tumours and only about 0,5-1% of all brain 
neoplasms in adults (Imbach, 2006; Sarkar et al., 2005; Taylor, 2006). The peak age incidence 
is 9 years, with 70% of all medulloblastomas occurring in patients less than 16 years of age. 
In adulthood, 80% of medulloblastomas arise before the fourth decade of life and rarely 
occur after the fifth decade. About 65% of patients are male (Louis et al., 2007; Reifenberger 
et al., 2006; Taylor, 2006). The annual incidence of medulloblastoma has been estimated at 
0.5 per 100,000 children less than 15 years (CBTRUS, 2010; Reifenberger et al., 2006). 
Medulloblastoma presents predominantly neuronal differentiation. It is composed of 
densely packed small round blue cells with carrot-shaped hyperchromatic nuclei, possibly 
presenting neuroblastic rosettes which are associated with marked nuclear pleomorphism 
and high mitotic activity (Huse & Holland, 2010; Imbach, 2006; Louis et al., 2007; Taylor, 
2006). The WHO classification of CNS tumours recognizes at least five different histological 
types of medulloblastoma: classic (70-85% of the cases); desmoplastic/nodular (15% in 
paediatric medulloblastoma compared to 30-40% in adults); anaplastic (about 10-22% of 
medulloblastomas); large cell (about 2-4% of cases) and medulloblastoma with extensive 
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nodularity (about 3%) (Brandes et al., 2009; Imbach, 2006; Louis et al., 2007; Taylor, 2006). 
There is an heterogeneity among medulloblastoma histologic subtypes which exhibit a 
highly variable clinical behaviour, with the anaplastic and large cell subtypes being 
associated with worse prognosis and desmoplastic/nodular medulloblastomas portending a 
more favourable outcome (Gilbertson & Ellison, 2008; Huse & Holland, 2010; Imbach, 2006). 
About 30% of the medulloblastoma patients, particularly paediatric tumours, present 
metastasis via the cerebrospinal fluid pathways at diagnosis, whereas spread outside the 
CNS is a rare event (Carrie et al., 1994; Frost et al., 1995; Reifenberger et al., 2006). Clinical 
prognostic factors include tumour size, presence of metastasis, age, and amount of tumour 
resected (Imbach, 2006). Stratification of medulloblastoma involves distinguishing high-risk 
and standard-risk patients, with high-risk patients those aged less than 3 years, with 
incomplete surgical resection of the tumour and/or with disseminated disease (Dubuc et al., 
2010; Imbach, 2006; Louis et al., 2007). Significant advances have been made in the treatment 
of childhood medulloblastoma, with the 5-year survival raised to 60% for high-risk disease 
and 80% for standard-risk tumours, however the long-term side effects of the treatment 
modalities applied can be severe. Actual treatment includes maximal safe surgical resection 
and the use of combined radio- and chemotherapy for children older than 3 years. Most 
therapeutic approaches for high-risk patients include relatively high doses of craniospinal 
radiotherapy and aggressive chemotherapeutic regimens (Hargrave, 2009; Imbach, 2006). 
The treatment of infants with medulloblastoma remains highly problematic as radiation 
therapy is especially damaging for the developing brain of very young children. 
2. Genetic instability of malignant brain tumours 
Cancer cells usually harbour mutations in oncogenes and tumour suppressor genes. These 
may play a role in key cellular processes such as proliferation, apoptosis or angiogenesis. 
Oncogenes are genes whose deregulated activation through mutation, translocation, 
amplification or over-expression promotes tumorigenesis. Tumour suppressors, on the other 
hand, play an inhibitory role, and can be inactivated in cancer through mutation, deletion, 
methylation or transcriptional repression. Genomic instability present in cancer cells occurs 
mainly through chromosomal instability (CIN) or microsatellite instability (MSI), together 
with increased frequencies of molecular alterations in cancer regulatory genes (Negrini et 
al., 2010; Nigg, 2005). CIN refers to the high rate by which chromosome structure and 
number (by gains or losses) changes over time in cancer cells compared with normal cells 
and MSI is characterized by the expansion or contraction of the number of oligonucleotide 
repeats present in microsatellite sequences (Venkatesan & Loeb, 2005).  
2.1.1 Patterns of copy number change 
CIN is characterised by an increased frequency of chromosomal alterations, resulting in gains, 
losses, deletions, insertions, translocations, amplifications, and rearrangements. Nearly all 
human tumours display the CIN phenotype and consequently aneuploidy. Tumours with the 
CIN usually harbour mutations in oncogenes and/or tumour suppressor genes, many of 
which are involved in the regulation of transcription (Nigg, 2005). During the last decade, the 
use of genome-scale profiling techniques to identify the key genetic alterations underlying 
different tumour types allowed fundamental findings about the drivers of oncogenesis, 
providing the rationale for specific targeted therapies in these malignancies. The first studies 
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and 51% of all gliomas, with glioblastoma representing 80% of malignant tumours 
(CBTRUS, 2010; Imbach, 2006; Louis et al., 2007; Reifenberger et al., 2006; Weingart et al., 
2006). High-grade glioma may arise de novo, and are designated primary tumours, or may be 
considered secondary tumours developing from lower grade lesions. Whereas the great 
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III and finally to grade IV astrocytoma, the long-term risk of malignant transformation in 
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Nevertheless, the majority (about 95%) of glioblastomas are primary tumours, develop very 
rapidly in elderly patients (mean 62 years) after a short clinical history and present a poorer 
prognosis (Louis et al., 2007), whereas secondary glioblastoma mostly develop in younger 
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decade of life, representing only 1-2% of all CNS tumours in children (CBTRUS, 2010). There 
are two grades of malignancy for oligodendrogliomas, oligodendroglioma (grade II) and 
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Precise data on the incidence of oligoastrocytoma are not available, but reported frequencies 
vary from 1-20% of all gliomas, with the higher percentage thought to be overestimated due 
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tumours can also be divided in two grades of malignancy. 
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most common malignant CNS tumour in children, accounting together with other 
embryonic tumours for about 1.5% of all primary CNS tumours (CBTRUS, 2010), 
representing 12-25% of childhood brain tumours and only about 0,5-1% of all brain 
neoplasms in adults (Imbach, 2006; Sarkar et al., 2005; Taylor, 2006). The peak age incidence 
is 9 years, with 70% of all medulloblastomas occurring in patients less than 16 years of age. 
In adulthood, 80% of medulloblastomas arise before the fourth decade of life and rarely 
occur after the fifth decade. About 65% of patients are male (Louis et al., 2007; Reifenberger 
et al., 2006; Taylor, 2006). The annual incidence of medulloblastoma has been estimated at 
0.5 per 100,000 children less than 15 years (CBTRUS, 2010; Reifenberger et al., 2006). 
Medulloblastoma presents predominantly neuronal differentiation. It is composed of 
densely packed small round blue cells with carrot-shaped hyperchromatic nuclei, possibly 
presenting neuroblastic rosettes which are associated with marked nuclear pleomorphism 
and high mitotic activity (Huse & Holland, 2010; Imbach, 2006; Louis et al., 2007; Taylor, 
2006). The WHO classification of CNS tumours recognizes at least five different histological 
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nodularity (about 3%) (Brandes et al., 2009; Imbach, 2006; Louis et al., 2007; Taylor, 2006). 
There is an heterogeneity among medulloblastoma histologic subtypes which exhibit a 
highly variable clinical behaviour, with the anaplastic and large cell subtypes being 
associated with worse prognosis and desmoplastic/nodular medulloblastomas portending a 
more favourable outcome (Gilbertson & Ellison, 2008; Huse & Holland, 2010; Imbach, 2006). 
About 30% of the medulloblastoma patients, particularly paediatric tumours, present 
metastasis via the cerebrospinal fluid pathways at diagnosis, whereas spread outside the 
CNS is a rare event (Carrie et al., 1994; Frost et al., 1995; Reifenberger et al., 2006). Clinical 
prognostic factors include tumour size, presence of metastasis, age, and amount of tumour 
resected (Imbach, 2006). Stratification of medulloblastoma involves distinguishing high-risk 
and standard-risk patients, with high-risk patients those aged less than 3 years, with 
incomplete surgical resection of the tumour and/or with disseminated disease (Dubuc et al., 
2010; Imbach, 2006; Louis et al., 2007). Significant advances have been made in the treatment 
of childhood medulloblastoma, with the 5-year survival raised to 60% for high-risk disease 
and 80% for standard-risk tumours, however the long-term side effects of the treatment 
modalities applied can be severe. Actual treatment includes maximal safe surgical resection 
and the use of combined radio- and chemotherapy for children older than 3 years. Most 
therapeutic approaches for high-risk patients include relatively high doses of craniospinal 
radiotherapy and aggressive chemotherapeutic regimens (Hargrave, 2009; Imbach, 2006). 
The treatment of infants with medulloblastoma remains highly problematic as radiation 
therapy is especially damaging for the developing brain of very young children. 
2. Genetic instability of malignant brain tumours 
Cancer cells usually harbour mutations in oncogenes and tumour suppressor genes. These 
may play a role in key cellular processes such as proliferation, apoptosis or angiogenesis. 
Oncogenes are genes whose deregulated activation through mutation, translocation, 
amplification or over-expression promotes tumorigenesis. Tumour suppressors, on the other 
hand, play an inhibitory role, and can be inactivated in cancer through mutation, deletion, 
methylation or transcriptional repression. Genomic instability present in cancer cells occurs 
mainly through chromosomal instability (CIN) or microsatellite instability (MSI), together 
with increased frequencies of molecular alterations in cancer regulatory genes (Negrini et 
al., 2010; Nigg, 2005). CIN refers to the high rate by which chromosome structure and 
number (by gains or losses) changes over time in cancer cells compared with normal cells 
and MSI is characterized by the expansion or contraction of the number of oligonucleotide 
repeats present in microsatellite sequences (Venkatesan & Loeb, 2005).  
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CIN is characterised by an increased frequency of chromosomal alterations, resulting in gains, 
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use of genome-scale profiling techniques to identify the key genetic alterations underlying 
different tumour types allowed fundamental findings about the drivers of oncogenesis, 
providing the rationale for specific targeted therapies in these malignancies. The first studies 
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using large-scale genome profiling techniques to identify the key genetic alterations of brain 
tumours were only recently published (Kool et al., 2008; Parsons et al., 2008; The Cancer 
Genome Atlas Research Network [TCGA], 2008; Thompson et al., 2006). Nevertheless, the 
number of such studies have been increasing on the past few years, with the first studies in 
paediatric glioma patients starting to emerge (Barrow et al., 2011; Bax et al., 2010; Paugh et al., 
2010; Qu et al., 2010; Schiffman et al., 2010; Zarghooni et al., 2010).  
2.1.2 High-grade glioma 
Comprehensive mapping of the genome of adult glioblastoma has identified common 
regions of chromosomal instability and gene expression signatures, identifying frequently 
dysregulated molecular pathways (Bredel et al., 2005; de Tayrac et al., 2009; Gardina et al., 
2008; Kotliarov et al., 2006; Maher et al., 2006; Nigro et al., 2005; Parsons et al., 2008; TCGA, 
2008). The number of such studies specifically addressing childhood high-grade glioma has 
until recently been much lower. Nevertheless, several works specifically addressing these 
paediatric tumours, from ours and others groups, are beginning to emerge, providing 
increasing evidence that the paediatric high-grade glioma genome has certain key 
differences from that of histologically similar adult tumours (Barrow et al., 2011; Bax et al., 
2010; Paugh et al., 2010; Qu et al., 2010; Rao et al., 2010; Rickert et al., 2001; Schiffman et al., 
2010; K.K. Wong et al., 2006; Zarghooni et al., 2010). 
These studies have demonstrated that the retinoblastoma (RB), p53 and RTK/PI3K/MAPK 
pathways are commonly disrupted in adult and paediatric glioblastomas through various 
genetic mechanisms (TCGA, 2008; Parsons et al., 2008). Nevertheless, our data has 
demonstrated that paediatric tumours show deregulation of these core pathways by copy 
number alterations in less than half the frequency of that reported for adult tumours: 25% 
RTK/PI3K/MAPK, 19% p53 and 22% RB versus 59%, 70% and 66%, for adult glioblastoma 
(Figure 1) (Bax et al., 2010; TCGA, 2008). Even though isolated cases presented clear 
genomic events linked to activation of the sonic hedgehog (SHH) and Notch pathways 
activation, there is no evidence of consistently targeted pathways in paediatric high-grade 
gliomas. Nevertheless, low-frequency amplifications in childhood tumours included genes 
involved in cell cycle progression (CCND2, CDK4, MYC, and MYCN), receptor tyrosine 
kinases (RTKs) and ligands (EGFR, MET, IGF1R, PDGFB, and NRG1), members of the 
PI3K/MAPK pathway (PIK3C2B, PIK3C2G, PIK3R5, KRAS, AKT1, and S6K1), and p53 
pathway regulation (MDM4), some of them known to be deregulated also in adult 
glioblastoma (Figure 2) (Bax et al., 2010; Paugh et al., 2010). In addition, homozygous 
deletions of tumour suppressor genes of known importance within the adult glioblastoma 
core signalling pathways included CDKN2C, PTEN, RB1, TP53, and TP73 (Figure 1) (TCGA, 
2008; Parsons et al., 2008), albeit at considerably lower frequencies in paediatric versus adult 
tumours. These numerous low-frequency amplifications and deletions identified in 
paediatric high-grade gliomas, such as MYC/MYCN, CCND2, KRAS, and CDKN2C, suggest 
that paediatric high-grade gliomas may be molecularly more similar to secondary adult 
glioblastomas (Beroukhim et al., 2007; Maher et al., 2006). 
At the gross chromosomal level, paediatric glioblastomas can be distinguished from adult 
tumours by the more frequent gain of chromosome 1q and loss of 16q, and the relative 
scarcity of chromosome 7 gains and 10q losses. The most frequent focal amplifications are 
also different, with PDGFRA predominant in paediatric and EGFR adult tumours (Table 2). 
Moreover, paediatric cases without PDGFRA amplification seem to present overexpression 
of a specific PDGFRA-associated gene signature, which differs from that observed in adult  
 
 




Fig. 1. Copy number alterations in core signalling Pathways in Adult and Paediatric 
Glioblastoma.  RTK/PI3K/MAPK, p53 and RB pathways are more frequently deregulated 
in adult than in paediatric glioblastomas. Adapted from (Bax et al., 2010; TCGA, 2008). 
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(Figure 1) (Bax et al., 2010; TCGA, 2008). Even though isolated cases presented clear 
genomic events linked to activation of the sonic hedgehog (SHH) and Notch pathways 
activation, there is no evidence of consistently targeted pathways in paediatric high-grade 
gliomas. Nevertheless, low-frequency amplifications in childhood tumours included genes 
involved in cell cycle progression (CCND2, CDK4, MYC, and MYCN), receptor tyrosine 
kinases (RTKs) and ligands (EGFR, MET, IGF1R, PDGFB, and NRG1), members of the 
PI3K/MAPK pathway (PIK3C2B, PIK3C2G, PIK3R5, KRAS, AKT1, and S6K1), and p53 
pathway regulation (MDM4), some of them known to be deregulated also in adult 
glioblastoma (Figure 2) (Bax et al., 2010; Paugh et al., 2010). In addition, homozygous 
deletions of tumour suppressor genes of known importance within the adult glioblastoma 
core signalling pathways included CDKN2C, PTEN, RB1, TP53, and TP73 (Figure 1) (TCGA, 
2008; Parsons et al., 2008), albeit at considerably lower frequencies in paediatric versus adult 
tumours. These numerous low-frequency amplifications and deletions identified in 
paediatric high-grade gliomas, such as MYC/MYCN, CCND2, KRAS, and CDKN2C, suggest 
that paediatric high-grade gliomas may be molecularly more similar to secondary adult 
glioblastomas (Beroukhim et al., 2007; Maher et al., 2006). 
At the gross chromosomal level, paediatric glioblastomas can be distinguished from adult 
tumours by the more frequent gain of chromosome 1q and loss of 16q, and the relative 
scarcity of chromosome 7 gains and 10q losses. The most frequent focal amplifications are 
also different, with PDGFRA predominant in paediatric and EGFR adult tumours (Table 2). 
Moreover, paediatric cases without PDGFRA amplification seem to present overexpression 
of a specific PDGFRA-associated gene signature, which differs from that observed in adult  
 
 




Fig. 1. Copy number alterations in core signalling Pathways in Adult and Paediatric 
Glioblastoma.  RTK/PI3K/MAPK, p53 and RB pathways are more frequently deregulated 
in adult than in paediatric glioblastomas. Adapted from (Bax et al., 2010; TCGA, 2008). 
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tumours with the 4q12 amplification (Bax et al., 2010; Martinho et al., 2009; Paugh et al., 
2010; Rickert et al., 2001; K.K. Wong et al., 2006). Even if PDGFRA amplification, 1q+ and 
16q- events are more common in paediatric patients (Qu et al., 2010; Schiffman et al., 2010; 
Zarghooni et al., 2010), they are also present in a proportion of adult tumours. Similarly 
there is a small group of paediatric high-grade gliomas containing copy number alterations 
associated with adult tumours (EGFR amplification, 7+, 10q-) (Bax et al., 2010; Paugh et al., 
2010). The deletion of CDKN2A/CDKN2B is among the most frequent focal events found in 
paediatric high-grade gliomas, nevertheless it is even more commonly present in adult 
tumours (Table 2) (Bax et al., 2010; TCGA, 2008; Paugh et al., 2010). In adults, secondary 
glioblastomas show overexpression or amplification of PDGFRA but rarely contain EGFR 
aberrations. 
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Focal deletions    
CDKN2A 20% 55%* <0.001 
* n = 206 tumours 
Table 2. Summary of copy number changes in Paediatric and Adult Glioblastoma. Adapted 
from (TCGA, 2008; Paugh et al., 2010). 
Recently, missense mutations in IDH1 were found in a significant number of adult 
glioblastomas that tend to occur mostly in younger patients with more protracted clinical 
courses (Parsons et al., 2008). These mutations were found exclusively on the R132 residue 
in the active site region of the protein (Parsons et al., 2008; Yan et al., 2009). Interestingly, a 
separate group of gliomas harbour mutations in the IDH1 homologue IDH2 at the analogous 
residue (R172). Further investigations have shown that mutations in IDH1 and IDH2 are 
present in high proportions of grade II and III astrocytic, oligodendroglial and mixed 
tumours (72 to 100%) along with secondary glioblastomas (up to 85%), but are largely 
absent in primary glioblastomas (5%) (Hartmann et al., 2009; Ichimura et al., 2009; Parsons et 
al., 2008; Watanabe et al., 2009; Yan et al., 2009). Additionally, IDH mutations are associated 
with other genomic abnormalities that are typically seen in gliomas, such as TP53 mutation 
in low-grade astrocytoma, and 1p/19q deletion in oligodendrogliomas; they are also 
mutually exclusive with EGFR amplification and chromosome 10 loss (Sanson et al., 2009; 
Watanabe et al., 2009; Yan et al., 2009). These findings suggest that, although IDH mutations 
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probably contribute to the early evolution of low-grade gliomas, remaining in the higher-
grade lesions, they seem to have no role in the underlying biology of primary glioblastoma. 
Importantly, these IDH1 hotspot mutations are not found in childhood tumours (Balss et al., 
2008; Yan et al., 2009), biologically distinguishing paediatric high-grade gliomas from adult 
secondary glioblastoma. Nevertheless, IDH1 mutations was recently found in 7 of the 20 
high-grade gliomas from older children (14-18 years) and reported to be associated with a 
favourable prognosis, as observed in adults (Pollack et al., 2010a). 
Oligodendrogliomas harbour specific copy number alterations related to response to 
therapy or prognosis, however a comparison between adult in paediatric populations is 
difficult, as paediatric oligodendrogliomas are extremely rare neoplasms. Still, up to 80% of 
adult tumours show combined loss of chromosomes 1p and 19q, associated with increased 
chemosensitivity to treatment and favourable clinical outcome (Smith et al., 2000, 1999), 
whereas deletion of these regions are rare and did not seem to anticipate a survival 
advantage in paediatric high-grade gliomas (Kreiger et al., 2005; Pollack et al., 2003).  
Another feature of childhood high-grade gliomas that is almost entirely absent from adult 
tumours is the occurrence of very few or even no detectable copy number alterations in 
paediatric tumours (Bax et al., 2010; Paugh et al., 2010). This stable genomic profile is 
independent of histologic grade or type, and seems to confer an improved survival in high-
grade glioma patients, in contrast to those patients with an amplifier genomic profile, who 
do significantly worse (Bax et al., 2010). 
2.1.3 Medulloblastoma 
Similarly to glial tumours, studies of genomic copy number alterations analysing large 
cohorts of paediatric and adult medulloblastomas have recently begun to emerge (Kool et 
al., 2008; Thompson et al., 2006; Korshunov et al., 2010).  
The most frequent and consistent genetic event reported in medulloblastoma is the partial or 
complete loss of the chromosome 17p, often in association with gain of chromosome 17q 
(resulting in the isochromosome 17q: i(17)q), occurring in approximately 30–50% of the 
medulloblastomas (Biegel et al., 1997; Bigner et al., 1988; Cogen & McDonald, 1996; Lamont 
et al., 2004; Nicholson et al., 2000; Steichen-Gersdorf et al., 1997; Capodano et al., 1994). 
Although the precise mechanism by which this genomic abnormality contributes to 
tumorigenesis and its prognostic importance remain unclear, the common deletion region of 
17p13.2-13.3 includes several confirmed and putative tumour suppressor genes, including 
TP53 (Huse & Holland, 2010). Together with the deletion of 17p, MYC amplification is a 
molecular prognostic factor of medulloblastoma (Imbach, 2006). Genomic amplifications of 
MYCN and MYC were described as characteristics of a subset of clinically aggressive 
medulloblastomas that tend to exhibit large cell/anaplastic histological features (Aldosari et 
al., 2002; Tomlinson et al., 1994).  
Recently, Korshunov and colleagues (Korshunov et al., 2010) compared a large series of 
adult and paediatric subsets of tumours, using array-based comparative genomic 
hybridization (aCGH) (34 adult and 101 paediatric patients) and validating the results in an 
independent series (112 adult and 303 childhood patients) by fluorescent in situ 
hybridization (FISH) analysis. Although frequencies of loss of 17p (either isolated or via 
i(17)q formation) were similar in both populations, isolated gains of 17q were significantly 
more frequent in children than adult patients, with monosomy of chromosome 17  
exclusively found in adults (Table 3) (Korshunov et al., 2010). Additionally, amplifications 
of MYC/MYCN prevailed in the paediatric cohort, whereas amplification of CDK6 (at 
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tumours with the 4q12 amplification (Bax et al., 2010; Martinho et al., 2009; Paugh et al., 
2010; Rickert et al., 2001; K.K. Wong et al., 2006). Even if PDGFRA amplification, 1q+ and 
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there is a small group of paediatric high-grade gliomas containing copy number alterations 
associated with adult tumours (EGFR amplification, 7+, 10q-) (Bax et al., 2010; Paugh et al., 
2010). The deletion of CDKN2A/CDKN2B is among the most frequent focal events found in 
paediatric high-grade gliomas, nevertheless it is even more commonly present in adult 
tumours (Table 2) (Bax et al., 2010; TCGA, 2008; Paugh et al., 2010). In adults, secondary 
glioblastomas show overexpression or amplification of PDGFRA but rarely contain EGFR 
aberrations. 
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glioblastomas that tend to occur mostly in younger patients with more protracted clinical 
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in the active site region of the protein (Parsons et al., 2008; Yan et al., 2009). Interestingly, a 
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residue (R172). Further investigations have shown that mutations in IDH1 and IDH2 are 
present in high proportions of grade II and III astrocytic, oligodendroglial and mixed 
tumours (72 to 100%) along with secondary glioblastomas (up to 85%), but are largely 
absent in primary glioblastomas (5%) (Hartmann et al., 2009; Ichimura et al., 2009; Parsons et 
al., 2008; Watanabe et al., 2009; Yan et al., 2009). Additionally, IDH mutations are associated 
with other genomic abnormalities that are typically seen in gliomas, such as TP53 mutation 
in low-grade astrocytoma, and 1p/19q deletion in oligodendrogliomas; they are also 
mutually exclusive with EGFR amplification and chromosome 10 loss (Sanson et al., 2009; 
Watanabe et al., 2009; Yan et al., 2009). These findings suggest that, although IDH mutations 
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probably contribute to the early evolution of low-grade gliomas, remaining in the higher-
grade lesions, they seem to have no role in the underlying biology of primary glioblastoma. 
Importantly, these IDH1 hotspot mutations are not found in childhood tumours (Balss et al., 
2008; Yan et al., 2009), biologically distinguishing paediatric high-grade gliomas from adult 
secondary glioblastoma. Nevertheless, IDH1 mutations was recently found in 7 of the 20 
high-grade gliomas from older children (14-18 years) and reported to be associated with a 
favourable prognosis, as observed in adults (Pollack et al., 2010a). 
Oligodendrogliomas harbour specific copy number alterations related to response to 
therapy or prognosis, however a comparison between adult in paediatric populations is 
difficult, as paediatric oligodendrogliomas are extremely rare neoplasms. Still, up to 80% of 
adult tumours show combined loss of chromosomes 1p and 19q, associated with increased 
chemosensitivity to treatment and favourable clinical outcome (Smith et al., 2000, 1999), 
whereas deletion of these regions are rare and did not seem to anticipate a survival 
advantage in paediatric high-grade gliomas (Kreiger et al., 2005; Pollack et al., 2003).  
Another feature of childhood high-grade gliomas that is almost entirely absent from adult 
tumours is the occurrence of very few or even no detectable copy number alterations in 
paediatric tumours (Bax et al., 2010; Paugh et al., 2010). This stable genomic profile is 
independent of histologic grade or type, and seems to confer an improved survival in high-
grade glioma patients, in contrast to those patients with an amplifier genomic profile, who 
do significantly worse (Bax et al., 2010). 
2.1.3 Medulloblastoma 
Similarly to glial tumours, studies of genomic copy number alterations analysing large 
cohorts of paediatric and adult medulloblastomas have recently begun to emerge (Kool et 
al., 2008; Thompson et al., 2006; Korshunov et al., 2010).  
The most frequent and consistent genetic event reported in medulloblastoma is the partial or 
complete loss of the chromosome 17p, often in association with gain of chromosome 17q 
(resulting in the isochromosome 17q: i(17)q), occurring in approximately 30–50% of the 
medulloblastomas (Biegel et al., 1997; Bigner et al., 1988; Cogen & McDonald, 1996; Lamont 
et al., 2004; Nicholson et al., 2000; Steichen-Gersdorf et al., 1997; Capodano et al., 1994). 
Although the precise mechanism by which this genomic abnormality contributes to 
tumorigenesis and its prognostic importance remain unclear, the common deletion region of 
17p13.2-13.3 includes several confirmed and putative tumour suppressor genes, including 
TP53 (Huse & Holland, 2010). Together with the deletion of 17p, MYC amplification is a 
molecular prognostic factor of medulloblastoma (Imbach, 2006). Genomic amplifications of 
MYCN and MYC were described as characteristics of a subset of clinically aggressive 
medulloblastomas that tend to exhibit large cell/anaplastic histological features (Aldosari et 
al., 2002; Tomlinson et al., 1994).  
Recently, Korshunov and colleagues (Korshunov et al., 2010) compared a large series of 
adult and paediatric subsets of tumours, using array-based comparative genomic 
hybridization (aCGH) (34 adult and 101 paediatric patients) and validating the results in an 
independent series (112 adult and 303 childhood patients) by fluorescent in situ 
hybridization (FISH) analysis. Although frequencies of loss of 17p (either isolated or via 
i(17)q formation) were similar in both populations, isolated gains of 17q were significantly 
more frequent in children than adult patients, with monosomy of chromosome 17  
exclusively found in adults (Table 3) (Korshunov et al., 2010). Additionally, amplifications 
of MYC/MYCN prevailed in the paediatric cohort, whereas amplification of CDK6 (at 
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7q21.3), was frequently present in adult tumours and absent in paediatric 
medulloblastomas. Of note is that both MYC/MYCN and CDK6 amplifications were 
associated with poor survival in paediatric and adult populations, respectively. Besides 
chromosome 17q, alterations on additional chromosome arms were shown to be 
significantly different between adult and paediatric medulloblastoma. Gains of chromosome 
3q, 4 and 19 more frequently found in the adult tumours, while gains of 1q, 2 and 7 and loss 
of 16q was more abundant in children. The frequency of chromosome 6 deletions was 
similar across adult and childhood medulloblastoma, however the patterns of aberration 
were different, with complete loss of the chromosome and absence of concomitant 
aberrations frequently more present in paediatric medulloblastoma (Korshunov et al., 2010). 
This may explain the reason why the prognostic value of chromosome 6 deletion, a well 
established marker for favourable outcome in medulloblastoma (Clifford et al., 2006; Pfister 
et al., 2009; Thompson et al., 2006), was not found to be statistically significant for adult 
cases (Korshunov et al., 2010). A summary of the results from the validation cohort is 
presented on Table 3. 
 
Region Paediatric Medulloblastoma (n=303) 
Adult Medulloblastoma 
(n=112) P 







































Other Alterations    
i(17)q 39% 32% ** 
* P = 0.02 for total Chromosome 6 aberrations; ** P < 0.001 for total Chromosome 17 aberrations 
Table 3. Summary of copy number changes in Paediatric and Adult Medulloblastomas 
(validation set of adult tumours by FISH analysis). Adapted from (Korshunov et al., 2010). 
2.2 Microsatellite Instability 
DNA is continuously exposed to numerous different insults, endogenous and exogenous, 
that can ultimately result in DNA mutation and alteration of cell behaviour. DNA repair 
mechanisms are therefore essential for maintaining DNA integrity and preventing 
tumorigenesis (Li, 2008; Ljungman, 2010). Consequences of the failure of these molecular 
pathways are well illustrated in colorectal cancer, mainly HNPCC where it is present in 
about 90% of the tumours. In these cancers, mismatch repair (MMR)-deficient cells adopt a 
mutator phenotype in which there is a significant increase in cellular mutation rates (Loeb, 
1991; Marra & Jiricny, 2005). The most obvious molecular signature of this mutator 
phenotype is the presence of microsatellite instability (MSI) (Fishel & Kolodner, 1995). 
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The MMR system is the major pathway responsible for repairing base-base mispairs and 
short insertion/deletion loops that arise during DNA replication and as intermediates of 
homologous recombination (Arana & Kunkel, 2010; Kunkel & Bebenek, 2000; Nigg, 2005). 
Such a mechanism is essential to the cells because the fidelity of replicating DNA 
polymerases is insufficient to generate an error-free copy of genomic DNA. Single-base 
substitutions are estimated to arise once in every 104-106 nucleotides incorporated, and 
MMR reduces the error rate to a range of 10-9 to 10-10, which ensures that the human genome 
can be duplicated without mutations (Kunkel & Bebenek, 2000). Left unrepaired, these 
structures will give rise to base-substitution and frameshift mutations, respectively (Arana 
& Kunkel, 2010; Kunkel & Bebenek, 2000; Nigg, 2005). The role of the key factors of the 
human MMR system, the MutS homologues MSH2, MSH3 and MSH6, and the MutL 
homologues MLH1 and PMS2, have begun to be elucidated (Jiricny, 2006; Li, 2008; Schofield 
& Hsieh, 2003). MSH6 competes for binding to MSH2 with MSH3 (Boland et al., 2008), 
whilst MLH1 can form heterodimers with PMS2 (Li & Modrich, 1995), PMS1 (Raschle et al., 
1999) or MLH3 (Lipkin et al., 2000); MLH1/PMS2 is the only complex with an essential role 
in mismatch correction (Nigg, 2005; Shah et al., 2010). 
Microsatellites are short DNA sequence repeats that are scattered throughout the human 
genome (Lander et al., 2001), and whose copy number varies steadily through evolution 
(Ellegren, 2004). MSI is the expansion or retraction of the number of repeats within the 
microsatellites and it is assumed to be generated by slippage of DNA polymerases during 
copying of repeats, representing a hot spot for mutagenesis (Aaltonen et al., 1994; Cahill et 
al., 1999; Ionov et al., 1993). The classification of MSI more commonly adopted takes into 
account the number of markers presenting frameshift alterations. MSI tumours are therefore 
classified as MSI-H when, comparing to germline DNA, two or more markers present allelic 
shifts, or in the absence of constitutive DNA, at least three markers are altered. When one or 
two markers present alterations tumours are classified as MSI-L; when all markers are 
normal tumours are classified as microsatellite stable (MSS) (Buhard et al., 2006; Umar et al., 
2004; Y.F. Wong et al., 2006). In parallel with this classification, an alternative qualitative 
distinction of MSI, which considers the size of the allelic shifts in the markers, has been 
proposed (Giunti et al., 2009; Oda et al., 2005). Samples presenting small length changes (6 
bp) are designed Type A MSI whereas those with more extreme variations are defined as 
Type B MSI.  
The presence and frequency of MSI in brain tumours is a controversial and poorly studied 
issue. Previous studies have evaluated the presence of MSI in brain tumours, particularly in 
gliomas, while in medulloblastomas MSI status has not been properly addressed. Reports in 
the literature describe the absence or rare incidence of MSI in adult patients, while in 
children results have been contradictory, with reported frequencies in paediatric gliomas 
varying between 0 and 44% (Alonso et al., 2001; Amariglio et al., 1995; Cheng et al., 1999; 
Dams et al., 1995; Eckert et al., 2007; Izumoto et al., 1997; Kanamori et al., 2000; Leung et al., 
1998; Martinez et al., 2005; Sobrido et al., 2000; Vladimirova et al., 2007). Importantly, the 
methodologies for determining MSI have been highly diverse, making it difficult to draw 
accurate conclusions (Table 4). To clarify the role of MSI in paediatric versus adult malignant 
brain tumours, our group has used a highly sensitive and robust panel of MSI markers and 
studied series of high-grade glioma and medulloblastoma of adult and paediatric samples 
for the presence of MSI (Viana-Pereira et al., 2009, 2011). In our study of high-grade 
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7q21.3), was frequently present in adult tumours and absent in paediatric 
medulloblastomas. Of note is that both MYC/MYCN and CDK6 amplifications were 
associated with poor survival in paediatric and adult populations, respectively. Besides 
chromosome 17q, alterations on additional chromosome arms were shown to be 
significantly different between adult and paediatric medulloblastoma. Gains of chromosome 
3q, 4 and 19 more frequently found in the adult tumours, while gains of 1q, 2 and 7 and loss 
of 16q was more abundant in children. The frequency of chromosome 6 deletions was 
similar across adult and childhood medulloblastoma, however the patterns of aberration 
were different, with complete loss of the chromosome and absence of concomitant 
aberrations frequently more present in paediatric medulloblastoma (Korshunov et al., 2010). 
This may explain the reason why the prognostic value of chromosome 6 deletion, a well 
established marker for favourable outcome in medulloblastoma (Clifford et al., 2006; Pfister 
et al., 2009; Thompson et al., 2006), was not found to be statistically significant for adult 
cases (Korshunov et al., 2010). A summary of the results from the validation cohort is 
presented on Table 3. 
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mutator phenotype in which there is a significant increase in cellular mutation rates (Loeb, 
1991; Marra & Jiricny, 2005). The most obvious molecular signature of this mutator 
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Table 4. Summary of relevant studies reporting MSI analysis in brain tumours after the year 
2000. 
gliomas, the frequency of MSI was significantly higher in paediatric than adult tumours 
(Viana-Pereira et al., 2011), reflecting the bulk of the previously published data (Alonso et 
al., 2001; Cheng et al., 1999; Kanamori et al., 2000; Leung et al., 1998; Martinez et al., 2005). 
On the other hand, in medulloblastomas, no difference was observed in MSI frequency 
between adult and paediatric tumours, suggesting that the presence of MSI in these tumours 
is not age-related (Viana-Pereira et al., 2009). Overall, it seems that there are less molecular 
differences between adult and paediatric medulloblastomas than those reported in high-
grade gliomas, in concordance with our MSI data.  
One of the key considerations in the assessment of MSI is in the use of mononucleotides 
versus polynucleotides in the panel of markers used. In our studies we used a pentaplex of 
quasimonomorphic mononucleotide markers (NR27, NR21, NR24, BAT25 and BAT26), 
which is currently regarded as the most sensitive panel of markers available, with distinct 
advantages over the classic National Cancer Institute panel of markers (2 mononucleotide 
markers: BAT26 and BAT25; and 3 dinucleotide markers: D2S123, D5S346 and D17S250) to 
the determine MSI in populations of different ethnicities and in different types of human 
tumours (Buhard et al., 2004; Buhard et al., 2006; Goel et al., 2010; Y.F. Wong et al., 2006). 
Importantly, the use of quasimonomorphic mononucleotide markers overcomes the need 
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for using matching germline DNA, required when using dinucleotide polymorphic markers. 
Despite this, still there is the need for optimization of the quasi-monomorphic variation 
range (QMVR) for each marker, as the allelic size estimation for these quasimonomorphic 
markers can be influenced by the use of specific reagents or the sequencing machine (Goel et 
al., 2010).  
Previous studies have established MSI frequencies in gliomas using polynucleotide markers 
only, with frequencies ranging from 0 to 37% (Amariglio et al., 1995; Dams et al., 1995; 
Izumoto et al., 1997; Sobrido et al., 2000). Including both mononucleotide and 
polynucleotides repeat markers did not improve consistency, with contrasting results 
varying between 0 and 44% in paediatric gliomas cohorts or between 0 and 18% in adult 
tumours (Cheng et al., 1999; Kanamori et al., 2000; Leung et al., 1998; Martinez et al., 2005; 
Pollack et al., 2010b). Using mononucleotides only also provided contradictory results of 0 
to 27% MSI in paediatric gliomas (Alonso et al., 2001; Eckert et al., 2007; Vladimirova et al., 
2007). In addition to the heterogeneity of markers used to assess MSI frequency that likely 
accounts for the majority of variability in the data, many of the previous studies did not 
refer the establishment of a QMVR (for quasimonomorphic mononucleotide markers) or a 
direct comparison between tumour and germline DNA (for other markers).  
In contrast to colorectal cancer, which presents mainly Type B MSI, we and others have 
shown that high-grade gliomas harbour Type A MSI (Giunti et al., 2009; Viana-Pereira et al., 
2009, 2011). Moreover, we have observed that both MSI-positive medulloblastoma and high-
grade glioma presented small length alterations within the microsatellites and hypothesise 
that this can also contribute for the high variation frequency of MSI in brain tumours 
reported in the literature (Alonso et al., 2001; Amariglio et al., 1995; Cheng et al., 1999; Dams 
et al., 1995; Eckert et al., 2007; Izumoto et al., 1997; Kanamori et al., 2000; Leung et al., 1998; 
Martinez et al., 2005; Sobrido et al., 2000; Vladimirova et al., 2007).  
Importantly, the MSI-positive paediatric high-grade glioma mostly presented a stable 
genomic profile at the chromosomal level, even if microsatellite and chromosomal instability 
were not mutually exclusive. As mentioned above, the presence of a proportion of tumours 
with few or absent copy number alterations distinguishes paediatric high-grade gliomas 
from their adult counterparts and therefore we hypothesise that MSI might represent an 
alternative form of genetic instability, at least in a proportion of these paediatric tumours 
with no gross chromosome number alterations. 
Mismatch repair deficiencies have been associated with paediatric brain tumours in a 
hereditary context. Case reports have described MMR germline mutations combined with 
NF1-like clinical features in children presenting medulloblastoma or high-grade glioma, 
described as a “mismatch repair-deficiency (MMR-D) syndrome” (summary in Table 5)  
(Agostini et al., 2005; De Rosa et al., 2000; Giunti et al., 2009; Hegde et al., 2005; Kruger et al., 
2008; Menko et al., 2004; Ostergaard et al., 2005; Poley et al., 2007; Roy et al., 2009; Scott et 
al., 2007; Toledano et al., 2009; Viana-Pereira et al., submitted; Wagner et al., 2003; Wang et 
al., 1999). Also in our study there was a MSI-H paediatric high-grade glioma with clinical 
characteristics of NF1 (multiple café-au-lait spots). Even though there was no constitutional 
DNA available for evaluation of MMR germline mutations, data imply that this patient 
probably present a MSH6 germline mutation, harbouring a MMR-D syndrome (de Leeuw et 
al., 2000).  
Due to the widespread presence of microsatellites in DNA, mutations are expected to 
accumulate in the genome of tumour cells due to MMR deficiency, with some alterations  
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gliomas, the frequency of MSI was significantly higher in paediatric than adult tumours 
(Viana-Pereira et al., 2011), reflecting the bulk of the previously published data (Alonso et 
al., 2001; Cheng et al., 1999; Kanamori et al., 2000; Leung et al., 1998; Martinez et al., 2005). 
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for using matching germline DNA, required when using dinucleotide polymorphic markers. 
Despite this, still there is the need for optimization of the quasi-monomorphic variation 
range (QMVR) for each marker, as the allelic size estimation for these quasimonomorphic 
markers can be influenced by the use of specific reagents or the sequencing machine (Goel et 
al., 2010).  
Previous studies have established MSI frequencies in gliomas using polynucleotide markers 
only, with frequencies ranging from 0 to 37% (Amariglio et al., 1995; Dams et al., 1995; 
Izumoto et al., 1997; Sobrido et al., 2000). Including both mononucleotide and 
polynucleotides repeat markers did not improve consistency, with contrasting results 
varying between 0 and 44% in paediatric gliomas cohorts or between 0 and 18% in adult 
tumours (Cheng et al., 1999; Kanamori et al., 2000; Leung et al., 1998; Martinez et al., 2005; 
Pollack et al., 2010b). Using mononucleotides only also provided contradictory results of 0 
to 27% MSI in paediatric gliomas (Alonso et al., 2001; Eckert et al., 2007; Vladimirova et al., 
2007). In addition to the heterogeneity of markers used to assess MSI frequency that likely 
accounts for the majority of variability in the data, many of the previous studies did not 
refer the establishment of a QMVR (for quasimonomorphic mononucleotide markers) or a 
direct comparison between tumour and germline DNA (for other markers).  
In contrast to colorectal cancer, which presents mainly Type B MSI, we and others have 
shown that high-grade gliomas harbour Type A MSI (Giunti et al., 2009; Viana-Pereira et al., 
2009, 2011). Moreover, we have observed that both MSI-positive medulloblastoma and high-
grade glioma presented small length alterations within the microsatellites and hypothesise 
that this can also contribute for the high variation frequency of MSI in brain tumours 
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et al., 1995; Eckert et al., 2007; Izumoto et al., 1997; Kanamori et al., 2000; Leung et al., 1998; 
Martinez et al., 2005; Sobrido et al., 2000; Vladimirova et al., 2007).  
Importantly, the MSI-positive paediatric high-grade glioma mostly presented a stable 
genomic profile at the chromosomal level, even if microsatellite and chromosomal instability 
were not mutually exclusive. As mentioned above, the presence of a proportion of tumours 
with few or absent copy number alterations distinguishes paediatric high-grade gliomas 
from their adult counterparts and therefore we hypothesise that MSI might represent an 
alternative form of genetic instability, at least in a proportion of these paediatric tumours 
with no gross chromosome number alterations. 
Mismatch repair deficiencies have been associated with paediatric brain tumours in a 
hereditary context. Case reports have described MMR germline mutations combined with 
NF1-like clinical features in children presenting medulloblastoma or high-grade glioma, 
described as a “mismatch repair-deficiency (MMR-D) syndrome” (summary in Table 5)  
(Agostini et al., 2005; De Rosa et al., 2000; Giunti et al., 2009; Hegde et al., 2005; Kruger et al., 
2008; Menko et al., 2004; Ostergaard et al., 2005; Poley et al., 2007; Roy et al., 2009; Scott et 
al., 2007; Toledano et al., 2009; Viana-Pereira et al., submitted; Wagner et al., 2003; Wang et 
al., 1999). Also in our study there was a MSI-H paediatric high-grade glioma with clinical 
characteristics of NF1 (multiple café-au-lait spots). Even though there was no constitutional 
DNA available for evaluation of MMR germline mutations, data imply that this patient 
probably present a MSH6 germline mutation, harbouring a MMR-D syndrome (de Leeuw et 
al., 2000).  
Due to the widespread presence of microsatellites in DNA, mutations are expected to 
accumulate in the genome of tumour cells due to MMR deficiency, with some alterations  
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potentially contributing to tumorigenesis (Duval & Hamelin, 2002). Genes thought to 
harbour mutations in microsatellites due to the MSI phenotype are commonly designated 
MSI target genes. There are numerous MSI target genes described, however the relevance of 
several of them in cancer is not clear-cut (Mori et al., 2001; Woerner et al., 2003). In brain 
tumours, only a small number of the “classical” mutated MSI target genes have been 
reported: IGFIIR (Leung et al., 1998) and PTEN (Kanamori et al., 2000), each of them in a 
single case of MSI high-grade gliomas, and TGFRII, reported in 71% of samples (Izumoto et 
al., 1997), although this result was never confirmed (Kanamori et al., 2000; Leung et al., 
1998). We identified four additional alterations, not previously reported in brain tumours, 
all in genes involved in different DNA repair pathways: mutations in the MBD4, DNAPKcs, 
and MSH6 genes and a polymorphism in MRE11 (Viana-Pereira et al., 2009, 2011).  
In summary, MSI is present in a subset of medulloblastomas and paediatric high-grade 
gliomas associated with molecular alterations distinctive of this phenotype, suggesting a 
potentially new genetic pathway correlated with the development of these tumours. As MSI 
is associated in other tumour types to a differential response to chemotherapy, the presence 
of MSI even in a small subset of brain tumours may have important translational 
implications in these extraordinarily treatment refractory malignancies. 
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potentially contributing to tumorigenesis (Duval & Hamelin, 2002). Genes thought to 
harbour mutations in microsatellites due to the MSI phenotype are commonly designated 
MSI target genes. There are numerous MSI target genes described, however the relevance of 
several of them in cancer is not clear-cut (Mori et al., 2001; Woerner et al., 2003). In brain 
tumours, only a small number of the “classical” mutated MSI target genes have been 
reported: IGFIIR (Leung et al., 1998) and PTEN (Kanamori et al., 2000), each of them in a 
single case of MSI high-grade gliomas, and TGFRII, reported in 71% of samples (Izumoto et 
al., 1997), although this result was never confirmed (Kanamori et al., 2000; Leung et al., 
1998). We identified four additional alterations, not previously reported in brain tumours, 
all in genes involved in different DNA repair pathways: mutations in the MBD4, DNAPKcs, 
and MSH6 genes and a polymorphism in MRE11 (Viana-Pereira et al., 2009, 2011).  
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vital players in these forms of proximal and distal messaging, acting as discrete packets of 
information capable of altering recipient cell phenotypes, activities, and responses. These 
vesicles are part of the normal biologic repertoire of the organism, but are particularly 
exploited by neoplasmic growths and cancers to change both the local and systemic 
environments to aid in tumor proliferation, invasion, and metastases, and in the defense of 
the tumor. This chapter will focus on exosomes and microvesicles from brain tumors, but 
similar stories may be told about such vesicles from almost any tumor type. Following this 
general introduction on exosomes and microvesicles we will discuss the experimentally 
determined and putative roles of exosomes in brain tumor biology, particularly in stress 
responses, metabolism, migration, immunology, and protection against chemotherapeutics. 
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diameter ) (Johnstone 2006)—ie, “fat balls”. These vesicles exist essentially anywhere there is 
a cell-liquid interface such as in blood, urine, semen, breast milk, bronchoalveolar lavage 
fluid, synovial capsule fluid, saliva, ascites, amniotic fluid, cerebrospinal fluid, and in vitro 
spent culture media (Simpson et al. 2009). The obtuse vesicular nomenclature and lack of  
molecular definitions for these microparticles generates confusion (Mathivanan, Ji, and 
Simpson); in this chapter, for these cell-derived vesicles we will refer to exosomes as 
extracellularly-released components of the endocytic pathway, while microvesicles will refer 
to “shed” vesicles released directly from cell-surface membrane budding (Figure 1). Please 
note that in this work “exosome” does not refer to the intracellular multi-subunit RNA 
processing complex (Mitchell et al. 1997). 
Due to the directional nature of the biogenesis of the two forms of vesicle formation, 
exosomes and microvesicles largely retain the original topography of the cell itself, making 
these vesicles akin to tiny cellular surrogates (Figure 2). The contents include selected 
membrane lipids such as gangliosides GM1 and GM3, sphingomyelin, lyso-bis-phosphatidic 
acid/bis-monoacylglycerol phosphate (LBPA/BMP), and cholesterol. Protein contents are 
also strikingly conserved across exosomes and microvesicles from various cell types, 
including protein components of lipid raft membrane structures, tetraspanins, numerous 
metabolic enzymes, heat shock proteins, structural proteins, and nucleic acid binding 
proteins (Simpson, Jensen, and Lim 2008). Appropriately, messenger and microRNAs are 
also present in exosomes (Taylor and Gercel-Taylor 2008; Valadi et al. 2007) including those 





Fig. 1. Highly diagrammatic representation of the release of extracellular vesicles from a cell. 
Two basic mechanisms are depicted: 1) shedding or “blebbing” of vesicles directly from cell 
membrane surface, yielding microvesicles (sometimes called microparticles or “ectosomes”); 
2) following the endocytic pathway, endosomal compartments develop invaginations that 
bud off into the endosomal lumen as small vesicles. The endosome is now called a 
multivesicular body (MVB). At this stage, the MVB may fuse with the lysosome for 
degradation and recycling of its contents. However, if the MVB fuses with the cell 
membrane, the vesicles within it are exocytically released as exosomes. 
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they retain sufficient cell-specific material to frequently allow identification of the cell type 
source of origin (Denzer et al. 2000; Bobryshev et al. 2001; Blanchard et al. 2002; Graner et al. 
2009; Skog et al. 2008). Given that these durable vesicles, when released by tumors, circulate 
in blood and are found at particularly high levels in patients with cancer (Taylor and Gercel-
Taylor 2008), exosomes and microvesicles are considered potential sources of biomarkers 
obtainable with minimally invasive procedures (Duijvesz et al. ; Krutovskikh and Herceg ; 
Simpson et al. 2009), including from urine (Dimov, Jankovic Velickovic, and Stefanovic 2009; 
Pisitkun, Johnstone, and Knepper 2006). 
 
 
Fig. 2. The topography of exosomes mimics that of the cell of origin. Depicted is a highly 
diagrammatic cartoon of exosome formation showing the endocytosis of transmembrane 
proteins (purple lines) in the context of the outer lipid layer of the plasma membrane 
(shown in red) and the inner lipid layer facing the cytosol (shown in blue). During 
endosome formation, the cytoplasmic portion of the membrane protein remains in the 
cytosol; as the endosomes fuse to become more mature structures, invaginations occur, 
resulting in the pinching off of small vesicles into the luminal space of the endosome. These 
smaller vesicles may be referred to as intravesicular bodies (“IVBs”) while the whole 
structure is denoted as a multi-vesicular body (“MVB”). The former intracellular domain of 
the transmembrane protein is now sequestered away from the cytosol; cytoplasmic contents 
also enter the IVB during formation (green dots). The typical fate of the MVB is fusion with 
a lysosome for content degradation and recycling. However, if the MVB instead fuses with 
the plasma membrane, the IVBs will be release extracellularly, and are now called 
“exosomes”. Note that the membrane topography (red/blue positioning) and 
transmembrane protein orientation are the same as that of the original cell. 
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The mechanisms driving vesicle formation (at the level of invagination into the endosomal 
lumen and in the direct “blebbing” from the cell surface) have many of the same driving 
components, particularly the ESCRT (Endosomal Sorting Complex Required for Transport) 
machinery including ALIX/AIP1 (de Gassart et al. 2004) and PI3 kinase and related 
molecules (Stoorvogel et al. 2002). Lipid composition is also a key factor, with structure-
altering, membrane-bending lipids playing key roles in the curvature-induced vesicular 
invaginations (Trajkovic et al. 2008; Subra et al. 2007; Laulagnier et al. 2005) . The acidic pH 
of the endosomal lumen also enhances lipid bending away from the limiting membrane 
(Subra et al. 2007) and the low pH of the tumor microenvironment likely has similar effects 
on microvesicle budding and extracellular activity of the vesicles (Giusti et al. 2008), 
including exosomes (Parolini et al. 2009). As lipid moieties such as the 
phosphoinositides/phosphoinositol phosphates (PIPs) and proteins such as the Rab proteins 
are important in intracellular vesicular identification and trafficking (Perret et al. 2005), it is 
not surprising that these entities also play significant roles in extracellular vesicle formation 
(Ostrowski et al. ; Hsu et al.)  Various membrane-fusion proteins of the SNARE families are 
also likely involved (Thery, Zitvogel, and Amigorena 2002). Thus, the intra- and 
extracellular environments, various lipid players, and numerous proteins involved in 
intracellular vesicle identity and function all play roles in the formation , intracellular 
targeting, and possibly extracellular targeting,  of exosomes and microvesicles.  
2.1 Basics of exosome/microvesicle cargo loading: filling up the fat balls 
The sorting process/cargo loading of exosomes and microvesicles is still largely a mystery; 
whether certain proteins are destined or chosen to become vesicle content or are “trapped” 
into them is not clear. However, some fundamental principles seem to hold. One of the most 
common protein post-translational modifications that results in a vesicular destination is 
ubiquitination, frequently from E3 ubiquitin ligase activities; this may be regulated to some 
extent by deubiquitination complexes such as signalosomes (Liu et al. 2009). Curiously, cells 
that are the recipients of exosomes may also activate ubiquitin ligases as part of the 
downstream effects of extracellular vesicle interactions (Qu et al. 2009). There are also likely 
ubiquitination-independent mechanisms for vesicular assimilation of proteins as well 
(Gauvreau et al. 2009); these may include potentially ESCRT- or Rab-driven incorporation of 
proteins into a “frustrated” recycling pathway where the proteins are neither returned to the 
cell surface nor directed toward the lysosome (de Gassart et al. 2004). Curiously, lipid 
sorting into such compartments is a function of the length and/or saturation of their alkyl 
tails (Mukherjee, Soe, and Maxfield 1999). LBPA, an unconventional negatively-charged 
phospholipid, is also sequestered to late endosomes/MVBs with a potential structural role 
(Matsuo et al. 2004). Since LBPA is mostly enriched in internal membranes, whether it plays 
a role in plasma membrane dynamics is unclear. Membrane partitioning such as lipid raft 
formation is also a key player in exosome and microvesicle biogenesis and sorting (de 
Gassart et al. 2003; Calzolari et al. 2006; Staubach, Razawi, and Hanisch 2009; Del Conde et 
al. 2005). Proteins contained within those lipid rafts are thus sorted to exosomes and 
microvesicles and include GPI-linked proteins such as acetylcholinesterase (Graner et al. 
2009), the NKG2D ligands MICA and MICB (Hedlund et al. 2009), Gce1 and CD73 (Muller et 
al. 2009), and CD55 and CD59 (Rabesandratana et al. 1998), etc. As mentioned above, the 
gangliosides GM1 and GM3 are also present in lipid membrane microdomains (Janich and 
Corbeil 2007) and in exosomes (de Gassart et al. 2003; Parolini et al. 2009). 
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Membrane proteins that are not necessarily typical constituents of lipid raft domains may 
shuttle into exosomes or membrane patches of microvesicles by aggregation, such as the 
transferrin receptor (de Gassart et al. 2004) or by “higher-order oligomerization” induced by 
antibody cross-linking at the cell surface, or by artificially acylation tagging of cytosolic 
proteins resulting in oligomerization and trafficking to released microvesicles (Fang et al. 
2007). Further studies have shown that a variety of membrane anchors can target proteins to 
exosomes and microvesicles, but not all with the same efficiency (Shen et al.). A number of 
other membrane proteins are typically found in exosomes and microvesicles and are 
hallmarks of them. These include members of the tetraspanin network such as CD9, CD9P-1 
TSPAN8, CD63, CD81, and CO-029 (Abache et al. 2007; Gesierich et al. 2006; Pols and 




Fig. 3. Functional analysis of the proteomic content of exosomes/microvesicles derived from 
D283MED medulloblastoma cells. Over 130 proteins were identified by extraction of 
proteins from vesicles, separation of the proteins on SDS-PAGE, excision of the bands from 
BioSafe Coomassie Blue-stained gels, and tryptic digest of the excised bands. Peptides were 
separated and analyzed by LC-MS/MS, and peptides were mapped or identified by de novo 
sequencing using PROWL and Sequest algorithms. Proteins were categorized with 
Ingenuity Pathway Analysis software and by literature searches focusing on known 
functions; please note that many of the proteins identified were multifunctional, and this 
categorization represents the preponderance of evidence for function based on present 
literature. 
Many cytosolic proteins (or at least many that are not widely recognized to have membrane 
associations) are exosome components; these include members of the heat shock protein 
(HSP) family, HSP/HSC70 and HSP90 in particular, and numerous metabolic enzymes. We 
have identified these proteins previously in proteomic studies of murine brain tumor 
exosomes and have cataloged and categorized them (Graner et al. 2009). We have performed 
further proteomic studies on human brain tumor exosomes (from the medulloblastoma cell 
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Corbeil 2007) and in exosomes (de Gassart et al. 2003; Parolini et al. 2009). 
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Membrane proteins that are not necessarily typical constituents of lipid raft domains may 
shuttle into exosomes or membrane patches of microvesicles by aggregation, such as the 
transferrin receptor (de Gassart et al. 2004) or by “higher-order oligomerization” induced by 
antibody cross-linking at the cell surface, or by artificially acylation tagging of cytosolic 
proteins resulting in oligomerization and trafficking to released microvesicles (Fang et al. 
2007). Further studies have shown that a variety of membrane anchors can target proteins to 
exosomes and microvesicles, but not all with the same efficiency (Shen et al.). A number of 
other membrane proteins are typically found in exosomes and microvesicles and are 
hallmarks of them. These include members of the tetraspanin network such as CD9, CD9P-1 
TSPAN8, CD63, CD81, and CO-029 (Abache et al. 2007; Gesierich et al. 2006; Pols and 




Fig. 3. Functional analysis of the proteomic content of exosomes/microvesicles derived from 
D283MED medulloblastoma cells. Over 130 proteins were identified by extraction of 
proteins from vesicles, separation of the proteins on SDS-PAGE, excision of the bands from 
BioSafe Coomassie Blue-stained gels, and tryptic digest of the excised bands. Peptides were 
separated and analyzed by LC-MS/MS, and peptides were mapped or identified by de novo 
sequencing using PROWL and Sequest algorithms. Proteins were categorized with 
Ingenuity Pathway Analysis software and by literature searches focusing on known 
functions; please note that many of the proteins identified were multifunctional, and this 
categorization represents the preponderance of evidence for function based on present 
literature. 
Many cytosolic proteins (or at least many that are not widely recognized to have membrane 
associations) are exosome components; these include members of the heat shock protein 
(HSP) family, HSP/HSC70 and HSP90 in particular, and numerous metabolic enzymes. We 
have identified these proteins previously in proteomic studies of murine brain tumor 
exosomes and have cataloged and categorized them (Graner et al. 2009). We have performed 
further proteomic studies on human brain tumor exosomes (from the medulloblastoma cell 
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line D283MED) which confirm and extend the results of the murine studies. In particular, 
metabolic enzymes represent the largest class of exosome proteins (Figure 3). While their 
prevalence may reflect their cellular abundance, there is a clear enrichment of these proteins 
in exosomes/microvesicles. 
2.2 Functions and activities of tumor exosomes/microvesicles: fun with fat balls 
Originally regarded as a means of cellular content disposal, particularly if cells lack 
lysosome activity (Johnstone et al. 1987; Johnstone, Bianchini, and Teng 1989) (ie, “garbage 
bags”), exosomes and microvesicles have an extensive and increasing list of activities, roles, 
and functions locally and systemically when released by tumors into the extracellular 
environment. Here we will briefly overview some of those better-characterized activities, 
most of which are regarded as beneficial to the tumor in terms of growth, invasion, or 
protection. 
2.2.1 Immunologic effects: floating fat balls as stimulators or suppressants? 
Exosome/microvesicle studies in tumors were originally driven by the idea that as tiny, 
non-replicating cellular surrogates, these vesicles could be used as cell-free anti-cancer 
vaccines. The premise was that exosomes and microvesicles contained tumor-specific 
antigens (Andre et al. 2002; Cho et al. 2005) as a source of adaptive immune cell targeting. In 
addition, exosomes/microvesicles contain heat shock proteins, known “danger signals” that 
both carry peptide antigens themselves as well as provide a potent, adjuvant-like stimulus 
to the innate and adaptive immune systems, particularly at the level of antigen presenting 
cells (Graner and Bigner 2005, 2006).  
2.2.1.1 Dendritic Cell Exosomes (“DEX”) 
The initial works using exosome-based vaccines utilized exosomes derived from antigen-
pulsed dendritic cells (DCs). DCs are perhaps the most effective “professional” antigen 
presenting cells known (Banchereau et al. 2000), and like all immune cells, one important 
means of extracellular communication for them is via the release of exosomes and 
microvesicles (Chaput et al. 2006). DCs process and present antigens to CD4+ and CD8+ T 
cells (“helper” cells and “cytotoxic or killer”/cytotoxic T lymphocyte/CTL cells, 
respectively), and if appropriately activated, will prime and stimulate the T cells for 
enhanced immune activities. From a clinical perspective, antigen-loaded and ex vivo 
activated DCs have been used in immunotherapy protocols as anti-cancer vaccines for a 
wide variety of tumor types and using an extraordinary range of antigen sources that are 
“pulsed” (applied to) the DCs (Palucka et al.). In general, in vitro (or ex vivo) DC production 
protocols are not standardized, require a great deal of hands-on time and effort, and the 
resulting cell preparations can be difficult to freeze and recover from thawing for  repeated 
patient treatment (de Vries et al. 2005; Kalinski et al. 2009; Simon, Fonteneau, and Gregoire 
2009). Exosomes and microvesicles from DCs (sometimes called “dexosomes” or “DEX”) can 
be harvested from the culture supernatants, stored frozen, and thawed without loss of 
stimulating activity. They can be injected into hosts as cell-free DC-type vaccines capable of 
stimulating anti-tumor responses. These DEX were the first exosome-based vaccines 
(Zitvogel et al. 1998); DEX are capable of transferring antigen-loaded major 
histocompatibility class I molecules (MHC I) to recipient DCs for priming of naïve T cells in 
the host (Andre et al. 2004). These DC-derived vesicles were produced in a large-scale GMP 
setting (Lamparski et al. 2002) and were used to treat patients with metastatic melanoma in 
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a clinical trial; the vaccines were safe, feasible, and produced  one partial response with 
signs of specific immunity (Escudier et al. 2005). Another trial for patients with non-small 
cell lung cancer achieved similar results with some patients maintaining stable disease 
(Morse et al. 2005). As is the case for most immunotherapies, more work is needed on 
disabling the tumor-induced immune suppression and perhaps choosing patients with less 
tumor burden and lower stage, less advanced cancers to improve responses and outcomes. 
Nonetheless, the safety and feasibility of DEX as clinically-usable entities is evident; further 
advances in safe and tolerable immune stimulation, and the means to “suppression the 
suppression” of immunity driven by tumors are desperately needed. 
2.2.1.2 Tumor-derived Exosomes (“TEX”) 
Tumor-derived exosomes (sometimes call “TEX”) also have a history as vaccine material; as 
mentioned above, their antigen content and HSP-based adjuvant effects theoretically make 
them ideal cancer vaccines. This has proven true in a number of animal models of cancer 
(Altieri, Khan, and Tomasi 2004; Dai et al. 2005; Chen, Wang et al. 2006; Bu et al. 2006; Cho 
et al. 2009; Graner et al. 2009). One clinical trial performed in China using autologous tumor-
derived (from ascites fluid of colorectal cancer patients) combined (or not) with the immune 
stimulant GM-CSF has been reported. One patient treated with both TEX and GM-CSF had 
stable disease, and another in that group had a partial response.  In immune assays, 
delayed-type hypersensitivity (DTH) reactions were seen in patients immunized above a 
threshold amount, and selected patients had positive CTL assays (tetramer staining, 
cytotoxicity, interferon-gamma (IFN) release). No serious adverse events were reported 
(Dai et al. 2008). This trial seemed to bear out results from animal models. However, much 
of our current thought regarding TEX immunology is dominated by the pervading opinion 
that tumor-derived exosomes are purveyors of immune suppression thru increased 
regulatory T cell (Treg) activity, myeloid-derived suppressor cell activity, and suppression 
of activated T cells, natural killer (NK) cells, and inhibiting DC maturation (Taylor and 
Gercel-Taylor 2005; Liu et al. 2006; Valenti et al. 2007; Ichim et al. 2008; Xiang et al. 2009; 
Szajnik et al.). There is also evidence that TEX can prevent the binding of anti-tumor 
antibodies to their tumor-expressed target by essentially titrating out the antibodies, thus 
preventing antibody-dependent cellular cytotoxicity (ADCC) (Battke et al.). While a few of 
these studies have been performed in in vivo settings, most of the data are from human cells 
in in vitro assays. Thus, the complex interplay of in vivo and systemic immunity and immune 
suppression may be poorly represented in these assays, and our results in this area will be 
discussed later. 
2.2.2 Coagulation and thrombosis: fat balls and clotting 
Microvesicles, especially those derived from platelets, have long been known as 
procoagulant players in clot formation, particularly when the vesicles carry tissue factor (TF) 
(Freyssinet and Toti). There is an increasing awareness that microvesicles may also have 
roles in some of the thrombotic events that can occur in cancer (Aharon and Brenner 2009; 
Castellana, Kunzelmann, and Freyssinet 2009) indicating an interplay between microvesicles 
from other “normal” cell types such as platelets reacting with cancer cells. However, tumor-
derived exosomes and microvesicles are also likely involved in this cellular cross-talk as 
well (Milsom et al. 2008), with the potential for coagulation to aid in delivery of growth 
factors or other stimuli to tumor cells. Tumor-derived microvesicles are believed to be partly 
responsible for Trousseau’s syndrome, a coagulopathy associated with the cancerous state 
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line D283MED) which confirm and extend the results of the murine studies. In particular, 
metabolic enzymes represent the largest class of exosome proteins (Figure 3). While their 
prevalence may reflect their cellular abundance, there is a clear enrichment of these proteins 
in exosomes/microvesicles. 
2.2 Functions and activities of tumor exosomes/microvesicles: fun with fat balls 
Originally regarded as a means of cellular content disposal, particularly if cells lack 
lysosome activity (Johnstone et al. 1987; Johnstone, Bianchini, and Teng 1989) (ie, “garbage 
bags”), exosomes and microvesicles have an extensive and increasing list of activities, roles, 
and functions locally and systemically when released by tumors into the extracellular 
environment. Here we will briefly overview some of those better-characterized activities, 
most of which are regarded as beneficial to the tumor in terms of growth, invasion, or 
protection. 
2.2.1 Immunologic effects: floating fat balls as stimulators or suppressants? 
Exosome/microvesicle studies in tumors were originally driven by the idea that as tiny, 
non-replicating cellular surrogates, these vesicles could be used as cell-free anti-cancer 
vaccines. The premise was that exosomes and microvesicles contained tumor-specific 
antigens (Andre et al. 2002; Cho et al. 2005) as a source of adaptive immune cell targeting. In 
addition, exosomes/microvesicles contain heat shock proteins, known “danger signals” that 
both carry peptide antigens themselves as well as provide a potent, adjuvant-like stimulus 
to the innate and adaptive immune systems, particularly at the level of antigen presenting 
cells (Graner and Bigner 2005, 2006).  
2.2.1.1 Dendritic Cell Exosomes (“DEX”) 
The initial works using exosome-based vaccines utilized exosomes derived from antigen-
pulsed dendritic cells (DCs). DCs are perhaps the most effective “professional” antigen 
presenting cells known (Banchereau et al. 2000), and like all immune cells, one important 
means of extracellular communication for them is via the release of exosomes and 
microvesicles (Chaput et al. 2006). DCs process and present antigens to CD4+ and CD8+ T 
cells (“helper” cells and “cytotoxic or killer”/cytotoxic T lymphocyte/CTL cells, 
respectively), and if appropriately activated, will prime and stimulate the T cells for 
enhanced immune activities. From a clinical perspective, antigen-loaded and ex vivo 
activated DCs have been used in immunotherapy protocols as anti-cancer vaccines for a 
wide variety of tumor types and using an extraordinary range of antigen sources that are 
“pulsed” (applied to) the DCs (Palucka et al.). In general, in vitro (or ex vivo) DC production 
protocols are not standardized, require a great deal of hands-on time and effort, and the 
resulting cell preparations can be difficult to freeze and recover from thawing for  repeated 
patient treatment (de Vries et al. 2005; Kalinski et al. 2009; Simon, Fonteneau, and Gregoire 
2009). Exosomes and microvesicles from DCs (sometimes called “dexosomes” or “DEX”) can 
be harvested from the culture supernatants, stored frozen, and thawed without loss of 
stimulating activity. They can be injected into hosts as cell-free DC-type vaccines capable of 
stimulating anti-tumor responses. These DEX were the first exosome-based vaccines 
(Zitvogel et al. 1998); DEX are capable of transferring antigen-loaded major 
histocompatibility class I molecules (MHC I) to recipient DCs for priming of naïve T cells in 
the host (Andre et al. 2004). These DC-derived vesicles were produced in a large-scale GMP 
setting (Lamparski et al. 2002) and were used to treat patients with metastatic melanoma in 
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a clinical trial; the vaccines were safe, feasible, and produced  one partial response with 
signs of specific immunity (Escudier et al. 2005). Another trial for patients with non-small 
cell lung cancer achieved similar results with some patients maintaining stable disease 
(Morse et al. 2005). As is the case for most immunotherapies, more work is needed on 
disabling the tumor-induced immune suppression and perhaps choosing patients with less 
tumor burden and lower stage, less advanced cancers to improve responses and outcomes. 
Nonetheless, the safety and feasibility of DEX as clinically-usable entities is evident; further 
advances in safe and tolerable immune stimulation, and the means to “suppression the 
suppression” of immunity driven by tumors are desperately needed. 
2.2.1.2 Tumor-derived Exosomes (“TEX”) 
Tumor-derived exosomes (sometimes call “TEX”) also have a history as vaccine material; as 
mentioned above, their antigen content and HSP-based adjuvant effects theoretically make 
them ideal cancer vaccines. This has proven true in a number of animal models of cancer 
(Altieri, Khan, and Tomasi 2004; Dai et al. 2005; Chen, Wang et al. 2006; Bu et al. 2006; Cho 
et al. 2009; Graner et al. 2009). One clinical trial performed in China using autologous tumor-
derived (from ascites fluid of colorectal cancer patients) combined (or not) with the immune 
stimulant GM-CSF has been reported. One patient treated with both TEX and GM-CSF had 
stable disease, and another in that group had a partial response.  In immune assays, 
delayed-type hypersensitivity (DTH) reactions were seen in patients immunized above a 
threshold amount, and selected patients had positive CTL assays (tetramer staining, 
cytotoxicity, interferon-gamma (IFN) release). No serious adverse events were reported 
(Dai et al. 2008). This trial seemed to bear out results from animal models. However, much 
of our current thought regarding TEX immunology is dominated by the pervading opinion 
that tumor-derived exosomes are purveyors of immune suppression thru increased 
regulatory T cell (Treg) activity, myeloid-derived suppressor cell activity, and suppression 
of activated T cells, natural killer (NK) cells, and inhibiting DC maturation (Taylor and 
Gercel-Taylor 2005; Liu et al. 2006; Valenti et al. 2007; Ichim et al. 2008; Xiang et al. 2009; 
Szajnik et al.). There is also evidence that TEX can prevent the binding of anti-tumor 
antibodies to their tumor-expressed target by essentially titrating out the antibodies, thus 
preventing antibody-dependent cellular cytotoxicity (ADCC) (Battke et al.). While a few of 
these studies have been performed in in vivo settings, most of the data are from human cells 
in in vitro assays. Thus, the complex interplay of in vivo and systemic immunity and immune 
suppression may be poorly represented in these assays, and our results in this area will be 
discussed later. 
2.2.2 Coagulation and thrombosis: fat balls and clotting 
Microvesicles, especially those derived from platelets, have long been known as 
procoagulant players in clot formation, particularly when the vesicles carry tissue factor (TF) 
(Freyssinet and Toti). There is an increasing awareness that microvesicles may also have 
roles in some of the thrombotic events that can occur in cancer (Aharon and Brenner 2009; 
Castellana, Kunzelmann, and Freyssinet 2009) indicating an interplay between microvesicles 
from other “normal” cell types such as platelets reacting with cancer cells. However, tumor-
derived exosomes and microvesicles are also likely involved in this cellular cross-talk as 
well (Milsom et al. 2008), with the potential for coagulation to aid in delivery of growth 
factors or other stimuli to tumor cells. Tumor-derived microvesicles are believed to be partly 
responsible for Trousseau’s syndrome, a coagulopathy associated with the cancerous state 
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(Varki 2007); the involvement of tumor vesicles likely involves the presence of TF on their 
surfaces (Del Conde et al. 2007). These studies further indicate the systemic roles that tumor 
cell-derived vesicles may play in cancer growth, progression, and generation of other co-
morbidities in cancer patients. 
2.2.3 Signaling capacity:  influential fat balls 
Exosomes and microvesicles are carriers of protein and lipid molecules with direct and 
indirect signaling capacities and complexes (Record et al. ; Zumaquero et al.) including 
members of the EGFR family (Sanderson et al. 2008) including Her2/Neu/ErbB2 (EGFR2) 
(Ciravolo et al.) and the tumor-specific mutant EGRFvIII (Graner et al. 2009; Al-Nedawi et 
al. 2008). Importantly, both EGFR and EGFRvIII may actually passage from exosomes to 
recipient cells, leading to activation of those pathways with phenotypic changes induced in 
the recipient cells (Al-Nedawi et al. 2009). In addition, tumor exosomes and microvesicles 
also carry active EGFR ligands such as amphiregulin (Higginbotham et al.), thus indicating 
that the vesicles can carry not only the signal transducer, but the signal as well. 
Much of the signaling in cancer cells is devoted to proliferative drive. Exosomes and 
microvesicles are known to drive proliferation of tumor cells that are exposed to the vesicles 
(Koga et al. 2005; Skog et al. 2008); we have seen similar proliferation when pediatric and 
adult brain tumor cells are exposed to their endogenous exosomes (data not shown). 
Exosome-driven proliferation has been associated with the presence of the anti-apoptotic 
protein survivin in tumor exosomes (Khan et al.), and in a potential recruitment 
phenomenon, tumor microvesicles can enhance endothelial cell proliferation (Hong et al. 
2009) which presumably may promote tumor vascularization. The mechanisms behind these 
proliferative responses are not clear, although we have evidence that exosomes increase 
overall glycolytic metabolism of recipient cells (see below) which may be either a cause for 
cell growth or a means to abet it. To further complicate the issue, there is at least one report 
in the literature of tumor exosomes/microvesicles inducing apoptosis in the recipient tumor 
cells (Ristorcelli et al. 2008), so it is possible that exosome effects may be cell-type or cell 
context specific. 
2.2.4 RNA transport:  fat balls as diplomatic satchels 
As noted above (Figure 3) exosome/microvesicle proteomics revealed a relatively high 
percentage of RNA binding proteins typically present in exosomes. Since the biogenesis of 
exosomes and microvesicles intersects with some pathways of intercellular transmission of 
viruses, particularly at the levels of endosome (de Gassart et al. 2004; Mercer, Schelhaas, and 
Helenius) (also, see below), researchers began asking if exosomes and microvesicles 
themselves might have actual viral qualities, such as the ability to transport and transfer 
RNA molecules to recipient cells. This was first answered by Valadi et al (Valadi et al. 2007) 
when they demonstrated that exosomes did indeed possess both messenger and micro 
RNAs (mRNAs, miRNAs). Encapsulated in the vesicles, these RNAs were highly resistant to 
degradation by RNAses; furthermore, they demonstrated that mRNAs from one cell type 
could be passaged to another cell type, even of a different species (ie, mouse to human) 
resulting in translation of at least some of those messages (ie, humans cells now making 
mouse proteins). The numbers of mRNAs in exosomes/microvesicles and the genes 
represented by them are impressive (Mathivanan, Ji, and Simpson). One study involving 
brain tumor exosomes/microvesicles found that essentially the entire mRNA “expressome” 
is present in the population of collected vesicles, but there was significant enrichment for 
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certain mRNAs in exosomes/microvesicles that did not mirror the mRNA expression 
distributions from cells of origin (Skog et al. 2008). This type of horizontal transmission of 
epigenetic materials exists with normal cell types (Ogawa et al.) and even with viable tissues 
in culture (Aliotta et al.) as well as with tumor cells communicating with normal cells (Hong 
et al. 2009). 
microRNAs are recently-discovered small (22-25 nucleotide) non-coding RNAs that have 
potent regulatory potential (Carrington and Ambros 2003). miRNAs act as silencing RNAs, 
binding in an antisense fashion to regions of the 3’ untranslated regions (3’ UTRs) of 
mRNAs, resulting in either destabilization and degradation of the message, or prevention of 
translation; the net effect is translational repression of the message (Nelson et al. 2003). 
Following the discovery of miRNAs in exosomes (Valadi et al. 2007) there has been an 
explosion in the study of miRNAs in exosomes/microvesicles (for example, (Taylor and 
Gercel-Taylor 2008; Hunter et al. 2008; Rosell, Wei, and Taron 2009; Luo et al. 2009; Kosaka 
et al. ; Wang et al.)). There has been a particular emphasis on using circulating miRNAs (ie, 
those present in patient blood/serum) as disease biomarkers, presumably in the form of 
circulating exosomes/microvesicles (Rabinowits et al. 2009; Michael et al. ; De Smaele, 
Ferretti, and Gulino ; Kosaka, Iguchi, and Ochiya ; Wittmann and Jack ; Corcoran et al.). 
Thus, messenger and micro RNAs, when delivered to cells in the context of exosomes and 
microvesicles, have the potential to almost act virally by passaging epigenetic materials that 
could alter the phenotypes of the recipient cells. This represents an extraordinary form of 
extracellular communication, with vesicles as either mechanisms for delivery of RNAs, or 
perhaps as reservoirs to rapidly dispose of the RNA messages or regulatory activities. As 
biomarkers, the major advantage of such “circulating” RNAs over proteins or other subjects 
of molecular diagnostics is the ability to amplify the nucleic acid signal using PCR-based 
techniques, providing both increased signal and high specificity for the same biomarker, 
and relatively cheaply compared to some of the mass spectrometry or NMR methods 
needed for protein and metabolite markers. 
2.2.5 Passage of pathogens / pathogenic entities: fat balls gone bad 
As alluded above, the association of virus internalization, component packaging, and release 
in association with vesicles of the MVB and endosomal complexes or membrane lipid raft 
regions (Calistri et al. 2009) has prompted study of relationships between viruses and 
exosomes/microvesicles. For Human Immunodeficiency Virus (HIV), it has been proposed 
that the virus may hijack the system and egress from the cells via the plasma membrane 
microvesicle pathway (Booth et al. 2006) and from the exosome pathway (Nguyen et al. 
2003), leading to the “Trojan exosome” hypothesis (Gould, Booth, and Hildreth 2003). 
However, this concept remains controversial (Coren, Shatzer, and Ott 2008). Epstein-Barr 
Virus (EBV) has been another well-studied virus in the exosome/microvesicle field, where it 
was first noticed that the EBV protein LMP1 appears in exosomes from EBV-infected cells 
(Flanagan, Middeldorp, and Sculley 2003; Keryer-Bibens et al. 2006). The presence of LMP1 
and the immunomodulatory protein galectin-9 in exosomes derived from infected cells are 
implicated in immune suppression of NK and T cells, particularly affecting the 
inflammatory Th1-type responses (Dukers et al. 2000; Klibi et al. 2009). Hepatitis B and C 
viruses (HBV, HCV) are embedded in the etiology of hepatocellular carcinomas; envelope 
proteins from these viruses appear in exosomes from infected cells, and HBV requires MVBs 
for production of enveloped virons while subviral particles are released differently 
(Masciopinto et al. 2004; Watanabe et al. 2007). Human Herpes Virus 6 (HHV-6), an 
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(Varki 2007); the involvement of tumor vesicles likely involves the presence of TF on their 
surfaces (Del Conde et al. 2007). These studies further indicate the systemic roles that tumor 
cell-derived vesicles may play in cancer growth, progression, and generation of other co-
morbidities in cancer patients. 
2.2.3 Signaling capacity:  influential fat balls 
Exosomes and microvesicles are carriers of protein and lipid molecules with direct and 
indirect signaling capacities and complexes (Record et al. ; Zumaquero et al.) including 
members of the EGFR family (Sanderson et al. 2008) including Her2/Neu/ErbB2 (EGFR2) 
(Ciravolo et al.) and the tumor-specific mutant EGRFvIII (Graner et al. 2009; Al-Nedawi et 
al. 2008). Importantly, both EGFR and EGFRvIII may actually passage from exosomes to 
recipient cells, leading to activation of those pathways with phenotypic changes induced in 
the recipient cells (Al-Nedawi et al. 2009). In addition, tumor exosomes and microvesicles 
also carry active EGFR ligands such as amphiregulin (Higginbotham et al.), thus indicating 
that the vesicles can carry not only the signal transducer, but the signal as well. 
Much of the signaling in cancer cells is devoted to proliferative drive. Exosomes and 
microvesicles are known to drive proliferation of tumor cells that are exposed to the vesicles 
(Koga et al. 2005; Skog et al. 2008); we have seen similar proliferation when pediatric and 
adult brain tumor cells are exposed to their endogenous exosomes (data not shown). 
Exosome-driven proliferation has been associated with the presence of the anti-apoptotic 
protein survivin in tumor exosomes (Khan et al.), and in a potential recruitment 
phenomenon, tumor microvesicles can enhance endothelial cell proliferation (Hong et al. 
2009) which presumably may promote tumor vascularization. The mechanisms behind these 
proliferative responses are not clear, although we have evidence that exosomes increase 
overall glycolytic metabolism of recipient cells (see below) which may be either a cause for 
cell growth or a means to abet it. To further complicate the issue, there is at least one report 
in the literature of tumor exosomes/microvesicles inducing apoptosis in the recipient tumor 
cells (Ristorcelli et al. 2008), so it is possible that exosome effects may be cell-type or cell 
context specific. 
2.2.4 RNA transport:  fat balls as diplomatic satchels 
As noted above (Figure 3) exosome/microvesicle proteomics revealed a relatively high 
percentage of RNA binding proteins typically present in exosomes. Since the biogenesis of 
exosomes and microvesicles intersects with some pathways of intercellular transmission of 
viruses, particularly at the levels of endosome (de Gassart et al. 2004; Mercer, Schelhaas, and 
Helenius) (also, see below), researchers began asking if exosomes and microvesicles 
themselves might have actual viral qualities, such as the ability to transport and transfer 
RNA molecules to recipient cells. This was first answered by Valadi et al (Valadi et al. 2007) 
when they demonstrated that exosomes did indeed possess both messenger and micro 
RNAs (mRNAs, miRNAs). Encapsulated in the vesicles, these RNAs were highly resistant to 
degradation by RNAses; furthermore, they demonstrated that mRNAs from one cell type 
could be passaged to another cell type, even of a different species (ie, mouse to human) 
resulting in translation of at least some of those messages (ie, humans cells now making 
mouse proteins). The numbers of mRNAs in exosomes/microvesicles and the genes 
represented by them are impressive (Mathivanan, Ji, and Simpson). One study involving 
brain tumor exosomes/microvesicles found that essentially the entire mRNA “expressome” 
is present in the population of collected vesicles, but there was significant enrichment for 
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certain mRNAs in exosomes/microvesicles that did not mirror the mRNA expression 
distributions from cells of origin (Skog et al. 2008). This type of horizontal transmission of 
epigenetic materials exists with normal cell types (Ogawa et al.) and even with viable tissues 
in culture (Aliotta et al.) as well as with tumor cells communicating with normal cells (Hong 
et al. 2009). 
microRNAs are recently-discovered small (22-25 nucleotide) non-coding RNAs that have 
potent regulatory potential (Carrington and Ambros 2003). miRNAs act as silencing RNAs, 
binding in an antisense fashion to regions of the 3’ untranslated regions (3’ UTRs) of 
mRNAs, resulting in either destabilization and degradation of the message, or prevention of 
translation; the net effect is translational repression of the message (Nelson et al. 2003). 
Following the discovery of miRNAs in exosomes (Valadi et al. 2007) there has been an 
explosion in the study of miRNAs in exosomes/microvesicles (for example, (Taylor and 
Gercel-Taylor 2008; Hunter et al. 2008; Rosell, Wei, and Taron 2009; Luo et al. 2009; Kosaka 
et al. ; Wang et al.)). There has been a particular emphasis on using circulating miRNAs (ie, 
those present in patient blood/serum) as disease biomarkers, presumably in the form of 
circulating exosomes/microvesicles (Rabinowits et al. 2009; Michael et al. ; De Smaele, 
Ferretti, and Gulino ; Kosaka, Iguchi, and Ochiya ; Wittmann and Jack ; Corcoran et al.). 
Thus, messenger and micro RNAs, when delivered to cells in the context of exosomes and 
microvesicles, have the potential to almost act virally by passaging epigenetic materials that 
could alter the phenotypes of the recipient cells. This represents an extraordinary form of 
extracellular communication, with vesicles as either mechanisms for delivery of RNAs, or 
perhaps as reservoirs to rapidly dispose of the RNA messages or regulatory activities. As 
biomarkers, the major advantage of such “circulating” RNAs over proteins or other subjects 
of molecular diagnostics is the ability to amplify the nucleic acid signal using PCR-based 
techniques, providing both increased signal and high specificity for the same biomarker, 
and relatively cheaply compared to some of the mass spectrometry or NMR methods 
needed for protein and metabolite markers. 
2.2.5 Passage of pathogens / pathogenic entities: fat balls gone bad 
As alluded above, the association of virus internalization, component packaging, and release 
in association with vesicles of the MVB and endosomal complexes or membrane lipid raft 
regions (Calistri et al. 2009) has prompted study of relationships between viruses and 
exosomes/microvesicles. For Human Immunodeficiency Virus (HIV), it has been proposed 
that the virus may hijack the system and egress from the cells via the plasma membrane 
microvesicle pathway (Booth et al. 2006) and from the exosome pathway (Nguyen et al. 
2003), leading to the “Trojan exosome” hypothesis (Gould, Booth, and Hildreth 2003). 
However, this concept remains controversial (Coren, Shatzer, and Ott 2008). Epstein-Barr 
Virus (EBV) has been another well-studied virus in the exosome/microvesicle field, where it 
was first noticed that the EBV protein LMP1 appears in exosomes from EBV-infected cells 
(Flanagan, Middeldorp, and Sculley 2003; Keryer-Bibens et al. 2006). The presence of LMP1 
and the immunomodulatory protein galectin-9 in exosomes derived from infected cells are 
implicated in immune suppression of NK and T cells, particularly affecting the 
inflammatory Th1-type responses (Dukers et al. 2000; Klibi et al. 2009). Hepatitis B and C 
viruses (HBV, HCV) are embedded in the etiology of hepatocellular carcinomas; envelope 
proteins from these viruses appear in exosomes from infected cells, and HBV requires MVBs 
for production of enveloped virons while subviral particles are released differently 
(Masciopinto et al. 2004; Watanabe et al. 2007). Human Herpes Virus 6 (HHV-6), an 
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immunosuppressive, neurotropic virus, also has associations with hematologic and CNS 
malignancies (Ogata 2009; Saddawi-Konefka and Crawford). As with other viruses, mature 
virons in infected cells were found in MVB-like compartments and released in exosome-like 
vesicles. It is not known if these viron-containing exosomes are infectious, but the 
implications of infection and immune suppression aiding tumor take and progression are 
obvious. Finally, Cytomegalovirus (CMV) has become an increasingly interesting associate 
in high grade gliomas (Cobbs et al. 2002; Mitchell et al. 2008; Dziurzynski et al.). Exosomes 
from CMV infected cells contain CMV antigens (eg, gB) that are capable of stimulating 
CD4+ memory T cells (Walker, Maier, and Pober 2009), and while CMV DNA was amplified 
from glioblastoma (GBM) patient peripheral blood in one study (Mitchell et al. 2008), no 
CMV DNA was detected in another similar (but smaller) study (Lehrer et al.). However, 
neither of these studies used patient serum exosomes as target materials. In a proteomic 
study of murine SMA-560 brain tumor cell-derived exosomes, we identified the gag 
polyprotein pr65 and its precursor (Graner et al. 2009); these proteins originate from an 
endogenous murine retrovirus implicated in the progression of murine melanoma by 
subversion of immune surveillance (Mangeney et al. 2005). Thus, there remain many 
implications of viruses, virons, or viral particles/pieces in circulating tumor exosomes either 
as immune targets (potential antigens) or as further purveyors of immune suppression. 
The roles of exosomes/microvesicles in bacterial diseases are less well studied, but there 
have been significant works in the mycobacter area. Exosomes from macrophage infected 
with Mycobacterium avium display antigens such as glycolipids from that pathogen. These 
exosomes provide pro-inflammatory signals to resting macrophage (Bhatnagar and Schorey 
2007), as is true of exosomes from a number of pathogenically infected macrophage both in 
vitro and in vivo (Bhatnagar et al. 2007). However, while exosomes from Mycobacterium 
tuberculosis-infected macrophage contain proteomically-identified TB proteins/antigens 
(Giri et al.), exosomes from MTB-infected macrophage can actually suppress activation of 
naïve macrophage (Singh et al.). While the similarities, particularly immune relationships, 
between cancer and MTB infection have not gone unnoticed (Broxmeyer 2004; Schorey and 
Bhatnagar 2008; Cocito and Maes 1998), the roles of exosomes and microvesicles in these 
diseases likely remains complex. 
Another intriguing (and perhaps frightening) role played by exosomes and microvesicles is 
in the neurodegenerative disease arena. Experimentally, prion diseases such as scrapie have 
been shown to be transmissible from infected cells (those with the prion protein, PrP, 
misfolded into the scrapie form, PrPsc) to uninfected cells by application of exosomes from 
the infected cells to the uninfected cells. PrPsc was found in the exosomes from the infected 
cells, and these cells initiated scrapie when injected into mice (Fevrier et al. 2004). PrP is a 
GPI-linked protein (Miesbauer et al.), and as mentioned above, membrane proteins with this 
lipid anchor are frequently sorted into lipid rafts that become part of the IVBs within MVBs, 
and eventually become exosomes. It is uncertain whether PrP converts to PrPsc in/on 
exosomes (Fevrier et al. 2005) but abnormal folding makes it a candidate for ubiquitination 
and thus sorting into MVBs/IVBs. Blood is considered the most common bodily fluid of 
transmission, but another study showed that at least the naturally occurring PrP protein is 
present in pseudo-afferent lymph fluid, and is preferentially enriched in CSF from sheep 
(Vella et al. 2008). Thus, there may be a neuronal reservoir for PrP (and PrPsc or other 
transmissible infectious prion forms) in exosomes found in CSF. For another 
neurodegenerative disease, Alzheimer’s disease (AD), the etiology is believed to be related 
to the cleavage of cell surface amyloid precursor protein APP by  and -secretases, 
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resulting in formation of a peptide called A. Rajendran et al (Rajendran et al. 2006) found 
that from cells transfected with expression vectors for APP, they could find A peptides in 
the extracellular medium in the context of exosomes. The cells processed APP to A 
endosomally, with A ending up in MVBs and extracellularly with exosomes.  In 
immunoelectron microscopy sections of brains from afflicted patients, AD plaques 
contained exosome-associated proteins (eg, ALIX), further suggesting the role of MVBs and 
the potential for exosome involvement in the disease. Exosomes from cells expressing APP 
were found to contain a number of the secretases necessary for processing of APP into its 
secreted form, as well as the different C-terminal forms of cleaved APP, as well as A itself 
(Sharples et al. 2008). -secretase inhibition resulted in less A accumulation in exosomes, 
suggesting a potential therapeutic approach, but also suggesting the biomarker potential of 
A in exosomes to diagnose AD. Thus, not only can pathogenic organisms utilize the 
exosome/microvesicle pathways for infectious transmission, disease “particles” may utilize 
them as well to passage from infected or diseased cells to unaffected cells, a novel form of 
transmission that does not require cell-to-cell contact. 
2.2.6 Drug Efflux: fat balls as HazMat crews 
In our proteomic analyses of medulloblastoma exosomes, transporter molecules constituted 
> 10% of the proteins identified (see Figure 3). Thus, it may not be surprising that 
exosomes/microvesicles may be exit vehicles for chemotherapeutic agents applied to cancer 
cells as a mechanism of resistance. A cisplatin-insensitive ovarian carcinoma cell subline was 
found to have greatly reduced lysosome size and activity compared to its cisplatin-sensitive 
original line, and that insensitive line produced more exosomes than the parent line (Safaei 
et al. 2005). Those exosomes contained a number of lysosomal markers as well as transport 
molecules. When the insensitive line was treated with cisplatin,  2.5 fold more drug was 
effluxed from the insensitive line than the sensitive one, and at least a portion of that was 
found in the insoluble exosome pellet from the spent culture medium. Chen et al (Chen, 
Posada et al. 2006) further implicated the endosomal/MVB pathway for egress of 
doxorubicin, demonstrating a role for VPS4a in MVB and exosome function and packaging 
of drug. There may also be a role for microvesicle-based drug efflux, since the plasma 
membrane plays a role in resistance to doxorubicin in the K562 leukemia cell line used in 
these studies (Chen et al. 2007). While exosomes and microvesicles may provide drug 
resistance mechanisms for tumor cells, one must also consider the possibility that in normal 
cells, exosomes/microvesicles may perform similar cellular detoxification roles to remove 
noxious small molecule compounds to protect normal cells, as well. 
2.3 Summary 
Exosomes and microvesicles are akin to miniature versions of the cell itself, possessing 
lipids, proteins, and even RNAs from the originating cell; some even refer to exosomes 
and microvesicles as “extracellular organelles”. These extracellular vesicles are intimately 
involved in the extracellular local and distal cross-talk between and amongst cell, tissues, 
and organs, and have a variety of functions associated with them. In particular, the 
relationships between cancer cells and associated “normal” cells, such as those of 
the endothelium, the microenvironment, and immune system, are all profoundly 
mutually influenced by these secreted vesicles in ways we are only slowly beginning to 
understand. 
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3. Brain tumor exosomes and microvesicles: fat balls on the brain 
The primary literature on brain tumor extracellular vesicles is amazingly small (Graner, 
Cumming, and Bigner 2007; Al-Nedawi et al. 2008; Skog et al. 2008; Graner et al. 2009; 
Guescini, Genedani et al. ; Yang et al.), although one of the early microvesicle papers used C-6 
rat glioma cells and called their vesicular entities “exosomes”, but by current standards the 
vesicles would be called microvesicles or microparticles (Trams et al. 1981; Johnstone 2006). 
Our group was arguably the first to identify bona fide brain tumor exosomes, despite some 20 
years of previous study. Brain tumor exosomes and microvesicles appear structurally and 
proteomically like such vesicles from other cell/tumor types in culture, and from the sera of 
patients with diverse tumors (Graner, Cumming, and Bigner 2007; Graner et al. 2009; Al-
Nedawi et al. 2008; Skog et al. 2008). One difference has been that exosomes from both adult 
gliomas and pediatric medulloblastomas have proven extremely resilient to lysis and 
extraction (Graner et al. 2009) (M Graner, unpublished; Johan Skog, personal communication), 
making protein analysis in particular rather difficult. Another interesting feature is the 
putative presence of mitochondrial DNA contained within (and perhaps on the surface of) 
glioma cell line extracellular vesicles (Guescini, Genedani et al.), which has also been seen in 
murine myoblast vesicles as reported by the same group (Guescini, Guidolin et al.) ; this 
finding runs counter to other groups‘ findings (Valadi et al. 2007) and will likely be somewhat 
controversial. However, given the high glycolytic capacity of gliomas and the distressed and 
non-uniform appearance and activities of their mitochondria (Oudard et al. 1996; Oudard et al. 
1997; Ordys et al. ; Santandreu et al. 2008), relationships between exosomes and mitochondria 
in cancer cells could potentially be an area of fruitful and energetic study. In the next sections 
we will discuss the broad range signaling abilities, metabolic effects, and immunological 
properties of brain tumor exosomes/microvesicles, as well as the exosome-induced migratory 
and protective phenotypes cells experience upon exposure to exosomes. 
3.1 Brain tumor exosomes drive various activities in recipient cells: fat balls as game-
changers 
High grade gliomas such as glioblastomas (GBMs) are extremely heterogeneous with 
respect to cellular appearances and phenotypes, chromosomal abnormalities, gene and 
protein expression, etc, but almost universally share a lack of response to treatment 
(Mischel, Cloughesy, and Nelson 2004) whether the treatment is chemical, radiologic, or 
immunologic. Another commonality amongst GBMs is their extraordinary invasive 
potential that inevitably leads to tumor recurrence and patient demise (Hoelzinger, Demuth, 
and Berens 2007). Below we will describe mechanisms by which exosomes and 
microvesicles may contribute to these most nefarious features of high grade gliomas. 
3.1.1 Brain tumor exosomes and EGFR signaling: fat balls carry the mail 
The epidermal growth factor receptor (EGFR) has a long history as a major player and 
therapeutic target in brain tumors and many other tumors as well (Hatanpaa et al. ; Ye, Gao, 
and Cai ; Brandes et al. 2008; Vivanco and Mellinghoff ; Yarden 2001). Perhaps the most 
prominent mutation in EGFR in gliomas is the variant (either genomically mutated/encoded 
or resulting from a splice-site mutation and alternate usage) that eliminates exons 2-7 to yield 
“delta 2-7 EGFR” or “EGFR variant III” (EGFRvIII), reviewed in (Wikstrand et al. 1998; 
Pedersen et al. 2001; Sonabend, Dana, and Lesniak 2007).  This mutant EGFR does not 
necessarily need to dimerize to signal (Chu et al. 1997) , does not bind ligand but is nonetheless 
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constitutively active and is capable of inducing tumor growth in otherwise non-tumorigenic 
cells in animal models (Batra et al. 1995). EGFRvIII is expressed in 25%-67% of all GBMs 
(Pelloski et al. 2007; Heimberger et al. 2005) and is generally considered a marker of poorer 
prognosis. The receptor is heterogeneously expressed in human GBMs (generally pockets of 
expression) compared to the more uniform presence of the wild type EGFR (EGFRwt) 
(Nishikawa et al. 2004). Coupled with animal model studies, it is suspected that EGFRvIII 
results in both autocrine signaling loops that lead to enhance EGFRwt signaling (Ramnarain et 
al. 2006) and paracrine mechanisms driving increased proliferation of the bulk of the tumor 
mass (which expresses EGFRwt), thus maintaining tumor cell expression heterogeneity (Inda 
et al.). While one usually invokes soluble extracellularly-released signaling factors for these 
mechanisms, the work of Al-Nedawi (Al-Nedawi et al. 2008) indicates that tumor-derived 
microvesicles could carry and transfer EGFRvIII from cells that express the mutant receptor to 
cells that do not. This group transfected U373 cells to express the mutated EGFRvIII (these 
glioma cells normally express neither EGFR nor EGFRvIII) and collected microvesicles from 
the transfectants that displayed EGFRvIII. Recipient U373 [EGFRvII(-)] cells not only 
epigenetically “express” EGFRvIII following microvesicle receipt, but this also activates 
downstream signaling pathways associated with the presence of EGFRvIII including 
phosphorylation of ERK 1/2 and AKT, release of VEGF, increased Bcl-x expression with 
concurrent reduction in p27 expression, and enhanced soft agar colony formation. U373viii 
tumor-bearing mice also had EGFRvIII(+) microvesicles in their blood. We also found that 
murine glial tumor cells expressing EGFRvIII (SMA-560vIII) display the receptor on their 
exosome surfaces, and that patient serum exosomes/microvesicles (from 4 of 5 GBM patients) 
contained EGFRvIII, while all had EGFR in/on them (Graner et al. 2009). Skog et al (Skog et al. 
2008) also found EGFRvIII mRNA transcripts in microvesicles in sera from 7 of 25 patients 
with GBMs; 14 of 30 patients had transcript-positive tumor biopsies (and curiously, one 
patient had EGFRvIII(+) serum microvesicles but the biopsy was negative). They also found 
that GBM cell line microvesicles contained angiogenic factors and could stimulate brain 
endothelial cells to form tubules. These cumulative results beg the question as to whether the 
autocrine/paracrine signaling mechanisms and resultant enhanced tumor growth and features 
of aggressiveness may be in part due to the passage and reception of exosomes and 
microvesicles from EGFRvIII-expressing cells affecting ostensibly EGFRvIII(-) cells to enhance, 
maintain, or extend aggressive tumorigenic phenotypes. Aside from EGFR and the vIII 
mutant, exosomes and microvesicles are reservoirs of other factors potentially involved in cell-
cell signaling including L1-NCAM as we have shown. One of the highest scoring networks 
using Integrated Pathway Analysis from our proteomic efforts was “cell-to-cell signaling and 
interaction, cancer, hematologic system development and function” (Graner et al. 2009), 
implying that these vesicles have inherent signaling capacity or the ability to merge readily 
into signaling networks. Another important implication of the discovery of serum-borne 
tumor vesicles from patients with GBMs (and also, pediatric patients with medulloblastoma, 
data not shown) is that these vesicles escape the blood-brain barrier with potential for systemic 
effects, particularly involving immune function (Section 3.2). 
3.1.2 Brain tumor exosomes and metabolomics: fat balls grease the wheels of 
glycolysis 
Results from other brain tumor exosome/microvesicle experiments indicate that 
exogenously-added vesicles increase recipient tumor cell proliferation (Al-Nedawi et al. 
2008; Skog et al. 2008). We have seen similar dose-dependent results in modified 
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clonogenicity assays using U87MG cells while adding differential quantities of exosomes to 
those cells (Figure 4). 
 
 
Fig. 4. Exogenous tumor exosomes increase tumor cell proliferation in a dose-dependent 
manner. U87 glioma cells were grown under standard conditions for 48 hrs in the presence 
of 0, 25, or 100 g/ml exosomes and counted on a hemocytometer. Higher concentrations of 
exosomes significantly increased cell proliferation. 
Proliferation assays requiring redox readouts such as MTT/MTS assays in slower-growing 
cell lines pulsed with exosomes suggested that the proliferative effects may involve 
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by incorporation of 13C-labeled glucose as a metabolic tracer for an additional 4 hrs. Media 
and cells were extracted and analyzed by nuclear magnetic resonance/magnetic resonance 
spectroscopy (NMR/MRS), notably revealing very large increases in energy transfer 
compounds and glycolytic activity (Figure 5)     
Decreased glutathione levels and increased lactate output are associated with 
transformation and metastasis in cell line models (Lu et al.); the lipid profile, with the 
exception of monounsaturated fatty acids (MUFA) and cholesterol, is remarkably stable. In a 
somewhat controversial finding in the literature, incubation of cells with oleic acid, a 
MUFA, promotes secretion of matrix metalloproteinase-9 (MMP9) and invasion of breast 
cancer cells (Soto-Guzman et al.). Whether there is an endogenous relationship between 
increased cellular MUFA production (as opposed to exogenous supplementation) and MMP 
activity/invasion remains to be seen, although it is possible that exosome lipid content may 
act in that supplementary fashion. Finally, the energy compounds and glycolysis profile, 
along with the soluble metabolite outputs, demonstrate that exosomes do indeed 
profoundly increase cellular metabolic activity in the form of glycolysis, in keeping with the 
Warburg effect (Ferreira). The mechanisms behind this need to be elucidated--is there 
increased enzymatic metabolic activity, or is there increased gene/protein expression of 
those enzymes, or are such enzymes actually delivered to the cells by exosomes (or any 
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combination of these scenarios)?  From our proteomic studies we have identified more than 
half of the enzymes in both the “preparatory” and “pay-off” phases of glycolysis (Graner et 
al. 2009) (and data not shown), along with a variety of other enzymes in other metabolic 
cycles. Thus, it is not inconceivable that exosomes themselves directly provide, or at least 
contribute to, some of the glycolytic enzyme repertoire that leads to enhanced glycolysis in 
tumor cells pulsed with exosomes. The general renewed interest in tumor metabolism 
(Cairns, Harris, and Mak) will hopefully prompt more research into the area of exosome 







Fig. 5. U87MG exosomes applied to U87 recipient cells results in increased glycolytic 
activity. U87 cells were incubated with 25 g/ml U87 exosomes for 44 hrs prior to changing 
the medium into medium containing 13C-labeled glucose for 4 hrs (blue bars). Control cells 
were grown without the addition of exosomes (red bars). Cells and media were harvested 
and extracted for soluble and lipid-based compounds, and analyzed by NMR/MRS for 
quantification and determination of carbon flux. A shows levels of soluble metabolites 
compared to control (untreated) U87MG cells; B shows lipid profile changes following 
exosome pulsing; C shows phosphate/energy compound changes during exosome 
exposure, and D shows changes in the glycolytic profile of U87 cells following incubation 
with exosomes. 
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3.2 Brain tumor exosomes and immunology: fat balls vacillate between vaccines and 
vacuums 
As mentioned above (Section 2.2.1) tumor exosomes have gone from being seen as perfect 
vaccine material to their current status as infamous purveyors of immune suppression. Also 
as mentioned, most of those immune suppression studies have been performed in tissue 
culture settings that may not reflect the complexity of the mammalian immune system. 
Aside from our previous work demonstrating that murine brain tumor exosomes were 
potent prophylactic vaccines and drivers of antibody production (Graner et al. 2009), there 
has been only one other very recent study involving brain tumor exosomes and 
immunology (Bu et al.). That report determined that exosomes from culture supernatant of 
primary gliomas effectively provided antigens to autologous dendritic cells, which in turn 
could generate activated CD8+ T cells with potent cytotoxicity against autologous tumors 
cells in vitro. We pointed out in our publication (Graner et al. 2009) that there are a number 
of putative and known antigens in or on the glioma exosomes we utilized including the 
aforementioned EGFRvIII and glycoprotein nmb (GPNMB, also called osteoactivin, HGFIN, 
and DC-HIL). GPNMB is believed to be a bona fide antigen target in high grade gliomas 
(Kuan et al. 2006; Loging et al. 2000) and possibly in breast cancer (Rose et al.)  as well as in 
melanoma (Tse et al. 2006). The exosomes also had HSP70 on their vesicular surfaces along 
with HSPs 60, 90, calreticulin, and protein disulfide isomerase, all known immune 
stimulators or “danger signals”, and capable of providing antigens to DCs. However, those 
exosomes also had HSP25 (human HSP27) on their surfaces, which is associated with lower 
immunogenicity of exosomes (Alexzander Asea, personal communication) and more 
aggressive tumors when cell surface localized (Bausero et al. 2004). Also we found 
transforming growth factor beta (TGF-) with the exosomes, which is frequently associated 
with immune suppression (Flavell et al.); even the antigen GPNMB also has potential T cell 
inhibition activities (Tomihari et al.). Consequently, there seems to be a range of immune 
stimulatory and potentially immune suppressive moieties in/on the same population of 
exosomes. Also, quantity may be an issue. Our data suggest that tumor cell-derived 
exosomes at (relatively) low concentrations may inhibit interferon-gamma (IFN) release 
from mitogen-activated T cells, while at higher concentrations exosomes increase IFN 
release over control (mitogen-stimulated) T cells (Figure 6). Based on these data, context and 
quantity may be extremely relevant in the roles played by tumor exosomes in the double-
edged sword of immunity. One may imagine that if peripherally activated (eg, from a 
draining lymph node) circulating T cells encounter low concentrations of tumor exosomes 
also in the periphery, circulating in blood, those T cells may face the suppressive features of 
the exosomes. However, if the T cells are in the vicinity of high tumor exosome 
concentrations (tumor under stress, or in the context of a bolus of exosomes in the form of a 
vaccine following a priming protocol), this may switch the T cells to an even further 
activated phenotype. While that ostensibly should lead to better anti-tumor immunity, it 
may also lead to activation induced cell death (AICD) of the T cells.  
We found that tumor exosomes as antigen sources drive effective antibody production in 
short duration immunization protocols and with no adjuvant (Graner et al. 2009) (M Graner, 
unpublished) in mice. The significance of this in unclear; while antibody output is generally 
associated with Th2-type immune responses (ie, more regulatory than inflammatory), we 
nonetheless found IFN-producing T cells following tumor exosome vaccination concurrent 
with significant antibody titers against the exosomes (Graner et al. 2009). Similar enhanced 
simultaneous T- and B-cell immune responses have been seen when immunizing mice with  
 
 











Fig. 6. Medulloblastoma exosomes differentially and dose-dependently alter interferon-
gamma (IFN) release from mitogen activated human T cells. Peripheral blood mononuclear 
cells (PBMCs) were collected from a healthy donor and were stimulated with 
phytohemagglutinin (PHA) for 48 hrs (or not) in the presence of D283MED 
medulloblastoma exosomes harvested from tissue culture supernatants at the concentrations 
listed. After 48 hrs, media were harvested and IFN released from the cells was measured by 
specific ELISA. Statistical relationships (Student t tests) are shown. 
heat shock protein vaccines (Li et al. 2008; Manjili et al. 2003). The relevant question here is if 
the antibodies have any biologic, anti-tumor activity. In the situation of true human, pre-
established tumors, one may think of tumor-released exosomes acting as “auto-
immunizations” against tumor antigens. However, it may be that the tumor “sheds” 
antigens via exosomes/microvesicles, driving futile immune responses against “decoy” 
circulating antigens. This may have 2 benefits for the tumor—1) driving antibody responses 
may serve to maintain a Th2 cytokine environment, which is suboptimal for effective 
cellular anti-tumor immune responses; and 2) free-floating, released exosomes may titrate 
out potentially “dangerous” antibodies generated against tumor antigens, thus preventing 
those antibodies from ever reaching the solid tumor mass. Concepts similar to this are cited 
above (Battke et al.). As further evidence that tumors may “offer up” exosome-bound 
antigens we show here that antibodies in serum from a patient with GBM  show reactivity 
with the autologous tumor lysate on a Western blot but far more intense reactivity against 
the autologous serum exosomes (Figure 7) 
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Fig. 7. Patient serum antibodies react with autologous tumor lysate and serum 
exosomes/microvesicles. A patient with GBM had blood drawn at the time of tumor 
resection. Exosomes/microvesicles were harvested from the serum; the remainder of the 
serum was diluted 1:100 and used to probe reducing, denaturing gels/blots of tumor lysate 
and lysed serum exosomes (25 g loaded per lane). Secondary antibody was biotinylated 
anti-human IgA/G/M, and tertiary reagent was streptavidin HRP. ECL developing agent 
was used, and images captured on a FluroChem Imager. Molecular weight markers are 
shown to the left. 
We postulate that vaccination with exosomes, particularly in relatively naïve animals, may 
prompt effective antibody (and T cell) generation, but in situations where the tumor has had 
time to “self-vaccinate” by releasing tumor exosomes, the antibody repertoire may reflect 
immune editing and therefore actually benefit the tumor via “ironic immunity”. This 
concept bears further study, and such investigations are ongoing.  
Thus complex interplays between stimulation, suppression, and “decoy allocation” that tie 
the tumor to the host immune response are further complicated by the potential roles played 
by exosomes. With antigens and heat shock protein danger signals, exosomes may be good 
vaccines; however with TGF content and a host of other suppressive features, tumor-
released exosomes may ultimately skew the host immune response into a position that 
benefits the tumor by decoy antigen release and stealth regulatory cytokine environment. 
3.3 Brain tumor exosomes/microvesicles and tumor migration:  attractive fat balls 
blaze the trail 
Perhaps the most distressing activity performed by high grade gliomas is their ability to 
migrate and invade the parenchyma with devastating consequences of bilateral presentation 
if the tumor crosses the corpus callosum, with the possibility of disastrous leptomeningeal 
dissemination. The modulation of the extracellular environment, and the ability to 
proximally and distally signal extracellularly are critical factors in this manifestation of the 
glioma phenotype (Nakada et al. 2007; Berens and Giese 1999).  The cells may migrate out of 
the range of focused external beam radiation therapy, thus limiting its usefulness, and this 
migration is a clear danger in the multifocal recurrences more and more frequently seen 
following treatment with bevacizumab (Rahman et al. ; Iwamoto et al. 2009; de Groot et al. ; 
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Verhoeff et al. 2009). Obviously, glioma invasion makes truly complete surgical resections 
impossible. Exosomes and microvesicles, as nanovesicles released into the extracellular 
environment, seem like perfect vehicles for extracellular remodeling, possessing proteases 
such as insulin degrading enzyme (IDE) (Tamboli et al.), MMPs 1 and 14 (Medina and 
Ghahary ; Hakulinen et al. 2008)  and ADAMs 10 and 17  (Mathews et al. ; Stoeck et al. 2006). 
Exosomal Rabs (Hendrix et al.), HSP90 and plasminogen (McCready et al.),  and 
tetraspanins (Rana et al.) have been implicated in tumor cell migration/invasion as well. 
Recently it was shown that L1-NCAM (CD171) and its migration-inducing cleavage product 
were found in exosomes of brain tumor cell lines (Yang et al.), and exosomes were partially 
involved in an animal model of tumor metastasis by preparation of the pre-metastatic niche  
(Jung et al. 2009). Amidst this background we have determined that glioma exosomes (from 
U87MG cells, as well as D283MED cells—not shown) can promote tumor cell migration 
across a plastic membrane at higher levels than that promoted by FBS (Figure 8) 
 
 
       
Fig. 8. Glioma exosomes promote tumor cell migration in Boyden chamber assays and 
possess intrinsic matrix metalloproteinase activities. Left  U87MG cells were placed on the 
top chamber of an 8 m pore-size plastic insert in wells; the lower chambers contained 
serum-free media, fetal bovine serum (FBS, positive control) or increasing quantities of U87 
exosomes. Cells  migrated for 24 hrs; the inserts were removed, the tops washed, and the 
bottoms were stained with crystal violet, and 5 random fields of duplicate wells were 
counted (avg, SD, and t test results shown). Right U87 exosomes were separated in a 
zymogram (gelatin) gel; MMP activation was induced, and cleared areas in the gel 
correspond to gelatinase activities  of appropriate molecular weights for MMPs 2, 9, and 14 
(confirmed by Western blotting, data not shown). 
The Boyden chamber/migration assay is largely an attraction assay; the complexity of 
exosomes/microvesicles will make it interesting to determine what factors in or on these 
vesicles promote this migration and potentially could serve as attractants over a larger 
distance, akin to leaving “bread crumbs” of exosomes for cells to track and follow while 
migrating or metastasizing. The MMP activities suggest that exosomes will be able to also 
carve paths and remodel the extracellular matrix to allow for cells to migrate (either tumor 
cells out of the main mass, or even endothelial cells in for angiogenic events). These 
preliminary data indicate that brain tumor exosomes can both blaze paths and provide 
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attraction for glioma migration. As this is an important area of therapeutic attention, 
exosome biology may play a critical role in our attempts to regain local control of high grade 
gliomas following surgery, thus improving recurrent-free survival. 
3.4 Brain tumor exosomes/microvesicles and chemoresistance: fat balls provide 
protection 
High grade gliomas are extremely chemoresistant (Lu and Shervington 2008; Sarkaria et al. 
2008). As mentioned above (Section 2.2.6), exosomes have transporter molecules among 
their proteomic content, and we have also shown that MRP3 is in glioma exosomes (Graner 
et al. 2009). These may provide mechanisms for drug export, literally packaging the 
chemotherapeutic agent in exosomes/microvesicles. As shown above (Section 3.1.2), 
exosomes may also accelerate metabolic activity which could lead to increased breakdown 
or chemical modification of the drug compound. While these mechanisms are undoubtedly 
important in glioma chemoresistance (along with the natural protection of the blood-brain 
barrier), no one has ever demonstrated an impact of exosomes on cellular resistance to drugs 
in neuro-oncology. Since all of this discussion is currently theoretical, we have first tested 
this putative protective property of exogenously-added exosomes and have discovered that 
glioma exosomes can indeed provide protection or enhance resistance to temozolomide 
(Figure 9). In fact, even low concentrations of tumor exosomes fully complemented cell 
growth back to normal despite the presence of the drug (which is the chemotherapy of 
choice for high grade gliomas and is a component of the current standard of care for these 
tumors) (Stupp et al. 2005). 
 
 
Fig. 9. Exogenously added tumor exosomes protect glioma cells from cytotoxic 
chemotherapy. U87MG cells were either left untreated (“Cells only”) or were subjected to 
treatment with temozolomide/Temodar® (“TMZ”) at 200 nM concentrations for 48 hrs. 
Exosomes at the concentrations listed were also added (or not), and cell growth was 
quantified in a modified clonogenicity assay as describe for Figure 4. Exosomes provide 
significant protection against the chemotherapy agent, and return cell growth to normal (+ 
exosomes, not significant compared to cells only). 
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Exosomes, by currently unknown mechanisms, provide some means of chemoresistance to 
the therapeutic drug of choice as the standard of care for high grade gliomas. However, this 
does strongly suggest that discovering this underlying mechanism may be a critical point 
for improving therapeutic efficacy of our drug treatments. This may go back to the cellular 
mechanisms for generating exosomes; however, as this is a process common apparently 
almost all cells, it is unclear if there are particular aspects that are tumor-specific. Iero et al 
(Iero et al. 2008) have suggested that a number of pharmacologic agents may be able to 
interfere with exosome release, but so far this does not appear to have made an impact in 
most of our current chemotherapy regimens. 
3.5 Summary 
Exosomes and microvesicles from brain tumor cells affect signaling capacities, alter 
metabolism, impinge on immunity, and may promote two of the most nefarious 
characteristics of high grade gliomas (and medulloblastomas)—their abilities to migrate and 
invade normal tissue, and their inherent resistance to treatment. Obviously, there is a 
tremendous space for research in this area as well as a great need to understand these 
complex vesicles and their interactions with the tumor, the tumor microenvironment, the 
normal tissues, and the potential systemic effects as the tumor attempts to control its 
surroundings locally and distally. 
4. Conclusions 
Exosomes and microvesicles serve as unique and profoundly important extracellular 
signaling vehicles both locally in the area of release, as well as at potentially great distances 
via the circulatory system. Despite some 20 years of research efforts devoted to these “fat 
balls”, we are finding more and more fascinating features about them almost constantly. 
With intense study of the biochemical compositions of the vesicles (proteomics, ribonomics, 
lipidomics) we are learning more about the similarities, as well as the curious differences, 
between exosomes from different cellular sources. We are also developing much better 
understandings of the biology of vesicular formation and release—something that many 
viruses and pathogens have long exploited. All of this knowledge complements the ongoing 
work to understand our ever-increasing—and increasingly fascinating--knowledge of the 
biologic impacts that exosomes and microvesicles have on recipient cells, and on micro- and 
macroenvironments. From the perspective of neuro-oncology, there is a wealth of 
information waiting to be mined, particularly in the areas of immunology, proximal and 
distal cell signaling, microenvironment alteration for migration or protection, and how 
tumor cells may use the physiology of exosomes as a means of therapeutic resistance. The 
almost viral quality of exosomes and microvesicles as carriers of messenger and microRNAs 
is one example of a vastly open region ripe for progress, and it almost certainly intersects 
with many other areas of research. As studies of exosomes and microvesicles become 
accepted as legitimate science and gain mainstream appreciation, we should see further 
advances in the research that leads to translational applications of this knowledge. 
Interdisciplinary approaches will be required as expertise in genetics, proteomics,  
metabolomics, lipid biochemistry, and microparticle/nanovesicle technologies all have a 
place in these endeavors. For patients facing the dismal prognoses of brain tumors, new 
clinical applications resulting from more basic and translational research cannot come fast 
enough. 
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barrier), no one has ever demonstrated an impact of exosomes on cellular resistance to drugs 
in neuro-oncology. Since all of this discussion is currently theoretical, we have first tested 
this putative protective property of exogenously-added exosomes and have discovered that 
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Exosomes at the concentrations listed were also added (or not), and cell growth was 
quantified in a modified clonogenicity assay as describe for Figure 4. Exosomes provide 
significant protection against the chemotherapy agent, and return cell growth to normal (+ 
exosomes, not significant compared to cells only). 
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complex vesicles and their interactions with the tumor, the tumor microenvironment, the 
normal tissues, and the potential systemic effects as the tumor attempts to control its 
surroundings locally and distally. 
4. Conclusions 
Exosomes and microvesicles serve as unique and profoundly important extracellular 
signaling vehicles both locally in the area of release, as well as at potentially great distances 
via the circulatory system. Despite some 20 years of research efforts devoted to these “fat 
balls”, we are finding more and more fascinating features about them almost constantly. 
With intense study of the biochemical compositions of the vesicles (proteomics, ribonomics, 
lipidomics) we are learning more about the similarities, as well as the curious differences, 
between exosomes from different cellular sources. We are also developing much better 
understandings of the biology of vesicular formation and release—something that many 
viruses and pathogens have long exploited. All of this knowledge complements the ongoing 
work to understand our ever-increasing—and increasingly fascinating--knowledge of the 
biologic impacts that exosomes and microvesicles have on recipient cells, and on micro- and 
macroenvironments. From the perspective of neuro-oncology, there is a wealth of 
information waiting to be mined, particularly in the areas of immunology, proximal and 
distal cell signaling, microenvironment alteration for migration or protection, and how 
tumor cells may use the physiology of exosomes as a means of therapeutic resistance. The 
almost viral quality of exosomes and microvesicles as carriers of messenger and microRNAs 
is one example of a vastly open region ripe for progress, and it almost certainly intersects 
with many other areas of research. As studies of exosomes and microvesicles become 
accepted as legitimate science and gain mainstream appreciation, we should see further 
advances in the research that leads to translational applications of this knowledge. 
Interdisciplinary approaches will be required as expertise in genetics, proteomics,  
metabolomics, lipid biochemistry, and microparticle/nanovesicle technologies all have a 
place in these endeavors. For patients facing the dismal prognoses of brain tumors, new 
clinical applications resulting from more basic and translational research cannot come fast 
enough. 
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1. Introduction  
Malignant primary brain tumors exhibit high proliferation index and have the potential for 
local or distant dissemination. GBM is an example of this group of tumor. GBM is a World 
Health Organization (WHO) grade IV tumor. It represents 65% of all gliomas and 15-20% of 
all primary intracranial tumors (Louis et al., 2007). It is the most malignant astrocytic tumor, 
with histolopathological features of cellular polymorphism, high mitotic activity, 
microvascular proliferation, and necrosis (Louis et al., 2007). Despite advances in imaging 
techniques and multimodal treatment options, the overall prognosis of patients with GBM 
remains poor. In a large retrospective study, 2.2% of the cohort resulted in longer than 2-
year survival (Scott et al., 1998). The median survival is between 12-18 months with maximal 
treatment. With medical advancements in the past five years, there is a slight improvement 
in the median survival of these patients; It is estimated that about 24% of patients who 
underwent gross total resection followed by adjuvant chemotherapy and radiation therapy 
will survive 24 months, while those without any intervention succumb rapidly from time of 
diagnosis (Davis et al., 1998; McLendon and Halperin, 2003). Very few cases of curative 
outcome or long term survival have been reported (Salvati et al., 1998; Yoshida et al., 2000). 
Overall, the 5-year survival rate is less than 10% with a final mortality rate of near 100% 
(Deen et al., 1993; Kleihues and Sobin, 2000). 
GBM carries an unfavorable prognosis mainly due to its high propensity for tumor 
recurrence. It has been suggested that GBM recurrence is inevitable after a median survival 
time of 32-36 weeks (Ammirati et al., 1987; Choucair et al., 1986). The natural history of 
recurrent GBM (rGBM), however, is largely undefined due to the lack of uniform definition 
and criteria for tumor recurrence, the variability in treatment philosophy among treating 
physicians, and the heterogeneous nature of the disease, including distinct mechanisms 
believed to contribute to known subtypes of GBM. In this chapter, we have summarized the 
definition of recurrent GBM and provide an overview on the pathophysiology, the 
diagnostic pathways, and treatment algorithm of this disease. We have also included a brief 
synopsis on the future direction in the management and the experimental target-therapies of 
this disease. 
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2. Definition  
Tumor recurrence is defined as the growth of tumor after treatment. However, the criteria 
used to diagnose rGBM remain ambiguous due to the variety in which new lesions present. 
The infiltrative nature of GBM cells makes it difficult to eliminate microscopic disease 
despite macroscopic gross total resection. Studies have shown that GBM recurrence most 
often occurs in the form of a local continuous growth within 2-3 cm from the border of the 
original lesion (Gaspar et al., 1992; Halperin et al., 1988; Lee et al., 1999). Choucair et al. 
reported that over 90% of glioma cases showed recurrence at the original tumor location, 
while 5% developed multiple lesions after treatment (Choucair et al., 1986). Although less 
common (≈10%), GBM may also recur with the development of new lesions that have little 
evidence of being contiguous with previous resection cavity, intraventricular spread, or 
dissemination along any anatomically definable subcortical white matter tracts (Loeffler et 
al., 1990). Bauman et al. has shown that uncommon relapse patterns are more prevalent in 
midline tumors and tumors that infiltrate both hemispheres (Bauman et al., 1998). Likewise, 
in an attempt to preserve neurological function and maintain patient quality of life, subtotal 
resections are sometimes performed when tumors infiltrate eloquent areas of the brain. In 
those circumstances, the residual tumor is treated with focal radiation in addition to 
conventional radiation therapy and chemotherapy. Tumor recurrence is, therefore defined 
by the appearance of residual tumor growth on imaging studies or the manifestation of new 
clinical symptoms. However, tumor recurrence is frequently used synonymously with 
tumor progression. Recurrent GBM is commonly referred as a change from previously 
documented stable tumor or an absence of tumor; it is an escape from prior tumor control. 
Certain authors define tumor progression from a residual tumor as a 25% increase in cross-
sectional area of the tumor in the slice with the greatest amount of tumor or as a 25% 
increase in contrast enhancing volume (Suh and Olson, 1998 ), while recurrence has also 
been defined by a greater than 50% growth between two successive imaging studies (Barker 
et al., 1998). Setting aside the difference in the definition of rGBM, the “local” recurrence 
remains the single most striking common factor among all the patients whom have received 
a variety of chemotherapeutic agents, with different radiation dose and field volume, in 
addition to the extend of resection of the initial tumor. This suggests that the recurrence of 
GBM is intrinsic and independent to the choice of therapy.  
3. The pathophysiology of tumor recurrence 
Neural stem cell surface antigen CD133 has been used to prospectively isolate and 
characterize a rare population of cells within the tumor mass of GBM. This population of 
cells has a striking similarity to normal neural stem cells in its biology (Singh et al., 2004). 
Expansion of these cancer stem cells (CSC) replenishes the cells that constitute the 
expanding cells within the tumor. As these growing cells mature, they undergo terminal 
differentiation. It has been shown that there are at least two populations of cells in GBM 
specimens. They are the CD133+/telomeraseHigh which are presumed to be CSC and CD133- 
/telomeraseLow progenitor cells. There is general consensus that CD133+/telomeraseHigh CSC 
gives rise to CD133- /telomeraseLow progenitor cells. It is the proliferation of these 
progenitor cells that populate and makes up the tumor mass (Beier et al., 2011). Moreover, it 
has been shown that differentiated tumor cells are more susceptible to chemotherapy and 
radiation treatment, and are eliminated from the tumor mass. Additionally, terminally 
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differentiated tumor cells will eventually die off by initiating cell death cascades and there is 
accumulation of CD133+ glioma cells following high-dose irradiation by Gamma Knife 
surgery (GKS) plus external beam radiation (Tamura et al., 2010). Similarly, there is an 
accumulation of CD133+ glioma cells, in residual tumors particularly within the necrotic 
areas after GKS plus EBRT treatment, whereas CD133+ cells are infrequent in tumors prior to 
therapy. It is postulated that the longevity of cancer stem cells and their resilience to 
therapies, give them the ability to serve as the reservoir for regeneration of the whole tumor, 
which provides a plausible explanation for the recurrence of GBM (Liu et al., 2009). 
Additionally, CD133+ cancer stem cells have a higher expression of BCRP1 and MGMT. The 
presence of anti-apoptosis protein and inhibitors of apoptosis protein families explain their 
ability to withstand chemotherapy (Liu et al., 2006). 
An emerging hypothesis states that CSCs drive tumorigenesis by directly inducing an 
inflammatory phenotype within the tumor and facilitate immuno-editing. This occurs by 
recruiting immunocytes and promoting stromal remodeling as seen in aberrant stem cell–
vascular niche that contributes to myeloproliferative diseases (Walkley et al., 2007). In 
response to tumor-derived cytokines, these macrophages acquire the M2 phenotype (Stout 
et al., 2005). Macrophages are a potent source of the mediators that perpetuate the 
inflammatory process, and they release reactive oxygen and nitrogen species. ROS have also 
been shown to modify the activity of myeloid-derived suppressor cells (MDSCs). These cells 
inhibit anti-tumor immunity thus promoting tumors. In combination with nitric oxide, 
MDSC-derived ROS contribute to the generation of peroxynitrite (Nagaraj and Gabrilovich, 
2007). The latter causes the nitration of various proteins on Tyrosine, including the T-cell 
receptor CD8. This modification alters antigen recognition and thereby induces T-cell 
tolerance (Movahedi et al., 2008). Moreover, MDSCs are directly involved in tumor 
angiogenesis, they stimulate angiogenesis and ECM breakdown through the production of 
angiogenic growth factors and MMPs. Secretion of MMPs and other proteinases by 
macrophages enhance cancer-cell motility, dispersion and invasion. Collectively, CSCs 
promote expansion of tumor mass, invasion, and revival of senescence cells.  
4. The clinical profile of patients with recurrent glioblastomas 
The patients with rGBM tend to be male with a reasonable Karnofsky Performance Score 
(KPS) and in age group of 50 to 60. This skewed epidemiological profile can easily be the 
reflection of the variability of treatment algorithms and patients selection employed at 
different institutions. In a multi-center trial of 222 patients with rGBM for evaluation of 
intra-operative placement of biodegradable wafer, the patient cohort was predominantly 
male (64.5%) in the fifth decade of life (48 years old). (Brem et al., 1995). Among a cohort of 
301 GBM patients, Barker et al. identified 223 patients with tumor recurrence (Barker et al., 
1998). Without selection bias, 64% of patients had a KPS >70 at time of recurrence. These 
predominantly male patients (63%) had a mean age of 54 years. The median interval from 
initial diagnosis until clinical or radiographic evidence of tumor recurrence was 4.9 months. 
In majority of the patients, GBM recurrence is detected during imaging surveillance or by 
the development of new or recurring symptoms and signs. The single most commonly 
reported symptom is easy fatigue. In a questionnaire-based study, patients with rGBM or 
anaplastic astrocytoma with a KPS >70 self-reported the following symptoms: fatigue, 
uncertainty about the future, motor difficulties, drowsiness, communication difficulties, and 
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headaches (Osoba et al., 2000a). While most symptoms were likely due to tumor recurrence, 
the authors stated that confounding factors such as radiation necrosis and steroid treatments 
may have contributed to generalized fatigue, whereas headache and uncertainty of the 
future may have been nonspecific for brain cancer. Difficulties with motor-sensory function 
and vision may be directly related to mass effect or edema. 
The most commonly encountered dilemma in diagnosing rGBM is the uncertainty in 
differentiating real tumor progression from that of pseudo-progression/radiation necrosis at 
and around the previously treated site. Pseudo-progression is defined as progressive 
contrast enhancement in imaging study within the first three months (in 58% of the cases) of 
finishing treatment. Patients with pseudo-progression can be symptomatic but are highly 
responsive to steroid therapy. They account for 28-51% of the cases, and 9-14% of these 
patients will eventually show stable disease or resolution. The true mechanism of 
pseudoprogression is unclear. It is thought to be an exacerbated response to effective 
therapy (Chamberlain, 2008; Chamberlain et al., 2007; de Wit et al., 2004). Conversely, 
radiation is toxic to both rapid dividing tumor and the surrounding endothelium and 
oligodendroglial cells. This will result in demyelinating and coagulopathic necrotizing 
reaction 4-6 months after treatment. Importantly, radiation necrosis can mimic rGBM with 
its contrast enhancement, progression, and edema.  
Radiation necrosis versus progression of gliomas can be positively differentiated in biopsy 
specimens. Should a biopsy be non-feasible, imaging becomes the next best option for 
evaluation. Positron Emission Tomography (PET) is not used for initial diagnosis of GBM 
due to relatively inferior image resolution compared to MRI. Rather [18F] 
fluorodeoxyglucose (FDG)-PET is used to demonstrate increased regional glucose 
metabolism, which has been shown to correlate with tumor cellularity and patient survival 
(Ishikawa et al., 1993). In a study evaluating surgical outcomes of rGBM, Barker et al. 
included four patients whose PET suggested proliferation despite an MRI indication of a 
<50% increase in size of residual tumor (Barker et al., 1998). It is particularly useful in the 
early detection of rGBM in cases with unclear MRI information. While radiation necrosis 
mimics tumor recurrence on MRI, it is readily detectable with PET due to its low metabolic 
characteristics. Therefore, PET imaging plays an important role in the management of 
irradiated patients who develop new lesions or symptoms (Ishikawa et al., 1993). PET 
imaging has a specificity of >90% in distinguishing radiation necrosis from rGBM, however, 
it lacks the sensitivity to make it reliable (Thompson et al., 1999). The use of amino acid 
tracers such as [11C]methionine and [18F] tyrosine is shown to improve the sensitivity 
especially, when MRI-PET is used (Thiel et al., 2000). 
The use of serial proton magnetic resonance spectroscopy (MRS) is becoming a standard 
protocol in the imaging rGBMs. This imaging technique, which can append current 
conventional MR imaging protocols, allows serial monitoring of tumor progression. With 
the ability to characterize abnormal processes based on their metabolic signature, It has 
shown that MRS can be used to discriminate between localized radiation necrosis and 
recurrent tumor possessing elevated choline levels after brachytherapy (Wald et al., 1997) 
(See Table 1). In a recent study of 29 patients, Weybright et al. found that both tumor 
recurrence and radiation necrosis demonstrated increased Cho:Cr ratio, Cho/NAA ratio, 
and decreased NAA/Cr when compare to normal brain (Weybright et al., 1998). However, 
the changes appear significantly greater when comparing tumor recurrence and radiation 
necrosis (Cho/Cr: 2.52 vs 1.57; Cho/NAA: 3.48 vs 1.31; NAA/Cr: 0.79 vs 1.22). Similarly, 
Rock et. al. were able to correctly predict the histopathology of the subsequently resected 
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specimen in the case of pure radiation necrosis or pure tumor recurrence (Rock et al., 2002). 
However, it was noted that in specimens with mixed necrosis and neoplasm, the spectral 
patterns were less definitive. Histologically, radiation injury is characterized by damage to 
the vascular endothelium that may result in ischemia and necrosis. In those circumstances 
one will expect an elevated lactate reflecting severe tissue ischemia and a severely depressed 
levels of NAA, choline, and creatine. In addition, radiation necrosis shows a broad peak 
between 0 and 2 ppm corresponding to cellular breakdown products and probably 
consisting of free fatty acids, and amino acids; whereas, in tumor recurrence one will find an 
elevated choline/NAA, elevated choline/creatine, and the presence of lactate. 
Unfortunately, within the same mass, there may be areas of radiation necrosis in 
combination with areas of viable tumor, reducing the specificity of MR spectroscopy. Thus, 
while MRS can be a practical noninvasive screening technique, certain limitations exist at 
this time. 
 
 MRI  (w/ gadolinium) MRS MR Perfusion PET 
Tumor Hyperintense 
↑↑ Cho / NAA 
↑↑ Ch / Cr 
↓↓ NAA / Cr 
↑ rCBV (>2.6) 
↑ Enhancement rate 
(dI/dt) 
↑ Metabolic activity 
(↑ glucose uptake) 
Radiation 
Necrosis Hypointense 
↑ Cho / NAA 
↑ Ch / Cr 
↓ NAA / Cr 
↓ rCBV (<0.6) 
↓ Enhancement rate 
(dI/dt) 
↓ Metabolic activity 
(↓ glucose uptake) 
Table 1. The Characteristic of Tumor and Radiation Necrosis in MRI and PET imaging 
studies. 
Magnetic Resonance Perfusion (MRP) has recently been used to assess tissue vascular 
physiology and to distinguish the recurrence of tumors from radiation necrosis, especially 
with current interest in antiangiogenic therapy for the treatment of GBM. Contrast-
enhancing T2-weighted echo-planar imaging has been evaluated for use in determining 
treatment response of recurrent malignant gliomas, specifically to thalidomide and 
carboplatin and to identify radiation necrosis (Cha et al., 2000). In general, radiation necrosis 
typically shows decreased relative cerebral blood volume (rCBV), whereas tumor recurrence 
results in high rCBV (Aronen and Perkio, 2002). For example, using gradient-echo dynamic 
susceptibility perfusion MR imaging, Sugahara et al found that lesions with rCBV greater 
than 2.6 was indicative of tumor recurrence, while rCBV of less than 0.6 was consistent with 
radiation necrosis (Sugahara et al., 2000). However, there was significant overlap between 
the groups, requiring other modalities such as PET or single photon emission computed 
tomography (SPECT) to allow differentiation. Using more delayed, T1-weighted MR 
permeability methods, Hazle et al. reliably distinguished between tumor recurrence, 
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headaches (Osoba et al., 2000a). While most symptoms were likely due to tumor recurrence, 
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radiation necrosis, or a combination of both factors, using an empiric model to study the rate 
of contrast enhancement (Hazle et al., 1997). In this study of 95 patients, the authors found 
that radiation necrosis and glioma tissue enhance at different rates, with recurrent tumors 
having the greatest mean maximal enhancement rates, mixed radiation necrosis and tumor 
having intermediate rate, and pure tumor necrosis having slowest rate.  
5. Treatment options 
With treatment options for rGBM relatively limited, physicians, patients and the patients’ 
families have to be realistic with their therapeutic goals. The primary goal is palliative rather 
than curative. The ultimate aim is to preserve or restore neurological function to allow and 
prolong patients’ comfort, independency, dignity and improved quality of life. The 
Canadian GBM recommendation committee’s practical guideline-2007 addresses the issue of 
recurrent GBM and provides a relatively clear directive for practicing physicians. It states 
“Selected patients with recurrent GBM may be candidates for repeat resection when the 
situation appears favorable based on an assessment of individual patient factors such as 
medical history, functional status, and location of the tumor. Entry into a clinical trial is 
recommended for patients with recurrent disease” (Mason et al., 2007). It essentially stating 
that aggressive treatment should only be entertained if there is (1) reasonable chance to 
prolong meaningful survival and (2) there is “follow-up” experimental or salvaging 
treatment. Other than that, no aggressive treatment such as surgery or radiosurgery should 
be considered.  
Surgical intervention is essential in the initial treatment of GBM. It is well documented that 
the extent of surgery, ranging from biopsy to subtotal resection to gross total resection can 
effect overall patient survival (Black, 1991a, b; Chamberlain and Kormanik, 1998; Mahaley et 
al., 1989). Gross total resection can double median survival as compared to just having a 
biopsy, and in some study gross total resection has a significant survival advantage as 
compared to subtotal or partial resection (80, 48, and 44 weeks respectively) (Nitta and Sato, 
1995). When faced with evidence of rGBM, surgical intervention requires clear identification 
of short-term goals and a diligent consideration of overall prognosis including potential 
treatment side effects. In patients without medical contraindications, surgery can confirm 
tumor recurrence, reduce intracranial pressure, improve neurological status, and possibly 
improve efficacy of adjunctive therapy.  
In patients with low KPS score and/or other co-morbidity, stereotactic biopsy is particularly 
relevant in making management decisions and potentially can expand treatment options 
especially when imaging studies fail to differentiate between radiation necrosis and tumor 
recurrence. Stereotactic approach allows for the sampling of small, inaccessible, or even 
multiple lesions with minimal morbidity and mortality (estimated to be 2-5% and <1% 
respectively) (Suh and Olson, 1998 ). Stereotactic aspiration of tumor-associated cyst may 
offer short-term relief to patient symptoms secondary to mass effect. While uncommonly 
used, chemotherapy or radioactive agents for interstitial brachytherapy may also be 
introduced. Although stereotactic biopsy is frequently performed with relatively low risk, 
clinicians must be aware of potential complications associated with small sampling. 
Multiple-pass sampling may improve overall sensitivity but must be weighed against the 
increased risk of hemorrhage.  
The efficacy and utility of re-resection alone in rGBM remains controversial due to a lack of 
randomized clinical trials evaluating this intervention independently. The majority of 
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studies are confounded by the inherit selection bias to perform surgery on patients with 
high functional status, favorable anatomical locations, and lack of medical contraindications. 
The potential variability in the extent of surgical resection combined with the absence of 
uniform treatments for the initial disease render randomized control studies impractical. 
Despite these limitations, several studies in the literature provide anecdotal evidence and 
justification for re-resection in a select subset of patients with rGBM.  
Prior redo-craniotomy studies, have showed the median survival time after surgical 
resection to be 14-50 weeks (Ammirati et al., 1987; Barker et al., 1998; Brem et al., 1995; 
Nieder et al., 2000; Sipos et al., 1997; Subach et al., 1999). The median survival from the time 
of initial GBM diagnosis among these patients was 13-22 months (Nieder et al., 2000). 
Rostomily et al. reported a prolonged progression-free survival of 7 weeks in patients 
undergoing combined chemotherapy plus re-resection versus chemotherapy alone (21 vs. 14 
weeks) (Rostomily et al., 1994). However, the overall survival among this cohort of 51 
patients was equivocal.  Barker et al. performed a retrospective review of 222 patients with 
rGBM. In this study, the 46 patients who underwent secondary surgery and adjunctive 
therapy demonstrated a median survival time of 36 weeks post-resection (Barker et al., 
1998). In comparison, patients who received similar chemotherapy and/or radiation had a 
median survival time of 23 wks. Interestingly, 28% of patients in the re-resection group had 
an improved KPS, while 49% had similar functional status. The authors noted that while the 
results were likely secondary to selection bias, subset of patients with rGBM might 
potentially benefit from surgical re-resection.  
In addition to decreasing mass effect, redo-craniotomy allows for the potential 
administration of in situ delivery of chemotherapy or brachytherapy. In a randomized study 
evaluating the efficacy of Carmustine (BCNU) implantation during re-resection versus 
placebo, Brem et al. reported a 50% improvement in survival at 6 months following 
treatment (56% vs. 36%) (Brem et al., 1995). In this study, commonly discussed side effects 
such as serious intracranial infections (2.2%), post operative seizures, and steroid 
requirements for edema were reported to be within accepted ranges for redo surgery alone. 
The consensus belief that remains that the morbidity is higher in re-operation and wound 
dehiscence is relative common (5-18%).  
Overall, surgical resection in rGBM may provide a modest benefit in survival (extends 
median survival by 36 weeks) and/or improvement in quality of life (10 weeks of high 
quality survival when the pre-operative KPS is > 70) within a subset of patients. Brem et al. 
showed that pre-operative performance status and age were significant prognostic factors 
(Brem et al., 1995). Similarly, in a multivariate analysis by Ammirati et al, performance 
status was found to be a significant predictor of outcome, however patient age appeared to 
be noncontributory (Ammirati et al., 1987). The extent of initial resection has also been 
shown to influence patient survival (Durmaz et al., 1997). While minor discrepancies exist 
among different studies, the general consensus is that surgical resection should be seriously 
considered in those with a high KPS (>70) and whose lesions are in a favorable location. 
Similarly, the time from the initial resection to clinical recurrence is also a useful 
prognosticator for re-operation. 
6. Chemotherapy 
Chemotherapy remains the main component in the salvage treatment of recurrent malignant 
gliomas (Chamberlain and Kormanik, 1998; Combs et al., 2005). Chemotherapeutic agents 
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such as temozolomide (TMZ), carboplatin, procarabzine (PCB), Bevacizumab, irinotecan, 
and imatinib mesylate are currently been used in a variety of schema to treat rGBMs (Osoba 
et al., 2000b). These drugs have been administered as a single-agent, multi-agent, interstitial, 
intrathecal and combinatorial therapies, and are hypothesized to decrease the risk of death 
by approximately 15% (Stewart, 2002). In this study the 2-year survival for individuals with 
GBM increased from 9% to 13% when chemotherapy was used. 
The treatment of rGBM tumors with TMZ is promising and with a favorable toxicity 
profile. One has to differentiate between treatment failure and escape. Most of the patients 
with rGBM are relapsed from remission. In a study by Brandes et al., patients who were 
treated for recurrent or progressive GBM with a TMZ chemotherapy regimen showed an 
overall response rate of 19% and mean time to progression of 11.7 wks (Brandes et al., 
2002). Similarly, it was found that treatment of rGBM with a standard TMZ regimen (150 
to 200 mg/m2 x 5 days in 28-day cycles) produced a progression free survival of 6 months 
(PFS-6) of 21% vs. another chemo-agent PCB which produced an 8% PFS-6 (Yung et al., 
2000). However, more recent studies have shown that a more rigorous regimen (150 
mg/m2 daily on a week on/week off cycle) may yield a PFS-6 as high as 48% with an 
overall PFS-12 of 81% (Wick et al., 2004). A similar study has shown that PFS-6 as high as 
43.8% with an overall survival (OAS) of 8.4 months.  But when TMZ is used as a five days 
a week cycle, the PFS-6 is noted to be 39% and the OAS is 7.8 weeks. A Various 
combinatorial strategies have been examined including TMZ plus marimastat, a matrix 
metalloproteinase inhibitor, or 13-cis-retinoic acid, resulting in a PFS-6 of 39% and 32%, 
respectively (Jaeckle et al., 2003). 
7. Antiangiogenic treatment  
Increasingly, therapy that is targeting tumor angiogenesis has proven to be effective in 
tumor control and stabilization.  Bevacizumab targets tumor angiogenesis by neutralizing 
VEGF-A. In May 2009, the US food and Drug Aministration (FDA) has granted accelerated 
approval for Bevacizumab for use in patients with rGBM. A noticeable response (26%) with 
a median duration of response is 4.2 months is observed in the AV3708g trial, and a 20% 
response with a median duration of 3.9 months is reported in the NCI 06-C-0064E study, in 
which Bevacizumab is used on its own. However, it has been shown that antiangiogenic 
treatment in the form of monotherapy produces limited clinical effects; and its delayed onset 
allows tumor progression and reduces its use for end-stage disease (O'Reilly, 2006). 
However, the use of antiangiogenics in a combinatorial fashion may provide better results 
(Baumann et al., 2004). Often coupled with a chemotherapy agent, antiangiogenic therapies 
have been shown to be effective in primary GBM tumors producing a survival time of 16 
months (Tuettenberg et al., 2005). Similarly, in determining which chemotherapeutic to use, 
it has been shown that PTK-787 (a VEGF receptor inhibitor) combined with TMZ produced 
a median time to progression of 15.1 wks vs. PTK-787 combined with CCNU which resulted 
in 10.4 wks (Zhang and Chakravarti, 2006). One of the most promising combinations is the 
use of Bevacizumab with irinotecan (CPT-11). With this regimen the PFS-6 and OSA is 50% 
and 8.7 months while with Bevacizumab on its own, the PFS and OAS was 42% and 9.2 
months respectively (Jakobsen et al., 2011). 
In our institute, the choice of salvaging chemotherapy for patients with rGBM is mainly 
based on their past therapeutic history and the toxicity profile. In general, we like to use 
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Bevacizumab, or Bevacizumab/CPT-11 as the first line therapy. It is especially preferred 
when Stereotactic radiosurgery is planned. 
8. Stereotactic radiation and brachytherapy  
Stereotactic radiosurgery (SRS) and hypofractionated radiotherapy are non-invasive 
methods for the delivery of localized irradiation, and have been shown to be effective in 
treating rGBM (Combs et al., 2005; Romanelli et al., 2009). The median survival of patients 
undergoing single fraction SRS therapy (median dose of 15 Gy) for rGBM tumors was 10 
months (Combs et al., 2005). This finding is consistent with several other studies that report 
similar survival times (Mahajan et al., 2005; Shrieve et al., 1995). The risks associated with 
SRS treatment include the possibility of radiation induced necrosis, edema, hydrocephalus, 
worsening of pre-existing symptoms, and radiation toxicity. Specifically, the application of 
SRS to larger tumors has been avoided due to an increased risk of radiation induced toxicity 
and mass effect (Shaw et al., 2000). However, in a recent study hypofractionated stereotactic 
radiosurgery in combination with Bevacizumab resulted in a OAS of 12.5 months, PFS-6 of 
65% and an over all response rate of 50%, along with relatively lower radiation toxicity 
profile.  
The use of brachytherapy has evolved over the last decade. Primarily a treatment for 
rGBM, brachytherapy is associated with an increase in survival time. Interstitial 
brachytherapy is used to target greater radiation doses to tumor cells while limiting 
exposure to surrounding normal brain tissue. Latest brachytherapy techniques report a 
median survival time (post-brachytherapy) for rGBM of 9.1 months, a competitive figure 
when compared to re-resection alone, chemotherapy, or re-irradiation (Chan et al., 2005). 
Similarly, it has also been shown that treatment of rGBM tumors with high-activity 
removable iodine-125 interstitial brain implants elicits a long term (3-year) survival rate of 
15% (Scharfen et al., 1992). 
Unfortunately, the application of brachytherapy is limited. Only 20-30% of rGBM tumors 
meet the morphological and focal criteria necessary for the surgical intervention associated 
with brachytherapy (Salcman, 1994). In some cases, post-treatment reoperation is necessary 
to remove the therapeutic device or to address focal radiation necrosis. Possible 
complications associated with brachytherapy include the development of homonymous 
quadrantanopsia, focal necrosis, edema, and neurological deterioration (Shrieve et al., 1995). 
Nevertheless, the efficacy of brachytherapy treatment is similar to that of SRS. Comparing 
the outcome of patients treated with SRS vs. brachytherapy, there was an overall survival 
time of 10.2 months for SRS treated patients and 11.4 months for brachytherapy treated 
patients (Shrieve et al., 1995). 
9. Novel therapies 
Most of the recent developments in chemotherapy are focus on targeted molecular therapies 
against the epidermal growth factor receptor (EGFR), the mammalian target of rapamycin 
(mTOR), and other signal transduction pathway components. Small-molecule EGFR 
inhibitors such as gefitinib and erlotinib are well tolerated in patients with rGBM, but the 
results from multiple clinical trails are disappointing (Rich et al., 2004; van den Bent et al., 
2009).  
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such as temozolomide (TMZ), carboplatin, procarabzine (PCB), Bevacizumab, irinotecan, 
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Bevacizumab, or Bevacizumab/CPT-11 as the first line therapy. It is especially preferred 
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The use of Temsirolimus, an mTOR inhibitor, as a single agent shows marginal success. 
Combinations of several agents, such as EGFR inhibitors with inhibitors of mTOR and 
VEGF receptors (VEGFR), are now being evaluated. Agents targeting VEGF, VEGFR, and 
other proangiogenic signaling pathways are relatively promising. Cediranib, a small-
molecule inhibitor of VEGFR, shows a response rate of 56% PFS-6 of 26% (Batchelor et al., 
2007; Galanis et al., 2005). AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, 
normalizes tumor vasculature and alleviates edema in GBM patients (Batchelor et al., 2007).  
Sorafenib and sunitinib are FDA-approved TKi that target VEGFR, but they have limited 
activity in rGBM. Although antiangiogenic therapies are promising, the duration of 
response is limited. Other therapeutic approaches such as viral gene therapies, 
immunotherapies, and convection-enhanced delivery of targeted immunotoxins are 
undergoing evaluation, but their use in rGBM remains to be determined (Wen and Brandes, 
2009). 
10. Conclusion 
Patients with GBM continue to have a poor prognosis. In patients who have completed first-
line therapy, vigilant tumor surveillance with regularly scheduled imaging and clinical 
evaluations may enable early detection of tumor recurrence and allow for immediate 
treatments. With the frequent use of radiation therapy, potential radiation induced 
injury/necrosis remains the major nuance in differentiating patients who develop new or 
repeat symptoms due to tumor recurrence. Hopefully, novel imaging techniques can help to 
detect the activation of tumor progression at molecular and cellular levels before 
conventional radiographic changes are seen. But to date we still rely on MRS, MR Perfusion 
and diffusion studies, and PET imaging. 
Limited evidence from randomized studies have shown that among patients determined to 
be favorable surgical candidates (high KPS, non-eloquent location, no medical 
contraindications), the addition of salvaging chemotherapy appears to provide progression 
free survival. TMZ is now the standard chemotherapy agent due to its administrative ease, 
minimal side effect profile and proven survival improvement. Its use is not restricted by 
previous administration. Re-operation should be considered in patients with high 
preoperative KPS or in those whose symptoms are secondary to mass effect from superficial 
non-eloquent regions. The benefits of SRS treatment and chemotherapy are similar and 
should be chosen based on their corresponding side effect profiles. In general, improved 
outcomes are witnessed with combinatorial radiotherapy and chemotherapy as compared to 
each treatment alone.  
Current trends indicate that the treatment of rGBM will remain multimodal in nature. 
Further understanding of underlying tumor biology is essential in developing more 
effective strategies. Research in gene therapy, antiangiogenic antagonists, and 
immunotherapies, all hold great promises. With continual improvements in treatment and 
imaging technique it is the hope of clinicians, researchers, and patients that GBM may 
become a controllable disease with favorable prognosis. Nevertheless, there will be time 
when no further medical and surgical treatments are going to be effective in preserving the 
comfort and dignity of our patients. Then, as clinicians we have to have the insight to 
prepare our patients from the inevitable and address the end-of life issue, and introduce 
them to the expertise of our hospice service.  
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Agent Phase Target 
2ME2 Phase II inhibits HIF-1α 
Cediranib Phase II VEGFR and PDGFR inhibitor 
Enzastaurin Phase II Inhibits Protein Kinase C 
Pazopanib Phase II VEGFR and PDGFR inhibitor 
PTC299 Phase II inhibits VEGF at the post-transcriptionally 
sorafenib Phase I/II VEGFR, PDGFR and BRAF inhibitor 
Sunitinib Phase II VEGFR and PDGFR inhibitor 
Tandutinib Phase II Inhibits PDGFR 
Vandetanib Phase I/II inhibits VEGFR and EGFR 
Vatalanib Phase I/II VEGFR and PDGFR inhibitor 
Vorinostat Phase I Inhibits Histone Deacetylases 
ABT510 Phase II inhibits CD36 receptor 
Aflibercept Phase I/II decoy receptor for VEGF 
ATN161 Phase II peptide inhibits integrin a5ß1 
Bevacizumab Phase II/III monoclonal antibody binds to VEGF 
Cilengitide Phase II/III RGD synthetic peptide inhibits integrin avß3 and avß5 
CT322 Phase I Fibronectin based VEGFR inhibitor 
Interferon Alfa 2b Phase II inhibits angiogenesis 
TM601 Phase I peptide binds to Annexin A2 
The list includes use of agents as isolated or in combination with other dugs. Protein or 
peptide based inhibitors are shaded in grey. 
Table 2. Antiangiogenic agents at various stages of clinical trial for rGBM 
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1. Introduction 
1.1 Brain tumours/ glioma and medulloblastoma 
The total amount of brain tumours that effect humans is less than 2%. In children are brain 
tumours the second most common cancer type after leukaemia. Brain tumours and tumours 
in CNS (central nervous system) constitute 25% of all childhood tumours and is the most 
common cause of cancer mortality in children. Medulloblastoma is the most frequent 
malignant brain tumour type in children, whereas in adult glioblastoma multiforme (GBM) 
is the most malignant and common form. Although GBM occur in children but the diagnose 
is more uncommon.  
Primary brain tumours are classified according to the World Health Organization (WHO) 
which means grading (I-IV) of the tumours based on tumour histology and pathology 
(Louis, et al., 2007). However, other criteria such as the age of the patient, tumour location, 
radiological features, surgical resection, proliferation index and genetic alterations are 
important when predicting a response of therapy (Louis, et al., 2007). 
1.1.1 Glioma 
Gliomas, tumours arise from glial cells, are the most common primary brain tumours of the 
central nervous system. Gliomas can be divided into astrocytomas, oligodendrogliomas, 
oligoastrocytomas and ependymomas based on their histological pattern (Louis, et al., 2007).  
Gliomas are further divided into four clinical grades based on their histology and pathology 
where GBM is a grade IV glioma. High grade gliomas are often biphasic tumours composed 
of distinct histological parts and they contain a very heterogeneous cell population (Kattar, 
et al., 1997). GBM develops either de novo (primary GBM), or through progression of lower 
grade glioma (secondary GBM). The number of genes and chromosomal changes are often 
correlated to glioma grade. For patients diagnosed with GBM, the mean survival time is less 
than 1 year. Most gliomas diffusely infiltrate the surrounding brain tissue which makes it 
very difficult to completely eliminate the tumour and which later makes the tumour relapse 
after treatment (Louis, et al., 2007). The cell-of-origin for gliomas is still not known but the 
origin is suggested to be a glial stem-like cell or progenitor cell.  
Recently GBM is proposed to be subdivided in to four groups, classical, mesenchymal, 
proneural and neural, based on their specific gene-signature. The classical subgroup is 
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primarily characterized by EGFR (Epithelial growth factor receptor) amplification and 
expression of stem cell and neural progenitor markers. The mesenchymal group is 
distinguished with deletions in NF1 gene which results in low expression of NF1 
(Neurofibromatosis type 1) and expression of mesenchymal markers such as CHI3L1 and 
MET. GBM of proneural origin are characterized by PDGFR alterations and mutations in the 
IDH1 gene (isocitrate dehydrogenase 1). Further the proneural group express markers for 
oligodendrocytes as well as SOX genes. This group of GBM has somewhat longer survival. 
The features of the neural subgroup are expression of neural markers for instance NEFL, 
GABRA1, SYT1 and SLC12A5 (Phillips, et al., 2006; Verhaak, et al., 2010).  
1.1.2 Medulloblastoma 
Medulloblastoma is a highly invasive tumour located in the cerebellum, and belongs to the 
group of primitive neuroectodermal tumours (PNET), and generally affects children 
between three and nine years. Medulloblastoma is a grade IV tumour and the cell-of-origin 
is thought to be a pluripotent neural stem cells. Several chromosomal and genetical changes 
are identified in medulloblastoma. The most frequent change is isochromosome 17q. Other 
frequent genetical changes are affecting the Sonic hedgehog (Shh) signalling pathway, 
which are found in approximately 25% of medulloblastomas (Ellison, et al., 2003). 
Medulloblastoma is mainly divided into two subgroups, classical and desmoplastic 
medulloblastoma, and the tumour types differ in histology as well as in genetics (Ellison, et 
al., 2003). Recently medulloblastomas were subdivided into 5 different subtypes based on 
their characteristic gene-signature caused by genetic aberrations and mutations in specific 
signalling pathways as well as on their clinicopathological features (Kool, et al., 2008). The 
five subgroups are characterized by WNT-signalling (medulloblastoma type A), Shh-
signalling (type B), neuronal differentiation (type C and D) and phosphoreceptor 
differentiation (type D and E) (Kool, et al., 2008). 
A better insight and understanding of the molecular mechanisms behind infiltrative brain 
tumours and discovery of the cell-of-origin may help to generate novel ideas for treatment. 
Today treatment of brain tumours includes surgery if possible, radiation and chemotherapy 
but despite that tumours often recur and 50% of the GBM patients die within the first year 
(Holland, 2001). There have been many attempts to treat human gliomas but the success on 
the prognosis is still absent and this is mainly due to the diffuse infiltration of tumour cells 
into the normal brain tissue and unsuspected cell proliferation. Medulloblastomas are more 
sensitive to radiation and chemotherapy and about 60% are cured but many children suffer 
from severe side effects as motorical difficulties, learning problems and signs of fatigue 
(Ellison, et al., 2003).  
1.2 Cancer stem cells/ progenitor cells 
Current data suggest that initiation and progression of brain tumours are driven by cancer 
stem-like cells/progenitor cells. Cancer stem-like cells are rare tumour cells defined as cells 
which have the ability of unlimited self-renewal, the capacity to initiate and force tumour 
progression, and to differentiate into different cell lineages (Galderisi, et al., 2006). The 
cancer stem-like/progenitor cell has been identified in a number of studies of brain tumours 
(Galli, et al., 2004; Singh, et al., 2003; Yuan, et al., 2004) but exactly which cell that initially is 
transformed into the tumour initiating cell is still not clarified. Tumour progenitor cells have 
a slower division rate which could make them more resistant to treatment than the bulk 
tumour and which later can re-generate the tumour (Hirschmann-Jax, et al., 2004; G. Liu, et 
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al., 2006). Cancer stem-like cells are believed to be responsible for tumour initiation, 
progression and for tumour relapse, which make the cancer stem-like cell become a recent 
and very interesting target for novel and more effective therapies. There are many 
mechanisms involved in regulating neural stem cells and several of these seems to be 
involved in brain tumour development. To identify potential tumour stem-like cells in brain 
tumours, different neuronal precursor markers are used and further markers are used to 
study their differentiation capacity. In this chapter I will discuss certain transcription factors 
belonging to the Sox super-family. For example Sox1-4 are involved in regulating neural 
precursor cells as well as the developing CNS, these transcription factors have also recently 
been shown to be involved in the regulation of the brain tumour stem-like cell (Gangemi, et 
al., 2009; Ghods, et al., 2007; Ikushima, et al., 2009). In addition, other members of the Sox 
super-family are suggested to be involved in the differentiation process and several of the 
Sox protein family members are proposed to be used as markers for different types of brain 
tumours.  
I will discuss the new findings concerning the role of the Sox super-family in brain tumours 
and in brain tumour stem-like cells, as potential differentiation factors or as potential 
diagnostic markers of glioma but first there will be an overview of the Sox super-family and 
the normal expression of Sox proteins in the brain.    
2. The Sox super-family 
2.1 Sox structure and classification 
The first identified Sox gene was Sry, the mammalian sex-determining Y-linked gene. Sry 
contains a DNA-binding motiv known as the HMG domain (high mobility group domain) 
(Gubbay, et al., 1992; Sinclair, et al., 1990). The HMG domain is present in a number of genes 
which belongs to the HMG box super-family. The HMG domain consists of 79 amino acids 
and some of these amino acids are conserved within the HMG box super-family, although 
the HMG domains can alter to a large extent. One difference with HMG domains compare 
to other DNA-binding domains is that the HMG domains interact with the minor groove on 
the DNA helix and this binding bends the DNA drastically (for review (Wegner, 1999). The 
Sox protein family is a group of transcription factors which all contain a highly conserved 
HMG domain, the domain has more than 60% similarity to the Sry HMG domain (Sox - Sry 
related HMG box) (Laudet, et al., 1993). To date 20 different Sox genes are identified in 
humans and mice and they are divided into eight different subgroups, A-H (Table 1). 
Proteins in the same subgroup share >80% of the amino acids within the HMG domain (for 
review (Wegner, 1999). The binding properties of the HMG domains to the DNA are similar 
between the Sox proteins and the DNA sequence of recognition for binding is only 6-7 base 
pair (for review (Kamachi, et al., 2000). Except for the HMG domain, Sox proteins contain 
activating and/or repressing domains, which play a part in there transcription activity 
(Pusch, et al., 1998; van de Wetering, et al., 1993). In addition there is evidence that Sox 
proteins perform their function by a complex interplay with specific partner factors to 
regulate gene transcription. The partner factors can be different depending on cell type, 
promoter and developmental stage. This enhances the specificity of the transcriptional 
regulation by a particular Sox protein to a large extent (for review (Kamachi, et al., 2000).  
2.2 The function of Sox proteins during development and in adult 
Sox proteins are involved in several developmental and adult processes in a cell specific 
manner. A number of Sox proteins have partial overlapping expression patterns and others 
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not. Further, several of the Sox proteins have similar effects like Sox1, Sox2 and Sox3 are all 
expressed in progenitor cells during CNS development (Bylund, et al., 2003). Reduction in 
expression of one of Sox1-3 does not result in significant loss of function, e.g. deletion of 
Sox1 in mouse results in spontaneous seizures which give rise to a relatively mild CNS 
phenotype (Nishiguchi, et al., 1998) indicating that the similarities between Sox1-3 makes it 
possible for the proteins to at least some extent compensate for each other. In other cell types 
this may not be the case; for example Ferri et al show that neural precursors with deficient 
Sox2 expression in adult are dependent of correct Sox2 expression levels to generate new 
precursor cells and neurons (Ferri, et al., 2004). Sox2 is also essential in early embryonic 
development. Ablation of Sox2 in homozygous mouse case death at implantation and it is 
not even possible to generate Sox2 homozygous ES cells (Avilion, et al., 2003). Group C, 
containing Sox4, Sox11 and Sox12/22 is another group which often shows overlapping 
protein expression in both CNS and PNS (peripheral nervous system) (Cheung, et al., 2000; 
Hoser, et al., 2008).    
On the other hand the same cell type can express more than one Sox protein although the 
proteins can have counteracting effects. One example of that is the Group B of Sox genes, 
where Sox1-3, which belong to the B1 subgroup, contains an activating domain and on the 
other hand Sox14 and Sox21, subgroup B2, includes a repressive domain (Uchikawa, et al., 
1999). During embryogenesis and neurogenesis of the neural tube of chicken are genes of 
Group B1 and B2 expressed in an overlapping manner (Sandberg, et al., 2005; Uchikawa, et 
al., 1999). It is suggested that a proper balance between Group B1 and B2 proteins determine 
whether the cell stays in a progenitor/proliferating state or if the cells starts to differentiate 
(Sandberg, et al., 2005; Uchikawa, et al., 1999). It is shown that induced expression of Sox21 
in neural cells promote differentiation by disturbing the balance between Sox1-3 and Sox21 
(Sandberg, et al., 2005). Further, we have shown that an overexpression of Sox21 in glioma 
cells reduces glioma cell proliferation by inhibition of Sox2 (Ferletta, et al., 2011). 
2.3 Expression pattern of Sox proteins in the normal CNS 
The expression patterns of the different Sox proteins in brain and CNS are summarized in 
Table 1. Several of the Sox proteins are expressed during embryogenesis, one of the first is 
Sox2. Sox2 RNA is detected already at day 2.5 postcoitum (dpc) at the morula stage and 
Sox2 is shown to be important in the epiblast and the extra embryonic ectoderm as well as in 
pluripotent precursors of all embryonic and trophoblast cell types. Targed disruption of the 
Sox2 gene is embryonic lethal around implantation (Avilion, et al., 2003).  
Sox2 is important in early stages of the embryonic nervous system. In adult nervous system, 
Sox2 is mainly found in neuronal stem cells and in undifferentiated precursors (Wegner & 
Stolt, 2005) even though Sox2 is expressed in some differentiated neurons (Cavallaro, et al., 
2008). In adult is the expression of Sox2 found in the subventricular zone (SVZ) and in the 
hippocampus dentate gyrus (DG) and in these regions Sox2 is found to be co-expressed with 
GFAP and nestin and further these cells are thought to be the adult neural stem cells (Ellis, 
et al., 2004; Ferri, et al., 2004; Suh, et al., 2007). All proteins of the SoxB group (Sox1-3, Sox14 
and Sox21) are expressed in the developing brain to different extent during the development 
and many of the Sox proteins coexist throughout the CNS (Uchikawa, et al., 1999). When 
SoxB1 genes (Sox1, Sox2 or Sox3) are overexpressed in chicken neural progenitor cells, the 
cells remain in their neural progenitor state (Bylund, et al., 2003; Graham, et al., 2003).  On 
the other hand inhibition of SoxB1 proteins force cell-cycle exit and neuronal differentiation 
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(Bylund, et al., 2003). As mentioned Sox21 is able to counteract the activity of SoxB1 proteins 
and overexpression of Sox21 in chick embryos drives the neural progenitor cells to neuronal 
differentiation (Sandberg, et al., 2005).  Even though all the members of the SoxB1 genes are 
expressed in neuronal stem cells neither the Sox1 nor the Sox3 deficient mice suffer from 







Expression in CNS References: 
A SRY Midbrain and hypothalamus in adult 
male brain. 
(Lahr, et al., 1995). 
B1 SOX1 Developing CNS. Neural stem cells. 
 Adult cerebellum: Purkinje cells, 
Bergman glia.  
(Alcock, et al., 2009; Alcock & 
Sottile, 2009; Bylund, et al., 
2003; Pevny, et al., 1998; 
Uchikawa, et al., 1999). 
B1 SOX2 Developing CNS. Embryonic stem 
cells, neural stem cells.  
Adult: Neural stem cells, postmitotic 
neurons, pyramidal cells, Purkinje 
cells, Bergman glia  
(Alcock, et al., 2009; Alcock & 
Sottile, 2009; Avilion, et al., 
2003; Bylund, et al., 2003; 
Ferri, et al., 2004; Uchikawa, 
et al., 1999; Zappone, et al., 
2000). 
B1 SOX3 Developing CNS. Neural stem cells, 
mature neurons of the ventral 
hypothalamus  
(Bylund, et al., 2003; Rizzoti, 
et al., 2004; Uchikawa, et al., 
1999). 
B2 SOX14/SOX28 Developing CNS. (Uchikawa, et al., 1999). 
B2 SOX21/SOX25 Developing CNS.  (Uchikawa, et al., 1999). 
C SOX4 Developing CNS. Oligodendrocyte 
precursors, neural precursors. Early 
differentiating cells in the CNS, 
neurons. 
(Cheung, et al., 2000; 
Kuhlbrodt, Herbarth, Sock, 
Enderich, et al., 1998). 
C SOX11 Developing CNS. Oligodendrocyte 
precursors, neural precursors, mature 
neurons and later in differentiating 
brain areas as cortical plate and 
inferior colliculus.  
(Kuhlbrodt, Herbarth, Sock, 
Enderich, et al., 1998; 
Uwanogho, et al., 1995). 
C SOX12; SOX22 Developing CNS  (Jay, et al., 1997). 
D SOX5 Developing CNS, oligodendrocyte 
progenitors, oligodendrocytes and 
neuronal subpopulations (as dorsal 
horn neurons).  
Adult: oligodendrocyte progenitors  
(Stolt, et al., 2006). 
D SOX6 Developing CNS, oligodendrocyte 
progenitors, oligodendrocytes and 
neuronal subpopulations. Adult: 
oligodendrocyte progenitors  
(Connor, et al., 1995; Stolt, et 
al., 2006). 
D SOX13 Developing CNS, neural progenitors 
and in differentiating neuronal cells. 
(Y. Wang, et al., 2005). 
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not. Further, several of the Sox proteins have similar effects like Sox1, Sox2 and Sox3 are all 
expressed in progenitor cells during CNS development (Bylund, et al., 2003). Reduction in 
expression of one of Sox1-3 does not result in significant loss of function, e.g. deletion of 
Sox1 in mouse results in spontaneous seizures which give rise to a relatively mild CNS 
phenotype (Nishiguchi, et al., 1998) indicating that the similarities between Sox1-3 makes it 
possible for the proteins to at least some extent compensate for each other. In other cell types 
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development. Ablation of Sox2 in homozygous mouse case death at implantation and it is 
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Hoser, et al., 2008).    
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Group B1 and B2 expressed in an overlapping manner (Sandberg, et al., 2005; Uchikawa, et 
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Sox2 is important in early stages of the embryonic nervous system. In adult nervous system, 
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Stolt, 2005) even though Sox2 is expressed in some differentiated neurons (Cavallaro, et al., 
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hippocampus dentate gyrus (DG) and in these regions Sox2 is found to be co-expressed with 
GFAP and nestin and further these cells are thought to be the adult neural stem cells (Ellis, 
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SoxB1 genes (Sox1, Sox2 or Sox3) are overexpressed in chicken neural progenitor cells, the 
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the other hand inhibition of SoxB1 proteins force cell-cycle exit and neuronal differentiation 
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(Bylund, et al., 2003). As mentioned Sox21 is able to counteract the activity of SoxB1 proteins 
and overexpression of Sox21 in chick embryos drives the neural progenitor cells to neuronal 
differentiation (Sandberg, et al., 2005).  Even though all the members of the SoxB1 genes are 
expressed in neuronal stem cells neither the Sox1 nor the Sox3 deficient mice suffer from 







Expression in CNS References: 
A SRY Midbrain and hypothalamus in adult 
male brain. 
(Lahr, et al., 1995). 
B1 SOX1 Developing CNS. Neural stem cells. 
 Adult cerebellum: Purkinje cells, 
Bergman glia.  
(Alcock, et al., 2009; Alcock & 
Sottile, 2009; Bylund, et al., 
2003; Pevny, et al., 1998; 
Uchikawa, et al., 1999). 
B1 SOX2 Developing CNS. Embryonic stem 
cells, neural stem cells.  
Adult: Neural stem cells, postmitotic 
neurons, pyramidal cells, Purkinje 
cells, Bergman glia  
(Alcock, et al., 2009; Alcock & 
Sottile, 2009; Avilion, et al., 
2003; Bylund, et al., 2003; 
Ferri, et al., 2004; Uchikawa, 
et al., 1999; Zappone, et al., 
2000). 
B1 SOX3 Developing CNS. Neural stem cells, 
mature neurons of the ventral 
hypothalamus  
(Bylund, et al., 2003; Rizzoti, 
et al., 2004; Uchikawa, et al., 
1999). 
B2 SOX14/SOX28 Developing CNS. (Uchikawa, et al., 1999). 
B2 SOX21/SOX25 Developing CNS.  (Uchikawa, et al., 1999). 
C SOX4 Developing CNS. Oligodendrocyte 
precursors, neural precursors. Early 
differentiating cells in the CNS, 
neurons. 
(Cheung, et al., 2000; 
Kuhlbrodt, Herbarth, Sock, 
Enderich, et al., 1998). 
C SOX11 Developing CNS. Oligodendrocyte 
precursors, neural precursors, mature 
neurons and later in differentiating 
brain areas as cortical plate and 
inferior colliculus.  
(Kuhlbrodt, Herbarth, Sock, 
Enderich, et al., 1998; 
Uwanogho, et al., 1995). 
C SOX12; SOX22 Developing CNS  (Jay, et al., 1997). 
D SOX5 Developing CNS, oligodendrocyte 
progenitors, oligodendrocytes and 
neuronal subpopulations (as dorsal 
horn neurons).  
Adult: oligodendrocyte progenitors  
(Stolt, et al., 2006). 
D SOX6 Developing CNS, oligodendrocyte 
progenitors, oligodendrocytes and 
neuronal subpopulations. Adult: 
oligodendrocyte progenitors  
(Connor, et al., 1995; Stolt, et 
al., 2006). 
D SOX13 Developing CNS, neural progenitors 
and in differentiating neuronal cells. 
(Y. Wang, et al., 2005). 
 








Expression in CNS References: 
E SOX8 During development of CNS in 
neurons. Oligodendrocyte precursors, 
astrocytes and oligodendrocytes. 
Immature Bergman glia and EGL cells 
(external granule layer), and 
macroglia. 
(Cheng, et al., 2001; Sock, et 
al., 2001; Stolt, et al., 2004). 
E SOX9 Neural stem cells, astrocytes, 
oligodendrocytes, Radial glia in 
developing CNS.  
Adult: neural stem cells, astrocytes 
and Bergman glia. Adult cerebellum: 
Purkinje cells  
(Alcock & Sottile, 2009; Scott, 
et al., 2010; Stolt, et al., 2003) 
(Alcock, et al., 2009). 
E SOX10 Precursor and mature 
oligodendrocytes during development 
and in adult  
(Kuhlbrodt, Herbarth, Sock, 
Hermans-Borgmeyer, et al., 
1998; Stolt, et al., 2002). 
F SOX7 Abundant expressed in the brain  (Takash, et al., 2001). 
F SOX17 No expression reported.   




Embryonic stem cells  (H. J. Lee, et al., 2004; 
Maruyama, et al., 2005). 
H SOX30 Developing CNS, midbrain-hindbrain 
boundary (zebrafish)  
(De Martino, et al., 1999). 
Table 1. Sox expression in CNS. 
Sox5 and Sox6, which belong to the SoxD group, are also expressed in the developing CNS 
and are mainly found in oligodendrocyte precursors, oligodendrocytes and different types 
of neurons (Stolt, et al., 2006). Sox5 and Sox6 are primarily co-expressed, as in the 
subventricular zone, but they can be differentially expressed as in dorsal–horn neurons 
where only Sox5 is found to be expressed (Stolt, et al., 2006). Further, Stolt et al showed that 
Sox5 and Sox6 are involved in the regulation of oligodendrocyte differentiation; the 
oligodendrocytes start the terminal differentiation when Sox5 and Sox6 are downregulated. 
Mice deficient in Sox5 and Sox6 have a higher number of oligodendrocyte precursors and 
the precursors are found earlier. This is the opposite to when SoxE proteins are absent 
(Sox8-10), which results in a reduced number or lack of oligodendrocytes (Stolt, et al., 2003; 
Stolt, et al., 2005). As Sox21 can counteract the function of Sox1-3 in neural stem cells, SoxD 
proteins are suggested to counteract the function of Sox10 in oligodendrocytes (Sandberg, et 
al., 2005; Stolt, et al., 2006). Sox13, also belonging to the SoxD proteins, is likewise found 
during the development of CNS and especially during active neurogenesis. Sox13 is 
primarily suggested to participate in specification and/or differentiation of neurons and 
Sox13 is mainly found in differentiated areas and missed in the dividing ventricular zone 
(Wang, et al., 2005). Sox13 starts to be expressed in neural progenitors when the 
differentiation program is initiated (Wang, et al., 2005). Moreover, in the developing 
neocortex the expression of Sox13 is very similar to the expression of Sox4 and Sox11 in the 
primordial plexiform layer. However later during the development only Sox13 and Sox4 are 
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found in more differentiated neurons of the cortical plate and the expression of Sox11 is 
instead found in differentiating neurons of the subventricular zone (Cheung, et al., 2000; 
Uwanogho, et al., 1995; Wang, et al., 2005). 
Sox4 and Sox11, belonging to the group of SoxC proteins, are shown to have an overlapping 
expression pattern during early development of the CNS particularly in differentiating 
areas, later the expression patterns differ to a higher extent (Cheung, et al., 2000). Both Sox4 
and Sox11 are found in neural progenitors which have exited mitosis and started to 
differentiate even though expression are lost when the cells are full differentiated (Cheung, 
et al., 2000). Further, Sox4 and Sox11 are found to have comparable expression profiles in 
oligodendrocyte precursor cells and in neurons, both proteins are reduced during 
oligodendrocyte differentiation (Kuhlbrodt, Herbarth, Sock, Enderich, et al., 1998). In Sox4- 
and Sox11-null mice there were no signs of severe CNS defects even though they died 
during embryogenesis or at birth (Schilham, et al., 1996; Sock, et al., 2004). The Sox11-null 
mice die from heart defects and mutations in the Sox11 gene are suggested to be important 
in human malformation syndromes (Sock, et al., 2004). Sox12 is widely expressed both 
during embryogenesis and adulthood, and consequently expressed in the developing CNS 
with sustained expression in adult (Jay, et al., 1997). Even though Sox12 has a broad 
expression pattern is the Sox12-null mice viable and fertile and since Sox12 is expressed in 
lower levels is the overlapping expression of Sox4 and Sox11 suggested to compensate for 
the loss of Sox12 (Hoser, et al., 2008).  
In addition to the SoxC group, the SoxE group is expressed during the development of CNS 
but the expression starts just before gliogenesis. The earliest oligodendrocyte precursors in 
the CNS are developed from neuronal stem cells in the ventral ventricular zone and are 
spread from there (Pringle & Richardson, 1993). In mice, Sox9 was deleted from neural stem 
cells, which resulted in defects in the specification of oligodendrocytes and astrocytes, 
oligodendrocyte progenitors were still detected but to a much lesser extent (Stolt, et al., 
2003).  Mice deficient in both Sox8 and Sox9 failed to generate oligodendrocytes almost 
completely (Stolt, et al., 2005). In the absence of only Sox8 oligodendrocytes are generated 
normally (Stolt, et al., 2004) suggesting that lack of Sox8 can be compensated by Sox9 and 
Sox10 as well as Sox8 can compensate to same extent for the lack of Sox9 and that is why 
there still are some oligodendrocytes generated. After specification Sox10 starts to be 
expressed in the developing CNS shortly after Sox8 and Sox9 in oligodendrocyte precursors 
but in contrast to Sox8 and Sox9, is the expression of Sox10 sustained in oligodendrocytes in 
adult (Kuhlbrodt, Herbarth, Sock, Hermans-Borgmeyer, et al., 1998; Stolt, et al., 2004; Stolt, 
et al., 2002). Sox10 is shown to be important for the terminal differentiation of 
oligodendrocytes (Stolt, et al., 2002) and at this stage Sox9 is downregulated and the 
expression of Sox8 is low which makes Sox10 crucial for the terminal differentiation and the 
myelination (Stolt, et al., 2004; Stolt, et al., 2002). Sox8, Sox9 and Sox10 are not essential for 
the neuronal stem cells but they are suggested to be important in the role of altering the 
neural stem cell fate to a gliogenic fate.  
The only member of the G group is Sox15. In addition to Sox2, Sox15 is expressed in mouse 
embryonic stem cells but the mRNA is hardly detectable in the brain (Ito, 2010; H. J. Lee, et 
al., 2004; Maruyama, et al., 2005). In addition, when Sox15 is targeted disrupted the mouse is 
viable and fertile and Sox15 is suggested to have an important role in skeletal muscle 
regeneration.  
 Sox genes are expressed in different systems and in different stages both during embryonic 
development and in adult. In addition to neural development and CNS, Sox proteins are 
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and Sox11-null mice there were no signs of severe CNS defects even though they died 
during embryogenesis or at birth (Schilham, et al., 1996; Sock, et al., 2004). The Sox11-null 
mice die from heart defects and mutations in the Sox11 gene are suggested to be important 
in human malformation syndromes (Sock, et al., 2004). Sox12 is widely expressed both 
during embryogenesis and adulthood, and consequently expressed in the developing CNS 
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 Sox genes are expressed in different systems and in different stages both during embryonic 
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reported do have important roles in lens development and in the developing PNS. Other 
important areas are cartilage development, chondrocyte development, haemopoiesis and 
sex determination (review (Wegner, 1999). Further, Sox proteins take part in several 
different cellular responses such as cell proliferation, survival, and differentiation in diverse 
cell types and tissues. Sox protein are also involved in different kinds of diseases as well as 
in cancer. In the next session the role of Sox proteins in brain tumourigenesis and especially 
the role in glioma development will be discussed.  
3. The role and expression pattern of Sox proteins in brain tumourigenesis 
Several of the Sox proteins have recently been identified in different kinds of brain tumours. 
Here I will focus on the Sox proteins which are reported to be expressed and play a role in 
brain tumourigenesis. I will mainly concentrate on the role in gliomagenesis but 
medulloblastoma and ependymoma will also be mentioned. Table 2 summaries the expression 
data reported in the literature and the IST (In Silico Transcriptomics) database is used to 
evaluate the mRNA expression of the different Sox genes in glioma (www.genesapiens.com) 
(Kilpinen, et al., 2008) and the Human protein atlas (HPA) is used to evaluate the protein 
expression (www.proteinatlas.org) (Berglund, et al., 2008; Uhlen, et al., 2005). Glioma is the 
only tumour type that is represented both in the IST and the HPA database. 
3.1 The essence of Sox2 and Sox21 in brain tumours 
There are surprisingly few reports about the role of Sox2 and Sox21 in brain tumour 
development and there are no reports about Sox1, Sox3 and Sox14, although the IST 
database tells us that Sox1 and Sox3 are expressed in glioma (Table 2).  
Considering the recent data that the tumour-initiating cell probably is a cell of immature 
nature makes Sox2 extra interesting since Sox2 is reported to be expressed in ES cells, stem 
cells and progenitor cells (as described above), both during development and adulthood 
(Ferri, et al., 2004). Further Sox2 is found in the subventricular zone of the lateral ventricles 
and in the subgranular layer of the adult hippocampus areas where brain tumours are 
thought to arise (Phi, et al., 2008; Suh, et al., 2007). All ready at an early stage we showed 
that Sox2 was expressed in different kinds of mouse glioma induced by retroviruses 
containing the PDGFB (platelet-derived growth factor B) gene (Ferletta, et al., 2007). Further, 
we and others have reported that Sox2 has a broad expression pattern in human brain 
tumours. Sox2 is found in all sorts of glioma both high and low grade as well as in 
ependymoma (Ferletta, et al., 2011; Phi, et al., 2008; Schmitz, Temme, et al., 2007). Sox2 is 
also reported to be expressed in different kinds of paediatric brain tumours such as PNET, 
medulloblastoma and glioma as well as in undifferentiated and differentiated neurospheres 
from these tumours (Ferletta, et al., 2011; Hemmati, et al., 2003; Phi, et al., 2010). The 
expression data of Sox2 in medulloblastoma is a bit contradictable. In our hands the 
medulloblastomas are positive for Sox2 expression (Ferletta, et al., 2011) but no expression is 
reported by Phi et al (Phi, et al., 2010). This discrepancy can be explained if different 
subgroups of medulloblastoma have been used. Moreover by studying paediatric tumour-
derived spheres it turned out that tumour-derived spheres were similar to normal neural 
stem cells, as they expressed the stem cell markers CD133, Musashi-1, melk, PSP, Bmi-1, 
nestin and Sox2 and the cells were able to migrate, proliferate and give rise to neurons and 
glia (Hemmati, et al., 2003), strengthening the idea that the brain tumours arise from a cell 
type of immature origin.  
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Up to date there is only one report about Sox21 and brain tumours. We have shown that 
Sox21 is expressed in gliomas of different grade, ependymoma, PNET and medulloblastoma 
(Ferletta, et al., 2011) (Ferletta unpublished data). In glioma, Sox2 and Sox21 are found to be 
co-expressed in the same cell and there is a correlation between the expression of Sox2 and 
Sox21, high expression of Sox2 is associated with high expression of Sox21 (Ferletta, et al., 
2011). During development it is suggested that Sox2 and Sox21 have a counteracting activity 
(Sandberg, et al., 2005). We suggest that in brain tumour cells this fine tuning effect between 
Sox2 and Sox21 is disturbed and Sox21 is not able to inhibit the proliferation stimulated by 
Sox2. Moreover, we suggest that glioma consists of at least two cell populations: in the first 
population Sox21 is co-expressed with both Sox2 and GFAP and negative for fibronectin, the 
other cell population is instead negative for the expression of Sox2, Sox21 and GFAP but 
express fibronectin (Ferletta, et al., 2011). The co-expression of Sox2 and GFAP supports the 
idea that an adult neural stem cell in the subventricular zone could be the tumour-initiating 
cell of gliomagenesis. Also Phi et al report that Sox2 and GFAP are co-expressed in glial 
tumours of astroglial, oligodendroglial and ependymal lineages (Phi, et al., 2008). The Sox2-
/GFAP-/Sox21-/fibronectin+ population could be of a more mesenchymal phenotype 
(Rieske, et al., 2009; Tso, et al., 2006). Further, in a study of isolation and characterization of 
cancer-stem-like cells from the 9L gliosarcoma cell line, they found that the expression of 
Sox2 was turned on when the cells were cultured as spheres compared to monolayer 
cultures. The cancer stem-like cells from the spheres were able to redevelop the tumour in 
vivo with a more aggressive phenotype compared to monolayer cells and sphere forming 
cells were less susceptible to chemotherapy, this could be a result of a slower division rate 
(Ghods, et al., 2007). This even more emphasizes the importance of targeting cancer stem-
like cells to treat glioma.  
There are a few studies where Sox2 is downregulated in glioma cells. In one investigation 
Sox2 expression is diminished by microRNA in GBM tumour-initiating cells which results in 
reduced cell proliferation and that tumour cells slowly exited the cell cycle. Reduced levels 
of Sox2 further result in decreased levels of Olig2 and BF1, which are transcription factors 
that normally are expressed in neural progenitor cells. Moreover, when tumour-initiating 
cells with a silenced Sox2 were orthotopically injected into NOD/SCID mice, the cells failed 
to recapitulate the tumour compared to tumour-initiating cells that still expressed Sox2 
(Gangemi, et al., 2009). This is supported by our study showing that siRNA against Sox2 
reduces the expression of Sox2 which results in decreased cell proliferation. Reduced 
expression levels of Sox2 additionally results in decreased expression of GFAP as well as 
Sox21, further supporting the correlation between Sox2, GFAP and Sox21 (Ferletta, et al., 
2011). We have also investigated the correlation of Sox2 and Sox21 by using tetracycline 
Sox21-inducible glioma cells (by adding tetracycline Sox21 is upregulated in U-343 MGa 
Cl2.6 cells). The upregulation of Sox21 results in reduced expression of Sox2 and the cell 
proliferation was apparently decreased and this was partially a consequence of induced 
apoptosis (Ferletta, et al., 2011). During chicken development it is suggested that Sox2 and 
Sox21 must be expressed in a proper balance (Sandberg, et al., 2005; Uchikawa, et al., 1999) 
which supports our finding that when Sox21 is overexpressed are Sox2 and Sox21 able to act 
in a counteracting manner in glioma cells. From our findings we propose that Sox2 
inhibitors or Sox21 activators or proteins downstream or upstream could be potential targets 
for novel glioma therapy.  
There are a few other reports where the expression of Sox2 has been affected. Korur et al 
show that while Bmi1 is downregulated is the expression of Sox2 and nestin reduced and 
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Up to date there is only one report about Sox21 and brain tumours. We have shown that 
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co-expressed in the same cell and there is a correlation between the expression of Sox2 and 
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(Sandberg, et al., 2005). We suggest that in brain tumour cells this fine tuning effect between 
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in a counteracting manner in glioma cells. From our findings we propose that Sox2 
inhibitors or Sox21 activators or proteins downstream or upstream could be potential targets 
for novel glioma therapy.  
There are a few other reports where the expression of Sox2 has been affected. Korur et al 
show that while Bmi1 is downregulated is the expression of Sox2 and nestin reduced and 
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the cells become more differentiated. Bmi1 is essential for self-renewal of neural stem cells 
and is highly expressed in GBM. In addition, while Bmi1 is reduced is the expression of 
GSK3 (glycogen synthesis kinase 3 beta) also diminished and differentiation is induced 
while proliferation, survival, migration and clonogenicity decreases (Korur, et al., 2009). 
From this the authors suggest that specific inhibitors for GSK3 or LiCl could be useful to 
downregulate Sox2 specifically and reduce the tumourigenic role of Sox2 in glioma. Further, 
Sox2 is also reported to be connected to the TGF- (transforming growth factor-) signalling 
pathway, in this study Sox2 is regulated by Sox4 (Ikushima, et al., 2009), this will be further 
mentioned in the discussion of Sox4 below.  
Yet another study shows that Sox2 is involved in self-renewal in glioma, by overexpressing 
Sox2 in glioma cells did the number and size of neurospheres increase. In addition there is a 
correlation between Sox2 expression and eIF4E (eukaryotic initiation factor 4E) in glioma 
tissue samples (Ge, et al., 2010). eIF4E is a mRNA 5’ cap-binding protein, which takes part in 
regulation of translational initiation (Richter & Sonenberg, 2005). The expression of eIF4E is 
upregulated in several kinds of cancer (Bjornsti & Houghton, 2004). In this study the authors 
suggest that eIF4E is regulating Sox2 on the protein level but not on the mRNA level and 
that the eIF4E-Sox2 affiliation could be a new potential therapeutic target (Ge, et al., 2010).  
An immunotherapy study has been performed by Schmitz et al, who first showed that Sox2 
is overexpressed in GBM. Thereafter they identified a Sox2 peptide that binds to 
immunogenic HLA-A*0201. The immunogenic HLA-A*0201-restricted peptide originated 
from Sox2 can activate tumour-directed CD8+ cytotoxic T lymphocytes (CTLs). The authors 
highlight the possible role of this Sox2-peptide in T-cell-based immunotherapy (Schmitz, 
Temme, et al., 2007).  
Moreover, there is one study of the genome-wide binding pattern for Sox2 in GBM, where  
4883 binding sites for Sox2 were identified. The expression of Sox2 in GBM was demolished 
and a microarray was performed which resulted in altered expression of 489 genes. The 
main groups of genes that were altered due to Sox2 knockdown were genes with signal 
transducer activity, transmembrane receptor genes and genes with kinase activity (Fang, et 
al., 2011). This study indicates that Sox2 probably is involved in several signalling pathways 
and cellular processes and it needs to be further investigated.   
Taken together these findings strengthen the feature of Sox2 as being important for the self-
renewal capacity and cell proliferation of neural stem cells as well as cancer stem-like cells 
and tumour cells. Several studies suggest that Sox2 or proteins up- or downstream of Sox2 
could be potential targets for brain tumour therapy. The genome-wide binding screen of 
Sox2 stressed the difficulty of finding one solution for treating glioma or identifying one 
potential target that will not be involved or be to harmful to the normal adult stem cell 
population. 
3.2 The role of Sox4 and Sox11 in glioma and medulloblastoma 
3.2.1 The role of SoxC in gliomagenesis 
Both Sox4 and Sox11 are reported to be expressed in glioma even though Sox4 mRNA 
expression was not found within the IST database (table 2). Sox11 is expressed during the 
development of CNS but in the adult brain is the expression of Sox11 downregulated. 
Compared to the adult brain Sox11 seems to be reactivated during gliomagenesis. With 
quantitative real-time PCR Sox11 is shown to be upregulated 5- to 600-fold in glioma 
(Weigle, et al., 2005). The same research group identified a ten amino-acid long peptide 
derived from Sox11 which has the ability to induce CD8+ cytotoxic T cells (CTLs) (Schmitz, 
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Wehner, et al., 2007). The Sox11 peptide was specifically expressed on glioma cells in large 
quantities and they suggest that this peptide could be suitable for T cell-based 
immunotherapy (Schmitz, Wehner, et al., 2007). Another research group confirms that Sox11 
is expressed in primary GBM (Hide, et al., 2009). Further, Hide et al establish a mouse 
glioma cell line by overexpressing HRas in p53-deficient neural stem cells and the cell line 
contained both glioma-initiating cells (GICs) and non-glioma-initiating cells (non-GICs) 
(Hide, et al., 2009). The GICs were transformed into the mouse brain and formed 
glioblastoma-like tumours. They found that the GIC did not express Sox11 compared to the 
non-GICs which still expressed Sox11. The loss of Sox11 in GICs was also confirmed in 
human GIC lines. When Sox11 was overexpressed in GICs the cells lost there tumourigenic 
ability and the cells started to differentiate towards the direction of neurons. In addition, 
when Sox11 was downregulated with short hairpin RNA in non-GICs they became 
tumourigenic (Hide, et al., 2009). Hide et al suggest that true GICs with neural stem cell 
characteristics should be negative for Sox11. Sox11 is primarily found in oligodendrocytes 
and neuronal precursors during development which fits with the finding that the GICs are 
negative for Sox11 if the tumour cell-of-origin is a neural stem cell (Kuhlbrodt, Herbarth, 
Sock, Enderich, et al., 1998; Uwanogho, et al., 1995).  
Taken together, since the expression of Sox11 seems to be high at least in primary glioma, 
Sox11 might be a target for T cell-based immunotherapy but if the GICs are negative for 
Sox11 they will escape the therapy with the risk that the relapsed tumour will be of an even 
more aggressive phenotype.  
Sox4 has in a few reports been connected to the TGF- cell signalling pathway in glioma. 
TGF- has been shown to play several roles in glioma promoting activities such as 
proliferation, invasion, metastasis and angiogenesis (review (Golestaneh & Mishra, 2005). 
The expression of Sox2 in GICs is induced by TGF- and while the TFG- signalling 
pathway is inhibited is Sox2 downregulated and the self-renewal capacity of GICs is lost 
(Ikushima, et al., 2009). In this study they propose that TGF- is not directly regulating Sox2, 
instead they found that Sox4 is a direct target of TGF- signalling. Further, Sox4 
overexpression is able to induce Sox2 expression and reduced expression of Sox4 in GICs 
results in a diminished self-renewal capacity, which suggests that Sox4 is important for 
maintaining the GICs (Ikushima, et al., 2009). On the contrary to Sox2, Sox4 is shown to be 
expressed in progenitor cells rather than in neuronal stem cells (Bylund, et al., 2003; Cheung, 
et al., 2000; Kuhlbrodt, Herbarth, Sock, Enderich, et al., 1998). The co-expression of Sox2 and 
Sox4 in glioma is supported in a DNA microarray analysis of 101 gliomas, where both Sox2 
and Sox4 are identified at high levels as well as Sox11 (Tso, et al., 2006) even though there is 
no evidence that they are expressed in the same cell. That the TGF- signalling pathway is 
mediated through Sox4 is supported by a study where the MPSS technology (massively 
parallel signature sequencing) was used on a pool of glioma tissue. Sox4 as well as TGFBI 
(transforming growth factor beta induced) were identified as alternative TGF- mediators in 
addition to SMAD mediated TGF- signalling (Lin, et al., 2010).  
3.2.2 The role of Sox4 and Sox11 in medulloblastoma 
The classical way to classify medulloblastomas are to divide them in to classical 
medulloblastoma and desmoplastic medulloblastoma (Rubinstein & Northfield, 1964). Both 
Sox4 and Sox11 are shown to be expressed in medulloblastoma and the expression pattern 
differ in the classical and the desmoplastic variants (C. J. Lee, et al., 2002). Sox4 has a strong 
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the cells become more differentiated. Bmi1 is essential for self-renewal of neural stem cells 
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expression in all most all classical medulloblastomas and the expression is mainly found in 
undifferentiated or poorly differentiated cells. In desmoplastic medulloblastoma Sox4 
expression is weak and located to more differentiated cells (C. J. Lee, et al., 2002). In normal 
cerebellum the expression of Sox4 and Sox11 is upgregulated in granule cells that have 
stopped the proliferation and Sox4 and Sox11 are continued to be expressed in the deep 
external granular layer (EGL). As the differentiation process continues the expression of 
Sox11 is lost but the expression of Sox4 is sustained for some time (Cheung, et al., 2000). The 
expression of Sox4 in normal cerebellum fits with the expression pattern shown in 
medulloblastoma and since Sox4 is not expressed in more mature cells of the 
medulloblastoma, Sox4 is suggested to be a marker for how differentiated the tumour cells 
are (C. J. Lee, et al., 2002). Further, Sox4 and Sox11 are differentially expressed in 
medulloblastoma using microarray analysis. Sox4 was identified as a prognostic marker 
towards slightly better survival, in this study the medulloblastomas were not grouped in 
classical respectively desmoplastic medulloblastomas (de Bont, et al., 2008).  
In other tissues Sox4 is suggested to take part in apoptosis, Sox4 is reported to both induce 
apoptosis as well as stimulate anti-apoptotic activities, which effect Sox4 has is probably cell 
and tissue dependent as well as depending on which extracellular signals is reaching the cell 
(Hur, et al., 2004; P. Liu, et al., 2006). The prognosis of a desmoplastic medulloblastoma is 
somewhat better compared to classical medulloblastoma (Ellison, et al., 2003). 
To correctly classify the different medulloblastomas are important in the view of prognosis 
and better treatment. Sox4 might be a potential prognostic marker for this together with 
other cell specific markers. On the other hand Sox11 might be a prognostic marker in glioma 
connected to better survival (Hide, et al., 2009). 
3.3 The feature of SoxD proteins in glioma and medulloblastoma 
3.3.1 The role of Sox5 in gliomagenesis 
Sox5 was first reported to be involved in gliomagenesis in our retroviral insertional 
mutagenesis study in mouse. We used a retrovirus containing the PDGFB gene to tag genes 
involved in the development of malignant glioma, these brain tumour lucis can mark both 
novel or known genes (Johansson, et al., 2004). One of the tagged genes was Sox5, three 
independent proviral insertions were found in three independent tumours. The integration 
sites suggest that Sox5 expression can be upregulated or truncated which can result in a 
truncated protein or no product at all (Johansson, et al., 2004). In the follow-up study by 
Tchougonova et al, Sox5 is suggested to be a suppressor gene in PDGFB-induced gliomas 
predominantly in the Ink4a-deficient mouse background (Tchougounova, et al., 2009). In 
human glioma cell lines the expression of Sox5 was low and overexpression of Sox5 reduced 
the clone formation and the cell proliferation was inhibited. The mechanism by which Sox5 
suppresses PDGFB-induced gliomas is suggested to be due to immediate cellular senescence 
through regulation of p27Kip and Akt (Tchougounova, et al., 2009). Another report confirms 
that Sox5 expression is lower in oligodendroglial and astrocytic tumours compared to the 
already low expression in normal adult brain (Schlierf, et al., 2007). Further, it is shown that 
Sox5 contains a putative binding site for miR-21, which is a microRNA that functions as an 
anti-apoptotic factor in GBM (Chen, et al., 2008). On the contrary, another study shows that 
Sox5 has a higher expression in gliomas compared to normal brain and that about 25% of the 
glioma patients have IgG antibodies against Sox5 in there sera (Ueda, et al., 2007). The 
expression of IgG against Sox5 is preferably found in younger patients and the authors suggest 
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that the presence of IgG against Sox5 is correlated to better prognosis i.e. the survival is 
prolonged (Ueda, et al., 2007). Taken together these data propose that Sox5 expression in 
glioma could have a suppressing role in gliomagenesis and the expression of Sox5 might 
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that the presence of IgG against Sox5 is correlated to better prognosis i.e. the survival is 
prolonged (Ueda, et al., 2007). Taken together these data propose that Sox5 expression in 
glioma could have a suppressing role in gliomagenesis and the expression of Sox5 might 
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Table 2. Reported expression of Sox proteins in different kinds of brain tumours, expression 
of Sox mRNA reported in the IST database and Sox protein expression reported in the HPA 
database. 
3.3.2 Sox6 is expressed in both medulloblastoma and glioma 
In addition to Sox5, Sox6 is reported to be expressed in glioma as well as in 
medulloblastoma and neurocytoma (Schlierf, et al., 2007; Ueda, Yoshida, et al., 2004a, 2004b) 
and the expression of Sox6 in gliomas is confirmed by the IST and HPA databases (Table 2). 
The presence of Sox6 in different kinds of glioma is slightly varying. Sox6 is reported to 
have higher mRNA expression levels in oligodendroglioma compared to astrocytomas. In 
GBM the expression levels are downregulated compared to normal adult brain and in 
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astrocytomas grade II and III are the levels slightly up- or downregulated (Schlierf, et al., 
2007). Another study showed that the Sox6 protein is expressed in GBM but not all cells are 
positive in the GBMs (Ueda, Iizuka, et al., 2004). As for Sox5 Ueda et al report that Sox6 has 
a higher expression in gliomas compared to normal brain and that one third of the patients 
develop IgG antibodies against Sox6 which is not found in the patients with other brain 
diseases or healthy persons (Ueda, Iizuka, et al., 2004). The same research group has 
continued to elucidate the possibility to vaccinate with Sox6 DNA. Glioma-bearing mice 
were vaccinated with a plasmid encoding the full-length Sox6 protein. The vaccinated mice 
developed CTLs specific for Sox6 expressing cells which resulted in a tendency of longer 
survival time compared to control mice (Ueda, et al., 2008). All though vaccination with 
Sox6 suggests an anti-tumourigenic effect, there is always a risk that the cells receiving the 
DNA transform (Munger, et al., 1989). 
3.3.3 The expression profile of Sox13 in glioma 
It is not very much known about the role of Sox13 in gliomagenesis or brain tumourigenesis. 
All though there is one report showing that the mRNA expression of Sox13 increased in 
oligodendroglioma, in astrocytomas can the expression levels be either up- or 
downregulated but in grade IV GBM is the expression mainly downregulated, all tumours 
are compared to Sox13 expression in adult brain (Schlierf, et al., 2007). 
3.4 The role of SoxE proteins in tumourigenesis 
3.4.1 The expression pattern of Sox8 in brain tumours 
Very little is known about the role of Sox8 in brain tumourigenesis. The expression of Sox8 
in gliomas is investigated by real-time RT-PCR and the expressed of Sox8 is significantly 
upregulated in most oligodendroglial tumours. The expression of Sox8 is increased in low-
grade astrocytomas, in grade III astrocytomas the expression is more heterogeneous and in 
GBM is the expression of Sox8 lower than in normal brain (Schlierf, et al., 2007). The IST 
database supports the expression of Sox8 in glioma (table 2). Moreover Sox8 is reported to 
be expressed in medulloblastoma and within medulloblastoma Sox8 is found in more 
immature cells and not in differentiated cells which fits with the normal expression of Sox8 
in microglia, oligodendrocyte progenitors as well as in EGL cells (Cheng, et al., 2001). The 
EGL cells have been suggested in several reports to be the cell-of-origin of medulloblastoma 
(Eberhart, 2007).    
3.4.2 The function of Sox9 in glioma and medulloblastoma 
Sox9 is found in both paediatric brain tumours as well as in adult brain tumours. In paediatric 
ependymoma Sox9 is predominantly overexpressed but in medulloblastoma the expression is 
reported to be low. Survival analysis showed that expression of Sox9 in ependymoma was 
associated with better overall survival (de Bont, et al., 2008). However there is another report 
indicating that Sox9 is expressed to a higher level in medulloblastoma (Kordes & Hagel, 2006). 
When studying different cell-of-origin of medulloblastoma in mice, Sox9 was identified as a 
stem cell marker on medulloblastomas arising from neural stem cells together with Sox2 and 
nestin, the expression of Sox9 or Sox2 and nestin were not found in medulloblastoma tumour 
cells originating from EGL cells. In human samples, a Sox2+ and nestin+ profile was identified 
on a subset of medulloblastoma which were more common in adult patients compared to 
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a higher expression in gliomas compared to normal brain and that one third of the patients 
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continued to elucidate the possibility to vaccinate with Sox6 DNA. Glioma-bearing mice 
were vaccinated with a plasmid encoding the full-length Sox6 protein. The vaccinated mice 
developed CTLs specific for Sox6 expressing cells which resulted in a tendency of longer 
survival time compared to control mice (Ueda, et al., 2008). All though vaccination with 
Sox6 suggests an anti-tumourigenic effect, there is always a risk that the cells receiving the 
DNA transform (Munger, et al., 1989). 
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It is not very much known about the role of Sox13 in gliomagenesis or brain tumourigenesis. 
All though there is one report showing that the mRNA expression of Sox13 increased in 
oligodendroglioma, in astrocytomas can the expression levels be either up- or 
downregulated but in grade IV GBM is the expression mainly downregulated, all tumours 
are compared to Sox13 expression in adult brain (Schlierf, et al., 2007). 
3.4 The role of SoxE proteins in tumourigenesis 
3.4.1 The expression pattern of Sox8 in brain tumours 
Very little is known about the role of Sox8 in brain tumourigenesis. The expression of Sox8 
in gliomas is investigated by real-time RT-PCR and the expressed of Sox8 is significantly 
upregulated in most oligodendroglial tumours. The expression of Sox8 is increased in low-
grade astrocytomas, in grade III astrocytomas the expression is more heterogeneous and in 
GBM is the expression of Sox8 lower than in normal brain (Schlierf, et al., 2007). The IST 
database supports the expression of Sox8 in glioma (table 2). Moreover Sox8 is reported to 
be expressed in medulloblastoma and within medulloblastoma Sox8 is found in more 
immature cells and not in differentiated cells which fits with the normal expression of Sox8 
in microglia, oligodendrocyte progenitors as well as in EGL cells (Cheng, et al., 2001). The 
EGL cells have been suggested in several reports to be the cell-of-origin of medulloblastoma 
(Eberhart, 2007).    
3.4.2 The function of Sox9 in glioma and medulloblastoma 
Sox9 is found in both paediatric brain tumours as well as in adult brain tumours. In paediatric 
ependymoma Sox9 is predominantly overexpressed but in medulloblastoma the expression is 
reported to be low. Survival analysis showed that expression of Sox9 in ependymoma was 
associated with better overall survival (de Bont, et al., 2008). However there is another report 
indicating that Sox9 is expressed to a higher level in medulloblastoma (Kordes & Hagel, 2006). 
When studying different cell-of-origin of medulloblastoma in mice, Sox9 was identified as a 
stem cell marker on medulloblastomas arising from neural stem cells together with Sox2 and 
nestin, the expression of Sox9 or Sox2 and nestin were not found in medulloblastoma tumour 
cells originating from EGL cells. In human samples, a Sox2+ and nestin+ profile was identified 
on a subset of medulloblastoma which were more common in adult patients compared to 
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children and the profile was associated with poorer prognosis (Sutter, et al., 2010). In human 
samples the presence of Sox9 was not investigated.The conflicting data on whether Sox9 is 
expressed to a higher extent in medulloblastoma or not could be due to the fact that different 
subgroups of medulloblastoma has been studied and not mentioned and if the different 
medulloblastomas are raised from different cancer initiating cells as Sutter et al show then the 
tumours will develop in different directions. Five subgroups of medulloblastomas has been 
identified on the bases of their characteristic gene expressing profile (Kool, et al., 2008) maybe 
it is possible/necessary to subdivide them into additional and more narrowed subgroups.   
The mRNA level of Sox9 in oligodendroglial tumours is lower compared to adult brain and 
in astrocytic tumours the expression is more varying (Schlierf, et al., 2007). On the protein 
level Sox9 is found in all grades of glioma with somewhat lower expression in pilocytic 
astrocytomas (grad I) (Kordes & Hagel, 2006). The reported expression data on Sox9 match 
nicely the expression data from the IST database as well as the data from the HPA database 
(Table 2). Moreover, we have investigated the effect of overexpressing cGKII (cyclic 
guanosine monophosphate (cGMP)-dependent protein kinase II) which results in reduced 
expression of Sox9 and PDGFR and this is followed by dephosphorylation of Akt, 
suggesting a connection between Sox9, PDGFR and the Akt signalling pathway in glioma 
(Swartling, et al., 2009). The Akt signalling pathway is often activated in gliomas and the 
PDGFR is frequently constitutively activated (Nister, et al., 1988; Phillips, et al., 2006). 
Further, reduced expression of Sox9 by siRNA is decreasing the cell proliferation rate in 
glioma cells (Swartling, et al., 2009). In addition to gliomas, Sox9 is expressed in prostate 
cancers and Sox9 suppression in prostate cancer cause a downregulation of cell growth 
(Wang, et al., 2007) which support our findings in glioma. Further, overexpression of Sox9 in 
prostate cancer cells caused enhanced cell proliferation and invasion (Wang, et al., 2008). In 
prostate cancer Sox9 is suggested to be regulated by the Wnt/-catenin pathway (Wang, et 
al., 2007). The Wnt/-catenin signalling pathway is one of the characteristics of subgroup 
type A of medulloblastoma which has activated Wnt-signalling (Kool, et al., 2008). In 
prostate cancer the expression of Sox9 is higher in recurrent tumours suggesting that Sox9 is 
partially expressed by the cancer initiating cells which manage to escape the treatment 
(Wang, et al., 2007). Sox9 is expressed in neural stem cells and in progenitor cells in adult as 
well as in the embryonic CNS (Scott, et al., 2010; Stolt, et al., 2003) indicating that Sox9 could 
be important also for the brain tumour initiating cell, even though the type A subgroup 
(Wnt-signalling) of medulloblastoma has a slightly better survival rate (Kool, et al., 2008). It 
is also shown that Shh induces Sox9 during early generation of neural stem cells and that 
the expression of Sox9 is essential to keep the multipotency of the neural stem cells (Scott, et 
al., 2010), the Shh-signalling pathway is one of the activated pathways in subset B of 
medulloblastoma and is mutated in about 25% of the cases (Ellison, et al., 2003; Kool, et al., 
2008). Recurrent gliomas are often of an even more aggressive and invasive phenotype 
compared to the primary tumour supporting the finding that Sox9 could be important for 
tumour cell invasion (Wang, et al., 2008). 
3.4.3 The presence of Sox10 in glioma may indicate better prognosis  
Sox10 was first reported to be involved in gliomagenesis in our retroviral insertional 
mutagenesis study as Sox5 (Johansson, et al., 2004). Five proviral integration sites were 
identified upstream of the transcriptional start site of Sox10 and the positions of the proviral 
insertions suggests improved expression of Sox10 (Ferletta, et al., 2007; Johansson, et al., 2004). 
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Consistently with several other studies we have reported that Sox10 is expressed in both 
paediatric and adult gliomas and ependymomas with a higher expression in low grade 
tumours compared to high grade tumours (Addo-Yobo, et al., 2006; Bannykh, et al., 2006; 
Colin, et al., 2007; Ferletta, et al., 2007). On the contrary Schlierf et al found that when 
investigating the mRNA levels of Sox10 in glioma the expression levels were lower 
compared to adult brain (Schlierf, et al., 2007). The authors suggest that this could be due to 
the high expression of Sox10 in differentiated oligodendrocytes (Stolt, et al., 2002), 
meanwhile the expression in more immature oligodendrocytes are lower which is reflected 
in the tumour cells (Schlierf, et al., 2007). Further, Etcheverry et al has performed a whole-
genome integrative analysis of methylation and gene expression profiles on GBM samples 
and found that the Sox10 promoter contains two hypermethylated CpG sites which are 
related to shorter survival. However, shorter survival time is correlated with low-expression 
of Sox10 in the GBM samples (Etcheverry, et al., 2010), which fits with the expression data 
that Sox10 is expressed to a higher extent in low grade brain tumours. We and others have 
not found any expression of Sox10 in medulloblastoma (Ferletta, et al., 2007; Gershon, et al., 
2005). The lack of Sox10 in medulloblastomas may be explained by the theory that gliomas 
and medulloblastomas probably originate from different tumour-initiating cells (Marino, et 
al., 2000).   
The expression of Sox10 by itself is not enough to characterize a subgroup of gliomas as 
pilocytic astrocytomas, but together with other markers it may be possible (Colin, et al., 
2007; Rousseau, et al., 2006). Some researchers have tried to subgroup well-characterized 
gliomas depending on their expression of GFAP, vimentin, Olig2, Nkx2.2, Sox10 and nestin. 
They suggest that gliomas with strong expression of GFAP, vimentin, Olig2, Nkx2.2 and 
Sox10 can be identified as pilocytic astrocytomas, further robust expression of GFAP, 
vimentin and nestin  can categorize GBM and oligodendrogliomas can be recognized by 
Olig2 expression in almost all tumour cells while Sox10 and Nkx2.2 was found in 
subpopulations of tumour cells, these findings are not definite but may to some degree 
extend the diagnostic possibilities (Colin, et al., 2007). Moreover the study indicate how 
heterogeneous the gliomas are and emphasize the difficulties in finding treatment that will 
target all different tumour cells from the bulk cells to the tumor-initiating cells.  
There are very few reports about how Sox10 regulates/is regulated in brain tumours. Sox10 
has in pilocytic astrocytomas been correlated with high expression of ErbB3 suggesting that 
Sox10 is driving the overexpression of ErbB3 which may result in induced cell proliferation 
(Addo-Yobo, et al., 2006). This finding is supported by the knowledge that Sox10 is 
regulating ErbB3 in neural crest cells during development (Britsch, et al., 2001). Further we 
have investigated the role of Sox10 in gliomagenesis by using the RCAS/tv-a mouse model 
where a gene(s) of interest can be expressed in a specific cell type as glial progenitor cells 
(Ntv-a mice). In this study we overexpressed Sox10 alone or together with the oncogene 
PDGFB in the RCAS system. We found that Sox10 overexpression alone was not enough to 
induce any tumour formation neither in the Ntv-a wild type mice nor in the Arf-/- transgenic 
mice (Ferletta, et al., 2007). The combination of the RCAS-Sox10 virus with the RCAS-PDGFB 
virus induced glioma and the induction was four times higher with the combination 
compared to RCAS-PDGFB alone in the Arf-/- null mice. Therefore we suggest that Sox10 is 
not a potent oncogene by itself but in combination with other oncogenes as PDGFB Sox10 is 
able to increase the gliomagenicity at least in mouse (Ferletta, et al., 2007). Autocrine 
stimulation of growth factors such as PDGFA are common event in human brain tumours 
(Nistér & Westermark, 1998). Moreover, in oligodendrocyte precursors is the expression of 
 
Molecular Targets of CNS Tumors 
 
114 
children and the profile was associated with poorer prognosis (Sutter, et al., 2010). In human 
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Sox10 presiding the expression of PDGFR and as soon as the expression of PDGFR is 
turned on, they are co-expressed (Stolt, et al., 2002). This supports the data that a combined 
overexpression of Sox10 and PDGFB gives raise to glioma-like tumours and that Sox10 can 
increase tumour incidence. In addition, the tumours induced with RCAS-PDGFB alone or 
together with RCAS-Sox10 both had a high expression of Sox10 suggesting that the tumour-
initiating cell is of immature origin as the oligodendrocyte precursor (Ferletta, et al., 2007) 
and this was further supported by the expression of markers for oligodendrocyte precursors 
as NG2 and PDGFR (Stallcup & Beasley, 1987) in the tumours, as well as Sox2 and nestin, 
markers for neural stem cells (Avilion, et al., 2003; Wiese, et al., 2004). 
The wide expression pattern of Sox10 in different types of human gliomas indicates that 
oligodendroglioma and astrocytoma may arise from a common tumour-initiating cell. Sox10 
does not appear to be an oncogene alone but when combined with other mutations Sox10 is 
able to increase the tumour incidence. Further, Sox10 may be used as a prognostic marker 
the presence of Sox10 is connected to better prognosis.  
4. Conclusion 
Lately there are a lot of new reports coming up about the Sox super-family and their roles in 
brain tumourigenesis, even though it is still a lot more to explore. Ten out of the 20 known 
Sox proteins are reported to be expressed in brain tumors. 
There are several discussions going on in the research field as the difference between cancer 
stem-like cells and normal neural stem cells. Sox2, Sox9 and to some extent Sox4 are shown 
to be involved in the regulation of cancer stem-like cells and the presence of these proteins 
seems to be important for the self-renewal capacity and the cell proliferation of cancer stem-
like cells. There are indications that cancer stem-like cells can escape the radiation better 
compared to the tumour bulk, this make the tumour able to relapse and often is the relapsed 
tumour even more aggressive and invasive. Specific inhibitors against Sox2, Sox9 and Sox4 
or up- or downstream targets could be of therapeutic interest if it is possible to avoid too 
much harm on the normal stem cells and the neural progenitor cells. We also show that it is 
possible to inhibit the cell proliferation induced by Sox2 with Sox21.  
In different studies specific peptides for T-cell-based immunotherapy have been made 
available for; Sox2, Sox4, Sox11, and Sox6. This needs to be further investigated, the risk 
with immunotherapy is that the cells receiving the DNA can transform and become 
tumourigenic itself. Other Sox proteins are suggested to be used as prognostic markers, as 
the expression of Sox5, Sox6, Sox4, Sox11 and Sox10 is associated with better survival. 
Unfortunately in most cases it is probably not enough with just one marker, it is a need of a 
combination of markers to get a prognostic overview of the tumours. 
Gliomas and medulloblastomas are very heterogeneous tumour types and lately they have 
been divided into different subgroups depending on their genetic background, which 
signalling pathways are activated and common genetic mutations all this to make it a little 
bit easier to find a potential target for therapy.  
Many of the Sox proteins are co-expressed in the same cell, some with interacting activity 
others with counteracting activity, but this has not been taken in to account in many of the 
reports about Sox proteins during brain tumourigenesis. Further, today there are several 
different brain tumour models in mice, both viral-induced models and transgenic models 
which can be used when studying the role of different Sox proteins during brain 
tumourigenesis to get new functional and new therapeutic ideas. 
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1. Introduction   
Angiogenesis is the process by which tumors induce the blood supply crucial for growth 
and progression. Therefore, angiogenesis has been proposed as a prognostic marker in a 
variety of human neoplasms (Bellamy et al., 1999). Although the importance of angiogenesis 
in solid tumors is well established, its role in the clinical implication of neoangiogenesis in 
brain tumors is enigmatic.  
Endoglin (CD105) is a receptor for transforming growth factors (TGF)-β1 and TGF-beta 3, 
and it modulates TGF-β signaling by interacting with the TGF-βa receptor I (TGF-βRI) 
and/or the TGF—β receptor II (TGF—β RII) whereas antibodies against panendothelial 
cells, such as anti-CD31 and anti-CD34 antibodies, have been commonly used in the 
evaluation of angiogenesis. These panendothelial antibodies react with not only newly 
forming vessels, but also with normal vessels trapped within tumor tissues (Duff et al., 
2003). On the other hand, endoglin (CD105) is predominantly expressed in cellular lineages 
within the vascular system and is overexpressed in proliferating endothelial cells that 
participate in tumor angiogenesis, with weak or negative expression in the vascular 
endothelium of normal tissues (Balza et al., 2001). Investigators have recently shown that 
endoglin (CD105) is a more specific and sensitive microvessel marker than other commonly 
used panendothelial antibodies in malignant neoplasms of the brain, breast, colon, 
esophagus, urothelial bladder, and lung (Dales et al., 2004; Bodey et al., 1998; Minhajat et al., 
2006; Saad et al., 2005; Santos et al., 2003; Tanaka F et al., 2010). 
From this perspective, this review summarizes our current knowledge regarding the role of 
endoglin (CD105) in the angiogenesis of primary brain tumors and further introduces the 
potential role of endoglin (CD105) targeting compounds for the treatment of primary brain 
tumors.  
2. Structure and function of endoglin (CD105) 
Endoglin was designated the cluster of differentiation number 105 at the Fifth International 
Workshop on Human Leukocyte Differentiation Antigen. Therefore, 
it was called, as an alias, CD105 (Dallas et al., 2008). Human endoglin (CD105) is a type I 
integral membrane protein with a large extracellular domain, a single hydrophobic 
transmembrane domain, and a short cytosolic domain. The expression of two alternatively 
spliced isoforms (L and S), long and short endoglin has been charcterized. L- endoglin and 
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S-endoglin are different from each other in thier cytoplasmic tails that have 47, 14 amino 
acids, respectively. L- endoglin is predominant and S-endoglin remains unobscure in the 
significance of it’s function (López-Novoa & Bernabeu, 2010). Endoglin is constitutively 
phosphorylated on serine and threonine residues. Endoglin is an accessory protein of the 
TGF-β receptor family (Barbara et al., 1999; Li et al., 1999). The TGF-β receptor family of 
ligands contains TGF-β type 1, TGF-β type 2, and TGF-β type 3 isoforms and activins, and 
bone morphogenic proteins. The cytostatic domain of endoglin serves as a receptor 
transforming factor (TGF)-β type 1 and TGF-β type 3, and modulate TGF-β signaling 
through it’s interaction with TGF-βRI and TGF-βRII. In endothelial cells, two TGF-β 
receptor type 1 pathways with opposite effects have been demonstrated: the ALK-5 that 
stimulates Smad 2/3 phosphorylation, and the ALK-1 that stimulates Smad 1/5 
phosphorylation. Endoglin (CD105) induces TGF-β1/ALK 5 signaling that promotes 
endothelial proliferation and migration. On the other hand, endoglin (CD105) indirectly 
inhibits TGF-β1/ALK 5 signaling (Dallas et al., 2008;Fonsatti et al., 2010). 
3. Endoglin (CD105) and hypoxia 
Hypoxia is a major stimulus of neovascularization including tumor angiogenesis, and 
collateral vessel formation in ischemic cardiovascular disease. As outlined above,  
endoglin (CD105), a marker of endothelial cells, is abundantly expressed in tissues 
undergoing angiogenesis and is a receptor for transforming growth factor β. The pivotal role 
of CD105 in the vascular system was demonstrated by the severe vascular defects that occur 
in CD105-knockout mice, but the exact mechanisms for CD105 regulation of vascular 
development have not been fully elucidated. In light of the function of CD105 and the 
importance of hypoxia in neovascularisation, Li et al. speculated that CD105 is involved in 
hypoxia-initiated angiogenesis, and they have investigated the effects of hypoxic stress on 
CD105 gene expression using tissue-cultured human microvascular endothelial cells (Li et 
al., 2003). As for the results, they considered that hypoxia is a potent stimulus for CD105 
gene expression in vascular endothelial cells, which in turn attenuates cell apoptosis and 
thus contributes to angiogenesis. They also speculated that the non-TGF β-binding endoglin 
(CD105) in endothelial cells plays a self-protective role against apoptotic factors such as 
hypoxia. 
Angiogenesis occurs in the human brain after a stroke, with endothelial proliferation after 3 
to 4 days, a dense capillary network by 1 week, and neovascular infiltration by 2 to 4 weeks. 
These alternations help to sustain cerebral circulation and prevent a recurrent stroke. 
Therefore, to investigate the mechanisms of angiogenesis after cerebral ischemia, Zhu et al. 
studied the effect of hypoxia on endoglin expression in murine cerebral microvascular 
endothelial cells (bEND.3 cells) in vitro and the possible involvement of mitogen-activated 
protein kinase (MAPK) pathways (Zhu et al., 2003). The results of their investigation are as 
follows; namely, hypoxia increased endoglin mRNA and protein expression in bEND.3 cells, 
which was associated with the phosphoactivation of extracellular signal-related kinase 
(ERK), p38 MAPK, and Jun amino-terminal kinase (JNK). Inhibitors of p38 decreased the 
hypoxic induction of endoglin expression, as did dominant negative MAPK kinase 3 
(MKK3), which activates p38. In contrast, constitutively active MKK3 or JNK1 potentiated 
the hypoxic induction of endoglin. Therefore, they considered that hypoxia induces the 
expression of endoglin at both the mRNA and protein levels and that induction is regulated 
by the p38 and perhaps also JNK pathways. In addition, Guo et al supported their theory 
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based on the data of human strokes, although it would limit the value of the findings of Zhu 
et al., which were based on the use of murine endothelial cell culture and an in vivo mouse 
model of focal cerebral ischemia (Guo et al., 2004). Furthermore, they demonstrated that 
knowledge of endoglin (CD105) signaling would have practical implications for the 
discovery of novel therapies in a host of angiogenic disease. 
Dziewulska et al. morphologically examined human brains several years after a territorial 
ischemic stroke to assess the development of progressing white matter damage and its 
pathomechanisms (Dziewulska et al., 2006). They focused on the role of TGF-β, one of the 
factors whose expression increases after tissue damage, and its receptor endoglin in the 
propagation of postischemic injury. The results of their investigation are as follows; namely, 
the examination of white matter adjacent to the postapoplectic cavity revealed structural 
changes in the capillary vessels, disturbed microcirculation, and deep endothelial cell 
damage with DNA fragmentation in the TUNEL reaction. Many oligodendrocytes also 
revealed DNA damage and an increased expression of caspase-3. In the rarefied white 
matter, the microvessel immune reaction to TGF-β was diminished while the expression of 
endoglin was heterogeneous: absent in some capillaries but increased in others in 
comparison to the vessels located more peripherally from the cavity and in the control 
material. Therefore, they considered that endoglin and TGF-β can be involved in the 
development of the microangiopathy responsible for the propagation of postischemic white 
matter injury in humans, and speculated that disturbances in endoglin expression can 
influence TGF-β signaling and, consequently, vessel structure and function. In addition, 
they considered that pronounced endoglin expression can lead to decreased vessel wall 
integrity while a lack of the constitutively expressed protein is probably a reflection of deep 
vessel damage. 
Collectively, these above studies indicate that endoglin (CD105) has an important role in 
angiogenesis in ischemic cardiovascular disease or cerebral stroke. 
4. Endoglin (CD105) and non-tumor angiogenesis    
Although endoglin is expressed at low levels in normal tissue, it is highly expressed in 
vascular endothelial cells during embryogenesis, in inflamed tissues, and healing wounds, 
psoriatic skin, inflamed synovial arthritis, and vascular injury. In addition, investigators 
pointed out the important role of endoglin in vascular pathology. Particularly, the 
representative example is hereditary hemorrhagic telangiectasia (HHT), or Rendu-Osler-
Weber syndrome (Fernández-L et al., 2006). This is manifested as epistaxis, mucocutaneous 
and gastrointestinal telangiectases, and arteriovenous malformations in the pulomanary, 
cerebral, or hepatic circulation. The recent isolation and characterization of circulating 
endothelial cells from HHT patients has revealed a decreased endoglin expression, impaired 
ALK1-and ALK5-dependent TGF-β signaling, disorganized cytoskelton and the failure to 
form cord-like structures which may lead to the fragility of small vessels with the bleeding 
characteristic of HHT vascular dysplasia, or to disrupted and abnormal angiogenesis after 
injuries and may explain the clinical symptoms associated with this disease. Furthermore, it 
is well known that a high incidence of arteriovenous malformations (AVMs) of central 
nervous system is associated with HHT type 1 and endoglin. The gene mutated in this 
disorder is expressed at reduced levels in the blood vessels of these patients. Since endoglin 
is a component of the transforming growth factor-β receptor complex critical for vascular 
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development and homeostasis, Matsubara et al. determined its expression in sporadic 
cerebral AVMs and in normal brain vessels (Matsubara et al., 2011). They examined twenty 
cerebral AVMs and 10 normal brain samples were analyzed for endoglin, platelet 
endothelial cell adhesion molecule 1 (PECAM-1), alpha-smooth muscle cell actin, vimentin, 
and desmin by immunohistochemistry. As for the results of their investigation, in the 
normal brain, endoglin was found not only in the endothelium of all vessels but also in the 
adventitial layer of arteries and arterioles. Namely, in cerebral AVMs, the numerous vessels 
presented expressed endoglin in both the endothelium and adventitia. Arterialized veins, 
identified by lack of elastin and an uneven thickness of smooth muscle cells, revealed 
endoglin-positive mesenchymal cells in the adventitia and perivascular connective tissue. 
They found that these cells were fibroblasts since they expressed vimentin but not actin 
and/or desmin, and that increasing numbers of endoglin-positive endothelial and 
adventitial cells were seen in sporadic cerebral AVMs, but endoglin density was normal. 
Thus, they considered that it was not involved in the generation of these lesions. However, 
since the presence of endoglin in fibroblasts in the perivascular stroma, they speculated that 
there is an active role for this protein in vascular remodeling in response to increased blood 
flow and shear stress.     
On the other hand, Sure et al. examined endoglin (CD105) expression of adult cavernous 
malformation of the central nervous system (CNS) to clarify their biological activity (Sure et 
al., 2005). They pointed out the histological similarities of HHT and the cavernous 
malformation of the CNS, and found endoglin (CD105) in the majority of cavernous 
malformations of the CNS. However, they considered that the role of endoglin (CD105) in 
cavernous malformations when compared with AVMs, since cavernous malformations are 
not associated with high blood flow or shear stress.  
Moyamoya disease is a cerebrovascular occlusive disease characterized by progressive 
stenosis or occlusion at the distal ends of the bilateral internal arteries. Histological 
investigations on autopsy samples have demonstrated the main vascular lesion in 
moyamoya disease is stenosis or occlusion caused by an intimal hyperplasia. Recently, 
evidence has been obtained indicating that hypoxia-inducing factor-1 regulates TGF-β3. 
Therefore, Takagi et al. surgically collected tiny pieces of the wall of the middle cerebral 
artery from patients with moyamoya disease and analyzed them using histological and 
immunohistochemical methods focusing on the mechanism of remodeling of the  
intracranial arterial walls of patients with moyamoya disease (Takagi et al., 2007). As for 
results of their study, middle cerebral artery specimens from moyamoya disease patients 
had a thicker intima than those from the control group. In moyamoya disease samples, the 
immunoreactivity indicating both hypoxia-inducing factor-1α and endoglin expression  
was higher in the endothelium and intima. No vascular endothelial growth factor 
immunoreactivity was detectable in the moyamoya disease samples. In addition, 
transforming growth factor-β3 immunoreactivity was also detected and was co-localized 
with that of hypoxia-inducing factor-1α and endoglin, mainly in the endothelium.  
Therefore, they considered that hypoxia-inducing factor-1α and endoglin were 
overexpressed in the intima of the middle cerebral artery of moyamoya disease patients, and 
that these factors play a role in the proliferating response of moyamoya disease. 
Collectively, these above studies indicate that endoglin (CD105) has an important role in the 
vascular remodeling of the CNS.   
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5. Endoglin (CD105) and tumor angiogenesis 
Angiogenesis is the formation of new blood vessels from preexisting vessels or circulating 
endothelial progenitor cells, and it is essential for tumor growth by providing nutrients and 
eliminating metabolic waste products. Therefore, angiogenesis has been proposed to be a 
prognostic marker in a variety of human neoplasms and investigators compared the 
expression of endoglin with other markers in cancers from various organs. 
It was reported by Saad et al. that they studied endoglin and the vascular endothelial 
growth factor (VEGF) expression as a possible prognostic marker in esophageal carcinoma 
(Saad et al., 2005). They have shown that the assesment of microvesell count using endoglin 
in esopageal carcinoma might be a valuable parameter for predicting patients who have a 
poor survival rate and higher risk of developing a metastatic disease. In addition, they 
reported that endoglin, by direct staining of proliferative vessels in esophageal 
adenocarcinoma, is a more specific and sensitive marker for tumor angiogenesis than the 
other commonly used panendothelial markers. Furthermore, endoglin staining also showed 
prognostic significance with a positive correlation with the presence of angiolymphatic 
invasion, tumor stage, and survival.    
In breast carcinomas, as in many tumor types, marked characteristics of neoangiogenesis 
have been found to correlate with a high rate of metastasis. Intratumoral tumoral 
microvessels can be identified with panendothelial markers that stain all tumor blood 
vessels to the same degree. Dales et al. therefore considered that they should examine other 
markers more specific to activated endothelial cells that should better reflect a tumor’s 
capability to produce new vessels, and they studied the long-term prognostic significance of 
neoangiogenesis in breast carcinoma by comparison of Tie-2/Tek, endoglin (CD105) and 
CD31 immunocytochemical expression (Dales et al., 2004). As a result, they showed that 
endoglin (CD105) immunoexpression in breast carcinomas is an independent prognostic 
indicator in node-negative patients, better in terms of overall survival than Tie-2/Tek and 
panendothelial marker CD31.  
Information regarding the role of angiogenin and endoglin (CD105) expression in head and 
neck squamous cell carcinoma is extremely sparse and limited exclusively to serum protein 
levels. Thus, Marioni et al. investigated angiogenin expression in laryngeal squamous cell 
carcinoma and evaluated the relationship between angiogenin expression and endoglin 
(CD105), clinicopathological and prognostic parameters. As a result, they showed that 
angiogenin expression in laryngeal carcinoma cells and endoglin (CD105) expression in 
vascular endothelial cells in the de novo blood vessels can be considered potentially useful 
to detect laryngeal squamous cell carcinoma patients with high risk of disease recurrence 
who might benefit from more aggressive therapy (Marioni et al., 2004).  
Most colorectal carcinomas are considered to originate from precursor lesions (adenomas). 
Adenomas are thought to progress to carcinoma over many years because of multiple 
accumulated molecular alternations, and angiogenesis is an important step in the process of 
colorectal carcinoma growth. Therefore, Minhajat et al. compared the expression of endoglin 
(CD105) in several hundred target spots with that of other endothelial markers in all tissue 
layers during the development of colon carcinoma using tissue microarrays and 
immunohistochemistry (Minhajat et al., 2006a, 2006b). As a result, they showed that 
endoglin (CD105) was expressed at high levels in vascular endothelial cells in the de novo 
blood vessels of the adenoma-carcinoma of the colon and was weakly expressed in blood 
vessels of the normal mucosal layers. Therefore, they considered that endoglin (CD105) was 
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more intensely expressed in de novo microvessels. In this review, Fig. 1 shows that endoglin 
(CD105) was expressed at high levels in vascular endothelial cells in the de novo blood 
vessels of the carcinoma of the colon. Namely, although vascular endothelial expression of 
panendothelial marker CD 34 in normal and neoplastic layers of adenoma and 
adenocarcinoma from all layers did not significantly differ, endoglin (CD105) was intensely 
expressed in vascular endothelial cells of the neoplastic mucosal adenoma and various 
layers of adenocarcinoma at a level corresponding to the depth of cancer invasion.  
 
 
A. Endoglin (CD105)-negative endothelial cells in normal colonic tissue adjacent to colonic carcinoma. 
B. Vessels in colonic carcinoma at submucosal level showing endoglin (CD105)-positive endothelial 
cells. C. Vessels in colonic carcinoma at muscular layer level showing endoglin (CD105)-positive 
endothelial cells. 
Fig. 1. Expression of endoglin (CD105).  
Collectively, these above studies indicate that endoglin (CD105) is a better marker than 
panendothelial markers such as CD31, 34, etc., in the evaluation of neoangiogenesis and 
prediction of prognosis in various cancers. 
6. Endoglin (CD105) and primary brain tumor angiogenesis  
6.1 Endoglin (CD105) and glioma angiogenesis 
Several investigators have shown that the degree of angiogenesis has a prognostic value in 
glial tumors, particularly astrocytic tumors, oligodendrogliomas. Yao et al. considered that 
the prognosis of glioma patients is largely determined by the histopathlogical malignacy 
grade, whereas within each grade, the clinical course of glioma patients is still variable 
because each grade tumor is not a single pathological entity but encompasses a spectrum of 
tumors with variable malignant potential. Also, the prediction of tumor biological behavior 
can thus hardly be made only by histological criteria and needs the predicting assistance of 
biological makers (Yao et al., 2005). Therefore, they assessed micovessel density (MVD) 
using an anti-105 monoclonal antibody to clarify the validity of endoglin (CD105) in the 
evaluation of angiogenesis in gliomas. They demonstrated that MVD expressed by endoglin 
(CD105) is more closely correlated the prognosis of glioma patients than MVD expressed by 
panendothelial marker CD 31.  
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The prototypic histopathology of glioblastomas is characterized by dense cellularity, 
striking pleomorphism, a complex form of microvascular proliferation and zones of 
coagulative necrosis lined by “pseudopalisading” tumor cells. It is also well known that 
numerous vascular changes occur at the transition of anaplastic astrocytomas to 
glioblastomas. Recent studies have further demonstrated that a dramatic shift in biological 
behavior occurs following the transition from anaplastic astrocytomas to glioblastomas. Brat 
and Van Meir reported that pseudopalisade formation results from the following sequence 
of events: i) vascular occlusion, which is related to endothelial apoptosis and associated with 
intravascular thrombosis; ii) hypoxia in regions surrounding vascular pathology; iii) 
outward migration of glioma cells away from hypoxia, creating a peripherally directed 
wave of cell movement; iv) death of nonmigrated cells leading to central necrosis; v) an 
exuberant angiogenic response creating microvascular proliferation in regions peripheral to 
the central hypoxia; and vi) enhanced outward expansion of infiltrating tumor cells toward 
a new vasculature (Brat &Van Meir, 2004). In addition, vascular glomeruli are observed in 
the white matter surrounding the tumor but less frequently in the cortex. The number, 
caliber and wall thickness mean values of the vessels are significantly higher than those of 
the normal brain. In this area, significant modifications in terms of vacularization and 
biomolecular features take place. Therefore, Sica et al. investigated that neovascularization in 
the tumor surrounding areas by examining endoglin (CD105) and nestin expression along 
with MVD while establishing their possible prognostic significance (Sica et al.,2011).. As a 
result, they demonstrated that a tumor neoangiogenesis occurs in glioblastoma peritumor 
tissue with intimate involvement of pericytes, and that endoglin (CD105)-MVD in the area 
located at a greater distance from the tumor margin carries prognostic significance. In this 
review, Fig. 2 shows that endoglin (CD105) is expressed at high levels in vascular endothelial 
cells in the de novo blood vessels of glioblastoma. Namely, although vascular endothelial 
expression of panendothelial marker CD 34 in normal and did not significantly differ 
normal brain, astrocytoma, and glioblastoma, endoglin (CD105) was intensely expressed in    
 
 
A. Endoglin (CD105)-negative endothelial cells in normal brain tissue adjacent to glioblastoma. B. 
Vessels in Glioblastoma(Grade IV, WHO classification) showing intensive endoglin (CD105)-expression 
of endothelial cells. C. Vessels in diffuse astrocytoma (Grade II, WHO classification) showing 
heterogenous endoglin (CD105)-expression of endothelial cells. 
Fig. 2. Expression of endoglin (CD105). 
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vascular endothelial cells of glioblastoma, but was heterogeneous in astrocytona and 
negative in normal brain, respectively.  
Regarding oligodendrgliomas, Netto et al. considered that oligodendrgliomas show typical 
vascularization with delicate and ramified blood vessels, but also the importance of 
angiogenesis (Netto et al., 2008). Therefore, they assessed micovessel density (MVD) using 
an anti-105 monoclonal antibody to clarify the validity of endoglin (CD105) in the evaluation 
of angiogenesis in oligodendrogliomas, and showed that endoglin (CD105)-MVD is greater 
in anaplastic oligodendrogliomas than oligodendrogliomas, indicating an increase in the 
vascular neoformation, something which must be evaluated as a possible prognostic factor 
in oligodendrogliomas. 
Based on these collective evidences, it is indicated that endoglin (CD105) is a better marker 
than panendothelial markers such as CD31, 34, etc., in the evaluation of neoangiogenesis 
and prediction of prognosis in glial tumors, particularly glioblastomas. 
6.2 Endoglin (CD105) and extraaxial tumor angiogenesis 
The grading of meningiomas is geneally based on tumor subtype and histological features. 
Although the MIB-1 labelling index is not an included criterion in the WHO grading system, 
it is sometimes used to assess the prognosis of patients with meningiomas. In addition, 
several studies have shown that the morbidity of meniniomas is related to the degree of 
tumor vascularity. As mentioned above, several investigators have already shown that the 
degree of angiogenesis has prognostic value in primary brain tumors, particularly astrocytic 
tumors, oligodendrogliomas. Regarding extraaxial tumor angiogenesis, Barresi et al. 
investigated endoglin (CD105) in immunoexpression in meningiomas and the 
corresponding normal leptomeninges in order to evaluate its ability to identify newly 
formed neoplastic vessels as well as establish whether a correlation exists between 
clinicopathological parameters, so as to verify if MVD documented by endoglin (CD105) 
could be utilized for prognostic purposes (Barresi et al., 2008). As a result, they showed that 
CD 34 stained both the host entrapped vessels in menngiomas and the newly formed 
vessels; thus CD34 may be considered a pan-endothelial marker, while endoglin (CD105) 
futher appears to be a more specific marker for neo-angigenesis, and that endoglin (CD105) 
positive vessels were evidenced in 70% of meningiomas and atypical meningiomas were 
charactraized by higher endoglin (CD105) immunoexpression in general. Interestingly, they 
also showed that cases with higher MIB-1 labelling indexed exhibit significantly higher CD 
105 counts. In this regard, they speculated that meningiomas with an intrinstically higher 
capability to proliferate undergo a hypoxic condition which is determined by their increased 
volume, and that hypoxia may be in turn responsible for the endoglin up-regulation, via the 
hypoxia inducible factor-1 and consequently for the higher neo-angiogenesis revealed by 
MVD. Furthermore, they speculated that endoglin (CD105) might be considered a target for 
anti-angiogenic selective immuno-therapies able to blood supply in meningiomas. 
Regarding pituitary tumors, there is controversy about the behavior of angiogenesis as a 
function of hormonal secretion or other characteristics of pituitary tumors. Pizarro et al. 
studied the anti-endoglin (CD105) antibody, a glycoprotein expressed in endothelial cells 
and conjunctive tissue particularly associated with neovascularization, in order to determine 
MVD in pituitary adenomas (Pizarro et al., 2009). Their data were as follows; No significant 
difference was found in MVD concerning the variables of age, clinical presentation, 
immunohistochemical phenotype or tumor size. MVD in males was significantly higher 
than in females. Cell proliferation, as evaluated by the MIB-1 antibody ranged from 0% to 
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19.58%. No correlation was found between MIB-1 and MVD. Therefore, they speculated that 
the lower MVD found in pituitary adenomas in females reflects an inhibitory estrogen 
action on TGF-β1, a protein involved in vascular remodeling, and that, because of its role as 
a TGF receptor ligand, endoglin proved to be sensitive in detecting this gender difference in 
pituitary tumor angiogenesis. 
6.3 Endoglin (CD105) and primary central nervous system lymphoma angiogenesis 
Primary central nervous system lymphomas (PCNSLs) are an uncommon variant of 
extranodal non-Hodgkin lymphomas that involve leptomeninges, eyes or the spinal cord 
without evidence of systemic disease. These lymphomas do not include systemic 
lymphomas that have spread to the CNS. The vast majority of PCNS lymphomas are of B-
cell origin (Paulus et al., 2007; Sugita et al., 2004). There have been two hypotheses to 
explain the pathologic processes of PCNS lymphomas. One hypothesis suggests that 
inflammatory lesions transform into neoplasms, such as lymphomas, in situ in the CNS. The 
other hypothesis suggests that a malignant B-cell clone homes to the CNS, although a 
putative homing signal has not been identified. 
There are conflicting descriptions as to whether the degree of angiogenesis as measured by 
microvessel density has prognostic value in lymphomas. For example, Zhao et al. reported 
that vascular endothelial growth factor-A was expressed both on lymphoma cells and 
endothelial cells in angioimmunoblastic T-cell lymphomas, and it thus was related to 
lymphoma progression (Zhao et al., 2004). Salven et al. also demonstrated the simultaneous 
serum elevation of vascular endothelial growth factor (VEGF) and basic fibroblast growth 
factor (bFGF) levels to be an independent predictor of a poor prognosis in non-Hodgkin’s 
lymphoma (Salven et al., 2000). On the other hand, Stewart et al. reported that non-
Hodgkin’s lymphoma may be less angiogenic than most solid tumors (Salven et al., 2002). 
Regarding PCNSLs, Rubenstein et al. speculated that angiotropism in PCNSLs may 
constitute an important paracrine growth mechanism for lymphoma progression 
(Rubenstein et al., 2002). However, Roser et al. commented that the lack of a correlation 
between apoptosis and vascularity may indicate that PCNSLs growth occurs independently 
of vessel formation, even though the high microvessel density in PCNSLs could play a 
significant role in the growth kinetics and infiltrating potential of the tumor. They also 
commented that this could be due to the various techniques for microvessel counting used 
by different laboratories rather than due to truly different results (Roser et al., 2004).  
It was described by Sugita et al that CD105 staining reduced the false-positive staining of 
blood vessels in comparison to the commonly used panendothelial marker CD34. In addition, 
the survival rate of the lower-MVD patients was significantly higher than that of the higher-
MVD patients when CD105 was used as a marker of angiogenesis. In contrast, when CD34 
was used as a marker of angiogenesis, the survival rates did not significantly differ between 
these two groups. In addition, using a multivariate analysis, CD105-MVD demonstrated 
independent prognostic impacts in this investigation. As a result, they considered that the 
growth of PCNSLs was dependent on angiogenesis and that the intratumoral-MVD 
determined by the anti-CD105 monoclonal antibody was a reliable prognostic marker in 
patients with PCNSLs (Sugita et al., 2007). In general, PCNSLs are typically patchy, poorly 
demarcated, and angiocentric at low magnification (Russel & Rubinstein, 1989). Namely, the 
neoplastic transformation itself may, especially at the periphery of the tumor, remain at first 
relatively confined to the Virchow-Robin spaces, but thereafter may acquire a more florid 
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vascular endothelial cells of glioblastoma, but was heterogeneous in astrocytona and 
negative in normal brain, respectively.  
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19.58%. No correlation was found between MIB-1 and MVD. Therefore, they speculated that 
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a TGF receptor ligand, endoglin proved to be sensitive in detecting this gender difference in 
pituitary tumor angiogenesis. 
6.3 Endoglin (CD105) and primary central nervous system lymphoma angiogenesis 
Primary central nervous system lymphomas (PCNSLs) are an uncommon variant of 
extranodal non-Hodgkin lymphomas that involve leptomeninges, eyes or the spinal cord 
without evidence of systemic disease. These lymphomas do not include systemic 
lymphomas that have spread to the CNS. The vast majority of PCNS lymphomas are of B-
cell origin (Paulus et al., 2007; Sugita et al., 2004). There have been two hypotheses to 
explain the pathologic processes of PCNS lymphomas. One hypothesis suggests that 
inflammatory lesions transform into neoplasms, such as lymphomas, in situ in the CNS. The 
other hypothesis suggests that a malignant B-cell clone homes to the CNS, although a 
putative homing signal has not been identified. 
There are conflicting descriptions as to whether the degree of angiogenesis as measured by 
microvessel density has prognostic value in lymphomas. For example, Zhao et al. reported 
that vascular endothelial growth factor-A was expressed both on lymphoma cells and 
endothelial cells in angioimmunoblastic T-cell lymphomas, and it thus was related to 
lymphoma progression (Zhao et al., 2004). Salven et al. also demonstrated the simultaneous 
serum elevation of vascular endothelial growth factor (VEGF) and basic fibroblast growth 
factor (bFGF) levels to be an independent predictor of a poor prognosis in non-Hodgkin’s 
lymphoma (Salven et al., 2000). On the other hand, Stewart et al. reported that non-
Hodgkin’s lymphoma may be less angiogenic than most solid tumors (Salven et al., 2002). 
Regarding PCNSLs, Rubenstein et al. speculated that angiotropism in PCNSLs may 
constitute an important paracrine growth mechanism for lymphoma progression 
(Rubenstein et al., 2002). However, Roser et al. commented that the lack of a correlation 
between apoptosis and vascularity may indicate that PCNSLs growth occurs independently 
of vessel formation, even though the high microvessel density in PCNSLs could play a 
significant role in the growth kinetics and infiltrating potential of the tumor. They also 
commented that this could be due to the various techniques for microvessel counting used 
by different laboratories rather than due to truly different results (Roser et al., 2004).  
It was described by Sugita et al that CD105 staining reduced the false-positive staining of 
blood vessels in comparison to the commonly used panendothelial marker CD34. In addition, 
the survival rate of the lower-MVD patients was significantly higher than that of the higher-
MVD patients when CD105 was used as a marker of angiogenesis. In contrast, when CD34 
was used as a marker of angiogenesis, the survival rates did not significantly differ between 
these two groups. In addition, using a multivariate analysis, CD105-MVD demonstrated 
independent prognostic impacts in this investigation. As a result, they considered that the 
growth of PCNSLs was dependent on angiogenesis and that the intratumoral-MVD 
determined by the anti-CD105 monoclonal antibody was a reliable prognostic marker in 
patients with PCNSLs (Sugita et al., 2007). In general, PCNSLs are typically patchy, poorly 
demarcated, and angiocentric at low magnification (Russel & Rubinstein, 1989). Namely, the 
neoplastic transformation itself may, especially at the periphery of the tumor, remain at first 
relatively confined to the Virchow-Robin spaces, but thereafter may acquire a more florid 
 
Molecular Targets of CNS Tumors 
 
136 
expression as it infiltrates and destroys the neural parenchyma. In view of their study on the 
angiogenesis of PCNSLs, there may be some validity to this theory. Therefore, they 
demonstrated that PCNSLs may not need sufficient neoangiogenesis at the start of PCNSLs, 
but instead may require a higher rate of neoangiogenesis as they infiltrate and destroy the 
brain parenchyma at an advanced stage. In this review, Fig. 3 shows that endoglin (CD105) is 
expressed at high levels in vascular endothelial cells in the de novo blood vessels of PCNSL.  
 
 
A. Endoglin (CD105)-negative endothelial cells in normal brain tissue adjacent to PCNSL. B. Endoglin 
(CD105)-negative endothelial cells in the periphery of PCNSL. C. Vessels in an advanced 
stage of PCNSL showing intensive endoglin (CD105)-expression of endothelial cells.  
Fig. 3. Expression of endoglin (CD105).  
7. Endoglin (CD 105) antagonists: a potential therapeutic tool for malignant 
brain tumors 
As outlined above, endoglin (CD105) has an important role in the tumorigenesis of 
malignant tumors. In addition, vascular targeting agents for the treatment of cancer are 
designated to cause a rapid and selective shutdown of blood vessels of tumors (Thorpe F et 
al., 2004). Thus, endoglin (CD105) is emerging as a prime vascular target of antiangiogenetic 
cancer therapy. Interestingly, Takase et al. assessed cases of small cell carcinomas at autopsy 
using immnuohistochemistry to investigate the degree of angiogenesis status in small cell 
carcinoma tissue (Takase et al., 2010). As a result,  they considered that small cell carcinomas 
are predominantly supported by newly formed vessels that are generated by endoglin 
(CD105)-mediated angiogenesis, and that anti-angiogenic therapy, especially endoglin 
(CD105)-targeting, proved an effective form of small cell carcinoma treatment. 
Recent studies have shown the systemic administration of naked antihuman endoglin 
monoclonal antibodies to suppress established tumors, and its efficacy was markedly 
enhanced by combination with a chemotherapeutic drug using an antiangiogenic schedule 
of drug dosing. For instance, the effect of anti-endoglin (CD105) monoclonal antibodies has 
been investigated in several animal models. Takahashi et al. showed that antiangiogenic 
therapy of established tumors in human skin/severe combined immunodeficiency mouse 
chimeras bearing human breast cancer by anti-endoglin (CD105) monoclonal antibodies, 
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SN6f, SN6j, SN6k (Takahashi et al., 2001). Namely, SN6j and SN6k were effective in 
suppressing established tumors, whereas tumor suppression was weaker with SN6f. A 
combination of SN6j and SN6k that defined mutually nonoverlapping epitopes showed an 
addictive antitumor effect. A combination of SN6j and cyclophosphamide using an 
antiangiogenic schedule of drug dosing showed synergistic antitumor efficacy. They 
therefore considered that systemic administration of naked antihuman endoglin monoclonal 
antibodies can suppress established tumors, and the efficacy is markedly enhanced by 
combining a chemotheraputic drug using an antiangiogenic schedule of drug dosing. 
Anti-metatstatic effects of an antitumor drug are extremely important. Thus, Uneda et al. 
investigated the anti-metatstatic activity of 3 anti-endoglin monoclonal antibodies (SN6a, 
SN6j, SN6k) in animal models. They showed that SN6a and SN6j effectively suppressed the 
formation of metastatic colonies of murine mammary carcinoma cells in the lung of 
metastaic models and that SN6j, SN6k and their immunoconjugates with deglycosylated 
ricin A-chain were effective in suppressing hepatic metastasis of murine colorectal 
carcinoma cells (Uneda et al., 2009). As a result, they considered that data of their 
investigation were clinically relevant in view of a clinical trial. 
Interestingly, it was shown by Lee et al that anti-angiogenic/anti-tumor effects achieved in a 
prophylactic setting with an oral DNA vaccine encoding murine endoglin, carried by double 
attenuated Salmonella typhimurium to secondary lymphoid organ, i.e., Peyer’s patches(Lee 
et al., 2006). Their approach was as follows; After vaccination, mice were injected with D2F2 
mouse mammary carcinomas and tumor progression was evaluated. As a result, 
unvaccinated mice had significantly more lung metastasis, but tumors in vaccinated mice 
were less angiogenic. In addtion, the vaccinated mice had a longer overall survival. 
Regarding the effects of an oral DNA vaccine, they speculated that a CD8+ T cell mediated 
immune response induced by this vaccine effectively suppressed dissemination of 
pulmonary metastasis of D2F2 breast carcinoma cells presumably by eliminating 
proliferating endothelial cells in the tumor vasculature. They therefore considered that the 
vaccine strategies can contribute to future therapies for breast carcinomas.  
Regarding brain tumors, Bodey et al. investigated 62 childhood brain tumors including 34 
medulloblastomas and 28 astrocytomas for the assessment of endoglin (CD105) expression 
(Bodey et al.,1998). Their assesment was as follows: Strong expression of endoglin (CD105) 
on endothelial cells was demonstrated in all 62 childhood brain tumor cases. The most 
striking feature of the newly formed tumor-related capillaries was the presence of a 
markedly enlarged perivascular space. Blood vessels in several normal human tissues 
(cortex, cerebellum, thymus, tonsil, spleen, lymph node, skin) used as control tissues 
contained significantly lower levels of endoglin (CD105), in accordance with the extremely 
slow turnover rate of normal endothelial cells. A close apposition between the capillaries 
and the adjacent parenchyma was also observed. VEGF/PF-R1 (flt-1) and VEGF/PF-R2 (flk-
1) are formed de novo in a glioma progression-dependent manner. Therfore, they 
considered that brain tumors, especially glioblastomas, are among the most vascularized 
human neoplasms, and thus are candidates for antiangiogenic therapy. In addition, they 
further demonstrated points that substantiate the importance of endoglin (CD105) in the 
earliest possible detection, diagnosis and neoplasm-related angiogenesis inhibition-based 
treatment of mammalian solid neoplasms, especially in childhood brain tumors.  
At present,  a phase 1, first-in human study with the human/murine chimeric anti endoglin 
(CD105) monoclonal antibody TRC105 is ongoing in patients with refactory advanced or 
metastaic solid carcinomas (Fonsatti et al., 2010, Seon et al., 2011).  
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antibodies can suppress established tumors, and the efficacy is markedly enhanced by 
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investigated the anti-metatstatic activity of 3 anti-endoglin monoclonal antibodies (SN6a, 
SN6j, SN6k) in animal models. They showed that SN6a and SN6j effectively suppressed the 
formation of metastatic colonies of murine mammary carcinoma cells in the lung of 
metastaic models and that SN6j, SN6k and their immunoconjugates with deglycosylated 
ricin A-chain were effective in suppressing hepatic metastasis of murine colorectal 
carcinoma cells (Uneda et al., 2009). As a result, they considered that data of their 
investigation were clinically relevant in view of a clinical trial. 
Interestingly, it was shown by Lee et al that anti-angiogenic/anti-tumor effects achieved in a 
prophylactic setting with an oral DNA vaccine encoding murine endoglin, carried by double 
attenuated Salmonella typhimurium to secondary lymphoid organ, i.e., Peyer’s patches(Lee 
et al., 2006). Their approach was as follows; After vaccination, mice were injected with D2F2 
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were less angiogenic. In addtion, the vaccinated mice had a longer overall survival. 
Regarding the effects of an oral DNA vaccine, they speculated that a CD8+ T cell mediated 
immune response induced by this vaccine effectively suppressed dissemination of 
pulmonary metastasis of D2F2 breast carcinoma cells presumably by eliminating 
proliferating endothelial cells in the tumor vasculature. They therefore considered that the 
vaccine strategies can contribute to future therapies for breast carcinomas.  
Regarding brain tumors, Bodey et al. investigated 62 childhood brain tumors including 34 
medulloblastomas and 28 astrocytomas for the assessment of endoglin (CD105) expression 
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human neoplasms, and thus are candidates for antiangiogenic therapy. In addition, they 
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As outlined above, endoglin (CD105) has an important role in tumorigenesis of malignant 
tumors. In addition, based on these collective evidences, it is indicated that endoglin 
(CD105) is a better marker than panendothelial markers, such as CD31, 34, etc., in the 
evaluation of neoangiogenesis and prediction of prognosis in primary brain tumors, 
particularly glioblastomas. Furthermore, endoglin (CD105) is emerging as a prime vascular 
target of antiangiogenetic cancer therapy. Recent studies have shown the systemic 
administration of naked antihuman endoglin monoclonal antibodies to suppress established 
tumors, and that its efficacy is markedly enhanced by combination with a chemotherapeutic 
drug using an antiangiogenic schedule of drug dosing. Therefore, the results of endoglin 
expression in gliomas, PCNLs, and other primary brain tumors could thus eventually lead 
to better performance of therapeutic trials on antiangiogenic treatment for patients with 
these primary brain tumors. 
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The Role of Aquaporines in Brain Tumors 
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1. Introduction 
As about 80% of the brain is water, cerebral edema, associated with various cerebral injuries 
is critical and crucial events as the accumulation of excessive fluids will cause fatal cerebral 
herniation.  
Water molecular channels called aquaporines (AQP) which are small membrane-spanning 
proteins which are expressed at plasma membranes1,2, There are thirteen AQPs which are 
divided by three groups. Recently AQPs plays roles of cell migration3 and proliferation4. In 
central nervous system, eight AQPs (1,3,4,5,6,8,9, and 11) are expressed. AQP4 is expressed 
in astrocytes and AQP1 in cholloid plexus, predominantly.  
Recent researches elucidated the physiological roles of AQPs expands from water channels 
to other function associated with tumor biology. Firstly, AQPs were found in high grade 
malignant tumors5,6. And the expression of AQPs was correlated with metastatic potentials 
of malignant tumors and made easier to tumor cell migrations3. 
To elucidate the characterization of the expression of AQPs especially of AQP 1 and 4, and 
the relation of the expression of VEGF family and their receptors, we had investigated the 
expression of these proteins in various tumors of the central nervous system, 
immunohistochemically 
In this review, we survey the physiological roles of AQP 1 and 4 in central nervous system 
tumor, using our data and recent reports. 
2. Materials and methods 
Thirty-one tumors and three cerebral tissue for control were used at our study until now7,8 
Astrocytomas were reclassified according to WHO classification9 Although we could not 
examine the histology of primary tumors, the histological type of metastatic carcinoma was 
confirmed by the charts. Non-neoplastic cerebral tissue was obtained from three patients 
who underwent cerebral resection for cerebral hemorrhage. No information about 
corticosteroid treatment including dexamemethasone, was obtained in this study. 
3. Immunostainings 
Tissue specimen were immuunostained by ABC methods using antihum an AQP 1, antihum 
an AQP4 polyclonal antibody (H80, diluted 1:50;Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), antihuman VEGF polyclonal antibody (C-1, diluted 1:1000: Santa Cruz  
Biotechnology) and antihuman MIB1-LI monoclonal antibody (diluted 1:100;DAKO, Kyoto 
Japan)   
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4. Results 
In glioma, immunoreaction for AQP1 and 4 were recognized in tumor cells. Negative 
reactions for AQP 1 and 4 in tumor cells of grade 1 meningioma, medulloblastoma, 
neurocytoma, and lymphoma. Some of metastatic carcinoma cells — some of metastatic 
carcinoma cells were negative for AQP4 but a few tumor cells were positive for AQP1. 
Positive reactions for AQP 1 and 4 were recognized in reactive astroglia in the surrounded 
cerebral area of tumor. Immunoreactions for AQP 1 were recognized only endothelial cells 
in neovasculature of gliomas and grade 2 meningioms but normal endothelial cells negative 
for AQP 1 or 4. In grade 2 meningiomas, immunoreactions for AQP1 were detected in tumor 
cells and endothelial cells in neovasculature. A positive correlation of distinctiveness for 
immunoreactions between VEGF-A and C were obtained of expression of AQPs of 
endothelial cells in neovasculature. 
5. Discussion 
Recent researches elucidated the physiological roles of AQPs expands from water channels 
to other functions associated with tumor biology. Firstly, AQPs were found in high grade 
malignant tumors. And the expression of AQPs was correlated with metastatic potentials of 
malignant tumors and made easier to tumor cell migrations. AQP 4 was first cloned from rat 
lung10, played major roles of pathogenesis of neuromyelitis optica11. 
In cerebral tissue, metastatic carcinoma show significant cerebral edema in the surrounded 
area. Reactive astrocytes show positive reactions for AQP1 and 4. The mechanisem of AQPs 
were still unclear., but As AQP4 did not alter blood-brain barrier integry or cerebral 
morphology12 but deletion increased cerebral edema. Tail et al suggested the AQP4 played 
the elimination of cerebral edema using rat experimental SAH models13.  
AQP4 was massively up regulated in high grade astrocytoma and the expression of VEGF 
families tended to show a positive relation to AQP1 and 4 in high grade astrocytoma and 
grade 2 meningioma. Neovasculature in high grade astrocytoma and the adjacent areas of 
metastatic carcinoma showed glomeruoid proliferation of neovasculaturein which the 
physiological blood-brain barrier impaired, showing high VEGFs expression14.  In 
meningiomas, significant peritumoral edema are associated frequently(50-92%)15. But a few 
studies are available for the expression of AQPs about meningioma, Ng et al. found 
increased expression of AQP4 with peritumoral edema in meningioma6. But all cases of 
menigiomas Ng et al studiesd were grade 1. No grade 2 or 3 meningioma was not included. 
Our report showed no expression of AQP4 in tumor cells of grade 1 meningiomas5. Cerebral 
edema in high grede glioma, metastatic carcinoma and meningioma was likely the result of 
the relationship between cerebral blood vessels and AQP4-mediated water transport. 
AQP is expressed in the apical membrane of the choroid plexus and plays a role in forming 
CSF16But Marton et al. reported over expression of AQP 1 in atypical meningioma of 
infancy17. Nagashima et al suggested the dural invasion of meningiomas facilitated  
Expressions of AQP1 played some physiological roles of cystic formation of cholloid plexus 
tumors18. As we describes, Nielsen et al reported that normal cerebral endothelial cells were 
negative for AQP1 but highly expressed in the endothelial cells of peripheral area of injuries, 
and cultured endothelial cells without astrocytes are also positive for AQP1. These data 
suggested that astrocytes endofeet may regulates adjacent endothelial cells in the 
endothelial cells in normal cerebral capillaries o switch off endothelial AQP 1 expression.  
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Our study could obtain the positive reactions of AQP1 in high grade glioma and grade 2 
meningiomas but not in benign tumors.  
In tumor biology, AQP1 deletion in mice reduceds tumor growth and migration of 
endothelial and astroglia19. The migration of cells are closely related tumor malignancy, The 
biological roles of AQP 1 for arachnoid cell differentiation were uncertain, but our results 
suggested AQPs played some roles of take a malignant potentials of meningiomas..  
 In this study we could not take no informations about cerebral edema. Furthers studies 
about the relations between cerebral edema and the expressions of AQPs of meningiomas 


















Fig. 1. Histological and immunohistochmeical findings of glioblastoma. 
Histological findings (upper left) and immnunohistochemical staining for AQP4 (upper left 
and lower left and right). Positive findings for AQP4 are recognized in endothelial cells and 
tumor cells. 
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Fig. 1. Histological and immunohistochmeical findings of glioblastoma. 
Histological findings (upper left) and immnunohistochemical staining for AQP4 (upper left 
and lower left and right). Positive findings for AQP4 are recognized in endothelial cells and 
tumor cells. 
 
























Fig. 2. Histological and immunohistochmeical findings of metastatic adenocrcinoma. 
Histological findings (upper left) and immnunohistochemical staining for AQP4 (upper left 
and lower left and right). Positive findings for AQP4 are recognized in endothelial cells and 
reactive astroglia. 
 























Fig. 3. Immunohistochemical findings of atypical meningioma. 
Immunohistochmeical staining for VEGF (upper left), for AQP1 (upper right and lower left) 
and for AQP4 (lower right).  
Positive findings for AQP4 in tumor cells and for AQP1 in tumor and  endothelial cells are 
recognized.  
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1. Introduction 
Gliomas are the most frequent primary brain tumors and are classified as grade I to IV 
according to their degree of malignancy (Daumas-Duport et al., 1988). Grade I and II 
gliomas are clinically benign or semi-benign with relatively long-term survival, while grade 
III and IV are malignant and lethal within several years. In particular, glioblastoma 
multiforme (GBM), the most malignant glioma as grade IV often relapse even after radical 
surgical resection and standard chemo/radiation therapies, because of their diffuse 
infiltration into the surrounding brain parenchyma and high degree of 
chemo/radioresistance. Despite extensive efforts, the overall survival of GBM patients 
remains still short and has not yet been dramatically improved for more than several 
decades. 
GBMs are often composed of various types of cells with distinct morphology and clinical 
phenotypes. Their histological and biological multiformity has been classically explained by 
the stochastic clonal evolution model (Nowell, 1976). According to this model, all tumor 
cells should have low but inheritable ability to form tumors. However, recent evidence has 
suggested another concept, the cancer stem cell (CSC) hierarchy model, which shows that 
only a rare stem cell population has high ability to proliferate (Jordan et al., 2006). CSCs 
have similar characters to normal stem cells in the way of having high ability to self-renew 
and differentiate into multiple types of progenies to organize tissue architectures. 
Exclusively, CSCs can proliferate uncontrollably to propagate tumor cells. CSC model have 
direct relevance with tumor replenishment, disease recurrence and metastatic activity, 
suggesting that CSCs should be the target to eradicate the tumors.  
The aim of this chapter is to provide our insights into how CSCs in human glioma; i.e. 
glioma stem cells (GSCs) should be attacked. In the first parts, we summarize the general 
basis of CSC concept inclusive of the current knowledge on how a CSC is defined, how 
CSCs should be technically prepared and modeled, and what characteristics CSCs possess. 
In the following part, we highlight what abnormal signaling pathways regulate CSCs as the 
potential therapeutic targets. Understanding the framework of a GSC research field could 
help us to think of novel treatment strategy. Most importantly, however, CSCs have 
enhanced resistance to conventional chemotherapies. Considering this fact, we finally 
propose that it could be most promising strategy to disrupt the extracellular environments 
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supporting GSCs, which is a newly emerging concept “niche therapy”. We present possible 
cellular and molecular components of GSC niche and discuss their potentiality as innovative 
therapeutic targets. 
2. General outlines of cancer stem cell 
2.1 Heterogeniety of cancer tissue 
Over the past several decades, the idea that cancer tissues are heterogeneous and composed 
of multiple subpopulation of cells differing in morphology, proliferation rate, metastatic 
potential, marker expression, and sensitivity to chemo/radiation therapies, has been highly 
appreciated by many investigators. This tumor heterogeneity has been classically explained 
by the following two models (Figure 1). 
Clonal evolution (stochastic) model: Cells may acquire various combinations of genetic and 
epigenetic mutations asynchronously and once such mutations confer selective advantages 
of tumor malignancy, more aggressive and adaptive clones can dominate the whole tumor 
population. 
In 1976, Nowell proposed the evolutionary view into tumor progression as a stochastic 
process of genetic instability and natural selection (Nowell, 1976). According to this model, 
tumor initiation occurs in the individual cells receiving multiple mutations, and cells having 
an advantageous mutation of growth can clonally proliferate and selectively occupy an 
entire tumor. During tumor progression, genetic instability yields the additional mutations 
by chance, resulting in a diversity of genome and cell characteristics, such as being invasive, 
metastatic and therapy-resistant. The adaptation to surrounding microenvironment is also a 
determinant of the selection. Standing on this concept, all the tumor cells should have low 
but inheritable ability to form tumors, therefore, the rational targets for cancer therapy is 
most or all of tumor cells. After this proposal, researchers have confirmed clonal expansions 
and genetic heterogeneity within various types of human neoplasms. 
Hierarchy (cancer stem cell) model: Cells may acquire various genetic and epigenetic 
mutations that confer stem-like characteristics, and divide to produce its identical copy (self-
renewal) and progenies terminally growth-arrested (differentiation). Such a hierarchy in a 
stem cell division manner results in cellular diversity of a rare stem cell and a majority of 
multiple types of progenies. 
The CSC model is not a newly emerging concept indeed. The efforts to gain insights into 
tumor’s malignant potential, especially their differential sensitivity to anticancer drugs were 
made on this concept with specimens from patients with myeloma and with ovarian cancer 
(Salmon et al., 1978). The technological advances of flow cytometry and discovery of stem 
cell surface antigens accelerated investigators to ascertain this concept, starting in human 
leukaemia (Bonnet and Dick, 1997) along with the subsequent identification in breast (Al-
Hajj et al., 2003) and brain tumor (Singh et al., 2003). 
Normal stem cells replenish normal tissues by fresh cells continuously throughout life in 
individual organs. Stem cells are characterized by two main hallmarks; those are 
multipotency and self-renewal capacity. The former is the ability to produce multiple types 
of functional progenies, which is associated with terminal growth-arrest. Self-renewal is the 
ability to produce new stem cells identical to original one with retaining the intact two main 
hallmarks, and thereby maintains the stem cell pool. Likewise, tumors are also organized as 
a hierarchy where rare CSCs stand at the top of pyramid with extensive potential to 
proliferate and self-renew and are responsible for maintaining the homeostasis of the tumor 
bulk, except that CSCs disorderly propagate tumor cells and increase cell number. 
 






























































Fig. 1. The color of the arrow for 2nd mutation in Hierarchy model is changed from pale 
yellow to light blue.  
In this concept, cancer heterogeneity means the different characteristics between CSC and 
differentiated cancer progenies. However, the clonal evolution model and the CSC model 
are not necessarily mutually exclusive. Despite types of primary cells to suffering the first 
set of mutations, CSCs also have genetic instability, which increases the probability of 
acquiring additional mutations. Potentially, CSCs might expand clonally by a symmetric 
division. The adaptation to surrounding microenvironment has also been recognized as 
important factors on normal stem cell maintenance, which is called stem cell niche. 
Therefore, we should consider the CSC model as a revised version by taking the idea of 
asymmetric division. However, we must note again that only rare CSCs are tumorigenic by 
definition and specific targets for cancer eradication is in a minority population within a 
tumor bulk. 
2.2 Definition of cancer stem cell 
CSCs are re-defined in the AACR Workshop 2006 on Cancer Stem Cells as “a small subset of 
malignant cells that constitute a pool of self-sustaining cells with the exclusive ability to 
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maintain the tumor” (Clarke et al., 2006), and in part share the fundamental properties with 
normal stem cells specific to their original organs; e.g. neural stem cell for glioma. 
2.3 Current methods to isolate cancer stem cell 
In current studies, CSCs from cancer tissues and cell lines are firstly isolated by using 
diverse experimental techniques as mentioned below. 
Sphere formation assay: Floating spherical cell clusters are formed in vitro when mitotic 
cells are cultured in serum-free media supplemented with mitogens (epidermal growth 
factor and fibroblast growth factor for neural stem cells) (Figure 2), which is originally 




Fig. 2. Glioma spheres generated from oncogenic Ras-transformed human astrocytes (A) and 
differentiation of dissociated sphere cells by culturing in 10%FBS media for 1 week (B). 
When cells are derived from brain, breast and others, each sphere is called neurosphere, 
mammosphere, and others, respectively. The number and diameter of spheres are thought 
to reflect the frequency of stem cells and mitotic activity of a single stem cell within the 
examined population, respectively. When a 1st sphere is picked up, re-dissociated into 
single cells, and re-cultured, the generated secondary spheres imply the sustained self-
renewal potential of a true stem cell. For a while, this method has been utilized to expand 
cancer stem cell population by serial passage, but Bexell et al. recently showed that sphere 
formation is not prerequisite for enrichment of CSCs, and pointed out that glioma cells 
growing as monolayers are also tumorigenic (Bexell et al., 2009), like in the case of neural 
stem cells that can be maintained in monolayer cultures (Johe et al., 1996). In addition, it is 
virtually impossible to form spheres of CSC that have arisen from a tissue in which the 
condition of sphere assay is unestablished for normal stem cells, and even if spheres are 
formed, it is uncertain if they have significance for stem cell activity in the tissues. Therefore, 
we must note that sphere formation assay has limited utility for isolation of some types of 
CSCs. 
Hoechst 33342 dye effluxing side population (SP): Hoechst 33342 is a fluorescent dye that 
binds to the AT-rich regions of DNA, and most cells are stained with this dye. In most cases, 
stem cells are not stained due to the high expression of ABC transporter family genes to 
efflux this dye. Human fetal neural stem/progenitor cells express high levels of multidrug 
resistance 1 (MDR1, also known as ABCB1, P-gp) gene and ATP-binding cassette sub-family 
G member 2 (ABCG2, also known as Bcrp), and these transporters have important roles in 
normal physiology on the active efflux of xenobiotics from cell body, protecting cells from 
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cytotoxic agents. Cells with the capacity to efflux the dye were first identified in the mouse 
bone marrow (Goodell et al., 1996). After staining with Hoechst 33342 dye and exposure to 
UV laser during FACS, a population is referred to as side population (SP) cells because it 
appears as a “side” relative to the positively stained “main” population (MP) in FACS plots 
(Figure 3). Since this discovery, SP technique is applied to enrich putative stem cells and 
progenitors in a number of normal tissues and malignant tumors, including glioma. SP cells 
preferentially express high levels of stemness genes and are capable of differentiating into 
multiple lineages, and thus are considered to function as stem cells in the original tissues 
and tumors (Dean et al., 2005). Importantly, this method itself may affect the tumorigenic 
potential because Hoechst dye is toxic for cells. Minimally toxic concentrations of Hoechst 
33342 should be also determined in the individual experiments. Rhodamine 123, which is a 
mitochondrial dye reflecting mitochondrial content and kinetics, has been used as a less 
toxic dye, by which quiescent stem cells display a low fluorescence in the flow cytometry 
plots. Human bone marrow hematopoietic stem cells (HSCs) have been demonstrated to be 
isolated by the combination of Hoechst 33342 and Rhodamine 123 (Leemhuis et al., 1996). In 
addition, some investigators have reported that MP cells in human GBM biopsies are also 
tumorigenic in mice, although transplantation of SP cells result in a shorter survival of mice 





















Fig. 3. FACS plots expanded by side population analysis (A) and representative images of 
SP (B) and MP (C) cells in the C6 glioma cell line. 
Stem cell surface antigens: Potential CSCs can be identified by striking variety of cell 
surface markers or their combinations; e.g. CD34(+)CD38(−) for AML (Bonnet and Dick, 
1997), CD44(+)CD24(−/low) for breast tumor (Al-Hajj et al., 2003) and CD133(+) for brain 
tumor (Singh et al., 2003). However, these methods based on the surface molecules have 
increased some contradiction. For instance, different stem cell markers identify distinct 
subpopulations of cells in one tumor, in all of which population CSC properties may 
sometimes confirmed. In melanoma, at least four subpopulations, CD20(+), CD133(+), BrdU 
label-retaining cells, and SP cells has been separately identified, all of which possess stem 
cell features (Zabierowski and Herlyn, 2008). This diversity of CSC markers suggests that 
one population isolated by certain surface molecules is still heterogeneous, and that 
complete enrichment of CSCs has not been achieved at least in some particular tumor types. 
Furthermore, the frequency of CSCs is highly variable even among the same type of tumors. 
In colorectal tumors, the frequency of tumor initiating cells assessed in NOD/SCID mice 
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Fig. 3. FACS plots expanded by side population analysis (A) and representative images of 
SP (B) and MP (C) cells in the C6 glioma cell line. 
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label-retaining cells, and SP cells has been separately identified, all of which possess stem 
cell features (Zabierowski and Herlyn, 2008). This diversity of CSC markers suggests that 
one population isolated by certain surface molecules is still heterogeneous, and that 
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broadly ranges from 1.8 to 24.5% (O'Brien et al., 2007), pointing out the requirement for 
more refined markers (or their combinations) and assay systems. Nevertheless, it is evident 
that these surface markers and their roles are important keys to unveil the regulatory 
pathway to maintain CSCs. Actually, in many studies on human brain tumors, GSCs are 
isolated by the elevated expression of CD133, and the CD133(+) subpopulation has the 
higher ability than the other populations to regenerate the original tumors in 
immunodeficient mice (Singh et al., 2004). 
ALDEFLUOR (aldehyde dehydrogenase activity): Measurement of ALDH activity is a 
recent approach for isolation of putative CSCs. The main function of ALDH enzyme is the 
oxidation of intracellular aldehydes. Several isoforms of ALDH family are identified in 
human, and ALDH1 is the primary isoform isolated from human hematopoietic progenitors. 
Recent studies have shown that human and murine hematopoietic progenitors can be 
isolated using the bodipy-aminoacetaldehyde (BAAA, commercially available in a diethyl 
acetate form as ALDEFLUOR), a fluorescent labeled substrate specific for ALDH activity 
(Ginestier et al., 2007). ALDH1 has a role in early differentiation of hematopoietic stem cells 
(HSCs) through conversion of retinol to retinoic acid (Chute et al., 2006). Increased ALDH 
activity is also found in normal neural stem cells and CSC in acute myeloid leukemia (AML) 
(Pearce et al., 2005) and breast carcinomas (Korkaya et al., 2008). 
Xenotransplantation into immunodeficient mice: The first evidence of CSCs was obtained 
by transplantation experiments in the severe combined immunodeficient (SCID) mouse 
(Lapidot et al., 1994), and it was later re-demonstrated in the nonobese diabetic 
(NOD)/SCID mouse (Bonnet and Dick, 1997). However, the use of NOD/SCID mice, which 
T cells and B cells are lacked, has the risk to underestimate the frequency of tumorigenic 
human cancer cells due to the immune response of natural killer cells against the xenobiotic 
cells. Actually, the percentage of melanoma stem cells that form tumors in NOD/SCID/ 
interleukin-2 receptor γ chain (IL2Rγ)-null (NOG) mice, which lack not only T and B but 
natural killer cells, is higher than that in NOD/SCID mice; one in 1000 melanoma cells form 
tumors in NOD/SCID mice, but 1 in 4 can form tumors in NOG mice (Quintana et al, 2008), 
suggesting that the reported frequency of CSCs should be reevaluated in some cancers by 
using the more highly immunocompromised model. Thus current gold standard assay for 
testing whether each cell population fulfils the criteria of CSC (self-renewal, differentiation 
and tumorigenicity) is the orthotopic xenograft experiment where cells are transplanted at 
limiting dilutions into NOD/Shi-scid/IL2Rγ-null (NOG) mice and the frequency of CSCs is 
determined. Especially, serial transplantation into NOG mice is regarded as the best 
functional assay for testing the long-term self-renewal capacity. However, even the use of 
NOG mouse might underestimate the frequency of CSCs due to different tissue 
environment between mouse and human. If mouse ligands such as growth factors and 
adhesion molecules do not have the compatibility with human receptors, tumorigenic 
human cells might lose the ability to proliferate and survive in mice. Also, even being 
compatible, rodent normal tissues could not precisely recapitulate the patients’ tumor 
microenvironment. Therefore, the challenges to establish humanized mouse models in 
which human microenvironment is recapitulated in an animal are recently highlighted.     
2.4 Clinical implications of cancer stem cell 
CSC model has important implications for clinical treatment of tumors, because some 
features of CSCs make them particularly difficult to kill. CSCs reside in relatively quiescent 
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state on cell cycle referred as in the state of “dormancy” and this allows them to evade from 
typical chemotherapeutic regimens that target actively proliferating cells. Many 
investigators attempt to kill tumor cells independently of the cell cycle state or to selectively 
prompt them to enter the cycling state. Moreover, CSCs express the high level of multidrug 
resistant proteins and transporters associated with detoxification, and they are consequently 
conferred multidrug resistance by expelling chemotherapeutic reagents (Dean et al., 2005). 
In addition, CSCs are frequently resistant to standard radiotherapy regimens owing to their 
elevated expression of reactive oxygen species (ROS) scavenging (Diehn et al., 2009) and 
DNA damage response (Bao et al., 2006) genes. Unexpectedly, conventional 
chemo/radiotherapy eventuates in an increased proportion of CSC fraction and in rapid 
relapse of original tumor. Long-term treatment of PTEN-/- neurospheres isolated from 
PDGF-induced gliomas with temozolomide, a standard therapy for GBM patients, induces 
an increase in the amount of SP cells (Bleau et al., 2009). An effective therapeutic approach 
to CSCs enhancing the sensitivity of chemotherapeutic drugs and radiation is therefore 
imperative to develop. 
2.5 Origin of cancer initiating cell 
The revival of CSC concept triggers a debate on whether cancer origin is stem cells or 
terminally differentiated cells. Since 1970s, a large corpus of studies on direct introduction of 
viral oncogenes and mutated genes isolated from patients’ tumors has demonstrated that 
most of normal cells are susceptible to genetic mutations leading to neoplastic 
transformation for the initiation and expansion of tumors. In addition to these findings, the 
observation that a large proportion of tumor cells retain the features of the surrounding 
differentiated epithelium has assured our common interpretation that oncogenic gene 
mutations occur in terminally differentiated cells. However, there are several controversial 
examples that are still difficult to explain standing on this concept for tumor cell origin. For 
example, malignant tumors histologically contain some degree of undifferentiated 
components, but differentiation of cells had been regarded as a unidirectional process under 
normal physiological conditions, and nuclear reprogramming had remained to be clarified 
until recent achievement of nuclear transfer, ES cell-fusion, or creating the induced 
pluripotent stem (iPS) cells (Yamanaka and Blau, 2010). In addition, terminally 
differentiated cells cannot normally divide to proliferate in vivo and thus the possibility is 
low that such sleeping cells have in sequence the opportunities to acquire oncogenic gene 
mutations, although they often undergo spontaneous immortalization in vitro and 
proliferate infinitely as cell lines. In fact, cancers prone to occur in specific tissues with the 
high rate of turnover in cell division, such as skin and gut but not heart. It is conceivable 
that this is a consequence of genetic instability during the frequent divisions of stem cells. 
3. Glioma stem cell 
3.1 Discovery and isolation 
Subsequent to the identification in human AML and breast tumor, CSCs in human glioma 
i.e. glioma stem cells (GSCs) were initially identified in 2004 according to the cell surface 
expression of CD133 protein (Singh et al., 2004). CD133 is one of two members of pentaspan 
transmembrane glycoprotein prominin family and a human homolog of originally isolated 
mouse PROM1 selectively localizing at the apical surface of murine neuroepithelial stem 
cells (Weigmann et al., 1997) and HSCs from human fetal liver, bone marrow and cord 
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blood (Yin et al., 1997). Notably, 100 CD133(+) cells recapitulated the original tumor 
identical to original patients’ tumors in histopathological features, whereas 100,000 
CD133(−) cells could not form any tumors in NOD/SCID mouse brains (Singh et al., 2004). 
Therefore, it was postulated that like normal neural stem-cells (NSCs), stem-like glioma cells 
may compose a glioma hierarchy upon differentiation and that their differentiation lineages 
determine tumor subtypes, i.e. astrocytomas or oligodendrogliomas. On the same year, 
Kondo et al. also succeeded in concentrating GSCs as stem-like SP cells from a rat C6 glioma 
cell line (Kondo et al., 2004). Since these discoveries, many investigators have confirmed the 
major utility of CD133, SP technique, and others for GSCs isolation (Table 1).  
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Kondo et al. 2004
A2B5 antigen Flow cytometry sorting by the expression of a glial progenitormarker A2B5 tumor formation Ogden et al. 2008
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Integrin alpha 6 Magnetic sorting or flow cytometry sorting by integrin alpha 6expression alone or in combination with CD133 expression
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Table 1. Cell surface markers and functional assays for the isolation of glioma stem cells 
However, these methods indeed produce some contradictory. First, accumulating reports 
have demonstrated the presence of CD133(-) GSCs (Ogden et al., 2008). Some of fresh GBM 
specimens and commonly used glioma cell lines do not express CD133, but nevertheless 
they can form tumors in vivo (Beier et al., 2007). Second, CD133(+) population in human 
gliomas are generally found at a very low frequency in flow cytometry and sometimes 
barely detectable, which lead to the concept that CSCs are a rare subpopulation in solid 
tumors, but immunohistochemical analysis by several groups and us have demonstrated 
that some of human GBMs contain high CD133(+) fractions (Figure 4B). This discrepancy 
has been thought to be partially caused by the limitation of FACS analysis; i.e. trypsin 
digestion during preparation of cell suspensions is predicted to cleave the 865-amino acids 
long-CD133 sequences at 79 different sites. And many of cleavage sites by trypsin are within 
the glycosylated extracellular loops containing AC133 or AC141 epitopes, although the 
majority of studies on CD133 have ever made use of antibodies against AC133 or AC141 
glycosylated epitopes. Third, CD133 expression was found to be retained in differentiated 
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cancer cells when a glucosylation-independent CD133 antibody was used (Florek et al., 
2005). Other studies also have demonstrated that the expression of AC133 and AC141 
epitopes is down-regulated independently of CD133 mRNA (Corbeil et al., 2000), and that 
the distribution of CD133 mRNA in adult tissues is much wider than that of 
immunoreactivity to the AC133 epitope (Miraglia et al., 1997). Furthermore, human CD133 
transcripts have alternatively spliced variants devoid of AC133 or AC141 epitopes (Fargeas 
et al., 2007), and cytoplasmic localization of CD133 is also observed in human glioma 
sections (Sakariassen et al., 2007). In addition, we also found in human GBM sections the 
broadly ranged frequency of CD133(+) cells using an antibody against C-terminal 
intracellular region of CD133 (Figure 4A and B) and distinct discordance on the expression 





Fig. 4. (A and B) Different levels of CD133 expression in two human GBM tissues. Each 
tissue was stained with an anti-CD133 antibody. Relatively high frequency of CD133(+) cells 
are observed in B, but rarely detected in A. (C and D) The expression levels of two neural 
stem cell markers CD133 and Nestin does not coincide in the same GBM tissue. A GBM 
tissue was stained with an anti-CD133 (C) and nestin (D) antibody. 
Given these unresolved problems might lead to our underestimation of the size of true 
GSCs, it must be again deliberated whether CD133 could be utilized as a marker for GSC 
isolation. It may be one goal in future studies to find other markers (or their combination 
with CD133) to accurately define GSC population. 
In contrast, SP method can compensate the disadvantage of cell surface marker-dependent 
isolation that fails when stem cell markers are unknown. Subsequently to the study with the 
C6 glioma cell line, SP cells have been detected in not only human glioma cell lines U87MG, 
T98G, U251 and U373, but also two primary gliomas in transgenic mouse models; Ntv-
a/Ink4a−/−Arf−/−PTENflox/flox mice (Bleau et al., 2009) and S100β-verbB:p53−/− mice (Harris 
et al., 2008), which are reported to be more self-renewable and tumorigenic than MP cells 
and able to reconstitute cellular heterogeneity. However, the isolation of SP cells from 
primary human GBMs and relevant correlation between SP and glioma malignancy have 
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been little reported. Interestingly, Pollard and colleagues have proposed a protocol for the 
efficient establishment of GSC lines as culturing on laminin-coated flask, in which GSCs 
could be expanded in adherent culture for at least 1 year (>20 passages) with retaining stem 
cell properties and tumor initiation capacity (Pollard et al., 2009). They pointed out some 
problems on the use of the traditional neurosphere culture in GSCs isolation and 
highthroughput assays i.e. drug screenings. First, they claimed that the efficiency to 
successfully establish GSC lines from primary tumors is very low (from 1 to 30%). Second, 
spheroid cells tend to spontaneously undergo differentiation and apoptosis, and therefore it 
is complicated to identify the precise molecular targets against the true GSCs. Finally, the 
non-adherent aggregates make real-time observation of cellular behaviors more challenging, 
compared to adherent cells. Actually, they provided a proof-of-principle chemical screen 
using a live-cell imaging system to monitor the effects of FDA (Food and Drug 
Administration)-approved 450 compounds for potential anti-GSC activity, and identified 23 
compounds having cytotoxic activity against all tested GSCs. This approach could greatly 
improve the work to probe GSC biology and to identify agents that selectively and directly 
target GSCs. 
3.2 Signalling to regulate GSC (Therapeutic candidate) 
GSC now attracts much attention with expectations that targeting GSCs could induce 
effective eradication of glioma. Currently, remarkable insights have been gained regarding 
intracellular and extracellular signalling pathways that are crucial in GSC malignancies 
(Figure 5), all of which are potential candidates for anti-GSC therapy.   
3.2.1 Membrane-bound receptor-mediated signalling 
Receptor tyrosine kinases (RTKs) 
RTKs are the cell surface receptors for many growth factors, cytokines, and hormones, and 
have been known as not only key regulators of normal cellular processes but also critical 
stimuli in the development of many cancers.  
The most frequent genetic alteration associated with human GBMs is amplification of EGF 
receptor (EGFR) gene, and its overexpression is observed in approximately 50–60% of GBM 
patients. The most common EGFR mutant is EGFRvIII, which is an in frame deletion variant 
that has a truncated extracellular domain with ligand-independent constitutive activity. The 
Ink4a/Arf−/− astrocytes dedifferentiate in response to EGF. Moreover, transduction of 
EGFRvIII into Ink4a/Arf−/− neural stem cells (NSCs)/astrocytes induces tumors displaying a 
common high-grade glioma phenotype (Bachoo et al., 2002). Soeda et al. (2008) have 
demonstrated that human GBM CSCs retain their self-renewal ability in the presence of EGF 
and that the tyrosine kinase inhibitors of EGF signaling, AG1478 and gefitinib suppress the 
proliferation and self-renewal of these cells. Mazzoleni et al. (2010) also have showed that 
EGFR expression is heterogenous in human GBMs and its high expression can identify tumor 
initiating cells. Interestingly, genomic heterogeniety of EGFR gene links to mutual 
communication between tumor cells, in which IL-6 and LIF proteins secreted from EGFRvIII-
expressing GBM cells enhance wild-type EGFR-expressing GBM cell growth (Inda et al., 2010). 
From these data, targeting of EGFR seems reasonable for eradication of GSCs. However, 
despite several inhibitors of EGFR are now available in the glioma clinic, their efficacy is 
limited, suggesting that some combinatorial approach could improve clinical outcome. 
 







































































Fig. 5. Extracellular signaling and intracellular factors regulating glioma stemness. 
PDGF functions in the later period in development as a potent mitogen of oligodendrocyte 
precursor cells (OPCs). OPCs express PDGF receptor (PDGFR), and PDGF is important for 
regulating OPC number and oligodendrocyte production. Additionally, PDGF signaling has 
been closely associated with the formation of glioma. Activation of PDGF pathway has been 
found in more than 80% of human oligodendrogliomas and in 50-100% of human 
astrocytomas. Daii et al. have reported that PDGF-B overexpression causes the proliferation 
of Nestin+ neural progenitors to form human oligodendroglioma-like tumors and also 
induces the dedifferentiation of GFAP(+) astrocyte into glial precursor-like cells (Dai et al., 
2001). Recently, PDGFRα-expressing cells in the adult subventricular zone (SVZ) have been 
proposed as adult NSCs, and they are known to exhibit hyperplastic proliferation in 
response to excessive PDGFR activation (Jackson et al., 2006). These data suggest that 
PDGF/PDGFR pathway may contribute to not only glioma progression but also glioma 
initiation originated from immature stem-like cells. 
 
Molecular Targets of CNS Tumors 
 
160 
been little reported. Interestingly, Pollard and colleagues have proposed a protocol for the 
efficient establishment of GSC lines as culturing on laminin-coated flask, in which GSCs 
could be expanded in adherent culture for at least 1 year (>20 passages) with retaining stem 
cell properties and tumor initiation capacity (Pollard et al., 2009). They pointed out some 
problems on the use of the traditional neurosphere culture in GSCs isolation and 
highthroughput assays i.e. drug screenings. First, they claimed that the efficiency to 
successfully establish GSC lines from primary tumors is very low (from 1 to 30%). Second, 
spheroid cells tend to spontaneously undergo differentiation and apoptosis, and therefore it 
is complicated to identify the precise molecular targets against the true GSCs. Finally, the 
non-adherent aggregates make real-time observation of cellular behaviors more challenging, 
compared to adherent cells. Actually, they provided a proof-of-principle chemical screen 
using a live-cell imaging system to monitor the effects of FDA (Food and Drug 
Administration)-approved 450 compounds for potential anti-GSC activity, and identified 23 
compounds having cytotoxic activity against all tested GSCs. This approach could greatly 
improve the work to probe GSC biology and to identify agents that selectively and directly 
target GSCs. 
3.2 Signalling to regulate GSC (Therapeutic candidate) 
GSC now attracts much attention with expectations that targeting GSCs could induce 
effective eradication of glioma. Currently, remarkable insights have been gained regarding 
intracellular and extracellular signalling pathways that are crucial in GSC malignancies 
(Figure 5), all of which are potential candidates for anti-GSC therapy.   
3.2.1 Membrane-bound receptor-mediated signalling 
Receptor tyrosine kinases (RTKs) 
RTKs are the cell surface receptors for many growth factors, cytokines, and hormones, and 
have been known as not only key regulators of normal cellular processes but also critical 
stimuli in the development of many cancers.  
The most frequent genetic alteration associated with human GBMs is amplification of EGF 
receptor (EGFR) gene, and its overexpression is observed in approximately 50–60% of GBM 
patients. The most common EGFR mutant is EGFRvIII, which is an in frame deletion variant 
that has a truncated extracellular domain with ligand-independent constitutive activity. The 
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Fig. 5. Extracellular signaling and intracellular factors regulating glioma stemness. 
PDGF functions in the later period in development as a potent mitogen of oligodendrocyte 
precursor cells (OPCs). OPCs express PDGF receptor (PDGFR), and PDGF is important for 
regulating OPC number and oligodendrocyte production. Additionally, PDGF signaling has 
been closely associated with the formation of glioma. Activation of PDGF pathway has been 
found in more than 80% of human oligodendrogliomas and in 50-100% of human 
astrocytomas. Daii et al. have reported that PDGF-B overexpression causes the proliferation 
of Nestin+ neural progenitors to form human oligodendroglioma-like tumors and also 
induces the dedifferentiation of GFAP(+) astrocyte into glial precursor-like cells (Dai et al., 
2001). Recently, PDGFRα-expressing cells in the adult subventricular zone (SVZ) have been 
proposed as adult NSCs, and they are known to exhibit hyperplastic proliferation in 
response to excessive PDGFR activation (Jackson et al., 2006). These data suggest that 
PDGF/PDGFR pathway may contribute to not only glioma progression but also glioma 
initiation originated from immature stem-like cells. 
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RTK signallings are transmitted into nucleus by intracellular molecules, such as Ras/ERK 
and PI3K/Akt. Given that the combined activation of Ras and Akt in nestin(+) neural 
progenitors induces GBM in mice (Holland et al., 2000) and that the activity of drug 
transporter ABCG2 is regulated by PI3K/Akt pathway (Bleau et al., 2009), RTK signalling 
might control multiple behaviors of GSC in glioma progression and therapy-resistance. 
Transforming growth factor-beta (TGF-β) 
TGF-β superfamily proteins play a critical role on morphogenesis and cell lineage 
specification during brain development. In response to TGF-β, Smad2/3 becomes 
phosphorylated and forms a heterodimeric complex with Smad4, and then its complex is 
translocated into the nucleus to transactivate downstream target genes. Bone morphogenetic 
proteins (BMPs) belonging to a subset of the TGF-β superfamily is known to maintain self-
renewal and multi-lineage differentiation potential of NSCs within the SVZ of the adult 
brain. In human GBMs, enhanced expression of the TGF-2 and TGF receptor I/II are 
detected. Two groups have reported that TGF-β enhances human GBM stemness and 
tumorigenic activity; one is through Sox4-mediated Sox2 induction (Ikushima et al., 2009) 
and another is through the induction of LIF secretion in an autocrine/paracrine fashion 
(Peñuelas et al., 2009). Consistent with these data, TGF-β receptor I inhibitor LY2109761 and 
SB431542 decrease the CD44high/Id1high GBM CSCs population through the repression of Id1 
and Id3 levels (Anido et al., 2010). However, TGF-β family proteins can function as both 
oncogenes and tumor suppressors. Lee et al. (2008) have reported that the expression of 
BMP receptor 1B is downregulated in human GBM CSCs through EZH2-dependent 
epigenetic silencing and thereby tumor stemness is maintained with impaired astroglial 
differentiation. Although these opposite roles of TGF-β on differentiation has remained to 
be resolved, these data indicate that TGF-β family proteins and their downstream targets 
have fundamental roles in glioma stemness and suggest that control of them could yield 
glioma eradication. 
Interleukin-6 (IL-6) 
IL-6 family of cytokines stimulate cells by forming the receptor complex composed of the 
each cytokine-specific receptor and the common component gp130 glycoprotein, leading to 
phosphorylation of signal transducers and activators of transcription (STAT3 and, to a less 
extent, STAT1) by gp130-associated janus kinases (JAKs). The phosphorylated STAT3 and 1 
homodimerize and translocate into the nucleus where downstream target genes are 
transactivated. Several reports have shown that GBM tissues contain significantly higher 
levels of IL-6 protein, and higher IL-6 mRNA correlates with poor survival of GBM patients. 
In addition, phosphorylation and nuclear translocation of STAT3 positively correlate with 
the histopathological grade in human glioma samples (Weissenberger et al., 2004). Recent 
papers have demonstrated that targeting of either IL-6 receptor alpha or IL-6 by using 
lentiviral transduced shRNA or IL-6 antibody decrease tumor growth and survival in mice 
bearing intracranially xenografted human glioma (Wang et al., 2009). Likewise, STAT3 
inhbitors (S3I-201 and STA-21) and RNAi-mediated knockdown of STAT3 prevent growth 
of human primary GBM CSCs (Sherry et al., 2009). Leukemia inhibitory factor (LIF), one of 
the cytokines of the IL-6 family which is known to be an essential factor for mouse 
embryonic stem cell self-renewal and maintenance, induces astrocytic differentiation of 
NSCs in cooperation with BMP2. As described above, transactivation of the LIF gene in 
glioma spheres by TGF-β enhances glioma stemness and then results in significantly shorter 
survival in mice when inoculated (Peñuelas et al., 2009). These effects of LIF on GSCs show 
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important contrast to those on NSCs and therefore LIF inhibition might be one potential 
approach whose side-effects are minimized during treatment.        
Sonic hedgehog (Shh), Notch, and Wnt 
Because GSCs share common properties with NSCs, molecular mechanisms underlying self-
renewal and differentiation are usually overlapped among them. The Shh, Notch and Wnt 
pathways play a major role in normal stem cell regulation and also there is much evidence 
that aberration of these pathways cause tumorigenesis.  
Sonic hedgehog binds to the Patched-1 (Ptc1) receptor and in turn activates the transcription 
factors of GLI family by cancelling the Patched-mediated inactivation of Smoothened (Smo). 
Shh signalling regulates neural progenitor proliferation and self-renewal in adult 
cerebellum, and it is well known that deregulation of Shh pathway in cerebellum neural 
progenitors induces medulloblastoma in mouse models. In human GBMs, amplification and 
overexpression of Gli-1 is reported in several types of gliomas. Hsieh et al. (2011) have 
reported that Shh/Gli1 signaling regulates insulin-like growth factor (IGF)-1-dependent 
GSC proliferation and chemo/radioresistance through insulin receptor substrate 1 (IRS1) 
gene transactivation. Xu et al. (2008) have identified Shh-dependent CSCs in some cases of 
human GBMs and found that activity of Shh signaling in PTEN-positive GBMs correlates 
with reduced patients’ survival. 
Notch is a membrane-bound receptor, and its intracellular domain is proteolytically released 
by binding of membrane-associated ligands Delta and Jagged and in turn binds to 
promoters of genes encoding bHLH transcription factors. Notch activation is involved in the 
regulation of NSC self-renewal, but it promotes glial differentiation in some conditions. 
Abnormal activation of Notch signaling has been found in a wide range of human cancers, 
including glioma. Fan et al. (2010) have reported that a γ-secretase inhibitor GSI-18, which 
prevents Notch secretion, suppresses neurosphere clonogenicity in vitro and growth of 
intracranial CD133-positive GBM cells through loss of AKT and STAT3 phosphorylation. 
Importantly, the combination of γ-secretase inhibitors and irradiation can attenuate cell 
growth and clonogenic survival of GBM CSCs (Wang et al., 2010a). 
Wnt signaling pathway also controls the size of the NSC population through β-catenin 
activation. Wnt binds to a transmembrane receptors Frizzled (Fzd), leading to the 
phosphorylation of the Dishevelled, which prevents glycogen synthase kinase 3β (GSK3β)-
dependent degradation of β-catenin. β-catenin translocates into the nucleus where it binds 
to TCF/LEF and displaces corepressors to induce expression of target genes. Although Wnt 
is mutated in a subgroup of medulloblastomas, its role in gliomas is little known. Zheng et 
al. (2010) have recently proposed Wnt signaling as promising targets for GBM treatment. 
They identified PLAGL2 as a protooncogene amplified and/or overexpressed in human 
GBMs. Enhanced PLAGL2 expression promotes GSC self-renewal and contributes to 
gliomagenesis. They showed that PLAGL2 modulates the transcription of Wnt6 and Fzd9 
and Fzd2 receptors, but in this paper transcriptome analysis is examined in only p53−/− 
NSCs, and therefore it remains still unclear whether Wnt contributes to the malignant 
behaviors of GSCs. 
L1CAM 
The neural cell adhesion molecule, L1CAM (CD171) regulates neural cell growth, survival, 
migration during brain development. Although the role of L1CAM in the normal adult 
brain is not well defined, L1CAM is overexpressed in human gliomas and associated with 
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RTK signallings are transmitted into nucleus by intracellular molecules, such as Ras/ERK 
and PI3K/Akt. Given that the combined activation of Ras and Akt in nestin(+) neural 
progenitors induces GBM in mice (Holland et al., 2000) and that the activity of drug 
transporter ABCG2 is regulated by PI3K/Akt pathway (Bleau et al., 2009), RTK signalling 
might control multiple behaviors of GSC in glioma progression and therapy-resistance. 
Transforming growth factor-beta (TGF-β) 
TGF-β superfamily proteins play a critical role on morphogenesis and cell lineage 
specification during brain development. In response to TGF-β, Smad2/3 becomes 
phosphorylated and forms a heterodimeric complex with Smad4, and then its complex is 
translocated into the nucleus to transactivate downstream target genes. Bone morphogenetic 
proteins (BMPs) belonging to a subset of the TGF-β superfamily is known to maintain self-
renewal and multi-lineage differentiation potential of NSCs within the SVZ of the adult 
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detected. Two groups have reported that TGF-β enhances human GBM stemness and 
tumorigenic activity; one is through Sox4-mediated Sox2 induction (Ikushima et al., 2009) 
and another is through the induction of LIF secretion in an autocrine/paracrine fashion 
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extent, STAT1) by gp130-associated janus kinases (JAKs). The phosphorylated STAT3 and 1 
homodimerize and translocate into the nucleus where downstream target genes are 
transactivated. Several reports have shown that GBM tissues contain significantly higher 
levels of IL-6 protein, and higher IL-6 mRNA correlates with poor survival of GBM patients. 
In addition, phosphorylation and nuclear translocation of STAT3 positively correlate with 
the histopathological grade in human glioma samples (Weissenberger et al., 2004). Recent 
papers have demonstrated that targeting of either IL-6 receptor alpha or IL-6 by using 
lentiviral transduced shRNA or IL-6 antibody decrease tumor growth and survival in mice 
bearing intracranially xenografted human glioma (Wang et al., 2009). Likewise, STAT3 
inhbitors (S3I-201 and STA-21) and RNAi-mediated knockdown of STAT3 prevent growth 
of human primary GBM CSCs (Sherry et al., 2009). Leukemia inhibitory factor (LIF), one of 
the cytokines of the IL-6 family which is known to be an essential factor for mouse 
embryonic stem cell self-renewal and maintenance, induces astrocytic differentiation of 
NSCs in cooperation with BMP2. As described above, transactivation of the LIF gene in 
glioma spheres by TGF-β enhances glioma stemness and then results in significantly shorter 
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important contrast to those on NSCs and therefore LIF inhibition might be one potential 
approach whose side-effects are minimized during treatment.        
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Because GSCs share common properties with NSCs, molecular mechanisms underlying self-
renewal and differentiation are usually overlapped among them. The Shh, Notch and Wnt 
pathways play a major role in normal stem cell regulation and also there is much evidence 
that aberration of these pathways cause tumorigenesis.  
Sonic hedgehog binds to the Patched-1 (Ptc1) receptor and in turn activates the transcription 
factors of GLI family by cancelling the Patched-mediated inactivation of Smoothened (Smo). 
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regulation of NSC self-renewal, but it promotes glial differentiation in some conditions. 
Abnormal activation of Notch signaling has been found in a wide range of human cancers, 
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prevents Notch secretion, suppresses neurosphere clonogenicity in vitro and growth of 
intracranial CD133-positive GBM cells through loss of AKT and STAT3 phosphorylation. 
Importantly, the combination of γ-secretase inhibitors and irradiation can attenuate cell 
growth and clonogenic survival of GBM CSCs (Wang et al., 2010a). 
Wnt signaling pathway also controls the size of the NSC population through β-catenin 
activation. Wnt binds to a transmembrane receptors Frizzled (Fzd), leading to the 
phosphorylation of the Dishevelled, which prevents glycogen synthase kinase 3β (GSK3β)-
dependent degradation of β-catenin. β-catenin translocates into the nucleus where it binds 
to TCF/LEF and displaces corepressors to induce expression of target genes. Although Wnt 
is mutated in a subgroup of medulloblastomas, its role in gliomas is little known. Zheng et 
al. (2010) have recently proposed Wnt signaling as promising targets for GBM treatment. 
They identified PLAGL2 as a protooncogene amplified and/or overexpressed in human 
GBMs. Enhanced PLAGL2 expression promotes GSC self-renewal and contributes to 
gliomagenesis. They showed that PLAGL2 modulates the transcription of Wnt6 and Fzd9 
and Fzd2 receptors, but in this paper transcriptome analysis is examined in only p53−/− 
NSCs, and therefore it remains still unclear whether Wnt contributes to the malignant 
behaviors of GSCs. 
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migration during brain development. Although the role of L1CAM in the normal adult 
brain is not well defined, L1CAM is overexpressed in human gliomas and associated with 
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invasive phenotype. L1CAM is highly expressed in CD133(+) glioma cells and that its 
knockdown suppresses glioma growth in vivo and increases survival of xenografted mice 
with downregulation of NSC transcription factor Olig2 and upregulation of cyclin-
dependent kinase inhibitor p21WAF1/CIP1 (Bao et al., 2008). These data suggest that L1CAM is 
a functional marker of GSC and its inhibition might be useful as a CSC–directed therapy. 
3.2.2 Nuclear transcriptional factors 
Signals and stresses from outside of the cells are transduced into nucleus, where expression 
of downstream targets is regulated by transcriptional and/or epigenetic factors, and lead to 
a variety of cellular phenotypes. Some nuclear factors are currently suggested to be essential 
for GSC behaviors and most of them regulate the self-renewal and differentiation. 
Myc 
Zheng et al. (2008) have performed wide-scale transcriptome/promoter studies and found 
strong enrichment of Myc binding elements in human primary GBMs. They revealed that 
the increase of Myc expression by the defect of p53 and PTEN in GBM CSCs withstands the 
differentiation and then enhances tumorigenic potential. These results strongly support pro-
differentiation as a potential strategy against GSCs and encourage the identification and 
screening of agents targeting these differentiation pathways.  
Sox11 
Hide et al. (2009) have identified Sox11 as a candidate to induce differentiation in GSCs. 
Sox11 is exclusively overexpressed in non-tumorigenic glioma cells, and overexpression of 
Sox11 inhibits tumorigenesis of GSCs by inducing their neuronal differentiation. Sox11 is 
expressed in the committed neuronal precursor cells but not in NSCs, and negatively 
regulates the expression of PLAGL1, which is expressed in developing neuroepithelial cells. 
Knockdown of PLAGL1 significantly improves overall survival of xenotransplanted mice. 
Considering that PLAGL2 also regulates GSC self-renewal (Zheng et al., 2010), these PLAG 
family genes of transcriptional factors might play essential oncogenic roles. As both 
PLAGL1 and PLAGL2 are known to activate IGF2 promoters, the relevance between PLAG 
genes, Shh, IGF, and Wnt suggest that highly complicated cross-talk of multiple signaling 
regulates GSC features. 
Nkx2.2 
Muraguchi et al. (2011) have recently identified the homeodomain transcription factor 
Nkx2.2 as an inducer of GSCs toward oligodendroglial differentiation by using a 
sophisticated mouse models developing glioma at 100% penetrance. During normal 
development of brain, Nkx2.2 cooperates with Olig2 to promote oligodendrocyte 
maturation. Overexpression of Nkx2.2 inhibits self-renewal of human GSCs by induction of 
oligodendroglial differentiation, and therefore reactivation of Nkx2.2 expression in glioma is 
suggested as a novel therapeutic strategy.  
Nanog 
The puluripotent protein Nanog promotes not only embryonic stem (ES) cell expansion but 
also GSC tumorigenicity. GBMs show ES-like stemness signature that includes the 
expression of Nanog, OCT4, SOX2 and c-Myc (Ben-Porath et al., 2008). Knockdown of 
Nanog1 or Nanog2 suppress tumor growth after orthotopic xenotransplantation of GBM 
spheres and this effect is mediated by a positive-feedback loop of Nanog with Gli-1, and 
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repression of Nanog by p53, which acts in a negative-regulatory loop with Gli-1, suggesting 
functional crosstalk among transcriptional factors in regulating the stem cell behavior and 
glioma growth (Zbinden et al., 2010). 
3.2.3 DNA-damage response (DDR) 
The large-scale genomic analyses have revealed genomic loss of at least one allele of ATR, 
ATM, CHEK1, or CHEK2 in 36% of human GBM samples, which are genes encoding key 
components of DDR required for cell-cycle checkpoint. Approximately 50% of GBM patients 
with CHEK2 alterations carry defects in the p53 signaling pathway (Squatrio et al., 2010). As 
the defect of DNA repair factors leads cells to genomic instability, genomic loss of DDR 
components might contribute to glioma initiation. However, Bao et al. (2008) have reported 
that CD133+ primary GBM cells, not CD133- cells, have high activity of DDR response and 
thereby can repair ionizing radiation-dependent DNA damages. Wang et al., (2010a) 
showed that Notch signaling promotes radioresistance through regulation of the PI3K/Akt 
pathway and myeloid cell leukemia 1 (Mcl-1), but it remains unelucidated why only GSCs 
acquire and/or retain the high activity of DDR response.  
3.2.4 Epigenetic factors 
The DNA-methylation and histone-modification patterns are associated with the 
development and progression of cancers. Hundreds of genes are subject to DNA 
hypermethylation at their CpG island promoters. On the contrary, DNA hypomethylation is 
also detected by locus-specific and genome-wide. Histone modifications are also likely 
important in the pathology of GBM. However, the molecular aspects of them are not yet 
fully determined. One important example of DNA hypermethylation is the silencing of O6-
methylguanine-DNA methyltransferase (MGMT) gene in human GBMs (Hegi et al., 2005). 
MGMT gene encodes a DNA repair protein that removes alkyl at the O6 position of guanine, 
which protect glioma cells from chemotherapeutic alkylating agents, such as temozolomide. 
MGMT hypermethylation has been considered as a predictor of outcome after treatment, 
but it is unrevealed if longer patients survival is directly due to reduced MGMT expression. 
As epigenetic modification can alter the differentiation properties of normal stem cells, some 
epigenetic factors have been examined their roles in GSC maintenance and tumor 
development. 
EZH2 
Enhancer of zeste homologue 2 (EZH2) is a component of the polycomb repressive 
complexes (PRC) 2 that participates in transcriptional repression of specific genes by mainly 
trimethylation of lysine 27 of histone H3. EZH2 is upregulated in a broad range of human 
neoplasms and its overexpression is correlated with poor prognosis. Suvà et al. (2009) have 
reported that pharmacologic depletion of EZH2 by the S-adenosylhomocysteine hydrolase 
inhibitor 3-Deazaneplanocin A (DZNep) reduces the self-renewal and tumor-initiating 
properties of GBM GSCs. Interestingly, their effects are mediated by c-myc downregulation, 
even though EZH2 belongs to a repressive complex. 
Bmi-1 
B lymphoma mouse Moloney leukemia virus insertion region (Bmi)-1 is a component of PRC1 
complex which allows stable silencing of gene expression. PRC1 and PRC2 cooperatively 
modify histone status. Abdouh et al. (2009) have reported that Bmi-1, as well as EZH2, is 
highly enriched in CD133(+) GBM cells and that knockdown of Bmi-1 can deplete the 
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invasive phenotype. L1CAM is highly expressed in CD133(+) glioma cells and that its 
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CD133(+) cell population and inhibit intracranial tumor formation. Bmi-1 directly represses 
p21Cip expression. It may also directly repress FOXOA3 expression, a potent inducer of 
apoptosis, and thereby supports cell-cycle progression and survival (Abdouh et al. 2009). 
Polycomb group proteins seem to regulate important aspects of GSC biology. 
3.2.5 microRNA (miRNA) 
microRNAs are non-coding RNAs of 22 nucleotides in length and regulate the translation 
and degradation of mRNAs by base-pairing to untranslated regions (UTRs) of targets. 
Approximately 1000 species of microRNA are thought to exist in the human genome. One 
microRNA has hundreds of targets, and one gene is targeted by multiple microRNAs (Krek 
et al., 2005). Increasing evidence strongly suggest that microRNAs are involved in neural 
development. The most highly expressed microRNAs in brain are miR-124 and miR-128, 
both of which are preferentially expressed in neurons. Some groups have investigated the 
direct roles of miRNAs in GSC features. SMAD3/4-controlled miR-451 expression has been 
shown to increase neurosphere formation of CD133(+) GBM cells (Gal et al., 2008). 
Interestingly, another group has reported that miR-451 regulates the expression of MDR1, 
which links to chemoresistant feature in cancer cells (Zhu et al., 2008). Conversely, the 
expression of miR-124 and miR-137 are significantly reduced in grade III and IV malignant 
gliomas and overexpression of these two microRNAs promotes differentiation of human 
GBM stem cells, indicating their tumor suppressive roles (Silber et al., 2008). miR-128 
targeting to the Bmi-1 gene expression is known to be down-regulated in human GBMs, and 
its restoration specifically blocks proliferation of glioma spheres (Godlewski et al., 2008).  
3.3 GSC niche (Therapeutic strategy) 
As well as normal NSCs, GSCs are believed to be physically situated in the specialized 
microenvironment called “stem cell niche”. Niche cells provide extrinsic cues as described 
above, including soluble factors, membrane-bound ligands, and extracellular matrix (ECM) 
proteins. Cell-to-cell communication between stem cells and the niche regulates self-
renewal, differentiation, and maintenance of proper stem cell numbers and functions. 
Tumor niche is thought to be composed of tumor vascular endothelial cells, stromal 
fibroblasts, and immune cells. Considering that CSCs display enhanced resistance to 
conventional chemotherapies due to their increased expression of membrane pumps, cancer 
treatment should be aimed at not the conventional elimination of the proliferating cancer 
cell population but the disruption of cellular niches to induce stem cell differentiation. The 
stromal components that function as niche would therefore be most promising targets to 
eradicate GSCs (Figure 6).  
Vascular niche 
Enhanced neovascularization is one of the characters of malignant gliomas and it 
significantly correlates with tumor aggressiveness and poor clinical prognosis. An initial 
report on GSC niche was proposed as a perivascular niche, where GSCs closely interact with 
vascular endothelium (Calabrese et al., 2007). It was verified by subsequent studies showing 
that glioma cells express high levels of laminin receptor integrin α6β1 in the perivascular 
niche and CD133(+)/integrinα6 (high) glioma cells exhibit stem cell properties (Lathia et al., 
2010). In addition, secreted nitric oxide (NO) from the vascular endothelium regulates 
adjacent Nestin(+) glioma cells (Charles et al., 2010). GSCs are themselves tightly involved 
in tumor angiogenesis. Folkins et al. (2009) have demonstrated that GSCs increase 
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endothelial cell proliferation and tube formation in vitro. In addition, GSCs in xenografted 
mice increase mobilization of bone marrow–derived endothelial progenitor cells and recruit 
them to the tumor through amplified secretion of vascular endothelial growth factor (VEGF) 
and stromal-derived factor 1 (SDF-1, also known as CXCL12). Surprisingly, two groups have 
provided strong evidence that a proportion of the vascular endothelial cells in human GBMs 
are originated from the tumor cell itself, which are differentiated ones from GSCs (Wang et 
al., 2010b; Ricci-Vitiani et al., 2010). DAPT, a γ-secretase inhibitor that effectively inhibits 
Notch signalling was found to induce significant suppression of the transition from 
CD133(+)/CD144(−) GSCs into CD133(+)/CD144(+) endothelial progenitors. In addition, 
bevacizumab, a VEGFA-binding antibody, blocked further maturation from endothelial 
progenitors into CD105(+) endothelial cells. These data suggested again that GSCs are 



































Fig. 6. The concept of niche therapy and components of GSC niche.  
Hypoxic niche 
Although the perivascular niche is well accepted, low oxygen areas away from tumor 
vessels are also recognized as secondary niches that play a role in GSC regulation. CD133 
expression increases by approximately two-fold when primary glioma spheres are 
incubated in physiological concentrations of oxygen (7%) (McCord et al., 2009). In addition, 
hypoxia (1%) increases the self-renewal capacity of CD133(+) human GSCs independent of 
PI3K/Akt or ERK pathways (Soeda et al., 2009). The hypoxia-inducible factors (HIFs) are 
transcription factors that help cells to adapt to changes in oxygen concentrations. HIFs have 
 
Molecular Targets of CNS Tumors 
 
166 
CD133(+) cell population and inhibit intracranial tumor formation. Bmi-1 directly represses 
p21Cip expression. It may also directly repress FOXOA3 expression, a potent inducer of 
apoptosis, and thereby supports cell-cycle progression and survival (Abdouh et al. 2009). 
Polycomb group proteins seem to regulate important aspects of GSC biology. 
3.2.5 microRNA (miRNA) 
microRNAs are non-coding RNAs of 22 nucleotides in length and regulate the translation 
and degradation of mRNAs by base-pairing to untranslated regions (UTRs) of targets. 
Approximately 1000 species of microRNA are thought to exist in the human genome. One 
microRNA has hundreds of targets, and one gene is targeted by multiple microRNAs (Krek 
et al., 2005). Increasing evidence strongly suggest that microRNAs are involved in neural 
development. The most highly expressed microRNAs in brain are miR-124 and miR-128, 
both of which are preferentially expressed in neurons. Some groups have investigated the 
direct roles of miRNAs in GSC features. SMAD3/4-controlled miR-451 expression has been 
shown to increase neurosphere formation of CD133(+) GBM cells (Gal et al., 2008). 
Interestingly, another group has reported that miR-451 regulates the expression of MDR1, 
which links to chemoresistant feature in cancer cells (Zhu et al., 2008). Conversely, the 
expression of miR-124 and miR-137 are significantly reduced in grade III and IV malignant 
gliomas and overexpression of these two microRNAs promotes differentiation of human 
GBM stem cells, indicating their tumor suppressive roles (Silber et al., 2008). miR-128 
targeting to the Bmi-1 gene expression is known to be down-regulated in human GBMs, and 
its restoration specifically blocks proliferation of glioma spheres (Godlewski et al., 2008).  
3.3 GSC niche (Therapeutic strategy) 
As well as normal NSCs, GSCs are believed to be physically situated in the specialized 
microenvironment called “stem cell niche”. Niche cells provide extrinsic cues as described 
above, including soluble factors, membrane-bound ligands, and extracellular matrix (ECM) 
proteins. Cell-to-cell communication between stem cells and the niche regulates self-
renewal, differentiation, and maintenance of proper stem cell numbers and functions. 
Tumor niche is thought to be composed of tumor vascular endothelial cells, stromal 
fibroblasts, and immune cells. Considering that CSCs display enhanced resistance to 
conventional chemotherapies due to their increased expression of membrane pumps, cancer 
treatment should be aimed at not the conventional elimination of the proliferating cancer 
cell population but the disruption of cellular niches to induce stem cell differentiation. The 
stromal components that function as niche would therefore be most promising targets to 
eradicate GSCs (Figure 6).  
Vascular niche 
Enhanced neovascularization is one of the characters of malignant gliomas and it 
significantly correlates with tumor aggressiveness and poor clinical prognosis. An initial 
report on GSC niche was proposed as a perivascular niche, where GSCs closely interact with 
vascular endothelium (Calabrese et al., 2007). It was verified by subsequent studies showing 
that glioma cells express high levels of laminin receptor integrin α6β1 in the perivascular 
niche and CD133(+)/integrinα6 (high) glioma cells exhibit stem cell properties (Lathia et al., 
2010). In addition, secreted nitric oxide (NO) from the vascular endothelium regulates 
adjacent Nestin(+) glioma cells (Charles et al., 2010). GSCs are themselves tightly involved 
in tumor angiogenesis. Folkins et al. (2009) have demonstrated that GSCs increase 
 
Glioma Stem Cells  
 
167 
endothelial cell proliferation and tube formation in vitro. In addition, GSCs in xenografted 
mice increase mobilization of bone marrow–derived endothelial progenitor cells and recruit 
them to the tumor through amplified secretion of vascular endothelial growth factor (VEGF) 
and stromal-derived factor 1 (SDF-1, also known as CXCL12). Surprisingly, two groups have 
provided strong evidence that a proportion of the vascular endothelial cells in human GBMs 
are originated from the tumor cell itself, which are differentiated ones from GSCs (Wang et 
al., 2010b; Ricci-Vitiani et al., 2010). DAPT, a γ-secretase inhibitor that effectively inhibits 
Notch signalling was found to induce significant suppression of the transition from 
CD133(+)/CD144(−) GSCs into CD133(+)/CD144(+) endothelial progenitors. In addition, 
bevacizumab, a VEGFA-binding antibody, blocked further maturation from endothelial 
progenitors into CD105(+) endothelial cells. These data suggested again that GSCs are 



































Fig. 6. The concept of niche therapy and components of GSC niche.  
Hypoxic niche 
Although the perivascular niche is well accepted, low oxygen areas away from tumor 
vessels are also recognized as secondary niches that play a role in GSC regulation. CD133 
expression increases by approximately two-fold when primary glioma spheres are 
incubated in physiological concentrations of oxygen (7%) (McCord et al., 2009). In addition, 
hypoxia (1%) increases the self-renewal capacity of CD133(+) human GSCs independent of 
PI3K/Akt or ERK pathways (Soeda et al., 2009). The hypoxia-inducible factors (HIFs) are 
transcription factors that help cells to adapt to changes in oxygen concentrations. HIFs have 
 
Molecular Targets of CNS Tumors 
 
168 
more than 60 putative downstream genes that are involved in angiogenesis, glucose 
transport, glycolysis, cell survival, and metastasis. Li et al. (2009) have reported that 
knockdown of either HIF-1α or HIF-2α in GSCs decreases tumorigenic potential and 
increases the survival of xenografted mice and that elevated HIF-2α expression is correlated 
with poor survival of human glioma patients. Méndez et al. (2010) have also demonstrated 
that HIF-1α plays a role in the survival and self-renewal potential of GSCs. Some 
chemotherapeutic agents which target RTKs, such as gefitinib (Iressa, an inhibitor of 
EGFR/ERBB1) and imatinib (Glivec, an inhibitor of Bcr-Abl and PDGFRβ), have been 
shown to inhibit HIF-1 activity (Pore et al., 2006; Kimura et al., 2007), and further evidence 
has shown that hypoxia mediates resistance to chemotherapy and radiation (Teicher, 1994). 
The formation of necrosis, which is a resultant of increasing cellularity and poorly organized 
tumor vasculature, is a biologic hallmark in a highly aggressvie gliomas. Therefore, 
understanding of stem cell biology in hypoxic environment could also provide useful clues 
for glioma biology and treatment. 
Cancer-associated fibroblast 
Stromal fibroblasts, which are potentially originated from bone marrow-derived 
mesenchymal stem cells (MSCs), are observed as a cellular component in the tumor 
microenvironment and have important roles in the tumor progression. Especially, during 
tumor-induced angiogenesis, fibroblasts actively contribute to neovascularization through 
secretion of VEGF. They also produce ECM proteins such as fibronectin and type I collagen, 
both of which are involved in the initiation of tumor angiogenesis. Additionally, fibroblast-
derived SDF-1 is responsible for recruiting endothelial progenitor cells into a tumor mass, 
thereby boosting tumor angiogenesis (Orimo et al., 2005). In parallel, the SDF-1 protein 
enhances tumor growth in a direct paracrine fashion via the CXCR4 receptor. Although 
whether stromal fibroblasts could affect GSCs behaviors is not yet so clear, it is worth noting 
that some MSCs are exactly detected as a tumor-stimulating component around the blood 
vessels and closely associated with endothelial cells/pericytes in tumor xenograft models 
(Spaeth et al., 2009). 
Tumor-associated macrophages 
Tumor-associated macrophages (TAMs) represent the major inflammatory component of the 
stroma in many tumors. TAMs are derived from circulating blood monocytes and recruited 
into the tumor region toward monocyte chemotactic protein-1 (MCP-1, also known as CCL2) 
and macrophage colony stimulating factor (M-CSF). TAMs display several pro-tumoral 
functions, including tumor growth (growth factors), neo-angiogenesis (VEGF and PDGF), 
matrix remodeling (MMPs), and anti-tumor immune suppression (prostaglandins, IL-10 and 
TGF-β) (Sica et al., 2006). There is no evidence on the exact roles of TAMs against GSCs, but 
ablation of TAMs might provide some therapeutic benefits against GSCs beyond disrupting 
vascular niche. 
4. Conclusion 
The existence of CSCs has altered our view on glioma biology, which prompts our re-
evaluation of conventional strategies in therapies for glioma. Although some controversy is 
still unresolved regarding the definition, isolation methods, characteristics, and their exact 
roles in vivo, it is assured that gliomas have a cellular hierarchy and that certain 
subpopulation within tumors has extraordinary potential for tumor progression, therapeutic 
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resistance, and tumor recurrence. Importantly, GSCs are highly resistant to 
chemo/radiotherapies, which are convinced by the currently poor record of clinical 
remission with conventional treatments. Therefore the development of novel therapies 
directed against GSCs is our urgent task. Remarkable insights into the molecular 
mechanisms or signaling pathways that are differentially regulated in GSCs and non-GSCs 
have accumulated in virtue of recent advance in this field. In this chapter, we have provided 
several key signaling pathways that are potentially useful for the future development of 
anti-GSC therapeutics, but at this point most of them are still far away from the clinical 
application. As an achievement, anti-vascular niche therapy with a humanized anti-VEGF-A 
monoclonal antibody bevacizumab, has displayed beneficial effects in phase II clinical trials, 
and approved for recurrent GBM patients in 2009. For relapsed or progressed GBMs, tumor 
responses were observed in 22 of 85 patients (26%) treated with bevacizumab alone 
(Friedman et al., 2009). This is the first major advance in glioma treatment over a decade. 
Nonetheless, our goal of glioma eradication has not been achieved. Additional basic and 
translational research must be carried out to exploit this promising concept for clinical 
advantage. 
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1. Introduction  
Tumors of the central nervous system (CNS) encompass a wide variety of entities, which span 
from benign to highly malignant. The classification of these tumors is typically based on their 
histopathological features or their location within the CNS. Despite these apparently simple 
criteria, there are a great number of independent CNS tumor types as defined by the most 
recent World Health Organization (WHO) classification of CNS tumors (Louis et al., 2007), 
which is the standard for the definition of CNS tumors worldwide. The WHO listing of CNS 
tumors is impressively vast and has, in fact, been surrounded by some controversy concerning 
the nosology of some tumor entities (e.g., the nosologic place of highly anaplastic 
oligoastrocytic tumors, glioblastoma with oligodendroglioma components). The age-
standardized incidence rate of all primary non-malignant and malignant CNS tumors in the 
US is 16.5 per 100,000 person–years (9.2 per 100,000 person–years for non–malignant tumors 
and 7.3 per 100,000 person–years for malignant tumors) (CBTRUS, 2010). This rate is higher in 
females (17.2 per 100,000 person–years) than males (15.8 per 100,000 person–years). 
Worldwide data is available only for malignant primary CNS tumors; in this setting, the 
incidence rates are higher in males (approximately 3.7 per 100,000 person-years) than females 
(2.6 per 100,000 person–years) (Ferlay et al., 2008). In Western Europe, the male and female 
incidence rates of malignant CNS tumors are 6.7 per 100,000 person-years and 4.5 per 100,000 
person-years, respectively. Very similar figures are observed in Northern America (6.0 and 4.5 
per 100,000 person-years for males and females, respectively). Interestingly, the incidence rates 
are higher in more developed countries than in less developed ones, but these differences may 
be a consequence of differences in diagnostic practices, completeness of reporting and access to 
adequate health care, rather than attributable to geographic and genetic variation. 
CNS tumors are considered to be primary when the tumor originally initiates in the CNS, as 
opposed to the far more common brain metastases derived from malignant tumors located 
in other organs, which are considered secondary brain tumors. Primary brain and CNS 
tumors account for only approximately 2% of all primary tumors (Louis et al., 2007), but 
they rank first among tumor types for the average years of life lost (~20 years, compared, for 
example, with ~6 years for prostate cancer and ~12 years for lung cancer) (Burnet et al., 
2005). These tumors are the most frequent solid malignancy in children, being the leading 
cause of cancer-related death in children under the age of 19 (Rickert & Paulus, 2001). The 
impact and nature of primary brain tumors in adults is somewhat different, but they still 
rank second as cause of cancer death in males aged 20 to 39 years, and fifth in females of 
 
Molecular Targets of CNS Tumors 
 
176 
the National Academy of Sciences of the United States of America, Vol.94, No.23, pp. 
12425-12430 
Weissenberger, J., Loeffler, S., Kappeler, A., Kopf, M., Lukes, A., Afanasieva, T. A., Aguzzi, 
A. & Weis, J. (2004). IL-6 is required for glioma development in a mouse model. 
Oncogene, Vol.23, No.19, pp. 3308-3316 
Xu, Q., Yuan, X., Liu, G., Black, K. L. & Yu, J. S. (2008). Hedgehog signaling regulates brain 
tumor-initiating cell proliferation and portends shorter survival for patients with 
PTEN-coexpressing glioblastomas. Stem Cells, Vol.26, No.12, pp. 3018-3026 
Yamanaka, S. & Blau, H. M. (2010). Nuclear reprogramming to a pluripotent state by three 
approaches. Nature, Vol.465, No.7299, pp. 704-712 
Yin, A. H., Miraglia, S., Zanjani, E. D., Almeida-Porada, G., Ogawa, M., Leary, A. G., 
Olweus, J., Kearney, J. & Buck, D. W. (1997). AC133, a novel marker for human 
hematopoietic stem and progenitor cells. Blood, Vol.90, No.12, pp. 5002-5012 
Zabierowski, S. E. & Herlyn, M. (2008). Melanoma stem cells: the dark seed of melanoma. 
Journal of Clinical Oncology, Vol.26, No.17, pp. 2890-2894 
Zbinden, M., Duquet, A., Lorente-Trigos, A., Ngwabyt, S. N., Borges, I. & Ruiz i Altaba, A. 
(2010). NANOG regulates glioma stem cells and is essential in vivo acting in a 
cross-functional network with GLI1 and p53. The EMBO Journal, Vol.29, No.15, pp. 
2659-2674 
Zheng, H., Ying, H., Wiedemeyer, R., Yan, H., Quayle, S. N., Ivanova, E. V., Paik, J. H., 
Zhang, H., Xiao, Y., Perry, S. R., Hu, J., Vinjamoori, A., Gan, B., Sahin, E., Chheda, 
M. G., Brennan, C., Wang, Y. A., Hahn, W. C., Chin, L. & DePinho, R. A. (2010). 
PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and 
gliomas. Cancer Cell, Vol.17, No.5, pp. 497-509 
Zheng, H., Ying, H., Yan, H., Kimmelman, A. C., Hiller, D. J., Chen, A. J., Perry, S. R., Tonon, 
G., Chu, G. C., Ding, Z., Stommel, J. M., Dunn, K. L., Wiedemeyer, R., You, M. J., 
Brennan, C., Wang, Y. A., Ligon, K. L., Wong, W. H., Chin, L. & DePinho, R. A. 
(2008). p53 and Pten control neural and glioma stem/progenitor cell renewal and 
differentiation. Nature, Vol.455, No.7216, pp. 1129-1133 
Zhu, H., Wu, H., Liu, X., Evans, B. R., Medina, D. J., Liu, C. G. & Yang, J. M. (2008). Role of 
MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein 
expression in human cancer cells. Biochemical Pharmacology, Vol.76, No.5, pp. 582-
588 
9 
Molecular Hallmarks of Gliomas 
Marta Pojo and Bruno Marques Costa 
Life and Health Sciences Research Institute (ICVS),  
School of Health Sciences, University of Minho, 
ICVS/3B’s - PT Government Associate Laboratory, Braga/Guimarães 
Portugal 
1. Introduction  
Tumors of the central nervous system (CNS) encompass a wide variety of entities, which span 
from benign to highly malignant. The classification of these tumors is typically based on their 
histopathological features or their location within the CNS. Despite these apparently simple 
criteria, there are a great number of independent CNS tumor types as defined by the most 
recent World Health Organization (WHO) classification of CNS tumors (Louis et al., 2007), 
which is the standard for the definition of CNS tumors worldwide. The WHO listing of CNS 
tumors is impressively vast and has, in fact, been surrounded by some controversy concerning 
the nosology of some tumor entities (e.g., the nosologic place of highly anaplastic 
oligoastrocytic tumors, glioblastoma with oligodendroglioma components). The age-
standardized incidence rate of all primary non-malignant and malignant CNS tumors in the 
US is 16.5 per 100,000 person–years (9.2 per 100,000 person–years for non–malignant tumors 
and 7.3 per 100,000 person–years for malignant tumors) (CBTRUS, 2010). This rate is higher in 
females (17.2 per 100,000 person–years) than males (15.8 per 100,000 person–years). 
Worldwide data is available only for malignant primary CNS tumors; in this setting, the 
incidence rates are higher in males (approximately 3.7 per 100,000 person-years) than females 
(2.6 per 100,000 person–years) (Ferlay et al., 2008). In Western Europe, the male and female 
incidence rates of malignant CNS tumors are 6.7 per 100,000 person-years and 4.5 per 100,000 
person-years, respectively. Very similar figures are observed in Northern America (6.0 and 4.5 
per 100,000 person-years for males and females, respectively). Interestingly, the incidence rates 
are higher in more developed countries than in less developed ones, but these differences may 
be a consequence of differences in diagnostic practices, completeness of reporting and access to 
adequate health care, rather than attributable to geographic and genetic variation. 
CNS tumors are considered to be primary when the tumor originally initiates in the CNS, as 
opposed to the far more common brain metastases derived from malignant tumors located 
in other organs, which are considered secondary brain tumors. Primary brain and CNS 
tumors account for only approximately 2% of all primary tumors (Louis et al., 2007), but 
they rank first among tumor types for the average years of life lost (~20 years, compared, for 
example, with ~6 years for prostate cancer and ~12 years for lung cancer) (Burnet et al., 
2005). These tumors are the most frequent solid malignancy in children, being the leading 
cause of cancer-related death in children under the age of 19 (Rickert & Paulus, 2001). The 
impact and nature of primary brain tumors in adults is somewhat different, but they still 
rank second as cause of cancer death in males aged 20 to 39 years, and fifth in females of 
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those same ages (Jemal et al., 2009). This chapter will not fully review all the types of brain 
and CNS malignancies, but rather focus more specifically and thoroughly in gliomas, the 
most common type of all primary brain tumors. 
2. Classification and epidemiology of gliomas 
Glioma is a broad category of tumors divided into histological subgroups based on the type 
of glial cell of origin or morphological similarities between tumor and normal glial cells: 
astrocytomas (derived from astrocytes or their precursors), oligodendrogliomas (derived 
from oligodendrocytes or their precursors), and  oligoastrocytomas (mixed lineage) are the 
three major subgroups, while ependymomas (derived from ependyma or their precursors) 
are less common  (Louis et al., 2007). They represent 36% of all primary brain and CNS 
tumors, and account for approximately 81% of those that are malignant, an occurrence most 
likely related to the fact that the number of glial cells in the CNS is an order of magnitude 
higher than that of neurons. In addition, glial cells retain the ability to proliferative 
throughout adulthood, while most neurons do not, a characteristic that may also contribute 
to the higher incidence of this tumor group.  
The WHO classification of CNS tumors is the most commonly used classification system 
among the medical and research community. This system classifies gliomas according to the 
presumed cell of origin based on similarities of tumor cells and non-neoplastic glial cells, as 
determined by histological analysis. Additionally, gliomas can be graded I to IV based on 
their degree of differentiation and malignancy (Louis et al., 2007), which can help predict the 
likely behavior of the tumor. Glioma grading is typically based on tumor cells’ 
characteristics like mitotic index, nuclear atypia, vascular proliferation and necrosis (Louis 
et al., 2007). Simply put, grade I tumors often present well differentiated cells, are 
biologically benign and can be cured; grade II gliomas are malignancies that may follow 
long clinical courses, but early diffuse infiltration of the surrounding brain renders them 
incurable by surgery; grade III tumors exhibit increased anaplasia and proliferation, being 
more rapidly fatal; grade IV tumors exhibit more advanced features of malignancy, such as  
vascular proliferation and necrosis, and are generally lethal within 12 months. In general, 
grades I and II tumors are considered low-grade, while grades III and IV are high-grade 
tumors. The cell of origin of gliomas is a matter surrounded by controversy: for a long time, 
gliomas were believed to arise from differentiated glial cells, but this paradigm has recently 
been called into question, as some evidences suggest that these tumors arise from stem cells 
or lineage-committed progenitor cells (Singh et al., 2004). For the purposes of this chapter, 
the three major histological types of glioma (astrocytomas, oligodendrogliomas, and 
oligoastrocytomas) are discussed with particular emphasis. 
2.1 Astrocytomas 
Astrocytic tumors, or astrocytomas, are the most common intracranial neoplasms, 
accounting for approximately 75% of all gliomas (CBTRUS, 2010). Despite sharing a same 
cell of origin, astrocytoma is a broad category of tumors with different characteristics that 
differ in their location within the CNS, age and gender distribution, morphological features, 
growth potential, extent of invasiveness, tendency for progression, and clinical course. 
These are distinctly classified into four major clinicopathological entities, mostly based on 
their degree of malignancy: pilocytic astrocytomas (WHO grade I), diffuse astrocytoma 
(WHO grade II), anaplastic astrocytoma (WHO grade III) and glioblastoma multiforme 
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(GBM, WHO grade IV). A brief summary of the main characteristics of these tumor types is 
given below, with a special emphasizes on the most common and malignant type, GBM. 
Pilocytic astrocytomas (WHO grade I) account for ~5.8% of all gliomas, with similar 
frequencies in both males and females. Sometimes these are also referred to as “juvenile 
pilocytic astrocytoma”, as they occur predominantly in children and teens, being the most 
common CNS tumor type among people under the age of 19 (CBTRUS, 2010). Diffuse 
astrocytomas (WHO grade II), sometimes called low-grade astrocytomas, account for ~1.5% 
of all gliomas and occur most commonly in young adults between the ages of 20 to 40. A 
slight male predominance (male-to-female ratio of 1.18:1) has been reported (Louis et al., 
2007). This diffusely infiltrative nature may in part contribute to the typical progression of 
these tumors to more malignant neoplasms like anaplastic astrocytoma and, ultimately, 
glioblastoma. Three histologic entities can be distinguished: fibrillary astrocytoma (the most 
common), gemistocytic astrocytoma, and protoplasmic astrocytoma (Louis et al., 2007). 
Anaplastic astrocytomas (WHO grade III) are high-grade gliomas which may arise from a 
low grade diffuse astrocytoma or may arise de novo, i.e., without clinical evidence of a less 
malignant precursor lesion. These tumors account for approximately 7.5% of all gliomas, 
affect males more frequently than females (reported male to female ratios range from 1.1:1 
to 1.6:1) and show a peak of incidence in adults aged between 30 to 50 years (Louis et al., 
2007). In most cases, these grade III malignancies will progress to glioblastoma, showing a 
mean time to progression of ~2 years (Louis et al., 2007).  Glioblastoma (WHO grade IV), or 
glioblastoma multiforme (GBM), is the most frequent and most malignant brain tumor, 
accounting for approximately 51% of all primary gliomas (CBTRUS, 2010). In Europe and 
North America, the incidence rates are approximately 3 new cases per 100,000 people per 
year. The peak of incidence occurs in adults aged 45 to 70 years, but glioblastoma can 
develop at any age.  Males are more frequently affected (male to female ratio 1.7:1), and the 
frequency of glioblastoma in Caucasians is two times higher than in blacks. From a clinical 
and biological perspective, two main subtypes of this malignancy can be distinguished: 
primary (or de novo) glioblastoma develop without the presence of any precursor neoplastic 
lesion and manifest after a short clinical history (usually less than 3 months); secondary 
glioblastoma develop from lower grade tumors (a diffuse astrocytoma or an anaplastic 
astrocytoma) (Ohgaki & Kleihues, 2007). Primary glioblastoma, which are by far the most 
common, affect primarily older patients, present a quicker tumor progression and a poorer 
prognosis, as compared to secondary GBM. Of note, primary and secondary glioblastomas 
are histologically indistinguishable, but a growing body of data has been suggesting that 
these two disease entities evolve through different molecular mechanisms (as further 
detailed later in this chapter). Two histological variants of glioblastoma include: i) giant cell 
glioblastoma (WHO grade IV) is a rare variant (less than 5% of glioblastomas) composed of 
atypic multinucleated giant tumor cells; ii) gliosarcoma (WHO grade IV) accounts for 
approximately 2-8% of all glioblastomas (Homma et al., 2006; Meis et al., 1991), and is 
characterized by a biphasic tissue pattern with alternating areas displaying glial and 
mesenchymal differentiation.  
2.2 Oligodendrogliomas 
Oligodendroglial tumors account for approximately 8.4% of all gliomas, affecting males 
slightly more frequent than females (male to female ratio 1.1:1) (CBTRUS, 2010). The age 
distribution of oligodendrogliomas shows a peak of incidence in adults aged 40 to 50 years, 
but they may also rarely affect children (only 2% of all brain tumors in patients younger 
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those same ages (Jemal et al., 2009). This chapter will not fully review all the types of brain 
and CNS malignancies, but rather focus more specifically and thoroughly in gliomas, the 
most common type of all primary brain tumors. 
2. Classification and epidemiology of gliomas 
Glioma is a broad category of tumors divided into histological subgroups based on the type 
of glial cell of origin or morphological similarities between tumor and normal glial cells: 
astrocytomas (derived from astrocytes or their precursors), oligodendrogliomas (derived 
from oligodendrocytes or their precursors), and  oligoastrocytomas (mixed lineage) are the 
three major subgroups, while ependymomas (derived from ependyma or their precursors) 
are less common  (Louis et al., 2007). They represent 36% of all primary brain and CNS 
tumors, and account for approximately 81% of those that are malignant, an occurrence most 
likely related to the fact that the number of glial cells in the CNS is an order of magnitude 
higher than that of neurons. In addition, glial cells retain the ability to proliferative 
throughout adulthood, while most neurons do not, a characteristic that may also contribute 
to the higher incidence of this tumor group.  
The WHO classification of CNS tumors is the most commonly used classification system 
among the medical and research community. This system classifies gliomas according to the 
presumed cell of origin based on similarities of tumor cells and non-neoplastic glial cells, as 
determined by histological analysis. Additionally, gliomas can be graded I to IV based on 
their degree of differentiation and malignancy (Louis et al., 2007), which can help predict the 
likely behavior of the tumor. Glioma grading is typically based on tumor cells’ 
characteristics like mitotic index, nuclear atypia, vascular proliferation and necrosis (Louis 
et al., 2007). Simply put, grade I tumors often present well differentiated cells, are 
biologically benign and can be cured; grade II gliomas are malignancies that may follow 
long clinical courses, but early diffuse infiltration of the surrounding brain renders them 
incurable by surgery; grade III tumors exhibit increased anaplasia and proliferation, being 
more rapidly fatal; grade IV tumors exhibit more advanced features of malignancy, such as  
vascular proliferation and necrosis, and are generally lethal within 12 months. In general, 
grades I and II tumors are considered low-grade, while grades III and IV are high-grade 
tumors. The cell of origin of gliomas is a matter surrounded by controversy: for a long time, 
gliomas were believed to arise from differentiated glial cells, but this paradigm has recently 
been called into question, as some evidences suggest that these tumors arise from stem cells 
or lineage-committed progenitor cells (Singh et al., 2004). For the purposes of this chapter, 
the three major histological types of glioma (astrocytomas, oligodendrogliomas, and 
oligoastrocytomas) are discussed with particular emphasis. 
2.1 Astrocytomas 
Astrocytic tumors, or astrocytomas, are the most common intracranial neoplasms, 
accounting for approximately 75% of all gliomas (CBTRUS, 2010). Despite sharing a same 
cell of origin, astrocytoma is a broad category of tumors with different characteristics that 
differ in their location within the CNS, age and gender distribution, morphological features, 
growth potential, extent of invasiveness, tendency for progression, and clinical course. 
These are distinctly classified into four major clinicopathological entities, mostly based on 
their degree of malignancy: pilocytic astrocytomas (WHO grade I), diffuse astrocytoma 
(WHO grade II), anaplastic astrocytoma (WHO grade III) and glioblastoma multiforme 
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(GBM, WHO grade IV). A brief summary of the main characteristics of these tumor types is 
given below, with a special emphasizes on the most common and malignant type, GBM. 
Pilocytic astrocytomas (WHO grade I) account for ~5.8% of all gliomas, with similar 
frequencies in both males and females. Sometimes these are also referred to as “juvenile 
pilocytic astrocytoma”, as they occur predominantly in children and teens, being the most 
common CNS tumor type among people under the age of 19 (CBTRUS, 2010). Diffuse 
astrocytomas (WHO grade II), sometimes called low-grade astrocytomas, account for ~1.5% 
of all gliomas and occur most commonly in young adults between the ages of 20 to 40. A 
slight male predominance (male-to-female ratio of 1.18:1) has been reported (Louis et al., 
2007). This diffusely infiltrative nature may in part contribute to the typical progression of 
these tumors to more malignant neoplasms like anaplastic astrocytoma and, ultimately, 
glioblastoma. Three histologic entities can be distinguished: fibrillary astrocytoma (the most 
common), gemistocytic astrocytoma, and protoplasmic astrocytoma (Louis et al., 2007). 
Anaplastic astrocytomas (WHO grade III) are high-grade gliomas which may arise from a 
low grade diffuse astrocytoma or may arise de novo, i.e., without clinical evidence of a less 
malignant precursor lesion. These tumors account for approximately 7.5% of all gliomas, 
affect males more frequently than females (reported male to female ratios range from 1.1:1 
to 1.6:1) and show a peak of incidence in adults aged between 30 to 50 years (Louis et al., 
2007). In most cases, these grade III malignancies will progress to glioblastoma, showing a 
mean time to progression of ~2 years (Louis et al., 2007).  Glioblastoma (WHO grade IV), or 
glioblastoma multiforme (GBM), is the most frequent and most malignant brain tumor, 
accounting for approximately 51% of all primary gliomas (CBTRUS, 2010). In Europe and 
North America, the incidence rates are approximately 3 new cases per 100,000 people per 
year. The peak of incidence occurs in adults aged 45 to 70 years, but glioblastoma can 
develop at any age.  Males are more frequently affected (male to female ratio 1.7:1), and the 
frequency of glioblastoma in Caucasians is two times higher than in blacks. From a clinical 
and biological perspective, two main subtypes of this malignancy can be distinguished: 
primary (or de novo) glioblastoma develop without the presence of any precursor neoplastic 
lesion and manifest after a short clinical history (usually less than 3 months); secondary 
glioblastoma develop from lower grade tumors (a diffuse astrocytoma or an anaplastic 
astrocytoma) (Ohgaki & Kleihues, 2007). Primary glioblastoma, which are by far the most 
common, affect primarily older patients, present a quicker tumor progression and a poorer 
prognosis, as compared to secondary GBM. Of note, primary and secondary glioblastomas 
are histologically indistinguishable, but a growing body of data has been suggesting that 
these two disease entities evolve through different molecular mechanisms (as further 
detailed later in this chapter). Two histological variants of glioblastoma include: i) giant cell 
glioblastoma (WHO grade IV) is a rare variant (less than 5% of glioblastomas) composed of 
atypic multinucleated giant tumor cells; ii) gliosarcoma (WHO grade IV) accounts for 
approximately 2-8% of all glioblastomas (Homma et al., 2006; Meis et al., 1991), and is 
characterized by a biphasic tissue pattern with alternating areas displaying glial and 
mesenchymal differentiation.  
2.2 Oligodendrogliomas 
Oligodendroglial tumors account for approximately 8.4% of all gliomas, affecting males 
slightly more frequent than females (male to female ratio 1.1:1) (CBTRUS, 2010). The age 
distribution of oligodendrogliomas shows a peak of incidence in adults aged 40 to 50 years, 
but they may also rarely affect children (only 2% of all brain tumors in patients younger 
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than 14 years). Based on their degree of malignancy and other histopathological features, 
two histological subtypes are distinguished: oligodendroglioma (WHO grade II) and 
anaplastic oligodendroglioma (WHO grade III). These two entities encompass a continuum 
of neoplasms which range from well-differentiated to highly malignant (Louis et al., 2007). 
Oligodendroglioma (WHO grade II) account for approximately 6% of all gliomas 
(CBTRUS, 2010). Anaplastic oligodendroglioma (WHO grade III) accounts for 
approximately 2.4% of all gliomas (CBTRUS, 2010). Similarly to high-grade astrocytomas, 
anaplastic oligodendroglioma may develop de novo or by progression from a pre-existing 
low grade oligodendroglioma (WHO grade II). 
2.3 Oligoastrocytomas (mixed gliomas) 
Oligoastrocytomas are diffusely infiltrating gliomas that present with a mixture of two 
morphologically distinct tumor cell types, resembling the neoplastic cells present in 
astrocytomas and oligodendrogliomas (Louis et al., 2007). As such, these tumors are also 
often called “mixed glioma”. Precise and consistent epidemiological data on 
oligoastrocytoma are not yet available, but they have been reported to account for 
approximately 2-9% of all gliomas, affecting preferentially males (male to female ratio 1.3:1). 
Median ages range from 35 to 45 years (CBTRUS, 2010). Oligoastrocytomas, like 
astrocytomas and oligodendrogliomas, are divided into low grade (WHO grade II) and 
high-grade (WHO grade III) oligoastrocytoma, based on the most aggressive type of 
neoplastic cell present in the tumor. 
3. Etiology and risk factors for glioma 
Typical risk factors for a variety of human tumors, including genetic and environmental 
factors (such as tobacco smoking, diet, excessive alcohol intake, occupational exposure to 
carcinogens, exposure to UV radiation, and some other personal habits), have not been 
consistently correlated with risk for glioma (Fisher et al., 2007). Epidemiological data 
suggest that approximately one third of all human cancers are related to dietary factors and 
lack of proper physical activity in adulthood. Additionally, a significant number of these 
could be prevented by vaccination (e.g., viral-related tumors) and/or behavioral changes 
(e.g., tobacco-related tumors and skin cancer), as their risk factors are well known. In 
contrast, reliable recommendations to prevent gliomas cannot be endorsed presently, as the 
etiology of glioma remains largely obscure. A brief summary of the most relevant potential 
risk factors for glioma are briefly reviewed below. 
3.1 Environmental risk factors 
Exposure to high-dose therapeutic radiation is the only firmly established exogenous 
environmental cause of glioma, which can clinically manifest only several years after the 
exposure (Ohgaki & Kleihues, 2005). Recent data suggest that use of high-dose 
chemotherapy to treat other tumors may also contribute to gliomagenesis (Edick et al., 
2005). Interestingly, the degree of risk from these exposures to radiotherapy and 
chemotherapy may be influenced by the individual’s genetic background; for example, a 
functional germline polymorphism in the thiopurine methyltransferase gene was shown to 
affect the susceptibility of children treated with cranial radiotherapy and intensive 
antimetabolite therapy for acute lymphocytic leukemia to further develop brain tumors 
(Relling et al., 1999).  However, similar studies are needed to confirm these observations and 
extend its conclusions to adults. 
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Throughout life, people are exposed to a variety of endogenous and exogenous chemicals 
(for example, reactive oxygen and nitrogen species, N-nitroso compounds, several 
industrially used chemicals, and polycyclic aromatic hydrocarbons) through cellular 
metabolism, diet, occupation, and personal habits. Some of these compounds have been 
shown to be biologically plausible neurocarcinogens in a great number of animal and other 
studies; however, inconsistent or null findings have been reported for these same factors in 
human studies (reviewed in Wrensch et al., 2005). These inconsistent data among several 
association studies may result from a variety of issues, including small study sample sizes, 
false-positive results (due to both small sample size and lack of accurate statistical 
hypothesis), imprecise exposure measures (from proxy reporting and exposure history recall 
issues), protective exposures or conditions unaccounted for (e.g., allergies), variation in 
metabolic and repair pathways in the brain, differential diffusion of chemicals across the 
blood–brain barrier, and disease heterogeneity. 
A currently hot topic is the potential association between cellular phone usage and glioma 
risk. While one study reported increased risk for glioma associated with long term (≥10 
years) use of cellular phones (Hardell et al., 2007), other larger studies have failed to 
replicate this (Lahkola et al., 2007; Inskip et al., 2001; Fisher et al., 2007). 
It is plausible that the failure to find strong and consistent associations between 
environmental risk factors and gliomas might be simply a reflection of absence of true 
associations (and not due to research issues). Nevertheless, considering the small number of 
studies examining environmental risk factors for specific well-defined glioma subtypes, it is 
premature to irrefutably conclude that environmental risks do not exist for glioma. 
3.2 Genetic syndromes, familial aggregation, and mutagen sensitivity 
Studies of genetic syndromes, familial aggregation, linkage, and mutagen sensitivity have 
suggested that genetics has an effect on susceptibility to glioma. Particular inherited rare 
genetic mutations cause a small number of genetic syndromes that have been associated 
with increased risk of glial tumors. Although these familial tumor syndromes account for a 
small proportion of cases (Ichimura et al., 2004), the elucidation of their molecular basis has 
greatly contributed to the understanding of gliomas, and has provided a valuable starting 
point for identifying candidate genes and pathways involved in gliomagenesis. 
In large, carefully-designed epidemiological studies, familial glioma risks have been 
reported to be approximately two-fold, a magnitude that is similar to the familial association 
reported for other cancers for which susceptibility genes have been identified (e.g., breast 
cancer) (Malmer et al., 1999; Hemminki et al., 2000; Wrensch et al., 1997). The underlying 
causes of the pattern of familial brain tumor occurrence have been attributed to a variety of 
causes: one study implicates environmental factors only (Grossman et al., 1999), while 
others attribute multifactorial causes, polygenic causes, and autosomal recessive inheritance 
(de Andrade et al., 2001; Malmer et al., 2001). 
Two case-control studies have suggested that peripheral lymphocytes from glioma patients 
are more sensitive to gamma-radiation than lymphocytes from matched controls, suggesting 
that increased sensitivity to radiation is an independent risk factor for gliomas (Bondy et al., 
1996; 2001). The authors also propose that inherited genetic variation in the capacity to 
repair radiation damage may partly influence mutagen sensitivity and, ultimately, glioma 
risk. 
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than 14 years). Based on their degree of malignancy and other histopathological features, 
two histological subtypes are distinguished: oligodendroglioma (WHO grade II) and 
anaplastic oligodendroglioma (WHO grade III). These two entities encompass a continuum 
of neoplasms which range from well-differentiated to highly malignant (Louis et al., 2007). 
Oligodendroglioma (WHO grade II) account for approximately 6% of all gliomas 
(CBTRUS, 2010). Anaplastic oligodendroglioma (WHO grade III) accounts for 
approximately 2.4% of all gliomas (CBTRUS, 2010). Similarly to high-grade astrocytomas, 
anaplastic oligodendroglioma may develop de novo or by progression from a pre-existing 
low grade oligodendroglioma (WHO grade II). 
2.3 Oligoastrocytomas (mixed gliomas) 
Oligoastrocytomas are diffusely infiltrating gliomas that present with a mixture of two 
morphologically distinct tumor cell types, resembling the neoplastic cells present in 
astrocytomas and oligodendrogliomas (Louis et al., 2007). As such, these tumors are also 
often called “mixed glioma”. Precise and consistent epidemiological data on 
oligoastrocytoma are not yet available, but they have been reported to account for 
approximately 2-9% of all gliomas, affecting preferentially males (male to female ratio 1.3:1). 
Median ages range from 35 to 45 years (CBTRUS, 2010). Oligoastrocytomas, like 
astrocytomas and oligodendrogliomas, are divided into low grade (WHO grade II) and 
high-grade (WHO grade III) oligoastrocytoma, based on the most aggressive type of 
neoplastic cell present in the tumor. 
3. Etiology and risk factors for glioma 
Typical risk factors for a variety of human tumors, including genetic and environmental 
factors (such as tobacco smoking, diet, excessive alcohol intake, occupational exposure to 
carcinogens, exposure to UV radiation, and some other personal habits), have not been 
consistently correlated with risk for glioma (Fisher et al., 2007). Epidemiological data 
suggest that approximately one third of all human cancers are related to dietary factors and 
lack of proper physical activity in adulthood. Additionally, a significant number of these 
could be prevented by vaccination (e.g., viral-related tumors) and/or behavioral changes 
(e.g., tobacco-related tumors and skin cancer), as their risk factors are well known. In 
contrast, reliable recommendations to prevent gliomas cannot be endorsed presently, as the 
etiology of glioma remains largely obscure. A brief summary of the most relevant potential 
risk factors for glioma are briefly reviewed below. 
3.1 Environmental risk factors 
Exposure to high-dose therapeutic radiation is the only firmly established exogenous 
environmental cause of glioma, which can clinically manifest only several years after the 
exposure (Ohgaki & Kleihues, 2005). Recent data suggest that use of high-dose 
chemotherapy to treat other tumors may also contribute to gliomagenesis (Edick et al., 
2005). Interestingly, the degree of risk from these exposures to radiotherapy and 
chemotherapy may be influenced by the individual’s genetic background; for example, a 
functional germline polymorphism in the thiopurine methyltransferase gene was shown to 
affect the susceptibility of children treated with cranial radiotherapy and intensive 
antimetabolite therapy for acute lymphocytic leukemia to further develop brain tumors 
(Relling et al., 1999).  However, similar studies are needed to confirm these observations and 
extend its conclusions to adults. 
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Throughout life, people are exposed to a variety of endogenous and exogenous chemicals 
(for example, reactive oxygen and nitrogen species, N-nitroso compounds, several 
industrially used chemicals, and polycyclic aromatic hydrocarbons) through cellular 
metabolism, diet, occupation, and personal habits. Some of these compounds have been 
shown to be biologically plausible neurocarcinogens in a great number of animal and other 
studies; however, inconsistent or null findings have been reported for these same factors in 
human studies (reviewed in Wrensch et al., 2005). These inconsistent data among several 
association studies may result from a variety of issues, including small study sample sizes, 
false-positive results (due to both small sample size and lack of accurate statistical 
hypothesis), imprecise exposure measures (from proxy reporting and exposure history recall 
issues), protective exposures or conditions unaccounted for (e.g., allergies), variation in 
metabolic and repair pathways in the brain, differential diffusion of chemicals across the 
blood–brain barrier, and disease heterogeneity. 
A currently hot topic is the potential association between cellular phone usage and glioma 
risk. While one study reported increased risk for glioma associated with long term (≥10 
years) use of cellular phones (Hardell et al., 2007), other larger studies have failed to 
replicate this (Lahkola et al., 2007; Inskip et al., 2001; Fisher et al., 2007). 
It is plausible that the failure to find strong and consistent associations between 
environmental risk factors and gliomas might be simply a reflection of absence of true 
associations (and not due to research issues). Nevertheless, considering the small number of 
studies examining environmental risk factors for specific well-defined glioma subtypes, it is 
premature to irrefutably conclude that environmental risks do not exist for glioma. 
3.2 Genetic syndromes, familial aggregation, and mutagen sensitivity 
Studies of genetic syndromes, familial aggregation, linkage, and mutagen sensitivity have 
suggested that genetics has an effect on susceptibility to glioma. Particular inherited rare 
genetic mutations cause a small number of genetic syndromes that have been associated 
with increased risk of glial tumors. Although these familial tumor syndromes account for a 
small proportion of cases (Ichimura et al., 2004), the elucidation of their molecular basis has 
greatly contributed to the understanding of gliomas, and has provided a valuable starting 
point for identifying candidate genes and pathways involved in gliomagenesis. 
In large, carefully-designed epidemiological studies, familial glioma risks have been 
reported to be approximately two-fold, a magnitude that is similar to the familial association 
reported for other cancers for which susceptibility genes have been identified (e.g., breast 
cancer) (Malmer et al., 1999; Hemminki et al., 2000; Wrensch et al., 1997). The underlying 
causes of the pattern of familial brain tumor occurrence have been attributed to a variety of 
causes: one study implicates environmental factors only (Grossman et al., 1999), while 
others attribute multifactorial causes, polygenic causes, and autosomal recessive inheritance 
(de Andrade et al., 2001; Malmer et al., 2001). 
Two case-control studies have suggested that peripheral lymphocytes from glioma patients 
are more sensitive to gamma-radiation than lymphocytes from matched controls, suggesting 
that increased sensitivity to radiation is an independent risk factor for gliomas (Bondy et al., 
1996; 2001). The authors also propose that inherited genetic variation in the capacity to 
repair radiation damage may partly influence mutagen sensitivity and, ultimately, glioma 
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3.3 Genetic polymorphisms 
Since high-dose therapeutic radiation and inherited rare mutations explain only a small 
proportion of gliomas, neuro-oncology research has focused on genetic polymorphisms that, 
together with environmental risk factors, might potentially affect susceptibility to gliomas. 
Some of the most frequently studied polymorphisms, in the context of glioma, are in genes 
involved in DNA repair, carcinogen metabolism, cell cycle regulation, and immunological 
responses.  
Because DNA repair is a mechanism of utmost importance in preserving genomic integrity, 
genes involved in this pathway have been extensively studied in human tumors. Glioma 
and some histological subtypes have been associated with specific polymorphic variants of 
particular DNA repair genes, such as ERCC1 (excision repair cross-complementing 1), 
ERCC2 (excision repair cross-complementing 2), GLTSCR1 (glioma tumor suppressor 
candidate region gene 1), PRKDC (protein kinase, DNA-activated, catalytic), and MGMT 
(O6-methylguanine-DNA methyltransferase) (Wang et al., 2004; Wiencke et al., 2005; 
Wrensch et al., 2005; Yang et al., 2005). However, the clear reliability of these findings is still 
requiring further studies to assess consistency. The DNA repair pathway is extraordinarily 
complex, as illustrated by the more than 130 genes known to be involved in base excision 
repair, direct reversal of damage, mismatch repair, nucleotide excision repair, homologous 
recombination, nonhomologous end joining, sanitization of nucleotide pools, activity of 
DNA polymerases, editing and processing of nucleases, and postreplicative repair (Wood et 
al., 2001). Studying genetic variants in this panoply of DNA repair genes might contribute to 
a better understanding of gliomagenesis, progression, and response to therapy (mostly DNA 
targeting agents). 
Some of the most intriguing and consistent findings of the past decade of neuro-oncology 
research are the statistically significant inverse associations between risk of gliomas in 
adults and histories of allergies and/or chickenpox, IgG antibodies to varicella-zoster virus, 
and levels of serum IgE (Wiemels et al., 2004; Wrensch et al., 2001; 2005). A later study used 
germline polymorphisms in genes associated with asthma and allergies (IL-4RA, IL-13 and 
ADAM33) as biomarkers for the presence of these conditions, as genetic polymorphisms 
could not be influenced by the presence of glioma. Remarkably, specific genotypic variants, 
which have been shown to increase asthma risk, were equally associated with decreased risk 
for glioblastoma (J. Schwartzbaum et al., 2005), further supporting the findings from self-
reported case-control studies. 
We have recently investigated genetic variants potentially relevant for glioma in the 
EGF/EGFR pathway, one of the most important growth signaling networks in human 
tumors, whose significance in gliomas has been well established. Previous studies have 
reached inconsistent conclusions regarding the relevance of a polymorphism in the EGF 
gene (EGF+61 A/G) as a risk factor for glioblastoma (Bhowmick et al., 2004; Vauleon et al., 
2007). Later, we showed that the G allele increases the risk for gliomas, including 
glioblastoma and oligodendroglioma (Costa et al., 2007). Importantly, we have conclusively 
showed that the G variant of EGF+61 is associated with increased promoter activity, which 
may partly explain its relevance for glioma risk. In the EGFR gene, three polymorphisms 
have been described as having a transcriptional regulatory function: two single nucleotide 
polymorphisms in the essential promoter region, -216G/T and -191C/A, and a polymorphic 
(CA)n microsatellite sequence in intron 1. Preliminary studies by our group seem to indicate 
that the -191CA genotype is associated with higher risk for glioma, particularly 
oligodendroglioma, and that shorter (CA)n repeat variants are significantly associated with 
 
Molecular Hallmarks of Gliomas  
 
183 
increased risk for glioma, particularly glioblastoma and oligodendroglioma (Costa et al., 
2010c). In contrast to a study by Carpentier et al. (2006), our preliminary data does not seem 
to implicate the -216G/T polymorphism as a risk factor for glioblastoma. 
Our understanding of cancer as a multi-factorial disease, in which several pathways 
contribute to various stages of tumorigenesis, warrants the need for more integrative studies 
to evaluate interactions among these pathways. Accordingly, the simultaneous study of 
DNA repair, detoxification metabolism, cell cycle, and immunological pathways will allow 
more proper evaluation of different molecular players in gliomagenesis. 
4. Molecular pathology of glioma 
During the past two decades, remarkable progress has been accomplished in the 
understanding of the molecular pathology of gliomas. Similarly to the multistep process of 
human tumorigenesis in other human tissues (Hanahan & Weinberg, 2000), malignant 
transformation of normal cells (either differentiated glial or stem or progenitor cells) into 
gliomas results from the sequential accumulation of molecular aberrations (Ohgaki & 
Kleihues, 2007; Furnari et al., 2007). Tumor-associated molecular dysregulation can occur at 
the genetic and epigenetic levels, including chromosomal gains or losses, gene mutation, 
amplification, deletion, DNA and histones methylation or demethylation, and 
transcriptional regulation (Ichimura et al., 2004); (Wen & Kesary, 2008). An overview of 
some important molecular pathways in the development of gliomas is summarized in 
Figure 1, and briefly discussed below. 
4.1 Chromosomal aberrations 
Cytogenetic studies of gliomas have identified several chromosomal regions with copy 
number alterations (deletions, amplifications, gains, and losses). Typically, the presence of 
loss of heterozygosity (LOH) and deletions in tumors might point to chromosomal regions 
with tumor suppressor genes (those that normally function to suppress tumor 
formation/progression), while amplifications and chromosomal gains might indicate 
regions with oncogenes (those whose function favors tumorigenesis). However, these 
hints may be more difficult to interpret; strikingly, some particular chromosomal regions 
are commonly gained or lost in glioma. To make things a little more complex, the 
definition of tumor suppressor genes and oncogenes is highly context-dependent (e.g., on 
the tumor’s location and intrinsic characteristics), as some proteins play roles that, 
depending on the tissue and cellular context,  may favor or hamper tumorigenesis (Haber 
& Harlow, 1997). 
Combined loss of chromosome arms 1p and 19q is the most frequently detected aberration 
in oligodendroglial tumors (Jeuken et al., 2004). Grade II and grade III oligodendrogliomas 
are equally affected by these chromosomal lesions, suggesting an early role in 
oligodendroglial tumorigenesis. Since losses of chromosome 1p and 19q are intimately 
correlated (Jenkins et al., 2006), it is plausible that the corresponding putative tumor 
suppressor genes may be involved in biologically distinct pathways, which may act 
synergistically in oligodendroglial tumorigenesis. Allelic losses of chromosomes 9p and 10q, 
and homozygous deletion of CDKN2A on chromosome 9p21, are also frequent in anaplastic 
oligodendroglioma (WHO grade III) (Bigner et al., 1999; Ueki et al., 2002). Chromosomal 
aberrations are also present in the majority (~70%) of both primary and secondary 
glioblastoma, which present LOH of chromosome 10q (Behin et al., 2003).  
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Fig. 1. Major signalling pathways commonly altered in glioblastomas: RTK/RAS/PI3K, p53, 
and RB. Red and blue boxes indicate proteins with activating and inactivating alterations, 
respectively, which can be genetic (gene amplifications or deletions, chromosomal copy 
number alterations and translocations, and mutations) and/or epigenetic (DNA CpG island 
hypermethylation, gene specific and global genome-wide DNA hypomethylation, and 
aberrant histone modifications). The frequency of alterations found in GBM in each pathway 
is indicated in the dashed boxes. 
4.2 Dysregulated pathways 
The histological heterogeneity of gliomas parallels with a substantial degree of molecular 
heterogeneity, both within and between histological subtypes of glioma (Rasheed et al., 
1999; Freije et al., 2004). Several interconnected pathways are commonly altered in glioma, 
typically those governing cell-cycle regulation (cellular proliferation and senescence), 
cellular survival (apoptosis and necrosis), invasion (adhesion and migration), and 
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angiogenesis. These molecular abnormalities result in cell’s self-sufficiency with respect to 
growth signals, insensitivity to growth-inhibitory stimuli, evasion of programmed cell 
death, “limitless” replicative potential, sustained angiogenesis, tissue invasion, and 
metastasis. 
4.2.1 Receptor tyrosine kinase (RTK) pathways 
Gliomas typically present overactivation of many mitogens (growth factors) and their 
specific membrane receptors. In order to proliferate, normal cells require activation of 
mitogenic signaling pathways (upon binding of diffusible growth factors to their specific 
transmembrane receptors) and subsequent intracellular signal transduction, which occurs 
mostly through the PI3K and MAPK signaling pathways. In contrast, acquired molecular 
alterations in tumor cells decrease their dependence on exogenous growth stimuli, 
facilitating their aberrant cell division, survival, and motility. While multiple mechanisms 
contribute to the ability of gliomas to overcome normal impositions on the control of 
mitogenic signaling (MAPK and PI3K/PTEN/AKT pathways, among others), abnormal 
activation of receptor tyrosine kinases (RTKs) seems to be the predominant (and better 
studied) mechanism. 
Activation of receptor tyrosine kinase pathways in gliomas occurs through a variety of 
mechanisms, including overexpression of both ligands and receptors (leading to autocrine 
activating loops), gene amplification, and/or mutation of the receptor (resulting in 
constitutive activation even in the absence of the ligand). In addition, particular genetic 
polymorphisms may influence the expression of some of the genes involved in these 
pathways. The two most important receptor-driven signaling pathways in both CNS 
development and gliomagenesis are the epidermal growth factor (EGF) and platelet-derived 
growth factor (PDGF) pathways. 
It is well established the importance of EGF receptor (EGFR) in development and 
differentiation of normal astrocytes (Burrows et al., 1997), but this RTK also plays critical 
roles in glial tumors (Kapoor & O'Rourke, 2003; Rao, et al., 2003). EGFR gene amplification is 
found in a variety of solid tumors, being notably frequent in astrocytomas (up to ~40% of all 
glioblastomas) (Viana-Pereira et al., 2008; Wong et al., 1992). These amplified versions of 
EGFR often undergo genetic rearrangements (e.g., EGFRvI, EGFRvII),  some of which are 
relevant for the oncogenic and malignant roles of EGFR (Ekstrand et al., 1992). EGFRvIII 
(also known as EGFR, or EGFR*), which shows  an in-frame deletion of exons 2–7, is the 
most common EGFR mutant allele,  occurring up to 30% of all human GBM (and in up to 
60% of those that have amplified wild-type EGFR) (Frederick et al., 2000). EGFRvIII protein, 
which exhibit constitutive ligand-independent tyrosine kinase activity, has been found to 
enhance tumorigenic behavior of human glioblastoma cells by reducing apoptosis and 
increasing proliferation (Nagane et al., 1996) and to malignantly transform murine Ink4a/Arf 
null neural stem cells (NSCs) or astrocytes in the mouse brain (Holland et al., 1998; Bachoo 
et al., 2002) making it an attractive and validated therapeutic target in glioma. 
PDGF receptor- (PDGFR-), along with its specific ligands PDGF-A and PDGF-B, are also 
commonly overexpressed in gliomas, particularly in high-grade tumors (Westermark et al., 
1995). In contrast, strong expression of PDGFR- occurs mostly in proliferating endothelial 
cells in glioblastoma. PDGF-C and PDGF-D are also frequently expressed in glioma cell lines 
and in glioblastoma tissues (Lokker et al., 2002). Autocrine and paracrine signaling loops 
may be the primary means by which the PDGFR axis exerts its effects in gliomas, as these 
tumors often demonstrate coexpression of both PDGF ligands and receptors. The 
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importance of this signaling axis in gliomas has been supported by several recent studies: 
PDGF was shown to stimulate NSCs in the adult subventricular zone that express PDGFR- 
to form glioma-like lesions in the mouse (Jackson et al., 2006); in addition, mice transgenic 
for neural progenitor PDGF-B expression resulted in the formation of oligodendrogliomas 
and forced elevation of PDGF-B levels increased overall tumor incidence (Dai et al., 2001; 
Shih et al., 2004). This growing body of data suggests that targeted therapy against this 
pathway could have therapeutic potential. 
4.2.2 The PI3K-AKT pathway 
Along with alterations in cell cycle regulatory pathways and RTK pathways, intracellular 
signaling pathways are also critical in glioma. Some important examples include the MAPK 
pathway (which plays a wide variety of cellular functions, such as regulation of cell-cell 
interactions, composition of extracellular matrix, and expression of genes promoting cell 
cycle progression (Dhanasekaran & Johnson, 2007), and the PI3K/AKT pathway (involved 
in an extraordinary diverse group of cellular functions, including cell growth, proliferation, 
differentiation, motility, survival and intracellular trafficking). Gliomas typically show 
increased activity of several molecular components of the MAPK and PI3K/AKT pathways, 
while some tumor suppressor genes that negatively regulate these pathways are often 
inactivated (Konopka & Bonni, 2003). For example, inactivating mutations in the tumor 
suppressor gene phosphatase and tensin homolog deleted on chromosome 10 (PTEN), 
whose protein is a negative regulator of the PI3K/AKT pathway, contribute to the abnormal 
activity of the pathway. 
The class IA PI3Ks are heterodimers consisting of one regulatory subunit [one of five 
isoforms encoded by three genes: p85, p55, and p50 (PIK3R1); p85 (PIK3R2); and p55 
(PIK3R3)] and a catalytic isoform [p110 (PIK3CA), p110 (PIK3CB) and p110 (PIK3CD)]. 
Activated RTKs recruit class IA PI3Ks to the membrane through their regulatory subunit. 
Activation of class IA PI3Ks at the membrane results in phosphorylation and conversion of 
the lipid phosphatidylinositol-(4,5)-bisphosphate (PIP2) into phosphatidylinositol-(3,4,5)-
triphosphate (PIP3), which in turn recruits and activates phosphatidylinositol-dependent 
kinase 1 (PDK1). Activated PDK1, in turn, phosphorylates and activates protein kinase B 
(PKB, also known as AKT). A subsequent signaling cascade downstream of AKT ultimately 
results in inhibition of cell cycle arrest and apoptosis, and increased cell proliferation and 
survival. The tumor-suppressor phosphatase and tensin homologue (PTEN) negatively 
regulates PI3K signalling by dephosphorylating PIP3, converting it back to PIP2 (Hawkins et 
al., 2006). 
The class IA PI3Ks are currently defined by their catalytic isoform, as the regulatory 
subunits appear to be functionally equivalent. Several studies have implicated class IA 
PI3Ks genes in glial tumors. Gain-of-function mutations in the PI3KCA gene have been 
found in some malignant gliomas (e.g., glioblastoma), with a reported mutation frequency 
up to 15% (Samuels et al., 2004; Gallia et al., 2006). Inactivation of PTEN by mutations or 
epigenetic mechanisms is a frequent event in high-grade gliomas (up to 50%), which results 
in uncontrolled PI3K signaling (Knobbe & Reifenberger, 2003; Ohgaki et al., 2004). Studies 
using elegant mouse models have recently shown that the specific inactivation of PTEN in 
the mouse brain caused its overgrowth and abnormal proliferation of astrocytes (Fraser et 
al., 2004). Also in mouse studies, inactivation of PTEN has been associated with increased 
angiogenesis, closely paralleling the progression from low-grade to high-grade 
astrocytomas in humans, which coincides with PTEN loss (Andrew Xiao et al., 2002; 2005).  
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Aberrant PI3K signaling commonly results in activation of Akt via phosphorylation of two 
key residues, T308 and S473, by PDK1 and the mammalian target of rapamycin (mTOR), 
respectively (Mora et al., 2004; Sarbassov et al., 2005). In fact, assessment of the 
phosphorylation status of these residues in Akt is often the method of choice for 
determining activation of the PI3K pathway in cell lines and primary tumors, including 
glioblastoma samples, 85% of which have been shown to exhibit activated Akt (Wang et al., 
2004). Additional mechanisms by which Akt activation may become dysregulated include 
decreased expression of PHLPP (PH domain leucine-rich repeat protein phosphatase, which 
dephosphorylates S473 in Akt), decreased expression of CTMP (C-terminal modulator 
protein, which binds to Akt and inhibits its phosphorylation), or overexpression of PIKE-A 
(phosphatidylinositol-3-kinase enhancer, which binds directly to phosphorylated Akt and 
enhances its anti-apoptotic function) in primary glioblastoma and glioma cell lines (Ahn et 
al., 2004). 
Despite most of the signaling pathways previously mentioned (p53, RB, RTK, MAPK, and 
PI3K/AKT pathways) are often considered as distinct entities, there is significant cross-talk 
and inter-dependence among them, which reinforces the inappropriate regulation of any 
single pathway perturbation. (Indeed, these pathways are sometimes referred to as genetic 
networks, to emphasize their highly complex relationships.) For example, since p53 
enhances transcription of PTEN (Stambolic et al., 2001), the loss of p53 in cells with 
constitutively active RTK signaling can further potentiate PI3K/AKT pathway activation. 
The NF1 tumor suppressor gene encodes neurofibromin-1, which functions primarily as a 
RAS negative regulator, and also plays a role in adenylyl cyclase and AKT-mTOR pathways. 
Loss of NF1 is a typical molecular aberration of WHO grade I pilocytic astrocytoma (Zhu & 
Parada, 2002), and is believed to be one of the precursor lesions in these tumors, as the 
absence of negative regulation of RAS oncoprotein may favor cell proliferation and, 
ultimately, tumor initiation. 
4.2.3 Cell cycle regulators 
Genes involved in cell cycle regulation have been frequently found mutated in glioma, 
highlighting the importance of such genes in cellular proliferation and senescence. The RB 
and p53 pathways, which regulate the cell cycle primarily by governing the G1-to-S-phase 
transition, are major targets of functional inactivation in glioma, through any of several 
molecular alterations. The inactivation of these key regulators renders tumors highly 
sensitive to uncontrolled cell proliferation driven by mitogenic signaling effectors, such as 
phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK). 
The RB protein exerts its anti-proliferative effects in quiescent cells by binding and 
sequestering the E2F family of transcription factors, preventing the transactivation of 
genes essential for cell cycle progression (Sherr & McCormick, 2002). Gliomas circumvent 
the RB-mediated negative regulation of the cell cycle by any of the following 
genetic/epigenetic aberrations: mutation of the Rb1 gene, loss of its chromosomal region 
(13q) when progression from low- to high-grade gliomas occurs, amplification of cyclin-
dependent kinases 4 and 6 (CDK4 and CDK6) genes (which encode negative regulators of 
RB activity), and inactivation of p16Ink4a (a negative regulator of CDKs) by allelic loss or 
DNA hypermethylation in high-grade gliomas (Louis et al., 2007). Even though the 
neutralization of the RB pathway alone is not sufficient to abrogate cell cycle control to 
the extent needed for cellular transformation (suggesting that other important cell cycle 
regulation pathways complement its activities in preventing gliomagenesis) (Xiao et al. 
 
Molecular Targets of CNS Tumors 
 
186 
importance of this signaling axis in gliomas has been supported by several recent studies: 
PDGF was shown to stimulate NSCs in the adult subventricular zone that express PDGFR- 
to form glioma-like lesions in the mouse (Jackson et al., 2006); in addition, mice transgenic 
for neural progenitor PDGF-B expression resulted in the formation of oligodendrogliomas 
and forced elevation of PDGF-B levels increased overall tumor incidence (Dai et al., 2001; 
Shih et al., 2004). This growing body of data suggests that targeted therapy against this 
pathway could have therapeutic potential. 
4.2.2 The PI3K-AKT pathway 
Along with alterations in cell cycle regulatory pathways and RTK pathways, intracellular 
signaling pathways are also critical in glioma. Some important examples include the MAPK 
pathway (which plays a wide variety of cellular functions, such as regulation of cell-cell 
interactions, composition of extracellular matrix, and expression of genes promoting cell 
cycle progression (Dhanasekaran & Johnson, 2007), and the PI3K/AKT pathway (involved 
in an extraordinary diverse group of cellular functions, including cell growth, proliferation, 
differentiation, motility, survival and intracellular trafficking). Gliomas typically show 
increased activity of several molecular components of the MAPK and PI3K/AKT pathways, 
while some tumor suppressor genes that negatively regulate these pathways are often 
inactivated (Konopka & Bonni, 2003). For example, inactivating mutations in the tumor 
suppressor gene phosphatase and tensin homolog deleted on chromosome 10 (PTEN), 
whose protein is a negative regulator of the PI3K/AKT pathway, contribute to the abnormal 
activity of the pathway. 
The class IA PI3Ks are heterodimers consisting of one regulatory subunit [one of five 
isoforms encoded by three genes: p85, p55, and p50 (PIK3R1); p85 (PIK3R2); and p55 
(PIK3R3)] and a catalytic isoform [p110 (PIK3CA), p110 (PIK3CB) and p110 (PIK3CD)]. 
Activated RTKs recruit class IA PI3Ks to the membrane through their regulatory subunit. 
Activation of class IA PI3Ks at the membrane results in phosphorylation and conversion of 
the lipid phosphatidylinositol-(4,5)-bisphosphate (PIP2) into phosphatidylinositol-(3,4,5)-
triphosphate (PIP3), which in turn recruits and activates phosphatidylinositol-dependent 
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Aberrant PI3K signaling commonly results in activation of Akt via phosphorylation of two 
key residues, T308 and S473, by PDK1 and the mammalian target of rapamycin (mTOR), 
respectively (Mora et al., 2004; Sarbassov et al., 2005). In fact, assessment of the 
phosphorylation status of these residues in Akt is often the method of choice for 
determining activation of the PI3K pathway in cell lines and primary tumors, including 
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The NF1 tumor suppressor gene encodes neurofibromin-1, which functions primarily as a 
RAS negative regulator, and also plays a role in adenylyl cyclase and AKT-mTOR pathways. 
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genes essential for cell cycle progression (Sherr & McCormick, 2002). Gliomas circumvent 
the RB-mediated negative regulation of the cell cycle by any of the following 
genetic/epigenetic aberrations: mutation of the Rb1 gene, loss of its chromosomal region 
(13q) when progression from low- to high-grade gliomas occurs, amplification of cyclin-
dependent kinases 4 and 6 (CDK4 and CDK6) genes (which encode negative regulators of 
RB activity), and inactivation of p16Ink4a (a negative regulator of CDKs) by allelic loss or 
DNA hypermethylation in high-grade gliomas (Louis et al., 2007). Even though the 
neutralization of the RB pathway alone is not sufficient to abrogate cell cycle control to 
the extent needed for cellular transformation (suggesting that other important cell cycle 
regulation pathways complement its activities in preventing gliomagenesis) (Xiao et al. 
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2002), the importance of its inhibition in progression from low- to higher-grade gliomas is 
underscored by the near-universal and mutually exclusive alterations of the molecular 
players of the RB pathway in both primary and secondary glioblastoma (Schmidt et al., 
1994; Ueki et al., 1996). 
The p53 tumor suppressor prevents the proliferation of cells with faulty genomes, mostly by 
halting the cell cycle in the G1 phase or by induction of an apoptotic program (Vousden & 
Lu, 2002). In sporadic (non-hereditary) gliomas, the p53 pathway is almost universally 
altered. A variety of molecular mechanisms may result in defective p53 function in glioma. 
Loss of p53 through either inactivating mutations in its DNA-binding domain or loss of 
chromosome 17p are common early events in the progression of secondary glioblastoma 
(Louis, 1994); in addition, germline p53 mutations in Li-Fraumeni patients, who have 
increased risk to develop gliomas, also underscore the importance of p53 in gliomagenesis 
(Malkin et al., 1990; Srivastava et al., 1990). Alternative inactivating alterations of the p53 
pathway in gliomas include deletion of p14ARF (whose protein stabilizes p53), amplification 
of the chromosomal region containing MDM2 and MDM4 genes (which encode negative 
regulators of p53 activity and expression) (Riemenschneider et al., 1999), and hemizygous 
deletion of the tumor suppressor gene CDH5 (whose protein plays a role in maintaining 
TP53 expression) (Bagchi et al., 2007). 
4.2.4 Isocitrate dehydrogenases (IDH1 and IDH2) genes 
Very recent studies have identified mutations in the genes encoding the cytosolic and 
mitochondrial isoforms of NADP+-dependent isocitrate dehydrogeneses (IDH1 and IDH2, 
respectively) in GBMs (Balss et al., 2008; Parsons et al., 2008; Ichimura et al., 2009; Watanabe 
et al., 2009; Yan et al., 2009; Zhao et al., 2009; Pollack et al., 2010; Christensen et al., 2011). 
These enzymes catalyze the decarboxylation of isocitrate to -ketoglutarate (-KG), in a 
reaction that utilizes NADP+ and produces NADPH. This cytosolic NAPDH is essential for 
the regeneration of reduced glutathione, which is important in the protection of cells against 
oxidative damage. These mutations in IDH1 and IDH2 are heterozygous and of somatic 
origin.  Until now, the mechanisms by which IDH mutant proteins contribute to 
gliomagenesis are not fully understood. The IDH1 R132H mutant variant, which is present 
in more than 90% of gliomas but rare in pilocytic astrocytomas, presents impaired substrate 
affinity, and dominantly inhibits wild-type IDH1 activity through the formation of 
catalytically inactive heterodimers (Zhao et al., 2009). The overexpression of mutant IDH1 
was shown to reduce the formation of -KG, and to increase the levels of HIF-1α, a critical 
transcription factor that promotes tumor growth under hypoxic conditions and whose 
stability depends on the levels of -KG. This HIF-1 regulation by mutant IDH1 suggested 
that this mutation may cause oncogenic gains of function. Indeed, a later study by Dang et 
al., (2009) showed that mutant IDH1 converts a -KG to 2-hydroxyglutarate (2-HG) in a 
NADPH-depend manner. Because mutations in IDH1 and IDH2 genes are restricted to a 
single amino acid, their detection for diagnostic purposes should be straightforward.  
Gliomas of astrocytic or oligodendrocytic lineage with IDH mutations have been shown to 
present distinct clinical and genetic characteristics as compared with gliomas with wild-type 
IDH genes (Yan et al., 2009), suggesting this mutation may be an early event in 
gliomagenesis from a stem/progenitor cell that can differentiate into both astrocytes and 
oligodendrocytes. Since IDH mutants occur in the large majority of WHO grade II or III 
gliomas, and in WHO grade IV secondary glioblastomas that develop from these lower-
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grade precursor lesions, suggests that tumors with mutated IDH’s encompass a specific 
subgroup of glioblastomas. 
4.2.5 Molecular pathways to glioblastoma 
As previously mentioned, glioblastomas can be subdivided into primary or secondary 
GBMs, based on their clinical and biological differences. Primary GBMs are by far the 
most common, affect older patients, and are genetically characterized by EGFR 
amplification and mutations, LOH of chromosome 10q, and deletion of the PTEN and the 
p16INK4a genes (Louis et al., 2007). Secondary GBMs affect younger patients who had 
previously been affected by a lower grade astrocytoma, and are molecularly characterized 
by mutations in the TP53 gene, overexpression of PDGFR, abnormalities in the p16 and Rb 
pathways, and LOH of chromosome 10q  (Louis et al., 2007). Importantly, some of these 
molecular abnormalities are not exclusive for a specific glioblastoma subtype, but are 
rather present at significantly different frequencies (for example, the frequency of TP53 
mutation in secondary GBM is more than ~65%, but only ~28% in primary GBM) (Ohgaki 
& Kleihues, 2007). Despite being morphologically and clinically indistinguishable, as 
reflected by an equally poor prognosis when adjusted for patient age, primary and 
secondary GBMs have markedly distinct molecular features, at the levels of gene 
transcriptional patterns and DNA copy number aberrations (Furnari et al., 2007). Thus, 
these molecular distinctions strongly suggest that these GBM entities may respond 
differently to targeted molecular therapies, warranting the need to change the current 
standardize clinical management of these truly distinct diseases. 
4.2.6 Epigenetic changes in glioma 
In addition to genetic aberrations, gliomas also present a variety of epigenetic alterations, 
defined as mitotically heritable changes in gene expression that are not due to changes in the 
primary DNA sequence. The most well-studied epigenetic changes in gliomas occur 
primarily at two levels: DNA methylation at CpG dinucleotides, and post-translational 
modifications of histone tails. Nevertheless, other epigenetic mechanisms include noncoding 
RNAs (e.g., microRNAs and small nucleolar RNAs), accumulation of histone variants, and 
chromatin remodeling, and may also be altered in brain tumors. Typical changes in DNA 
methylation levels observed in gliomas, as in other human tumors, include CpG island 
hypermethylation (associated with tumor suppressor gene silencing), gene-specific 
hypomethylation (resulting in aberrant oncogene activation), and genome-wide 
hypomethylation (potentially leading to chromosomal instability, loss of imprinting, and 
uncontrolled cellular proliferation). The histone modifications are quite more complex: 
firstly, because of the great variety of modifications that can occur in different histones 
(including, methylation, acetylation, phosphorylation, ubiquitylation, sumoylation, among 
others), and secondly, because a single histone tail residue can be mono-, di-, or tri-
methylated on a single, specific lysine. In general, epigenetics is just another layer of gene 
expression regulation that, when altered in specific genes, may favor tumor formation and 
progression. While genetic and epigenetic changes in gliomas have been mostly studied 
independently, there is evidence that these mechanisms interact on specific genes, signaling 
pathways, and chromosomal domains. A summary of some of the epigenetic changes 
previously found in gliomas is presented in Table 1, and elegantly reviewed by Nagarajan & 
Costello, 2009. 
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5. Molecular prognostic factors of malignant glioma 
Recent studies started to identify potential biological and molecular characteristics in the 
tumors that may have prognostic value and help in making therapeutic decisions (Phillips et 
al., 2006), although such studies clearly require validation in prospectively followed and 
uniformly treated patients. Until now, work on the identification of prognostic markers in 
gliomas grants reasons for both optimism and caution with respect to improvements in the 
diagnosis and treatment of patients. In practice, the multitude of studies on the 
identification of such markers has led so far to development of only one molecular test with 
clinical relevance: 1p/19q testing in oligodendrogliomas. Much more effort is required for 
the identification of markers that truly and consistently distinguish glioma patients in ways 
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that can assist therapeutic decisions. Below we briefly discuss the current most promising 
molecular prognostic factors in these tumors, which are summarized in Table 2. 
 
Molecular Prognostic Marker Glioma Type 
Chromosome 1p/19q co-deletion Oligodendroglioma and oligoastrocytoma 
MGMT promoter methylation GBM and anaplastic astrocytoma 
Loss of chromosome 10 GBM 
Activation of the PI3K/AKT pathway  GBM 
Activation of MAPK members GBM 
EGFR mutation (EGFRvIII) GBM 
PTEN expression (wild-type) GBM 
Molecular signatures (proneural, 
proliferative and mesenchymal) GBM 
High expression of angiogenic genes Diffusely infiltrating gliomas of all histologic types 
Stem-cell like gene expression signatures GBM 
CHI3L1 (YKL-40) expression GBM 
PTEN and DLL3 expression GBM 
EGFR expression GBM 
HOXA overexpression GBM 
IDH1-2 mutations All gliomas, but not very frequent in primary GBM 
Table 2. Selected Molecular Prognostic Markers for Gliomas. 
5.1 Malignant astrocytomas 
O6-methylguanine-DNA methyltransferase (MGMT, also known as AGT) is an important 
DNA repair enzyme that contributes to glioblastoma resistance to temozolomide. The 
methyl group at the O6 position of guanine can be removed by MGMT, which is consumed 
by this event (Spiro et al., 2001). In a similar study to the one from the EORTC–NCIC, Hegi 
et al., 2005, examined the DNA methylation at the promoter region of the MGMT gene in 
tumor samples from glioblastoma patients. This epigenetic event silences MGMT, which 
decreases tumor cells’ ability to repair temozolomide-induced DNA damage, resulting in 
increased susceptibility of the tumor cells to temozolomide. Hegi reported that glioblastoma 
patients with a methylated MGMT promoter who were treated with temozolomide had a 
significantly longer median overall survival (21.7 months) and a higher 2-year survival rate 
(46%) than patients without MGMT promoter methylation who were similarly treated with 
temozolomide (median survival of only 12.7 months and a 2-year survival rate of 13.8%), 
suggesting that glioblastoma patients whose tumors do not have a methylated MGMT 
promoter do not benefit from temozolomide. Despite the striking and encouraging findings 
supporting MGMT as a glioma prognostic marker and a specific predictor of temozolomide-
based chemotherapy, there is a significant body of controversial data surrounding the 
reproducibility of such findings (summarized in Costa et al., 2010a). Much of the 
controversy around the prognostic value of MGMT is due in part to studies including very 
heterogeneous groups of patients, with different glioma histologies, grades, and treatment 
types often grouped together in the same analysis. Additionaly, different studies analyzed 
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MGMT at different levels, including methylation by methylation-specific PCR, mRNA 
expression by RT-PCR, and protein levels by immunohistochemistry and quantitative 
immunofluorescence. Due to the widely acknowledged need of replicating Hegi’s findings, 
we investigated the potential of MGMT methylation as a prognostic marker of glioblastoma 
in a set of 90 prospectively followed patients uniformly treated with postoperative 
temozolomide-based chemoradiation. In line with some other reports, we found a trend for 
longer overall and progression-free survival in glioblastoma patients whose tumors had 
MGMT promoter methylation, but the differences failed to reach statistical significance in 
our data set (Costa et al., 2010a). 
Recent evidences are revealing striking similarities between developmental and tumorigenic 
processes, suggesting that some of the molecular regulatory mechanisms necessary for 
normal development may be equally relevant in tumors. Homeobox (HB) genes encode 
transcription factors that play critical roles during normal development. These genes are 
broadly divided into two classes: class I includes clustered homeobox (HOX) genes, while 
class II includes divergent HB (non-HOX) genes that are dispersed throughout the genome 
(McGinnis & Krumlauf, 1992). The expression of some HOX genes has been shown to be 
altered in leukemias and several types of solid tumors. In recent years, a growing body of 
data has been implicating the aberrant expression of HOXA genes as an important 
mechanism in the pathophysiology of malignant astrocytomas. A study by (Abdel-Fattah et 
al., 2006) assessed the expression status of all HOX genes in primary astrocytomas and non-
tumoral brain specimens, showing that a portion of these genes are aberrantly 
overexpressed in malignant astrocytomas. However, the relevance of these genes in glioma 
pathogenesis, malignancy, and prognosis was not addressed in that study. Later, Murat et 
al., 2008, suggested HOX genes may be part of a glioma stem cell signature with prognostic 
significance in patients treated with chemo-radiotherapy. We have recently shown that 
several HOXA genes are preferentially overexpressed in high-grade rather than in low-
grade primary astrocytomas, and we have implicated the reactivation of HOXA9 expression 
in GBM as a novel, independent, and negative prognostic factor in 2 independent sets of 
GBM patients (Costa et al., 2010b). Additionally, HOXA9 reactivation was particularly 
frequent in a subgroup of GBM with aberrant chromosomal domains of transcriptional 
activation encompassing the HOXA cluster. Importantly, we demonstrated the PI3K-
associated epigenetic mechanism by which this domain of activation is reversible: activation 
of the PI3K pathway in GBM cells decreased the levels of histone H3 lysine 27 
trimethylation through inhibition of EZH2, a key histone methyltransferase. Finally, we 
provided functional data on the effects of HOXA9 expression in GBM cells and 
immortalized astrocytes, which support its pro-proliferative and anti-apoptotic properties. 
Our findings revealed prognostic and therapeutic implications for oncogenic expression of 
the developmental transcription factor HOXA9 in malignant brain tumors, including the 
evaluation of PI3K inhibitors, which are being extensively tested in clinical trials. Finally, a 
recent study by (Gaspar et al., 2010) showed that high levels of HOX genes expression was a 
signature of resistance to temozolomide in pediatric GBM cell lines; in addition, pediatric 
high-grade glioma patients whose tumors expressed HOXA genes (particularly HOXA9 and 
HOXA10) presented significantly shorter survival. Taken together, these recent studies point 
out to a very relevant role of HOXA genes in rendering high-grade gliomas even more 
malignant and resistant to therapy, resulting in particularly lethal tumors. 
A genomic study by Parson and colleagues in 2008 showed that a subset of GBM patients 
had IDH1 R132H mutations, and that this mutation occurred mostly in younger patients 
(mean age 33 years in IDH1 mutant patients versus 53 years for patients with wild-type 
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IDH1). In addition, this mutation was particularly frequent in secondary GBMs (5 out of 6 
secondary GBMs versus 7 out of 99 primary GBMs with IDH1 mutation), and was 
significantly associated with an increase in patients overall survival (Parsons et al., 2008). 
Yan et al. (2009) subsequently showed that IDH1 mutation was commonly present in a 
variety of gliomas, including diffuse astrocytoma, anaplastic astrocytoma, and 
oligodendroglioma. In addition, the authors also identified a mutation affecting the 
analogous aminoacid residue (R172) of the IDH2 gene, which was present in tumors without 
IDH1 mutation. Importantly, the presence of either IDH mutation was associated with better 
survival of GBM and anaplastic astrocytoma patients. Christensen et al. (2011) also verified 
that IDH1 mutation occurs more frequently than IDH2 mutation in gliomas, and showed 
that the presence of IDH1 or IHD2 mutation was significantly associated with better survival 
of glioma patients, independently of patient age, sex, and grade-specific histology. 
5.2 Malignant oligodendrogliomas and oligoastrocytomas 
Tumors with 1p/19q codeletion are particularly sensitive to chemotherapy with PCV, with 
response rates as high as 100%, whereas patients whose tumors do not present 1p/19q 
codeletion show response rates of 23-31% (Ino et al., 2001; Cairncross et al., 1998). Indeed, 
oligodendroglioma is the first CNS neoplasm in which a molecular signature (1p and 19q 
codeletion) has been categorically associated with patient outcome within the context of 
large clinical trials (Felsberg et al., 2004). Even though the reasons for such associations are 
still unclear, the status of 1p and 19q, rather than classic histological analysis, is currently 
used as an eligibility criterion in studies involving patients with pure or mixed anaplastic 
oligodendrogliomas. This truly reflects a paradigm shift in the design of clinical trials for 
patients with these tumors, and has been regarded as a key example of the value of 
molecular signatures as prognostic markers of disease. Again, codeletion of 1p/19q was 
associated with improved survival in both studies. Although most studies of patients with 
pure or mixed oligodendroglioma were performed with PCV chemotherapy, temozolomide 
is arguably likely to have similar activity with less side effects (van den Bent, 2007; Yung et 
al., 1999); however, studies comparing the efficacy of these two chemotherapeutic regimens 
are still lacking. 
6. Conclusion 
Human gliomas are particularly dramatic diseases, not only because of their high lethality, 
but also because their etiological and prognostic factors are still not fully understood. 
Integrating multi-disciplinary teams to collaborate in the identification of new molecular 
and exogenous glioma risk factors is urgent. Possibly even more important is to rapidly 
improve the clinical management of glioma patients. While the current therapies used for 
malignant glioma and patients’ outcome are not satisfactory, the recent insights on the 
biological and clinical features of glioma offer appealing opportunities for the development 
of more effective targeted therapy. The use of comprehensive genome-wide approaches to 
analyze genetic and epigenetic alterations, as it is the case of The Cancer Genome Atlas 
(TCGA, http://cancergenome.nih.gov/about/mission.asp), may foster our understanding 
of the complex mechanisms underlying the various layers of glioma biology (formation, 
progression, resistance to therapy, etc) and aid in the identification of new avenues for drug 
development, particularly targeted therapies. Indeed, recent developments in second 
generation sequencing technologies and its more widespread application hold promise to 
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achieve these goals. Much more effort is required for the identification of molecular markers 
that truly and consistently distinguish glioma patients in ways that can assist therapeutic 
decisions. The integration of clinical and molecular data, now becoming available using 
recently developed tools such as  gene microarrays, proteomics, and molecular imaging, will 
take us to an era where more targeted and effective treatments may be developed and 
implemented. We are cautiously optimistic that the development of a consensual molecular 
marker set predictive of therapy response in malignant gliomas, particularly glioblastoma, 
can arise in the future. Such marker set would substantially change the clinical management 
of these patients as it could aid the neuro-oncologist in individualizing therapy for each 
patient. Particularly, such marker set could allow the identification of the subset of patients 
who are likely to benefit from a specific therapy alone. Conversely, the ability to 
prospectively identify patients who are not be likely to respond to such therapy would also 
allow those patients to make an informed decision to participate in clinical trials with 
alternative novel therapies, avoiding adverse effects of specific treatments in the absence of 
anticipated clinical benefit. Additionally, a more in depth knowledge of the molecular 
determinants of treatment resistance could be the rational for designing the next generation 
of clinical trials for these highly malignant tumors. Finally, the identification of true 
molecular markers is also invaluable in the first steps of new drugs’ development. Despite 
all the gaps in our understanding, a large amount of information is now available about the 
clinical and biological behavior of gliomas, and the molecular pathways that are relevant in 
their genesis and progression. In the quest toward individualization of glioblastoma 
treatment, the discovery of particular tumor molecular features, such as the status of MGMT 
methylation, IDH1-2 mutations, and HOXA genes expression, may be the initial building 
blocks of a panel of molecular markers that truly have clinical implications. The challenge in 
the future will not only be to discover additional molecular markers of glioblastoma, but 
also to integrate all this new knowledge in an interdisciplinary manner to create an 
intelligible puzzle, which allows a more rational and efficient fight against this disease. 
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Glioblastoma is the most common and aggressive type of primary brain tumor in humans. It 
is located preferentially in the cerebral hemispheres. Glioblastoma arises from complex 
interactions between a variety of genetic, epigenetic alterations and environmental 
perturbations. However, the precise mechanism of glioblastoma is unknown and its survival 
rate is very low. The Cancer Genome Atlas (TCGA) generates large-scale multi-dimensional 
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reconstruct genetic and epigenetic networks involved in tumorigenesis and study how these 
networks respond to perturbation such as somatic mutations and methylation. Information 
that defines the path from genomic variations to tumors flows from mutations and 
methylation through mRNA and miRNA expressions to tumor formation. Therefore, the 
components of complex genetic and epigenetic networks that determine cell function and 
response to perturbation of external stimuli include genes harboring DNA variations, 
mRNAs, miRNAs,  and methylation connected by their co-expressions or interactions. These 
networks consist of three levels. The subnetworks in the first level consist of mRNA and 
miRNA co-expression networks, mRNA and miRNA interaction networks. The 
subnetworks in the second level are miRNA target gene networks. The subnetworks in the 
third level are eQTL networks which connect mutations to gene and miRNA expression.  
Somatic mutations that are likely to cause tumorigenesis are traditionally identified by 
comparing differences in mutation frequencies between tumor and normal tissues 
individually. However, most somatic mutations are rare mutations. Due to their rarity, the 
frequencies of rare alleles may be compatible with sequencing errors. As a consequence, 
individual tests of association of rare variants with disease have little power and may not be 
robust. To overcome this limitation, we develop group association tests in which a group of 
rare genetic variants are jointly tested for assessing association of rare mutations and LOH 
with cancer. Multiple rare mutations, each with a minor marginal genetic effect, but 
collectively may make big contributions.  
We reconstructed two types of networks that connect mRNAs or miRNAs. One is mRNA or 
miRNA co-expression networks. To take inherent sparse structure of co-expression 
networks, we use partial correlation method and sparse regression techniques to infer co-
expression networks. Although co-expression networks are very useful for revealing 
transcriptional regulatory actions, they do not directly provide information on differences in 
regulatory effects between tumor and normal tissues. It is differences in regulatory effects 
that cause cancer. Therefore, we propose a new concept of a regulatory difference network 
that is formally referred to as mRNA or miRNA interaction networks. We detect interaction 
between mRNAs or miRNAs by measuring differences in their mutual information between 
tumor and normal tissues and develop a novel MI-based statistic to test interaction between 
two mRNAs or miRNAs.  
miRNAs are short endogenous noncoding RNAs of 22 nt that negatively regulate gene 
expression through base pairing with target mRNAs (Huang, et al., 2007; Huang, et al., 2007). 
It is increasingly recognized that miRNAs have emerged as an important component in the 
regulation of gene expression, with imperfect base pairing, to target sites in the 3’ UTR of 
messenger RNAs (Gennarino, et al., 2009). Three types of methods have been used to identify 
potential target genes: sequence analysis, miRNA-mRNA regression analysis, and machine 
learning (Huang, et al., 2007; Maziere and Enright, 2007; Yang, et al., 2008). Sequence analysis 
methods rely on knowledge of the base pairing between and second structure of the miRNA 
and the target gene. However, the sequence approach has limited specificity due to imperfect 
miRNA-target pairing (Huang, et al., 2007; Huang, et al., 2007). Regressing the expression of a 
target gene on the expression of miRNA for identifying miRNA target is based on a linear 
relationship between miRNA and its target mRNA. However, the relationship between 
miRNA and target mRNA may be nonlinear, which leads to inaccurate prediction of the 
miRNA target. The precision of miRNA target prediction by machine learning depends on the 
number of experimentally validated miRNA targets; however, the number of experimentally 
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validated targets is limited. To improve the accuracy of target prediction, we will combine 
sequence analysis with regression analysis for target prediction.  
2. Materials and methods 
2.1 Test association of somatic mutations and LOH with glioblastoma 
Cancers arise from mutations that confer growth advantage on cells (Greenman, et al., 
2007).The somatic mutations in cancers can be classified either as “drivers” or “passengers” 
(Wood, et al., 2007). As the number of tumor tissues and normal tissues increases we can 
observe somatic mutations in both tumor and normal tissues. The current popular method 
for identifying driver mutations is to compare the difference in the mutation rates (Kuhn, et 
al., 2008; Parsons, et al., 2008). However, there is debate about how to assess a significant 
excess of mutations in tumors (Rubin and Green, 2007). We need to develop formal tests to 
detect differences in mutation rates between tumor and normal tissues. Most traditional 
statistical methods that often test the association of genetic variants individually were 
designed for testing association of common alleles with common diseases and are 
inappropriate for testing the association of rare somatic mutations. A feasible approach is to 
record rare sequence variants at different genome positions and to collectively test 
association of a set of rare variants. It has been shown that the number of rare alleles in large 
samples is approximately distributed as a Poisson process with its intensity depending on 
the total mutation rate(Joyce and Tavare, 1995). The intensity of the Poisson process within a 
segment of genome can be interpreted as the mutation rate. Similar to standard 2 test for 
association of SNPs which compare the difference in allele frequencies between cases and 
controls, the proposed statistics are to compare difference in the mutation rates between 
tumor and normal samples. Specifically, letU andV be the average number of rare 
mutations which is the intensity of the Poisson process underlying the rare variants, in the 
tumor and normal samples, respectively. Let uvS be the pooled sample variance of the rare 
variants. Define the test statistic: 
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where An and Gn  are the number of sampled tumor tissues and normal tissues, 
respectively. Under the null hypothesis of no association of the set of rare variants with the 
disease, the average number of rare alleles in cases and controls should be equal and the 
statistic GT is asymptotically distributed as a central
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have a homozygous genotype of rare mutations. To improve the power, in this case, we can 
count it twice. Instead of defining statistics in terms of genotype, we can similarly define the 
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To examine the validity of the test statistics, we performed a series of simulation studies. We 
used infinitely many allele models and software (GENOME) to generate rare variants. 
Suppose that the mutation rate per generation per base pair is 81.00 10 , the recombination 
rate between consecutive fragments is 0.0001, the migration rate per generation per 
individual is 0.00025, we have simulated 100 fragments with the length of each fragment 
equals 10k in base pair. Total of 100,000 individuals who were equally divided into cases 
and controls were generated in the general population. 500 to 2,000 individuals were 
randomly sampled from each of the cases and controls. 10,000 simulations were repeated.   
Table 1 summarized the type I error rates of two statistics. Table 1 showed that the 
estimated type I error rates of the statistics for testing association of a set of rare variants 
with the disease were not appreciably different from the nominal levels 0.05,  0.01   
and 0.001  .   
A LOH mutation was recorded when the genotype in blood or normal tissue is 
heterozygous, and in the tumor tissue, the reference allele loses normal function and the 
genotype becomes homozygous. The statistic GT can be used to test association of LOH with 
glioblastoma.  
 
Sample Sizes  GT  aT  
2,000  =0.001 0.0012 0.001 
 =0.01 0.0093 0.0096 
 =0.05 0.0489 0.0494 
1,500  =0.001 0.0015 0.001 
 =0.01 0.0106 0.0092 
 =0.05 0.0521 0.0500 
1,000  =0.001 0.0012 0.0007 
 =0.01 0.0106 0.0097 
 =0.05 0.0522 0.0459 
500  =0.001 0.0009 0.0008 
 =0.01 0.0102 0.0117 
 =0.05 0.0504 0.0548 
Table 1. Type 1 error rates of the statistics ,G aT T . 
2.2 Lasso for co-expression networks 
A co-mRNA expression or co-miRNA expression network can be constructed by joint sparse 
regression for estimating the concentration matrix in which off-diagonal elements represents 
the covariance between the corresponding variables given all other variables in the network 
(Peng, et al., 2009 ) . Sparse regression for reconstruction of co-expression network is briefly 
introduced here. (For details, please see(Peng, et al., 2009 )). Denote the mRNA or miRNA 
expression levels as variables 1 ,... qy y . A variable is represented by a node. An edge 
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connecting two nodes indicates that the connected two variables are conditionally 
dependent, given all other variables. Assume that the vector of q variables 
1[ ,... ]
T
qY y y follow a normal distribution (0, )N  . Denote the partial correlations as 
( , )( , | )
ij
i j i jCorr y y y   for 1 i j q   and ( , ) { : 1 , }i j k k i j q     . If we assume the 
normality of the variables, then  two variables iy and jy are conditionally dependent, given 







    
                                                       
 (2) 
When sample size is much larger than the number of variables, the concentration matrix can 
be directly estimated from the inverse of the sampling covariance matrix. However, when 
the number of variables in the network is larger than the sample size, the inverse of 
sampling covariance matrix may not exist. We use sparse regression for network modeling 
via estimating sparse concentration matrix.  
2.3 Functional module identification and gene set enrichment analysis 
Co-expression networks are usually organized into functional modules that perform specific 
biological tasks. Genes within coexpression modules often share conserved biological 
functions. A dynamic tree cut procedure was used to identify modules(Langfelder, et al., 
2008). A co-expression network was clustered using hierarchical clustering. Modules are 
defined as braches of dendrogram. One sided Fisher exact test that calculates the probability 
of seeing observed number of genes within a pathway or a GO category in the module by 
chance was used to test for enrichment of a pathway or a GO category in the module. We 
assembled 465 pathways from KEGG(Hashimoto, et al., 2006) and Biocarta 
(http://www.biocarta.com).  
2.4 miRNA interaction and mRNA Interaction networks 
Modern complex theory assumes that the complexity is the degree to which components 
engage in organized structured interactions. Intuitively, complexity can also be viewed as 
the degree of dependence among components. Therefore, interaction has been considered as 
a sensible measure of complexity of biological systems. The more interactions between 
components, the more complex the system is. We identify mRNA or miRNA interaction 
networks via detecting pair-wise interaction between mRNAs or miRNAs. We view mRNA 
or miRNA expressions as continuous variables. Formally, interactions can generally be 
defined as a stochastic dependence between two random variables. The concept of mutual 
information proposed by Shannon(Cover and Thomas, 1991) can serve as a general measure 
of interaction (dependence) between two random variables(Jakulin, et al., 2003; Matsuda, 
2000; Nakahara, et al., 2003). It quantifies the stochastic dependence between two random 
variables. An additional asset is that mutual information measures more than linear 
dependence(Brillinger, 2004; McGill, 1954 ). Therefore, information theory will provide an 
unified framework for developing statistical methods to detect interaction between mRNAs 
or miRNAs. Similar to the detection of interaction between two SNPs where interaction 
between two SNPs is measured and tested as the difference in linkage disequilibrium(LD) 
between cases and controls(Wu, et al., 2008; Zhao, et al., 2006), we detect interaction 
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between mRNAs or miRNAs by measuring differences in mutual information between 
tumor and normal tissues.  
The expression of mRNAs and miRNAs are continuous variables. Usually, we assume that 
they follow a normal distribution. Let random variables X and Y denote the expression of a 
pair of mRNAs or miRNAs. Let ( ), ( )f x f y and ( , )f x y be the distribution functions of X and 
Y and their joint distribution function, respectively. The mutual information between two 
continuous variables is defined as  
 ( , )( , ) log
( ) ( )
f x yI X Y E





                   
(3) 
This formula shows(Cover and Thomas, 1991) that mutual information is always 
nonnegative and is equal to zero if and only if two random variables are independent. 
Therefore, mutual information can be used to measure the degree of stochastic dependence. 
Assuming the normal distribution of two random variables, mutual information can easily 
be calculated by  
 21( , ) log(1 ),
2
I X Y     
                    
(4) 
where  is a canonical correlation. Similar to using LD to test interaction between two SNPs 
where tests for interaction between unlinked and linked loci are developed separately, we 
consider two cases in testing interaction between mRNAs or miRNAs: (1) a pair of mRNAs 
or miRNAs in the normal tissues are independent and (2) a pair of mRNAs or miRNAs in 
the normal tissues are dependent. 
2.4.1 A pair of mRNAs or miRNAs in the normal tissues is independent 
Let ( , )TI X Y and ( , )NI X Y be mutual information between 1x and 2x in tumor and normal 
tissues, respectively. Let An  and Gn  be the number of tumor and normal samples, 
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where 0( )K  is the modified Bessel function of the second kind of order 0 (Jeffrey and 
Zwillinger, 2000). 
2.4.2 A pair of mRNAs or miRNAs in the normal tissues is dependent 
When a pair of mRNAs or miRNAs in the normal tissues is dependent, we can define a test 
statistic that has a much simpler distribution than that of test statistic IT . Let ˆA and ˆG be 
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the canonical correlation in tumor and normal tissues, respectively. We propose a novel 
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(1)  distribution under the null hypothesis of no difference in mutual information between 
tumor and normal tissues. To evaluate the validity of the test statistic DT , we calculated its 
type 1 error rates. We simulated a population of size 1,000,000 from a bivariate normal 
distribution with mean[0,0]T . Then, we equally sampled 100, 200 and 400 subjects as tumor 
and normal samples and calculated the test statistic DT . We repeated this with 10,000 
simulations. The type 1 error rates for different samples and correlation coefficients were 
listed in Table 2. Type I error rates for the statistics DT to test for the interactions between 
two mRNAs or miRNAs were not appreciably different from the nominal levels 0.05  , 
0.01   and 0.001  .   
 
  Sample 
Sizes 
Nominal Level 
0.001   0.01   0.05   
0.2 100 0.0023 0.0113 0.0552 
 200 0.0010 0.0086 0.0494 
 400 0.0011 0.0115 0.0529 
0.5 100 0.0008 0.0103 0.0532 
 200 0.0011 0.0108 0.0528 
 400 0.0012 0.0104 0.0496 
Table 2. Type 1 error rates of DT for testing interaction between two continuous variables 
2.5 Ranking of the nodes in the network 
Biological functions and mechanisms are encoded in network properties. An important 
strategy for unraveling the mechanisms of initiation and progression of cancer is to conduct 
analysis of complex biological networks and study their behaviors under genetic and 
epigenetic perturbations. Robustness of a biological network, ability to retain much of its 
functionality in the face of perturbation(Dartnell, et al., 2005), has emerged as a fundamental 
concept in the study of network topological properties(Demetrius and Manke, 2005 ). 
Widely used measures of network robustness include ranking importance of the nodes in 
the network. One of the most efficient measures of importance in robustness analysis of the 
network is the damage value of a node which quantifies the effect of the removal of that 
particular node from the network. Formally, we define the damage value of a node as 
follows. Let ( , )G V E be the connected component that contains node h V , and 
 
Molecular Targets of CNS Tumors 
 
206 
between mRNAs or miRNAs by measuring differences in mutual information between 
tumor and normal tissues.  
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let ( , )G V E   be the largest connected component of G , after the removal of node h . Then, 
the value ( ) | | | |D h V V   is the damage value of node h .  
2.6 Identify the genetic variants that have cis or trans regulatory effects on miRNA or 
mRNA expressions 
Loci that are significantly associated with expression are called expression quantitative trait 
loci (eQTL). Somatic mutations may directly or indirectly regulate the expression of mRNAs 
or miRNAs. The traditional statistical methods to regress the expression levels on the 
individual genetic variant for identifying eQTL is inappropriate for studying the regulatory 
effect of somatic mutations due to their low allele frequencies. An alternative approach to 
current variant-by-variant regression method is groupwise regression methods in which a 
group of rare genetic variants are jointly analyzed. It is well known that eQTL include cis-
eQTL in which an association exists between the expression of a specific gene (mRNA) and 
the genetic variants at that gene’s locus, or between the expression of miRNA and the 
genetic variants at its host gene, and trans-eQTL in which there is an association between the 
expression of a gene or a miRNA and the genetic variants at a non-local genomic locus.  
Regression methods that regress the expression of a mRNA or a miRNA on the number of 
all mutated alleles across the region of interest to identify cis- or trans-eQTL . 
2.7 miRNA target networks 
miRNAs down regulate gene expressions by base-pairing with  the 3’-noncoding region of 
the target mRNAs. It is estimated that up to 30% of genes might be regulated by 
miRNAs(Sassen, et al., 2008). It is hypothesized that miRNAs and their targets form 
complex networks to perform various biological functions. To reveal mechanisms of the 
GBM, we identified target genes of miRNAs and constructed miRNA target networks. 
Procedures for discovering the target genes consisted of two steps. The first step was to 
conduct sequence analysis that used sequence complementarities of miRNA and its target 
site to predict potential miRNA target genes. We searched the predicted potential miRNA 
targets in  miRGen(Megraw, et al., 2007), which integrated animal miRNA targets according 
to combinations of four widely used target prediction programs: miRanda, PicTar, 
TargetScan, DIANA-microT, and experimentally supported targets from TarBase 
(Sethupathy, et al., 2006) and miR2Disease(Jiang, et al., 2009). Since miRNAs repress the 
expression of their target genes, the second step was to test the inverse relationship between 
the expression profile of miRNA and that of its potential targets. To achieve this,   we 
regressed the expression of target mRNAs on the expression of miRNAs and select mRNAs 
with significant negative regression coefficients as miRNA targets. P-value for declaring 
significant evidence of miRNA target was 41.00 10 .  
3. Results 
3.1 Test association of somatic mutations and LOH mutations with glioblastoma 
The first step for deciphering the path from somatic mutations to the GBM is to test 
association of somatic mutations with the GBM. The statistic aT  and GT  was applied to 
glioblastoma in TCGA dataset. The tumor tissues of 179 glioblastoma patients and 179 
matched normal tissues were sequenced. A somatic mutation was recorded when the 
mutation was detected only in the tumor tissue. There were 306 genes in which at least one 
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somatic mutation was detected. A LOH mutation was recorded when the genotype in blood 
or normal tissue is heterozygous, and in the tumor tissue, the reference allele loses normal 
function and the genotype becomes homozygous. There were 124 genes in which at least 
one LOH mutation was detected. We identified association of somatic mutations in 14 genes 
by the statistics aT (Table 3), and association of LOH in 11 genes by the statistic GT with 
glioblastoma with false discovery rate (FDR) less than 0.05 (Table 4). Genes TP53, PTEN, 
EGFR, NF1, RB1 and ERBB2 were reported to be associated with GBM in the previous 
TCGA data analysis (The Cancer Genome Atlas Research Network, 2008). The remaining 8 
somatic mutated genes and 10 LOH mutated genes were newly identified by the 
statistics GT or aT . NCBI Entrez gene database (Maglott, et al., 2007) reported that : CHEK2 is 
  
Gene P-value FDR Mutation frequency 
TP53 3.46E-11 5.90E-10 0.1453 
PTEN 2.25E-07 1.92E-06 0.0698 
EGFR 1.22E-06 6.92E-06 0.0587 
FKBP9 1.38E-04 5.89E-04 0.0363 
CHEK2 1.39E-03 4.73E-03 0.0475 
GSTM5 2.41E-03 6.86E-03 0.0251 
DST 4.28E-03 8.12E-03 0.0223 
RB1 3.54E-03 8.62E-03 0.0251 
NF1 4.17E-03 8.89E-03 0.0363 
BCL11A 1.36E-02 2.33E-02 0.0168 
ERBB2 1.57E-02 2.43E-02 0.0307 
PIK3C2G 2.45E-02 3.49E-02 0.0140 
FN1 3.30E-02 4.33E-02 0.0168 
COL3A1 4.46E-02 4.75E-02 0.0112 
Table 3. P-values for testing association of somatic mutations with the GBM 
 
Gene P-value FDR Mutation frequency 
NRAP 5.71E-07 6.24E-06 0.1173 
MKI67 8.19E-07 4.47E-06 0.1229 
C10orf54 1.02E-04 3.70E-04 0.0391 
C9orf66 1.63E-04 4.46E-04 0.0419 
MYO3A 6.40E-04 1.40E-03 0.0307 
PRAME 2.14E-03 3.90E-03 0.0251 
EGFR 3.20E-03 4.99E-03 0.0279 
IL1RL1 7.11E-03 9.71E-03 0.0196 
HLA-DOA 1.30E-02 1.57E-02 0.0168 
ABCA13 2.37E-02 2.59E-02 0.0140 
CYP1B1 2.37E-02 2.59E-02 0.0140 
Table 4. P-values for testing association of LOH with the GBM 
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let ( , )G V E   be the largest connected component of G , after the removal of node h . Then, 
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effect of somatic mutations due to their low allele frequencies. An alternative approach to 
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the genetic variants at that gene’s locus, or between the expression of miRNA and the 
genetic variants at its host gene, and trans-eQTL in which there is an association between the 
expression of a gene or a miRNA and the genetic variants at a non-local genomic locus.  
Regression methods that regress the expression of a mRNA or a miRNA on the number of 
all mutated alleles across the region of interest to identify cis- or trans-eQTL . 
2.7 miRNA target networks 
miRNAs down regulate gene expressions by base-pairing with  the 3’-noncoding region of 
the target mRNAs. It is estimated that up to 30% of genes might be regulated by 
miRNAs(Sassen, et al., 2008). It is hypothesized that miRNAs and their targets form 
complex networks to perform various biological functions. To reveal mechanisms of the 
GBM, we identified target genes of miRNAs and constructed miRNA target networks. 
Procedures for discovering the target genes consisted of two steps. The first step was to 
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site to predict potential miRNA target genes. We searched the predicted potential miRNA 
targets in  miRGen(Megraw, et al., 2007), which integrated animal miRNA targets according 
to combinations of four widely used target prediction programs: miRanda, PicTar, 
TargetScan, DIANA-microT, and experimentally supported targets from TarBase 
(Sethupathy, et al., 2006) and miR2Disease(Jiang, et al., 2009). Since miRNAs repress the 
expression of their target genes, the second step was to test the inverse relationship between 
the expression profile of miRNA and that of its potential targets. To achieve this,   we 
regressed the expression of target mRNAs on the expression of miRNAs and select mRNAs 
with significant negative regression coefficients as miRNA targets. P-value for declaring 
significant evidence of miRNA target was 41.00 10 .  
3. Results 
3.1 Test association of somatic mutations and LOH mutations with glioblastoma 
The first step for deciphering the path from somatic mutations to the GBM is to test 
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somatic mutation was detected. A LOH mutation was recorded when the genotype in blood 
or normal tissue is heterozygous, and in the tumor tissue, the reference allele loses normal 
function and the genotype becomes homozygous. There were 124 genes in which at least 
one LOH mutation was detected. We identified association of somatic mutations in 14 genes 
by the statistics aT (Table 3), and association of LOH in 11 genes by the statistic GT with 
glioblastoma with false discovery rate (FDR) less than 0.05 (Table 4). Genes TP53, PTEN, 
EGFR, NF1, RB1 and ERBB2 were reported to be associated with GBM in the previous 
TCGA data analysis (The Cancer Genome Atlas Research Network, 2008). The remaining 8 
somatic mutated genes and 10 LOH mutated genes were newly identified by the 
statistics GT or aT . NCBI Entrez gene database (Maglott, et al., 2007) reported that : CHEK2 is 
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a cell cycle checkpoint regulator and putative tumor suppressor, and associated with GBM; 
GSTM5 was reported to be involved in cancer, BCL11A is a proto-oncogene, and FN1 is 
involved in tumor metastasis and angiogenesis. Gene PRAME was reported to be associated 
with melanoma and acute leukemias.  Association of the other 9 genes such as NRAP, 
MK167, C10orf54 and C9orf66 with GBM was first reported here 
3.2 Network analysis of gene expressions  
3.2.1 Differential expression analysis 
Comparative studies of gene expression between normal and tumor tissues is one of the 
most widely used strategies for unraveling the molecular circuitry underlying cancer (Liang 
and Pardee, 2003). To uncover the mechanisms of glioblastoma, expressions of 12,042 genes 
were measured in 243 tumor tissue samples and 10 normal tissue samples and 1 cell line by 
Affymetrix HT Human Genome U133 Array Plate Set. A total of 1,697 genes were 
differentially expressed between tumor and normal tissues by Wilcoxon rank-sum test (P-
value for declaring significance after Bonferroni correction is 64.15 10 ). Of the 1,697 genes, 
72 genes were  cancer genes or cancer candidate genes, 25 of which were GBM related genes 
including TCF12, TP53, COL4A1, COL3A1 and COL5A2, 11 of them were oncogenes 
including CDK4 and RAF4; 21 of them were tumor suppressor genes including TP53 and 
RB1 (We got the oncogene and tumor suppressor gene list from database: TSGDB(Yang and 
Fu, 2003) and UNSW Embryology DNA Tumor Suppressor and Oncogene 
Database(Ackermann and Strimmer, 2009)), 242 genes were in signal transduction 
pathways, 908 genes were down regulated and 789 genes were up regulated. From 1,697 
significantly differentially expressed genes, we identified 97 genes that were reported to be 
cancer related in the literatures (Table 5).  
 
Gene P-value Up-down Cancer Gene TSG Cancer Signaling 
ICAM5 2.52E-08 Down CAN-gene
TCF12 2.84E-08 Up Cancer Gene regulation 
THRB 3.2E-08 Down oncogene
ABR 3.2E-08 Down TSG
BTG1 3.28E-08 Up Cancer Gene TSG
KIAA0774 3.97E-08 Down CAN-gene
TMEM123 3.97E-08 Up CAN-gene
IGFBP7 4.57E-08 Up TSG
MAP2K4 4.68E-08 Down Cancer Gene TSG Kinase 
ELK1 4.68E-08 Down oncogene TF
COL4A1 4.91E-08 Up GBM
CD93 5.14E-08 Up CAN-gene
CDK2AP1 6.21E-08 Up TSG
ITGAV 7.49E-08 Up GBM
EDIL3 8.81E-08 Down GBM
RB1 1.24E-07 Up Cancer Gene TSG TF
GRM1 1.33E-07 Down CAN-gene
TP53 1.40E-07 Up Cancer Gene TSG TF
CDH11 1.46E-07 Up Cancer Gene
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Gene P-value Up-down Cancer Gene TSG Cancer Signaling 
CDKN2C 1.49E-07 Up GBM CDK inhibitors 
SNAP25 1.53E-07 Down GBM Vesicle 
LDOC1 1.67E-07 Down TSG
IGFBP2 1.67E-07 Up GBM
BCL11B 1.75E-07 Down Cancer Gene
FABP3 1.77E-07 Down   TSG   
RARG 1.88E-07 Down GBM
PTPN13 2.3E-07 Up TSG cytoskeleton 
GABRB2 2.40E-07 Down GBM
EIF4A2 2.46E-07 Down Cancer Gene
SP110 2.69E-07 Up CAN-gene
GAS1 2.75E-07 Up TSG
RIMS2 3.59E-07 Down CAN-gene
VSNL1 3.83E-07 Down GBM Adapter 
CDH12 4.01E-07 Down Cancer Gene
RAP1GDS1 4.38E-07 Down CAN-gene
LMO7 4.57E-07 Down CAN-gene
ATM 4.99E-07 Up Cancer Gene TSG Kinase 
PDE4DIP 5.21E-07 Down Cancer Gene
HIP1 5.69E-07 Up Cancer Gene cytoskeleton 
PRPF4B 5.94E-07 Up CAN-gene
NUP214 6.34E-07 Up Cancer Gene Transporter 
HSP90AB1 6.77E-07 Down Cancer Gene
LYN 7.07E-07 Up oncogene Kinase 
COL5A2 7.54E-07 Up GBM
BCL10 8.04E-07 Up Cancer Gene apoptosis 
NCKIPSD 8.04E-07 Down Cancer Gene
TRIM24 8.40E-07 Up Cancer Gene
CLTC 8.95E-07 Down Cancer Gene SP
RAF1 9.55E-07 Up oncogene Kinase 
SYK 1.02E-06 Up Cancer Gene Kinase 
PIM1 1.03E-06 Up Cancer Gene oncogene
SYT1 1.04E-06 Down CAN-gene Vesicle 
MAPK8IP2 1.08E-06 Down CAN-gene
CHI3L2 1.13E-06 Up GBM
YES1 1.21E-06 Up oncogene Kinase 
ATP8A2 1.31E-06 Down TSG Molecule 
GABRA1 1.31E-06 Down GBM Receptor 
RASSF1 1.34E-06 Up TSG
CHIC2 1.43E-06 Up CAN-gene
MYT1L 1.55E-06 Down GBM
COL3A1 1.55E-06 Up GBM
NBL1 1.62E-06 Down TSG
NONO 1.80E-06 Up Cancer Gene
TPR 1.80E-06 Up Cancer Gene
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FABP3 1.77E-07 Down   TSG   
RARG 1.88E-07 Down GBM
PTPN13 2.3E-07 Up TSG cytoskeleton 
GABRB2 2.40E-07 Down GBM
EIF4A2 2.46E-07 Down Cancer Gene
SP110 2.69E-07 Up CAN-gene
GAS1 2.75E-07 Up TSG
RIMS2 3.59E-07 Down CAN-gene
VSNL1 3.83E-07 Down GBM Adapter 
CDH12 4.01E-07 Down Cancer Gene
RAP1GDS1 4.38E-07 Down CAN-gene
LMO7 4.57E-07 Down CAN-gene
ATM 4.99E-07 Up Cancer Gene TSG Kinase 
PDE4DIP 5.21E-07 Down Cancer Gene
HIP1 5.69E-07 Up Cancer Gene cytoskeleton 
PRPF4B 5.94E-07 Up CAN-gene
NUP214 6.34E-07 Up Cancer Gene Transporter 
HSP90AB1 6.77E-07 Down Cancer Gene
LYN 7.07E-07 Up oncogene Kinase 
COL5A2 7.54E-07 Up GBM
BCL10 8.04E-07 Up Cancer Gene apoptosis 
NCKIPSD 8.04E-07 Down Cancer Gene
TRIM24 8.40E-07 Up Cancer Gene
CLTC 8.95E-07 Down Cancer Gene SP
RAF1 9.55E-07 Up oncogene Kinase 
SYK 1.02E-06 Up Cancer Gene Kinase 
PIM1 1.03E-06 Up Cancer Gene oncogene
SYT1 1.04E-06 Down CAN-gene Vesicle 
MAPK8IP2 1.08E-06 Down CAN-gene
CHI3L2 1.13E-06 Up GBM
YES1 1.21E-06 Up oncogene Kinase 
ATP8A2 1.31E-06 Down TSG Molecule 
GABRA1 1.31E-06 Down GBM Receptor 
RASSF1 1.34E-06 Up TSG
CHIC2 1.43E-06 Up CAN-gene
MYT1L 1.55E-06 Down GBM
COL3A1 1.55E-06 Up GBM
NBL1 1.62E-06 Down TSG
NONO 1.80E-06 Up Cancer Gene
TPR 1.80E-06 Up Cancer Gene
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Gene P-value Up-down Cancer Gene TSG Cancer Signaling 
NOV 1.87E-06 Down oncogene GF
CDK4 1.87E-06 Up GBM oncogene Kinase 
TCF3 1.95E-06 Up Cancer Gene TF
NEFM 1.95E-06 Down GBM Cytoskeleton 
SYN2 2.08E-06 Down GBM
FLT3 2.17E-06 Down Cancer Gene   Generics 
CCK 2.17E-06 Down GBM
IDH1 2.26E-06 Up GBM
CDC23 2.31E-06 Up TSG
CHI3L1 2.31E-06 Up GBM
BCL6 2.35E-06 Up Cancer Gene
RTN1 2.40E-06 Down GBM
DLEU2 2.43E-06 Up TSG
SH3GL2 2.50E-06 Down GBM Vesicle 
BLM 2.56E-06 Up Cancer Gene
SMAD4 2.56E-06 Up Cancer Gene TF
CACNA2D2 2.95E-06 Down TSG
PRRX1 2.95E-06 Up Cancer Gene
SV2B 2.95E-06 Down GBM
NEFL 3.01E-06 Down GBM
MCF2 3.14E-06 Down oncogene Cytoskeleton 
CTNNA1 3.14E-06 Up TSG Cytoskeleton 
BMPR1A 3.27E-06 Up Cancer Gene Receptor 
MSN 3.40E-06 Up Cancer Gene
RPN1 3.54E-06 Up Cancer Gene
LPP 3.69E-06 Up Cancer Gene
GABRG2 3.77E-06 Down GBM
TRIM8 3.77E-06 Down TSG 
COX6C 3.84E-06 Down Cancer Gene
FBXW7 4.00E-06 Down Cancer Gene Generics 
ETS2 4.34E-06 Down oncogene TF
EWSR1 4.8E-06 Up oncogene
ST5 4.99E-06 Up TSG 
*TSG:  tumor suppressor gene; TF: transcription factor; SP: Structural Protein,  GF: Growth Factor 
Table 5. A list of 97 genes was differentially expressed. 
3.2.2 Gene co-expression network analysis 
To investigate the functions of the genes at the system-level and uncover the mechanism of 
GBM, we used partial correlation method and sparse regression techniques to infer gene co-
expression networks. The largest connected coexpression network with the average shortest 
path 20.4 and diameter 74 had 2,115 genes and 2,276 edges (Figure 1).  
To explore the relationship between co-expressions of the genes and physical interaction 
between their corresponding proteins, we compared the constructed co-expression gene 
network with the protein-protein interaction (PPI) network (Chuang, et al., 2007), 
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comprising 57, 235 interactions among 11, 203 proteins. The human PPI network was 
integrated from yeast two-hybrid experiments, predicted interactions based on orthology 
and co-citation, and curation of literature. We restricted our analysis to 3,991 genes present 
in both co-expression and PPI networks, consisting of 2, 131 and 12, 182 edges, respectively. 
The two networks shared 85 edges involving 133 genes in common. The 133 genes and their 
connections were shown in Figure 2. We performed functional enrichment analysis of the 
133 genes using DAVID(Huang da, et al., 2009). Enriched gene functional categories include 
protein biosynthesis/ribosome, development processes, metabolic processes and RNA 
splicing. It is noticeable that the largest connected component, which consists of 29 genes, in 




Fig. 1. The largest connected gene co-expression network. The network had 2,115 genes and 
2,276 edges. Genes related to GBM were highlighted in red. 
The network had 133 genes and 700 edges. This figure gives the sub-network of gene co-
expressions in which a node contains both gene co-expressions and protein-protein 
interactions with other nodes in this sub-network. 
Co-expression networks are usually organized into modules that perform specific biological 
process. 13 modules were significantly enriched for at least one pathway(Figure 3 and Table 
6), indicating that co-expression network was organized into functional units. Enriched 
pathways in the modules were involved in neurodegenerative diseases, development 
 
Molecular Targets of CNS Tumors 
 
212 
Gene P-value Up-down Cancer Gene TSG Cancer Signaling 
NOV 1.87E-06 Down oncogene GF
CDK4 1.87E-06 Up GBM oncogene Kinase 
TCF3 1.95E-06 Up Cancer Gene TF
NEFM 1.95E-06 Down GBM Cytoskeleton 
SYN2 2.08E-06 Down GBM
FLT3 2.17E-06 Down Cancer Gene   Generics 
CCK 2.17E-06 Down GBM
IDH1 2.26E-06 Up GBM
CDC23 2.31E-06 Up TSG
CHI3L1 2.31E-06 Up GBM
BCL6 2.35E-06 Up Cancer Gene
RTN1 2.40E-06 Down GBM
DLEU2 2.43E-06 Up TSG
SH3GL2 2.50E-06 Down GBM Vesicle 
BLM 2.56E-06 Up Cancer Gene
SMAD4 2.56E-06 Up Cancer Gene TF
CACNA2D2 2.95E-06 Down TSG
PRRX1 2.95E-06 Up Cancer Gene
SV2B 2.95E-06 Down GBM
NEFL 3.01E-06 Down GBM
MCF2 3.14E-06 Down oncogene Cytoskeleton 
CTNNA1 3.14E-06 Up TSG Cytoskeleton 
BMPR1A 3.27E-06 Up Cancer Gene Receptor 
MSN 3.40E-06 Up Cancer Gene
RPN1 3.54E-06 Up Cancer Gene
LPP 3.69E-06 Up Cancer Gene
GABRG2 3.77E-06 Down GBM
TRIM8 3.77E-06 Down TSG 
COX6C 3.84E-06 Down Cancer Gene
FBXW7 4.00E-06 Down Cancer Gene Generics 
ETS2 4.34E-06 Down oncogene TF
EWSR1 4.8E-06 Up oncogene
ST5 4.99E-06 Up TSG 
*TSG:  tumor suppressor gene; TF: transcription factor; SP: Structural Protein,  GF: Growth Factor 
Table 5. A list of 97 genes was differentially expressed. 
3.2.2 Gene co-expression network analysis 
To investigate the functions of the genes at the system-level and uncover the mechanism of 
GBM, we used partial correlation method and sparse regression techniques to infer gene co-
expression networks. The largest connected coexpression network with the average shortest 
path 20.4 and diameter 74 had 2,115 genes and 2,276 edges (Figure 1).  
To explore the relationship between co-expressions of the genes and physical interaction 
between their corresponding proteins, we compared the constructed co-expression gene 
network with the protein-protein interaction (PPI) network (Chuang, et al., 2007), 
 
Integrated Network Analysis of Genetic and Epigenetic Factors in Glioblastoma Multiform 
 
213 
comprising 57, 235 interactions among 11, 203 proteins. The human PPI network was 
integrated from yeast two-hybrid experiments, predicted interactions based on orthology 
and co-citation, and curation of literature. We restricted our analysis to 3,991 genes present 
in both co-expression and PPI networks, consisting of 2, 131 and 12, 182 edges, respectively. 
The two networks shared 85 edges involving 133 genes in common. The 133 genes and their 
connections were shown in Figure 2. We performed functional enrichment analysis of the 
133 genes using DAVID(Huang da, et al., 2009). Enriched gene functional categories include 
protein biosynthesis/ribosome, development processes, metabolic processes and RNA 
splicing. It is noticeable that the largest connected component, which consists of 29 genes, in 




Fig. 1. The largest connected gene co-expression network. The network had 2,115 genes and 
2,276 edges. Genes related to GBM were highlighted in red. 
The network had 133 genes and 700 edges. This figure gives the sub-network of gene co-
expressions in which a node contains both gene co-expressions and protein-protein 
interactions with other nodes in this sub-network. 
Co-expression networks are usually organized into modules that perform specific biological 
process. 13 modules were significantly enriched for at least one pathway(Figure 3 and Table 
6), indicating that co-expression network was organized into functional units. Enriched 
pathways in the modules were involved in neurodegenerative diseases, development 
 
Molecular Targets of CNS Tumors 
 
214 
processes, cancer related signaling pathways and metabolism. Parkinson’s disease pathway 
was enriched in module 11 with olive green color. Genes UQCRC1, ATP5H, COX7C, 
NDUFA1, COX5R and COX4I1 in the module 11 are involved in mitochondria dysfunction 
(http://www.genome.jp/kegg/pathway/hsa/hsa05012.html). Cell cycle pathway was 
enriched in module 7 with yellow color. We can see that co-expressed genes CHEK2, 
CCNB2, CCNA2, CCNE2, MAD2L1 and BUB1 in module 7 are directly or indirectly 
connected in cell cycle pathway (http://www.genome.jp/dbget-bin /show_ pathway? 







Fig. 2. Gene co-expressions and interactions supported by protein-protein interactions.  
The architecture of a co-expression network is important for uncovering the genes which are 
involved in cancer. To identify the most important genes in the co-expression network, we 
used the damage value of a node as a measure to rank the importance of a node. We ranked 
all differentially expressed genes in the largest co-expression sub-network according to their 
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damage values. Top 5% genes in the ranked list with the damage values greater than 15 
were summarized. These genes were essential to the function of co-expression network. We 
suspect that these genes may be involved in the development of GBM. For example, T1A1 
that had the largest damage value 38 and was over expressed in the GBM tissues plays a 
role in apoptosis (Forch and Valcarcel, 2001). KIAA1279 was reported to be associated with 
the nervous systems (Brooks, et al., 2005). It was also reported that CACYBP participates in 
p53-induced beta-catenin degradation and can suppress proliferation and tumorigenesis of 
renal cancer cells (Sun, et al., 2007). CACYBP was under expressed in gastric cancer (Ning, 
et al., 2007) and renal cancer (Sun, et al., 2007). 
 
 
Fig. 3. 13 functional modules in the largest connected gene-coexpression network in Figure 
1. The modules were indexed by the number and also represented by color. Enriched 
pathways in the modules were listed in Table 6.  
There were three genes: TP53, COL3A1, and RAP1GDS1 whose damage values ranked the 
top among the cancer and cancer candidate genes (Table 5). Their removal from the network 
may disconnect some components in the network and hence compromise the functions of 
the genes in coexpression networks. TP53 and COL3A1 are GBM related genes and 
RAP1GDS1 is a cancer candidate gene. The p53 pathway is central to oncogenesis (El 
Hallani, et al., 2009). TP53, which was up regulated in GBM tissue samples, particularly, was 
highly over-expressed in CEREBRUM tissue samples. It was observed that TP53 had 
damage value 23, but was only connected with two up regulated genes: TGIF2 and EIF4A1. 
TGIF2 was differentially expressed (P-value< 71.43 10 ) and had damage value 24. TGIF2 is 
a novel TALE superclass homeodomain protein and a transcriptional co-repressor that 
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interacts with Smad2 and Smad3 to negatively regulate the TGFb/Smad response in a cell, 
which in turn affects apoptosis and leads to cellular proliferation and differentiation. TGIF2 
plays an oncogenic role through inhibition of TGFb (Imoto, et al., 2000).  EIF4A1 was over 
expressed in tumor tissue (P-value< 65.09 10 ) and had damage value 22. EIF4A1 is ATP-
dependent RNA helicase and required for mRNA binding to ribosome. EIF4A1 inhibit 
translation initiation and act as a tumor suppressor by forming complex with Programmed 
Cell Death 4 (PDCD4) (Yang, et al., 2004). COL3A1 was over expressed in GBM tissue 
samples (P-value< 61.6 10 ) and had damage value 21. It was also reported to be over  
 
# color Category Name P-value 
1 Purple Cell Signaling Ion Channel and Phorbal Esters Signaling 8.60E-03 
2 Wind-Stawberry 
Apoptosis Apoptotic DNA fragmentation and tissue homeostasis 3.52E-02 
Cell Cycle 
Regulation 
Activation of Src by Protein-
tyrosine phosphatase alpha 4.23E-02 
Cell Cycle 
Regulation 
AKAP95 role in mitosis and 
chromosome dynamics 4.98E-02 
Cell Cycle 
Regulation 
Sonic Hedgehog (SHH) Receptor 
Ptc1 Regulates cell cycle 4.23E-02 





One carbon pool by folate 4.72E-02 
5 Black Cell Signaling 
Ca++/ Calmodulin-dependent 
Protein Kinase Activation 3.59E-03 
6 Green-Yellow Immunology 
Cells and Molecules involved in 
local acute inflammatory response 4.68E-02 
7 Yellow 
Cell Growth and 
Death Cell cycle 2.62E-02 
8 Orange Immunology Classical Complement 2.85E-02 
9 Lavender Cell Signaling IFN alpha signaling 1.03E-02 
10 Blue Cell Activation Th1/Th2 Differentiation 3.79E-02 
11 OliveGreen
Metabolism Electron Transport Reaction in Mitochondria 1.31E-02 
Energy 
Metabolism Oxidative phosphorylation 9.00E-03 
Neurodegene-
rative Diseases Parkinson's disease 8.67E-03 
12 Maroon Translation Ribosome 1.13E-03 
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# color Category Name P-value 
13 Red 
Metabolism| 
Neuroscience Vitamin C in the Brain 9.11E-03 
Cell Activation Angiotensin-converting enzyme 2 regulates heart function 1.27E-02 
Metabolism Intrinsic Prothrombin Activation 3.83E-02 
Metabolism Platelet Amyloid Precursor Protein 1.47E-02 
Hematopoiesis Regulators of Bone Mineralization 2.58E-03 
Table 6. 13 Modules in gene co-expression network in Figure 3 with their enriched 
pathways. 
expressed in ovarian cancer and breast cancer (Helleman, et al., 2006; Turashvili, et al., 
2007). COL3A1 encodes a fibrillar collagen which is a major component of the extracellular 
matrix protein surrounding cancer cells. Presence of ECM protein prevents apoptosis of 
cancer cells. COL3A1 plays an important role in apoptosis, proliferation regulation and 
anticancer drug resistance (Sethi, et al., 1999). RAP1GDS1 was under expressed in GBM 
tissue samples (P-value < 4.4 710 ) and had damage value 18 in the co-expression network. 
RAP1GDS1 is a transcription factor (Cimino, et al., 2001). It was reported that translocation 
fusion of the NUP98 and RAP1GDS1 genes was recurrent in T-cell acute lymphocytic 
leukemia (Hussey, et al., 1999). 
3.2.3 Gene interaction network analysis 
To further uncover the mechanism of the GBM, the proposed MI-based statistic was applied 
to expressions of 12,042 genes which were measured in 243 tumor tissue samples and 10 
normal tissue samples and 1 cell line to detect pair-wise mRNA interaction between the 
genes. We detected 967 interaction with theoretic P-values< 151.0 10 accounting for 0.1% 
proportion of total interactions. Pair-wise mRNA interactions were assembled into 
interaction networks defined by representing genes as nodes, with an edge between two 
nodes if an interaction was observed between the corresponding genes. The resulting largest 
connected mRNA interaction network consists of 187 genes and 196 edges (Figure 4) . Its 
average shortest path length was 5.88 and diameter was 23.  
Top 10 genes with the largest damage value were SIVA1, SLC27A5, PFDN5, GBAS, 
COX6A1, AKR1B1, NPM3, UBE2W, CDK4 and SGCG. The gene with both the largest degree 
(32) and damage value (62) in the mRNA interaction network was SIVA1, an apoptosis-
inducing factor. SIVA1 was over expressed in the GBM tissue samples (P-value < 0.00061). 
Although it was not significantly differentially expressed, regulatory relationship between 
SIVA1 and each one of 32 genes was significantly different between the GBM tumor tissue 
and normal tissue samples. This indicated that SIVA1 can act synergistically to influence the 
development of the GBM. SIVA1 is a pro-apoptotic protein. Function of SIVA1 is to promote 
DNA damage induced apoptosis and inhibit NF- B (Barkinge, et al., 2009). SIVA1 plays an 
important role in cell proliferation and death (Spinicelli, et al., 2002). It was reported that 
SIVA1 was involved in breast cancer (Chu, et al., 2005). GBAS named as Glioblastoma-
amplified sequence, was located in Chromosomal region 7p12, which contains the EGFR 
gene, and was reported to be co-amplified with EGFR in glioblastomas (Wang, et al., 1998). 
It was over expressed with p-value 51.01 10 in our expression data.CDK4 with degree (8) 
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and normal tissue samples. This indicated that SIVA1 can act synergistically to influence the 
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and damage value (13) was up regulated in the GBM tumor tissue samples and significantly 
differentially expressed (P-value < 81.87 10 ). CDK4 was a member of the Ser/Thr protein 
kinase family and involved in Glioma pathway(Zhu and Parada, 2002). CDK4 was an 
oncogene and was reported to be associated with multiple tumors(Kim and Diehl, 2009). 
3.3 Network analysis of miRNA expressions  
3.3.1 Differential expression analysis 
To unravel the pattern of differential regulation of miRNA, expressions of 534 microRNAs 
including 470 human microRNAs were profiled in 240 tumor tissue samples and 10 normal 
tissue samples by Agilent 8 x 15K Human microRNA-specific microarray. A total of 149 
miRNAs were differentially expressed between the GBM tumor tissue and normal tissue 
samples which were identified by Wilcoxon rank-sum test (P-value for declaring 
significance after Bonferroni correction is 59.36 10 ). Of 149 differentially expressed 
miRNAs, 73 miRNAs were up-regulated and 76 down-regulated. Among them, 21, 81 and 
15 miRNAs were reported to be associated with the GBM, other cancers and other diseases, 
respectively, in the literatures(Jiang, et al., 2009) . 
 
 
Fig. 4. Gene interaction network. The largest connected gene interaction network consists of 
187 genes and 196 edges. Genes with different damage value were marked in different 
colors. 
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3.3.2 MiRNA co-expression network analysis 
Similar to genes, miRNAs are not isolated, instead they act together to perform biological 
functions. Initiation and progression of cancer are influenced not only by individual 
miRNAs, but also by the coordinated effect of many miRNAs. To understand how miRNAs 
regulate biological processes at a system level, we reconstruct miRNA co-expression 
network. The largest connected miRNA coexpression network with the average shortest 
path 10.75 and diameter 49 had 385 miRNAs and 451 edges (Figure 5). One main feature of 
this miRNA coexpression network is that mir-770-5p and mir-329 divided the whole 
network into three subnetworks: the left, the middle and the right subnetwork. The middle 




Fig. 5. MiRNAs coexpression network. MiRNAs with damage value larger than 20 were 
highlighted in red and yellow, where red nodes denoted significantly differentially expressed 
miRNAs (p-value< 59.36 10 ) and yellow nodes denoted they were not significant. 
Similar to gene co-expression network, we used the damage value of a node as a robustness 
measure to rank the importance of a miRNA in miRNA co-expression network. We ranked 
all differentially expressed miRNAs in the largest miRNA co-expression network according 
to their damage values. There were 19 differentially expressed miRNAs with the largest 
damage values (>20) which we referred to as fragile miRNAs. Among the 19 fragile 
miRNAs, 16 miRNAs (14 miRNAs were over expressed in the GBM tissues) were in the left 
coexpression subnetwork, and 3 under expressed miRNAs were in the right coexpression 
subnetwork. The middle coexpression subnetwork contains no fragile miRNAs. Figure 5 
showed that miRNAs in the middle coexpression subnetwork were densely connected. The 
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and damage value (13) was up regulated in the GBM tumor tissue samples and significantly 
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Fig. 4. Gene interaction network. The largest connected gene interaction network consists of 
187 genes and 196 edges. Genes with different damage value were marked in different 
colors. 
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3.3.2 MiRNA co-expression network analysis 
Similar to genes, miRNAs are not isolated, instead they act together to perform biological 
functions. Initiation and progression of cancer are influenced not only by individual 
miRNAs, but also by the coordinated effect of many miRNAs. To understand how miRNAs 
regulate biological processes at a system level, we reconstruct miRNA co-expression 
network. The largest connected miRNA coexpression network with the average shortest 
path 10.75 and diameter 49 had 385 miRNAs and 451 edges (Figure 5). One main feature of 
this miRNA coexpression network is that mir-770-5p and mir-329 divided the whole 
network into three subnetworks: the left, the middle and the right subnetwork. The middle 




Fig. 5. MiRNAs coexpression network. MiRNAs with damage value larger than 20 were 
highlighted in red and yellow, where red nodes denoted significantly differentially expressed 
miRNAs (p-value< 59.36 10 ) and yellow nodes denoted they were not significant. 
Similar to gene co-expression network, we used the damage value of a node as a robustness 
measure to rank the importance of a miRNA in miRNA co-expression network. We ranked 
all differentially expressed miRNAs in the largest miRNA co-expression network according 
to their damage values. There were 19 differentially expressed miRNAs with the largest 
damage values (>20) which we referred to as fragile miRNAs. Among the 19 fragile 
miRNAs, 16 miRNAs (14 miRNAs were over expressed in the GBM tissues) were in the left 
coexpression subnetwork, and 3 under expressed miRNAs were in the right coexpression 
subnetwork. The middle coexpression subnetwork contains no fragile miRNAs. Figure 5 
showed that miRNAs in the middle coexpression subnetwork were densely connected. The 
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middle coexpression network with large number of redundant miRNAs was highly robust 
in response to perturbation of external forces. From Figure 5, we can see that mir-487a, mir-
487b, mir-502 and mir-532 were the most important components in the miRNA co-
expression network. Removal of one of them would cause disconnection between the left 
part and right part of miRNA co-expression network and hence lead to dysfunction of the 
whole miRNA co-expression network. We observed that mir-487a and mi-487b were down-
regulated, and mir-502 and mir-532 were up-regulated in the GBM tissues. We searched 
miR2disease database (Jiang, et al., 2009) and found that 7 of the 19 miRNAs were associated 
to GBM/glioma/ neuroblastoma (mir-15b, mir-25, mir-93, mir-17-5p, mir-323, mir-106a, 
mir-92), 6 others were associated with cancer and neuro-diseases(mir-487b, mir-15a, mir-16, 
mir-106b, mir-218, mir-320). 
3.3.3 MiRNA interaction network analysis 
We also used MI to quantify interaction between miRNAs and MI-based statistic to detect 
pair-wise interaction between miRNAs. We assembled the interacted miRNAs into miRNA 
interaction network. Significant P-values for declaring an interaction between miRNAs were 
78.51 10  accounting for 1% proportion of total interactions. An assembled largest 
connected miRNA interaction network was shown in Figure 6. The network included 333 




Fig. 6. MiRNA interaction network. miRNAs with damage value larger than 4 were marked 
in blue and miRNAs with degree larger than 9 were marked in red. Significantly 
differentially expressed miRNAs (p-value< 59.36 10 ) were marked in black box. 
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To examine topological network properties of miRNA interaction networks, we also used 
the damage value and the degree of a node to identify cancer relevant miRNAs. Among all 
the miRNAs with either damage values greater than 4 or degrees greater than 9, miR-539 
was associated with autism spectrum disorder (ASD), a brain development disorder(Abu-
Elneel, et al., 2008). It was reported that mir-563 is involved in modulating tumors in 
variable microenvironments (Hebert, et al., 2007), miR-125a and miR-125b were indentified 
to control human neuroblastoma cell proliferation by repressing a common target gene 
NTRK3 (neurotrophic tyrosine kinase, receptor, type 3)(Laneve, et al., 2007). They were 
found to be down-modulated in primary neuroblastoma tumors and were under expressed 
with p-value 54.83 10 and 0.03 respectively in our dataset. 
3.4 miRNA target networks 
We compiled miRNA and mRNA expression data in 237 tumor tissue samples and 10 
normal tissue samples for 1,697 differentially expressed mRNAs and 149 differentially 
expressed miRNAs. This resulted in extremely complex miRNA target networks. We found 
3,953 matched miRNA-mRNA pairs for 127 differentially expressed miRNAs and 1, 089 
differentially expressed genes. Of the 3,953 target-pairs, 65 down-regulated miRNAs targets 
468 over expressed genes while 62 up-regulated miRNAs target 621 under expressed genes. 
A total of 14 experimentally verified targets of 7 miRNAs were listed in Table 7. Of 8 
miRNAs, 4 under expressed miRNAs (mir-124a, mir-29b, mir-29c and mir-33) function as 
tumor-suppressors and 4 over expressed miRNAs (mir-155, mir-16, mir-21 and mir-210) 
function as oncogenes. It has been reported that CTDSP1 was a validated target gene of mir-
124a (Karginov, et al., 2007), RTN4 and SLC25A22 was validated targets of mir-16 (Selbach, 
et al., 2008). mir-21 was found to be over expressed in multiple cancers and down regulated 
tumor suppressor genes: TPM1, PTEN, PDCD4 BASP1 and RTN4 in invasion and metastasis 
of cancer(Yang, et al., 2009).  BASP1 is a transcriptional cosuppressor for the Wilms' tumor 
suppressor protein WT1, thus it can regulate WT1 transcriptional activity (Carpenter, et al., 
2004). Nogo-A , one protein isoforms encoded by RTN4, had turned out to be a neuronal 
protein involved in diverse processes that go from axonal fasciculation to 
apoptosis(Mingorance, et al., 2004). Mir-155 targeted a regulator of apoptosis gene: LDOC1 
(Skalsky, et al., 2007). Up-regulation of miR-210 directly targeted gene EFNA3, which is 
crucial for endothelial cell response to hypoxia, affecting cell survival, migration, and 
differentiation (Fasanaro, et al., 2008). Mir-29c was reported to be under expressed in 
Nasopharyngeal Carcinomas and up-regulated genes COL4A1, COL4A2 and TDG 
(Sengupta, et al., 2008). COL4A1, COL4A2 were genes encoding extracellular matrix 
proteins, as we discussed previously, they played an important role in apoptosis, 
proliferation regulation and anticancer drug resistance (Sethi, et al., 1999) . COL4A2 was 
validated to be also targets of mir-29b in another research group (Li, et al., 2009). TDG was 
involved in DNA repair, a process frequently dysregulated in many cancers (Sengupta, et 
al., 2008). In mouse and human cells, miR-33 inhibits the expression of ABCA1, thereby 
attenuating cholesterol efflux to apolipoprotein A1 (Rayner, et al., 2010). It was also reported 
that the role of miR-33 controlling the hematopoietic stem cells self-renewal through p53 
may lead to the prevention and treatment of hematopoietic disorders (Herrera-Merchan, et 
al., 2010). 
The resulting miRNA target networks have several remarkable features. First, many 
important genes in the mRNA co-expression networks were targets of differentially 
expressed miRNAs. Top 17 genes with damage values greater than 19 in the gene co-
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middle coexpression network with large number of redundant miRNAs was highly robust 
in response to perturbation of external forces. From Figure 5, we can see that mir-487a, mir-
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whole miRNA co-expression network. We observed that mir-487a and mi-487b were down-
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mir-106b, mir-218, mir-320). 
3.3.3 MiRNA interaction network analysis 
We also used MI to quantify interaction between miRNAs and MI-based statistic to detect 
pair-wise interaction between miRNAs. We assembled the interacted miRNAs into miRNA 
interaction network. Significant P-values for declaring an interaction between miRNAs were 
78.51 10  accounting for 1% proportion of total interactions. An assembled largest 
connected miRNA interaction network was shown in Figure 6. The network included 333 




Fig. 6. MiRNA interaction network. miRNAs with damage value larger than 4 were marked 
in blue and miRNAs with degree larger than 9 were marked in red. Significantly 
differentially expressed miRNAs (p-value< 59.36 10 ) were marked in black box. 
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To examine topological network properties of miRNA interaction networks, we also used 
the damage value and the degree of a node to identify cancer relevant miRNAs. Among all 
the miRNAs with either damage values greater than 4 or degrees greater than 9, miR-539 
was associated with autism spectrum disorder (ASD), a brain development disorder(Abu-
Elneel, et al., 2008). It was reported that mir-563 is involved in modulating tumors in 
variable microenvironments (Hebert, et al., 2007), miR-125a and miR-125b were indentified 
to control human neuroblastoma cell proliferation by repressing a common target gene 
NTRK3 (neurotrophic tyrosine kinase, receptor, type 3)(Laneve, et al., 2007). They were 
found to be down-modulated in primary neuroblastoma tumors and were under expressed 
with p-value 54.83 10 and 0.03 respectively in our dataset. 
3.4 miRNA target networks 
We compiled miRNA and mRNA expression data in 237 tumor tissue samples and 10 
normal tissue samples for 1,697 differentially expressed mRNAs and 149 differentially 
expressed miRNAs. This resulted in extremely complex miRNA target networks. We found 
3,953 matched miRNA-mRNA pairs for 127 differentially expressed miRNAs and 1, 089 
differentially expressed genes. Of the 3,953 target-pairs, 65 down-regulated miRNAs targets 
468 over expressed genes while 62 up-regulated miRNAs target 621 under expressed genes. 
A total of 14 experimentally verified targets of 7 miRNAs were listed in Table 7. Of 8 
miRNAs, 4 under expressed miRNAs (mir-124a, mir-29b, mir-29c and mir-33) function as 
tumor-suppressors and 4 over expressed miRNAs (mir-155, mir-16, mir-21 and mir-210) 
function as oncogenes. It has been reported that CTDSP1 was a validated target gene of mir-
124a (Karginov, et al., 2007), RTN4 and SLC25A22 was validated targets of mir-16 (Selbach, 
et al., 2008). mir-21 was found to be over expressed in multiple cancers and down regulated 
tumor suppressor genes: TPM1, PTEN, PDCD4 BASP1 and RTN4 in invasion and metastasis 
of cancer(Yang, et al., 2009).  BASP1 is a transcriptional cosuppressor for the Wilms' tumor 
suppressor protein WT1, thus it can regulate WT1 transcriptional activity (Carpenter, et al., 
2004). Nogo-A , one protein isoforms encoded by RTN4, had turned out to be a neuronal 
protein involved in diverse processes that go from axonal fasciculation to 
apoptosis(Mingorance, et al., 2004). Mir-155 targeted a regulator of apoptosis gene: LDOC1 
(Skalsky, et al., 2007). Up-regulation of miR-210 directly targeted gene EFNA3, which is 
crucial for endothelial cell response to hypoxia, affecting cell survival, migration, and 
differentiation (Fasanaro, et al., 2008). Mir-29c was reported to be under expressed in 
Nasopharyngeal Carcinomas and up-regulated genes COL4A1, COL4A2 and TDG 
(Sengupta, et al., 2008). COL4A1, COL4A2 were genes encoding extracellular matrix 
proteins, as we discussed previously, they played an important role in apoptosis, 
proliferation regulation and anticancer drug resistance (Sethi, et al., 1999) . COL4A2 was 
validated to be also targets of mir-29b in another research group (Li, et al., 2009). TDG was 
involved in DNA repair, a process frequently dysregulated in many cancers (Sengupta, et 
al., 2008). In mouse and human cells, miR-33 inhibits the expression of ABCA1, thereby 
attenuating cholesterol efflux to apolipoprotein A1 (Rayner, et al., 2010). It was also reported 
that the role of miR-33 controlling the hematopoietic stem cells self-renewal through p53 
may lead to the prevention and treatment of hematopoietic disorders (Herrera-Merchan, et 
al., 2010). 
The resulting miRNA target networks have several remarkable features. First, many 
important genes in the mRNA co-expression networks were targets of differentially 
expressed miRNAs. Top 17 genes with damage values greater than 19 in the gene co-
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expression network were negatively regulated by 34 differentially expressed miRNAs. All 





* LDOC1 and RTN4 are tumor suppressor genes 
Table 7. Experimentally verified targets. 
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coexpression networks. Their altered expressions played an important role in tumorigenesis. 
Among them, overexpressed RBBP4 (P-value 81.8 10 ) with the largest damage value (37) 
in the table was negatively regulated by under expressed mir-29b (P-value 72.07 10 and 
mir-29c (P-value 73.66 10 ), underexpressed TRIM8 (P-value 63.77 10 ) with the damage 
value 29 was negatively regulated by overexpressed mir-629 (P-value 72.02 10 ),  
overexpressed TP53 ((P-value 71.40 10 ) with damage value 23 was negatively regulated 
by underexpressed mir-485-5p. RBBP4 has been implicated in chromatin remodeling and 
regulation of cell proliferation. It has been reported that RBBP4 is overexpressed in different 
human tumors, such as lung, liver and thyroid cancer, acute myelocytic leukemia, and acute 
lymphoblastic leukemia (Pacifico, et al., 2007). TRIM8 is thought of as a new tumor 
suppressor gene (Caligo, et al., 1997).  
Second, many genes targeted by critical components in miRNA co-expression network, 
played important roles in regulation of neural process and tumor genesis. To study the 
function of the top 19 differentially expressed miRNAs with the largest damage values, we 
constructed mRNA target network of these 19 miRNAs with 476 nodes and 1,128 arcs and 
174 edges shown in Figure 7A, where 5 underexpressed miRNAs negatively regulated 85 
over expressed genes and 14 overexpressed miRNA negatively regulated 372 
underexpressed genes, 1,128 arcs were miRNA-mRNA pairs, 15 edges connected co-
expressed miRNAs, and remaining 159 edges linked co-expressed genes. The genes with 
large damage value or related to cancer in the gene co expression network were highlighted 
and those gene were marked in the Figure 7A.  8 genes with the damage values greater than 
15 were regulated by 11 miRNAs with the damage values greater than 20. 14 of the15 cancer 
genes in Figure 7A were under-expressed FBXW7, GABRA1, MYT1L, NEFL, RTN1, 
SH3GL2, SNAP25, SV2B, SYN2, KIAA0774, VSNL1, NEFM, RIMS2, SYT1. These genes were 
regulated by 10 overexpressed miRNAs: mir-15b, mir-25, mir-16, mir-92, mir-15a, mir-320, 
mir-106b, mir-93, mir-106a, mir-17-5p, which were connected in the mRNA co-expression 
network (Figure 7B). They are involved in synaptic transmission process. Neuron 
communication occurs at the synapse via neurotransmitters. MYT1L (myelin transcription 
factor 1-like) regulates nervous system development. Both SYT1 and VSNL1 serve as Ca(2+) 
sensors in synaptic transmission(Maglott, et al., 2007). SNAP25 is a presynaptic plasma 
membrane protein and regulates neurotransmitter release. It is reported that SNAP25 is 
implicated in neuritogenesis in human neuroblastoma(Heraud, et al., 2008). GABRA1 
encodes a gamma-aminobutyric acid (GABA) receptor and GABA is the major inhibitory 
neurotransmitter in the mammalian brain. Both NEFL and NEFM are Neurofilaments. They 
play a role in intracellular transport to axons and dendrites. NRGN encodes a postsynaptic 
protein kinase substrate that binds calmodulin in the absence of calcium and is a direct 
target for thyroid hormone in human brain(Maglott, et al., 2007). FBXW7 serves as a 
negative regulator of oncoprotein and is a general tumor suppressor. It regulates cell 
differentiation and proliferation. It has been reported that FBXW7 is implied in various 
cancers including glioblastoma(Hagedorn, et al., 2007). Remaining genes that were involved 
in neuron communication include SLC6A15, SYN2, SV2B and RIMS2. SLC6A15 is a 
neurotransmitter transporter, SYN2 is a member of the synapsin gene family, SV2B is 
synaptic vesicle glycoprotein and RIMS2 regulates synaptic membrane exocytosis(Maglott, 
et al., 2007).  
Table 8 summarizes the major functions of target genes of miRNAs in Figure 7A where  
right-railed Fisher’s exact test were used to test for significantly enriched GO categories or 
pathways. Table 8 shows that the target genes of these miRNAs were mainly involved in 
cancer related signaling pathways and nerves systems process including synapse, 
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synaptic transmission, neurotransmitter transport, nervous system development and 
neurological system process. It is interesting to note that co-expressed mir-15a, mir-15b, 
mir-16, mir-25 and mir-92 were major miRNAs that targeted genes in both cancer related 
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Fig. 7. MiRNA target (sub)network. (A) mRNA target networks of the 19 miRNAs with 476 
nodes and 1,128 arcs and 174 edges, where 1128 arcs were miRNA-mRNA pairs, 15 edges 
connected coexpressed miRNAs, and remaining 159 edges linked coexpressed genes. The 
genes with large damage value or related to cancer in the co expression network genes were 
highlighted and those gene names were marked in the figure. (B) MiRNA target 
subnetwork. 7 genes with the damage values greater than 15 and 14 cancer related genes 
were regulated by 11 miRNAs with the damage values greater than 20. Those nodes and 
edges were extracted from Figure 7A mRNA target network. 
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Third, contribution of miRNAs to expression variation of some genes is very high. The 
proportion of expression variation of target gene explained by the linear influence of 
miRNA variation can be measured by the coefficient of determination ( 2R ). There were a 
total of 78 under-expressed genes with the coefficient of determination greater than 20% 
which were negatively regulated by 7 overexpressed miRNAs: mir-15a, mir-15b, mir-16, 
mir-25, mir-93, mir-106a and mir-106b. Surprisingly, up to 33% of expression variations of 
underexpressed gene GCC2 were explained by single overexpressed mir-25. Functional 
roles of GCC2 in cancer are unknown. The gene with the second largest coefficient of 
determination was CAMK2N1. Its 28% of expression variations were explained by 
overexpressed mir-106b. It was reported that CAMK2N1 is a candidate tumor suppressor 
(Wang, et al., 2008). Function of CAMK2N1 is to inhibit MEK/ERK activity and induce p27 
accumulation which negatively regulates cell-cycle progression. Reducing expression of 
CAMK2N1 will accelerate tumor growth. 26% of expression variation of CPEB1 that 
regulates synaptic plasticity and is implied in cancer development (Hansen, et al., 2009) and 
GRM1 that is involved in neurotransmitter in the central nervous system and implicated in 
Melanoma (Namkoong, et al., 2007) was explained by overexpressed mir-25 and mir-15b, 
respectively. Expressions of genes SYT1, SNAP25, GABRA1, VSNL1, MYT1L, SV2B, SYN2 
and SLC12A5 which were involved in synaptic transmission, were also largely regulated by 
miRNAs. 
Fourth, we observed that one miRNA may target multiple genes (up to 179 mRNAs) directly 
or indirectly, and multiple miRNAs (up to 9 miRNAs) can target a given gene. More than 
40% of expression variation of each of six genes (YWHAH, GABRA1, DYNC1I1, ERC2, 
PEX5L and CAMK2G) was explained by several miRNAs. Expressions of these genes were 
largely regulated by multiple differentially expressed miRNAs. YWHAH and GABRA1 are 
implied in neural diseases, and CAMK2G is involved in regulation of plasticity at 
glutamatergic synapses(Maglott, et al., 2007). Functions of other three genes are unknown. 
 
3.5 DNA methylation analysis  
To study how genes are regulated by DNA methylation in GBM, two methylation datasets: 
OMA-002 dataset and OMA-003 dataset were generated by TCGA project. OMA-002 dataset 
used the Illumina GoldenGate Methylation Cancer Panel 1 platform, which contains 1,505 
CpG loci selected from 813 genes. OMA-002 dataset included 239 GBM tumor tissue 
samples and 1 cell line, 228 of which were shared among the miRNA expression, gene 
expression datasets and thus used for Methylation-miRNA regression and Methylation-gene 
regression analysis. OMA-003 dataset used the Custom Illumina Goldengate Methylation 
Cancer Panel, which contains 1,489 gene promoters. 245 GBM tumor samples and 1 cell line 
were used for experimented, 234 of which were shared among the miRNA expression, gene 
expression datasets and used for Methylation-miRNA regression and Methylation-gene 
regression analysis.   
A total number of 341 genes were hypomethylated genes (average methylation ratio < 0.25 
and fold changes <0.5) in two datasets and 113 hypermethylated genes (average methylation 
ratio > 0.75 and fold changes > 1.5) in glioblastomas. For OMA002 dataset we averaged the 
methylation ratio for several probes in one gene. To investigate the effects of aberrant 
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highlighted and those gene names were marked in the figure. (B) MiRNA target 
subnetwork. 7 genes with the damage values greater than 15 and 14 cancer related genes 
were regulated by 11 miRNAs with the damage values greater than 20. Those nodes and 
edges were extracted from Figure 7A mRNA target network. 
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PEX5L and CAMK2G) was explained by several miRNAs. Expressions of these genes were 
largely regulated by multiple differentially expressed miRNAs. YWHAH and GABRA1 are 
implied in neural diseases, and CAMK2G is involved in regulation of plasticity at 
glutamatergic synapses(Maglott, et al., 2007). Functions of other three genes are unknown. 
 
3.5 DNA methylation analysis  
To study how genes are regulated by DNA methylation in GBM, two methylation datasets: 
OMA-002 dataset and OMA-003 dataset were generated by TCGA project. OMA-002 dataset 
used the Illumina GoldenGate Methylation Cancer Panel 1 platform, which contains 1,505 
CpG loci selected from 813 genes. OMA-002 dataset included 239 GBM tumor tissue 
samples and 1 cell line, 228 of which were shared among the miRNA expression, gene 
expression datasets and thus used for Methylation-miRNA regression and Methylation-gene 
regression analysis. OMA-003 dataset used the Custom Illumina Goldengate Methylation 
Cancer Panel, which contains 1,489 gene promoters. 245 GBM tumor samples and 1 cell line 
were used for experimented, 234 of which were shared among the miRNA expression, gene 
expression datasets and used for Methylation-miRNA regression and Methylation-gene 
regression analysis.   
A total number of 341 genes were hypomethylated genes (average methylation ratio < 0.25 
and fold changes <0.5) in two datasets and 113 hypermethylated genes (average methylation 
ratio > 0.75 and fold changes > 1.5) in glioblastomas. For OMA002 dataset we averaged the 
methylation ratio for several probes in one gene. To investigate the effects of aberrant 
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methylation on gene expressions, we regressed gene expression on the methylation profile. 
We found that 120 hypermethylated genes negatively regulated 404 under expressed genes, 
and 41 hypomethylated genes negatively regulated 85 overexpressed genes. One methylated 
gene might influence expressions of up to 142 genes and multiple methylated genes (up to 
32) might regulate a given gene. Interestingly, we found that 56.3% of expression variation 
of  underexpressed tumor-suppressor gene BCL11B (P-value 71.75 10 )  is explained by 
hypermethylated gene HLA-DPB1 with Average methylation 0.9631 and fold change 7.4. 
We also found that a total of 24 hypermethylated genes that silenced expression of BCL11B 
(Table 9). These hypermethylated genes include PMP22, a major component of myelin in the 
peripheral nervous system, GPR116, involved in neuropeptide signaling pathway, LTA, 
involved in apoptosis.  Another gene with the largest coefficient of determination was 
ANXA5(P-value 63.07 10 ). ANXA5 binds to phosphatidylserine, which is one of the "eat 
me" signals at the surface of the apoptotic cell, thus involved in apoptosis and cancers 
(Boersma, et al., 2005). Up to 11 hypormethylated genes were negatively correlated with 
overexpression of ANXA5 (Table 9). 
Methylation also directly or indirectly regulates expression of miRNAs. We observed that 29 
underexpressed and 26 overexpressed miRNAs were directly or indirectly regulated by 82 
hypermethylated genes. One hypermethylated gene might significantly influence 
expressions of up to 25 miRNAs and multiple hypermethylated genes (up to 30) might 
influence expression of one miRNA. We also found that a total of 67 hypomethylated genes 
directly or indirectly induced expression variation of 38 down regulated and 23 up 
regulated miRNAs. One hypomethylated gene might influence expression of up to 25 
miRNAs and multiple hypomethylated genes (up to 22) might influence expression of one 
miRNA. 
A total of 542 underexpressed and 218 overexpressed genes were directly or indirectly 
regulated by 61 underexpressed and 62 overexpressed miRNAs, and 300 hypomethylated 
and 149 hypermethylated genes. In general, multiple miRNAs and methylated genes jointly 
contribute (in many cases, indirectly) to the variation of gene expressions. In many cases, 
both miRNAs and methylation repressed gene expression. However, surprisingly we 
observed that indirect effect of methylation on the regulation of gene expression was to 
increase gene expression rather than repressing gene expression. Functions of the many 
genes regulated by both miRNAs and methylation such as ANXA5, CACYBP, SLC17A7, 
SLC6A15, INA, SHANK2, PAK3, RIMS2, NBEA, VSNL1, GABRG2, PCLO, VAMP2, PLCB1, 
GRM7 and SNAP25 were involved in neuron communication and in nervous system. We 
also found that expressions of the cancer relevant genes TRIM8 (which has been tested for 
association with Glioblastoma), TP53, FGF13, ENC1, FBXW7, BCL2L2 were influenced by 











coefficient  P-value  
Coeffi-
cient  
HLA- 0.963075314 7.408272 BCL11B -2.01E+02 0.00E+00 5.63E-01 
TNF 0.954752441 5.967203 BCL11B -1.30E+02 2.22E-16 2.59E-01 
PMP22 0.912672293 40.56321 BCL11B -5.31E+01 6.94E-13 2.06E-01 
GPR116 0.945111576 7.270089 BCL11B -7.32E+01 6.84E-11 1.72E-01 
 












coefficient  P-value  
Coeffi-
cient  
FLJ25084 0.881295918 2.037678 BCL11B -6.56E+01 5.84E-11 1.69E-01 
EGF 0.870425384 2.451902 BCL11B -3.42E+01 2.84E-09 1.45E-01 
FCRLM1 0.819928571 46.85306 BCL11B -2.57E+01 4.03E-09 1.39E-01 
LTA 0.887046722 18.67467 BCL11B -5.02E+01 9.74E-09 1.36E-01 
TRPM5 0.84431311 2.447284 BCL11B -4.26E+01 8.54E-08 1.19E-01 
MPL 0.841936275 7.165415 BCL11B -3.40E+01 9.62E-08 1.19E-01 
BLK 0.954205021 42.40911 BCL11B -1.01E+02 5.84E-07 1.05E-01 
IL4 0.846998588 2.540996 BCL11B -3.64E+01 8.17E-07 1.03E-01 
HLA-DOB 0.886698047 39.4088 BCL11B -4.82E+01 9.44E-07 1.01E-01 
CD1D 0.955290456 3.746237 BCL11B -6.56E+01 1.09E-06 9.92E-02 
CLDN4 0.843246165 16.06183 BCL11B -3.49E+01 1.29E-06 9.87E-02 
CXCL9 0.76874477 2.520475 BCL11B -2.14E+01 1.36E-06 9.83E-02 
KISS1 0.925806122 4.571882 BCL11B -5.68E+01 1.59E-06 9.47E-02 
APOC2 0.88015625 1.614966 BCL11B -4.65E+01 1.33E-05 9.29E-02 
TNFRSF10 0.929268207 2.323171 BCL11B -4.22E+01 4.64E-06 8.92E-02 
C18orf2 0.755978723 4.142349 BCL11B -1.77E+01 1.24E-05 8.26E-02 
PLA2G2A 0.785191771 31.40767 BCL11B -2.25E+01 1.11E-05 8.21E-02 
EPHX1 0.900292887 1.809634 BCL11B -5.92E+01 1.16E-05 8.17E-02 
PLA2G2A 0.809780335 2.816627 BCL11B -2.74E+01 2.04E-05 7.74E-02 
KLK11 0.873908647 2.39427 BCL11B -3.44E+01 2.33E-05 7.63E-02 
MMP14 0.214993026 0.217165 ANXA5 -2.11E+03 0.00E+00 2.91E-01 
MST150 0.230010204 0.2788 ANXA5 -1.44E+03 1.09E-13 2.12E-01 
COL5A2 0.201823129 0.260417 ANXA5 -2.06E+03 1.55E-12 1.94E-01 
FRZB 0.152287308 0.491249 ANXA5 -1.62E+03 2.91E-11 1.78E-01 
PAX6 0.094173729 0.396521 ANXA5 -2.43E+03 3.41E-10 1.62E-01 
MMP14 0.165882148 0.402139 ANXA5 -2.45E+03 3.66E-09 1.43E-01 
DES 0.192259414 0.359363 ANXA5 -1.37E+03 1.66E-07 1.14E-01 
LOX 0.125711297 0.177058 ANXA5 -1.69E+03 2.65E-07 1.11E-01 
NEBL 0.06257483 0.161483 ANXA5 -2.18E+03 2.55E-06 9.12E-02 
SPARC 0.150543933 0.174039 ANXA5 -1.99E+03 6.49E-06 8.62E-02 
FGFR2 0.048397711 0.116621 ANXA5 -2.32E+03 1.94E-05 7.98E-02 
 
Table 9. 24 hypermethylated genes negatively regulated expression of gene BCL11B and 11 
hypomethylated genes regulated expression of gene ANXA5. 
3.6 Deciphering the path connecting mutations to gene and miRNA expression. 
To study function of somatic mutations and LOH and connect them with disease through 
gene expressions and miRNAs, we study their cis or trans regulatory effects on gene or 
miRNA expression traits. We applied the group regression method to expression profiles of 
12,042 genes and expression profiles of 470 human microRNAs in 169 tumor tissue samples 
from glioblastomas patients, which were shared among the gene expression, miRNA 
expression and mutation datasets. 
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methylation on gene expressions, we regressed gene expression on the methylation profile. 
We found that 120 hypermethylated genes negatively regulated 404 under expressed genes, 
and 41 hypomethylated genes negatively regulated 85 overexpressed genes. One methylated 
gene might influence expressions of up to 142 genes and multiple methylated genes (up to 
32) might regulate a given gene. Interestingly, we found that 56.3% of expression variation 
of  underexpressed tumor-suppressor gene BCL11B (P-value 71.75 10 )  is explained by 
hypermethylated gene HLA-DPB1 with Average methylation 0.9631 and fold change 7.4. 
We also found that a total of 24 hypermethylated genes that silenced expression of BCL11B 
(Table 9). These hypermethylated genes include PMP22, a major component of myelin in the 
peripheral nervous system, GPR116, involved in neuropeptide signaling pathway, LTA, 
involved in apoptosis.  Another gene with the largest coefficient of determination was 
ANXA5(P-value 63.07 10 ). ANXA5 binds to phosphatidylserine, which is one of the "eat 
me" signals at the surface of the apoptotic cell, thus involved in apoptosis and cancers 
(Boersma, et al., 2005). Up to 11 hypormethylated genes were negatively correlated with 
overexpression of ANXA5 (Table 9). 
Methylation also directly or indirectly regulates expression of miRNAs. We observed that 29 
underexpressed and 26 overexpressed miRNAs were directly or indirectly regulated by 82 
hypermethylated genes. One hypermethylated gene might significantly influence 
expressions of up to 25 miRNAs and multiple hypermethylated genes (up to 30) might 
influence expression of one miRNA. We also found that a total of 67 hypomethylated genes 
directly or indirectly induced expression variation of 38 down regulated and 23 up 
regulated miRNAs. One hypomethylated gene might influence expression of up to 25 
miRNAs and multiple hypomethylated genes (up to 22) might influence expression of one 
miRNA. 
A total of 542 underexpressed and 218 overexpressed genes were directly or indirectly 
regulated by 61 underexpressed and 62 overexpressed miRNAs, and 300 hypomethylated 
and 149 hypermethylated genes. In general, multiple miRNAs and methylated genes jointly 
contribute (in many cases, indirectly) to the variation of gene expressions. In many cases, 
both miRNAs and methylation repressed gene expression. However, surprisingly we 
observed that indirect effect of methylation on the regulation of gene expression was to 
increase gene expression rather than repressing gene expression. Functions of the many 
genes regulated by both miRNAs and methylation such as ANXA5, CACYBP, SLC17A7, 
SLC6A15, INA, SHANK2, PAK3, RIMS2, NBEA, VSNL1, GABRG2, PCLO, VAMP2, PLCB1, 
GRM7 and SNAP25 were involved in neuron communication and in nervous system. We 
also found that expressions of the cancer relevant genes TRIM8 (which has been tested for 
association with Glioblastoma), TP53, FGF13, ENC1, FBXW7, BCL2L2 were influenced by 











coefficient  P-value  
Coeffi-
cient  
HLA- 0.963075314 7.408272 BCL11B -2.01E+02 0.00E+00 5.63E-01 
TNF 0.954752441 5.967203 BCL11B -1.30E+02 2.22E-16 2.59E-01 
PMP22 0.912672293 40.56321 BCL11B -5.31E+01 6.94E-13 2.06E-01 
GPR116 0.945111576 7.270089 BCL11B -7.32E+01 6.84E-11 1.72E-01 
 












coefficient  P-value  
Coeffi-
cient  
FLJ25084 0.881295918 2.037678 BCL11B -6.56E+01 5.84E-11 1.69E-01 
EGF 0.870425384 2.451902 BCL11B -3.42E+01 2.84E-09 1.45E-01 
FCRLM1 0.819928571 46.85306 BCL11B -2.57E+01 4.03E-09 1.39E-01 
LTA 0.887046722 18.67467 BCL11B -5.02E+01 9.74E-09 1.36E-01 
TRPM5 0.84431311 2.447284 BCL11B -4.26E+01 8.54E-08 1.19E-01 
MPL 0.841936275 7.165415 BCL11B -3.40E+01 9.62E-08 1.19E-01 
BLK 0.954205021 42.40911 BCL11B -1.01E+02 5.84E-07 1.05E-01 
IL4 0.846998588 2.540996 BCL11B -3.64E+01 8.17E-07 1.03E-01 
HLA-DOB 0.886698047 39.4088 BCL11B -4.82E+01 9.44E-07 1.01E-01 
CD1D 0.955290456 3.746237 BCL11B -6.56E+01 1.09E-06 9.92E-02 
CLDN4 0.843246165 16.06183 BCL11B -3.49E+01 1.29E-06 9.87E-02 
CXCL9 0.76874477 2.520475 BCL11B -2.14E+01 1.36E-06 9.83E-02 
KISS1 0.925806122 4.571882 BCL11B -5.68E+01 1.59E-06 9.47E-02 
APOC2 0.88015625 1.614966 BCL11B -4.65E+01 1.33E-05 9.29E-02 
TNFRSF10 0.929268207 2.323171 BCL11B -4.22E+01 4.64E-06 8.92E-02 
C18orf2 0.755978723 4.142349 BCL11B -1.77E+01 1.24E-05 8.26E-02 
PLA2G2A 0.785191771 31.40767 BCL11B -2.25E+01 1.11E-05 8.21E-02 
EPHX1 0.900292887 1.809634 BCL11B -5.92E+01 1.16E-05 8.17E-02 
PLA2G2A 0.809780335 2.816627 BCL11B -2.74E+01 2.04E-05 7.74E-02 
KLK11 0.873908647 2.39427 BCL11B -3.44E+01 2.33E-05 7.63E-02 
MMP14 0.214993026 0.217165 ANXA5 -2.11E+03 0.00E+00 2.91E-01 
MST150 0.230010204 0.2788 ANXA5 -1.44E+03 1.09E-13 2.12E-01 
COL5A2 0.201823129 0.260417 ANXA5 -2.06E+03 1.55E-12 1.94E-01 
FRZB 0.152287308 0.491249 ANXA5 -1.62E+03 2.91E-11 1.78E-01 
PAX6 0.094173729 0.396521 ANXA5 -2.43E+03 3.41E-10 1.62E-01 
MMP14 0.165882148 0.402139 ANXA5 -2.45E+03 3.66E-09 1.43E-01 
DES 0.192259414 0.359363 ANXA5 -1.37E+03 1.66E-07 1.14E-01 
LOX 0.125711297 0.177058 ANXA5 -1.69E+03 2.65E-07 1.11E-01 
NEBL 0.06257483 0.161483 ANXA5 -2.18E+03 2.55E-06 9.12E-02 
SPARC 0.150543933 0.174039 ANXA5 -1.99E+03 6.49E-06 8.62E-02 
FGFR2 0.048397711 0.116621 ANXA5 -2.32E+03 1.94E-05 7.98E-02 
 
Table 9. 24 hypermethylated genes negatively regulated expression of gene BCL11B and 11 
hypomethylated genes regulated expression of gene ANXA5. 
3.6 Deciphering the path connecting mutations to gene and miRNA expression. 
To study function of somatic mutations and LOH and connect them with disease through 
gene expressions and miRNAs, we study their cis or trans regulatory effects on gene or 
miRNA expression traits. We applied the group regression method to expression profiles of 
12,042 genes and expression profiles of 470 human microRNAs in 169 tumor tissue samples 
from glioblastomas patients, which were shared among the gene expression, miRNA 
expression and mutation datasets. 
 




Fig. 8. Somatic and LOH mutation eQTL network. (A) Somatic mutation eQTL network. A 
network that connects 14 genes with somatic mutations associated with GBM, their 
regulated mRNAs and miRNA expressions was shown. (B) LOH mutation eQTL network. A 
network that connects 11 genes with LOH associated with GBM, their regulated mRNAs 
and miRNA expressions was shown. 
 




Table 10. Genes with somatic mutations regulate both mRNA and miRNA expressions, and 
formed triangle regulation cycles. 
We first studied cis regulatory effects of somatic and LOH mutations on mRNA or miRNA 
expression traits. For somatic mutation, we found four cis-eQTL: TP53, EGFR, NF1and 
PIK3C2G.  P-values for testing association of somatic mutations in TP53 , EGFR, NF1 and 
PIK3C2G with their expressions were 0.033, 0.019, 0.028 and 0.006, respectively. Fold 
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changes (defined as the ratio of their average expressions of the samples with somatic 
mutations over the average expressions of the samples without somatic mutations) for the 4 
genes were 1.10,1.73, 0.86,1.23, respectively. Although regression analysis did not show 
significant association of somatic mutations in BCL11A, FN1 and COL3A1 with their 
expressions due to very low frequencies of mutations, the fold changes were 1.45, 0.60 and 
0.20, respectively.  We still observed some regulatory effects of somatic mutations on these 
two genes. For LOH mutation, two cis-eQTL: NRAP and EGFR were detected with P-values 
0.030, 0.034 and fold change 0.90 and 2.32, respectively. Regression analysis did not show 
significant association of LOH mutations in gene CYP1B1 with their expressions, but the 
fold change were 0.48.   
Next we identified trans-regulatory effects of somatic and LOH mutations on mRNA or 
miRNA expression traits. The thresholds for declaring significant association of the set of 
somatic mutation and LOH in the gene with mRNA and miRNA expression after Bonferroni 
correction for multiple tests were 41.63 10  and 44.03 10 , respectively. A network that 
connects 14 genes with somatic mutations associated with GBM, and their regulated 
mRNAs and miRNA expressions was shown in Figure 8A. Somatic mutations in these 14 
genes were strongly correlated with expressions of 177 significantly differentially expressed 
genes, 45 of which were under-expressed and 132 were over-expressed in tumor tissue 
samples, a total of 262 trans gene eQTL were found. These mutations also significantly 
affected expressions of 23 miRNAs, 11 of which were underexpressed and 12 were 
overexpressed and a total of 26 trans miRNA eQTL were found. Remarkably, we found 5 
paths: (1) RB1 with association of somatic mutations with GBM regulated expressions of 
gene LAMP2 and mir-340, and mir-340 in turn targeted gene LAMP2; (2) DST with  
association of somatic mutations regulated expressions of both gene OTUB1 and mir-15b  
and mir-15b in turn targeted gene OTUB1; (3) FN1 with association of somatic mutations  
regulated expressions of both SSR2 and mir-125a and mir-125a in turn targeted gene SSR2; 
(4) FN1 with association of somatic mutations regulated expressions of both gene TDG and 
mir-125a and mir-125a in turn targeted gene TDG; and (5) TP53 with association of somatic 
mutations regulated expressions of both gene TP53 and mir-504 and mir-504 in turn 
targeted TP53 (Table 10). 
Similarly, Figure 8B showed a network that connects 11 genes with LOH mutations 
associated with GMB, their regulated mRNAs and miRNA expressions. These 11 genes with 
LOH as trans-eQTL affected 323 differentially expressed or interacted genes, 190 of which 
were underexpressed genes and 133 were overexpressed, a total of 409 trans gene-eQTL were 
found. The LOH also affected expressions of 19 miRNAs, 9 of which were underexpressed 
and 10 were overexpressed, 2 of them were differentially expressed and a total of 27 trans 
miRNA-eQTL were found.   
Sources for regulating gene expressions include DNA variations, miRNAs, and methylation. 
To provide a comprehensive view of how DNA variations, miRNA and methylation directly 
or indirectly regulate gene expression, we found a total of 87 underexpressed and 48 
overexpressed genes which were commonly regulated by 38 underexpressed and 28 
overexpressed miRNAs, 14 hypomethylated and 107 hypemethylated genes, and 9 
significant somatic mutation and 10 significant LOH mutation. Surprisingly, multiple 
genetic perturbations such as multiple genes with somatic mutations or LOH, multiple 
miRNAs and multiple methylation may directly or indirectly regulate expression of a single 
gene. For example, expression levels of BCL11b which is a haploinsufficient tumor 
suppressor gene were positively regulated by genes DST and BCL11A, with associated 
somatic mutations, and were negatively affected by over-expressed mir-155, mir-23a, mir-
92b and mir-30a-5p, and 24 hypermethylated genes. 
 
Integrated Network Analysis of Genetic and Epigenetic Factors in Glioblastoma Multiform 
 
233 
4. Discussion and conclusion 
Genetic and epigenetic alternations that are likely to cause tumor formation are often 
organized into complex biological networks. Genetic and epigenetic risk factors individually 
cannot fully explain initiation and progression of cancer. The purpose of this report is (1) to 
explore the possibility of integrating altered DNA variations, mRNA and miRNA 
expression variation, and methylation patterns into multi-level complex genetic and 
epigenetic networks that contribute to tumorigenesis; (2) decipher paths from somatic 
mutations and LOH to tumor formation through genetic and epigenetic networks; and (3) 
identify key genetic and epigenetic alternations causing tumor formation by network 
analysis.  
The approach developed here for integrating genetic and epigenetic alternations into 
molecular networks consists of three steps. The first step is to reconstruct single type 
molecular networks whose components are of the same type of molecules, either mRNAs or 
miRNAs. We reconstructed mRNA co-expression networks and miRNA co-expression 
networks for glioblastoma using partial correlation approach. The co-expression networks 
attempt to uncover the regulatory relationships among mRNAs or miRNAs. However, 
many examples show that the regulatory relationships may be changed when normal 
tissues become tumor tissues. To identify the alternated regulations we developed a novel 
mutual information-based statistic for testing interactions between mRNAs or miRNAs, 
which allow detecting differential regulations between tumor and normal tissues, and 
reconstructed mRNA and miRNA interaction networks. The second step is to identify 
miRNA target and reconstruct miRNA target networks that connect mRNA and miRNA co-
expression networks or mRNA and miRNA interaction networks. 
The third step is to decipher the paths from somatic and LOH mutations to tumor 
formation. The first issue is how to test association of somatic mutations or LOH with 
glioblastoma. We developed a group association test that is based on population genetics for 
assessing association of somatic mutations and LOH with cancer. We identified 14 genes 
harboring somatic mutations associated with glioblastoma and 11 genes harboring LOH 
associated with glioblastoma. The second issue is how to uncover the components of mRNA 
or miRNA co-expression networks and interaction networks that respond to somatic 
mutations and LOH associated with glioblastoma. Traditionally, when alleles are common, 
these components are identified by mapping cis-eQTL or trans-eQTL. However, when alleles 
are rare, these components are hard to find by individually mapping cis-eQTL or trans-
eQTL.  The approach developed here is to extend group tests for a qualitative trait to a 
quantitative trait. The components that respond to perturbation of rare somatic genetic 
variants were identified by regressing the expression of an mRNA or an miRNA on the 
number of all mutated alleles across the gene. We discovered large comprehensive genetic 
and epigenetic networks that connect genes harboring associated mutations or LOH, 
mRNAs and miRNAs. Interestingly, we found five triangle cycles in the networks which 
indicated that significantly associated somatic mutations or LOH regulated   both 
differentially expressed mRNA and miRNA and the miRNA in turn also affected expression 
levels of the mRNA. The approach presented here has two remarkable features. First, it 
offered a powerful tool for differentiating driver mutations from passenger mutations. 
Second, it provides functional information on how somatic or LOH mutations lead to 
tumorigenesis through complex genetic and epigenetic networks. Similar to mutations, 
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changes (defined as the ratio of their average expressions of the samples with somatic 
mutations over the average expressions of the samples without somatic mutations) for the 4 
genes were 1.10,1.73, 0.86,1.23, respectively. Although regression analysis did not show 
significant association of somatic mutations in BCL11A, FN1 and COL3A1 with their 
expressions due to very low frequencies of mutations, the fold changes were 1.45, 0.60 and 
0.20, respectively.  We still observed some regulatory effects of somatic mutations on these 
two genes. For LOH mutation, two cis-eQTL: NRAP and EGFR were detected with P-values 
0.030, 0.034 and fold change 0.90 and 2.32, respectively. Regression analysis did not show 
significant association of LOH mutations in gene CYP1B1 with their expressions, but the 
fold change were 0.48.   
Next we identified trans-regulatory effects of somatic and LOH mutations on mRNA or 
miRNA expression traits. The thresholds for declaring significant association of the set of 
somatic mutation and LOH in the gene with mRNA and miRNA expression after Bonferroni 
correction for multiple tests were 41.63 10  and 44.03 10 , respectively. A network that 
connects 14 genes with somatic mutations associated with GBM, and their regulated 
mRNAs and miRNA expressions was shown in Figure 8A. Somatic mutations in these 14 
genes were strongly correlated with expressions of 177 significantly differentially expressed 
genes, 45 of which were under-expressed and 132 were over-expressed in tumor tissue 
samples, a total of 262 trans gene eQTL were found. These mutations also significantly 
affected expressions of 23 miRNAs, 11 of which were underexpressed and 12 were 
overexpressed and a total of 26 trans miRNA eQTL were found. Remarkably, we found 5 
paths: (1) RB1 with association of somatic mutations with GBM regulated expressions of 
gene LAMP2 and mir-340, and mir-340 in turn targeted gene LAMP2; (2) DST with  
association of somatic mutations regulated expressions of both gene OTUB1 and mir-15b  
and mir-15b in turn targeted gene OTUB1; (3) FN1 with association of somatic mutations  
regulated expressions of both SSR2 and mir-125a and mir-125a in turn targeted gene SSR2; 
(4) FN1 with association of somatic mutations regulated expressions of both gene TDG and 
mir-125a and mir-125a in turn targeted gene TDG; and (5) TP53 with association of somatic 
mutations regulated expressions of both gene TP53 and mir-504 and mir-504 in turn 
targeted TP53 (Table 10). 
Similarly, Figure 8B showed a network that connects 11 genes with LOH mutations 
associated with GMB, their regulated mRNAs and miRNA expressions. These 11 genes with 
LOH as trans-eQTL affected 323 differentially expressed or interacted genes, 190 of which 
were underexpressed genes and 133 were overexpressed, a total of 409 trans gene-eQTL were 
found. The LOH also affected expressions of 19 miRNAs, 9 of which were underexpressed 
and 10 were overexpressed, 2 of them were differentially expressed and a total of 27 trans 
miRNA-eQTL were found.   
Sources for regulating gene expressions include DNA variations, miRNAs, and methylation. 
To provide a comprehensive view of how DNA variations, miRNA and methylation directly 
or indirectly regulate gene expression, we found a total of 87 underexpressed and 48 
overexpressed genes which were commonly regulated by 38 underexpressed and 28 
overexpressed miRNAs, 14 hypomethylated and 107 hypemethylated genes, and 9 
significant somatic mutation and 10 significant LOH mutation. Surprisingly, multiple 
genetic perturbations such as multiple genes with somatic mutations or LOH, multiple 
miRNAs and multiple methylation may directly or indirectly regulate expression of a single 
gene. For example, expression levels of BCL11b which is a haploinsufficient tumor 
suppressor gene were positively regulated by genes DST and BCL11A, with associated 
somatic mutations, and were negatively affected by over-expressed mir-155, mir-23a, mir-
92b and mir-30a-5p, and 24 hypermethylated genes. 
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4. Discussion and conclusion 
Genetic and epigenetic alternations that are likely to cause tumor formation are often 
organized into complex biological networks. Genetic and epigenetic risk factors individually 
cannot fully explain initiation and progression of cancer. The purpose of this report is (1) to 
explore the possibility of integrating altered DNA variations, mRNA and miRNA 
expression variation, and methylation patterns into multi-level complex genetic and 
epigenetic networks that contribute to tumorigenesis; (2) decipher paths from somatic 
mutations and LOH to tumor formation through genetic and epigenetic networks; and (3) 
identify key genetic and epigenetic alternations causing tumor formation by network 
analysis.  
The approach developed here for integrating genetic and epigenetic alternations into 
molecular networks consists of three steps. The first step is to reconstruct single type 
molecular networks whose components are of the same type of molecules, either mRNAs or 
miRNAs. We reconstructed mRNA co-expression networks and miRNA co-expression 
networks for glioblastoma using partial correlation approach. The co-expression networks 
attempt to uncover the regulatory relationships among mRNAs or miRNAs. However, 
many examples show that the regulatory relationships may be changed when normal 
tissues become tumor tissues. To identify the alternated regulations we developed a novel 
mutual information-based statistic for testing interactions between mRNAs or miRNAs, 
which allow detecting differential regulations between tumor and normal tissues, and 
reconstructed mRNA and miRNA interaction networks. The second step is to identify 
miRNA target and reconstruct miRNA target networks that connect mRNA and miRNA co-
expression networks or mRNA and miRNA interaction networks. 
The third step is to decipher the paths from somatic and LOH mutations to tumor 
formation. The first issue is how to test association of somatic mutations or LOH with 
glioblastoma. We developed a group association test that is based on population genetics for 
assessing association of somatic mutations and LOH with cancer. We identified 14 genes 
harboring somatic mutations associated with glioblastoma and 11 genes harboring LOH 
associated with glioblastoma. The second issue is how to uncover the components of mRNA 
or miRNA co-expression networks and interaction networks that respond to somatic 
mutations and LOH associated with glioblastoma. Traditionally, when alleles are common, 
these components are identified by mapping cis-eQTL or trans-eQTL. However, when alleles 
are rare, these components are hard to find by individually mapping cis-eQTL or trans-
eQTL.  The approach developed here is to extend group tests for a qualitative trait to a 
quantitative trait. The components that respond to perturbation of rare somatic genetic 
variants were identified by regressing the expression of an mRNA or an miRNA on the 
number of all mutated alleles across the gene. We discovered large comprehensive genetic 
and epigenetic networks that connect genes harboring associated mutations or LOH, 
mRNAs and miRNAs. Interestingly, we found five triangle cycles in the networks which 
indicated that significantly associated somatic mutations or LOH regulated   both 
differentially expressed mRNA and miRNA and the miRNA in turn also affected expression 
levels of the mRNA. The approach presented here has two remarkable features. First, it 
offered a powerful tool for differentiating driver mutations from passenger mutations. 
Second, it provides functional information on how somatic or LOH mutations lead to 
tumorigenesis through complex genetic and epigenetic networks. Similar to mutations, 
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methylation is another source for causing tumorigenesis. By regressing expression levels of 
mRNA or miRNA on methylation level, we can incorporate methylation into network. 
Finally we identified large genetic and epigenetic networks including associated mutations, 
LOH, methylation, differentially expressed mRNAs and miRNAs to explain how mutations 
and methylation cause tumorigenesis through molecular networks.  
Our studies support the hypothesis that cancer may be the emergent properties of large 
genetic and epigenetic networks that are highly interconnected. Genetic, epigenetic and 
environmental stimuli can be viewed as random attacks to genetic and epigenetic networks. 
Topological properties of the genetic and epigenetic networks are closely related to the 
function of cells. Cancer arises from the failure of genetic and epigenetic networks to 
respond to attacks. In other words, the attacked networks are unable to return to their 
normal states and remain functional in the face of random perturbations. We suspect that 
key components of network contributing to the robustness of the network also play an 
important role in the function of cells. We modeled over- or under-expression of mRNA and 
miRNA, methylation, and genetic alternation as deletion of a node in the network which 
will cause dynamical changes in the network and used a damage value of the node to 
measure its contribution to the robustness of the network. We found the several cancers 
related genes such as TP53 have large damage values in the genetic and epigenetic 
networks. These key components in the network may serve as therapeutic intervention 
points.  
Our results are preliminary. Although network analysis may have the potential to unravel 
the mechanism of tumor initiation and progression, the presented network structures and 
their properties in this report may depend on sample size. Whether the structures of our 
reconstructed genetic and epigenetic network can be replicated in other samples or not is a 
key to the success of network analysis in cancer studies.  
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1. Introduction 
High-grade gliomas are the most prevalent and lethal form of primary intracranial tumors. 
Despite significant progress in surgical and adjuvant therapeutic treatments for gliomas, 
patient prognosis still remains dismal. The ability of gliomas to invade the normal 
surrounding brain tissue contributes to their capacity to evade therapeutic interventions, 
ultimately leading to tumor recurrence and subsequent disease progression (Rich & Bigner, 
2004).  Another major therapeutic obstacle comes from the high degree of intratumoral 
cellular heterogeneity.  The tumor mass is comprised of both terminally differentiated cells, 
cells that exhibit finite capabilities of self-renewal and multipotency, and a smaller 
subpopulation of cells that exhibit stem cell-like qualities. These stem-like cells, termed 
Glioma Initiating Cells (GICs), exihibit pluripotency, self-renewal and, importantly, are 
capable of repopulating the original parental tumor. Therefore, more effective therapies may 
be derived from targeting both the infiltrative nature of gliomas and GICs (Louis, 2006; Park 
& Rich, 2009). 
The ability of glioma tumor cells to infiltrate the normal surrounding brain tissue is a 
property that is restricted to intracranial tumors that are phenotypically glial within the 
central nervous system (CNS). As metastatic tumor cells that are highly invasive in the 
periphery fail to invade surrounding brain tissue once within the confines of the CNS, and 
invasive glioma tumors that originate in the brain rarely metastasize outside of the CNS. 
These findings suggest that the unique interaction between glioma tumor cells and the 
neural extracellular environment mediate glioma invasion (Bellail et al., 2004; Nutt et al., 
2001a).  
A defining attribute of the neural extracellular environment is the unique composition of the 
neural extracellular matrix (ECM), which unlike other peripheral matrices has low levels of 
fibrilliar proteins like collagens, fibronectin, and laminin (Ruoslahti, 1996). In both neural 
development and pathogenesis, the neural ECM regulates key biological processes 
including cellular migration, maturation, synapse formation, and plasticity. In the adult 
brain the composition of the neural ECM is largely inhibitory to cellular reorganization 
(Galtrey & Fawcett, 2007; Zimmermann & Dours-Zimmermann, 2008). Therefore, glioma 
tumor cell invasion into the normal surrounding brain tissue is derived from their ability to 
overcome this normally inhibitory extracellular environment. Decades of research has 
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demonstrated that glioma tumor cells are capable of remodeling the neural extracellular 
space by changing the expressions of proteins involved in intercellular and extracellular 
interactions. Glioma tumor cells also secrete proteases that cleave the adult neural ECM and 
temporary produced glioma ECM to create a permissive extracellular environment 
supportive of tumor cell invasion (Viapiano & Matthews, 2006). In addition, recent studies 
have determined that the expressions of several constituents of the neural ECM are enriched 
in the GIC subpopulation (Gunther et al., 2008; Phillips et al., 2006), suggesting that 
components of the neural ECM may facilitate the stem cell-like qualities of these cells by 
creating a permissive extracellular niche. 
Targeting either the expression of proteins that mediate intercellular or extracellular 
interactions or the proteases responsible for the cleavage and turnover of these proteins 
represent potential therapeutic avenues that require further exploration.  This chapter will 
focus on the role of the neural ECM, proteolytic cleavage, and alterations that occur in 
proteins that mediate intercellular interactions to facilitate glioma tumorigenicity and 
invasion and their therapeutic potential. 
2. The neural extracellular matrix in normal and developing brain 
2.1 The neural extracellular matrix 
During both neurodevelopment and in several neuropathologies, the neural ECM and 
molecular determinants of cell-ECM and cell-cell interactions regulate key biological 
processes including cellular migration, maturation, differentiation, and synapse formation 
(Hartmann & Maurer, 2001). The composition of the neural ECM largely dictates the 
permissive or inhibitory properties of the neural extracellular environment, creating a 
permissive environment favoring cell migration and process outgrowth during 
development and a notoriously inhibitory environment in the mature CNS. The neural ECM 
is capable of undergoing dynamic remodeling resulting from alterations in both the 
expression levels of ECM components and alterations in proteolytic processing 
(Zimmermann & Dours-Zimmermann, 2008). 
2.2 The composition of the neural extracellular matrix in normal brain 
The composition of the neural ECM, while most similar to cartilage, is unique and 
distinguishes the neural extracellular environment from that of other tissues and organs. 
The neural ECM is chiefly comprised of Hyaluronic Acid (HA), a repeating sugar 
disaccharide, proteoglycans and glycoproteins, which through their interactions organize 
the extracellular space of the CNS (Delpech & Delpech, 1984). The neural ECM accounts for 
ten to twenty percent of the total volume of the mature brain and occupies an even larger 
percentage in the developing brain (Ruoslahti, 1996). Unlike peripheral matrices, the neural 
ECM has low levels of fibrillar proteins including laminin, collagens, and fibronectin with 
the majority of these proteins being localized to substructures of the CNS including 
basement membranes, the subpial space, blood vessels, and in white matter tracts (Liesi, 
1984). Instead, the backbone of the neural ECM is HA, a non-sulfated glycosaminoglycan 
made up of alternating glucuronic acid and N-acetylglucosamine disaccharide subunits and 
devoid of a protein core (Ruoslahti, 1996; Toole, 2000, 2004). HA  is produced and secreted 
by hyaluronan synthases located at the surface of the cellular plasma membrane, recent 
evidence suggests that HA synthases may also play a role in tethering HA  to the cellular 
surface to facilitate its interactions with other components of the neural ECM (DeAngelis, 
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1999; Itano & Kimata, 2002; Weigel et al., 1997; Spicer & McDonald, 1998; Spicer & Tien, 
2004). 
Since HA forms the backbone of the neural matrix, proteins that organize and bind HA to 
the cell surface are particularly important for defining neural ECM structure and function. 
In many peripheral tissues the best studied HA receptor is CD44 but it is expressed at low 
levels in the adult CNS.  Instead, the major HA binding proteins expressed in the CNS are 
the lectican family members of chondroitin sulfate proteoglycans (CSPGs), also called 
hyalectans, which include versican, aggrecan, and brain-specific neurocan, and Brain 
Enriched Hyaluronan Binding protein (BEHAB)/brevican (B/b) (Bandtlow & Zimmermann, 
2000; Ruoslahti, 1996; Yamaguchi, 2000). Additionally, the HA Proteoglycan binding Link 
Proteins (HAPLNs) work in concert with lecticans to mediate HA binding (Spicer et al., 
2003). CSPGs are glycosylated proteins that are decorated with chondroitin sulfate 
glycosaminoglycan (CS-GAG) chains. The number and sulfation of CS-GAG chains varies 
for individual proteoglycans and can modulate their functions and interactions with ligands 
(Maeda, 2010). 
The structure and molecular interactions of lecticans in the normal brain has been reviewed 
thoroughly in previous publications and therefore is not included here, however, the model 
structure of the neural matrix and the position and interactions of lecticans in this matrix is 
shown in Figure 1 (Ruoslahti, 1996; Viapiano & Matthews, 2006; Yamaguchi, 2000). A 
complete understanding of the molecular interactions and functions of lecticans in the 
normal brain is, however, challenging. This is due in large part to the production of several 
protein isoforms resulting from alternative splicing, which causes a vast and 
microheterogeneous array of protein products (Viapiano et al., 2003, 2005; Dours-
Zimmerman & Zimmerman, 1994). Adding to this complexity, different protein isoforms 
from the same gene are expressed in specific temporal and regional patterns (Milev et al., 
1998; Seidenbecher et al., 1998). In addition, all lecticans are cleaved by A Disintegrin And 
Metalloproteinase with Thrombospondin Motifs (ADAMTS) and Matrix Metalloproteinase 
(MMPs) family members (Westling et al., 2004; Matthews et al., 2000). Finally the 
glycosylation of lecticans is extremely microheterogeneous and specific glycoforms can be 
expressed in a very anatomically distinct and precise manner in the normal CNS (Matthews 
et al., 2002). The molecular heterogeneity as well as the distinct spatial and temporal 
expression patterns of ECM components dictates the broad functional impact the neural 
ECM has over the CNS in both the physiological and pathophysiological state. 
2.3 The function of the neural extracellular matrix 
The neural ECM regulates a diverse array of functions in both the developing and mature 
CNS. During neurodevelopment the ECM has been shown to play a role in cell migration, 
process outgrowth, cell fate decisions, synaptogenesis and regulating cortical plasticity 
(Bandtlow & Zimmermann, 2000; Berardi et al., 2004; Frischknecht & Seidenbecher, 2008; 
Maeda et al., 2010). The composition of the ECM during neurodevelopment is largely 
permissive and favorable for cellular migration and process outgrowth (Zimmermann & 
Dours-Zimmermann, 2008). The expressions of certain lectican isoforms that aid in cellular 
movement and process outgrowth are also elevated and undergo increased proteolytic 
cleavage, which enables the turnover of ECM components to facilitate cellular migration. In 
fact, the proteolytic activities of certain proteases have been shown to be critical for normal 
development to proceed (Ethell & Ethell, 2007). As the mature synaptic circuitry is 
established the composition of the neural ECM changes to aid in stabilizing these 
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Fig. 1. Schematic Diagram of the Neural Extracellular Matrix. Diagram demonstrates the 
model composition of the ECM and cell-surface receptors in the normal adult brain (A) and 
the changes in the extracellular environment in gliomas (B). Arrows represent activation of 
signaling cascades. 
connections, creating the notoriously inhibitory extracellular environment of the adult CNS 
(Galtrey & Fawcett, 2007). The expression of HA is substantially reduced and lectican family 
members and their specific isoforms that are inhibitory to extracellular reorganization 
appear (Frischknecht & Seidenbecher, 2008; Margolis et al., 1975). Often disorders and 
diseases that affect the CNS are accompanied by alterations in the composition of the neural 
ECM, which facilitates the pathophysiological condition by modifying the extracellular 
environment (Galtrey & Fawcett, 2007; Zimmermann & Dours-Zimmermann, 2008). 
3. Extracellular matrix in brain tumors 
3.1 The neural matrix facilitates glioma tumor cell invasion 
While the extracellular environment of the mature CNS is notably resistant to plasticity and 
cellular dynamics that favor reorganization, glioma cells are capable of overcoming this 
inhibition to invade into the normal surrounding brain tissue. The invasive attributes of 
glioma cells leads to tumor cell dispersion and highly diffuse tumor-stromal boundaries, 
making complete surgical removal of tumor cells nearly impossible and tumor recurrence 
almost inevitable (Nakada et al., 2007). Brain tumor cell invasion into the normal 
surrounding brain tissue is a property that is restricted to tumors that are phenotypically 
glial and located within the CNS environment. Both non-glial tumors that originate in the 
CNS and tumors of non-neuroepithelial origin that metastasize to the CNS fail to invade the 
surrounding brain tissue, typically exhibiting well-defined brain-tumor boundaries (Bellail 
et al., 2004). Furthermore, gliomas rarely infiltrate the vasculature of the CNS and 
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disseminate outside of the nervous system environment (Kleihues et al., 1993, 2002; Bellail et 
al., 2004). The ability of glioma cells to invade the mature CNS strongly suggests that the 
unique interaction between these tumors and the extracellular neural environment is critical 
in this invasive process. The unique composition of the neural ECM defines the extracellular 
environment of the CNS and, therefore, the unique ability of glioma cells to interact with the 
neural ECM is a critical component of their invasiveness. Consistent with this hypothesis is 
work from a number of labs demonstrating that glioma tumor cells synthesize and secrete a 
specialized composition of ECM components and cell adhesion molecules that facilitate this 
interaction leading to tumor cell invasion (Bellail et al., 2004; Gladson, 1999). 
The composition of the ECM produced by glioma cells closely resembles that during early 
neurodevelopment, as both the expression levels and presence of specific protein isoforms 
predominately expressed during neurodevelopment are overrepresented in the ECM of 
gliomas. As in several invasive and metastatic tumors, the synthesis of HA is dramatically 
increased in glioma along with HA receptors CD44 and RHAMM which mediate aspects of 
glioma invasion (Delpech et al., 1993; Kuppner et al., 1992; Merzak et al., 1994; Okada et al., 
1996; Park et al., 2008; Radotra & McCormick, 1997). The expression of several lectican 
family members and their isoforms that are predominately expressed during early nervous 
system development and promote cellular reorganization are also upregulated in human 
glioma tumors. Exemplary to this are the elevated expressions of versican ( Paulus et al., 
1996), B/b (Jaworski et al., 1996), neurocan (Rauch,  2004), and Receptor Protein Tyrosine 
Phosphatase   (RPTP, also known as RPTP) (Norman et al., 1998; Peles et al., 1998). A 
specific model of a lectican isoform that is highly expressed during neurodevelopment and 
reappears in glioma tumors is a variant of B/b, B/bg. The B/bg form of brevican is 
expressed for a short developmental window in normal human brain spanning from 16 
gestational weeks to one year of age. The expression of the B/bg isoform reemerges in 
human glioma tumors causing it to be expressed in a tumor-specific manner within the 
adult CNS (Viapiano et al., 2005). Additionally, unlike normal adult ECM, the tumoral ECM 
contains traditional fibrillar matrix proteins like laminin and fibronectin, which have been 
shown to bind to proteoglycans to enhance tumor cell motility (Hu et al., 2008; Zheng et al., 
2004). While the expressions of typical fibrillar proteins are low in the extracellular milieu of 
the adult brain, these common matrix elements are expressed in localized regions of the 
developing brain (Rutka et al., 1988; Ruoslahti, 1996). Therefore, with respect to the neural 
ECM, oncology recapitulates ontogeny. 
While the expression of unique ECM components in glioma cells is detailed above, glioma 
cells also modulate the expression of cell-surface receptors, which enhances their ability to 
interact within the neural environment. One class of surface receptors altered in glioma 
tumors are cell-cell adhesion molecules, which comprise several different molecular families 
of receptors (Barami et al., 2006).  Cell-cell adhesion molecules play important roles in 
regulating cell motility through interactions with ECM components and other cell adhesion 
molecules. Several signal transduction pathways directly regulate the cellular repertoire of 
adhesion molecules to dictate both extracellular and intercellular interactions. The inverse is 
also true, as activated cell adhesion molecules are capable of modulating intracellular 
signaling to influence cellular processes like adhesion, motility and even cell fate (Cavallaro 
& Christofori, 2004). In terms of glioma tumor pathophysiology, the activation of cell 
adhesion molecules are equally as important as the activation of signal transduction 
cascades, as signaling from both modulate tumor cell behavior. 
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work from a number of labs demonstrating that glioma tumor cells synthesize and secrete a 
specialized composition of ECM components and cell adhesion molecules that facilitate this 
interaction leading to tumor cell invasion (Bellail et al., 2004; Gladson, 1999). 
The composition of the ECM produced by glioma cells closely resembles that during early 
neurodevelopment, as both the expression levels and presence of specific protein isoforms 
predominately expressed during neurodevelopment are overrepresented in the ECM of 
gliomas. As in several invasive and metastatic tumors, the synthesis of HA is dramatically 
increased in glioma along with HA receptors CD44 and RHAMM which mediate aspects of 
glioma invasion (Delpech et al., 1993; Kuppner et al., 1992; Merzak et al., 1994; Okada et al., 
1996; Park et al., 2008; Radotra & McCormick, 1997). The expression of several lectican 
family members and their isoforms that are predominately expressed during early nervous 
system development and promote cellular reorganization are also upregulated in human 
glioma tumors. Exemplary to this are the elevated expressions of versican ( Paulus et al., 
1996), B/b (Jaworski et al., 1996), neurocan (Rauch,  2004), and Receptor Protein Tyrosine 
Phosphatase   (RPTP, also known as RPTP) (Norman et al., 1998; Peles et al., 1998). A 
specific model of a lectican isoform that is highly expressed during neurodevelopment and 
reappears in glioma tumors is a variant of B/b, B/bg. The B/bg form of brevican is 
expressed for a short developmental window in normal human brain spanning from 16 
gestational weeks to one year of age. The expression of the B/bg isoform reemerges in 
human glioma tumors causing it to be expressed in a tumor-specific manner within the 
adult CNS (Viapiano et al., 2005). Additionally, unlike normal adult ECM, the tumoral ECM 
contains traditional fibrillar matrix proteins like laminin and fibronectin, which have been 
shown to bind to proteoglycans to enhance tumor cell motility (Hu et al., 2008; Zheng et al., 
2004). While the expressions of typical fibrillar proteins are low in the extracellular milieu of 
the adult brain, these common matrix elements are expressed in localized regions of the 
developing brain (Rutka et al., 1988; Ruoslahti, 1996). Therefore, with respect to the neural 
ECM, oncology recapitulates ontogeny. 
While the expression of unique ECM components in glioma cells is detailed above, glioma 
cells also modulate the expression of cell-surface receptors, which enhances their ability to 
interact within the neural environment. One class of surface receptors altered in glioma 
tumors are cell-cell adhesion molecules, which comprise several different molecular families 
of receptors (Barami et al., 2006).  Cell-cell adhesion molecules play important roles in 
regulating cell motility through interactions with ECM components and other cell adhesion 
molecules. Several signal transduction pathways directly regulate the cellular repertoire of 
adhesion molecules to dictate both extracellular and intercellular interactions. The inverse is 
also true, as activated cell adhesion molecules are capable of modulating intracellular 
signaling to influence cellular processes like adhesion, motility and even cell fate (Cavallaro 
& Christofori, 2004). In terms of glioma tumor pathophysiology, the activation of cell 
adhesion molecules are equally as important as the activation of signal transduction 
cascades, as signaling from both modulate tumor cell behavior. 
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In glioma tumors, ECM receptors like tenascin, integrins and certain cell-cell adhesion 
molecules mediate interactions between the extracellular environment and surface of the cell 
to influence cell behavior by modulating intracellular signaling. Tenascins are large 
molecular weight cell-surface glycoproteins that can function as receptors for proteoglycans 
including the lectican family members. Importantly, tenascin family members are also 
overexpressed in glioma specimens and have been linked to tumor cell invasion and 
angiogenesis (Aspberg et al., 1995; 1997; Hirata et al., 2009; Leins et al., 2003; Zagzag et al., 
2002). While tenascin can function as receptors for proteoglycans, they are also secreted 
proteins that depend in part on interactions with cell-adhesion molecules at the cellular 
plasma membrane to confer their functionality. Tenascin has been shown to interact with 
integrins, which are integral membrane cell surface receptors involved in cell-ECM 
interactions (Deryugina & Bourdon, 1996; Giese et al., 1996). In addition to binding tenascin, 
integrins also bind fibrillar proteins like laminin and fibronectin that are expressed in the 
tumoral extracellular environment (Knott et al., 1998; Ohnishi et al., 1998). The interaction of 
integrins with both tenascin and fibrillar matrix proteins in the tumor microenvironment 
have been shown to enhance the motility and invasive properties of glioma tumor cells 
(Deryugina & Bourdon, 1996; Hirata et al., 2009).  Upon binding to ECM ligands, integrins 
effectively transduce changes in the ECM into alterations in cellular behavior by activating 
signal transduction cascades that reorganize components of the cellular cytoskeleton to 
facilitate cell movement (D'Abaco & Kaye, 2007). 
Cell-cell and cell-ECM interactions of glioma tumor cells are also critically regulated by 
extracellular proteases. Tumor cell invasion is strongly influenced by the proteolytic 
cleavage of ECM components and certain cell adhesion molecules, as proteolysis creates an 
extracellular environment permissive to cellular migration by facilitating the turnover of 
ECM components (Rao, 2003 and section 2.2). The complex interplay between HA, 
proteoglycans and their receptors, integrins, cell-cell adhesion molecules, and proteases 
present within the tumor stroma facilitate glioma invasion through the normally inhibitory 
extracellular environment of the mature CNS. 
The restricted invasive profile of gliomas suggests that nervous system-specific proteins 
expressed only by neoplastic cells that are phenotypically glial may be key mediators of 
glioma invasion. Thus, making components of the neural ECM and adhesion molecules with 
expressions that are restricted or specifically enriched within the CNS appealing avenues of 
research for future therapeutic targets. Proteins with CNS enriched or specific expression 
that are overexpressed in human glioma tumors include but are not limited to B/b  
(Jaworski et al., 1996), specific isoforms of versican (Dours-Zimmermann & Zimmermann, 
1994; Paulus et al., 1996), and RPTP ( Muller et al., 2003). Inhibiting molecular mechanisms 
leading to glioma tumor cell invasion is critical to effectively curing these deadly tumors. 
Furthermore, the identification of pro-invasive mediators that are both nervous system and 
tumor-specific would create molecular targets for novel therapies with reduced off-target 
effects, thus limiting the potential of inducing broad systemic toxicity. 
3.2 Proteolytic degradation of the neural extracellular matrix is critically involved in 
tumor cell invasion 
In order for glioma tumor cells to invade the normal surrounding brain tissue, tumor cells 
must both interact with the ECM of the adult CNS, which is accomplished through the 
synthesis of tumor-produced ECM, altered receptor expression, and proteolytic cleavage. 
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Several different families of proteases are overexpressed in gliomas including MMPs, 
ADAMTS, serine, cysteine, and asparate and play important roles in mediating glioma 
tumor invasion and progression (Levicar et al., 2003). Proteases expressed by glioma tumor 
cells degrade the mature inhibitory ECM of the adult CNS and the glioma-expressed matrix 
elements. Proteolytic activity allows for turnover of ECM components and facilitates 
invasion by dynamically remodeling the extracellular environment to become more 
permissive to cellular reorganization (Yamamoto et al., 2002). Therefore, glioma tumor cell 
invasion is dependent on both the overproduction and proteolytic cleavage of ECM 
components. The importance of ECM cleavage is highlighted by previous work on B/b that 
showed both its overexpression and proteolytic processing are required for increased 
glioma cell invasion, as a mutated non-cleavable form of B/b did not enhance cell invasion 
(Viapiano et al., 2008). In addition to mediating aspects of invasion, proteases belonging to 
these families have also been linked to increases in glioma tumor cell proliferation and 
angiogenesis (Lakka et al., 2005). The regulation of proteolytic activity in gliomas is complex 
with each level of regulation representing a facet for potential therapeutic intervention. 
Proteolytic activity can be regulated at different levels resulting from either an increase in 
transcription or activation, as most proteases require cleavage of an inactive pro-peptide 
form for enzymatic activity. The proteolytic activity of both ADAMTS and MMP family 
members are naturally inhibited by endogenously occurring proteins belonging to the 
Tissue Inhibitor of Metalloproteinases (TIMP) family (Brew & Nagase, 2010). In several 
disease pathologies including gliomas, an imbalance between protease activity and TIMP 
expression accounts for elevated levels of proteolysis in the pathogenic state (Kachra et al., 
1999). Therefore, both the overexpression and activation of ADAMTS and MMP proteases 
along with the TIMP family of endogenous protease inhibitors are attractive therapeutic 
targets for their role as molecular determinants of glioma tumor cell invasion. 
The functional role of proteases in glioma tumor pathology is exemplified by the MMP 
family members, which have important roles in the progression of most neoplasms and 
happen to be the most well characterized protease family in glioma tumors (Levicar et al., 
2003).  The MMPs comprise a large family of matrix peptidases that are classified on the 
basis of their preferred substrate, for which there is considerable overlap between family 
members (Rao, 2003). MMPs are produced both by glioma tumor cells and endothelial cells 
that comprise the tumor vasculature (Raithatha et al., 2000). Two of the most well 
documented MMPs in glioma are MMP-2 and MMP-9, also known as gelatinase-A and 
gelatinase-B, respectively. Their expressions are increased in glioma tumors and have been 
correlated with increased glioma tumor cell invasiveness (Nakagawa et al., 1996; Wild-Bode 
et al., 2001; Levicar et al., 2003). Additionally, the expression of these proteases correlated 
with the degree of glioma tumor malignancy, as increased levels of MMP-2 and MMP-9 
were observed in high-grade glioma tumors relative to low-grade (Wang et al., 2003). 
Knocking down the expression of MMP-9 in an invasive glioma cell line resulted in 
decreased tumor cell infiltration into the surrounding brain tissue and decreased cell 
motility and invasion in vitro (Zhao et al., 2010). Upstream signaling molecules that regulate 
the expressions of MMP-2 and MMP-9 are also potential therapeutic targets of interest. 
Previous studies have shown that JNK and ERK signaling positively regulate the expression 
of MMP-9, and interfering with either of these pathways reduced the invasiveness of a 
glioma cell line (Lakka et al., 2000). 
Based on elevated MMP expression, activation, and function in glioma tumor invasion and 
progression, a considerable amount of investigation into using chemical inhibitors of MMPs 
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expressions that are restricted or specifically enriched within the CNS appealing avenues of 
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as therapeutic agents to reduce the pathogenesis of glioma tumors has ensued. Clinical trials 
using a broad MMP inhibitor failed to improve patient prognosis and caused systemic 
toxicity in patients, in the form of joint pain (Groves et al., 2006; Levin et al., 2006). The 
expression of MMPs in cartilage and their role in maintaining normal cartilage and joint 
physiology presumably accounted for these deleterious affects (Itoh et al., 2002). Findings 
from these studies suggest that the function of MMPs in both the pathogenesis of glioma 
tumors and its role in normal physiology are more complex than is currently understood. 
Additionally, these findings suggest that other proteases that play less of a role in 
maintaining normal physiology while still mediating aspects of glioma tumor invasion may 
be better candidates for therapeutic intervention. 
Specific ADAMTS family members exemplify proteases that are attractive therapeutic 
candidates on the basis of their contribution to glioma tumor invasion and disease 
progression and seemingly less critical role in maintaining normal physiology (Majumdar et 
al., 2007; Nakada et al., 2005). Interestingly, the expression and activity of ADAMTS-4 and 5 
are enriched in human glioma tumors relative to normal adult brain (Held-Feindt et al., 
2006), with the expression of ADAMTS-5 being the most significantly upregulated in glioma 
(Nakada et al., 2005). Their expression has been shown to contribute significantly to glioma 
invasion and disease progression, which is mediated by their ability to cleave components 
of the extracellular matrix such as B/b (Matthews et al., 2000; Nakada et al., 2005) and 
versican (Sandy et al., 2001). Therefore, the preferred substrates of ADAMTS-4 and 5 in the 
CNS are presumably more restricted than other proteases, favoring extracellular matrix 
components that are enriched in glioma tumors with CNS-specific expression. Importantly, 
ADAMTS-4 and 5 are seemingly dispensable for normal physiology, as double knockout 
animals exhibited no deleterious affects and were indistinguishable from controls 
(Majumdar et al., 2007). Thus suggesting that targeting the systemic expression of 
ADAMTS-4 and 5 would have fewer off-target effects. 
The pro-invasive contribution of ADAMTS-4 and 5 to proteolytic cleavage is further 
enhanced by recent work that described a novel molecular mechanism between these 
proteases and glioma produced ECM to facilitate glioma cell invasion. Importantly, the 
proteolytic cleavage of B/b by ADAMTS-4 and 5 was found to reveal cryptic binding sites 
on B/b to promote its motogenic effects (Hu et al., 2008).  The proteolytic cleavage 
fragments of B/b were shown to effectively bind to fibronectin, which caused the 
polymerization of fibronectin microfibrils surrounding the surface of the cell and increased 
glioma tumor cell adhesion and motility. The interaction between B/b and fibronectin was 
only observed for the N-terminal proteolytic cleavage fragment of B/b and not for the full-
length form of the protein. B/b mediated increases in cell adhesion and motility were found 
to be dependent on both its proteolytic processing and interaction with fibronectin, as a 
forced reduction in fibronectin expression attenuated the motogenic effects of B/b (Hu et al., 
2008). In the adult brain the proposed mechanisms would be inconceivable given the lack of 
fibronectin expression, however the tumor-specific expression of it by glioma cells enables 
mechanisms of B/b-mediated cell motility to proceed in a nervous system specific manner 
that is critically dependent on proteolysis. 
4. Tumoral cellular interactions within the extracellular space of the CNS 
4.1 Extracellular interactions mediate tumor cell invasion 
Dispersion of cells within the brain requires direct interactions of the tumor cells with the 
surrounding environment and ultimately activation of signaling pathways downstream of 
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these interactions. In gliomas, cellular interactions within the environment are mediated by 
a number of key receptor systems. 
The most well-studied matrix receptors are the Integrins. Integrins are a family of cell 
surface receptors that communicate changes in the extracellular environment to intracellular 
mediators by activating several signal transduction cascades. Integrins are comprised of a 
large family of heterodimeric transmembrane glycoproteins, the dimerization of different 
integrin subunits dictates the specificity and preference of these receptors for particular 
ECM components (Akiyama, 1996). In gliomas the tumor-specific overexpression of 
integrins V3 and V5 have been described along with their localization along blood 
vessels and on the surface of glioma tumor cells, suggesting they play a role in angiogenesis 
and cell motility (Bello et al., 2001; D'Abaco & Kaye, 2007; Gladson, 1996; Schnell et al., 
2008). Cilengitide, a synthetic RGD pentapeptide that acts as an inhibitor of integrins V3 
and V5, has shown promising clinical results and is now being evaluated in Phase III 
clinical trials (Nabors et al., 2007, Tabatabai et al., 2010). 
In addition to integrins, HA binding proteins like the lecticans mediate the interaction 
between the extracellular environment and glioma tumor cells. BEHAB/ brevican (B/b), a 
nervous-system specific lectican family member, is significantly upregulated in human 
glioma specimens relative to normal brain (Jaworski et al., 1996). The expression of B/b is 
limited to invasive tumors of glial phenotype within the intracranial environment, thus 
mirroring the restricted invasive profile of gliomas (Jaworski et al., 1996). Of importance, 
previous studies have shown that increased B/b expression led to elevated tumor cell 
invasion and tumor aggressiveness in animal models (Nutt et al., 2001b). Likewise, RNAi 
mediated knockdown of B/b decreased tumor cell invasion and reduces tumor 
aggressiveness leading to prolonged survival of animal models (RTM, unpublished 
findings).  It has been determined that the upregulation of B/b expression in gliomas occurs 
at both the level of transcription and translation, suggesting that a glioma-specific signaling 
pathway is responsible for regulating increased B/b expression (Gary et al., 2000; Viapiano 
et al., 2005). These unknown regulatory mechanisms represent potentially valuable 
therapeutic candidates, as they presumably would be regulators of glioma cell motility with 
nervous system and tumor specific expression. 
Understanding the function of B/b overexpression is challenging due to the presence of 
several post-translationally modified protein isoforms, all of which are present in glioma 
specimens at levels far greater than normal brain. These include the full-length secreted 
protein, proteolytic cleavage fragments, and tumor-specific isoforms B/bsia and B/bg 
(Viapiano et al., 2003, 2005). B/bsia is an over sialidated form of B/b, exhibiting typical post-
translational increases in sialic acid modifications observed in many neoplasms (Viapiano et 
al., 2005). B/bg is a hypoglycosylated full-length protein isoform resulting from decreased 
decoration of the full-length core protein with O-linked oligosaccharides. Interestingly, 
B/bg is bound to the cellular plasma membrane by unknown mechansisms that are 
distinct from those tethering other B/b isoforms to the cellular surface. While the exact 
contribution of the B/bg isoform to B/b-mediated increases in cell motility and invasion is 
undetermined, B/bg is the most highly upregulated isoform of B/b present in human and 
rodent glioma tumor specimens and its localization to the cellular plasma membrane is 
suggestive of an important pathogenic function (Viapiano et al., 2003, 2005). Both the tumor-
specific expression and cellular localization of B/bg make it an attractive therapeutic target 
for either its participation in B/b-mediated motogenic effects or for targeted drug delivery 
methods. 
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decoration of the full-length core protein with O-linked oligosaccharides. Interestingly, 
B/bg is bound to the cellular plasma membrane by unknown mechansisms that are 
distinct from those tethering other B/b isoforms to the cellular surface. While the exact 
contribution of the B/bg isoform to B/b-mediated increases in cell motility and invasion is 
undetermined, B/bg is the most highly upregulated isoform of B/b present in human and 
rodent glioma tumor specimens and its localization to the cellular plasma membrane is 
suggestive of an important pathogenic function (Viapiano et al., 2003, 2005). Both the tumor-
specific expression and cellular localization of B/bg make it an attractive therapeutic target 
for either its participation in B/b-mediated motogenic effects or for targeted drug delivery 
methods. 
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B/b also undergoes proteolytic processing by the ADAMTS-4 and 5 family members 
resulting in cleavage of the 150kDa full-length protein into a 50kDa and 100kDa N and C-
terminal cleavage fragments, respectively (Matthews et al., 2000, Viapiano, 2005). The 
proteolytic processing of B/b is required for B/b-mediated increases in tumor cell motility 
as discussed previously (Viapiano et al., 2008; Hu et al., 2008). The overexpression and 
proteolytic processing of B/b was found to activate Epidermal Growth Factor Receptor 
(EGFR) signaling resulting in elevated levels of fibronectin expression which was assembled 
into microfibrils at the cells surface in a B/b-dependent manner. Increased expression of 
integrin 3 and N-cadherin were also observed in response to B/b overexpression and these 
affects were found to be specific to glioma cells cultured in the presence of fibronectin (Hu et 
al., 2008). The summation of findings on B/b expression and function in glioma suggests 
that targeting B/b at the levels of transcriptional regulation, post-translational 
modifications, and proteolytic processing all represent novel avenues that could potentially 
reduce glioma tumor cell invasion. 
Versican, another member of the lectican family of CSPGs, is also highly expressed in 
glioma specimens along with other systemic cancer types like breast cancer. In human 
glioma specimens and cell lines many different spice variants of versican are overxpressed 
including both the nervous system-specific V2 isoform and the more broadly expressed 
V0/V1 isoforms (Arslan et al., 2007; Dours-Zimmerman & Zimmerman, 1994; Paulus et al., 
1996). The expression of versican in glioma has been linked to increased tumor size, 
angiogenesis and glioma cell motility (Zheng et al., 2004). Protein isoforms containing the 
G3 domain of versican, which consists of the C-terminal domains common to lectican family 
members, has been shown to be abundantly expressed in glioma specimens and play a role 
in regulating tumor growth and angiogenesis. Overexpression of the versican G3 domain in 
glioma cells resulted in tumors of increased size and enhanced vasculature in animal 
xenographs compared to controls. Versican G3 conditioned media was found to enhance 
endothelial cell adhesion, proliferation and migration. Furthermore, the overexpression of 
versican G3 was found to increase the expression of fibronectin and Vascular Endothelial 
Growth Factor (VEGF). The elevated expression levels of fibronectin and VEGF formed a 
complex with versican G3 that could be co-immunoprecipitated, the additive effects of all 
three components of the complex – versican, fibronectin and VEGF to endothelial cells 
exacerbated the effect that either component alone or in pairs had on the adhesion, 
proliferation and migration of endothelial cells, substantially increasing it (Zheng et al., 
2004). More recently, the ability of transforming growth factor - 2 (TGF- 2) was shown to 
have an enhancing effect on the expression of versican V0/V1 isoforms. Furthermore, the 
addition of TGF- 2 exerted a motogenic effect on glioma cells that was partially mediated 
by increased V0/V1 expression (Arslan et al., 2007). 
The overexpression of versican VI was found to induce neuronal differentiation of PC12 
cells, an immortal cell line used to model neural precursor cells, through an integrin-
dependent mechanism resulting from activation of EGFR and downstream signaling 
through ERK (Wu et al., 2004). While a versican-mediated affect on EGFR signaling in 
glioma tumor cells remains unexplored, mechanisms leading to B/b-mediated increases in 
cell invasion closely resemble those described for versican (Hu et al., 2008). Therefore it is 
interesting to speculate that overexpression of certain lecticans (B/b or versican or perhaps 
neurocan) by glioma tumor cells may be sufficient to mediate tumor cell motility by utilizing 
similar pathomechanisms stemming from increased fibronectin expression, EGFR activation, 
and integrin expression. Versican also undergoes proteolytic processing in glioma, however 
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the function of this cleavage in the pathogenesis of glioma remains unexplored (Westling et 
al., 2004). Versican represents an attractive therapeutic target for its functional role in glioma 
tumor growth, angiogenesis and cell motility. 
The pro-invasive function of proteoglycans like B/b and versican may be, in-part, mediated 
by their interaction with cell-surface receptors, like tenascins. Tenascins are large secreted 
extracellular glycoproteins that bind to the cell surface through interactions with integrins 
(Bourdon & Ruoslahti, 1989). Tenascin-C and tenasin-R have been shown to bind to 
proteoglycans with high affinity to bridge the molecular gap between secreted 
proteoglycans in the extracellular space and the cellular plasma membrane (Aspberg et al., 
1995, 1997; Barnea et al., 1994; Milev et al., 1997). Pioneering studies demonstrated that 
tenascin proteins are expressed by glioma cell lines in vitro and are present at higher levels 
in glioma specimens relative to normal brain tissue (Ventimiglia et al., 1992; Zagzag et al., 
1995). Additionally, the use of tenascin as an immobilized protein substrate was found to 
enhance human glioma cell migration through an 21 integrin-dependent mechanism 
(Deryugina and Bourdon, 1996). 
Subsequent to these studies, four tenascin family members were identified including 
tenascin-C, R, W, and X, all of which have been implemented in several physiological and 
pathophysiological functions including embryonic development, wound healing and are 
present in several solid tumor types. Tenascin-R expression is restricted to the CNS, while 
other tenascin family members are ubiquitously expressed (Hirata et al., 2009). The 
expressions of both tenascin-C and W have been identified surrounding tumor vasculature 
in glioma specimens, however tenascin-C is the best studied in glioma for its role in 
enhancing tumor cell invasion. In GBM patients, increased expression of tenascin-C is 
correlated with an adverse prognosis. Moreover, the endogenous expression of tenascin-C 
in GBM tumor cells was found to enhance cell invasion and correlated with reactive changes 
in the normal brain tissue surrounding GBM tumors in patients (Hirata et al., 2009).  Like 
several ECM components, tenascin-C-mediated increases in glioma cell invasion are 
dependent on proteolytic processing. In glioma tumor cells tenascin-C is cleaved 
predominantly by MMP-12, and the inhibition of MMP-12 activity attenuated tenascin-C 
mediated glioma cell invasion (Sarkar et al., 2006). The tumor-specific upregulation of 
tenascin-C along with its pro-invasive function make it an attractive therapeutic target for 
anti-invasive therapies and it has shown some promise in clinical trials (Riva et al., 1999a ,b). 
Another proteoglycan that has also been shown to interact with tenascins and is 
upregulated in glioma specimens is (RPTP)/ Phosphacan (Adamsky et al., 2001; Muller et 
al., 2003). RPTP is a transmembrane receptor tyrosine kinase phosphatase, which like the 
lecticans is also a CSPG bearing extensive decoration with CS-GAG chains. However unlike 
the lecticans, RPTP lacks an HA binding domain and does not interact directly with the HA 
scaffold of the neural extracellular space. The N-terminal protein domains of RPTP, are 
comprised of a carbonic anhydrase-like domain and a fibronectin type III-like domain. The 
central domain, which contains the transmembrane domain bears CS-GAG moieties that 
modulate the interaction of RPTP with several of its ligands, and the C-terminal protein 
domains are made up of two intracellular phosphatase domains (Peles et al., 1998). 
While the protein structures of RPTP and lectican CSPGs are highly divergent, both RPTP, 
neurocan and versican have several common ligands including tenascins, NCAM, L1-CAM, 
contactin, and Transient Axonal Glycoprotein 1 (TAG-1/ axonin-1) (Peles et al., 1998; Rauch 
et al., 2001). RPTP is encoded from the PTPRZ1 gene and has four known isoforms 
resulting from alternative splicing. These include the full-length receptor form RPTP, a 
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B/b also undergoes proteolytic processing by the ADAMTS-4 and 5 family members 
resulting in cleavage of the 150kDa full-length protein into a 50kDa and 100kDa N and C-
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al., 2008). The summation of findings on B/b expression and function in glioma suggests 
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modifications, and proteolytic processing all represent novel avenues that could potentially 
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complex with versican G3 that could be co-immunoprecipitated, the additive effects of all 
three components of the complex – versican, fibronectin and VEGF to endothelial cells 
exacerbated the effect that either component alone or in pairs had on the adhesion, 
proliferation and migration of endothelial cells, substantially increasing it (Zheng et al., 
2004). More recently, the ability of transforming growth factor - 2 (TGF- 2) was shown to 
have an enhancing effect on the expression of versican V0/V1 isoforms. Furthermore, the 
addition of TGF- 2 exerted a motogenic effect on glioma cells that was partially mediated 
by increased V0/V1 expression (Arslan et al., 2007). 
The overexpression of versican VI was found to induce neuronal differentiation of PC12 
cells, an immortal cell line used to model neural precursor cells, through an integrin-
dependent mechanism resulting from activation of EGFR and downstream signaling 
through ERK (Wu et al., 2004). While a versican-mediated affect on EGFR signaling in 
glioma tumor cells remains unexplored, mechanisms leading to B/b-mediated increases in 
cell invasion closely resemble those described for versican (Hu et al., 2008). Therefore it is 
interesting to speculate that overexpression of certain lecticans (B/b or versican or perhaps 
neurocan) by glioma tumor cells may be sufficient to mediate tumor cell motility by utilizing 
similar pathomechanisms stemming from increased fibronectin expression, EGFR activation, 
and integrin expression. Versican also undergoes proteolytic processing in glioma, however 
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the function of this cleavage in the pathogenesis of glioma remains unexplored (Westling et 
al., 2004). Versican represents an attractive therapeutic target for its functional role in glioma 
tumor growth, angiogenesis and cell motility. 
The pro-invasive function of proteoglycans like B/b and versican may be, in-part, mediated 
by their interaction with cell-surface receptors, like tenascins. Tenascins are large secreted 
extracellular glycoproteins that bind to the cell surface through interactions with integrins 
(Bourdon & Ruoslahti, 1989). Tenascin-C and tenasin-R have been shown to bind to 
proteoglycans with high affinity to bridge the molecular gap between secreted 
proteoglycans in the extracellular space and the cellular plasma membrane (Aspberg et al., 
1995, 1997; Barnea et al., 1994; Milev et al., 1997). Pioneering studies demonstrated that 
tenascin proteins are expressed by glioma cell lines in vitro and are present at higher levels 
in glioma specimens relative to normal brain tissue (Ventimiglia et al., 1992; Zagzag et al., 
1995). Additionally, the use of tenascin as an immobilized protein substrate was found to 
enhance human glioma cell migration through an 21 integrin-dependent mechanism 
(Deryugina and Bourdon, 1996). 
Subsequent to these studies, four tenascin family members were identified including 
tenascin-C, R, W, and X, all of which have been implemented in several physiological and 
pathophysiological functions including embryonic development, wound healing and are 
present in several solid tumor types. Tenascin-R expression is restricted to the CNS, while 
other tenascin family members are ubiquitously expressed (Hirata et al., 2009). The 
expressions of both tenascin-C and W have been identified surrounding tumor vasculature 
in glioma specimens, however tenascin-C is the best studied in glioma for its role in 
enhancing tumor cell invasion. In GBM patients, increased expression of tenascin-C is 
correlated with an adverse prognosis. Moreover, the endogenous expression of tenascin-C 
in GBM tumor cells was found to enhance cell invasion and correlated with reactive changes 
in the normal brain tissue surrounding GBM tumors in patients (Hirata et al., 2009).  Like 
several ECM components, tenascin-C-mediated increases in glioma cell invasion are 
dependent on proteolytic processing. In glioma tumor cells tenascin-C is cleaved 
predominantly by MMP-12, and the inhibition of MMP-12 activity attenuated tenascin-C 
mediated glioma cell invasion (Sarkar et al., 2006). The tumor-specific upregulation of 
tenascin-C along with its pro-invasive function make it an attractive therapeutic target for 
anti-invasive therapies and it has shown some promise in clinical trials (Riva et al., 1999a ,b). 
Another proteoglycan that has also been shown to interact with tenascins and is 
upregulated in glioma specimens is (RPTP)/ Phosphacan (Adamsky et al., 2001; Muller et 
al., 2003). RPTP is a transmembrane receptor tyrosine kinase phosphatase, which like the 
lecticans is also a CSPG bearing extensive decoration with CS-GAG chains. However unlike 
the lecticans, RPTP lacks an HA binding domain and does not interact directly with the HA 
scaffold of the neural extracellular space. The N-terminal protein domains of RPTP, are 
comprised of a carbonic anhydrase-like domain and a fibronectin type III-like domain. The 
central domain, which contains the transmembrane domain bears CS-GAG moieties that 
modulate the interaction of RPTP with several of its ligands, and the C-terminal protein 
domains are made up of two intracellular phosphatase domains (Peles et al., 1998). 
While the protein structures of RPTP and lectican CSPGs are highly divergent, both RPTP, 
neurocan and versican have several common ligands including tenascins, NCAM, L1-CAM, 
contactin, and Transient Axonal Glycoprotein 1 (TAG-1/ axonin-1) (Peles et al., 1998; Rauch 
et al., 2001). RPTP is encoded from the PTPRZ1 gene and has four known isoforms 
resulting from alternative splicing. These include the full-length receptor form RPTP, a 
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short-receptor form, a secreted form, phosphacan, which lacks the transmembrane regions 
and intracellular phosphatase domains, and a truncated secreted form, PSI (Phosphacan 
Short Isoform) (Garwood et al., 2003). RPTP expression is enriched in the CNS and is 
upregulated in human glioma tumors along with its soluble ligand pleiotrophin (PTN)/ HB-
GAM relative to normal brain (Muller et al., 2003). Upon binding to PTN, RPTP receptors 
cluster resulting in the inactivation of endogenous phosphatase activity, which leads to 
increased phosphorylation of downstream effector molecules like -catenin. 
Phosphorylation of -catenin stabilizes the protein and facilitates canonical -
catenin/cadherin and WNT pathway signaling, which have implications in cell motility, 
proliferation and cell fate decisions (Meng et al., 2000). In glioma tumor cells, RNAi 
mediated knockdown of RPTP in a human glioma cell line reduced the size of engrafted 
tumors in rodent models and decreased the proliferation rate of tumor cells in vitro. The 
reduction in RPTP expression also decreased PTN-mediated increases in cell proliferation 
and motility (Ulbricht et al., 2006). A similar study also found that RPTP knockdown cells 
had reduced motility on a PTN-immobilized substrate but did not see any affects on cell 
proliferation (Muller et al., 2003). Given that RPTP is upregulated in human glioma tumors, 
localized to the cellular surface and regulates complex cellular behaviors that contribute to 
glioma pathogenesis, RPTP is a prime candidate target for future glioma therapies. Both 
cell-ECM and cell-cell adhesion molecules play critical roles in translating changes in the 
extracellular environment to alterations in the cellular cytoskeleton 
4.2 Intercellular interactions mediate tumor cell invasion 
While interactions with the ECM mediate aspects of glioma invasion, this process also 
involves interactions between both adjacent tumor cells and tumor cells with normal cells 
within the CNS, which are typically mediated by cell adhesion molecules.  
Cell-cell adhesion molecules typically exhibit homophilic binding to mediate intercellular 
interactions with adjacent cells expressing the same cell-adhesion molecule but have also 
been shown to interact with constituents of the ECM through heterophilic binding (Hinsby 
et al., 2004). In addition to mediating intercellular adhesion, molecules like the 
Immunoglobulin (Ig) superfamily of Cell Adhesion Molecules (CAMs) and cadherins also 
modulate signal transduction cascades to translate extracellular interactions into 
intracellular changes by impinging on the activation of receptor tyrosine kinases, molecular 
components of the WNT signaling cascade, and RhoGTPases  (Cavallaro & Christofori, 
2004). The functional roles of cell-cell adhesion molecules in glioma invasion are complex, as 
either their ability to enhance or inhibit glioma cell motility is dependent on both post-
translational modifications and interactions with specific ligands. Neuronal- cadherin (N-
cadherin) provides an exemplary model of this, as the degree of organization and 
maturation of N-cadherin cell-cell junctions impacts the migratory capacity of glioma cells, 
wherein more organized cell-cell junctions inhibit cell motility. However, the organization 
and maturation of cell-cell junctions depends critically on the presence or absence of specific 
ECM ligands (Perego et al., 2002). As a result of these complex biochemical underpinnings, 
the expressions and functions of specific cell-cell adhesion molecules have been 
differentially reported, most likely resulting from context-specific interactions that have yet 
to be fully understood. 
The Ig-CAMs play important roles in cell migration and invasion in several physiological 
and pathophysiological functions including development, wound healing and cancer 
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metastasis. The Neural Cell Adhesion Molecule (NCAM) has a complex role in mediating 
aspects of glioma tumor cell adhesion, migration and invasion. The overexpression of 
NCAM was found to decrease glioma tumor cell motility through non-homophilic 
interactions by blocking binding of glioma tumor cells to extracellular substrates. Both the 
intracellular and extracellular portions of the NCAM receptor independently were found to 
block glioma cell motility, for which the extracellular Ig domains were determined to be 
critical. Therefore the attenuation of motility by the overexpression of the NCAM 
extracellular domain was believed to be due to the heterophilic interaction of the Ig domains 
with a constituent of the ECM thereby competing off endogenous motogenic receptors (Prag 
et al., 2002). More recently, a loss of NCAM expression in gliomas of increasing WHO grade 
was determined, suggesting that the negative regulation of NCAM is involved in glioma 
progression.  The loss of NCAM expression was also correlated with more diffuse brain-
tumor interfaces (Duenisch et al. 2011). 
Interestingly, NCAM is the major substrate for Poly Sialic Acid (PSA) modifications 
resulting in PSA-NCAM. The overexpression of enzymes that attach the PSA moiety 
resulted in increased invasion of intracranial grafts compared to PSA negative NCAM alone. 
Furthermore, increased tumor cell invasion was observed for both PSA positive and 
negative NCAM glioma tumor cells in NCAM knockout mice, lacking NCAM expression in 
the nervous system environment, suggesting that the PSA modification serves to attenuate 
NCAM homophilic interactions to mediate increased glioma cell invasion (Suzuki et al., 
2005). Furthermore, the expression of PSA-NCAM was found to correlate with an adverse 
progonisis for GBM patients (Amoureux et al. 2010). Therefore the negative regulation of 
NCAM homophilic binding resulting from either a decrease in NCAM expression or the 
glycosylation of NCAM to yield PSA-NCAM enhances glioma tumor cell motility and 
invasion. 
The cadherin family members are calcium dependent cell-cell adhesion molecules that 
interact with catenins to signal changes in the actin cyctoskleton. Studies have demonstrated 
that N-cadherin is expressed by glioma cells, however conflicting evidence exists as to the 
function of this expression (Barami et al., 2006).  Regardless of these conflicting reports, it 
has been determined that N-cadherin proteolytic cleavage by the ADAMTS-related protease 
ADAM-10 is a key mediator of GBM cell motility (Kohutek et al., 2009). Both epithelial-
cadherin (E-cadherin) and N-cadherin have been found to play important roles in mediating 
glioma tumor cell motility with the CNS, but recent studies suggest that elevated E-cadherin 
levels at the expense of N-cadherin in glioma cell lines has been associated with increased 
tumor aggressiveness (Lewis-Tuffin et al. 2010). Further investigation into the complex 
pathomechanisms of cell-cell adhesion molecules and their heterophilic interactions with 
ligands of the ECM in the context of glioma cell dissemination is important to 
understanding the macroscopic contribution of the neural extracellular environment to 
glioma invasion and progression. 
5. Glioma tumor initiating cells and the neural ECM 
In addition to the ability of glioma tumor cells to invade the normal surrounding brain 
tissue, another major therapeutic obstacle is the presence of a tumor stem cell-like 
population of cells that reside within the solid tumor mass. This small cellular 
subpopulation is resistant to radiotherapy and capable of repopulating the original parental 
tumor leading to tumor recurrence and disease progression (Chalmers, 2007). Interestingly, 
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short-receptor form, a secreted form, phosphacan, which lacks the transmembrane regions 
and intracellular phosphatase domains, and a truncated secreted form, PSI (Phosphacan 
Short Isoform) (Garwood et al., 2003). RPTP expression is enriched in the CNS and is 
upregulated in human glioma tumors along with its soluble ligand pleiotrophin (PTN)/ HB-
GAM relative to normal brain (Muller et al., 2003). Upon binding to PTN, RPTP receptors 
cluster resulting in the inactivation of endogenous phosphatase activity, which leads to 
increased phosphorylation of downstream effector molecules like -catenin. 
Phosphorylation of -catenin stabilizes the protein and facilitates canonical -
catenin/cadherin and WNT pathway signaling, which have implications in cell motility, 
proliferation and cell fate decisions (Meng et al., 2000). In glioma tumor cells, RNAi 
mediated knockdown of RPTP in a human glioma cell line reduced the size of engrafted 
tumors in rodent models and decreased the proliferation rate of tumor cells in vitro. The 
reduction in RPTP expression also decreased PTN-mediated increases in cell proliferation 
and motility (Ulbricht et al., 2006). A similar study also found that RPTP knockdown cells 
had reduced motility on a PTN-immobilized substrate but did not see any affects on cell 
proliferation (Muller et al., 2003). Given that RPTP is upregulated in human glioma tumors, 
localized to the cellular surface and regulates complex cellular behaviors that contribute to 
glioma pathogenesis, RPTP is a prime candidate target for future glioma therapies. Both 
cell-ECM and cell-cell adhesion molecules play critical roles in translating changes in the 
extracellular environment to alterations in the cellular cytoskeleton 
4.2 Intercellular interactions mediate tumor cell invasion 
While interactions with the ECM mediate aspects of glioma invasion, this process also 
involves interactions between both adjacent tumor cells and tumor cells with normal cells 
within the CNS, which are typically mediated by cell adhesion molecules.  
Cell-cell adhesion molecules typically exhibit homophilic binding to mediate intercellular 
interactions with adjacent cells expressing the same cell-adhesion molecule but have also 
been shown to interact with constituents of the ECM through heterophilic binding (Hinsby 
et al., 2004). In addition to mediating intercellular adhesion, molecules like the 
Immunoglobulin (Ig) superfamily of Cell Adhesion Molecules (CAMs) and cadherins also 
modulate signal transduction cascades to translate extracellular interactions into 
intracellular changes by impinging on the activation of receptor tyrosine kinases, molecular 
components of the WNT signaling cascade, and RhoGTPases  (Cavallaro & Christofori, 
2004). The functional roles of cell-cell adhesion molecules in glioma invasion are complex, as 
either their ability to enhance or inhibit glioma cell motility is dependent on both post-
translational modifications and interactions with specific ligands. Neuronal- cadherin (N-
cadherin) provides an exemplary model of this, as the degree of organization and 
maturation of N-cadherin cell-cell junctions impacts the migratory capacity of glioma cells, 
wherein more organized cell-cell junctions inhibit cell motility. However, the organization 
and maturation of cell-cell junctions depends critically on the presence or absence of specific 
ECM ligands (Perego et al., 2002). As a result of these complex biochemical underpinnings, 
the expressions and functions of specific cell-cell adhesion molecules have been 
differentially reported, most likely resulting from context-specific interactions that have yet 
to be fully understood. 
The Ig-CAMs play important roles in cell migration and invasion in several physiological 
and pathophysiological functions including development, wound healing and cancer 
The Neural Extracellular Matrix, Cell Adhesion Molecules 
and Proteolysis in Glioma Invasion and Tumorigenicity 
 
251 
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constituents of the neural ECM and cell-cell adhesion molecules are also implicated in the 
pathomechanisms of this small but lethal cellular subpopulation. 
5.1 Cancer initiating cells are present in human glioma tumors 
Cancer initiating cells (CICs) also called “cancer stem cells” were initially identified in 
human leukemia, and have since been described in several solid tumor types including 
gliomas (Galli et al., 2004; Singh et al., 2003, 2004 ). CICs were first isolated from human 
glioma tumors by culturing tumor cells in a media composition that closely resembles 
neural stem cell media, comprised of a serum-free base with Epidermal Growth Factor 
(EGF) and basic Fibroblast Growth Factor (bFGF). The resulting GIC population exhibited 
several distinct phenotypic characteristics from other glioma tumor cells, which serve as 
criterion to operationally define GICs and are: 1. the ability to self-renew, 2.  multipotency – 
the ability to differentiate into every cellular subclass present within the CNS, and 3. the ability 
to phenotypically recapitulate the original parental tumor upon orthotopic transplantation 
(Galli et al., 2004; Singh et al., 2004). The presence of a GIC subpopulation within human 
glioma tumors suggests a complex intratumoral heterogeneity, wherein GICs are molecularly 
and phenotypically distinguishable from other glioma tumor cells. Recent evidence suggests 
that GICs are highly refractory to current adjuvant therapeutic treatments resulting from their 
slow progression through the cell cycle and upregulation of DNA repair mechanisms (Bao et 
al., 2006).  According to the controversial “cancer stem cell hypothesis”, CICs maintain stem-
like characteristics that fuel the growth of the tumor by giving rise to all other tumor cell types 
through a process that closely resembles normal cellular differentiation and effective 
eradication of tumors requires the ablation of the CIC population. 
While a significant amount of research supports the role of GICs in the pathophysiology of 
gliomas and the resemblance of GICs to their glial and neural stem cells counterparts, the 
utility of GICs as a model for primary glioma tumors is unparalleled. Initial evidence 
suggested that glioma tumor cells cultured in serum free media with EGF and bFGF more 
closely resembled original parental tumors both molecularly and phenotypically than serum 
cultured cell lines (Lee et al., 2006). These findings were seminal as they suggested, 
regardless of the controversy surrounding “cancer stem cells”, that GICs are likely a more 
representative model of primary glioma tumors than traditional serum cultured cell lines.  
GICs are highly tumorigenic and a significant amount of research has gone into identifying 
molecular markers of the most highly tumorigenic subpopulation. Although controversial, 
CD133 expression has been correlated to increased GIC tumorigenicity (Campos & Herold-
Mende, 2011). While both CD133+ and CD133- GIC cells have been found to be highly 
tumorigenic, recent evidence suggests that two subpopulations of CD133- cells are present 
within glioma tumors; one which is tumorigenic and gives rise to CD133+ cells and another 
that is not (Chen et al., 2010). Thus offering a solution to the long-standing conundrum 
surrounding the correlation between CD133 expression and tumorigenicity. 
5.2 Neural extracellular matrix expression denotes subtypes of gliomas and glioma 
initiating cells 
High-grade gliomas, glioblastoma muliforme, were so named for the considerable intra as 
well as intertumoral heterogeneity observed across individual glioma tumors. In efforts to 
better characterize glioma subtypes and begin an investigation into the value of 
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individualized patient-tailored therapies, molecular subclasses of hundreds of primary 
glioma tumors were evaluated on the basis of their gene expression profile signatures. In 
this seminal study by Phillips and colleagues, three molecular subpopulations of glioma 
tumors were identified proneural, proliferative, and mesenchymal (Phillips et al., 2006). The 
identification of different molecular subclasses of glioma tumors set the stage for an 
investigation into the presence of distinct molecular subtypes of GICs. Gunther and 
colleagues created GIC cell lines from nine human GBM tumors and their molecular gene 
profile signatures determined (Gunther et al., 2008). Interestingly, two distinct molecular 
subpopulations of GICs emerged as separate clusters, cluster-1 and cluster-2. GIC cell-lines 
belonging to cluster-1 cells grew as spheres, had increased multipotency, expressed high 
levels of CD133, and created highly invasive intracranial tumors. In contrast, cluster-2 GICs 
grew as adherent or semi-adherent cultures, were restricted in cell fate, had little or no 
expression of CD133 expression, and exhibited low tumorigenicity and resulted in poorly 
invasive tumors in vivo (Gunther et al., 2008). 
Lottaz and colleagues determined that cluster-1 GICs were most similar to proneural GBM 
tumors, while cluster-2 GICs were closely related to the mesenchymal GBM subtype (Lottaz 
et al., 2010). In accordance with these findings, the expression of BCAN was specifically 
enriched in the proneural GBM subtype and cluster-1 GICs which were found to be more 
highly tumorigenic than cluster-2 GICs and correlated with increased CD133 expression 
(Gunther et al., 2008). Work from our own lab has replicated these findings demonstrating 
that B/b is highly expressed by GICs with a phenotype similar to that described for cluster-1 
cells. While the exact function of B/b expression by GICs is currently under investigation, 
the unique pathophysiological properties of GICs suggest that B/b may have broader 
functionality than observed in terminally differentiated glioma tumor cells. Likewise the 
restricted expression of CD44 was also identified in cluster-2 GICs along with integrins 1 
and 5 (Gunther et al., 2008), again suggesting that differential expression of neural ECM 
components may contribute to differences in the pathophysiology of distinct molecular 
subclasses of GICs. The identification of neural ECM expression by GICs suggests that 
molecular constituents of the neural ECM could be employed as therapeutic targets that also 
impinge on the highly tumorigenic GIC subpopulation to reduce tumor recurrence and 
improve patient prognosis. Further research is needed to characterize the function of neural 
ECM components and cell adhesion molecules in the GIC population to fully evaluate  
the efficacy of targeting their expression to improve the prognosis of patients with GBM 
tumors. 
5.3 The neural extracellular matrix and glioma initiating cells 
While the function of neural ECM expression by GICs remains largely unknown, GICs are 
phenotypically and molecularly similar to normal neural stem cells (NSCs) (Rebetz et al., 
2008). Suggesting that the microenvironment, or stem cell-like niche, surrounding GICs may 
share several parallels with the composition and function of the microenvironment 
surrounding NSCs during neurodevelopment and in the adult brain (Denysenko et al., 
2010). In support of this hypothesis, the stem-cell niche that comprises the normal NSC 
microenvironment contains elevated levels of several ECM components whose expressions 
are enriched in GICs and gliomas including but not limited to laminin (Shen et al., 2008) and 
tenascin-C (Garcion et al., 2004). Moreover, NSCs themselves have been shown to express 
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constituents of the neural ECM and cell-cell adhesion molecules are also implicated in the 
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the same neural ECM constituents expressed by GICs including the lectican family members 
(Kabos et al., 2004), phosphacan/ RPTP (Abaskharoun et al., 2010b, a), tenascin-C 
(Abaskharoun et al., 2010a), integrin 61 (Shen et al., 2008). 
Of importance, both GICs and NSCs reside in highly vascularized niches and are often 
localized surrounding blood vessels (Gilbertson and Rich, 2007; Shen et al., 2008). Normal 
NSCs reside in the subventricular zone (SVZ) of the developing brain, which is inherently 
highly vascularized (Shen et al., 2008). In the adult SVZ, the association between endothelial 
cells comprising the vasculature of the stem cell microenvironment and NSCs are mediated 
by an interaction between laminin on endothelial cells and a major laminin binding integrin, 
61. The inhibition of integrin 6 was found to disrupt the association between endothelial 
cells and NSCs and caused a significant decline in NSC proliferation. These findings 
highlight the functional significance of a close association between vascular endothelial cells 
and stem cells in maintaining their stem cell-like properties (Shen et al., 2008). Similar 
findings have also been reported for GICs, which further supports the hypothesis that the 
composition of the microenvironment surrounding GICs closely mirrors that for NSCs and 
as a result may have common functions in maintaining the stem cell-like state. 
In gliomas the vasculature that comprises the GIC microenvironment typically arises de 
novo as part of tumorigenesis, or as recent evidence suggests from the differentiation of 
GICs into endothelial cells (Ricci-Vitiani et al., 2010). The close association between tumor 
vasculature endothelial cells and GICs was found to be imperative for maintaining the stem 
cell-like phenotype of this cellular population (Williams et al., 2010). Moreover, the 
expression of integrin 6 was identified as a marker of GICs residing within the 
perivascular niche. The inhibition of this cell adhesion molecule was found to block the 
interaction between laminin on vascular endothelial cells and GICs, which subsequently 
impeded GIC self-renewal, proliferation, and tumorigenic capacity (Lathia et al., 2010). 
These studies suggest that targeting the microenvironment, or stem cell-like niche, 
surrounding GICs may be a therapeutically advantageous approach to force the GIC 
subpopulation out of its stem cell-like state and to become subsequently more responsive to 
adjuvant therapies. Therefore, the components that comprise this unique stem cell-like 
microenvironment surrounding GICs represent attractive therapeutic candidates to inhibit 
tumor recurrence. 
6. Conclusion 
The ability of glioma cells to interact with and invade into the extracellular environment 
within the CNS is a critical contributor to the pathogenesis of these tumors and poor patient 
prognosis. Gliomas modulate their surrounding environment through the expression of 
unique matrix elements and cleavage of the normal matrix. In addition, they alter 
expression of cell surface receptors to mediate unique interactions within this neural 
environment. Recently, work suggests that GICs also employ a similar strategy to surround 
themselves with a neurogenic microenvironment. Therefore, therapeutic interventions that 
interfere with the expressions of neural ECM constituents, cell surface receptors, and cell 
adhesion molecules may represent ideal targets both to impede glioma invasion and also the 
tumorigenic qualities of GICs, thus targeting two major contributors to tumor recurrence 
and disease progression. Further work understanding the role of the ECM in glioma tumor 
pathogenesis is critical to develop better strategies for treatment of patients with gliomas. 
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Glioblastoma multiforme (GBM) is among the most lethal of all human tumors, with the 
average survival of approximately 1 year from diagnosis (Avgeropoulos and Batchelor, 
1999). In glioblastomas, LOH 10q is the most frequent genetic alteration (69%), followed by 
EGFR amplification (34%), TP53 mutations (31%), p16INK4a deletion (31%), and PTEN 
mutations (24%)(Ohgaki and Kleihues, 2005).  
Treatments of patients with GBM include surgery, radiotherapy and parallel adjuvant 
chemotherapy (Stupp et al., 2005). While radiotherapy has been found to significantly 
prolong survival rates for GBM patients, a poor prognosis and radioresistance are typical 
characteristics of this disease (Stupp et al., 2007).  
The antitumoral drug Temozolomide (TMZ) constitutes, in combination with radiotherapy, 
the current standard of care for glioblastoma (Stupp et al., 2005). However, the action of 
TMZ may be counteracted in tumors by the expression of the DNA repair enzyme MGMT, 
which repairs TMZ-induced DNA lesions (Hegi et al., 2005). MGMT activity and resistance 
to TMZ were highly correlated, indicating that MGMT is a major predictor of response to 
TMZ in glioma cells (Hermisson et al., 2006). According to the authors, collectively, MGMT 
expression and TP53 status may become valuable parameters to predict cell responses to 
TMZ treatment in patients with GBM. Modulation of MSH6, PARP1 and NTL1, DNA repair 
genes involved in mismatch repair and base excision repair (BER), were found at 
transcription and protein levels in GBM cells resistant to TMZ (Zhang et al., 2010).  
Other genotoxic agents exert different effects in GBM cells with different TP53 status. UV 
light (UV-C) (Batista et al., 2009) and chloroethylating agents (ACNU and BCNU) (Batista et 
al., 2007), significantly induce apoptosis in TP53-mutated glioma cells, while WT TP53 cells 
are more sensitive to methylating agents, including TMZ (Hermisson et al., 2006; Roos et al., 
2007).  
Efforts have been made to overcome drug and radio-resistance of GBM cells, but the 
heterogeneity of these tumors seems to be critical, and molecular analysis is an important 
tool to elucidate the mechanisms underlying cellular responses to antitumoral agents. 
Recently, application of genome-scale methodologies has opened the opportunity to study 
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transcript profiles for thousands of genes simultaneously, thus providing a picture on how 
different biological processes can be modulated under irradiation, drug treatment or even 
between different cell types, on the basis of the lists of differentially expressed genes (either 
induced or repressed genes) provided by the microarray experiments. This approach allows 
comparisons between different biological situations (Tusher et al., 2001; Sakamoto-Hojo et 
al., 2003; Fachin et al., 2007; Fachin et al., 2009). In a previous work, several stress 
response/DNA repair genes, such as HSPA9B, INPP5A, PIP5K1A, FANCG, and TPP2 were 
found up-regulated in U343MG-a GBM cells analyzed at 6 h following irradiation with 1 Gy, 
reflecting the radio-resistance of these cells; at this condition, the survival rate was 61%, and 
a broad spectrum of other biological processes was found associated to the list of 
differentially expressed genes in irradiated cells (Bassi et al., 2008). 
TP53 gene plays a role in drug and radioresistance mechanisms, but the complex network of 
signaling pathways involving this gene is not well elucidated. TP53 is a multifunctional 
protein that acts in cell cycle blockage and signaling pathways towards DNA repair, 
contributing to the maintenance of genome integrity in response to a variety of genotoxic 
stresses (Bartussek et al., 1999). Alternatively, TP53 protein triggers a cascade of signaling 
pathways culminating in apoptosis, depending on the extent of DNA damage (Prise et al., 
2005). The TP53 protein is also a transcription factor that regulates the expression of a large 
number of target genes (Vogelstein et al., 2000). Many TP53 target genes have been 
described (el-Deiry, 1998; Horn and Vousden, 2007; Laptenko and Prives, 2006; Sbisa et al., 
2007), and some other targets have been computationally predicted by the analysis of their 
binding sites (Hoh et al., 2002; Smeenk et al., 2008; Veprintsev and Fersht, 2008).  
According to the literature data, there are controversial findings about the outcome of 
patients in relation to the TP53 status of tumors; this gene may positive or negatively 
influences the cell radioresistance, as well as it can exert no influence in cellular responses to 
therapies (McIlwrath et al., 1994; Slichenmyer et al., 1993; Smith et al., 1995).  
2. Objective  
In the present work, we aim to compare gene expression profiles displayed by four GBM 
cell lines in the absence of any kind of treatment, using the microarray method, looking for 
molecular signatures that can provide new clues towards the understanding of GBM 
biology and radioresistance mechanisms. The results on the transcriptional profiles 
presented by a number of genes with different biological functions are discussed on the light 
of literature data regarding GBM cell responses to ionizing radiation and antitumor drugs, 
generally provided by survival assays. 
3. Materials and methods  
3.1 GBM cell lines  
Human GBM U343 MG-a cell line was kindly donated by Dr. James T. Rutka (The Arthur 
and Sonia Labatt Brain Tumour Research Center, Canada), while T98G, U251MG, and 
U87MG were supplied by the American Type Culture Collection (ATCC) (Rockville, 
Maryland, USA). T98G and U251MG cell lines harbor three mutations (TP53, CDKN2A, and 
PTEN) while U343MG-a and U87MG cells are wild-type (WT) for TP53, and mutant (MT) 
for CDKN2A and PTEN genes (Ishii et al., 1999). 
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3.2 Cell culture and total RNA extraction 
For gene expression analysis, cells were thawed from the nitrogen and sub-cultured for four 
passages in the presence of HAM F10 + DEM medium plus 15% fetal bovine serum and kept 
at 37°C and 5% CO2. After the fourth sub-culturing, they were incubated for two days, and 
total RNA extraction was performed in replicate at 48 h, by using the Trizol reagent 
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. The quality of 
RNA samples was evaluated by denaturing agarose gel electrophoresis under standard 
conditions. To remove the contaminating DNA, RNA samples used in cDNA microarrays 
were treated with the Deoxyribonuclease I (Amplification Grade kit, Invitrogen), according 
to manufacturer’s instructions.  
3.3 cDNA microarray method 
Four experiments in duplicate using GBM cells were carried out using a glass slide 
microarray containing 4500 clones of cDNA probe (in duplicates) from the human IMAGE 
Consortium cDNA library [http://image.llnl.gov/image/; kindly provided by Dr. 
Catherine Nguyen (INSERM-CNRS, Marseille, France)], and prepared according to the 
protocol described by Hegde et al (2000).  
Microarrays were spotted onto glass slides (Corning) using a Generation III Array Spotter 
Amersham-Molecular Dynamics according to the manufacturer’s instructions. Each cDNA 
sample was spotted twice on the slide (duplicate spots). The cDNA complex probes were 
prepared using the CyScribe Post Labelling Kit (Amersham Biosciences, England) (Fachin et 
al., 2009). Hybridizations were carried out using an automatic system (Automatic Slide 
Processor, Amersham Biosciences, England) and signals were immediately captured after 
the final wash procedure, using a Generation III laser scanner (Amersham Biosciences, 
England). 
In an attempt to characterize the clones present in the array slide, the gene set was 
submitted to the NIH-DAVID bioinformatic tool, in order to obtain biological functions 
associated with the gene sequences present in the arrays, as well as the number of genes 
associated with each biological process. Among all clones, 2334 were identified by official 
gene symbol (HUGO), distributed in classes according to biological processes (Table 1). 
3.3.1 Data acquisition and gene expression analysis 
The image quantification was performed using the Spot software, 
(http://spot.cmis.csiro.au/spot/, CSIRO, Australia). Filtering, normalization and data 
analysis were done using the R statistical environment (Ihaka and Gentleman, 1996), in 
addition to Limma (Smyth et al., 2005), Bioconductor (Ihaka and Gentleman, 1996), Aroma 
(Bengtsson, 2004) and KTH (Wirta, 2004). The background to each feature was subtracted 
from the foreground value. Furthermore, the spots were evaluated by their circularity and 
calculations on the median versus mean deviation, so that those presenting irregular 
circularity, or with large differences between mean and median values, were considered 
unreliable. The raw data (red – R and green – G) was transformed into MA format before 
normalization, where M = log2(R/G) and A = 1/2 × log2(R × G). These procedures were 
followed by the application of the Print-tip Lowess normalization for each slide. Following 
the normalization procedure, microarray data were exported to tab-delimited tables in MEV 
format and analyzed in MEV (v. 3.1) software (Saeed et al., 2003). The microarrays data 
analysis involved the application of the statistical method SAM - Significance Analysis of  
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GOTERM-BIOLOGICAL PROCESS - FAT % PValue 
GO:0007242~intracellular signaling cascade 10.28 3.90E-09 
GO:0006793~phosphorus metabolic process 9.43 8.50E-16 
GO:0006468~protein amino acid phosphorylation 6.73 6.81E-13 
GO:0008104~protein localization 6.68 2.00E-04 
GO:0042981~regulation of apoptosis 6.47 1.20E-05 
GO:0007049~cell cycle 5.96 2.63E-04 
GO:0033554~cellular response to stress 5.78 1.27E-11 
GO:0006259~DNA metabolic process 4.50 4.42E-06 
GO:0006974~Response to DNA damage stimulus 4.07 5.32E-10 
GO:0006281~DNA repair 3.43 8.95E-11 
GO:0007243~protein kinase cascade 3.43 1.53E-05 
GO:0007167~enzyme linked receptor protein 
signaling pathway 3.08 1.04E-04 
GO:0009314~response to radiation 1.93 5.82E-04 
GO:0000165~MAPKKK cascade 1.89 1.69E-04 
GO:0022604~regulation of cell morphogenesis 1.41 4.85E-04 
GO:0006310~DNA recombination 1.29 9.19E-05 
GO:0031344~regulation of cell projection 
organization 1.11 2.05E-04 
GO:0006302~double-strand break repair 0.94 3.35E-05 
GO:0006289~nucleotide-excision repair 0.86 5.76E-05 
GO:0050770~regulation of axonogenesis 0.81 3.26E-04 
GO:0051291~protein heterooligomerization 0.77 2.99E-04 
GO:0050772~positive regulation of axonogenesis 0.51 1.85E-04 
GO:0000723~telomere maintenance 0.51 6.05E-04 
GO:0032925~regulation of activin receptor 
signaling pathway 0.30 7.62E-04 
Table 1. Percentage of genes for each biological process analyzed for a total of 2334 genes 
present in a glass slide microarray. The array gene set (containing 4300 image clones) was 
submitted to NIH-DAVID (Dennis et al. 2003).  
Microarray (Tusher et al., 2001), with the objective to compare MT versus WT TP53 cell lines 
in terms of expression profiles. We used FDR< 0.68% to select only highly significant 
differentially expressed genes. 
Information regarding biological functions were obtained at S.O.U.R.C.E. (http://genome-
www5.stanford.edu/cgi-bin/SMD/source/source), and NCBI (http://www.ncbi. 
nlm.nih.gov/). Gene functional groups were given by DAVID tool (Dunne et al., 2003), 
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choosing Homo sapiens as the current background, Gene Ontology: GOTERM_BP_FAT as 
parameters, and Functional Annotation Chart as the analyzing tool. The main biological 
functions associated to the list of differentially expressed genes were selected.   
Every modulated gene was compared to a list of previously identified genes with TP53 
binding sites using genome-wide tiling Chromatin immunoprecipitation (ChIP)-on-chip 
approach (Smeenk et al., 2008) or (ChIP) with the paired-end ditag (PET) (Wei et al., 2006) in 
order to point out genes that could be modulated by TP53 transactivation.  
4. Results  
4.1 Transcript profiles displayed by GBM cell lines  
4.1.1 Hierarchical cluster analysis 
Gene expression profiles studied by the cDNA microarray method generated interesting 
results about the transcriptional profiles exhibited by each cell line. Analysis of gene cluster 
uses standard statistical algorithms in order to arrange genes according to similarity of 
expression patterns, and the results can be graphically represented (Eisen et al., 1998). The 
analysis of hierarchical clustering was performed to compare MT and WT TP53 cells 
regarding transcript profiles by using a set of genes previously selected by the SAM 
analysis. The results of the hierarchical clustering showed that MT TP53 cells were grouped 
apart from the WT TP53 cells. The mutant cell lines (T98G and U251) were not separated 
within a gene cluster, indicating more similarity in the basal transcription levels between 
cell lines; in contrast, the proficient cell lines (U87 and U343) were clustered apart from each 
other (Fig.1). 
4.1.2 Differentially expressed genes indicated by Significant Analysis of Microarrays 
(SAM) 
The statistical analysis performed by SAM indicated that MT TP53 cell lines showed 29 
down-regulated and 68 up-regulated genes, compared with WT TP53 cells, for FDR ≤ 0.68%. 
For this small list of highly significant differentially expressed genes, the magnitude of fold-
changes ranged from –1.68 to +1.93 by comparing MT versus WT TP53 (Supp. Table 1). 
For the list of differentially expressed genes, biological gene functions were studied by the 
DAVID-NIH bioinformatic tool (Dennis et al., 2003; Huang da et al., 2009). Out of 97 
modulated genes, 73 were suitable for functional grouping procedure, since 10 genes were 
not grouped and 14 I.D. clones were still unknown. The most relevant categories 
(represented by a variable number of genes) were related to neurological system process 
(11%), regulation of apoptosis (10%), cellular response to stress (8%), regulation of cell 
proliferation (8%), cell-cell adhesion (5%), DNA repair (5%), response to ionizing radiation 
(4%), histone modification (4%), cell division (4%), etc. (Fig.2.). For discussion, we selected 
36 genes on the basis of biological functions that can be possibly related to responses to 
genotoxic agents (Table-2), in order to find out clues for understanding the mechanisms 
underlying the sensitivity or resistance to anticancer therapies. Some of candidate genes that 
may participate in chemo- and/or radioresistance are involved in stress responses (RUVBL2, 
ASNS, RNF8, LIG4 and CAV1) and cell adhesion (CDH8, CDH13, CD93 and ITGA5), and 
other important cathegories, such as regulation of cell proliferation (IGF1R, CDH13, CAV1, 
DUSP22, ADAMTS1, LIG4) and apoptosis (IGF1R, CDH13, IFT57, CRH, HSPB1, ASNS and 
LIG4.  
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Fig. 1. Hierarchical clustering obtained for a gene set previously selected by the SAM 
method (FDR≤0.68%) for the results displayed by four GBM cell lines (T98G, U251MG, 
U343MG-a e U87MG), under normal proliferation in culture. The data set was provided by 4 
experiments in duplicate. Experiments are represented by numbers (1-4) and the replicates 
are represented by letters (A and B). The expression level of each gene is represented 
according to the scale at the top (red indicates induction; green means repression; grey color 
represents data loss). 
 




Fig. 2. Main Biological functions associated to the list of differentially expressed genes (out 
of 97 genes, 73 genes were recognized by the system) when comparing MT and WT TP53 
GBM cell lines. The results were analyzed by DAVID-NIH (Dennis et al., 2003; Huang da et 
al., 2009) as a bioinformatic tool to group differentially expressed genes according to their 
functions. 
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A comparative analysis of differentially expressed genes (obtained by SAM) was carried out 
with previously identified genes with TP53 binding sites using ChIP-PET and ChIP-on-chip 
analysis (Smeenk et al., 2008; Wei et al., 2006). When comparing with ChIP- PET gene lists, 
we observed only one common gene (LASS6), while the comparison involving the gene list 
of our work with the ChIP-on-chip list, we found five common genes (ARSJ, RCC2, CDH8, 
CDH13 and HTRA1). 
5. Discussion  
Expression profiles displayed by GBM cells provided results to compare these cells  with 
other tumor types (Castells et al., 2010; Castells et al., 2009; Dreyfuss et al., 2009; Marucci et 
al., 2008; Reddy et al., 2008),  normal tissues  (Sallinen et al., 2000), or even regions in the 
same tumor (Mehrian Shai et al., 2005). However, there is no data in the literature 
comparing transcript profiles of GBM cell lines presenting similar genetic background. 
While T98G and U251MG harbor mutations for TP53, CDKN2A, and PTEN, U343MG-a and 
U87MG cell lines differ from others by the presence of a known WT TP53 (Ishii et al., 1999). 
Expression profiles displayed by GBM cell lines were studied in the absence of any 
treatment. The hierarchical clustering analysis compared WT and MT TP53 GBM cells 
regarding transcript profiles using a set of highly significant differentially expressed genes 
previously selected by SAM (FDR ≤ 0.68%). The results showed distinct expression profiles 
for WT TP53 and MT TP53 cells, whose patterns separate the mutant from WT cells. The 
mutant cell lines (T98G and U251MG) were not completely separated from each other 
within the cluster, indicating similarity of transcript patterns between the two cell lines. In 
contrast, TP53 proficient cell lines (U87MG and U343MG-a) were clustered apart from each 
other. These results indicate the potential of the DNA microarray analysis to discriminate 
molecular profiles displayed by GBM cell lines presenting similar mutational background 
for CDKN2A and PTEN genes, but with different TP53 status. 
The statistical analysis performed by SAM (FDR ≤ 0.68%) indicated that MT TP53 cell lines 
showed 28 down-regulated and 66 up-regulated genes, when compared to WT TP53 cells 
(Table. 2). For the list of differentially expressed genes, biological gene functions were 
studied by the DAVID-NIH bioinformatic tool (Dennis et al., 2003; Huang da et al., 2009), 
and several biological processes were associated to the list of significant differentially 
expressed genes, such as: metabolism, response to ionizing radiation, cell adhesion, cell 
motion, apoptosis, DNA repair and transcription. 
In addition, metabolic process was directly related with several biological functions as 
follow: insulin receptor signalling, water soluble vitamin metabolic process, steroid 
hormone receptor signalling, cellular response to nutrient levels, amine biosynthetic process, 
lipid biosynthetic process, calcium ion transport, lipid transport, glucose metabolic process, 
carboxylic acid biosynthetic process, and cellular amino acid derivative metabolic process.  
Other gene functions related to learning/memory, regulation of neuron apoptosis, synaptic 
transmission, and neurological system processes are intrinsic to the neural nature of GBM 
cells. DNA and RNA metabolism/regulation were also associated to several differentially 
expressed genes (Table. 2).  
Three genes (RNF8, CAV1 and LIG4) playing roles in ionizing radiation responses were 
found up-regulated in MT TP53 cells, and this feature may influence the responsiveness to 
radiotherapy. It is already known that ionizing radiation causes DNA double-strand breaks 
(DSBs) that are highly cytotoxic lesions. Cells have a complex DNA-damage response that  
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SPRY2 40262 cell-cell signaling, development, organogenesis, regulation of signal transduction 1.93 0.00 
CAV1 24651 cellular calcium ion homeostasis, cholesterol efflux, response to gamma radiation, regulation of apoptosis, 1.86 0.00 
CDH13 31093 cell adhesion, homophilic cell adhesion 1.61 0.00 
HTRA1 132044 proteolysis and peptidolysis, regulation of cell growth 1.55 0.00 
ADAMT
S1 34684 
integrin-mediated signaling pathway, negative 
regulation of cell proliferation, heart trabecula formation, 
kidney development, ovulation from ovarian follicle, 
proteolysis 
1.54 0.00 
ITGA5 135671 cell-matrix adhesion, integrin-mediated signaling pathway 1.35 0.75 
GPR68 22652 G-protein coupled receptor protein signaling pathway, inflammatory response, signal transduction 1.34 0.00 
GPR44 25625 
G-protein coupled receptor protein signaling pathway, 
immune response, calcium-mediated signaling, 
chemotaxis 
1.34 0.75 
RUVBL2 22267 chromatin modification, DNA recombination, DNA repair, regulation of growth, regulation of transcription 1.33 0.00 
MKLN1 33715 cell motility, cell-matrix adhesion, signal transduction 1.31 0.00 
KSR1 220655 Ras protein signal transduction, intracellular signaling cascade, protein amino acid phosphorylation 1.31 0.75 
GNG13 178213 G-protein coupled receptor protein signaling pathway, signal transduction 1.30 0.75 
CDH8 38939 cell adhesion, homophilic cell adhesion 1.30 0.00 
DNAJA
1 24473 protein folding, response to unfolded protein 1.28 0.75 
RHOQ 131061 small GTPase mediated signal transduction 1.26 0.00 
FBXL3 25778 protein ubiquitination 1.26 0.00 
CRH 34671 immune response, learning and/or memory, pregnancy, signal transduction,  synaptic transmission 1.24 0.00 
IGF1R 21519 
axonogenesis, brain development, exocrine pancreas 
development, male sex determination, regulation of 
apoptosis 
1.24 0.00 
ASNS 27208 amino acid biosynthesis 1.23 0.90 
CD93 35503 cell-cell adhesion, macrophage activation, phagocytosis 1.19 0.00 
COPB2 24627 intracellular protein transport, vesicle-mediated transport 1.18 0.00 
CACNB
2 34651 Synaptic transmission, ion transport 1.16 0.71 
LASS6 35147 lipid biosynthetic process, regulation of transcription, DNA-dependent 1.15 0.75 
LIG4 39274 single strand break repair 1.14 0.75 
RNF8 39161 protein ubiquitination 1.14 0.00 
 
Molecular Targets of CNS Tumors 
 
272 
A comparative analysis of differentially expressed genes (obtained by SAM) was carried out 
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studied by the DAVID-NIH bioinformatic tool (Dennis et al., 2003; Huang da et al., 2009), 
and several biological processes were associated to the list of significant differentially 
expressed genes, such as: metabolism, response to ionizing radiation, cell adhesion, cell 
motion, apoptosis, DNA repair and transcription. 
In addition, metabolic process was directly related with several biological functions as 
follow: insulin receptor signalling, water soluble vitamin metabolic process, steroid 
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KCNIP4 21478 ion transport -1.13 0.00 
RCC2 136887 cell cycle, cell division, mitosis -1.14 0.90 
RBM4 141446 
DNA recombination, DNA repair, DNA replication, 
estrogen receptor signaling pathway, glucocorticoid 
receptor signaling pathway, mRNA splicing 
-1.19 0.00 
DENND
1A 21467 synaptic vesicle endocytosis -1.21 0.74 
HSPB1 23827 cell death, response to heat -1.23 0.00 
ARSJ 32854 Unknown -1.24 0.00 
ATP6AP
2 131821 
angiotensin maturation, positive regulation of 
transforming growth factor-beta1 production, regulation 
of MAPKKK cascade 
-1.29 0.00 
UGDH 139835 UDP-glucose metabolism, electron transport -1.41 0.00 
DUSP22 182999 apoptosis, cell proliferation, development, inactivation of MAPK, protein amino acid dephosphorylation -1.55 0.00 
PFKFB2 53158 glucose catabolic process, positive regulation of insulin secretion, pyruvate metabolic process -1.68 0.00 
Table 2. List of highly significant differentially expressed genes provided by SAM (FDR 
≤0.68%), comparing MT and WT TP53 GBM cell lines. Positive fold-change value means up-
regulation, while negative fold-change value means down-regulation in MT TP53 cells, 
compared to WT TP53 cells. 
includes the spatial reorganization of DSB repair and signalling proteins into subnuclear 
structures surrounding DSB sites (Bartek and Lukas, 2007; Maser et al., 1997). In this context, 
RNF8 protein is an important component of the DNA damage response; it can be recruited 
to the DNA damage sites, thus triggering the formation of ubiquitin conjugates, promoting 
the recruitment of important proteins to DSB sites, thereby enhancing DNA-damage 
checkpoint events (G2/M) and guaranting cell survival (Kolas et al., 2007). There is also 
evidence that RNF8 participates in histone ubiquitylation and protects the genome integrity 
by licensing the DSB-flanking chromatin to concentrate repair factors near the DNA lesions 
(Mailand et al., 2007). LIG4 is also a key protein playing role in DSB repair by non-
homologous end joining (NHEJ) pathway (Helleday et al., 2007), while CAV1 presents a 
tumor suppressor function in non-neoplastic tissue, being down-regulated upon 
transformation, but re-expressed upon progression in metastatic and multidrug-resistant 
tumors (Burgermeister et al., 2008). CAV1 was also associated with multidrug resistance 
(Belanger et al., 2004; Belanger et al., 2003), and radioresistance (Barzan et al., 2010; Cordes 
et al., 2007; Li et al., 2005). 
In MT TP53 cells, other stress response genes (RUVBL2 and ASNS) were up-regulated, while 
RBM4 was down-regulated. RUVBL2 participates in chromatin-remodelling (Lee et al., 
2010), which could also let the lesion available to DNA repair genes. ASNS is a gene whose 
response elements function as an enhancer to mediate the transcriptional activation of the 
gene, either by the amino acid response (AAR) or the unfolded protein response (UPR 
pathway), triggered by amino acid limitation or endoplasmic reticulum stress (Siu et al., 
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2002), respectively. These pathways initiate a wide array of adaptive mechanisms and 
ultimately, if necessary, programmed cell death (Harding et al., 2003; Zinszner et al., 1998);  
The role of RBM4 in response to stress stimulus is the activation of internal ribosome entry 
site (IRES)-mediated translation, promoting the expression of stress-response genes; 
therefore, the down-regulation of RBM4 in MT TP53 cells might compromise  the 
translational regulation of stress-associated mRNAs (Markus and Morris, 2009).  
 Several genes playing roles in cell adhesion were also differentially expressed in GBM cell 
lines, and this result is in accordance with the association of these genes in acquired chemo- 
and radioresistance (Kraus et al., 2002). In the present work, three cadherins (CDH8, CDH13 
and CD93), and one integrin ITGA5 were found up-regulated in MT TP53 cells, relatively to 
WT counterparts. Cadherins are integral membrane proteins that mediate calcium-
dependent cell-cell adhesion. They may play an important role in the development and 
maintenance of tissues, and possibly are involved in the invasion and metastasis of 
malignant tumors. While CDH8 participates in neural circuitry, CD93 is involved in 
phagocytosis (Bohlson et al., 2005), CDH13 play a role in apoptosis (Chan et al., 2008), and 
ITGA5 in cell spreading (Fang et al., 2010).  
A comparative analysis of differentially expressed genes (provided by SAM) was performed 
with previously identified genes with TP53 binding sites; this comparison was possible by 
using ChIP-PET and ChIP-on-chip analyses (Smeenk et al., 2008; Wei et al., 2006).  For the 
ChIP- PET gene lists, we observed only one common gene (LASS6), which was up-regulated 
in MT TP53 cells. LASS6 is a ceramide sintase, producing ceramides that have 
antiproliferative and pro-apoptotic effects (Ruvolo, 2003). This gene plays a role in apoptosis 
induction in colon cancer cells (Schiffmann et al., 2010), and enhanced tumor development 
and growth in vivo in human head and neck squamous cell carcinomas (HNSCCs) (Senkal et 
al., 2010). 
In addition, the comparison involving our modulated gene list, comparing MT and WT 
TP53 GBM cells, using the ChIP-on-chip list, provided five common genes: ARSJ, RCC2, 
CDH8, CDH13 and HTRA1). While CDH8, CDH13 and HTRA1 were up-regulated, ARSJ 
and RCC2 were down-regulated in MT TP53 cells. CDH8 and CDH13 are cadherins and 
were already discussed as possible targets to chemo- and radioresistance (Kraus et al., 
2002). HTRA1 is a tumor suppressor-like factor when overexpressed in cancer cell lines. 
(Baldi et al., 2002; Chien et al., 2004). This gene was also associated to cisplatin therapy 
responses in various cancer types (Catalano et al., 2011; Chien et al., 2006; Komatsu et al., 
2006). These genes cannot be transactivated by TP53, according to the TP53 status in T98G 
and U251MG cells. However, the majority of the genome-wide TP53 target sites can also 
be bounded by overexpressed p63 and p73 in vivo, suggesting that they may possibly 
play an important role at TP53 binding sites (Smeenk et al., 2008). ARSJ and RCC2 genes 
were not described to be related with stress responses or cancer, and were up-regulated in 
WT TP53 GBM cells, compared to MT, and probably, they can be associated to 
transactivation properties of TP53. 
Thus, in the present work, most genes involved in stress responses (RUVBL2, ASNS, 
RNF8, LIG4 and CAV1), cell adhesion (CDH8, CDH13, CD93 and ITGA5), and genes 
associated to p63 and p73 binding sites (LASS6 and HTRA1) were up-regulated in MT 
TP53 cells. At least some of them may have the potential to be directly involved in radio- 
or chemoresistance. Therefore, the loss of TP53 function may compromise cellular 
responses to anticancer agents. 
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responses to anticancer agents. 
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It is already known that mechanisms underlying the cellular radiosensitivity seem to vary 
among different cell lineages, but at what extent the radiosensitivity depends on TP53 
function is a matter of investigation since long time ago. Several authors demonstrated that 
the loss of TP53 function decreases the sensitivity of GBM cells to irradiation (Bartussek et 
al., 1999; McIlwrath et al., 1994; Roy et al., 2006; Yount et al., 1996), and the same was 
observed for other tumor types (Fan et al., 1994; Komarova et al., 1997; Merritt et al., 1994). 
However, in primary gliomas, the TP53 mutation confers an improved prognosis in adult 
glioma patients due to a better response to radiation therapy (Tada et al., 1998). This is 
consistent with the results obtained in in vitro studies, in which glioma cells lacking WT 
TP53 function were more susceptible to radiation-induced apoptosis than their isogenic 
counterparts expressing WT TP53 (Hara et al., 2004).  
It is important to emphasize that all these articles in the literature took into account the TP53 
status, but not other mutations inherent to GBM. In the present work, we studied four GBM 
cell lines with different TP53 status; T98G and U251MG are mutated and U343MG-a and 
U87MG are wild-type for TP53 gene, but they are similar regarding the fact that they harbor 
mutations for CDKN2A and PTEN, according to Ishi et al. (1999). In experiments on cell 
survival performed by the  clonogenic survival assay, the results provided by several 
authors indicated that MT TP53 cells were, in general, more radioresistant than WT TP53 
cells (Bassi et al., 2008; Chautard et al., 2010; de la Pena et al., 2006; Lee et al., 2006; Roy et al., 
2006). 
As described above, several differentially expressed genes provided by the comparison 
between MT versus WT TP53 GBM cells are involved in the mechanism of resistance to 
ionizing radiation and/or multidrug resistance. In general, cytotoxicity of DNA damaging 
agents correlates with the induction of DSB, which can be produced directly or indirectly 
into the DNA molecule. Whereas ionizing radiation induces DSB directly, the drug TMZ 
generates DSB only after two or more cycles of DNA replication, as a secondary effect 
(Caporali et al., 2004). Therefore, TP53 mutation has the potential to change the sensitivity of 
GBM cells to anticancer agents currently used in therapy, and probably, the changes in the 
expression profiles exhibited by several genes acting down-stream in the signalling cascade 
of damage responses may compromise the outcome of drug- and radio- therapies. In order 
to understand these alterations in terms of transcript profiles, we are currently studying at 
what extent TP53 status influences gene expression profiles in irradiated GBM cells 
(manuscript in preparation); we found several differentially expressed genes in irradiated MT 
TP53 cells that are probably implicated in tumor resistance; among them, we can mention 
CLSTN2, ROBO2, and BMPR1B (with role in cell-cell adhesion), BTRC, CYP26B1, and ANLN 
(cell cycle regulators). 
However, the data in the literature regarding the role of TP53 in mediating sensitivity to 
anticancer agents still present controversies. It has been reported that the absence of a 
functional TP53 increases TMZ sensitivity in glioma cell lines, an effect that is independent 
of MGMT status (Blough et al., 2011). Glioma cell lines that did not express a functional 
TP53 were significantly more sensitive to TMZ than cell lines that were functionally intact 
for TP53 expression (Blough et al., 2011). An example of this inconsistency comes from the 
results obtained with T98G cell line (MT TP53), in with the role of MGMT in mediating TMZ 
resistance was confirmed by the co-exposure to the MGMT inhibitor O6-BG, causing a 
reduction in the EC50, as evaluated by the clonogenic survival assay (Hermisson et al., 
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2006). Nevertheless, the roles of TP53 in terms of its influence on drug sensitivity are 
difficult to elucidate, since the dependence on the cell type, and the kind of antitumor agent 
used(Fukushima et al., 2009). In addition, the genetic background is also critical, since GBM 
cells often harbor other mutations for cell cycle regulator genes, and other tumor suppressor 
genes, as already mentioned for the four GBM cell lines studied in the present work, which 
carry two other mutations (CDKN2A and PTEN). 
The control of cell proliferation is very critical in the tumor development, and may also be 
influenced by the TP53 status (Facoetti et al., 2008). Several genes playing roles in the 
regulation of cell proliferation were found differentially expressed in MT TP53 cells, 
relatively to WT: IGFR1, CDH13, DUSP22, ADAMTS1, CAV1, and LIG4. These last two 
genes also play a role in stress responses, as mentioned before.  
Tumor growth also depends on the rate of apoptosis (Amirlak and Couldwell, 2003), and 
apoptosis is directly involved in gliomagenesis and resistance towards classical genotoxic 
approaches in cancer therapy. It has been reported that GBM cells are virtually resistant to 
different apoptotic stimuli (Adamson et al., 2009; Eisele and Weller, 2011), but the 
mechanisms underlying these responses are still unclear, and may depend on several 
treatment conditions and type of genotoxic agent. In the present work, the list of 
differentially expressed genes also indicated several genes implicated in apoptosis. Those 
genes, such as IGF1R, CDH13, IFT57, CRH, HSPB1 and ASNS, were up-regulated in MT 
TP53 GBM cells, relatively to WT cells. IGF1R participates in cell proliferation and protection 
of cell death (Trojan et al., 2007), while CDH13, ITF57, CRH and ASNS participates in 
apoptosis induction (Andreeva and Kutuzov, 2010; Chan et al., 2008; Gdynia et al., 2008; 
Gervais et al., 2002; Minas et al., 2007; Siu et al., 2002). Considering that the ability of cells to 
undergo apoptosis is dependent of a complex signaling cascade involving pro- and anti-
apoptotic genes, among other gene classes, the up-regulation of several apoptosis related 
genes in MT TP53 cells might influence responses of GBM cells submitted to anticancer 
agents.  
In this work, we showed some distinct transcript profiles for MT and WT TP53 GBM cells, 
pointing out several genes that might influence cell sensitivity to chemo- and/or 
radiotherapy.  
6. Conclusions 
The present data comparing transcript profiles displayed by GBM cell lines with different 
TP53 status showed that several biological processes were associated to the list of highly 
significant differentially expressed genes. Gene classes associated with those genes (stress 
response, DNA repair, proliferation, cell division, cell adhesion, apoptosis, etc) provided a 
picture on transcript profiles under normal conditions of cell proliferation in cultured GBM 
cell lines. However, these gene classes reflect wide amplitude of cellular processes that 
might be involved in cellular defense mechanisms under conditions of cell injury provoked 
by irradiation or drug treatment. These results support the hypothesis that MT TP53 cells 
might be more resistant than WT TP53 cells to some genotoxic stresses, such as ionizing 
radiation and TMZ. While this hypothesis still should be tested, altogether, the information 
obtained in this work provides a relevant basic contribution towards the understanding of 
GBM responses to therapies, and for designing novel therapeutic strategies for patients with 
GBM, based on their TP53 status, but also considering other gene mutations.  
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7. Supplementary data 




SPRY2 Sprouty homolog 2 (Drosophila) 40262 1.93 0.00 
CAV1 Caveolin 1, caveolae protein, 22kDa 24651 1.86 0.00 
MINA MYC induced nuclear antigen 139217 1.79 0.00 
 Clone 25220 mRNA sequence 25220 1.63 0.00 
CDH13 Cadherin 13, H-cadherin (heart) 31093 1.61 0.00 
HTRA1 HtrA serine peptidase 1 132044 1.55 0.00 
ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 34684 1.54 0.00 
MPND MPN domain containing 24532 1.39 0.00 
ARRB1 Arrestin, beta 1 21814 1.38 0.00 
ACSL4 Acyl-CoA synthetase long-chain family member 4 133988 1.36 0.00 
ITGA5 Integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 135671 1.35 0.75 
P4HB Prolyl 4-hydroxylase, beta polypeptide 132702 1.34 0.00 
GPR68 G protein-coupled receptor 68 22652 1.34 0.00 
GPR44 G protein-coupled receptor 44 25625 1.34 0.75 
PDLIM1 PDZ and LIM domain 1 135689 1.33 0.00 
RUVBL2 RuvB-like 2 (E. coli) 22267 1.33 0.00 
 In multiple ClusterIDs 261714 1.32 0.00 
 Unknown 134004 1.32 0.00 
ZXDB Zinc finger, X-linked, duplicated B 38972 1.31 0.90 
MKLN1 Muskelin 1, intracellular mediator containing kelch motifs 33715 1.31 0.00 
LARP4 La ribonucleoprotein domain family, member 4 41347 1.31 0.71 
KSR1 Kinase suppressor of ras 1 220655 1.31 0.75 
JAKMIP1 Janus kinase and microtubule interacting protein 1 32109 1.30 0.00 
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GNG13 Guanine nucleotide binding protein (G protein), gamma 13 178213 1.30 0.75 
ANKRD42 MRNA; cDNA DKFZp761C0524 (from clone DKFZp761C0524) 30094 1.30 0.00 
CDH8 cadherin 8, type 2 38939 1.30 0.00 
NRGN Neurogranin (protein kinase C substrate, RC3) 178825 1.30 0.75 
USP53 Ubiquitin specific peptidase 53 142468 1.30 0.69 
PIP5K2C Phosphatidylinositol-5-phosphate 4-kinase, type II, gamma 133173 1.30 0.75 
WDR34 WD repeat domain 34 133474 1.29 0.00 
TCBA1 Na+/K+ transporting ATPase interacting 2 41427 1.29 0.00 
MGC14376 Chromosome 17 open reading frame 91 24659 1.28 0.00 
DNAJA1 DnaJ (Hsp40) homolog, subfamily A, member 1 24473 1.28 0.75 
KLF12 Kruppel-like factor 12 34367 1.28 0.00 
UNC13C unc-13 homolog C (C. elegans) 22137 1.27 0.00 
RHOQ Ras homolog gene family, member Q 131061 1.26 0.00 
FBXL3 F-box and leucine-rich repeat protein 3 25778 1.26 0.00 
RP11-
484I6.3 Chromosome 13 open reading frame 27 24463 1.25 0.00 
 Unknown 132487 1.25 0.75 
CRH Corticotropin releasing hormone 34671 1.24 0.00 
IGF1R insulin-like growth factor 1 receptor 21519 1.24 0.00 
ASNS Asparagine synthetase (glutamine-hydrolyzing) 27208 1.23 0.90 
CSGlcA-T Chondroitin polymerizing factor 2 39955 1.23 0.75 
NBPF12 Neuroblastoma breakpoint family, member 1 24976 1.23 0.90 
BAMBI BMP and activin membrane-bound inhibitor homolog (Xenopus laevis) 41406 1.22 0.00 
PDXK Pyridoxal (pyridoxine, vitamin B6) kinase 25360 1.22 0.00 
 Transcribed locus 136399 1.21 0.75 
TNRC15 Transcribed locus 37482 1.21 0.75 
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 Calneuron 1 39092 1.20 0.75 
3-Mar Membrane-associated ring finger (C3HC4) 3 24707 1.20 0.00 
  Unknown 39306 1.19 0.69 
CD93 CD93 molecule 35503 1.19 0.00 
C20orf39 Transmembrane protein 90B 35704 1.19 0.00 
 In multiple ClusterIDs 41186 1.19 0.71 
 CXXC finger protein 5 136782 1.18 0.00 
PPCDC Phosphopantothenoylcysteine decarboxylase 135984 1.18 0.00 
COPB2 Clone 24627 mRNA sequence 24627 1.18 0.00 
 CDNA FLJ34038 fis, clone FCBBF2005645 38618 1.18 0.00 
FLJ41130 hypothetical LOC401113 40009 1.18 0.00 
CPD Carboxypeptidase D 40521 1.18 0.75 
 Unknown 34967 1.16 0.90 
CACNB2 calcium channel, voltage-dependent, beta 2 subunit 34651 1.16 0.71 
CUTL2 Cut-like homeobox 2 41354 1.16 0.90 
 Unknown 34966 1.15 0.00 
LASS6 LAG1 homolog, ceramide synthase 6 35147 1.15 0.75 
LIG4 Ligase IV, DNA, ATP-dependent 39274 1.14 0.75 
RNF8 Ring finger protein 8 39161 1.14 0.00 
IFT57 Intraflagellar transport 57 homolog (Chlamydomonas) 34942 1.12 0.00 
PIGO Phosphatidylinositol glycan anchor biosynthesis, class O 21678 -1.12 0.71 
KCNIP4 Kv channel interacting protein 4 21478 -1.13 0.00 
RCC2 Regulator of chromosome condensation 2 136887 -1.16 0.90 
PKIB Protein kinase (cAMP-dependent, catalytic) inhibitor beta 152289 -1.17 0.00 
DDX18 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 149416 -1.17 0.00 
SIN3A SIN3 homolog A, transcription regulator (yeast) 26455 -1.18 0.00 
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RBM4 RNA binding motif protein 4 141446 -1.19 0.00 
NKIRAS2 NFKB inhibitor interacting Ras-like 2 137971 -1.20 0.00 
DENND1A DENN/MADD domain containing 1A 21467 -1.21 0.74 
TMLHE Trimethyllysine hydroxylase, epsilon 21457 -1.22 0.00 
HSPB1 heat shock 27kDa protein 1 23827 -1.23 0.00 
ZNF630 Zinc finger protein 630 141069 -1.24 0.00 
ARSJ Arylsulfatase family, member J 32854 -1.24 0.00 
NUP160 Nucleoporin 160kDa 33299 -1.25 0.00 
SCP2 Sterol carrier protein 2 137004 -1.26 0.68 
NRN1 Neuritin 1 140197 -1.28 0.00 
ATP6AP2 ATPase, H+ transporting, lysosomal accessory protein 2 131821 -1.29 0.00 
PRPS2 Phosphoribosyl pyrophosphate synthetase 2 146194 -1.32 0.00 
 
Transcribed locus, weakly similar to 
XP_933787.2 PREDICTED: hypothetical 
protein [Homo sapiens] 
53331 -1.34 0.00 
PRSS23 Protease, serine, 23 143887 -1.35 0.00 
CMPK Cytidine monophosphate (UMP-CMP) kinase 1, cytosolic 140570 -1.36 0.00 
UGDH UDP-glucose 6-dehydrogenase 139835 -1.41 0.00 
VSNL1 Visinin-like 1 26570 -1.42 0.00 
 Transcribed locus 139645 -1.44 0.00 
SSFA2 Sperm specific antigen 2 140589 -1.45 0.00 
ABCA7 ATP-binding cassette, sub-family A (ABC1), member 7 182933 -1.45 0.00 
 Unknown 181796 -1.54 0.00 
DUSP22 Dual specificity phosphatase 22 182999 -1.55 0.00 
PFKFB2 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 53158 -1.68 0.00 
 
 
Table 1. List of significantly modulated genes provided by the statistical analysis by SAM 
(FDR ≤0.68%), comparing MT versus WT TP53 GBM cell lines. 
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1. Introduction  
Glioblastoma multiforme (GBM), the most common and biologically aggressive type of glioma 
is characterized by intra and intertumoral heterogeneity on the cytopathological, 
transcriptional, and genomic levels. GBMs account for 17.1% of brain and central nervous 
system (CNS) tumors and constitute 60-70% of all gliomas (The Central Brain Tumor Registry 
of the United States (CBTRUS) Statistical Report: NPCR/SEER, 2004-2006). Glial tumors can 
arise anywhere in the brain, but usually localize in the cerebral hemispheres and very rarely 
metastasize outside the CNS. In general, GBM affects individuals of both sexes and all age 
groups, but are usually more frequent in male patients (Bondy, et al., 2008) and the peak age at 
onset is between the fifth and the seventh decades of life (Wen, & Kesari, S., 2008). 
Due to this complexity, and to the existence of  a cancer stem cell (CSC) subpopulation, 
GBM presents an uncontrolled cellular proliferation, diffuse infiltration, propensity for 
necrosis, angiogenesis, resistance to apoptosis, and genomic instability (Louis, 2006) that 
makes this cancer one of the most difficult to treat. Despite multimodal aggressive treatment 
that includes surgical resection, followed by local radiotherapy and systemic chemotherapy 
(Furnari, et al., 2007), the median survival of GBM patients is 12-14 months. Unfortunately, 
only a small fraction of GBM patients (˂ 3%) survive for more than 36 months (Sonoda, et 
al., 2009). The existence of the blood-brain barrier and the diffuse infiltration into the 
surrounding brain limits the delivery of therapeutic agents, and increases the possibility of 
therapeutic toxicity. On the other hand, GBM tumors seem to overcome the effect of these 
therapies, through the ability to repair radiation-induced injury accomplished by aberrant or 
amplified growth and survival signaling pathways (Noda, et al., 2009), and ultimately 
becoming resistant to treatment.  
Molecular therapeutic strategies targeting altered signaling pathways have successfully 
improved patient outcome, however, it is still not possible to distinguish, in advance, which 
patients are the most likely to effectively benefit from specific drugs. Favorable prognostic 
factors associated with longer survival include young age at the time of diagnosis, absent or 
minimal neurological damage signs and a good initial Karnofsky performance score (KPS) 
(Bussiere, et al., 2005). Recent data have reported that hypermethylation of the O6-
methylguanine-DNA methyltransferase (MGMT) gene promoter is associated with 
prolonged progression-free survival in GBM patients treated with alkylating agents (Hegi, 
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et al., 2005), and the extent of tumor resection is also found to enhance the chances for a 
favorable outcome (Stummer, et al., 2006). Additionally, recent large-scale studies 
integrating genetic and gene expression datasets, have identified molecular subtypes within 
GBM that seem to have relevance to predict patient outcome and response to treatment 
(Freije, et al., 2004;  Phillips, et al., 2006).  
2. Histological characterization of GBM  
Histological classification and grading criteria for glial neoplasms are well established, 
basing on morphologic evidences of cellular differentiation and on the presence or absence 
of histopathological features, such as cellularity, nuclear pleomorphism, mitotic activity, 
endothelial cell proliferation and necrosis (Furnari,  et al., 2007). 
Although the specific cell type of glioma origin is currently unknown, these brain tumors 
are probably originated from glial cells (or their precursors), the generic name of the non-
neuronal cells that provide nutrients to neuronal cells, regulate metabolism and synaptic 
transmission. There are three main types of glial cells: astrocytes, oligodendrocytes and 
ependymal cells. Gliomas are classified as astrocytomas, oligodendrogliomas, 
oligoastocytomas (tumors presenting morphological features of both astrocytes and 
oligodendrocytes), or ependymomas, according to their presumable line of differentiation, 
that is, whether they resemble to these three types of glial cells. In the most widely accepted 
histological classification system of the CNS tumors, proposed by the World Health 
Organization (WHO) and recently revised (Louis, et al., 2007), each glioma type is further 
subdivided based on an increasing malignancy scale from grade I to IV, using a combination 
of criteria with predictive value in determining clinical outcome. Grade I tumors are 
biologically benign, displaying low proliferative potential and the possibility of cure 
following surgical resection alone. Grade II (diffuse) tumors are low-grade malignancies 
that may follow long clinical courses, with 5 to 8-years median survival, and some of these 
neoplasms tend to progress to higher grades of malignancy. Despite low-level proliferative 
activity, early diffuse infiltration of the surrounding brain renders them incurable by 
surgery. Grade III (anaplastic) tumors exhibit histological evidence of malignancy, including 
increased focal or dispersed anaplasia, cell proliferation, nuclear atypia and mitotic activity, 
and are more rapidly fatal, with survival times often less than 3 years. Grade IV designation 
is assigned to tumors exhibiting advanced cytologically malignant features, such as 
microvascular proliferation and necrosis, and as they are resistant to radio/chemotherapy 
they are generally lethal. Therefore, the type and grade of the tumor, as well as its 
localization, are currently recognized as the major factors determining patient prognosis. 
GBM is classified as WHO grade IV astrocytomas due to the resemblance of the tumor cells 
to astrocytes, to the existence of microvascular proliferation and areas of necrosis (Brat, & 
Van Meir, 2004). This is a highly cellular tumor with pleomorphic, basophilic nuclei and 
either indistinct cytoplasmic borders or plump, pink cytoplasm with fibrillary backgrounds. 
Yet, even within a single tumor, the cellular composition can vary widely and mixed 
histologic features are typical. Most frequently, these tumors arise de novo as an aggressive 
highly invasive tumor, usually with no evidence of prior symptoms, antecedent or lower 
grade pathology - primary GBMs. Two-thirds of patients with this GBM subtype have a 
clinical history of <3 months (Ohgaki, et al., 2004), presenting a very rapid development of 
clinical symptoms. In contrast, secondary GBMs derive from the progressive transformation 
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of lower grade astrocytomas, with ~70% of grade II gliomas transforming into grade III/IV 
within 5–10 years of diagnosis (Maher, et al., 2001; Ohgaki, & Kleihues, 2009). True 
secondary GBMs are uncommon, accounting for ≤ 10% of all GBM cases (Ohgaki, et al., 
2004). These two GBM types also affect patients at different ages: primary GBM constitute 
the great majority of GBM cases in older patients, while secondary GBM are quite rare and 
tend to occur in patients below the age of 45 years (Ohgaki, & Kleihues,  2007). Regardless of 
their distinct clinical histories or likely differences in prognosis and response to therapy, 
primary and secondary GBMs are usually histologically indistinguishable. Though both 
GBM subtypes achieve a common phenotypic endpoint, recent genomic profiles have 
revealed different transcriptional patterns and different DNA alterations, suggesting that 
these tumors arise through two different genetic pathways (Ohgaki,  & Kleihues, 2007).  
In addition to those subtypes, there are two other uncommon GBM variants, recognized as 
distinct clinico-pathological entities in the current WHO classification: i) gliosarcoma (GS) 
represents about 2% of GBMs and contains a biphasic growth pattern with clearly 
identifiable of both glial and sarcomatous components, the latter of which is associated with 
aberrant mesenchymal differentiation and is absent in all other glioma subtypes; ii) giant 
cell GBM (GC-GBM) constitutes approximately 5% of GBMs and is characterized by well-
circumscribed masses of enlarged and bizarre tumor cells, often appearing multinucleated. 
This histological variant has been associated with longer survival (Shinojima, et al., 2004). In 
addition, other GBM subtypes with divergent patterns of differentiation have been 
described: i) small-cell GBM (SC-GBM), which can morphologically resemble anaplastic 
oligodendroglioma (AO), displays a monomorphic cell population characterized by small, 
round to slightly elongated, densely packed cells with mildly hyperchromatic nuclei and 
minimal discernible cytoplasm; ii) GBM with oligodendroglioma component (GBM-O), 
containing variable oligodendroglial foci, have a significantly better prognosis than other 
variants of GBMs (Klink,  et al., 2010).  
As these GBM subtypes/variants share similar morphologic features, precise GBMs 
subclassification is becoming increasingly important. Conventional histological analysis is 
still the primary methodology to determine diagnosis and treatment. Despite its current 
utility, it still relies on a subjective interpretation which has an impact on its reproducibility 
between different observers (Figarella-Branger, & Bouvier, 2005). Moreover, tumors sharing 
a common morphology can behave differently, even within the same tumor type and 
grading subgroup, which renders the histological classification of limited value in 
determining optimal therapy or response to treatment. Taken together, these evidences 
suggest that underlying genetic and molecular abnormalities, other than the histological 
parameters alone, may account for tumoral variability and could be predictive of clinical 
behavior and survival (Gravendeel, et al., 2009).  
3. Cells of origin of GBM 
GBMs display a rather heterogeneous cellular composition and, to date, the specific cells of 
origin for the formation of these malignant gliomas remain unknown. Traditional neuro-
oncology postulated that tumors with an astrocytic phenotype arise from astrocytes. 
However, to undergo oncogenic events, mature glial cells would have to be proliferative 
and it is currently accepted that most brain cells do not undergo division, during adult life. 
Additionally, no epidemiological evidence indubitably relates processes likely to evoke 
 
Molecular Targets of CNS Tumors 
 
290 
et al., 2005), and the extent of tumor resection is also found to enhance the chances for a 
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they are generally lethal. Therefore, the type and grade of the tumor, as well as its 
localization, are currently recognized as the major factors determining patient prognosis. 
GBM is classified as WHO grade IV astrocytomas due to the resemblance of the tumor cells 
to astrocytes, to the existence of microvascular proliferation and areas of necrosis (Brat, & 
Van Meir, 2004). This is a highly cellular tumor with pleomorphic, basophilic nuclei and 
either indistinct cytoplasmic borders or plump, pink cytoplasm with fibrillary backgrounds. 
Yet, even within a single tumor, the cellular composition can vary widely and mixed 
histologic features are typical. Most frequently, these tumors arise de novo as an aggressive 
highly invasive tumor, usually with no evidence of prior symptoms, antecedent or lower 
grade pathology - primary GBMs. Two-thirds of patients with this GBM subtype have a 
clinical history of <3 months (Ohgaki, et al., 2004), presenting a very rapid development of 
clinical symptoms. In contrast, secondary GBMs derive from the progressive transformation 
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represents about 2% of GBMs and contains a biphasic growth pattern with clearly 
identifiable of both glial and sarcomatous components, the latter of which is associated with 
aberrant mesenchymal differentiation and is absent in all other glioma subtypes; ii) giant 
cell GBM (GC-GBM) constitutes approximately 5% of GBMs and is characterized by well-
circumscribed masses of enlarged and bizarre tumor cells, often appearing multinucleated. 
This histological variant has been associated with longer survival (Shinojima, et al., 2004). In 
addition, other GBM subtypes with divergent patterns of differentiation have been 
described: i) small-cell GBM (SC-GBM), which can morphologically resemble anaplastic 
oligodendroglioma (AO), displays a monomorphic cell population characterized by small, 
round to slightly elongated, densely packed cells with mildly hyperchromatic nuclei and 
minimal discernible cytoplasm; ii) GBM with oligodendroglioma component (GBM-O), 
containing variable oligodendroglial foci, have a significantly better prognosis than other 
variants of GBMs (Klink,  et al., 2010).  
As these GBM subtypes/variants share similar morphologic features, precise GBMs 
subclassification is becoming increasingly important. Conventional histological analysis is 
still the primary methodology to determine diagnosis and treatment. Despite its current 
utility, it still relies on a subjective interpretation which has an impact on its reproducibility 
between different observers (Figarella-Branger, & Bouvier, 2005). Moreover, tumors sharing 
a common morphology can behave differently, even within the same tumor type and 
grading subgroup, which renders the histological classification of limited value in 
determining optimal therapy or response to treatment. Taken together, these evidences 
suggest that underlying genetic and molecular abnormalities, other than the histological 
parameters alone, may account for tumoral variability and could be predictive of clinical 
behavior and survival (Gravendeel, et al., 2009).  
3. Cells of origin of GBM 
GBMs display a rather heterogeneous cellular composition and, to date, the specific cells of 
origin for the formation of these malignant gliomas remain unknown. Traditional neuro-
oncology postulated that tumors with an astrocytic phenotype arise from astrocytes. 
However, to undergo oncogenic events, mature glial cells would have to be proliferative 
and it is currently accepted that most brain cells do not undergo division, during adult life. 
Additionally, no epidemiological evidence indubitably relates processes likely to evoke 
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reactive proliferation or astrogliosis, such as trauma, with the development of glial tumors 
(Bondy, et al., 2008; Fisher, et al., 2007). On the other hand, gliomas mostly occur in adults, 
suggesting that their cells of origin must be present in the adult brain. It is now known that 
in addition to glial progenitor cells, neural stem cells (NSCs) also reside in the 
subventricular zone (SVZ) of adult human brain (Gil-Perotin, et al., 2009;  Sanai, et al., 2005). 
During human development, the one important source of NSCs is the SVZ, and this region 
is widely viewed as the source of cells that can initiate primary brain tumors (Sanai, et al., 
2005). Indeed, many gliomas are either periventricular or contiguous with the SVZ (Lim, et 
al., 2007).  
The “neural-stem cell hypothesis” proposes that a rare subset of cells within GBM tumors 
may have significant expansion capacity and the ability to generate new tumors. The 
remainder of tumor cells, which predominantly constitutes GBM tumors, may represent 
partially differentiated cells with limited progenitor capacity or terminally differentiated 
cells that cannot form new tumors. Evidences sustain the observation that transformation of 
NSCs and their progenitors, through a sequence of genetic and/or epigenetic alterations, 
may lead to the formation of tumor-initiating cells (TICs) also in gliomas (Dietrich, et al., 
2008; Singh, et al., 2004), rather than from a differentiated cell type. In fact, TICs are 
identified in the early stages of tumor development and may not yet have acquired the full 
tumorigenic potential of other premalignant cells with additional genetic mutations, 
referred to as cancer stem cells (CSCs). It was demonstrated that GBM-CSCs share some 
characteristics with normal NSCs, including the ability to self-renew and proliferate, as well 
as the capacity to engraft and migrate (Galli, et al., 2004;  Sanai, et al., 2005;  Singh, et al., 
2003). The self-renewal ability of both NSCs and CSCs is provided by either symmetric cell 
division, which produces two daughter stem cells, or by asymmetric cell division, which 
produces a stem cell and a progenitor cell. The progenitor cell will then differentiate and 
migrate, while the stem cell retains the capacity of self-renewal and remains in the germinal 
zone (Berger, et al., 2004), maintaining intact the core population of stem cells. CSCs can also 
express stem cell markers typical of normal NSCs such as the cluster of differentiation 133 
(CD133), also known as prominin-1 (originally described in mouse neuroepithelium and 
hematopoietic stem and progenitor cells), and the intermediate filament protein nestin 
(NES) (Galli, et al., 2004;  Sanai, et al., 2005;  Singh, et al., 2003). Several studies reported that 
CD133+ cells isolated from human brain tumor, when implanted into the brain of 
immunodeficient mice, were capable to generate a new and highly invasive tumor at low 
inoculation numbers, whereas CD133- GBM cells failed to have a tumor-initiating activity 
(Marumoto,  et al., 2009;  Singh, et al., 2004). However, recent studies indicate that CD133- 
cell subpopulation can also form orthotopic tumors, thus acting as brain tumor stem cells 
(Chen, et al., 2010). These evidences may partially reflect the presence of other types of 
GBM-CSCs devoid of CD133, which are not entirely defined by the expression of typical 
NSCs markers. Thus, the CD133 marker used to identify GBM-CSCs is likely only one of a 
variety of cell specific markers, still unknown to this point. Although the clinical value of 
CD133-expression in GBM tumors remains unclear, some groups have reported that the 
increased expression of CD133 was correlated with the poor prognosis and the decreased 
survival of glioma patient (Pallini, et al., 2008;  Zeppernick, et al., 2008). Moreover, the 
frequency of CD133+ cells was shown to increase with tumor grade, suggesting that CD133 
expression could serve as a prognostic factor for malignant progression and tumor 
regrowth. In this sense, several studies have provided evidence that GMB-CSCs may 
contribute to resistance to radiotherapy and chemotherapy in GBM (Eramo, et al., 2006; 
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Kang, & Kang, 2007). In CD133+ cells, the overexpression of drug resistance genes such as 
BCRP1,  DNA-mismatch repair genes, such as MGMT, as well as genes related to the 
inhibition of the apoptosis (Juillerat-Jeanneret, et al., 2008), seems to contribute to the 
tumor’s resistance to chemotherapy.  
Like normal NSCs, brain CSCs are thought to reside in the perivascular area of the tumor, 
called “the vascular niche”, where they are sheltered from apoptotic stimuli and maintain a 
proper balance between self-renewal and differentiation (Calabrese, et al., 2007;  Gilbertson, 
& Rich, 2007). Evidences of reciprocal relationship between GBM-CSCs and their 
microenvironment demonstrated that CSCs not only receive the signals from surrounding 
niche, but are also capable of modulating it. It was also demonstrated that CSCs stimulated 
angiogenesis by secreting vascular endothelial growth factor (VEGF) but these cells also 
depended on the factors brought by vasculature  (Calabrese,  et al., 2007). Thus, GMB-CSCs 
and vascular niche may give positive feed-back to each other in order to promote tumor 
maintenance and expansion. Moreover, it was also hinted that vascular microenvironment 
might protect CSCs from chemo- and radiotherapies, enabling these cells to reform an initial 
clinical response (Dick, & Lapidot, 2005). The influence of the tumor microenvironment may 
also be reflected on the phenotypic endpoint of gliomas. In this way, the occurrence of 
specific genetic events on precursor cells or mature cells, in combination with the local 
environment, possibly alters the activity of particular cellular control pathways. 
Accordingly, progenitor cells that undergo TP53 mutations generally activate pathways that 
induce astrocytic differentiation, whereas similar cells that undergo chromosomal loss of 1p 
and 19q most often become committed to an oligodendroglial phenotype (Alcantara 
Llaguno, et al., 2009). Several lines of evidence in the literature indicate that loss of TP53 
affects the properties of adult neural stem cells by providing a proliferative advantage 
(Armesilla-Diaz, et al., 2009; Gil-Perotin, et al., 2006). Regarding the effect of different 
tumorigenic events, more evidences come from targeting oncogenic stimuli to specific cell 
types. For instance, whereas overexpressing oncogenic Ras and Akt in progenitor cells 
results in mouse brain tumors that are histologically similar to human GBMs (Holland, et 
al., 2000), overexpression of platelet-derived growth factor-B (PDGF-B) in the same cells 
produces tumors histologically similar to oligodendrogliomas (Dai, et al., 2001). Taken 
together, these evidences point at the involvement of immature precursor cells in the 
development of tumor malignant phenotype. On the contrary, the existence of cells in the 
adult brain capable to revert to a less mature state, in response to certain stimuli (Canoll, & 
Goldman, 2008), supports the hypothesis that mature glial cells may be the target of 
transformation in gliomagenesis. In fact, these cells may be induced to dedifferentiate into 
transformed glia with stem cell–like properties, as observed in mice models, through 
retroviral transfection of EGF receptor (EGFR) in association with Ink4a/Arf (Bachoo, et al., 
2002), or by generating pluripotent stem cells from mouse embryonic and adult 
differentiated fibroblast (Takahashi, & Yamanaka, 2006). However, the concept of 
dedifferentiation of mature glia is questionable and fails to explain adequately the origin of 
some gliomas, such as mixed oligoastrocytomas and gliosarcomas. These types are 
composed by a biphasic tissue pattern with areas of astrocytic and oligodendroglial 
differentiation or gliomatous and mesenchymal differentiation, respectively (Louis, et al., 
2007). The presence of two morphologically distinct cell types within a tumor suggests 
either independent transformation events in two terminally differentiated cells or, more 
likely, the transformation of a single, bipotential progenitor cell (Chekenya, & Pilkington, 
2002) that retains the capacity to differentiate into both cell types. If malignant 
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reactive proliferation or astrogliosis, such as trauma, with the development of glial tumors 
(Bondy, et al., 2008; Fisher, et al., 2007). On the other hand, gliomas mostly occur in adults, 
suggesting that their cells of origin must be present in the adult brain. It is now known that 
in addition to glial progenitor cells, neural stem cells (NSCs) also reside in the 
subventricular zone (SVZ) of adult human brain (Gil-Perotin, et al., 2009;  Sanai, et al., 2005). 
During human development, the one important source of NSCs is the SVZ, and this region 
is widely viewed as the source of cells that can initiate primary brain tumors (Sanai, et al., 
2005). Indeed, many gliomas are either periventricular or contiguous with the SVZ (Lim, et 
al., 2007).  
The “neural-stem cell hypothesis” proposes that a rare subset of cells within GBM tumors 
may have significant expansion capacity and the ability to generate new tumors. The 
remainder of tumor cells, which predominantly constitutes GBM tumors, may represent 
partially differentiated cells with limited progenitor capacity or terminally differentiated 
cells that cannot form new tumors. Evidences sustain the observation that transformation of 
NSCs and their progenitors, through a sequence of genetic and/or epigenetic alterations, 
may lead to the formation of tumor-initiating cells (TICs) also in gliomas (Dietrich, et al., 
2008; Singh, et al., 2004), rather than from a differentiated cell type. In fact, TICs are 
identified in the early stages of tumor development and may not yet have acquired the full 
tumorigenic potential of other premalignant cells with additional genetic mutations, 
referred to as cancer stem cells (CSCs). It was demonstrated that GBM-CSCs share some 
characteristics with normal NSCs, including the ability to self-renew and proliferate, as well 
as the capacity to engraft and migrate (Galli, et al., 2004;  Sanai, et al., 2005;  Singh, et al., 
2003). The self-renewal ability of both NSCs and CSCs is provided by either symmetric cell 
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produces a stem cell and a progenitor cell. The progenitor cell will then differentiate and 
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express stem cell markers typical of normal NSCs such as the cluster of differentiation 133 
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hematopoietic stem and progenitor cells), and the intermediate filament protein nestin 
(NES) (Galli, et al., 2004;  Sanai, et al., 2005;  Singh, et al., 2003). Several studies reported that 
CD133+ cells isolated from human brain tumor, when implanted into the brain of 
immunodeficient mice, were capable to generate a new and highly invasive tumor at low 
inoculation numbers, whereas CD133- GBM cells failed to have a tumor-initiating activity 
(Marumoto,  et al., 2009;  Singh, et al., 2004). However, recent studies indicate that CD133- 
cell subpopulation can also form orthotopic tumors, thus acting as brain tumor stem cells 
(Chen, et al., 2010). These evidences may partially reflect the presence of other types of 
GBM-CSCs devoid of CD133, which are not entirely defined by the expression of typical 
NSCs markers. Thus, the CD133 marker used to identify GBM-CSCs is likely only one of a 
variety of cell specific markers, still unknown to this point. Although the clinical value of 
CD133-expression in GBM tumors remains unclear, some groups have reported that the 
increased expression of CD133 was correlated with the poor prognosis and the decreased 
survival of glioma patient (Pallini, et al., 2008;  Zeppernick, et al., 2008). Moreover, the 
frequency of CD133+ cells was shown to increase with tumor grade, suggesting that CD133 
expression could serve as a prognostic factor for malignant progression and tumor 
regrowth. In this sense, several studies have provided evidence that GMB-CSCs may 
contribute to resistance to radiotherapy and chemotherapy in GBM (Eramo, et al., 2006; 
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BCRP1,  DNA-mismatch repair genes, such as MGMT, as well as genes related to the 
inhibition of the apoptosis (Juillerat-Jeanneret, et al., 2008), seems to contribute to the 
tumor’s resistance to chemotherapy.  
Like normal NSCs, brain CSCs are thought to reside in the perivascular area of the tumor, 
called “the vascular niche”, where they are sheltered from apoptotic stimuli and maintain a 
proper balance between self-renewal and differentiation (Calabrese, et al., 2007;  Gilbertson, 
& Rich, 2007). Evidences of reciprocal relationship between GBM-CSCs and their 
microenvironment demonstrated that CSCs not only receive the signals from surrounding 
niche, but are also capable of modulating it. It was also demonstrated that CSCs stimulated 
angiogenesis by secreting vascular endothelial growth factor (VEGF) but these cells also 
depended on the factors brought by vasculature  (Calabrese,  et al., 2007). Thus, GMB-CSCs 
and vascular niche may give positive feed-back to each other in order to promote tumor 
maintenance and expansion. Moreover, it was also hinted that vascular microenvironment 
might protect CSCs from chemo- and radiotherapies, enabling these cells to reform an initial 
clinical response (Dick, & Lapidot, 2005). The influence of the tumor microenvironment may 
also be reflected on the phenotypic endpoint of gliomas. In this way, the occurrence of 
specific genetic events on precursor cells or mature cells, in combination with the local 
environment, possibly alters the activity of particular cellular control pathways. 
Accordingly, progenitor cells that undergo TP53 mutations generally activate pathways that 
induce astrocytic differentiation, whereas similar cells that undergo chromosomal loss of 1p 
and 19q most often become committed to an oligodendroglial phenotype (Alcantara 
Llaguno, et al., 2009). Several lines of evidence in the literature indicate that loss of TP53 
affects the properties of adult neural stem cells by providing a proliferative advantage 
(Armesilla-Diaz, et al., 2009; Gil-Perotin, et al., 2006). Regarding the effect of different 
tumorigenic events, more evidences come from targeting oncogenic stimuli to specific cell 
types. For instance, whereas overexpressing oncogenic Ras and Akt in progenitor cells 
results in mouse brain tumors that are histologically similar to human GBMs (Holland, et 
al., 2000), overexpression of platelet-derived growth factor-B (PDGF-B) in the same cells 
produces tumors histologically similar to oligodendrogliomas (Dai, et al., 2001). Taken 
together, these evidences point at the involvement of immature precursor cells in the 
development of tumor malignant phenotype. On the contrary, the existence of cells in the 
adult brain capable to revert to a less mature state, in response to certain stimuli (Canoll, & 
Goldman, 2008), supports the hypothesis that mature glial cells may be the target of 
transformation in gliomagenesis. In fact, these cells may be induced to dedifferentiate into 
transformed glia with stem cell–like properties, as observed in mice models, through 
retroviral transfection of EGF receptor (EGFR) in association with Ink4a/Arf (Bachoo, et al., 
2002), or by generating pluripotent stem cells from mouse embryonic and adult 
differentiated fibroblast (Takahashi, & Yamanaka, 2006). However, the concept of 
dedifferentiation of mature glia is questionable and fails to explain adequately the origin of 
some gliomas, such as mixed oligoastrocytomas and gliosarcomas. These types are 
composed by a biphasic tissue pattern with areas of astrocytic and oligodendroglial 
differentiation or gliomatous and mesenchymal differentiation, respectively (Louis, et al., 
2007). The presence of two morphologically distinct cell types within a tumor suggests 
either independent transformation events in two terminally differentiated cells or, more 
likely, the transformation of a single, bipotential progenitor cell (Chekenya, & Pilkington, 
2002) that retains the capacity to differentiate into both cell types. If malignant 
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transformation occurs in the progenitor cell, one would expect a similar genetic profile in 
both cell types, especially on the level of chromosomal changes. Indeed, loss of 
heterozygosity (LOH) on chromosomes 1p and 19q was observed in both the astrocytic and 
oligodendrocytic components of mixed oligoastrocytomas, strongly suggesting a common 
cell of origin for both cells types (Kraus, et al., 1995).  
Despite all the evidences already mentioned, GBM may develop from cells with different 
origins or via different molecular steps, which accounts for their heterogeneity. In this sense, 
the availability of more reliable and precise approaches for the classification of gliomas 
based on tumorigenic mechanisms would be extremely useful. Recently, integrated 
molecular genetic analysis has assumed an increasing part in the improvement of 
classification and therapeutic strategies for GBM patients.  
4. Molecular characterization of GBM  
It is recognized that morphologic changes observed during the process of malignant 
transformation, reflect the sequential acquisition of genetic alterations. So far, several studies 
have identified DNA copy number (CN) alterations, such as chromosomal and gene 
deletions, amplifications and gains, LOH and mutations as recurrent events in 
gliomagenesis, suggesting the involvement of tumor suppressor genes and oncogenes in 
tumor initiation or progression (Dahlback, et al., 2009;  Furnari, et al., 2007a;  Kotliarov, et 
al., 2006;  Ohgaki, & Kleihues, 2009;  Parsons, et al., 2008). CN changes are thought to affect 
genes expression either through overexpression of large amplification regions or 
inactivation of genes in deleted regions (Bralten, et al., 2010; Rao, et al., 2010). Ultimately, 
these genetic alterations seem to modify crucial cellular processes and often result in 
deregulation of metabolic key pathways affecting growth signaling and cell cycle control 
(Kanu, et al., 2009), as will be further discussed in the following section.  
Over the past years, specific alterations associated with abnormal GBM features were 
identified, using classical cytogenetics and molecular methodologies, including interphase 
fluorescence in situ hybridization (iFISH) and comparative genomic hybridization (CGH). 
Given the large heterogeneity within GBMs, particular genetic changes may occur in some 
tumors and not in others, pointing out to distinct molecular subtypes of histologically defined 
GBM (Liang, et al., 2005). In fact, GBM profiling has identified differences in the molecular 
abnormalities observed between primary and secondary GBM. Specifically, primary GBMs 
typically harbor amplification and/or a high rate of EGFR mutation, cyclin-dependent kinase 
inhibitor 2A (CDKN2A/p16), deletion in chromosome 9p, and phosphatase and tensin 
homologue (PTEN) deletion in chromosome 10. The most common EGFR mutant type -variant 
3 (EGFRvIII)- is due to an in-frame deletion of exons 2–7, and it is constitutively active in 
EGFR-mediated signal-transduction pathway, what confers cell proliferation and survival 
advantages (Ohgaki, & Kleihues, 2007;  Van Meir, et al., 2010). The deletion in PTEN results in 
increased protein kinase B /mammalian target of rapamycin (AKT/mTOR) activity, which 
promotes cell survival, proliferation, and invasion (Louis, 2006; Sathornsumetee, & Rich, 2008). 
Recently, ERBB2 mutations have also been identified as a recurrent event in primary GBMs. In 
contrast, secondary GBM are characterized by the occurrence of early detected mutations in 
the tumor suppressor gene TP53 on chromosome 17p, especially those involving codons 248 
and 273 or G:C→A:T mutations at CpG sites (Ohgaki, et al., 2004), abnormalities in the p16 and 
retinoblastoma (RB) pathways, and loss of heterozygosity of chromosome 10q. Isocitrate 
dehydrogenase 1 (IDH1) mutations have been recently identified as a very early and frequent 
 
Genetics and Biology of Glioblastoma Multiforme 
 
295 
genetic alteration in the pathway to secondary GBMs, but rarely occurring in primary GBMs 
(Ichimura, et al., 2009).  
Similarly, primary and secondary GBMs show significantly different mRNA and protein 
expression profiles, reflecting their significant differences in genetic alterations (Ohgaki, & 
Kleihues, 2007). Genes typically expressed in primary GBMs include Fas (Tohma, et al., 
1998), VEGF (Karcher, et al., 2006), and VEGF fms-related tyrosine kinase 1, probably 
reflecting large ischemic necrosis (Tohma, et al., 1998). The insulin-like growth factor 
binding protein-2 (IGFBP-2), a modulator of the action of insulin-like growth factors, is also 
typically expressed at a high level in primary GBMs (Godard, et al., 2003). Primary GBMs 
also preferentially express genes characteristic of a stromal response, suggesting the 
importance of extracellular signaling (Tso, et al., 2006). The adipocyte lipid binding protein 1 
(AEBP1), a transcriptional repressor that has been shown to interact with PTEN inhibiting 
its function (Reddy, S. P. et al., 2008), is up-regulated in the majority of primary GBMs. 
Proteins expressed uniquely in primary GBMs include tenascin-X precursor (TN-X), enolase 
1 (ENO1), centrosome-associated protein 350 (CAP350), and EGFR.  
On the other hand, achaete-scute complex homolog 1 (ASCL1), a protein that activates 
transcription and plays a role in the neuronal commitment and differentiation, is found to 
be highly overexpressed in secondary GBMs, which is accompanied by inhibition of Notch 
signaling (Somasundaram, et al., 2005). Other proteins typically expressed in secondary 
GBMs include excision repair cross-complementing 6 (ERCC6), dual oxidase 2 (DUOX2), 
heterogeneous nuclear ribonucleoprotein A3 (HNRPA3), WNT-11 protein precursor, 
cadherin-related tumor suppressor homolog precursor, ADAMTS-19 (Furuta, et al., 2004), 
platelet–derived growth factor-AB (PDGF-AB) (Karcher, et al., 2006), and PDGF receptor 
(PDGFR). 
From the different genetic profiles recognized within GBM, it became clear that the 
underlying molecular characteristics of the tumor are essential to understand its variability 
and to identify potential therapeutic targets, however, do not allow by themselves to predict 
patient's outcome or response to treatment. Thus, in the past few years, efforts have been 
made to further characterize GBM into specific molecular subclasses, defined by 
combinations of over- or underexpressed genes with potential impact on survival. Recently, 
the availability of large-scale microarray-based genomic/expression profiling, together with 
advances in bioinformatics methods provided a comprehensive view of the genome-wide 
aberrations in malignant gliomas. Emerging studies integrating DNA CN alterations and 
gene expression data allowed refining GBM’s classification (Liang, et al., 2005;  Marko, et al., 
2008;  Mischel, et al., 2003;  Tso, et al., 2006), and revealed a significant correlation between 
tumor subsets and survival (Freije, et al., 2004;  Nutt, et al., 2003;  Phillips, et al., 2006). 
Promising findings from whole-genome analysis came also from The Cancer Genome Atlas 
(TCGA) Research Network (The Cancer Genome Atlas (TCGA) Research Network, 2008; 
Verhaak, et al., 2010). In a recent multidimensional study expanding previous GBM 
classification, patterns of somatic mutations, DNA CN, and gene expression were assessed 
in a large cohort, to perform an integrated molecular classification of GBM (Verhaak, et al., 
2010). Consequently, on the basis of prior naming and considering the expression profiles 
observed, four subtypes of tumors with a common morphologic diagnosis of GBMs were 
identified into Classical, Mesenchymal, Proneural and Neural. The first GBM subtype was 
labeled “Classical” since tumors of this subtype have a characteristic profile of highly 
proliferative cells and common gains on chromosome 7, paired with losses on chromosome 
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transformation occurs in the progenitor cell, one would expect a similar genetic profile in 
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genetic alteration in the pathway to secondary GBMs, but rarely occurring in primary GBMs 
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10 and frequent focal losses on chromosome 9p21.3. High-level amplification of the EGFR 
gene or gene rearrangements (point or vIII EGFR mutation) are frequently observed in this 
subtype and uncommon in other subtypes. Homozygous 9p21.3 deletion, targeting 
CDKN2A, is almost mutually exclusive with aberrations of other RB pathway components, 
such as Rb1, CDK4, and CCDN2, suggesting that the RB pathway is almost exclusively 
affected through CDKN2A deletion, in samples with focal EGFR amplification. Alterations in 
the TP53, neurofibromin 1(NF1), PDGFRA, or IDH1 genes are nearly absent. Classical GBMs 
are responsiveness to the radiation and chemotherapies. At the gene expression level, the 
Classical subtype demonstrates elevated expression of the neural precursor and stem cell 
marker NES, and both Notch (NOTCH3, JAG1, and LFNG) and Sonic hedgehog (SMO, 
GAS1, and GLI2) signaling pathways.  
The second GBM subtype was labeled as “Mesenchymal” since tumors display 
overexpression of mesenchymal markers, such as CHI3L1/YKL40 and MET genes, as well as 
the astrocytic markers CD44 and MERTK. Mesenchymal GBMs have frequent inactivation of 
the NF1, TP53, and PTEN genes. Comutations of NF1 and PTEN, both intersecting with the 
AKT pathway, are also observed in the Mesenchymal subtype. Genes in the tumor necrosis 
factor (TNF) super family and NF-kB pathways are highly expressed in this subtype, 
potentially as a consequence of higher overall necrosis and associated inflammatory 
infiltrates. These tumors are responsive to aggressive chemotherapy and radiation therapies 
and might in addition be responsive to Ras, phosphoinositide 3-kinase (PI3K), and 
angiogenesis inhibitors.  
The third GBM subtype was called “Proneural,” and these tumors are characterized by an 
expression profile reminiscent of gene activation in neuronal development. Thus, they 
present activation of oligodendrocytic (PDGFRA, OLIG2, TCF3, and NKX2-2) and proneural 
(SOX, DCX, DLL3, ASCL1, and TCF4) development genes. These tumors are also 
characterized by TP53 gene mutations and LOH, and mutations in PDGFRA, IDH1, and 
PIK3CA/PIK3R1 genes are also observed. Focal amplification of the PDGFRA locus, 
associated with high levels of PDGFRA expression, is seen almost exclusively in this tumor 
type. Interestingly, PIK3CA/PIK3R1 mutations in the Proneural subtype is mostly observed 
in samples with no PDGFRA abnormalities. Amplification of chromosome 7 and loss on 
chromosome 10 are significant, but less frequent findings than in the Classical subtype. This 
GBM subtype may be responsive to inhibitors of the hypoxia-inducible factor (HIF), PI3K, 
and PDGFRA pathways. In this group, patients are younger and survival is slightly better 
than in the other 3 tumor subtypes.  
The fourth GBM subtype called “Neural” is less well defined and has gene expression 
signatures similar to those found in normal brain tissue, with activation of neuron markers 
such as NEFL, GABRA1, SYT1, and SLC12A5. These tumors demonstrate a low degree of 
infiltration by normal cells; nevertheless, their expression signature is suggestive of cells 
with a differentiated phenotype.  
Despite the existence of well defined differences in the genetic profile of the four subtypes, 
all tumor subgroups present inactivation of the p53 and RB tumor suppressor pathways, 
and activation of the receptor tyrosine kinase pathway. These observations suggest rather 
strongly that although molecular genetic profiling may eventually guide therapeutic 
decisions for patients with specific GBM subtypes, further studies linking the genetic 
alterations and the consequent affected signaling pathways, may be the key to better 
understand the occurrence and progression of these tumors. 
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5. Signaling pathways altered in GBM  
5.1 EGFR/Akt/PTEN pathway 
EGFR is a member of the erbB family receptor tyrosine kinase proteins, which comprises 
EGFR itself (ErbB1) (EGFR/HER1), ErbB2 (HER2/neu), ErbB3 (HER3), and ErbB4 (HER4) 
(Mellinghoff, et al., 2005; Ranson, 2004). These receptors are composed of an extracellular 
ligand-binding domain, a transmembrane lipophilic domain, and an intracellular tyrosine 
kinase domain. The binding of a specific set of ligands [EGF; transforming growth factor-α 
(TGF-α)] to the receptor promotes EGFR dimerization and the autophosphorylation of the 
receptors on tyrosine residues (Arora, & Scholar, 2005; Baselga, 2006). Upon 
autophosphorylation, several signal transduction pathways downstream of EGFR become 
activated such as the Ras/Raf/mitogen-activated protein kinase pathway, the PI3K/Akt 
pathway, protein kinase C (PKC), the signal transduction and activator of transcription 
(STAT), an the VEGF among others (Arora, & Scholar, 2005;  Baselga, 2006). Taking in 
consideration that these signaling pathways control cell growth, regulate cell survival and 
apoptosis and that it was reported and overexpression of EGFR in several epithelial tumors, 
the EGFR/Akt/PTEN pathway is considered a potential target for cancer therapy (Arora, & 
Scholar, 2005;  Baselga, 2006).  
Regarding the activation of PI3K by EGFR it is known that there is a recruitment of PI3K to 
the cell membrane and phosphorylation of phosphatidynositol-4,5-bisphosphate to the 
respective 3-phosphate (PIP3), which in turns activates downstream effectors molecules 
such as Akt (Hirose, et al., 2005; Furnari, et al., 2007). Activated Akt regulates the function of 
downstream signaling proteins involved in cell cycle, proliferation, apoptosis and invasion, 
therefore, once deregulated, Akt may contribute to tumorigenesis. Activated Akt 
deregulates cell growth by stabilization of cyclin D and promotion of the nuclear entry of 
the mouse double minute protein 2 (MDM2), leading to the degradation of p53 (Han, et al., 
2010). Akt might also inhibit p21 expression through its phosphorylation and activation of 
MDM2 (Zhou, et al., 2001). On the other hand, activated Akt exerts anti-apoptotic activity by 
phosphorylating and inactivating pro-apoptotic signaling proteins, such as BAD and 
caspase 9 (Dasari, et al., 2010). The involvement of Akt in diverse tumorigenic activities 
suggests that Akt activation alone might be sufficient to induce cancer (Testa, & Bellacosa, 
2001). Moreover, Akt activation may contribute to tumor invasion/metastasis by 
stimulating secretion of matrix metalloproteinases (Dasari, et al., 2010). The action of PI3K 
enzyme is directly antagonized by a phosphatase encoded by the PTEN gene located at 
10q23.3. 
PTEN is a tumor suppressor gene that encodes a central domain with homology to the 
catalytic region of protein tyrosine phosphatases. For that reason, PTEN is a negative 
regulator of the PI3K pathway by removing the third phosphate from the inositol ring of the 
second messenger PIP3 (Mellinghoff, et al., 2005). Therefore, PTEN inactivation results in 
accumulation of PIP3 levels and persistent signaling through the serine/threonine kinase 
Akt. In addition, the amino terminal domain of PTEN, with homology to tensin and auxilin, 
is important in regulating cell migration and invasion by directly dephosphorylating focal 
adhesion kinase (FAK) (Furnari, et al., 2007;  Ohgaki, & Kleihues, 2007). There are also some 
reports indicating that PTEN plays a significant role in inducing G1 cell cycle arrest and 
apoptosis, along with regulating cell differentiation (Di Cristofano, & Pandolfi, 2000). 
As it is referred, EGFR mutation was detected in several tumor types. In GBMs, 
amplification of the EGFR gene occurs in 40% of primary GBMs but rarely in secondary 
 
Molecular Targets of CNS Tumors 
 
296 
10 and frequent focal losses on chromosome 9p21.3. High-level amplification of the EGFR 
gene or gene rearrangements (point or vIII EGFR mutation) are frequently observed in this 
subtype and uncommon in other subtypes. Homozygous 9p21.3 deletion, targeting 
CDKN2A, is almost mutually exclusive with aberrations of other RB pathway components, 
such as Rb1, CDK4, and CCDN2, suggesting that the RB pathway is almost exclusively 
affected through CDKN2A deletion, in samples with focal EGFR amplification. Alterations in 
the TP53, neurofibromin 1(NF1), PDGFRA, or IDH1 genes are nearly absent. Classical GBMs 
are responsiveness to the radiation and chemotherapies. At the gene expression level, the 
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PIK3CA/PIK3R1 genes are also observed. Focal amplification of the PDGFRA locus, 
associated with high levels of PDGFRA expression, is seen almost exclusively in this tumor 
type. Interestingly, PIK3CA/PIK3R1 mutations in the Proneural subtype is mostly observed 
in samples with no PDGFRA abnormalities. Amplification of chromosome 7 and loss on 
chromosome 10 are significant, but less frequent findings than in the Classical subtype. This 
GBM subtype may be responsive to inhibitors of the hypoxia-inducible factor (HIF), PI3K, 
and PDGFRA pathways. In this group, patients are younger and survival is slightly better 
than in the other 3 tumor subtypes.  
The fourth GBM subtype called “Neural” is less well defined and has gene expression 
signatures similar to those found in normal brain tissue, with activation of neuron markers 
such as NEFL, GABRA1, SYT1, and SLC12A5. These tumors demonstrate a low degree of 
infiltration by normal cells; nevertheless, their expression signature is suggestive of cells 
with a differentiated phenotype.  
Despite the existence of well defined differences in the genetic profile of the four subtypes, 
all tumor subgroups present inactivation of the p53 and RB tumor suppressor pathways, 
and activation of the receptor tyrosine kinase pathway. These observations suggest rather 
strongly that although molecular genetic profiling may eventually guide therapeutic 
decisions for patients with specific GBM subtypes, further studies linking the genetic 
alterations and the consequent affected signaling pathways, may be the key to better 
understand the occurrence and progression of these tumors. 
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GBMs. EGFR overexpression is also more common in primary GBMs (60%) than in 
secondary GBMs (10%). All primary GBMs with amplification of the EGFR gene, also show 
EGFR overexpression (Ohgaki, & Kleihues, 2007; Van Meir, et al., 2010). EGFR amplicons 
are often mutated, being the most frequent type the variant 3 (EGFRvIII) with an in-frame 
deletion of exons 2 to 7 within the extracellular ligand-binding domain. This in-frame 
deletion is associated with constitutive activation of the receptor and failure to attenuate 
signaling by receptor down-regulation (Ohgaki, & Kleihues, 2007; Van Meir, et al., 2010). 
The constitutively active EGFRvIII can enhance cell proliferation through activation of the 
PI3K/Akt pathway and therefore may play a very important role in gliomagenesis 
(Mellinghoff, et al., 2005;  Mizoguchi, et al., 2006).  
For this reason, EGFR has been a prime target for therapeutic intervention in GBM with 
small molecule kinase inhibitors, antibody-based immunotherapy and, more recently, with 
small interfering RNA (siRNA)-directed neutralization of either wild-type EGFR or the 
EGFRvIII allele (Van Meir, et al., 2010). In fact, several small-molecule EGFR-inhibitors such 
as gefitinib and erlotinib have been used in clinical trials but progression-free survival was 
not prolonged (van den Bent, et al., 2009). The inability to increase survival of GBM patients 
was also observed with lapatanib (EGFR/HER-2 inhibitor) (Neyns, et al., 2009; Thiessen, et 
al., 2009), and with the cetuximab, the monoclonal antibody against EGFR (Neyns, et al., 
2009).  
The unsuccess of EGFR inhibitors in GBM treatment seems to be associated to the 
inactivation of PTEN and to the activation of the PI3K/Akt. Mutations in PTEN were 
detected in 15 to 40% of GBMs and almost exclusively in primary GBMs (Ohgaki, & 
Kleihues, P., 2007; Zhou, et al., 1999). PTEN loss could thus promote resistance to EGFR 
kinase inhibitors by dissociating EGFR/EGFRvIII inhibition from downstream inhibition of 
the PI3K signaling pathway.  
The activation of PI3K/Akt pathway could also be due to the occurrence of mutations. In 
fact, it was reported that in up to 10% of GBMs, Akt activation is due to mutations that 
amplify or activate the catalytic and regulatory subunits of PI3K (Stommel, et al., 2007;  The 
Cancer Genome Atlas (TCGA) Research Network, 2008). It was also reported that PI3K 
could be activated by c-MET and PDGFR alpha, which could be co-activated in EGFR-
amplified tumors (Furnari, et al., 2007).  
Taken together, these results indicate that PI3K activation plays a central role in the 
resistance of GBM to EGFR inhibitors, since there are several mechanisms that may provide 
alternative routes for maintaining PI3K activation. Haas-Kogan et al. demonstrated in vitro 
and in glioma patients that high levels of EGFR coupled with low levels of activated Akt 
were associated with a favorable response to EGFR inhibitors (Haas-Kogan, et al., 2005). 
Therefore, a possible therapeutic strategy in GBM should control the activation of EGFR and 
the activation of PI3K or key mediators of PI3K. However, since PI3K upon activation may 
potentially phosphorylate several proteins involved in cell proliferation, apoptosis and 
migration, it remains to be determined which downstream effectors of Akt are most critical 
for gliomagenesis. One of those downstream effectors, associated with increased cell 
proliferation, is the serine/threonine kinase mTOR which forms the catalytic core of at least 
two functionally distinct complexes (mTORC1 and mTORC2). mTOR integrates growth-
inhibitory signals such as deprivation of glucose and amino acids, ATP depletion, hypoxia 
and lack of growth factors, in order to generate adaptive cellular responses (Wullschleger, et 
al., 2006). Deregulated mTOR signaling sustains proliferation of malignant cells by 
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antagonizing these physiological starvation signals (Wullschleger, et al., 2006). Therefore, it 
seems plausible that the commonly observed activation of mTOR signaling in GBM 
contributes to the typical pattern of GBM pathology, with necrotic cores and aggressive 
growth at the tumor margins (Masri, et al., 2007). 
Once activated, the mechanism of mTOR action could occur through different mechanisms 
depending on the activated complex: mTOR complex 1 or complex 2. The mTORC2 is 
composed by rictor (rapamycin-insensitive regulator of mTOR), mSIN1, protor and mLST8. 
This complex is activated by PI3K, phosphorylates Akt on serine 473 (Ser473) of its C-
terminal hydrophobic motif, promoting maximal Akt activity and acting as an upstream 
activator of Akt (Foster, & Fingar, 2010). mTORC2 also activates additional kinases, 
including serum glucocorticoid-induced protein kinase and PKCα, all of which may play 
important roles in regulating cellular proliferation and growth (Foster, & Fingar, 2010). 
mTORC2 activity is  elevated in glioma cell lines and seems to enhance motility and to 
promote glioma cell proliferation in vitro (Akhavan, et al., 2010). Further, in a recent 
drosophila model of gliomagenesis promoted by constitutive coactivation of EGFR-Ras-Akt, 
mTORC2 activity was required for glial proliferation suggesting that mTORC2 signaling is 
essential for growth in the context of enhanced signal flux through the PI3K pathway 
(Akhavan, et al., 2010; Read, et al., 2009). However, the mechanism of mTORC2 is not clearly 
understood and future studies will be needed to determine the role of mTORC2 in 
gliomagenesis.  
The mTOR complex 1 (mTORC1 or the mTOR-raptor complex which is rapamycin-
sensitive) is regulated by both nutrients and growth factor signaling. mTORC1 acts as a 
downstream effector of PI3K/Akt signaling, regulates the translation initiation and 
ribosome biogenesis and plays a role in cell growth, proliferation and survival (Akhavan, et 
al., 2010;  Foster, & Fingar, 2010;  Manning, & Cantley, 2007). The translational effects of 
mTOR1 signaling are mediated by phosphorylation of its two direct target molecules, 
eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) and ribosomal protein 
S6 kinase 1 (S6K1), at specific sites. In a serial cell line transformation model, mTORC1 
signaling through S6K1 was required for glioma formation, highlighting its functional 
importance (Akhavan, et al., 2010; Foster, & Fingar, 2010;  Manning, & Cantley, 2007). 
In the preclinical studies, mTOR inhibitors, specially rapamycin, were very promising since 
it was reported an increase in apoptotic and non-apoptotic cell death (Rao, et al., 2005), cell 
cycle arrest (Tanaka, et al., 2007) and decreased angiogenesis (Del Bufalo, et al., 2006). 
However, the results from phase I and II single-agent clinical trials of rapamycin conducted 
in glioma were disappointing (Heimberger, et al., 2005). The unsuccess could be related to 
the fact that mTORC1 plays a dual role as a positive and negative regulator of PI3K/Akt 
signaling and to the inability of rapamycin and its derivatives to target mTORC2. Recently, 
it was suggested a different interpretation of the clinical failure of rapamycin in GBM 
patients, namely, that the lack of efficacy is a consequence of incomplete inhibition rather 
than an injudicious choice of molecular target (Cloughesy, & Mischel, 2011). Cloughesy and 
Mischel hypothesize that since mTORC1 is both a positive and a negative regulator of the 
PI3K/Akt signaling pathway, the treatment with rapamycin causes derepression of 
mTORC1-mediated feedback and may paradoxically induce a more rapid clinical 
progression by promoting PI3K activity in GBM patients treated with rapamycin. To test 
this possibility, rapamycin treatment was reinstituted in patients after surgery and patients 
were monitored for progression. The results showed that rapamycin treatment led to Akt 
activation in seven of 14 patients, presumably due to loss of negative feedback, which was 
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GBMs. EGFR overexpression is also more common in primary GBMs (60%) than in 
secondary GBMs (10%). All primary GBMs with amplification of the EGFR gene, also show 
EGFR overexpression (Ohgaki, & Kleihues, 2007; Van Meir, et al., 2010). EGFR amplicons 
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PI3K/Akt pathway and therefore may play a very important role in gliomagenesis 
(Mellinghoff, et al., 2005;  Mizoguchi, et al., 2006).  
For this reason, EGFR has been a prime target for therapeutic intervention in GBM with 
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antagonizing these physiological starvation signals (Wullschleger, et al., 2006). Therefore, it 
seems plausible that the commonly observed activation of mTOR signaling in GBM 
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signaling through S6K1 was required for glioma formation, highlighting its functional 
importance (Akhavan, et al., 2010; Foster, & Fingar, 2010;  Manning, & Cantley, 2007). 
In the preclinical studies, mTOR inhibitors, specially rapamycin, were very promising since 
it was reported an increase in apoptotic and non-apoptotic cell death (Rao, et al., 2005), cell 
cycle arrest (Tanaka, et al., 2007) and decreased angiogenesis (Del Bufalo, et al., 2006). 
However, the results from phase I and II single-agent clinical trials of rapamycin conducted 
in glioma were disappointing (Heimberger, et al., 2005). The unsuccess could be related to 
the fact that mTORC1 plays a dual role as a positive and negative regulator of PI3K/Akt 
signaling and to the inability of rapamycin and its derivatives to target mTORC2. Recently, 
it was suggested a different interpretation of the clinical failure of rapamycin in GBM 
patients, namely, that the lack of efficacy is a consequence of incomplete inhibition rather 
than an injudicious choice of molecular target (Cloughesy, & Mischel, 2011). Cloughesy and 
Mischel hypothesize that since mTORC1 is both a positive and a negative regulator of the 
PI3K/Akt signaling pathway, the treatment with rapamycin causes derepression of 
mTORC1-mediated feedback and may paradoxically induce a more rapid clinical 
progression by promoting PI3K activity in GBM patients treated with rapamycin. To test 
this possibility, rapamycin treatment was reinstituted in patients after surgery and patients 
were monitored for progression. The results showed that rapamycin treatment led to Akt 
activation in seven of 14 patients, presumably due to loss of negative feedback, which was 
 
Molecular Targets of CNS Tumors 
 
300 
associated with a significantly shorter time to progression, during postsurgical maintenance 
of rapamycin therapy (Guertin, & Sabatini, 2009). These results highlight the importance of 
pathway cross-talk in determining response to targeted therapy and put in evidence the 
importance of combined therapy (Cloughesy, & Mischel, 2011). 
In fact, in the last years, several clinical trials used dual PI3K/mTOR inhibitors. Some of 
those inhibitors showed efficacy against a panel of GBM cell lines but, surprisingly, in 
preclinical GBM models, dual PI3K/mTOR inhibitors have failed to promote tumor cell 
apoptosis (Maira, et al., 2008). The remarkable plasticity of tumor cells was recently 
demonstrated in studies showing that mTORC1 inhibition leads to MAPK pathway 
activation through a PI3K-dependent mechanism (Carracedo, et al., 2008; Cloughesy, et al., 
2008). 
Mitogen-activated protein kinases (MAPKs) are serine/threonine protein kinases that 
transmit signals from the membrane to the nucleus in response to growth factors and 
cellular stress. Three principal isoforms of MAPKs exist: extracellular signal regulated 
kinase (ERK), c-jun NH2-terminal kinase (JNK) and p38 MAPK (p38). Activation of MAPKs 
occurs through phosphorylation of threonine and tyrosine residues of the Thr-X-Tyr motif 
by MAPK kinases (MEKs). In GBM, the existence of mutations affecting the expression or 
the activity of these serine/threonine protein kinases was not reported. However, since 
MAPKs may contribute to cellular proliferation and could be activated in response to the 
inhibition of PI3K/mTOR, its role in gliomagnesisis is under investigation. 
In spite of the unsuccess of the mTOR inhibitors, the mTOR signaling pathway remains one 
of the most important therapeutic targets and several studies are being carried on, in order 
to evaluate the role of mTORC2 and of mTORC1, the interaction between PI3K/mTOR, and 
the interaction between mTOR, EGFR and MAPK.  
5.2 p53 and cell cycle progression 
The tumor suppressor p53 encoded by TP53 gene was discovered in 1979 (DeLeo, et al., 
1979; Lane, & Crawford, 1979; Linzer, & Levine, 1979). At the beginning, p53 was considered 
a tumor antigen but today it is known that the wild-type gene product functions as a tumor 
suppressor that regulates cell cycle progression and apoptosis in response to a wide variety 
of stress signals, including DNA damage (Baker, et al., 1989). When cells are exposed to 
various genotoxic agents, p53 is stabilized, accumulates in the nucleus, binds and 
transcriptionally regulates the promoters of >2500 potential effectors genes (Levine, et al., 
2006). This leads to the expression of cell cycle checkpoint proteins and prevents the 
propagation of cells with unstable genomes, predominantly by halting the cell cycle in the 
G1 phase, or by initiating a program of apoptosis or proliferative arrest (Van Meir, et al., 
2010). The best characterized of these effectors is the p21 gene, which once transcriptionally 
activated blocks cell cycle progression in the G1 phase by inhibiting the function of the 
cyclin D family of proteins (Van Meir, et al., 2010). The cyclin D family is constituted by the 
regulatory subunits of the cyclin/cyclin–dependent kinase complexes that regulate cell cycle 
entry and progression by inducing the phosphorylation and inactivation of RB (Van Meir, et 
al., 2010). Due to the ability to coordinate the cellular responses to cellular stress factors, p53 
was called “cellular gatekeeper” (Levine, 1997) or “the guardian of the genome” (Lane, 
1992).  
Since p53 function is critical for normal cell growth and development, its activity is tightly 
regulated by phosphorylation, which is the first step to induce stabilization of p53, and also 
through its interaction with MDM2, the endogenous E3-ligase that targets p53 for 
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proteasome degradation (Michael, & Oren, 2003). MDM2 itself is transcriptionally activated 
by p53, thus creating a negative feedback loop that maintains p53 at very low levels in the 
absence of cellular damage. Upon stress, particularly DNA damage, Ser15 and Ser20 within 
the p53 N-terminal are phosphorylated by a broad range of kinases, including ATM, ATR, 
DNA-PK, Chk1, and Chk2 in a manner that prevents MDM2 from interacting with p53, thus 
resulting in p53 stabilization (Soussi, & Wiman, 2007;  Wade, et al., 2010). Another 
mechanism to stabilize p53 is by direct inhibition of the MDM2 ubiquitin ligase activity 
through its association with Arf, the alternative transcript of the Ink4a tumor suppressor 
locus, which may induce G1- and G2-phase arrest (Matheu, et al., 2008). 
In 50% of the human tumors, the p53 pathway is inactivated via indirect mechanisms such 
as MDM2 amplification, viral infection or loss of Arf, leading to p53 destabilization (Brooks, 
& Gu, 2006). The other 50% of the tumors present missense mutations that originate a subset 
of p53 mutant proteins with oncogenic properties that may contribute to the neoplastic 
transformation (Soussi, & Wiman, 2007;  Wade, et al., 2010).  
In GBM, TP53 is the most frequently mutated gene, and the majority of its mutations occur 
in “Proneural” subtype of GBM samples (The Cancer Genome Atlas (TCGA) Research 
Network, 2008;  Verhaak, et al., 2010). In addition, the TCGA reported that mutations are 
clustered in the DNA binding domain, a hotspot for p53 mutations in human cancers (The 
Cancer Genome Atlas (TCGA) Research Network, 2008). In secondary GBM, loss of p53 is 
detectable in two thirds of the tumors and may occur through either point mutations that 
prevent DNA binding, or loss of chromosome 17p. In primary GBM, TP53 inactivation is 
now considered a common event which may occur via amplification or overexpression of 
the p53 negative regulators MDM2 and MDM4, which suppresses p53’s transcriptional 
activity (Foster, & Fingar, 2010;  Ohgaki, et al., 2004;  Zheng, et al., 2008).  
According to the TCGA, in GBM the inactivation of the p53 pathway occurs in the form of 
Arf deletions (55%), amplifications of MDM2 (11%) and MDM4 (4%), in addition to 
mutations of p53 itself (The Cancer Genome Atlas (TCGA) Research Network, 2008). Among 
the 91 samples sequenced by this Network, genetic lesions in TP53 were mutually exclusive 
of those in MDM2 or MDM4 but not of those in ARF (encoded by CDKN2A).  
Since MDM2 is considered the main regulator of p53, the inhibition of p53-MDM2 
interaction is regarded as having therapeutic potential. A number of different strategies 
have been employed to develop small molecules that bind specifically to the N-terminal 
region of MDM2, that interacts with p53 (Shangary, & Wang, 2009). The most promising 
candidate described so far has been nutlin-3A (Vassilev, et al., 2004). In fact, glioma C6 cells 
were quite sensitive to nutlin-3A treatment but further studies will be needed to understand 
the real potential of this strategy (Merkel, et al., 2010). 
5.3 Retinoblastoma signaling pathway 
The RB pathway consists of several proteins: the cyclin-dependent kinase inhibitor (CDKN), 
the cyclin D-dependent protein kinases (cdk4, cdk6), the E2F-family of transcription factors 
(heterodimers of E2F1-8 with DP1-2) and the RB-family (RB, p107, p130) (Knudsen, & Wang, 
2010;  Scambia, et al., 2006;  Van Meir, et al., 2010). The Rb gene is localized on the 13q14 
chromosome and was the first known human suppressor of tumors (Huang, et al., 1988). 
The RB family consists of pRb/p105, p107 and pRb2/p130 which have an homologous 
functional domain known as the pocket region. This region allows the interaction of RB 
proteins with multiple peptides and the assembly of nuclear protein-complexes that regulate 
transcription factor activities, G1-phase cell cycle arrest, cell proliferation and differentiation 
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associated with a significantly shorter time to progression, during postsurgical maintenance 
of rapamycin therapy (Guertin, & Sabatini, 2009). These results highlight the importance of 
pathway cross-talk in determining response to targeted therapy and put in evidence the 
importance of combined therapy (Cloughesy, & Mischel, 2011). 
In fact, in the last years, several clinical trials used dual PI3K/mTOR inhibitors. Some of 
those inhibitors showed efficacy against a panel of GBM cell lines but, surprisingly, in 
preclinical GBM models, dual PI3K/mTOR inhibitors have failed to promote tumor cell 
apoptosis (Maira, et al., 2008). The remarkable plasticity of tumor cells was recently 
demonstrated in studies showing that mTORC1 inhibition leads to MAPK pathway 
activation through a PI3K-dependent mechanism (Carracedo, et al., 2008; Cloughesy, et al., 
2008). 
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cellular stress. Three principal isoforms of MAPKs exist: extracellular signal regulated 
kinase (ERK), c-jun NH2-terminal kinase (JNK) and p38 MAPK (p38). Activation of MAPKs 
occurs through phosphorylation of threonine and tyrosine residues of the Thr-X-Tyr motif 
by MAPK kinases (MEKs). In GBM, the existence of mutations affecting the expression or 
the activity of these serine/threonine protein kinases was not reported. However, since 
MAPKs may contribute to cellular proliferation and could be activated in response to the 
inhibition of PI3K/mTOR, its role in gliomagnesisis is under investigation. 
In spite of the unsuccess of the mTOR inhibitors, the mTOR signaling pathway remains one 
of the most important therapeutic targets and several studies are being carried on, in order 
to evaluate the role of mTORC2 and of mTORC1, the interaction between PI3K/mTOR, and 
the interaction between mTOR, EGFR and MAPK.  
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The tumor suppressor p53 encoded by TP53 gene was discovered in 1979 (DeLeo, et al., 
1979; Lane, & Crawford, 1979; Linzer, & Levine, 1979). At the beginning, p53 was considered 
a tumor antigen but today it is known that the wild-type gene product functions as a tumor 
suppressor that regulates cell cycle progression and apoptosis in response to a wide variety 
of stress signals, including DNA damage (Baker, et al., 1989). When cells are exposed to 
various genotoxic agents, p53 is stabilized, accumulates in the nucleus, binds and 
transcriptionally regulates the promoters of >2500 potential effectors genes (Levine, et al., 
2006). This leads to the expression of cell cycle checkpoint proteins and prevents the 
propagation of cells with unstable genomes, predominantly by halting the cell cycle in the 
G1 phase, or by initiating a program of apoptosis or proliferative arrest (Van Meir, et al., 
2010). The best characterized of these effectors is the p21 gene, which once transcriptionally 
activated blocks cell cycle progression in the G1 phase by inhibiting the function of the 
cyclin D family of proteins (Van Meir, et al., 2010). The cyclin D family is constituted by the 
regulatory subunits of the cyclin/cyclin–dependent kinase complexes that regulate cell cycle 
entry and progression by inducing the phosphorylation and inactivation of RB (Van Meir, et 
al., 2010). Due to the ability to coordinate the cellular responses to cellular stress factors, p53 
was called “cellular gatekeeper” (Levine, 1997) or “the guardian of the genome” (Lane, 
1992).  
Since p53 function is critical for normal cell growth and development, its activity is tightly 
regulated by phosphorylation, which is the first step to induce stabilization of p53, and also 
through its interaction with MDM2, the endogenous E3-ligase that targets p53 for 
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proteasome degradation (Michael, & Oren, 2003). MDM2 itself is transcriptionally activated 
by p53, thus creating a negative feedback loop that maintains p53 at very low levels in the 
absence of cellular damage. Upon stress, particularly DNA damage, Ser15 and Ser20 within 
the p53 N-terminal are phosphorylated by a broad range of kinases, including ATM, ATR, 
DNA-PK, Chk1, and Chk2 in a manner that prevents MDM2 from interacting with p53, thus 
resulting in p53 stabilization (Soussi, & Wiman, 2007;  Wade, et al., 2010). Another 
mechanism to stabilize p53 is by direct inhibition of the MDM2 ubiquitin ligase activity 
through its association with Arf, the alternative transcript of the Ink4a tumor suppressor 
locus, which may induce G1- and G2-phase arrest (Matheu, et al., 2008). 
In 50% of the human tumors, the p53 pathway is inactivated via indirect mechanisms such 
as MDM2 amplification, viral infection or loss of Arf, leading to p53 destabilization (Brooks, 
& Gu, 2006). The other 50% of the tumors present missense mutations that originate a subset 
of p53 mutant proteins with oncogenic properties that may contribute to the neoplastic 
transformation (Soussi, & Wiman, 2007;  Wade, et al., 2010).  
In GBM, TP53 is the most frequently mutated gene, and the majority of its mutations occur 
in “Proneural” subtype of GBM samples (The Cancer Genome Atlas (TCGA) Research 
Network, 2008;  Verhaak, et al., 2010). In addition, the TCGA reported that mutations are 
clustered in the DNA binding domain, a hotspot for p53 mutations in human cancers (The 
Cancer Genome Atlas (TCGA) Research Network, 2008). In secondary GBM, loss of p53 is 
detectable in two thirds of the tumors and may occur through either point mutations that 
prevent DNA binding, or loss of chromosome 17p. In primary GBM, TP53 inactivation is 
now considered a common event which may occur via amplification or overexpression of 
the p53 negative regulators MDM2 and MDM4, which suppresses p53’s transcriptional 
activity (Foster, & Fingar, 2010;  Ohgaki, et al., 2004;  Zheng, et al., 2008).  
According to the TCGA, in GBM the inactivation of the p53 pathway occurs in the form of 
Arf deletions (55%), amplifications of MDM2 (11%) and MDM4 (4%), in addition to 
mutations of p53 itself (The Cancer Genome Atlas (TCGA) Research Network, 2008). Among 
the 91 samples sequenced by this Network, genetic lesions in TP53 were mutually exclusive 
of those in MDM2 or MDM4 but not of those in ARF (encoded by CDKN2A).  
Since MDM2 is considered the main regulator of p53, the inhibition of p53-MDM2 
interaction is regarded as having therapeutic potential. A number of different strategies 
have been employed to develop small molecules that bind specifically to the N-terminal 
region of MDM2, that interacts with p53 (Shangary, & Wang, 2009). The most promising 
candidate described so far has been nutlin-3A (Vassilev, et al., 2004). In fact, glioma C6 cells 
were quite sensitive to nutlin-3A treatment but further studies will be needed to understand 
the real potential of this strategy (Merkel, et al., 2010). 
5.3 Retinoblastoma signaling pathway 
The RB pathway consists of several proteins: the cyclin-dependent kinase inhibitor (CDKN), 
the cyclin D-dependent protein kinases (cdk4, cdk6), the E2F-family of transcription factors 
(heterodimers of E2F1-8 with DP1-2) and the RB-family (RB, p107, p130) (Knudsen, & Wang, 
2010;  Scambia, et al., 2006;  Van Meir, et al., 2010). The Rb gene is localized on the 13q14 
chromosome and was the first known human suppressor of tumors (Huang, et al., 1988). 
The RB family consists of pRb/p105, p107 and pRb2/p130 which have an homologous 
functional domain known as the pocket region. This region allows the interaction of RB 
proteins with multiple peptides and the assembly of nuclear protein-complexes that regulate 
transcription factor activities, G1-phase cell cycle arrest, cell proliferation and differentiation 
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(Weinberg, 1995). Since RB is phosphorylated and dephosphorylated during the cell cycle, 
its activity depends on the phosphorylation status: the hyperphosphorylated (inactive) form 
predominates in proliferating cells, whereas the hypophosphorylated (active) form is 
generally more abundant in quiescent or differentiating cells (Harbour, & Dean, 2000). In 
quiescent cells, hypophosphorylated RB blocks proliferation by binding and sequestering 
the E2F family of transcription factors, which prevents the activation of genes essential for 
cell cycle progression, ensuring that transcription factors remain inactive during M and G0 
phases (Furnari, et al., 2007). In proliferating cells, growth factors lead to the induction of 
cyclin D1, as well as to the degradation of the Cdk2/cyclin E inhibitor, p27Kip1 (White, et 
al., 2005). These activated Cdk complexes trigger the phosphorylation of RB in late G1-
phase, which is maintained in S-, G2-, and M-phases. The pRB enables E2F release leading to 
transcriptional activation of growth promoting genes which are required for transcription of 
cellular genes that participate in growth control and DNA synthesis (Furnari, et al., 2007;  
Harbour, & Dean, 2000;  Malumbres, & Barbacid, 2001). Among the E2F-regulated genes are 
cyclin E, cyclin A2 and Emi1, which are key effectors of the G1/S transition in normal cells 
(Furnari, et al., 2007;  Knudsen, & Wang, 2010).  
One of the negative regulators of the RB signaling pathway is the Ink4-family of proteins, 
p16Ink4a, p15Ink4b, p18Ink4c, and p19Ink4d which are small heat-stable proteins 
containing the AKN (ankyrin repeat) domain (Knudsen, & Wang, 2010). Each of the Ink4 
proteins can bind to and inhibit the activity of Cdk4 and Cdk6. The Ink4 proteins compete 
with the D-cyclins for Cdk4/6 to prevent the formation of the active kinase complex that 
phosphorylates pRB (Knudsen, & Wang, 2010).  
In the comprehensive analysis of the genome and transcriptome of 206 primary GBM 
tumors performed by the TCGA project, the sequence of 601 genes in 91 of the 206 tumor 
samples was analyzed.  The results have shown that the RB pathway was altered in 78% 
of the primary GBM tumor samples, directly by mutations, deletions or promoter 
methylations at Rb loci, as well as indirectly by alterations on the positive or negative 
regulators (The Cancer Genome Atlas (TCGA) Research Network, 2008). Rb promoter 
methylation and gene silencing were more frequently found in secondary GBMs (43%) 
than in primary GBMs (14%) (Grzmil, & Hemmings, 2010; Xiao, et al., 2002). The 
alterations in the RB-pathway included homozygous deletion and mutation of CDKN2A 
(p16Ink4a) and Rb1 (RB) in 52% and 11% of the samples, respectively, and homozygous 
deletion of CDKN2B (p15Ink4b) and CDKN2C (p18Ink4c) in 47% and 2% of the tumor 
samples, respectively. On the other hand, the CDK4, CDK6, and CCND2 (cyclin D2) genes 
were amplified in 18%, 1%, and 2% of the GBM tumors examined (The Cancer Genome 
Atlas (TCGA) Research Network, 2008).  
In spite of the importance of RB pathway, several in vitro and in vivo studies demonstrated 
that the neutralization of this pathway alone is insufficient to abrogate cell cycle control, 
suggesting that cell cycle is also regulated by other signaling pathways (Furnari, et al., 
2007). 
In the last years, several studies have been performed in order to establish a therapeutic 
strategy based on the manipulation of the cyclin–RB–E2F pathway. The development of 
small molecules that specifically inhibit certain cyclin/CDK complexes, or that could affect 
E2F-dependent transcription, as well as peptides that can mimic the functional regions of RB 
proteins inactivated in specific tumors, is currently under investigation (Scambia, et al., 
2006). 
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5.4 Vascular endothelial growth factors  
Vascular endothelial growth factors (VEGFs) were originally described as vascular 
permeability factors (VPF), since they were released by tumor cells that promote vascular 
leakage (Keck, et al., 1989). VEGFs are predominantly produced by endothelial, 
hematopoietic and stromal cells in response to hypoxia, and upon stimulation with growth 
factors such as transforming growth factors, interleukins or PDGF.  
VEGFs are dimeric cysteine-linked secreted glycoproteins with a molecular weight of 
approximately 40 kDa. In mammals, VEGFs are encoded by a family of genes that includes 
VEGF-A, -B, -C, -D and PlGF (Cebe-Suarez, et al., 2006; Van Meir, et al., 2010). 
VEGFs bind to three variants of type III receptor tyrosine kinases, VEGF receptor 1, 2 and 3 
(Cebe-Suarez, et al., 2006). The binding of VEGF to its cognate receptors induces dimerization 
and subsequent phosphorylation of the receptors, leading to the activation of several 
intracellular signaling molecules such as PI3K, phospholipase Cg (PLCg), PKC, nitric oxide 
synthase (NOS), MAPKs and focal adhesion kinases (FAKs) (Karkkainen, & Petrova, 2000). 
VEGF has been demonstrated to be one of the dominant drivers of angiogenesis 
contributing to tumor growth and progression (Criscuolo, G. R. et al., 1990). Due to this role, 
inhibitors of VEGF are widely used in cancer therapy in order to reduce angiogenesis 
(Ferrara, & Kerbel, 2005;  Huang, et al., 2003), to cause regression of tumor vessels, and to 
reduce tumor growth (Huang, et al., 2003). 
Extensive experimental data support the concept that angiogenesis is required for GBM 
growth (Jain, et al., 2007;  Schmidt, et al., 1999;  Van Meir, et al., 2010). The process is driven 
primarily by tumor secreted VEGF-A, but there are a large number of alternative secreted 
proangiogenic factors, including basic FGF (bFGF), angiopoietins, PDGF, interleukin-8 (IL-
8), and hepatocyte growth factor/scatter factor (HGF/SF). Endothelial cells in the vicinity of 
the tumor express VEGFR2, which establishes a paracrine signaling loop that stimulates 
endothelial cell growth and proliferation. The level of VEGF production in a tumor increases 
with the degree of malignancy. In a study of surgical glioma specimens, high-grade tumors 
produced greater than 10-fold more VEGF compared with low-grade tumors (Schmidt, et 
al., 1999). It was also demonstrated that EGFR activation transcriptionally upregulates VEGF 
expression in GBM cells (Mischel, et al., 2003). 
A targeted molecular therapy for GBM included agents that interfere with angiogenesis. The 
early trials with the first generation of anti-angiogenic agents (for example, thalidomide), 
conducted in GBM patients, had disappointing results (Jain, et al., 2007). The new 
generation of antiangiogenic drugs evaluated in clinical trials uses the anti-VEGF antibody 
bevacizumab, which neutralizes VEGF, and the VEGF-receptor tyrosine kinase inhibitors 
(TKIs) (sorafinib and sunitinib) (Jain, et al., 2007). Bevacizumab, a humanized anti-VEGF 
antibody, has shown promising results in exploratory phase II trials of recurrent GBM. 
However, these results are based on small patient cohorts and, because anti-angiogenic 
agents directly affect vessel permeability, the imaging response assessment based on 
contrast enhancement (CE) is highly ambiguous (Vredenburgh, et al., 2007). However, there 
is increasing interest in targeting proangiogenic molecules that function by alternative 
mechanisms (Van Meir, et al., 2010). For example, the neuropilins are nontyrosine kinase 
receptors that are activated by VEGF binding and potentiate VEGFR signaling. The 
angiopoietins (Ang-1 and Ang-2) are involved in the stability and maintenance of the tumor 
vasculature. Binding of Ang-2 to its cognate receptor, Tie-2 destabilizes vessels, which is a 
requirement for angiogenesis to proceed (Holash, et al., 1999). Inhibitors of specific 
chemotactic signaling may also have therapeutic value, since tumor cells secrete chemokines 
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(Weinberg, 1995). Since RB is phosphorylated and dephosphorylated during the cell cycle, 
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cell cycle progression, ensuring that transcription factors remain inactive during M and G0 
phases (Furnari, et al., 2007). In proliferating cells, growth factors lead to the induction of 
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that serve to recruit proangiogenic myeloid cells to the tumor (Van Meir, et al., 2010). 
However, it must be noted that antibodies and many of these low-molecular weight 
compounds may not cross the blood-brain barrier. 
6. Conclusion  
Despite all the evidences already mentioned, the mechanism of gliomagenesis and the cells 
of origin for GBM remain unknown. Several studies suggest that different cells of origin 
give rise to distinct types of GBM-CSC. Thus, GBM may also develop differently from 
different cells of origin or via different molecular steps, which accounts for their 
heterogeneity. From the therapeutic point of view, the inter- and intratumoral heterogeneity 
presents a unique challenge for GBM treatment.  
In the last years, many progresses were done in order to identify the molecular signature of 
GBM, and these recent studies confirmed that each GBM is characterized by alterations in 
several signaling pathways that control cellular proliferation and apoptosis such as 
EGFR/mTOR/Akt/PTEN, p53, RB, VEGF, which contribute to the unsuccess of 
monotherapies and put in evidence the need to perform combined therapy, adjusted to the 
genetic and molecular alterations of each patient. 
In addition, these studies reinforced the remarkable plasticity of GBM cells that allow cells 
to switch from one signaling pathway to another, according to the difficulties imposed by 
the therapeutic agents. 
Thus, combined therapeutic strategies, targeting both the brain tumor stem cells and the 
molecular alterations that characterize the brain tumor of each patient, could turn out to be 
the most effective approach to increase the survival of GBM patients.  
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1. Introduction 
Gliomas represent a formidable challenge in terms of pathophysiologic and clinical 
behaviour. 
The frequently used term “glioma” applies to neoplasms derived from components of 
neuroglia: astrocytes, oligodendrocytes and ependima cells with the corrisponding tumors, 
astrocytomas, oligodendrogliomas and ependymomas (Louis et al 2007, Graham et al 2006). 
They represent the most common primary intra-axial brain tumor (40% of intracranial tumors 
with an estimated incidence of 12.000 new cases /year in the U.S.). Importantly, when 
discussing gliomas, the terms benign and malign have little meaning; the WHO classification 
provides a grading system to subdivide gliomas. Grading is based on cellularity, presence of 
giant cells, anaplasia, mitotic activity, microvascular proliferation with or without endothelial 
proliferation, necrosis and pseudopalisading. Astrocytomas and oligodendrogliomas are 
usually defined as grade II (III in the anaplastic form) while glioblastomas are grade IV. So a 
simpler classification describes these tumors as being of low or high grade. 
From a clinical point of view the grading system has an inverse correlation to patient 
survival and it is important in taking decisions as to the therapeutic strategies. 
With the exception of one or two entities (e.g. pilocytic astrocytoma-grade I), a low grade 
glioma will continue to acquire genetic mutations and eventually will transform into a high 
grade neoplasm. This process is defined dedifferentiation and represents the major cause of 
morbidity with low-grade astrocytomas. Genetic markers that correlate with a higher degree 
of malignant degeneration include loss of heterozygosity at chromosomes 10 & 17, alteration 
in tumor suppressor genes 9p, 13q, 19q & 22q, changes in epidermal growth factor receptor 
(EGRF) and platelet derived growth factor (PDGF) and mutation of the p53 suppressor gene. 
To underline the importance of this behaviour, the gliomas that developed in the adult are 
frequently defined as “diffuse” because of  their ability to profoundly infiltrate the brain 
parenchyma (Louis et al 2007).  
Glioblastomas (the most malignant form of glial tumors) are characterized by extensive 
dissemination of tumor cells within the brain that are hallmarked histologically by the 
presence of vascular endothelial proliferation and wide areas of necrosis often presenting 
hemorrhagic components. Besides invasion, enhanced proliferation, angiogenesis and 
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resistance to apoptosis are all involved in the progression and maintenance of this 
malignancy. 
As mentioned above gliomas still represent a formidable clinical challenge. In spite of 
optimal and multidisciplinary treatment (in high grade forms, surgery followed by 
chemotherapy and radiotherapy) the prognosis of patients affected with gliomas is poor and 
it becomes dramatic in patients with glioblastomas. As a matter of fact patients with 
glioblastomas survive less than 1 year and prognosis has not consistently changed over the 
last two decades. Again, the reason of this defeat can be found in the rapidly expanding 
nature of these tumors and their capability of invading the normal brain by active cell 
migration. 
Inflammatory cells are a key component of the tumor microenvironment (Mantovani et al 
2008; Hanahan and Weinberg  2011). Chemokines play an important role in orchestrating 
leukocytes recruitment in tumors including gliomas. Moreover, these molecules affect 
various aspects of tumor cell function (Balkwill et al 2004, Mantovani et al 2006-2008, 
Lazennec and Richmond 2010). Here we will review available information on the expression 
and role of chemokines in gliomas.  
2. The chemokine universe  
Chemokines are a large family of small chemoattractant cytochines. They comprise 
approximately 50 ligands and 20 receptors in humans. The number and position of 
conserved cysteine residues divide this family of related molecules into two major (CXC and 
CC) and two minor (C and CX3C) chemokine classes (Mantovani et al 2006, Charo and 
Ransohoff  2006).  
Chemokine receptors are G-protein coupled, seven transmembrane receptors. Based on the 
chemokine class they bind, the receptors have been named CXCR1-7 (bind to CXC 
chemokines); CCR1 through CCR10 (bound to CC chemokines), XCR1 (bound to the C 
chemokine, lymphotactin/XCL1) and CX3CR1 (bound to the CX3C chemokine, 
fractalkine/CXCL1) (Zlotnik 2006). Another classification is between homeostic and 
inflammatory molecules according to the chemokine constitutive (e.g. SDF1/CXCL12) or 
inflammatory-induced (e.g. CCL2) production, respectively Importantly, if this classification 
is useful it can be criticized because it does not take into account chemokines classified as 
inflammatory that are locally but constitutively expressed by tumor cells or in a tissue 
specific manner (e.g. CX3CL1 in brain).  
The most important targets of chemokines are leukocytes. Their ability to orchestrate 
leucocyte trafficking under basal and inflammatory conditions is generally named as 
chemotaxis, but chemokine control is also exerted on cell adhesion, proliferation, survival 
and gene transcription (Campbell and Butcher 2000). 
Moreover, chemokine action is not only limited to white cells but it extends to many other 
cell populations. In particular, chemokine and chemokine receptors are widely expressed 
into the central nervous system both by neurons and glial cells. The chemokine network in 
the central nervous system is involved in several brain processes such as cell migration, 
regulation of neuronal survival, neurotransmission and cell-cell communication (Ambrosini 
and Aloisi 2004). For this reason chemokine and chemokine receptors can be considered the 
third major transmitter system in the brain (Adler et al 2005). Interestingly, the chemokine 
universe seems to be altered in neurodegenerative disorders such as Alzheimer like 
dementia, multiple sclerosis and brain tumors (Ransohoff et al 2009, Sciumè et al 2010-2011, 
Marchesi et al 2010, Trettel et al 2010). 
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3. Chemokines in gliomas  
3.1 Glioma cell expression of chemokine and chemokine receptors 
The migratory ability of gliomas has been investigated by electron microscopy and it was 
shown that neoplastic cells easily adjust their shape and size to slip through the narrow 
brain spaces, a process that requires Cl channels (Mc Coy and Sontheimer 2007). 
It is now established that migrating malignant cells exploit chemokine receptors to invade 
surrounding tissues thus leading to distant metastasis (Balkwill 2004, Zlotnik 2006, 
Mantovani et al 2010). 
The expression of chemokines and chemokine receptors is considered to play a role in tumor 
cell proliferation, invasion, migration and ability to metastasize. This expression can be 
activated or amplified by both stromal cells and tumor cells themselves (Mantovani et al 
2010).  
Moreover the immune cell infiltration in the neoplastic area largely depends on the 
chemokine expression.  
Since 1990 the production of chemokines by cell lines of glioma has been described (IL-
8/CXCL8; MCP1/CCL2 etc). In particular, CCL2 was described to be expressed in low and 
high grade glioma cells both “in vitro” and “in vivo” (Jiang et al 1990, Kasahara et al 1991, 
Nitta et al 1992, Kuratsu et al 1993). In 1997 Desbaillets and colleagues demonstrated high 
levels of expression of CXCL8 and its receptors CXCR1 and CXCR2 within the  necrotic 
areas surrounding brain tumor cells. Significantly, the presence of these two receptors was 
described in endothelial cells of new blood vessels, suggesting they may be implicated in 
neoangiogenesis. 
At the early 2000s an important role of the CXCR4/CXCL12 axis has been identified for the 
regulation of different aspects of glioma tumor progression. High levels of this complex 
expression were demonstrated in areas nearby tumor necrosis (Rempel et al 2000). CXCR4 
as well as CXCL8 were also demonstrated to be expressed both in glioma cells lines and 
primary glioblastomas. Interestingly, CXCL8 and CXCL12 “in vivo” secretion can also arise 
from other cellular populations such as endothelial cells and macrophage/microglial cells, 
and these populations are  implied in gliomagenesis (Hong et al 2009). The expression of 
CXCL10, CXCL8 and CCL2 is increased by CXCL12-induced CXCR4 stimulation in gliomas 
thus creating a sort of amplification loop which influence tumor growth, angiogenesis and 
immune cells infiltration. 
The increased expression of  IP10/CXCL10 and of CCL3L1 and their receptors found in 
glioma cells compared to “normal” astrocytes lead to hypothesize an autocrine role for these 
axes in glioma control (Maru et al 2008). The high expression of CX3CL1 (or fractalkine) in 
the brain has suggested that also CX3CL1/CX3CR1 axis may play a role in malignancies of 
the central nervous system (Locatelli et al 2010, Marchesi et al 2010, Sciumè et al 2010). 
Indeed, neurons and astrocytes are major producers of the ligand and microglia express the 
receptor CX3CR1 expression has been detected both in glial cells and in neurons. 
Experimental evidence established that this axis play a major role in the neuron/microglia 
cross-talk and in neuroprotection under conditions of inflammation (Cardona et al 2006, 
Gunther et al 2005, Miller et al 2008).  
Using a murine model a positive in situ hybridization for CX3CR1 corresponding with the 
localisation of CD11b-positive microglia was described (Liu et al 2008). As for human 
glioblastomas CX3CR1 immunopositivity was found in neoplastic cells (Ludwig et al 2005, 
Locatelli et al 2010).  
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Moreover, Sciumè and colleagues in 2010 described that glioblastomas cells express both the 
membrane-bound and the secreted form of CX3CL1 and its receptor CX3CR1. Marked 
expression of CX3CR1 was similar across low and high grade tumor though it was highest 
in glioblastomas. The presence of receptor expression in low grade tumor suggests that its 
upregulation is an early event during malignant transformation. In a recent paper (Erreni et 
al 2010) CX3CR1 was similarly detected in low and high grade tumors while the uppermost 
score of CX3CL1 were found in grades II and IV. Accordingly, the expression of fractlakine 
was inversely correlated to the patient survival. 
Notably, constitutive expression of CX3CL1 in CX3CR1 positive glioblastomas negatively 
regulates tumor cell invasiveness by promoting their aggregation (Sciumè et al 2010). 
CX3CL1 is induced by TNF α and TNF β in neurons (Chen et al 2002, Sciumè et al 2010). 
These mediators are frequently present in tumors including gliomas and may be involved in 
the modulation of CX3CL1/CX3CR1 axis in neoplastic conditions (Mantovani et al 2008, 
Balkwill et al 2009).  
In 2005 Ludwig and colleagues demonstrated that another membrane-bound chemokine, 
CXCL16 is upregulated in human glioma being this chemokine expression low in normal 
brain and substantially limited to brain endothelial cells. 
Expression of chemokines and their receptors is modulated by factors produced by gliomas 
or by the tumor microenvironment. Examples are CXCL8, CXCL12 anCXCR4 which are up 
regulated in hypoxic conditions or upon stimulation with VEGF, an angiogenetic growth 
factor expressed in glioma tissues (Desbaillets et al 1997, Zagzag et al 2008). 
3.2 Chemokines in glioma invasion 
The peculiar adhesive function of fractalkine in the nervous system suggests that this 
chemokine/receptor complex plays a role in the neurotropism of cancer cells to peripheral 
nerves. This is a distinct and largely underestimated way of metastasis compared to blood 
and lymphatic routes; many human carcinomas such as bladder, prostate and pancreas take 
advantage of this route (Marchesi et al 2010). 
The invasive process of glioma cells requires the detachment of invading cells from the 
primary mass of the tumor, attachment to extracellular matrix components and degradation 
of this matrix. At this point tumor cell migration into brain structures can take place. 
CX3CL1 would have a negative role in this process, as suggested by the increase in glioma 
cell invasion properties by the blockade  induced by CX3CR1-CX3CL1 axis. Moreover, the 
reduced CX3CR1 expression consequent to TGF-beta 1 activation can favour glioma 
invasiveness (Sciumè et al 2010).  
Another axis which is acquiring an increasing consideration in this complex process is the 
CXCL12/CXCR4 axis. This axis has been linked to glioma progression both “in vitro” and 
“in vivo” (Zhou et al 2002, Zhang et al 2005, Ehtesham et al 2006, Bajetto et al 2006)  because 
of its ability to activate metalloproteinases, including the membrane type-2-MMP. 
Accordingly, invasive human glioma cell overexpress CXCR4 while noninvasive glioma cell 
do not. These data were confirmed “in vivo” in neoplastic cells from a rat C6 glioma cell line 
(Ehtesham et al 2006). 
 Co-expression of CXCL12 and its receptors is mainly localized to the pseudopalisade zones 
that surround necrotic foci (Rempel et al 2000). These regions are believed to represent 
tumor cells which are leaving necrotic regions because of their low or absent oxygen levels. 
In hypoxic condition, tumor cells release an angiogentic growth factor (VEGF) which 
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promotes the over-expression of CXCL12 and consequently tumor invasion outside the 
hypoxic area (Zagzag et al 2008). 
Promotion of glioma cell invasion is also mediated by Gro-alpha/CXCL1 that is expressed 
by oligodendroglioma and anaplastic astrocytomas (Zhou et al 2005). Interestingly CXCL1 
overexpression conferred increased tumorigenicity to U251 cells following implantation into 
the brain of nude mice (Zhou et al 2005). 
3.3 Chemokine role in glioma proliferation 
In addition to CXCL12, also CXCL8, CXCL10 and CCL3L1 have been described to promote 
glioma cell proliferation in vitro (Kouno et al 2004, Maru et al 2008). Notably, a correlation 
between CXCL8 expression levels in cells surrounding necrotic areas and histologic grade in 
glioma has been demonstrated (Desbaillets et al 1997). 
Chemokines also contribute to create a proangiogenic microenvironment by promoting 
attraction of endothelial cells and leukocytes to the tumor. The chemokine receptor panel of 
human microvascular endothelial cells includes CXCR2, CXCR3B, CXCR4 and CX3CR1 
(Bernardini et al 2003). 
As mentioned above, CXCR4 is expressed by both tumor cells and vascular endothelial cells in 
different grades of gliomas; this is associated with CXCL12 production in the tumor 
microenvironment, which is capable  to modulate migration, proliferation and survival of 
endothelial and tumor cells (Salmaggi et 2004). It was demonstrated that CXCR4 is expressed 
by both tumor cells and vascular endothelial cells in all grades of gliomas. The administration 
of AMD-3100, a CXCR4 antagonist, inhibits the growth of glioblastoma xenografts in mouses, 
demonstrating the dependence of tumor cells proliferation on CXCR4 (Rubin et al 2003). 
3.4 Chemokine network and leukocyte infiltration  
Besides its direct effects on tumor growth, the network of chemokines implicated in human 
astrcytomas can influence the degree and phenotype of immune cell infiltration. However,  
it is well accepted that glioma cells can be recognized by both innate and adaptive immunity 
(Mantovani et al 2008, Friese et al 2004, Dunn et al 2007). T-cell infiltration has been 
described to be present in neuroephitelial tumors, on the contrary NK cells are poorly 
included in the glioma lymphocyte infiltrate (Vaquero et al 1989). 
To date, data regarding the specificity and function of  tumor –infiltrating lynphocytes such 
as the involvement of the chemokine network in the recruitment of these cells or tumor 
infiltrating microglia/macrophages are lacking. Glia derived CCL2 might be implicated in 
the process leading to the abundant tumor infiltration by macrophages/microglia and T 
cells (Jordan et al 2008). CCL2 expression by glioma cells would be advantageous for tumor 
progression thanks to the attraction of T regulatory cells that suppress lymphocyte anti 
tumor effector functions and of microglia cells with reduce anti-tumor functions. Another 
effect would be the secretion of metalloproteinases. The corresponding receptors were the 
CCR2 on microglia and CCR4 on T regulatory cells (Hussain et al 2006). The role of the 
CX3CL1/CX3CR1 chemokine/receptor pair in microglial and lymphocyte infiltration 
remains to be defined.(Liu et al 2008, Rodero et al 2008) 
3.5 Concluding remarks 
Available information strongly suggest that chemokines play an important role in gliomas. 
In particular, evidence suggests that they are orchestrators of leukocyte recruitment in the 
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Notably, constitutive expression of CX3CL1 in CX3CR1 positive glioblastomas negatively 
regulates tumor cell invasiveness by promoting their aggregation (Sciumè et al 2010). 
CX3CL1 is induced by TNF α and TNF β in neurons (Chen et al 2002, Sciumè et al 2010). 
These mediators are frequently present in tumors including gliomas and may be involved in 
the modulation of CX3CL1/CX3CR1 axis in neoplastic conditions (Mantovani et al 2008, 
Balkwill et al 2009).  
In 2005 Ludwig and colleagues demonstrated that another membrane-bound chemokine, 
CXCL16 is upregulated in human glioma being this chemokine expression low in normal 
brain and substantially limited to brain endothelial cells. 
Expression of chemokines and their receptors is modulated by factors produced by gliomas 
or by the tumor microenvironment. Examples are CXCL8, CXCL12 anCXCR4 which are up 
regulated in hypoxic conditions or upon stimulation with VEGF, an angiogenetic growth 
factor expressed in glioma tissues (Desbaillets et al 1997, Zagzag et al 2008). 
3.2 Chemokines in glioma invasion 
The peculiar adhesive function of fractalkine in the nervous system suggests that this 
chemokine/receptor complex plays a role in the neurotropism of cancer cells to peripheral 
nerves. This is a distinct and largely underestimated way of metastasis compared to blood 
and lymphatic routes; many human carcinomas such as bladder, prostate and pancreas take 
advantage of this route (Marchesi et al 2010). 
The invasive process of glioma cells requires the detachment of invading cells from the 
primary mass of the tumor, attachment to extracellular matrix components and degradation 
of this matrix. At this point tumor cell migration into brain structures can take place. 
CX3CL1 would have a negative role in this process, as suggested by the increase in glioma 
cell invasion properties by the blockade  induced by CX3CR1-CX3CL1 axis. Moreover, the 
reduced CX3CR1 expression consequent to TGF-beta 1 activation can favour glioma 
invasiveness (Sciumè et al 2010).  
Another axis which is acquiring an increasing consideration in this complex process is the 
CXCL12/CXCR4 axis. This axis has been linked to glioma progression both “in vitro” and 
“in vivo” (Zhou et al 2002, Zhang et al 2005, Ehtesham et al 2006, Bajetto et al 2006)  because 
of its ability to activate metalloproteinases, including the membrane type-2-MMP. 
Accordingly, invasive human glioma cell overexpress CXCR4 while noninvasive glioma cell 
do not. These data were confirmed “in vivo” in neoplastic cells from a rat C6 glioma cell line 
(Ehtesham et al 2006). 
 Co-expression of CXCL12 and its receptors is mainly localized to the pseudopalisade zones 
that surround necrotic foci (Rempel et al 2000). These regions are believed to represent 
tumor cells which are leaving necrotic regions because of their low or absent oxygen levels. 
In hypoxic condition, tumor cells release an angiogentic growth factor (VEGF) which 
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promotes the over-expression of CXCL12 and consequently tumor invasion outside the 
hypoxic area (Zagzag et al 2008). 
Promotion of glioma cell invasion is also mediated by Gro-alpha/CXCL1 that is expressed 
by oligodendroglioma and anaplastic astrocytomas (Zhou et al 2005). Interestingly CXCL1 
overexpression conferred increased tumorigenicity to U251 cells following implantation into 
the brain of nude mice (Zhou et al 2005). 
3.3 Chemokine role in glioma proliferation 
In addition to CXCL12, also CXCL8, CXCL10 and CCL3L1 have been described to promote 
glioma cell proliferation in vitro (Kouno et al 2004, Maru et al 2008). Notably, a correlation 
between CXCL8 expression levels in cells surrounding necrotic areas and histologic grade in 
glioma has been demonstrated (Desbaillets et al 1997). 
Chemokines also contribute to create a proangiogenic microenvironment by promoting 
attraction of endothelial cells and leukocytes to the tumor. The chemokine receptor panel of 
human microvascular endothelial cells includes CXCR2, CXCR3B, CXCR4 and CX3CR1 
(Bernardini et al 2003). 
As mentioned above, CXCR4 is expressed by both tumor cells and vascular endothelial cells in 
different grades of gliomas; this is associated with CXCL12 production in the tumor 
microenvironment, which is capable  to modulate migration, proliferation and survival of 
endothelial and tumor cells (Salmaggi et 2004). It was demonstrated that CXCR4 is expressed 
by both tumor cells and vascular endothelial cells in all grades of gliomas. The administration 
of AMD-3100, a CXCR4 antagonist, inhibits the growth of glioblastoma xenografts in mouses, 
demonstrating the dependence of tumor cells proliferation on CXCR4 (Rubin et al 2003). 
3.4 Chemokine network and leukocyte infiltration  
Besides its direct effects on tumor growth, the network of chemokines implicated in human 
astrcytomas can influence the degree and phenotype of immune cell infiltration. However,  
it is well accepted that glioma cells can be recognized by both innate and adaptive immunity 
(Mantovani et al 2008, Friese et al 2004, Dunn et al 2007). T-cell infiltration has been 
described to be present in neuroephitelial tumors, on the contrary NK cells are poorly 
included in the glioma lymphocyte infiltrate (Vaquero et al 1989). 
To date, data regarding the specificity and function of  tumor –infiltrating lynphocytes such 
as the involvement of the chemokine network in the recruitment of these cells or tumor 
infiltrating microglia/macrophages are lacking. Glia derived CCL2 might be implicated in 
the process leading to the abundant tumor infiltration by macrophages/microglia and T 
cells (Jordan et al 2008). CCL2 expression by glioma cells would be advantageous for tumor 
progression thanks to the attraction of T regulatory cells that suppress lymphocyte anti 
tumor effector functions and of microglia cells with reduce anti-tumor functions. Another 
effect would be the secretion of metalloproteinases. The corresponding receptors were the 
CCR2 on microglia and CCR4 on T regulatory cells (Hussain et al 2006). The role of the 
CX3CL1/CX3CR1 chemokine/receptor pair in microglial and lymphocyte infiltration 
remains to be defined.(Liu et al 2008, Rodero et al 2008) 
3.5 Concluding remarks 
Available information strongly suggest that chemokines play an important role in gliomas. 
In particular, evidence suggests that they are orchestrators of leukocyte recruitment in the 
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glioma microenvironment. Moreover, glioma cells express a defined repertoire of 
chemokine receptors including CXCR4/CXCL12, CX3CL1/CX3CR1 axis. 
On the basis of available information and extrapolation from other tumors, chemokine 
receptors expressed on gliomas may have a broad impact on biological and clinical 
behaviour of the tumor, affecting different functions including invasion, cell survival and 
proliferation. 
Despite increasing evidence on this complexity, further investigations of this network will 
allow a better understanding of tumor specificities, biological behaviour and therapeutic 
failures. 
These data and considerations raise the possibility of targeting components of the 






Fig. 1. Inflammatory mediators in gliomas. Innate and adaptive immune cells together with 
inflammatory molecules and cancer cells are part of an inflammatory microenvironment 
which may have an impact on biological and clinical behaviour of gliomas. 
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1. Introduction  
According to the analysis of American Brain Tumor Association, the brain tumors are 
common with an incidence of 12.8 per 100,000 people. Glioma is the most common 
subgroup of brain tumors. It is a type of tumor that origins in the brain or spine. It is called a 
“glioma” because it arises from glial cells. According to the specific type of cells from which 
they originate, gliomas are categorized as glioblastoma (WHO grade IV), astrocytoma 
(WHO grades I–III), oligodendro -glioma (WHO grades II and III), and mixed glioma (WHO 
grades II and III) (McCarthy et al, 2011). It is reported that about 50% gliomas are 
glioblastomas, which are the most common and malignant phenotypic astrocytoma. They 
are most common in adults from ages 45-55, and affect more men than women. About 9% of 
brain tumors in childhood are glioblastomas. 
Gliomas are difficult to treat. Usually the prognosis for patients with high-grade gliomas 
(especially for glioblastomas) is very poor, which has a mean survival only from 10 to 12 
months (Reddy, et al, 2008). It is found that about 10,000 Americans are diagnosed annually 
with malignant gliomas, about half of these patients are survival 1 year after diagnosis, and 
25% after two years. The traditional approach to treat the glioma contains surgery, radidtion 
therapy and chemotherapy. Although with these treatments or combined approaches, the 
tumor will be suppressed at some means, the survival rate of the patients is still very low. 
Biomarker is a characteristic that is objectively measured as an indicator of normal biological 
processes, pathogenic processes or a pharmacological response to a therapeutic intervention 
(Atkinson et al., 2001; Marrer & Dieterle, 2007). And tumor/cancer biomarkers are involved 
in tumors which contain a wide variety of objects, including DNA, mRNA, secreted 
proteins, cell surface receptors, transcription factors, and metabolites, or processes such as 
apoptosis, angiogenesis or proliferation. The markers are produced either by the tumor itself 
or by other tissues or cells, in response to the presence of tumors or other associated 
irritation, like inflammation (Kulasingam & Diamandis, 2008). They can be found in the 
tumor tissues, tumor cell lines, secreted molecules and in the serum or other body fluid, and 
so on. The tumor/cancer biomarkers can help doctors to profile the cancer predisposition, 
state of cancerous development, early diagnosis, prognosis after tretment, and decide which 
drugs and at what does it might be most effective to the patients with tumors. They are also 
benefit to screen the targeted drug for the tumor treatment. 
Recent years, the tumor/cancer biomarkers have played important roles in the diagnosis, 
therapy and prognosis in tumors. For example, prostate-specific antigen (PSA), as a best-
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known cancer biomarker, is widely used to screen and diagnosis the prostate cancer (Barry, 
2001). In the United States (US), most prostate cancers are diagnosed through measurement 
of serum PSA. The serum PSA level correlates directly with prostate cancer risk and 
aggressiveness, as well as the outcomes after treatment. PSA testing is also useful in 
monitoring patients for tumor recurrence after treatment (Loeb & Catalona, 2007). The 
HER2/neu gene or protein has been found over-expression in 10% to 34% of breast cancers. It 
has been used as a diagnostic biomarker and also a treatment target in breast cancer. The 
clinical trial presented that systemic administration of anti-HER2 antibodies trastuzumab 
(Herceptin), alone and in combination with chemotherapy in patients with HER-2/neu 
overexpressing primary tumors, can increase the time to recurrence and overall response 
rates in metastatic breast cancer (Ross & Fletcher, 1998).  
Gliomas are difficult to remove due to several reasons. Firstly, some drugs can not get into 
gliomas directly because of the blood-brain barrier. Secondly, the gliomas can infiltrate the 
tissues around them, the traditional approaches, including surgery, radidtion therapy and 
chemo-therapy, can not get rid of them completely. Finally, gliomas may have more than 
one kind of tumor cells in them, so chemotherapy drug, which is only directed at one kind 
of tumor cells, can not kill the all tumor cells. Therefore, the investigations of glioma 
biomarkers for diagnosis, prognosis and therapy are an urgent mission for the scientist in 
future. 
2. The research progress of glioma biomarkers 
As far as we known, glioma biomarkers can be identified from the serum, cerebrospinal 
fluid, glioma cell lines or directly from glioma tissues. These biomarkers will help us to 
diagnose the gliomas in the earlier period, treat the glioma against the specific target and 
monitor the prognosis after treatment.  
2.1 Diagnostic biomarkers for glioma  
Currently, the examinations used in clinical diagnosis for glioma include computed 
tomography (CT) scan, magnetic resonance imaging (MRI) scan, angiogram, skull x-ray, 
spinal tap, myelogram and biopsy. But it is still difficult to diagnose in the earlier period of 
gliomas, until if we can find some specific biomarkers associated with the eraly 
development of gliomas, the diagnosis will be easy to decide. Diagnostic (or screening) 
biomarkers are used to detect and identify a given type of cancer in an individual. These 
markers are expected to have high specificity and sensitivity (Kulasingam & Diamandis, 
2008). 
(1) YKL-40 
YKL-40, also known as CHI3L1 or human cartilage glycoprotein-39, is a secreted 
glycoprotein. High levels of YKL-40 in serum have been implicated as a serum marker in a 
number of cancers including breast (Johansen et al, 1995; Jensen et al, 2003), colorectal 
(Cintin et al, 1999), and ovarian cancer (Dehn et al, 2003; Hogdall et al, 2003). Although the 
function of YKL-40 is not well elucidated, it is often over-expressed in epithelial cancers and 
gliomas. Previous studies suggested that YKL-40 was a marker associated with a poorer 
clinical outcome and a genetically defined histological subgroup of high-grade gliomas 
(Nutt et al, 2005).TheYKL-40 was also implicated as an important marker of radiation 
therapeutic response and overall survival in glioblastoma (Pelloski et al, 2005).  
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Later, Hormigo et al. found that except for YKL-40, matrix metalloproteinase-9 (MMP-9) 
protein was also highly differentially expressed in malignant gliomas (Hormigo et al, 2006). 
YKL-40 and MMP-9 were determined by ELISA using serum samples from patients with 
gliomas, and the results indicated that the values correlated with the patient’s radiographic 
status and survival. So , YKL-40 and MMP-9 may be used as a biomarker in glioma patients’ 
serum and help confirm the absence of active disease in glioblastoma multiforme.  
(2) GFAP 
Another protein, glial fibrillary acidic protein (GFAP), first reported by Eng et al. in 1971, is 
a member of the cytoskeletal protein family and is widely detected in astroglial cells and 
neural stem cells (Eng et al, 1971, 2000; Doetsch, 2003; Jung et al, 2007). It is also expressed in 
astrocytoma and glioblastoma multiforme (Jacque et al, 1978; Hamaya et al, 1985; Abaza et 
al, 1998). A serum marker for malignant gliomas may improve both differential diagnoses 
with different histological subtypes and clinical management of glioma tumor patients. Jung 
et al. investigated GFAP levels in the serum of glioblastoma multiforme patients and 
various control groups. Their studies showed that the serum GFAP levels of these patients 
were significantly higher than those of patients with WHO grade II or III astrocytomas or of 
patients with brain metastases. And the serum GFAP concentration was closely linked with 
the glioblastoma volume and tumor necrosis volume imaged from magnetic resonance 
imaging scans. Therefore, the serum GFAP may be used as a diagnostic biomarker for 
glioblastoma multiforme. But it is necessary to evaluate whether the serum GFAP could be 
used to monitor therapeutic effects or have a prognostic value in future studies (Jung et al, 
2007). Furthermore, it is reported that GFAP does not provide a better staining for 
distinguishing histologic subtypes of high-grade glioma by immunohistochemistry. 
Compared with GFAP, YKL-40 staining, is a stronger marker, provided a better class 
distinction. In addition, using a combination of YKL-40 and GFAP staining could afford 
even greater diagnostic accuracy (Nutt et al, 2005).  
(3) Other potential biomarkers  
Cerebrospinal fluid (CSF) was usually used to screen glioma biomarkers because of its 
closer relation with glioma and its relative ease of collection (Maurer et al, 2003). 
Furthermore, CSF has about 1000 proteins, which is 100~400 fold lower than in serum, and 
this will be facilitated to screen the specific protein biomarkers (Omenn, 2005). In the past 
decades, many markers have been found in CSF of glioma patients, such as S100, neuron-
specific enolase (NSE), recoverin (protein A) and vascular endothelial growth factor (VEGF) 
(Gronowitz et al, 1984; Cochran & Wen, 1985; Taomoto et al., 1987; Sampath et al., 2004; 
Khwaja et al, 2007). However, these biomarkers could not be widespread used due to the 
limitation of repetition in CSF examinations.  
Recently, new candidate biomarkers have been identified by proteomics analysis for CSF 
samples. For example, Khwaja et al. used two-dimensional gel electrophoresis (2-DE) and 
cleavable Isotope-Coded Affinity Tag (cICAT) to analyze CSF proteome to detect specific 
biomarkers in brain tumors with differing histologies and grades (Khwaja et al, 2007). 
Finally, 20 potential tumor-specific markers were specially identified in high-grade 
astrocytoma. These potential markers may also play important role in the development and 
malignant progression of human astrocytoma and will be the treatment targets in glioma. 
Furthermore, exosome is now becoming a hot spot to look for cancer biomarkers. Exosomes 
are 50-90 nm vesicles-like objects secreted by various mammalian cells. An exosome is 
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formed intracellularly when a segment of cell membrane spontaneously invaginates and is 
endocytosed (Keller et al, 2006). It is reported that dendritic cells and B cells could secrete 
exosomes, which indicated that exosomes may play a functional role in mediating adaptive 
immune responses to pathogens and tumors (Li et al, 2006). Exosomes can also be detected 
in urine and they might serve as a diagnosis and treatment response marker in prostate 
cancer (Pisitkun et al, 2004; Nilsson et al, 2009). Therefore, exosomes, which are released 
from tumors into the blood, can also be used for diagnosis. The released exosomes by 
glioblastoma tumor cells contain mRNA, microRNA and angiogenic proteins (Balaj et al, 
2011). Furthermore, the glioblastoma-derived exosomes serve as a vehicle to deliver genetic 
information and proteins in the tumor environment. Tumor mutations in glioma can be 
detected in exosomes from serum, which is also facilitating a blood-based biomarker 
detection for solid tumors (Skog et al, 2008). Thus, tumor-derived exosomes may be used as 
a diagnostic biomarker and aid in therapeutic decisions for glioma patients.  
  Although the histopathologic methods are often used to classify the pathologic grade of 
gliomas in clinical diagnosis, the results are usually subjective and less accurate. To 
overcome the limitations, cDNA microarray has been performed to screen diagnostic and 
prognostic markers for glioblastoma. The growth arrest and DNA-damage-inducible α 
(GADD45α ) and follistatin-like 1 (FSTL1) were over-expressed in most primary and 
secondary glioblastomas, whereas superoxide dismutase 2 and adipocyte enhancer binding 
protein 1 were up-regulated in the majority of primary glioblastomas (Reddy et al, 2008). All 
the results were validated by real-time reverse transcription quantitative PCR and 
immunohistochemical analysis. These findings suggested that GADD45α and FSTLI are 
glioblastoma-specific whereas superoxide dismutase 2 and adipocyte enhancer binding 
protein1 are primary glioblastoma-specific diagnostic markers. It is interesting to found that 
the diffusion parameters could also be evaluated as early biomarkers of disease progression 
in glioblastoma multiforme (Khayal et al, 2010).  
2.2 Prognostic biomarkers for glioma  
Tumor prognostic biomarkers are used once the tumor status has been confirmed. These 
biomarkers are expected to predict the probable course of the tumors including its 
recurrence, and they therefore have important influences on the aggressiveness of therapy 
(Kulasingam & Diamandis, 2008). 
It is known that O(6)-methylguanine-DNA methyltransferase (MGMT) can recover the 
carcinogenic lesion in DNA induced by alkylating mutagens. What’s more, it has been 
showed that methylation of the MGMT’s promoter plays a significant role in carcinogenesis 
(Hegi et al, 2005). The hypermethylation in MGMT promoter has been detected in other 
various of human cancers, such as colon cancer, nonsmall-cell lung cancer, head and neck 
carcinoma, lymphomas, Leukemias, pancreatic carcinoma , melanoma, renal carcinoma and 
bladder carcinoma (Esteller et al, 1999). The hypermethylation frequency of MGMT 
promoter varies widely in different subtype glioma. It has ranged from 35% to 73% in 
glioblastoma, about 50%~84% in diffusely infiltrating anaplastic gliomas (World Health 
Organization grade III), as well as about 43%~93% in the WHO grade II counterparts 
(Deimling et al, 2011). Although the methylation of MGMT status appears to be a useful 
prognostic marker in the elderly patients with newly diagnosed glioblastoma (Gerstner et al, 
2009). In fact, MGMT immunohistochemistry analysis had some lacks for routine diagnostic 
purposes due to the observer variability as well as lack of association with the MGMT 
promoter methylation status (Preusser et al, 2008). 
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As is known to all, the ras GTPase-activating-like protein IQGAP1 functions as a scaffold 
protein which is involved in cellular motility and morphogenesis (Mateer et al, 2003). It is 
participated in many signaling pathways to regulate cell adhesion, polarization and 
migration. For example, IQGAP1 was played as a VEGFR2-associated scaffold protein to 
organize ROS-dependent VEGF signaling, which could promote the migration and 
proliferation of endothelial cell to repair the injured vessels (Yamaoka-Tojo et al, 2004). It is 
also identified as a core component of neuronal motility signal transduction and it is 
involved in epithelial carcinogenesis and metastasis (Briggs & Sacks, 2003; Kholmanskikh et 
al, 2006; Balenci et al, 2006). But, one recent study found that IQGAP1 may be used as a 
marker to discriminate the human glioblastoma from oligodendroglioma (Balenci et al, 
2006) 
Another known protein，the insulin-like growth factor-binding protein 2 (IGFBP2) is 
usually detected in many human tumors, including malignancies of the lung, colon, adrenal 
glands, ovary, prostate, CNS and lymphoid tumors (Dunlap et al, 2007). Its overexpression 
is often linked with an increasingly malignant status of the tumor, indicating a potential 
oncogene function of IGFBP-2 in tumorigenesis (Hoeflich et al, 2001). IGFBP2 was also 
identified as a specific marker for central nervous system (CNS) tumors and might serve as 
a marker of tumor differentiation (Muller et al, 1994; Akmal et al, 1995). Furthermore, the 
plasma IGFBP2 levels are obviously higher in high-grade glioma patients than in low-grade 
glioma patients and healthy subjects. All these data indicate the plasma IGFBP2 has a 
biomarker’s role in glioma (Lin et al, 2009).  
The coexpression of IQGAP1 and IGFBP2 is strongly associated with poor prognosis in 
astrocytoma and oligodendroglioma. These findings might complement the WHO 
classification system to permit more precise classification for glioma subtypes. Besides, in 
glioblastoma patients who had shown long-term survival of >3 years after initial diagnosis, 
the expression of IQGAP1 and IGFBP2 were not be detected. Thus, the absence of IQGAP1 
and IGFBP2 may be a good prognostic marker in glioblastoma patients. However, the 
relationship between IQGAP1 and IGFBP2 and their roles in glioma biology are still need to 
be elucidated in future (McDonald et al, 2007).  
Matrix-assisted laser desorption ionization- mass spectrometry (MALDI-MS) is a high-
throughput and accurate tool in proteomics research. It has been used to profile the glioma-
specific protein patterns which can provide clinically relevant information on tumor 
malignancy. The glioma-specific protein patterns could accurately classify glioma subtypes 
and discriminate patient survival patterns. Still, there are several discriminatory proteins 
were identified, including calcyclin, dynein light chain 2 (DLD2), calpactin I light chain, 
astrocytic phosphoprotein (PEA-15), fatty acid-binding protein 5 (FABP5) and tubulin -
specific chaperone A. These proteins were reported to be involved in various aspects of 
tumorigenesis. These differential expression proteins in gliomas may provide as diagnostic 
and prognostic markers (Schwartz et al, 2005).  
Tumor is a disease coupled with multiple gene alterations. The gene expression pattern may 
predict the survival time in patients with high-grade gliomas independently of other factors 
(Czernicki et al, 2007). Proteins are the true executors that directly perform functions 
regulated by genes. Therefore, the protein changes would be more attractive in cancer 
biomarker discovery (Liang et al, 2011). Khalil used the two-dimensional difference gel 
electrophoresis (2D-DIGE) compared protein patterns between glioma tissues and non-
tumor brain tissues. About 20 unique differential proteins were identified, and these 
proteins with diagnostic or prognostic value are still needed to be validated in future 
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As is known to all, the ras GTPase-activating-like protein IQGAP1 functions as a scaffold 
protein which is involved in cellular motility and morphogenesis (Mateer et al, 2003). It is 
participated in many signaling pathways to regulate cell adhesion, polarization and 
migration. For example, IQGAP1 was played as a VEGFR2-associated scaffold protein to 
organize ROS-dependent VEGF signaling, which could promote the migration and 
proliferation of endothelial cell to repair the injured vessels (Yamaoka-Tojo et al, 2004). It is 
also identified as a core component of neuronal motility signal transduction and it is 
involved in epithelial carcinogenesis and metastasis (Briggs & Sacks, 2003; Kholmanskikh et 
al, 2006; Balenci et al, 2006). But, one recent study found that IQGAP1 may be used as a 
marker to discriminate the human glioblastoma from oligodendroglioma (Balenci et al, 
2006) 
Another known protein，the insulin-like growth factor-binding protein 2 (IGFBP2) is 
usually detected in many human tumors, including malignancies of the lung, colon, adrenal 
glands, ovary, prostate, CNS and lymphoid tumors (Dunlap et al, 2007). Its overexpression 
is often linked with an increasingly malignant status of the tumor, indicating a potential 
oncogene function of IGFBP-2 in tumorigenesis (Hoeflich et al, 2001). IGFBP2 was also 
identified as a specific marker for central nervous system (CNS) tumors and might serve as 
a marker of tumor differentiation (Muller et al, 1994; Akmal et al, 1995). Furthermore, the 
plasma IGFBP2 levels are obviously higher in high-grade glioma patients than in low-grade 
glioma patients and healthy subjects. All these data indicate the plasma IGFBP2 has a 
biomarker’s role in glioma (Lin et al, 2009).  
The coexpression of IQGAP1 and IGFBP2 is strongly associated with poor prognosis in 
astrocytoma and oligodendroglioma. These findings might complement the WHO 
classification system to permit more precise classification for glioma subtypes. Besides, in 
glioblastoma patients who had shown long-term survival of >3 years after initial diagnosis, 
the expression of IQGAP1 and IGFBP2 were not be detected. Thus, the absence of IQGAP1 
and IGFBP2 may be a good prognostic marker in glioblastoma patients. However, the 
relationship between IQGAP1 and IGFBP2 and their roles in glioma biology are still need to 
be elucidated in future (McDonald et al, 2007).  
Matrix-assisted laser desorption ionization- mass spectrometry (MALDI-MS) is a high-
throughput and accurate tool in proteomics research. It has been used to profile the glioma-
specific protein patterns which can provide clinically relevant information on tumor 
malignancy. The glioma-specific protein patterns could accurately classify glioma subtypes 
and discriminate patient survival patterns. Still, there are several discriminatory proteins 
were identified, including calcyclin, dynein light chain 2 (DLD2), calpactin I light chain, 
astrocytic phosphoprotein (PEA-15), fatty acid-binding protein 5 (FABP5) and tubulin -
specific chaperone A. These proteins were reported to be involved in various aspects of 
tumorigenesis. These differential expression proteins in gliomas may provide as diagnostic 
and prognostic markers (Schwartz et al, 2005).  
Tumor is a disease coupled with multiple gene alterations. The gene expression pattern may 
predict the survival time in patients with high-grade gliomas independently of other factors 
(Czernicki et al, 2007). Proteins are the true executors that directly perform functions 
regulated by genes. Therefore, the protein changes would be more attractive in cancer 
biomarker discovery (Liang et al, 2011). Khalil used the two-dimensional difference gel 
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research (Khalil, 2007). In addition, the gelsolin protein is significantly lower expressed in 
the increscent glioma histopathologic grade. And in astrocytoma, the overall survival in the 
low-expression group was significantly poorer than in the high expression group. Therefore, 
gelsolin may be a prognostic marker for astrocytoma patients (Ohnishi et al, 2009). Besides, 
the B-chain of α2 -heremans-schmid glycoprotein in serum can be used as a potential 
biomarker for glioma prognosis (Petrik et al, 2008).  
DNA microarray is usually used to measure gene expression levels, single nucleotide 
polymorphisms or genotype. It is one of the fastest-growing new technologies in cancer 
research. By DNA microarray, it was found that metalloproteinase-4 (TIMP-4) and its 
putative partner CD63 were coexpressed in glioblastomas and pilocytic astrocytomas. High 
TIMP-4 /CD63 co-expression level has been found to be an independent prognostic marker 
associated with progression and shorter survival in glioblastomas. On the contrary,the 
higher co-expression indicted adverse outcomes in diffuse astrocytoma and 
oligoastrocytoma patients (Rorive et al, 2010). Similarly, a high level of osteopontin protein 
in serum indicates a poor prognosis in glioblastoma patients, and it may be a poor 
prognostic biomarker in glioblastoma patients (Sreekanthreddy et al, 2010).  
Gene mutation is another factor in carcinogenesis. Recently, the isocitrate dehydrogenase 1 
(IDH1) was analyzed by direct sequencing in a series of 404 glioma patients with different 
grade. It is found that the mutation rates in the codon 132 of IDH1 were obviously decreased 
with increscent glioma grade, which indicated that the codon 132 mutations of IDH1 could 
be an important prognostic marker in grade 2 to 4 gliomas (Sanson et al, 2009). The codon 
132 mutation of IDH1was detected in more than 70% of WHO grade II - III astrocytomas , 
oligodendrogliomas, as well as in glioblastomas which are developed from those lower-
grade gliomas. Gliomas, without mutations in IDH1 codon 132, often had mutations in 
codon 172 of the IDH2 gene. The results showed that patients with such mutations in IDH 
usually had a better prognosis than those with wild-type IDH genes (Yan et al, 2009).  
2.3 Therapeutic targets for glioma  
Recent developments in the field of tumor biology have elucidated signalling pathways and 
genes involved in the development of gliomas, which represent new potential therapeutic 
targets, and many targeted therapies are currently being tested in clinical trials (Sanson, 
2008).  
(1) Receptor tyrosine kinases (RTKs)-mediated signaling 
The antiangiogenesis strategy has been widely used in molecularly targeted therapy for 
malignant glioma. Angiogenesis in tumors is caused by a number of factors involved in 
many signaling pathways, in which the VEGF-VEGFR2 is a major and more attractive 
pathway. Currently, many angiogenesis inhibitors or antibodies have been applied in 
clinical studies. These inhibitors or antibodies were usually design to anti-specific factors, 
including VEGF itself, VEGFR, and other upstream /downstream factors regulated the 
VEGF signaling pathway, such as Cox-2, HIF-1α, and so on(Chi et al, 2009).  
Gliomas are highly heterogeneous in terms of biological alterations. Mutations in EGFR and 
genes for other receptor tyrosine kinases (RTKs), namely platelet-derived growth factor 
(PDGFR), HER2/neu and MET, lead to activation of downstream PI3K-AKT and ERK-MEK 
pathways in gliomas. Therefore, several antiangiogenic inhibitors, which downregulate 
EGFR-mediated signaling, have recently been developed and tested as therapeutic agents, 
including cediranib (Recentin, AstraZeneca), vatalanib (Novartis Pharmaceuticals, Basel, 
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Switzerland), sunitinib (Sutent, Pfizer), sorafenib (Nexavar, Bayer Pharmaceuticals, 
Leverkusen, Germany), vandetanib (Zactima, AstraZeneca) and VEGF trap (Aflibercept, 
Regeneron Pharmaceuticals, NY,USA) (Lukas et al,2009; Roesler et al, 2010). Besides small-
molecule inhibitors, therapies can be targeted to tumor cells (e.g., EGFR inhibitors) or tumor 
blood vessels with the monoclonal antibody against VEGF, bevacizumab (Avastin; 
Genentech, CA, USA).  
However, followed by the antiangiogenesis therapy at long time, the patients will have a 
high resistance to anti-VEGF therapies. Soda et al. investigated the resistance mechanism of 
anti-VEGF therapy to glioma in the transduction of p53+/− heterozygous mice containing 
oncogenes and in the GFAP-Cre recombinase (Cre) mice. It was found that mouse 
glioblastoma cells could be transdifferented into vascular endothelial cells (tumor -derived 
endothelial cells, TDECs) in the hypoxia situation, and this process was independent of 
VEGF. A further study has showed that the formation of TDECs are also presented in the 
xenograft model of human glioblastoma spheres directly from the patients with 
glioblastoma (Sodaa et al, 2011). These studies show that the TDECs may have an important 
role in the resistance to anti-VEGF therapy, and hence they could be a candidate target for 
glioblastoma therapy. But there are still many questions need to be answered. For example, 
what are the signaling molecules that participate in the production of TDECs? Is this 
mechanism of VEGF-A resistance uniform to all glioblastoma or are there alternate 
pathways used for different subsets of glioblastoma? (Sodaa et al, 2011; Hormigo et al, 2011).  
(2) PI3K/AKT/mTOR pathways 
PI3K pathways regulate several malignant phenotypes including antiapoptosis, cell growth, 
and proliferation. Activation of PI3K pathway is associated with poor prognosis in glioma 
patients (Sathornsumetee et al, 2007). Activated PI3K phosphorylates several downstream 
effectors including AKT. AKT is a serine/threonine kinase that regulates cell growth, 
proliferation, and apoptosis. The mTOR is a serine/threonine kinase downstream from AKT.  
Several mTOR inhibitors have been studied in the treatment of malignant glioma. These 
include sirolimus (Rapamune; Wyeth Pharmaceuticals,Madison, NJ) FDA-approved for the 
prophylaxis of solid organ transplant rejection, and temsirolimus (CCI-779, Torisel; Wyeth 
Pharmaceuticals) FDA-approved for use in renal cancer (Lukas et al, 2009). And everolimus 
(RAD001; Novartis Oncology, East Hanover, NJ) and deferolimus (AP23573; 
ARIAD/Merck), still experimental, have all been evaluated in clinical trials alone or in 
combination with other therapies in gliomas. Although data strongly support the view of 
the PI3K–AKT–mTOR pathway as an important target, current clinical results on the use of 
mTOR inhibitors remain disappointing. For example, the Phase II studies using 
temsirolimus as monotherapy found only limited activity in recurrent glioblastoma 
multiforme. Because pathways are complex interactive networks characterized by cross-talk 
and homeostatic feedback loops that can greatly influence response to therapy. 
(3) Histone deacetlyase (HDAC) 
Histone deacetylases (HDACs), regulating histone acetylation, are now considered to be a 
promising target for gliomas. The epigenetic therapies, particularly HDAC inhibitors 
(HDACis), have been proposed as potential novel drugs. Suberoylanilide hydroxamic acid 
(SAHA, vorinostat, Zolinza; Merck), FDA-approved for cutaneous T-celllymphoma, is being 
evaluated in clinical trials of multiple cancers, including malignant gliomas 
(Sathornsumetee et al, 2007; Roesler et al, 2010).  
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(4) Other targets and therapeutic approaches 
Advances in the understanding of cellular and molecular alterations in gliomas have led to 
the emergence of experimental molecularly targeted therapies. The targeted therapies for 
glioma include small molecules and antibodies targeted at growth factor pathways, 
intracellular signaling cascades and epigenetic molecular targets, as well as RNAi, gene 
therapy and neural stem cells as therapeutic tools (Roesler et al, 2010). 
The receptor protein tyrosine phosphatase β (RPTPβ) have a role to facilitate tumor cell 
adhesion and migration by interactions with extracellular matrix components and the 
growth factor pleiotrophin. Over-expression of RPTPβ was found in several types of solid 
tumor, but with low expression in normal tissue (Foehr et al, 2006). It is reported that RPTPβ 
was displayed strong staining in oligodendrogliomas, and may be a novel 
oligodendroglioma marker (Hӓgerstrand et al, 2008). Therefore, RPTPβ may perform a role 
of potential therapy target in gliomas and other tumors. The monoclonal antibodies of 
RPTPβ obtained from immunizing mice could kill glioma cells in vitro and significantly 
suppress the growth of human glioma tumors in a xenograft mouse model (Foehr et al, 
2006).  
The PBEF1 (Pre-B-cell colony enhancing factor 1) gene may be a potential malignant 
astrocytoma serum marker and prognostic indicator in glioblastoma (Reddy et al, 2008). 
PBEF1 gene encodes nicotinamide phosphoribosyltransferase (NMPRTase), which has an 
important role in the salvage pathway of NAD+ biosynthesis. The inhibitor of NMPRTase, 
such as FK866, can reduce cellular NAD+ levels and induce apoptosis in tumors (Khan et al, 
2006). Therefore, the novel inhibitor of NMPRTase may be used as an anti-tumor drug in 
glioma therapy (Chandra et al, 2011).  
However, targeting a single component of cell signaling, or a single signaling pathway, is 
not likely to effectively reduce tumor growth in glioma patients. Preclinical studies should 
characterize the effects of multi-targeted inhibitors, combining several targeted inhibitors, 
and combining targeted therapies with cytotoxic chemotherapy. 
Tumor stem cells are a kind of specific tumor cells which have the stem cell like properties. 
It is reported that glioma stem cells display self-renewal and proliferation properties, 
unlimited life span, a high migration rate and resistance to chemotherapy, and they are 
capable of replenishing the whole tumor cell population (Singh et al, 2003; 2004). The glioma 
stem cells have been involved in many signaling pathways, including Notch, Hedgehog, 
Wnt, Myc, PI3K and MAPK cascades, and so on (Das et al, 2008; Li et al, 2009; Roesler et al, 
2010). According to the important roles of glioma stem cells, the drugs that directly and 
specifically kill the glioma stem cells will be more effective than other ways in glioma 
therapy. Some studies have proposed the possible strategies to target the glioma stem cells. 
One way is using differentiating agents (like bone morphogenetic proteins, BMPs)to induce 
the glioma stem cells into mature, astrocytic cells, and another way is regulating the 
expression of targeting genes involved in glioma stem cell proliferation (Piccirillo et al, 2006; 
Horvath et al, 2006). 
3. Discussion and outlook 
It is clear that more and more high-throughput, accurate technologies or strategies have 
been used in identification of glioma biomarkers (shown in Figure 1). These techniques 
include ELISA (Hormigo et al, 2006; Lin et al, 2009; Sreekanthreddy et al, 2010), 2-DE 
(Khwaja et al, 2007; Khalil, 2007; Ohnishi et al, 2009), DNA microarray (Reddy et al, 2008), 
 
 




Fig. 1. Current different techniques are used in the glioma biomarker discovery. 
a. CSF: Cerebrospinal fluid; IHC: immunohistochemistry; ELISA: enzyme linked 
immunosorbent assay; 2-DE: two-dimensional electrophoresis; MS: mass spectrometry.  
b. The quantitative approaches here contain the isotope-coded affinity tag (ICAT), stable 
isotope labeling with amino acids in cell culture (SILAC), isobaric tagging for relative and 
absolute quantitation (iTRAQ). 
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MALDI-MS or SELDI-TOF -MS (Petrik et al, 2008; Schwartz et al, 2005),direct sequencing 
(Sanson et al, 2009), ICAT (Khwaja et al, 2007), and transgenic mouse etc (Sodaa et al, 2011). 
A number of quantitative approaches summarized in Figure 1, with different technical 
advantages and challenges, have been developed for glioma biomarker discovery. However, 
many complementary technologies are being developed and either alone or in combination 
will undoubtedly allow their potential in biomedical research and translation into clinical 
practice. 
Recently, we have investigated the protein prfiling in low-grade gliomas by a quantative 
SILAC (stable isotope labeling with amino acids in cell culture) –based protemoics strategy 
in order to screen novel glioma-specific proteins (Liang et al, 2009a; Shen et al, 2010). 
Besides, the quantative protemoics strategy also contains the isotope-coded affinity tag 
(ICAT), isobaric tagging for relative and absolute quantitation (iTRAQ), and so on. With 
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promised to need a further validation and confirmation (shown in Table 2). There have 
some limitations for application of glioma biomarkers in the clinical trial. Firstly, the 
specification of biomarkers is always not certainly. Because of the biomarkers are usually 
detected in both normal and tumor samples, and other diseases can also cause the changes 
of biomarkers. And then, the investigation strategy of biomarkers are significantly various. 
Even if used the same type samples, the results will be remarkably difference. Finally, the 
patients with tumors are usually difference from each other, also called the individual 
difference. Besides, the overall samples used in biomarker identification are still limited due 
to various gaps. In spite of this, the studies of glioma biomarker identification still have a 
bright future by the continuous efforts of biologists. 
4. Acknowledgments 
This work was financially supported by the grants from National Key Basic Program of 
China (2011CB910703), National Natural Sciences Foundation of China (30970654, 
31071235), Program for New Century Excellent Talents in University (NCET-10-0595) and 
Sichuan Science Research Program for Young Scholars (2010JQ0016).  
5. References  
Abaza, MS.; Shaban, F.; Narayan, R. & Atassi, M. (1998). Human glioma associated 
intermediate filament proteins: over-expression, co-localization and 
cross-reactivity. Anticancer Res., Vol.18, pp.1333–1340. 
Akmal, S., Yun, K., MacLay, J., Higami, Y., & Ikeda, T. (1995). Insulin-like growth factor 2 
and insulin-like growth factor binding protein 2 expression in hepatoblastoma. 
Hum. Pathol, Vol.26, pp.846–851. 
Atkinson, A.; Colburn, W.; DeGruttola,V.; DeMets, D.; Downing, G.; Hoth, D.; Oates, J.;Peck, 
C.; Schooley R.; Spilker B.; Woodcock, J. & Zeger, S. (2001). Biomarkers and 
surrogate endpoints: preferred definitions and conceptual framework. Clin 
Pharmacol Ther, Vol.69, pp.89-95. 
Balaj, L.; Lessard, R.; Dai, L.; Cho,Y.; Pomeroy, S.; Breakefield, X. & Skog, Johan. 
(2011).Tumour microvesicles contain retrotransposon elements and amplified 
oncogene sequences. Nature Communications, Vol.2, doi:10.1038 /ncomms1180. 
Balenci, L.; Clarke, I.; Dirks, P.; Assard, N.; Ducray, F.; Jouvet, A.; Belin, M.; Honnorat, J. &  
Baudier, J. (2006). IQGAP1 Protein Specifies Amplifying Cancer Cells in 
Glioblastoma Multiforme. Cancer Res, Vol.66, No.18, pp.9074-9082. 
Barry, M. Clinical practice. (2001). Prostate-specific-antigen testing for early diagnosis of 
prostate cancer. N. Engl. J. Med., Vol.344, No.18, pp.1373-1377. 
Briggs, M. & Sacks, D. (2003). IQGAP proteins are integral components of cytoskeletal 
regulation. EMBO Rep, Vol.4, pp.571–574. 
Chandra, N.; Bhagavat, R.; Sharma, E.; Sreekanthreddy, P. & Somasundaram, K. (2011). 
Virtual screening, identification and experimental testing of novel inhibitors of 
PBEF1/Visfatin/ NMPRTase for glioma therapy. Journal of Clinical Bioinformatics, 
Vol.1, pp.5 
Chi, A.; Sorensen, A.; Jain, R. & Batchelor, T. (2009). Angiogenesis as a Therapeutic Target in 
Malignant Gliomas. The Oncologist 2009;14:621–636 
 
Biomarkers of Glioma 
 
337 
Cintin, C.; Johansen, J.; Christensen, I.; Price, P.; Sorensen, S. & Nielsen, H. (1999). Serum 
YKL-40 and colorectal cancer. Br J Cancer, Vol.79, pp.1494–1499. 
Czernicki, T.; Zegarska, J.; Paczek, L.; Cukrowska,B.; Grajkowska, W.; Zajaczkowska, A.; 
Brudzewski, K.; Ulaczyk, J. & Marchel, A. (2007). Gene expression profile as a 
prognostic factor in high-grade gliomas. Int J Oncol, Vol.30, pp. 55-64.Das, S.; 
Srikanth, M.; Kessler, J. (2008). Cancer stem cells and glioma. Nat. Clin. 
Pract.Neurol., Vol. 4, No.8, pp.427-435. 
Dehn, H.; Høgdall, E.; Johansen J.; Price, J.; Jørgensen, M.; Engelholm, S. & Høgdall, C. 
(2003). Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. 
Acta Obstet Gynecol Scand, Vol.82, pp.287–293. 
Doetsch, F. (2003).The glial identity of neural stem cells. Nat Neurosci., Vol.6, pp.1127–1134. 
Dunlap, S.; Celestino, J.; Wang, H.; Jiang, R. & Hollan, E. (2007).Insulin-like growth factor 
binding protein 2 promotes glioma development and progression. PNAS,  2007 vol. 
104, no. 28, 11736–11741 
Eng, L.; Vanderhaeghen, J.; Bignami, A. & Gerstl, B. (1971). An acidic protein isolatedfrom 
fibrous astrocytes. Brain Res., Vol.28, pp.351–354. 
Eng, L.; Ghirnikar, R. & Lee, Y. (2000). Glial fibrillary acidic protein: GFAP-thirty-one years 
(1969-2000). Neurochem Res., Vol. 25, pp. 1439–1451. 
Esteller, M.; Hamilton, S.; Burger, P.; Baylin, S. & Herman, J. (1999). Inactivation of the DNA 
repair gene O6-methylguanine-DNA methyltransferase by promoter 
hypermethylation is a common event in primary human neoplasia. Cancer Res, 
Vol.59, pp.793–797. 
Foehr, E.; Lorente, G.; Kuo, J.; Ram, R.; Nikolich, K. & Urfer, R. (2006). Targeting of the 
Receptor Protein Tyrosine Phosphatase B with a Monoclonal Antibody Delays 
Tumor Growth in a Glioblastoma Model. Cancer Res, Vol.66, pp.2271-2278. 
Gerstner, E.; Yip, S.; Wang, D.; Louis, D.; Iafrate, A. & Batchelor,T. (2009). MGMT 
methylation is a prognostic biomarker in elderly patients with newly diagnosed 
glioblastoma. Neurology, Vol.73, pp.1509-1510. 
Hägerstrand, D.; Smits, A.; Eriksson, A.; Sigurdardottir, S.; Olofsson,T.; Hartman,M.; Nistér, 
M.; Kalimo, H. & Östman, A. (2008). Gene expression analyses of grade II gliomas 
and identification of rPTPβ/ζ as a candidate oligodendroglioma marker. Neuro-
Oncology, Vol.10, pp. 2-9. 
Hamaya, K.; Doi, K.; Tanaka, T. & Nishimoto, A. (1985).The determination of glial fibrillary 
acidic protein for the diagnosis and histogenetic study of central nervous system 
tumors: a study of 152 cases. Acta Med Okayama, Vol.39, pp. 453–462. 
Hegi, M.; Diserens, A.; Gorlia, T, Hamou, M.; de Tribolet, N.; Weller, M.; Kros, J.; 
Hainfellner, J.; Mason, W.; Mariani, L.; Bromberg, J.; Hau, P.; Mirimanoff, R.; 
Cairncross, J.; Janzer,R. & Stupp R. (2005). MGMT gene silencing and benefit from 
temozolomide in glioblastoma. N. Engl. J. Med., Vol.352, No.10, pp.997–1003. 
Hoeflich, A.; Reisinger, R.; Lahm, H.; Kiess, W.; Blum, W.; Kolb, H.; Weber, M. & Wolf, E. 
(2001). Insulin-like growth factor-binding protein 2 in tumorigenesis : protector or 
promoter? Cancer Res, Vol.61, pp.8601-8610. 
 
Molecular Targets of CNS Tumors 
 
336 
promised to need a further validation and confirmation (shown in Table 2). There have 
some limitations for application of glioma biomarkers in the clinical trial. Firstly, the 
specification of biomarkers is always not certainly. Because of the biomarkers are usually 
detected in both normal and tumor samples, and other diseases can also cause the changes 
of biomarkers. And then, the investigation strategy of biomarkers are significantly various. 
Even if used the same type samples, the results will be remarkably difference. Finally, the 
patients with tumors are usually difference from each other, also called the individual 
difference. Besides, the overall samples used in biomarker identification are still limited due 
to various gaps. In spite of this, the studies of glioma biomarker identification still have a 
bright future by the continuous efforts of biologists. 
4. Acknowledgments 
This work was financially supported by the grants from National Key Basic Program of 
China (2011CB910703), National Natural Sciences Foundation of China (30970654, 
31071235), Program for New Century Excellent Talents in University (NCET-10-0595) and 
Sichuan Science Research Program for Young Scholars (2010JQ0016).  
5. References  
Abaza, MS.; Shaban, F.; Narayan, R. & Atassi, M. (1998). Human glioma associated 
intermediate filament proteins: over-expression, co-localization and 
cross-reactivity. Anticancer Res., Vol.18, pp.1333–1340. 
Akmal, S., Yun, K., MacLay, J., Higami, Y., & Ikeda, T. (1995). Insulin-like growth factor 2 
and insulin-like growth factor binding protein 2 expression in hepatoblastoma. 
Hum. Pathol, Vol.26, pp.846–851. 
Atkinson, A.; Colburn, W.; DeGruttola,V.; DeMets, D.; Downing, G.; Hoth, D.; Oates, J.;Peck, 
C.; Schooley R.; Spilker B.; Woodcock, J. & Zeger, S. (2001). Biomarkers and 
surrogate endpoints: preferred definitions and conceptual framework. Clin 
Pharmacol Ther, Vol.69, pp.89-95. 
Balaj, L.; Lessard, R.; Dai, L.; Cho,Y.; Pomeroy, S.; Breakefield, X. & Skog, Johan. 
(2011).Tumour microvesicles contain retrotransposon elements and amplified 
oncogene sequences. Nature Communications, Vol.2, doi:10.1038 /ncomms1180. 
Balenci, L.; Clarke, I.; Dirks, P.; Assard, N.; Ducray, F.; Jouvet, A.; Belin, M.; Honnorat, J. &  
Baudier, J. (2006). IQGAP1 Protein Specifies Amplifying Cancer Cells in 
Glioblastoma Multiforme. Cancer Res, Vol.66, No.18, pp.9074-9082. 
Barry, M. Clinical practice. (2001). Prostate-specific-antigen testing for early diagnosis of 
prostate cancer. N. Engl. J. Med., Vol.344, No.18, pp.1373-1377. 
Briggs, M. & Sacks, D. (2003). IQGAP proteins are integral components of cytoskeletal 
regulation. EMBO Rep, Vol.4, pp.571–574. 
Chandra, N.; Bhagavat, R.; Sharma, E.; Sreekanthreddy, P. & Somasundaram, K. (2011). 
Virtual screening, identification and experimental testing of novel inhibitors of 
PBEF1/Visfatin/ NMPRTase for glioma therapy. Journal of Clinical Bioinformatics, 
Vol.1, pp.5 
Chi, A.; Sorensen, A.; Jain, R. & Batchelor, T. (2009). Angiogenesis as a Therapeutic Target in 
Malignant Gliomas. The Oncologist 2009;14:621–636 
 
Biomarkers of Glioma 
 
337 
Cintin, C.; Johansen, J.; Christensen, I.; Price, P.; Sorensen, S. & Nielsen, H. (1999). Serum 
YKL-40 and colorectal cancer. Br J Cancer, Vol.79, pp.1494–1499. 
Czernicki, T.; Zegarska, J.; Paczek, L.; Cukrowska,B.; Grajkowska, W.; Zajaczkowska, A.; 
Brudzewski, K.; Ulaczyk, J. & Marchel, A. (2007). Gene expression profile as a 
prognostic factor in high-grade gliomas. Int J Oncol, Vol.30, pp. 55-64.Das, S.; 
Srikanth, M.; Kessler, J. (2008). Cancer stem cells and glioma. Nat. Clin. 
Pract.Neurol., Vol. 4, No.8, pp.427-435. 
Dehn, H.; Høgdall, E.; Johansen J.; Price, J.; Jørgensen, M.; Engelholm, S. & Høgdall, C. 
(2003). Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. 
Acta Obstet Gynecol Scand, Vol.82, pp.287–293. 
Doetsch, F. (2003).The glial identity of neural stem cells. Nat Neurosci., Vol.6, pp.1127–1134. 
Dunlap, S.; Celestino, J.; Wang, H.; Jiang, R. & Hollan, E. (2007).Insulin-like growth factor 
binding protein 2 promotes glioma development and progression. PNAS,  2007 vol. 
104, no. 28, 11736–11741 
Eng, L.; Vanderhaeghen, J.; Bignami, A. & Gerstl, B. (1971). An acidic protein isolatedfrom 
fibrous astrocytes. Brain Res., Vol.28, pp.351–354. 
Eng, L.; Ghirnikar, R. & Lee, Y. (2000). Glial fibrillary acidic protein: GFAP-thirty-one years 
(1969-2000). Neurochem Res., Vol. 25, pp. 1439–1451. 
Esteller, M.; Hamilton, S.; Burger, P.; Baylin, S. & Herman, J. (1999). Inactivation of the DNA 
repair gene O6-methylguanine-DNA methyltransferase by promoter 
hypermethylation is a common event in primary human neoplasia. Cancer Res, 
Vol.59, pp.793–797. 
Foehr, E.; Lorente, G.; Kuo, J.; Ram, R.; Nikolich, K. & Urfer, R. (2006). Targeting of the 
Receptor Protein Tyrosine Phosphatase B with a Monoclonal Antibody Delays 
Tumor Growth in a Glioblastoma Model. Cancer Res, Vol.66, pp.2271-2278. 
Gerstner, E.; Yip, S.; Wang, D.; Louis, D.; Iafrate, A. & Batchelor,T. (2009). MGMT 
methylation is a prognostic biomarker in elderly patients with newly diagnosed 
glioblastoma. Neurology, Vol.73, pp.1509-1510. 
Hägerstrand, D.; Smits, A.; Eriksson, A.; Sigurdardottir, S.; Olofsson,T.; Hartman,M.; Nistér, 
M.; Kalimo, H. & Östman, A. (2008). Gene expression analyses of grade II gliomas 
and identification of rPTPβ/ζ as a candidate oligodendroglioma marker. Neuro-
Oncology, Vol.10, pp. 2-9. 
Hamaya, K.; Doi, K.; Tanaka, T. & Nishimoto, A. (1985).The determination of glial fibrillary 
acidic protein for the diagnosis and histogenetic study of central nervous system 
tumors: a study of 152 cases. Acta Med Okayama, Vol.39, pp. 453–462. 
Hegi, M.; Diserens, A.; Gorlia, T, Hamou, M.; de Tribolet, N.; Weller, M.; Kros, J.; 
Hainfellner, J.; Mason, W.; Mariani, L.; Bromberg, J.; Hau, P.; Mirimanoff, R.; 
Cairncross, J.; Janzer,R. & Stupp R. (2005). MGMT gene silencing and benefit from 
temozolomide in glioblastoma. N. Engl. J. Med., Vol.352, No.10, pp.997–1003. 
Hoeflich, A.; Reisinger, R.; Lahm, H.; Kiess, W.; Blum, W.; Kolb, H.; Weber, M. & Wolf, E. 
(2001). Insulin-like growth factor-binding protein 2 in tumorigenesis : protector or 
promoter? Cancer Res, Vol.61, pp.8601-8610. 
 
Molecular Targets of CNS Tumors 
 
338 
Hogdall, E.; Johansen, J.; Kjaer, S.; Price, P.; Christensen, L.; Blaakaer, J.; Bock, J.; Glud, E. & 
Hogdall, C. (2003). High plasmaYKL-40 level in patients with ovarian cancer stage 
III is related to shorter survival. Oncol. Rep., Vol.10, pp.1535-1538. 
Hormigo, A.; Gu, B.; Karimi, S.; Riedel, E.; Panageas, K.; Edgar, M.; Tanwar, M.; Rao, J.; 
Fleisher, M.; DeAngelis, L. & Holland, E. (2006). YKL-40 and Matrix 
Metalloproteinase-9 as potential serum biomarkers for patients with high-grade 
gliomas. Clin Cancer Res, Vol.12, No.19, pp.5698-5704. 
Hormigo, A.; Ding, B. & Rafiia, S. (2011). A target for antiangiogenic therapy: vascular 
endothelium derived from glioblastoma. PNAS, Vol. 108, No. 11,pp. 4271–4272. 
Horvath, S.; Zhang, B.; Carlson, M.; Lud, K.; Zhu, S.; Felciano, R.; Laurance, M.; Zhao, W.; 
Qi, S.; Chen, Z.; Lee, Y.; Scheck, A.; Liau, L.; Wu, H.; Geschwind, D.; Febbo, P.; 
Kornblum, H.; Cloughesy, T.; Nelsona, S.; Mischel, P. (2006). Analysis of oncogenic 
signaling networks in glioblastoma identifies ASPM as a molecular target. PNAS, 
Vol.103, pp.17402-17407. 
Jacque, C.; Vinner, C.; Kujas, M.; Raoul, M.; Racadot, J. & Baumann, N. (1978). 
Determination of glial fibrillary acidic protein (GFAP) in human brain tumors. J 
Neurol Sci., Vol.35, pp.147–155. 
Jensen, B.; Johansen, J. & Price, P. (2003). High levels of serum HER-2/neu and YKL-40 
independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res, 
Vol.9, pp.4423-4434. 
Johansen, J.; Cintin C.; Jorgensen, M.; Kamby, C. & Price, P.  (1995). Serum YKL-40: a new 
potential marker of prognosis and location of metastases of patients with recurrent 
breast cancer. Eur J Cancer, Vol.31, pp.1437– 1442. 
Jung, C.; Foerch, C.; Schänzer, A.; Heck, A.; Plate, K.; Seifert, V.; Steinmetz, H.; Raabe, A. 
&Sitzer, M. (2007). Serum GFAP is a diagnostic marker for glioblastoma 
multiforme. Brain, Vol.130, pp.3336-3341. 
Keller, S.; Sanderson, M.; Stoeck, A. & Altevogt, P. (2006). Exosomes: from biogenesis and 
secretion to biological function. Immunol. Lett., Vol.107, No.2, pp.102–108. 
Khalil, A. (2007). Biomarker discovery: a proteomic approach for brain cancer profiling. 
Cancer Sci, Vol.98, pp.201-213. 
Khan, J.; Tao, X. & Tong, L. (2006). Molecular basis for the inhibition of human NMPRTase, a 
novel target for anticancer agents. Nature Struct. Mol. Biol., Vol.13,pp. 582-588.  
Khayal, I.; Polley, M.; Jalbert, L.; Elkhaled, A.; Chang, S.; Cha, S.; Butowski, N. & Nelson S. 
(2010). Evaluation of diffusion parameters as early biomarkers of disease 
progression in glioblastoma multiforme. Neuro-oncology, Vol.12, No.9, pp.908-916. 
Kholmanskikh, S.; Koeller, H.; Wynshaw-Boris, A.; Gomez, T.; Letourneau, P. & Ross, M. 
(2006). Calcium-dependent interaction of Lis1 with IQGAP1 and Cdc42 
promotesneuronal motility. Nat Neurosci, Vol.9, pp.50–57. 
Khwaja, F.; Reed, M.; Olson, J.; Schmotzer, B.; Gillespie, G.; Guha, A.; Groves, M.; Kesari, S.;     
Pohl, J. & Meir, E. (2007). Proteomic identification of biomarkers in the 
cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res., Vol.6, pp.559-570.  
Kulasingam, V. & Diamandis, E. (2008). Strategies for discovering novel cancer biomarkers 
through utilization of emerging technologies. Nat Clin Prac Oncol, Vol.5, No.10, 
pp.588-599. 
 
Biomarkers of Glioma 
 
339 
Li, X.; Zhang, Z.; Schluesener, H. & Xu, S. (2006). Role of exosomes in immune regulation. J. 
Cell. Mol. Med, Vol.10, No.2, pp. 364–375. 
Li, Z.; Wang, H.; Eyler, C.; Hjelmeland, A.; Rich, J. (2009). Turning cancer stem cells 
insideout: an exploration of glioma stem cell signaling pathways. J. Biol. Chem., 
Vol.284, No.25, pp.16705-16709. 
Liang, S.; Shen, G.; Liu, Q.; Xu, Y.; Zhou, L.; Xiao, S.; Xu, Z.; Gong, F.; You, C. & Wei, Y. 
(2009a). Isoform-specific expression and characterization of 14-3-3 proteins in 
human glioma tissues discovered by SILAC-based Proteomic analysis. Proteomics 
Clin. Appl., Vol. 3, pp. 743-753.  
Liang, S.; Shen, G.; Xu, X.; Xu, X.; Wei, Y. (2009b) Affinity purification combined with mass 
spectrometry-based proteomics to study mammalian protein complex and protein-
protein interactions. Current Proteomics, Vol.6(1), pp.25-31 
Liang, S.; Xu, Z.; Xu, X.; Zhao, X.; Huang, C.; Wei, Y. (2011). Quantitative proteomics for 
cancer biomarker discovery. Comb Chem High T Scr, in press. 
Lin,Y.; Jiang,T.; Zhou, K.; Xu, L.; Chen, B.; Li, G.; Qiu, X.; Jiang, T.; Zhang, W. & Song, S. 
(2009). Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade 
gliomas. Neuro-Oncology, Vol.11, pp. 468–476. 
Liu, Mi.; Dai, B.; Kang, S.; Ban, K.; Huang, F.; Lang, F.; Aldape, K.; Xie, T.; Pelloski, C.; 
Xie, K.; Sawaya, R. & Huang, S. (2006). FoxM1B is overexpressed in human glioblastomas 
and critically regulates the tumorigenicity of glioma cells. Cancer Res., Vol. 66, No.7, 
pp. 3593-3602. 
Loeb, S. & Catalona, W. (2007). Prostate-specific antigen in clinical practice. Cancer Lett., 
Vol.249, pp.30–39. 
Lukas, R.; Boire, A.; Nicholas, M. (2009). Targeted therapy in the treatment of malignant 
gliomas. OncoTargets & Therapy, Vol.2, pp. 115-133. 
Marrer, E. & Dieterle, F. (2007). Promises of biomarkers in drug development –a reality 
check. Chem Biol Drug Des., Vol.69: 381-394. 
Mateer, S.; Wang, N. & Bloom, G. (2003). IQGAPs: integrators of the cytoskeleton, cell 
adhesion machinery, and signaling networks. Cell Motil Cytoskeleton, Vol.55, pp. 
147–155. 
Maurer, M.; Berger, C.; Wolf, M.; Futterer, C.; Feldmann,R., Jr.; Schwab, S. & Kuschinsky, 
W.(2003). The proteome of human brain microdialysate. Proteome Sci., Vol.1, pp.7-
15. 
McCarthy, B.; Rankin, K.; Il’yasova, D.; Erdal, S.; Vick, N.; Ali-Osman, F.; Bigner, D. & 
Davis, F. (2011). Assessment of type of allergy and antihistamine use in the 
development of glioma. Cancer Epidemiol Biomarkers Prev, Vol.20, pp.370-378. 
McDonald, K.; O’Sullivan, M.; Parkinson, J.; Shaw, J.; Payne, C.; Brewer, J.; Young, L.; 
Reader, D.; Wheeler, H.; Cook, R.; Biggs, M.; Little, N.; Teo, C.; Stone, G. & 
Robinson, B. (2007). IQGAP1 and IGFBP2: valuable biomarkers for determining 
prognosis in glioma patients. J Neuropathol Exp Neurol, Vol. 66, No. 5, pp.405-417. 
Muller, H., Oh, Y., Lehrnbecher, T., Blum, W., & Rosenfeld, R. (1994). Insulin-like growth 
factor-binding protein-2 concentrations in cerebrospinal fluid and serum of 
children with malignant solid tumors or acute leukemia. J. Clin. Endocrinol. Metab, 
Vol.79, pp. 428–434. 
 
Molecular Targets of CNS Tumors 
 
338 
Hogdall, E.; Johansen, J.; Kjaer, S.; Price, P.; Christensen, L.; Blaakaer, J.; Bock, J.; Glud, E. & 
Hogdall, C. (2003). High plasmaYKL-40 level in patients with ovarian cancer stage 
III is related to shorter survival. Oncol. Rep., Vol.10, pp.1535-1538. 
Hormigo, A.; Gu, B.; Karimi, S.; Riedel, E.; Panageas, K.; Edgar, M.; Tanwar, M.; Rao, J.; 
Fleisher, M.; DeAngelis, L. & Holland, E. (2006). YKL-40 and Matrix 
Metalloproteinase-9 as potential serum biomarkers for patients with high-grade 
gliomas. Clin Cancer Res, Vol.12, No.19, pp.5698-5704. 
Hormigo, A.; Ding, B. & Rafiia, S. (2011). A target for antiangiogenic therapy: vascular 
endothelium derived from glioblastoma. PNAS, Vol. 108, No. 11,pp. 4271–4272. 
Horvath, S.; Zhang, B.; Carlson, M.; Lud, K.; Zhu, S.; Felciano, R.; Laurance, M.; Zhao, W.; 
Qi, S.; Chen, Z.; Lee, Y.; Scheck, A.; Liau, L.; Wu, H.; Geschwind, D.; Febbo, P.; 
Kornblum, H.; Cloughesy, T.; Nelsona, S.; Mischel, P. (2006). Analysis of oncogenic 
signaling networks in glioblastoma identifies ASPM as a molecular target. PNAS, 
Vol.103, pp.17402-17407. 
Jacque, C.; Vinner, C.; Kujas, M.; Raoul, M.; Racadot, J. & Baumann, N. (1978). 
Determination of glial fibrillary acidic protein (GFAP) in human brain tumors. J 
Neurol Sci., Vol.35, pp.147–155. 
Jensen, B.; Johansen, J. & Price, P. (2003). High levels of serum HER-2/neu and YKL-40 
independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res, 
Vol.9, pp.4423-4434. 
Johansen, J.; Cintin C.; Jorgensen, M.; Kamby, C. & Price, P.  (1995). Serum YKL-40: a new 
potential marker of prognosis and location of metastases of patients with recurrent 
breast cancer. Eur J Cancer, Vol.31, pp.1437– 1442. 
Jung, C.; Foerch, C.; Schänzer, A.; Heck, A.; Plate, K.; Seifert, V.; Steinmetz, H.; Raabe, A. 
&Sitzer, M. (2007). Serum GFAP is a diagnostic marker for glioblastoma 
multiforme. Brain, Vol.130, pp.3336-3341. 
Keller, S.; Sanderson, M.; Stoeck, A. & Altevogt, P. (2006). Exosomes: from biogenesis and 
secretion to biological function. Immunol. Lett., Vol.107, No.2, pp.102–108. 
Khalil, A. (2007). Biomarker discovery: a proteomic approach for brain cancer profiling. 
Cancer Sci, Vol.98, pp.201-213. 
Khan, J.; Tao, X. & Tong, L. (2006). Molecular basis for the inhibition of human NMPRTase, a 
novel target for anticancer agents. Nature Struct. Mol. Biol., Vol.13,pp. 582-588.  
Khayal, I.; Polley, M.; Jalbert, L.; Elkhaled, A.; Chang, S.; Cha, S.; Butowski, N. & Nelson S. 
(2010). Evaluation of diffusion parameters as early biomarkers of disease 
progression in glioblastoma multiforme. Neuro-oncology, Vol.12, No.9, pp.908-916. 
Kholmanskikh, S.; Koeller, H.; Wynshaw-Boris, A.; Gomez, T.; Letourneau, P. & Ross, M. 
(2006). Calcium-dependent interaction of Lis1 with IQGAP1 and Cdc42 
promotesneuronal motility. Nat Neurosci, Vol.9, pp.50–57. 
Khwaja, F.; Reed, M.; Olson, J.; Schmotzer, B.; Gillespie, G.; Guha, A.; Groves, M.; Kesari, S.;     
Pohl, J. & Meir, E. (2007). Proteomic identification of biomarkers in the 
cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res., Vol.6, pp.559-570.  
Kulasingam, V. & Diamandis, E. (2008). Strategies for discovering novel cancer biomarkers 
through utilization of emerging technologies. Nat Clin Prac Oncol, Vol.5, No.10, 
pp.588-599. 
 
Biomarkers of Glioma 
 
339 
Li, X.; Zhang, Z.; Schluesener, H. & Xu, S. (2006). Role of exosomes in immune regulation. J. 
Cell. Mol. Med, Vol.10, No.2, pp. 364–375. 
Li, Z.; Wang, H.; Eyler, C.; Hjelmeland, A.; Rich, J. (2009). Turning cancer stem cells 
insideout: an exploration of glioma stem cell signaling pathways. J. Biol. Chem., 
Vol.284, No.25, pp.16705-16709. 
Liang, S.; Shen, G.; Liu, Q.; Xu, Y.; Zhou, L.; Xiao, S.; Xu, Z.; Gong, F.; You, C. & Wei, Y. 
(2009a). Isoform-specific expression and characterization of 14-3-3 proteins in 
human glioma tissues discovered by SILAC-based Proteomic analysis. Proteomics 
Clin. Appl., Vol. 3, pp. 743-753.  
Liang, S.; Shen, G.; Xu, X.; Xu, X.; Wei, Y. (2009b) Affinity purification combined with mass 
spectrometry-based proteomics to study mammalian protein complex and protein-
protein interactions. Current Proteomics, Vol.6(1), pp.25-31 
Liang, S.; Xu, Z.; Xu, X.; Zhao, X.; Huang, C.; Wei, Y. (2011). Quantitative proteomics for 
cancer biomarker discovery. Comb Chem High T Scr, in press. 
Lin,Y.; Jiang,T.; Zhou, K.; Xu, L.; Chen, B.; Li, G.; Qiu, X.; Jiang, T.; Zhang, W. & Song, S. 
(2009). Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade 
gliomas. Neuro-Oncology, Vol.11, pp. 468–476. 
Liu, Mi.; Dai, B.; Kang, S.; Ban, K.; Huang, F.; Lang, F.; Aldape, K.; Xie, T.; Pelloski, C.; 
Xie, K.; Sawaya, R. & Huang, S. (2006). FoxM1B is overexpressed in human glioblastomas 
and critically regulates the tumorigenicity of glioma cells. Cancer Res., Vol. 66, No.7, 
pp. 3593-3602. 
Loeb, S. & Catalona, W. (2007). Prostate-specific antigen in clinical practice. Cancer Lett., 
Vol.249, pp.30–39. 
Lukas, R.; Boire, A.; Nicholas, M. (2009). Targeted therapy in the treatment of malignant 
gliomas. OncoTargets & Therapy, Vol.2, pp. 115-133. 
Marrer, E. & Dieterle, F. (2007). Promises of biomarkers in drug development –a reality 
check. Chem Biol Drug Des., Vol.69: 381-394. 
Mateer, S.; Wang, N. & Bloom, G. (2003). IQGAPs: integrators of the cytoskeleton, cell 
adhesion machinery, and signaling networks. Cell Motil Cytoskeleton, Vol.55, pp. 
147–155. 
Maurer, M.; Berger, C.; Wolf, M.; Futterer, C.; Feldmann,R., Jr.; Schwab, S. & Kuschinsky, 
W.(2003). The proteome of human brain microdialysate. Proteome Sci., Vol.1, pp.7-
15. 
McCarthy, B.; Rankin, K.; Il’yasova, D.; Erdal, S.; Vick, N.; Ali-Osman, F.; Bigner, D. & 
Davis, F. (2011). Assessment of type of allergy and antihistamine use in the 
development of glioma. Cancer Epidemiol Biomarkers Prev, Vol.20, pp.370-378. 
McDonald, K.; O’Sullivan, M.; Parkinson, J.; Shaw, J.; Payne, C.; Brewer, J.; Young, L.; 
Reader, D.; Wheeler, H.; Cook, R.; Biggs, M.; Little, N.; Teo, C.; Stone, G. & 
Robinson, B. (2007). IQGAP1 and IGFBP2: valuable biomarkers for determining 
prognosis in glioma patients. J Neuropathol Exp Neurol, Vol. 66, No. 5, pp.405-417. 
Muller, H., Oh, Y., Lehrnbecher, T., Blum, W., & Rosenfeld, R. (1994). Insulin-like growth 
factor-binding protein-2 concentrations in cerebrospinal fluid and serum of 
children with malignant solid tumors or acute leukemia. J. Clin. Endocrinol. Metab, 
Vol.79, pp. 428–434. 
 
Molecular Targets of CNS Tumors 
 
340 
Nilsson, J.; Skog, J.; Nordstrand, A.; Baranov, V.; Mincheva-Nilsson, L.; Breakefield, X. & 
Widmark, A. (2009). Prostate cancer-derived urine exosomes: a novel approach to 
biomarkers for prostate cancer. Br J Cancer, Vol.100, Noo.10, pp. 1603–1607.  
Nutt, C.; Betensky, R.; Brower, M.; Batchelor, T.; Louis, D. & Stemmer-Rachamimov, A. 
(2005). YKL-40 is a differential diagnostic marker for histologic subtypes of high-
grade gliomas.Clin Cancer Res, Vol.11, pp.2258-2264. 
Ohnishi, M.; Matsumoto,T.; Nagashio, R.; Kageyama, T.; Utsuki, S.; Oka, H.; Okayasu, I. & 
Sato, Y. (2009). Proteomics of tumor-specific proteins in cerebrospinal fluid of 
patients with astrocytoma: usefulness of gelsolin protein. Pathol Int, Vol. 59, pp. 
797–803. 
Omenn, G. (2005). Exploring the human plasma proteome. Proteomics, Vol.5, pp.3223- 3225. 
Pelloski, C.; Mahajan, A.; Maor, M.; Chang, E.; Woo, S.; Gilbert, M.; Colman, H.; Yang, H.; 
Ledoux, A.; Blair, Hi.; Passe, S.; Jenkins, R. & Aldape, K. (2005). YKL-40 Expression 
is associated with poorer response to radiation and shorter overall survival in 
glioblastoma. Clin Cancer Res, Vol.11, pp.3326-3334. 
Petrik, V.; Saadoun, S.; Loosemore, A.; Hobbs, J.; Opstad, K.; Sheldon, J.; Tarelli, E.; Howe,F.; 
Bell, B. & Papadopoulos, M. (2008). Serum α2-HS glycoprotein predicts survival in 
patients with glioblastoma. Clinical Chemistry, Vol.54, pp.4 713-4722. 
Piccirillo, S.; Reynolds, B.; Zanetti, N.; Lamorte, G.; Binda, E.; Broggi, G.; Brem, H.; Olivi, A.; 
Dimeco, F.;Vescovi, A. (2006). Bone morphogenetic proteins inhibit the tumorigenic 
potential of human brain tumour-initiating cells. Nature, Vol.444, pp.761-765. 
Pisitkun, T.; Shen, R. & Knepper, M. (2004). Identification and proteomic profiling of 
exosomes in human urine. PNAS, Vol.101, No.36, pp.13368–13373.  
Preusser, M.; Janzer, R.; Felsberg, J.; Reifenberger, G.; Hamou, M.; Diserens, A.; Stupp, R.; 
Gorlia, T.; Marosi, C.; Heinzl, H.; Hainfellner, J. & Hegi, M. (2008). Anti-O6 -
Methylguanine-Methyltransferase (MGMT) immunohistochemistry in gioblastoma 
multiforme: observer variability and lack of association with patient survival 
impede its use as clinical biomarker. Brain Pathology, Vol.18, pp. 520-532. 
Reddy, P.; Umesh, S.; Thota, B.; Tandon, A.; Pandey, P.; Hegde, A.; Balasubramaniam, A.; 
Chandramouli, B.; Santosh,V.; Rao, M.; Kondaiah, P. & Somasundaram, K. (2008). 
PBEF1/NAmPRTase /Visfatin .a potential malignant astrocytoma/glioblastoma 
serum marker with prognostic value. Cancer Biol. Ther., Vol.7, No.5, 665-670. 
Reddy, S.; Britto, R.; Vinnakota, K.; Aparna, H.; Sreepathi, H.; Thota, B.; Kumari, A.; Shilpa, 
B.; Vrinda, M.; Umesh, S.; Samuel,C.; Shetty, M.; Tandon, A.; Pandey, P.; Hegde,S.; 
Hegde, A.; Balasubramaniam, A.; Chandramouli, B.; antosh, V.; Kondaiah, P.; 
Somasundaram, K. & Rao, M. (2008). Novel glioblastoma markers with diagnostic 
and prognostic value identified through transcriptome analysis. Clin Cancer Res, 
Vol.14, No.10, pp.2978-2987. 
Roesler, R.; Brunetto, A.; Abujamra, A.; de Farias, C.; Brunetto, A.; Schwartsmann, G. 
(2010).Current and emerging molecular targets in glioma. Expert Rev. Anticancer 
Ther. Vol.10, No.11, 1735-1751. 
Rorive, S.; Lopez, X.; Maris, C.; Trepant, A.; Sauvage, S.; Sadeghi, N.; Roland, I.; 
Decaestecker, C. & Salmon, I. (2010). TIMP-4 and CD63: new prognostic biomarkers 
in human astrocytomas. Mod pathol, Vol.23, pp.1418-1428.  
 
Biomarkers of Glioma 
 
341 
Ross, J. & Fletcher, J. (1998). The HER-2/neu oncogene in breast cancer: prognostic factor, 
predictive factor, and target for therapy. The Oncologist, Vol.3, pp.237-252. 
Sanson, M.; Marie, Y.; Paris, S.; Idbaih, A.; Laffaire, J.; Ducray, F.; Hallani, S.; Boisselier, B.; 
Mokhtari, K.; Hoang-Xuan, K. & Delattre, J. (2009). Isocitrate dehydrogenase 1 
codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. , 
Vol. 27, No.25, pp.4150-4154. 
Sanson M. (2008). Targets for glioma treatment: from bench to bedside. Curr Opin Oncol. 
,Vol.20(6),pp.650-651. 
Schwartz, S.; Weil, R.; Thompson, R.; Shyr, Y.; Moore, J.; Toms, S.; Johnson, M & Caprioli1, 
R. (2005). Proteomic-based prognosis of brain tumor patients using direct-tissue 
matrix -assisted laser desorption ionization mass spectrometry. Cancer Res, Vol.65, 
No.17, pp. 7674-81. 
Shen, G.; Liang, S.; Xu, Z.; Zhou, L.; Xiao, S.; Xia, X.; Li, R.; Liao, Y.; You, C. & Wei, Y. 
(2010).Downregulated expression of HSP27 in human low-grade glioma tissue 
discovered by a quantitative proteomic analysis. Proteome Sci., Vol.8, pp.17-28. 
Singh, S.; Clarke, I.; Terasaki, M.;, Bonn,V.; Hawkins, C.; Squire, J.; Dirks, P. (2003). 
Identification of a cancer stem cell in human brain tumors. Cancer Res., Vol.63, 
No.18, pp.5821-5828. 
Singh, S.; Hawkins, C.; Clarke, I.; Squire, J.; Bayani, J.; Hide, T.; Henkelman, R.; Cusimano, 
M.; Dirks, P. (2004). Identification of human brain tumour initiating cells. Nature, 
Vol. 432, No.7015, pp.396-401. 
Skog, J.;, Würdinger, T.; van Rijn, S.; Meijer, D.; Gainche, L.; Sena-Esteves, M.; Curry, W., 
Jr.;Carter, B.; Krichevsky, A. & Breakefield, X. (2008). Glioblastoma microvesicles 
transport RNA and proteins that promote tumour growth and provide diagnostic 
biomarkers. Nat Cell Biol., Vol.10, No.12, pp.1470–1476. 
Sodaa,Y.; Marumotoa, T.; Friedmann-Morvinskia, D.; Sodaa, M.; Liua, F.; Michiuec, H.; 
Pastorinod, S.; Yange, M.; Hoffmane, R.; Kesarid, S. & Vermaa, I. (2011).  
Transdifferentiation of glioblastoma cells into vascular endothelial cells. PNAS, 
Vol.108, No. 11, PP. 4274–4280. 
Sreekanthreddy, P.; Srinivasan, H.; Kumar, D.; Nijaguna, M.; Sridevi, S.; Vrinda, M.; 
Arivazhagan, A.; Balasubramaniam, A.; Hegde, A.; Chandramouli, B.; Santosh, V.;  
Rao, M.; Kondaiah, P. & Somasundaram, K. Identification of potential serum biomarkers of 
glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer 
Epidemiol Biomarkers Prev, Vol.19, No.6, pp.1409–1422. 
von Deimling, A.; Korshunov, Andrey. & Hartmann, C. (2011). The next generation of 
glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain 
Pathology, Vol.21, pp.74–87. 
Yamaoka-Tojo, M.; Ushio-Fukai, M.; Hilenski, L.; Dikalov, S.; Chen, Y.; Tojo, T.; Fukai, T.; 
Fujimoto, M.; Patrushev, N.; Wang, N.; Kontos, C.; Bloom, G. & Alexander, R. 
(2004). IQGAP1, a novel vascular endothelial growth factor receptor binding 
protein, is involved in reactive oxygen species–dependent endothelial migration 
and proliferation. Circ. Res., Vol.95, pp.276-283. 
Yan, H.; Parsons, D.; Jin, G.; McLendon, R.; Rasheed, B.; Yuan, W.; Kos, I.; Batinic-Haberle, 
I.; Jones, S.; Riggins, G.; Friedman, H.; Friedman, A.; Reardon, D.; Herndon, J.; 
 
Molecular Targets of CNS Tumors 
 
340 
Nilsson, J.; Skog, J.; Nordstrand, A.; Baranov, V.; Mincheva-Nilsson, L.; Breakefield, X. & 
Widmark, A. (2009). Prostate cancer-derived urine exosomes: a novel approach to 
biomarkers for prostate cancer. Br J Cancer, Vol.100, Noo.10, pp. 1603–1607.  
Nutt, C.; Betensky, R.; Brower, M.; Batchelor, T.; Louis, D. & Stemmer-Rachamimov, A. 
(2005). YKL-40 is a differential diagnostic marker for histologic subtypes of high-
grade gliomas.Clin Cancer Res, Vol.11, pp.2258-2264. 
Ohnishi, M.; Matsumoto,T.; Nagashio, R.; Kageyama, T.; Utsuki, S.; Oka, H.; Okayasu, I. & 
Sato, Y. (2009). Proteomics of tumor-specific proteins in cerebrospinal fluid of 
patients with astrocytoma: usefulness of gelsolin protein. Pathol Int, Vol. 59, pp. 
797–803. 
Omenn, G. (2005). Exploring the human plasma proteome. Proteomics, Vol.5, pp.3223- 3225. 
Pelloski, C.; Mahajan, A.; Maor, M.; Chang, E.; Woo, S.; Gilbert, M.; Colman, H.; Yang, H.; 
Ledoux, A.; Blair, Hi.; Passe, S.; Jenkins, R. & Aldape, K. (2005). YKL-40 Expression 
is associated with poorer response to radiation and shorter overall survival in 
glioblastoma. Clin Cancer Res, Vol.11, pp.3326-3334. 
Petrik, V.; Saadoun, S.; Loosemore, A.; Hobbs, J.; Opstad, K.; Sheldon, J.; Tarelli, E.; Howe,F.; 
Bell, B. & Papadopoulos, M. (2008). Serum α2-HS glycoprotein predicts survival in 
patients with glioblastoma. Clinical Chemistry, Vol.54, pp.4 713-4722. 
Piccirillo, S.; Reynolds, B.; Zanetti, N.; Lamorte, G.; Binda, E.; Broggi, G.; Brem, H.; Olivi, A.; 
Dimeco, F.;Vescovi, A. (2006). Bone morphogenetic proteins inhibit the tumorigenic 
potential of human brain tumour-initiating cells. Nature, Vol.444, pp.761-765. 
Pisitkun, T.; Shen, R. & Knepper, M. (2004). Identification and proteomic profiling of 
exosomes in human urine. PNAS, Vol.101, No.36, pp.13368–13373.  
Preusser, M.; Janzer, R.; Felsberg, J.; Reifenberger, G.; Hamou, M.; Diserens, A.; Stupp, R.; 
Gorlia, T.; Marosi, C.; Heinzl, H.; Hainfellner, J. & Hegi, M. (2008). Anti-O6 -
Methylguanine-Methyltransferase (MGMT) immunohistochemistry in gioblastoma 
multiforme: observer variability and lack of association with patient survival 
impede its use as clinical biomarker. Brain Pathology, Vol.18, pp. 520-532. 
Reddy, P.; Umesh, S.; Thota, B.; Tandon, A.; Pandey, P.; Hegde, A.; Balasubramaniam, A.; 
Chandramouli, B.; Santosh,V.; Rao, M.; Kondaiah, P. & Somasundaram, K. (2008). 
PBEF1/NAmPRTase /Visfatin .a potential malignant astrocytoma/glioblastoma 
serum marker with prognostic value. Cancer Biol. Ther., Vol.7, No.5, 665-670. 
Reddy, S.; Britto, R.; Vinnakota, K.; Aparna, H.; Sreepathi, H.; Thota, B.; Kumari, A.; Shilpa, 
B.; Vrinda, M.; Umesh, S.; Samuel,C.; Shetty, M.; Tandon, A.; Pandey, P.; Hegde,S.; 
Hegde, A.; Balasubramaniam, A.; Chandramouli, B.; antosh, V.; Kondaiah, P.; 
Somasundaram, K. & Rao, M. (2008). Novel glioblastoma markers with diagnostic 
and prognostic value identified through transcriptome analysis. Clin Cancer Res, 
Vol.14, No.10, pp.2978-2987. 
Roesler, R.; Brunetto, A.; Abujamra, A.; de Farias, C.; Brunetto, A.; Schwartsmann, G. 
(2010).Current and emerging molecular targets in glioma. Expert Rev. Anticancer 
Ther. Vol.10, No.11, 1735-1751. 
Rorive, S.; Lopez, X.; Maris, C.; Trepant, A.; Sauvage, S.; Sadeghi, N.; Roland, I.; 
Decaestecker, C. & Salmon, I. (2010). TIMP-4 and CD63: new prognostic biomarkers 
in human astrocytomas. Mod pathol, Vol.23, pp.1418-1428.  
 
Biomarkers of Glioma 
 
341 
Ross, J. & Fletcher, J. (1998). The HER-2/neu oncogene in breast cancer: prognostic factor, 
predictive factor, and target for therapy. The Oncologist, Vol.3, pp.237-252. 
Sanson, M.; Marie, Y.; Paris, S.; Idbaih, A.; Laffaire, J.; Ducray, F.; Hallani, S.; Boisselier, B.; 
Mokhtari, K.; Hoang-Xuan, K. & Delattre, J. (2009). Isocitrate dehydrogenase 1 
codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. , 
Vol. 27, No.25, pp.4150-4154. 
Sanson M. (2008). Targets for glioma treatment: from bench to bedside. Curr Opin Oncol. 
,Vol.20(6),pp.650-651. 
Schwartz, S.; Weil, R.; Thompson, R.; Shyr, Y.; Moore, J.; Toms, S.; Johnson, M & Caprioli1, 
R. (2005). Proteomic-based prognosis of brain tumor patients using direct-tissue 
matrix -assisted laser desorption ionization mass spectrometry. Cancer Res, Vol.65, 
No.17, pp. 7674-81. 
Shen, G.; Liang, S.; Xu, Z.; Zhou, L.; Xiao, S.; Xia, X.; Li, R.; Liao, Y.; You, C. & Wei, Y. 
(2010).Downregulated expression of HSP27 in human low-grade glioma tissue 
discovered by a quantitative proteomic analysis. Proteome Sci., Vol.8, pp.17-28. 
Singh, S.; Clarke, I.; Terasaki, M.;, Bonn,V.; Hawkins, C.; Squire, J.; Dirks, P. (2003). 
Identification of a cancer stem cell in human brain tumors. Cancer Res., Vol.63, 
No.18, pp.5821-5828. 
Singh, S.; Hawkins, C.; Clarke, I.; Squire, J.; Bayani, J.; Hide, T.; Henkelman, R.; Cusimano, 
M.; Dirks, P. (2004). Identification of human brain tumour initiating cells. Nature, 
Vol. 432, No.7015, pp.396-401. 
Skog, J.;, Würdinger, T.; van Rijn, S.; Meijer, D.; Gainche, L.; Sena-Esteves, M.; Curry, W., 
Jr.;Carter, B.; Krichevsky, A. & Breakefield, X. (2008). Glioblastoma microvesicles 
transport RNA and proteins that promote tumour growth and provide diagnostic 
biomarkers. Nat Cell Biol., Vol.10, No.12, pp.1470–1476. 
Sodaa,Y.; Marumotoa, T.; Friedmann-Morvinskia, D.; Sodaa, M.; Liua, F.; Michiuec, H.; 
Pastorinod, S.; Yange, M.; Hoffmane, R.; Kesarid, S. & Vermaa, I. (2011).  
Transdifferentiation of glioblastoma cells into vascular endothelial cells. PNAS, 
Vol.108, No. 11, PP. 4274–4280. 
Sreekanthreddy, P.; Srinivasan, H.; Kumar, D.; Nijaguna, M.; Sridevi, S.; Vrinda, M.; 
Arivazhagan, A.; Balasubramaniam, A.; Hegde, A.; Chandramouli, B.; Santosh, V.;  
Rao, M.; Kondaiah, P. & Somasundaram, K. Identification of potential serum biomarkers of 
glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer 
Epidemiol Biomarkers Prev, Vol.19, No.6, pp.1409–1422. 
von Deimling, A.; Korshunov, Andrey. & Hartmann, C. (2011). The next generation of 
glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain 
Pathology, Vol.21, pp.74–87. 
Yamaoka-Tojo, M.; Ushio-Fukai, M.; Hilenski, L.; Dikalov, S.; Chen, Y.; Tojo, T.; Fukai, T.; 
Fujimoto, M.; Patrushev, N.; Wang, N.; Kontos, C.; Bloom, G. & Alexander, R. 
(2004). IQGAP1, a novel vascular endothelial growth factor receptor binding 
protein, is involved in reactive oxygen species–dependent endothelial migration 
and proliferation. Circ. Res., Vol.95, pp.276-283. 
Yan, H.; Parsons, D.; Jin, G.; McLendon, R.; Rasheed, B.; Yuan, W.; Kos, I.; Batinic-Haberle, 
I.; Jones, S.; Riggins, G.; Friedman, H.; Friedman, A.; Reardon, D.; Herndon, J.; 
 
Molecular Targets of CNS Tumors 
 
342 
Kinzler, K.; Velculescu, V.; Vogelstein, B. & Bigner, D. (2009). IDH1 and IDH2 
mutations in gliomas. N. Eng. J. Med., Vol.360, pp.765-773. 
http://en.wikipedia.org/wiki/Glioma 
16 
MicroRNA (miRNA) Regulation in Glioma: 
Implications in Development, Progression, 
Grading, Prognosis and Therapy 
Kumaravel  Somasundaram*, Soumya Alige Mahabala Rao 
and Zahid Nawaz 
Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore  
India 
1. Introduction   
Neoplasms, which arise in cells originating from central nervous system (CNS) or peripheral 
nervous system (PNS) result in a class of tumours called neuroectodermal tumours. 
Generally after development ceases, neurons become post-mitotic and only the glial cells 
retain the capacity to divide and proliferate. So it is quite appreciable that most of the brain 
tumours are of glial origin and are referred as gliomas. Based on the cell type involved in 
malignancy, gliomas can be astrocytomas (astrocytes), oligodendrogliomas 
(oligodendrocytes), oligoastrocytomas (mixture of astrocytes and oligodendrocytes) and 
ependymomas (ependymal cells). Astrocytomas account for more than 60% of all primary 
brain tumours hence forming the majority of neoplasms of the CNS. On the other hand, 
neurofibroma and schwannoma are the two most common glial tumours of the PNS.  
According to WHO (2007) classification, astrocytomas are classified into grades I–IV based 
on the intensity of malignancy as determined by histopathological criteria. Grade I (Pilocytic 
astrocytoma; PA) gliomas are generally benign and often circumscribed, whereas grade II 
(Diffuse astrocytoma; DA), III (Anaplastic astrocytoma; AA) and IV (Glioblastoma; GBM) 
gliomas are malignant and they diffusely infiltrate the brain. The most malignant and 
common form of infiltrating astrocytic tumours is glioblastoma with a median survival of 
less than one year.  GBM can be further divided into two subtypes based on certain genetic 
and clinical features: primary and secondary GBM. Primary GBM arises as a de novo process, 
without any antecedent history of low grade lesions, whereas secondary GBM develops 
progressively from lower grades, generally over a period of 5–10 years.  
Like any other neoplasm, the underlying cause of gliomagenesis is the genomic alterations 
like deletions, amplifications, mutations, aberrant DNA methylation and chromosomal 
rearrangements, which result in the activation of oncogenes and inactivation of tumour 
suppressors. With the discovery of hundreds of miRNA genes in the past few years that 
produce non-coding RNA transcripts with no significant open reading frame, it has become 
evident that the genomic complexity of the cancer cell is far greater than expected.  
miRNAs are single-stranded non coding RNAs of 19–25 nucleotides in length, generated 
from endogenous transcripts that contain a local hairpin structure. They function as guide 
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molecules in post-transcriptional gene silencing by base pairing with target mRNAs, leading 
either to the cleavage of the target mRNA or its translational repression. miRNAs are one of 
the largest gene families, accounting for ~1% of the genome (Kim, 2005). According to recent 
studies, miRNAs play key roles in diverse regulatory pathways which control development, 
differentiation, apoptosis, cell proliferation and organogenesis. miRNAs and their targets 
seem to form intricate regulatory networks, as a single miRNA can bind to and regulate 
different mRNA targets and conversely, a single mRNA can be synergistically controlled by 
multiple miRNAs. Recently, the work by the Bartel and Burge laboratories predicted that 
over one third of the human genes are regulated by miRNAs (Lewis et al., 2005).  
The location of miRNA genes in fragile sites of the genome provides a circumstantial 
evidence of an etiological role of miRNAs in tumour formation. Because miRNAs are 
generally negative regulators of gene expression, changes in the amounts of these RNAs can 
be tumorigenic if they target a tumour suppressor or an oncogene. For example, over 
accumulation of an miRNA that targets a tumour suppressor would result in less of that 
protective factor. In contrast, reduced accumulation of an miRNA that targets a proto-
oncogene could lead to excessive amounts of the oncogenic protein. Either way, the net 
outcome is an imbalance in the activities of tumour suppressor genes and oncogenes, hence 
resulting in malignancy.   
We review here the discovery and biology of miRNAs including their structure, regulation 
and biogenesis along with different methods available today to assay miRNA expression. A 
detailed account of the literature on differential miRNA expression and their functional 
characterization in glioma is provided. In addition, the potential utility of miRNAs in 
glioma diagnosis, classification, prognosis and targeted therapy is also discussed.  
2. Discovery and biology of miRNAs   
miRNAs were initially discovered as small temporal RNAs (stRNAs) that played a role in 
the developmental transitions in Caenorhabditis elegans. The first miRNA to be discovered 
was lin-4 in C. elegans in the year 1993 (Lee et al., 1993). The discovery of lin-4 and its target 
specific translational repression pointed to a new way of gene regulation. In the year 2000, 
the second miRNA, let-7 was discovered in the same organism and since then a huge 
number of miRNAs have been discovered. A total of 15172 miRNA entries have been 
recorded so far from various organisms (Release 16, miRBase) which also include 1048 
miRNAs from Homo sapiens (http://www.mirbase.org/).  
A small RNA must fulfill the following criteria to be classified as an miRNA. Its expression 
should be authenticated by hybridization to a size-fractionated RNA sample by employing 
northern blotting. It should be detected by methods like PCR after reverse transcription of 
RNA (RT-PCR), primer extension analysis, RNase protection assay and microarray. 
However, northern blotting remains the method of choice for the confirmation of miRNAs, 
as the blot generally detects both the mature form (a ~22-nucleotide band) and the hairpin 
precursor (a ~70-nucleotide band) of the predicted miRNA. The small RNA sequence must 
exist in the stem portion of the hairpin precursor. The precursors are ~60–80 nucleotides in 
animals, but the lengths are more variable in plants. In addition, the small RNA sequences 
should be conserved phylogenetically. Lastly, the evidence can be consolidated if the 
precursor of the predicted miRNA accumulates in ablated Dicer background. However, this 
criterion is not in vogue, because of the technical challenges that are involved in depleting 
Dicer in different cells. 
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2.1 miRNA gene structure 
Most of the miRNA genes are transcribed as independent transcription units. The 
transcripts thus synthesized are referred as primary miRNAs and are equipped with a 7-
methyl guanosine cap in the 5' end as well as a poly A tail in the 3' end which are the unique 
features of class II gene transcripts. This evidence supports the fact that majority of miRNAs, 
if not all, are transcribed by RNA polymerase II (Lee et al., 2004). Treatment of human cells 
with α-amanitin at levels which inhibit RNA polymerase II activity, also brings down the 
global levels of primary miRNAs. Furthermore, chromatin immunoprecipitation (ChIP) 
experiments have also revealed the physical association of RNA polymerase II with miRNA 
promoters and thereby establishing the fact that miRNAs are RNA polymerase II 
transcribed. 
miRNAs can be transcribed either individually i.e. a single primary transcript gives rise to a 
single mature miRNA or they can be transcribed in a polycistronic fashion, in which case 
distinct miRNAs are produced from a single primary transcript. The miRNAs arising from a 
single gene cluster can be related to each other, suggesting that the miRNAs might have 
assembled as a result of gene duplication and may be playing a synergistic role in the 
production of a particular phenotype. 
Based on the genomic location of the transcription units of miRNAs, they can be grouped 
broadly as: intergenic miRNAs and intragenic miRNAs. Intergenic miRNAs exist as 
independent genetic elements, their transcription being driven by their own promoter. The 
intragenic class can be either intronic or exonic in nature owing to the fact whether the stem 
loop sequence of the precursor miRNA comes from the intron or exon of the protein coding 
gene or sometimes a non-protein coding gene. In both types, the miRNA gene can be mono 
or polycistronic. The expression of intragenic miRNAs can be either controlled by their own 
independent promoter or the miRNAs would be co-transcribed with the parent gene, in 
which case the pre-miRNA would be processed subsequent to intron splicing. Some 
miRNAs derive their stem loop sequence from rather short introns and hence bypass the 
processing action of Drosha and are called Mirtrons (Ruby et al., 2007).  
2.2 miRNA gene regulation 
The expression of miRNAs can be modulated at a number of levels, which broadly include 
the transcription of the primary transcript and the multiple steps of the miRNA biogenesis. 
But it continues to remain a dilemma that which step is regulated and how the regulation is 
achieved. Regulation at the level of transcription seems more likely to be the major control 
mechanism. A number of RNA polymearse II associated transcription factors regulate the 
expression of miRNA genes, for instance TP53, a tumour suppressor, transactivates the miR-
34 family of miRNAs (He et al., 2007). Overall, the expression of a particular miRNA seems 
to be under the control of developmental and tissue specific signalling. Apart from this, 
there are reports that miRNAs are also modulated post transcriptionally. Post 
transcriptional regulation is attributed to differential Drosha processing. An example of post 
transcriptional regulation involves the induction of miR-21 in response to bone 
morphogenetic protein (BMP) / transforming growth factor beta (TGF-β) signalling without 
actual transcriptional activation (Davis et al., 2008). TGF-β and BMP signalling activates the 
Smad mediated Drosha processing of the pri-miR-21. 
Majority of miRNA genes being transcribed by the same RNA polymerase as protein coding 
genes, the mechanisms of epigenetic control known for protein coding genes are likely to be 
applicable to miRNA loci as well. Aberrant DNA methylation of tumour suppressor genes is 
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a common occurrence in cancer; accordingly several miRNA loci including miR-9-1, miR-
193a, miR-137, miR-342, miR-203 and miR-34b/c, are found to be hypermethylated in 
multiple human cancers (Lujambio et al., 2008). Conversely, the let-7a-3 locus is 
hypomethylated in lung adenocarcinoma and elevated expression of this locus results in 
enhanced oncogenic gene transcription (Brueckner et al., 2007;). miRNA promoters are also 
regulated by histone modifications during development and pathogenesis (Davis and Hata, 
2009).  
2.3 Biogenesis of miRNAs 
miRNA biogenesis involves initial transcription as a largely unstructured precursor, termed 
as primary miRNA (pri-miRNA), which is subsequently processed in the nucleus to give 
rise to a 70-nucleotide precursor miRNA hairpin intermediate (pre-miRNA). The pre-
miRNA gets transported to the cytoplasm where it undergoes further processing to give rise 
to a mature miRNA (Figure.1). 
Most of the miRNA genes are transcribed by RNA polymerase II to generate a stem-loop 
containing primary miRNA (pri-miRNA), which can range in size from hundreds of 
nucleotides to tens of kilobases (Lee et al., 2004). Like mRNAs, RNA polymerase II 
transcribed pri-miRNAs contain 5' cap structures, are polyadenylated, and may be spliced 
(Cai et al., 2004). The pri-miRNA is processed within the nucleus by a multiprotein complex 
called the microprocessor. The microprocessor is a 650 kDa complex in humans and is 
constituted by two key components: Drosha, an RNase III enzyme and DiGeorge syndrome 
critical region 8 gene (DGCR8), a double-stranded RNA-binding domain (dsRBD) protein 
(Gregory et al., 2004; Landthaler et al., 2004). DGCR8 is also known as Pasha in D. 
melanogaster and C. elegans. The activity of Drosha and DGCR8 results in the production of a 
∼70 nucleotide hairpin structure known as the precursor miRNA (pre-miRNA). The 2-
nucleotide 3' overhang, characteristic of RNase III mediated cleavage, is recognized by 
exportin-5, which transports the pre-miRNA into the cytoplasm via a Ran-GTP-dependent 
mechanism (Bohnsack et al., 2004; Lund et al., 2004; Yi et al., 2003). The pre-miRNA is finally 
cleaved off the loop to produce the mature miRNA duplex about 22 nucleotide in length by 
Dicer, yet another member of RNase III superfamily of bidentate nucleases.  
Dicer is accompanied by dsRBD proteins like TRBP (TAR-RNA binding protein) 
(Chendrimada et al., 2005; Lee et al., 2006). Dicer and TRBP recruit members of the 
Argonaute family and the trimeric complex thus formed is referred to as RNA Induced 
Silencing Complex (RISC) (Gregory et al., 2005; Maniataki and Mourelatos, 2005). Argonaute 
proteins form the catalytic component of the RISC complex as they aid in strand selection of 
the miRNA duplex in addition to the possession of slicer activity by virtue of which they 
slice the target mRNA. In mammals, Ago2 is the sole enzyme equipped with 
endonucleolytic activity (Liu et al., 2004; Meister et al., 2004). One of the miRNA strands 
which has relatively less stability at the 5' end is incorporated into the RISC complex while 
as the other miRNA strand is generally degraded (Du and Zamore, 2005). It is often possible 
that both strands of the miRNA duplex could function as mature miRNAs but their 
abundance may be drastically different (Ruby et al., 2006).   
The miRNA then guides the RISC to specific mRNA targets, the basis of which is sequence 
complementarity generally in the 3' UTR of the target mRNA. In cases of perfect or near 
perfect complementarity to the mRNA, the target mRNA can be cleaved and degraded and 
if there is less complementarity, it results in translational repression (Hutvagner and 
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Zamore, 2002). Most animal miRNAs bind imperfectly to their targets and promote 
translational repression, rather than cleavage and degradation. However, the seed sequence 
representing 2-8 nucleotides from the 5’ end of miRNA requires a perfect complementarity. 
The mechanism of translational repression is somewhat vague with some evidences 
suggesting that miRNAs block translational initiation while as others suggest a block in 




Fig. 1. Schematic representation of miRNA biogenesis pathway. 
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3. Methods to quantitate miRNA levels 
An array of techniques and methodologies can be employed to quantify the levels of 
miRNAs both absolutely and relatively. These include northern blotting, microarrays, bead 
based arrays and quantitative real-time RT-PCR. Northern blotting is a low throughput 
technique as well as less sensitive requiring more input RNA but it can be used to detect 
both mature and pre-miRNA molecules. Genome wide miRNA expression studies are 
chiefly carried out by employing various microarray platforms provided by different private 
firms and are based on different concepts. 
Microarray based detection involves a set of oligonucleotide probes which are spotted on a 
glass slide and can capture the small molecule RNAs like miRNAs, if allowed to hybridize 
under optimum conditions. Availability of high density microarrays, where one can spot 
several thousands of oligonucleotide probes, provides the liberty to detect hundreds of 
miRNAs simultaneously on a single slide. Agilent Inc (http://www.agilent.com/) has 
developed a microarray based application for studying miRNAs that combines a unique 
miRNA direct labeling method with an innovative probe design and established high-
performance SurePrint inkjet synthesis technology. miRNAs being small in size have an 
inherent limitation to hybridize at a single melting temperature (Tm) without compromising 
the sensitivity and specificity of the method. This problem has been overcome by employing 
locked nucleic acids (LNAs) developed by Exiqon Inc (http://www.exiqon.com/). Locked 
nucleic acids differ from regular nucleic acids by a methylene bridge between 2’ oxygen 
atom and the 4’ carbon atom of the ribose moiety. LNA monomers increase the Tm of the 
nucleic acid duplex by 2-10C and hence by adjusting the number of LNA units in the 
oligonucleotide, the hybridization can be carried out at a higher temperature thereby 
increasing the specificity.  
Bead-based arrays also allow simultaneous quantification of hundreds of miRNAs (Luminex 
Inc). This methodology also uses oligonucleotide probes which are coupled to carboxylated 
polystyrene microspheres that incorporate variable mixtures of two fluorescent dyes hence 
allows the detection of each microsphere with a distinct color by a flow cytometer. Each 
microsphere is coupled with oligonucleotide molecules that are specific for a particular 
miRNA. The method involves RNA extraction, followed by biotinylation and finally 
hybridization. The microspheres are washed, incubated with streptavidin–phycoerythrin, 
and analyzed on a Luminex analyzer. The analyzer identifies the fluorescent microsphere as 
well as quantitates the intensity of the streptavidin–phycoerythrin fluorescence, resulting in 
the identification of miRNAs present in the sample.  
Expression analysis is more commonly performed by quantitative real-time RT-PCR. 
Quantification of mature miRNAs usually involves reverse transcription of the miRNA with 
a stem–loop primer. miRNA specific cDNA is then used in the real-time PCR reaction. A 
mixture of forward and reverse primers and a dual-labeled probe (TaqMan®) are used to 
amplify and detect the specific cDNA (Life Technologies Corp.). The probe has a reporter 
dye on the 5’ end and a quencher on the 3’ end. If the target sequence is present during the 
PCR, the probe binds to the target sequence. During the extension stage of the PCR cycle, 
the reporter dye is released by the 5’ exonuclease activity of Taq polymerase, and because 
the reporter and quencher have been separated, the fluorescence from the reporter dye is 
detected. A variation of quantitative real time RT-PCR using SybrGreen based chemistry has 
also been employed (System Biosciences, Qiagen etc.). The technique involves cDNA 
synthesis for the miRNA pool followed by real time PCR using a miRNA specific forward 
primer and a reverse primer essentially derived from RT primer.  
MicroRNA (miRNA) Regulation in Glioma: 
Implications in Development, Progression, Grading, Prognosis and Therapy 
 
349 
4. miRNA regulation in glioma 
Since the initial reports by Ciafre et al and Chan et al, there is an increasing body of literature 
accumulated on the role of miRNAs in glioma development (Table. 1) (Chan et al., 2005; 
Ciafre et al., 2005). Various miRNA profiling studies carried out in glioma tissue samples 
identified differentially regulated miRNAs in gliomas. Several studies also reported the in-
depth investigation of specific miRNAs in glioma cells including functional characterization 
to understand the effects of regulation of miRNA in glioma cells with respect to various 
transformation related phenotypes like cell proliferation, cell death, migration and invasion. 
Many of these studies also included the prediction and experimental validation of targets of 
miRNA by using various accepted techniques.   
4.1 Large scale expression profiling of miRNAs in glioma 
The first report of expression profiling of large number of miRNAs in glioma was almost 
simultaneously reported by two groups (Chan et al., 2005; Ciafre et al., 2005). Ciafre et al 
used a microarray chip to profile the expression of 245 miRNAs in GBM tissue samples 
(Ciafre et al., 2005). The samples included nine GBM tissue samples, matched adjacent 
peripheral region as normal brain tissue and glioma cell lines. With the additional 
validation by northern blotting, this study identified miR-221 as GBM upregulated and 
miR-128, miR-181a, miR-181b and miR-181c as GBM downregulated miRNAs. Chan et al 
analyzed the expression of 180 mammalian miRNAs using a nylon membrane based 
oligonucleotide array in three primary high-grade gliomas and eight non-neoplastic fetal 
and adult brain tissues. They found miR-21 as the most upregulated miRNA in high grade 
gliomas among a total eight miRNAs (Chan et al., 2005). Silber et al analyzed the 
expression of 192 miRNAs by quantitative RT-qPCR with four AAs, four GBMs and four 
Glioses (as normal brain tissues) and found that 35 miRNAs were significantly 
deregulated in AA or GBM tumours (Silber et al., 2008). Thirteen (37%) of these miRNAs 
were differentially expressed in both AA and GBM in comparison to glioses, 16 (45%) 
were differentially expressed only in GBM tumours and 6 (17%) were differentially 
expressed only in AA tumours. Another study carried out microarray based expression 
profiling of 245 miRNAs and found that eleven miRNAs were downregulated and eight 
miRNAs were upregulated in GBM (Godlewski et al., 2008). Malzkorn et al analyzed the 
expression of 157 miRNAs in four glioma patients who had the progression of grade II to 
grade IV by real time RT-PCR (Malzkorn et al.). This revealed the differential expression 
of 14 miRNAs – of which, 12 miRNAs (miR-9, miR-15a, miR-16, miR-17, miR-19a, miR-
20a, miR-21, miR-25, miR-28, miR-130b, miR-140 and miR-210) were upregulated during 
progression whereas 2 (miR-184 and miR-328) of them were downregulated (Malzkorn et 
al.). The authors validated the expression of selected miRNAs (miR-16, miR-17, miR-19a, 
miR-20a, miR-140 and miR-184) in an independent set of low grade and secondary GBM 
samples thus confirming the grade associated regulation of these miRNAs. Modulation of 
miR-17 and miR-328 in glioma cell lines revealed an important role of these miRNAs in 
glioma cell proliferation, apoptosis and cell invasion phenotypes (Malzkorn et al.).  
While the above studies were relatively small, investigating couple of hundred miRNAs and 
used fewer tissue samples, Rao et al recently profiled the expression of 756 human miRNAs 
in malignant astrocytoma- AA (n=13) and GBM (n=26), along with the normal brain 
samples (n=7) and found that 55 miRNAs were upregulated and 29 miRNAs were 
downregulated in malignant astrocytomas in comparison to normal brain samples  
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3. Methods to quantitate miRNA levels 
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well as quantitates the intensity of the streptavidin–phycoerythrin fluorescence, resulting in 
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Quantification of mature miRNAs usually involves reverse transcription of the miRNA with 
a stem–loop primer. miRNA specific cDNA is then used in the real-time PCR reaction. A 
mixture of forward and reverse primers and a dual-labeled probe (TaqMan®) are used to 
amplify and detect the specific cDNA (Life Technologies Corp.). The probe has a reporter 
dye on the 5’ end and a quencher on the 3’ end. If the target sequence is present during the 
PCR, the probe binds to the target sequence. During the extension stage of the PCR cycle, 
the reporter dye is released by the 5’ exonuclease activity of Taq polymerase, and because 
the reporter and quencher have been separated, the fluorescence from the reporter dye is 
detected. A variation of quantitative real time RT-PCR using SybrGreen based chemistry has 
also been employed (System Biosciences, Qiagen etc.). The technique involves cDNA 
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miRNAs were upregulated in GBM (Godlewski et al., 2008). Malzkorn et al analyzed the 
expression of 157 miRNAs in four glioma patients who had the progression of grade II to 
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20a, miR-21, miR-25, miR-28, miR-130b, miR-140 and miR-210) were upregulated during 
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al.). The authors validated the expression of selected miRNAs (miR-16, miR-17, miR-19a, 
miR-20a, miR-140 and miR-184) in an independent set of low grade and secondary GBM 
samples thus confirming the grade associated regulation of these miRNAs. Modulation of 
miR-17 and miR-328 in glioma cell lines revealed an important role of these miRNAs in 
glioma cell proliferation, apoptosis and cell invasion phenotypes (Malzkorn et al.).  
While the above studies were relatively small, investigating couple of hundred miRNAs and 
used fewer tissue samples, Rao et al recently profiled the expression of 756 human miRNAs 
in malignant astrocytoma- AA (n=13) and GBM (n=26), along with the normal brain 
samples (n=7) and found that 55 miRNAs were upregulated and 29 miRNAs were 
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(Rao et al.). Besides the validation of several deregulated miRNAs, this study also developed 
a 23 miRNA expression signature that could distinguish between AA and GBM with high 
accuracy. 
4.2 Specific miRNAs in glioma development  
4.2.1 miR-21 
miR-21 is found to be upregulated in different kinds of human cancers including glioma. 
miR-21, being one of the well studied miRNAs in cancer, is shown to have oncogenic roles 
by targeting multiple tumour suppressors in human cancers. The expression profiling of 
miRNAs in glioblastoma tissues as well as in glioma cell lines identified miR-21 as an 
upregulated miRNA in glioma (Chan et al., 2005). Subsequently, the over expression of miR-
21 in gliomas was confirmed by several studies (Ciafre et al., 2005; Conti et al., 2009; Gabriely 
et al., 2008); (Papagiannakopoulos et al., 2008; Rao et al., ; Silber et al., 2008).   
Modulation of miRNA levels in glioma cell lines indicated that miR-21 had pro-proliferative 
(Chan et al., 2005; Papagiannakopoulos et al., 2008; Zhou et al.) and anti-apoptotic effects 
(Chan et al., 2005; Papagiannakopoulos et al., 2008). miR-21 also affected cell cycle 
progression (Papagiannakopoulos et al., 2008) and the tumour growth in vivo (Corsten et al., 
2007; Zhou et al.). miR-21 was also shown to modulate the chemosensitivity of glioma cells 
to many chemotherapeutic agents like doxorubicin, secretable tumour necrosis factor related 
apoptosis inducing ligand (S-TRAIL), taxol, VM-26 and temozolomide (Corsten et al., 2007; 
Li et al., 2009b; Papagiannakopoulos et al., 2008; Ren et al., ; Shi et al.). Papagiannakopoulos et 
al undertook systems biology approach to understand the role of miR-21 in glioblastoma 
development. The network analysis of bioinformatically predicted targets of miR-21 showed 
that the over expressed miRNA was linked to three major cancer pathways – p53, TGF beta 
and mitochondrial apoptosis pathways. The knock down of miR-21 in glioma cell line 
upregulated many tumour suppressor proteins like p53, Bax, DAXX, APAF1, p21, TAp63 
and TGFBR2 (Papagiannakopoulos et al., 2008).   
Since miR-21 is one of the most upregulated miRNAs, efforts are being made to identify its 
direct targets. While the tumour suppressor proteins like PTEN (phosphatase and tensin 
homolog), TPM1 (Tropomyosin 1) and maspin were well characterized as direct targets of 
miR-21 in other cancers, they were not validated in glioblastoma (Novakova et al., 2009). 
Nevertheless, it was shown that the anti-apoptotic nature of the miR-21 can be partly 
attributed to its target PDCD4 (programmed cell death 4), as the over-expression of miR-21 
inhibited PDCD4-dependent apoptosis (Chen et al., 2008). In addition to its effects on 
growth, miR-21 also affected the property of invasion that causes infiltrating pattern of 
glioma growth in vivo (Gabriely et al., 2008). Using the target prediction algorithms and the 
transcript profiling, the matrix metalloprotease inhibitors, RECK and TIMP3 were identified 
as miR-21 targets thus substantiating a pro-invasion and -migration role for miR-21 
(Gabriely et al., 2008). The promotion of invasion was also attributed to another target of 
miR-21, sprouty, the negative regulator of Ras/MAPK pathways (Kwak et al.).  
4.2.2 miR-26a 
The upregulation of miR-26a and its consequence on cellular pathways leading to the pro-
tumorigenic effects are well studied in glioblastoma. In GBM, PTEN expression was found 
to be directly regulated by miR-26a (Huse et al., 2009). The miR-26a locus was found to be 
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amplified and it was often associated with the monoallelic loss of PTEN suggesting that the 
residual PTEN transcript made in PTEN +/- cases was nullified by miR-26a, analogous to 
loss of heterozygosity. Using The Cancer Genome Atlas (TCGA) data, authors demonstrated 
that, in patients with monoallelic PTEN deletion, amplification of miR-26a locus served as 
another mechanism to inactivate PTEN. In the mouse glioma model, miR-26a mediated 
PTEN repression enhanced tumour formation and substituted the loss of heterozygosity of 
PTEN locus. Further studies carried out by Kim et al demonstrated that hsa-miR-26a is a 
cooperating component of a frequently occurring oncogenic amplicon containing CDK4 and 
CENTG1 which regulate the RB1 and PI3 kinase/AKT pathways (Kim et al.). By integrating 
the TCGA data for copy number, mRNA, miRNA, and DNA methylation, they identified 
PTEN, RB1, and MAP3K2/MEKK2 to be the functional targets of miR-26a in GBM. They 
also demonstrated that miR-26a alone could transform NIH3T3 cells and promote the 
growth of glioma cells in vivo by directly regulating the expressions of PTEN, RB1, and 
MAP3K2/MEKK2. This led to the increased AKT activation and decreased c-JUN N-
terminal kinase-dependent apoptosis resulting in increased proliferation. In both PTEN-
positive and PTEN-deficient glioma cells, the over expression of miR-26a induced the 
tumour growth in vivo, and it was further increased if the cells were over expressing CDK4 
or CENTG1. GBM patients with the amplification of miR-26a-CDK4 locus had markedly 
decreased survival. Thus, the amplification of hsa-miR-26a, CDK4, and CENTG1 increased 
the aggressiveness of the tumour by cooperately regulating RB1, PI3K/AKT, and JNK 
pathways (Kim et al.).  
4.2.3 miR-221 and miR-222  
The comprehensive analysis of miRNA expression during serum stimulation of quiescent 
T98 glioblastoma cells revealed that miR-221 and miR-222 were upregulated as cells 
progressed beyond the G1-S phase transition (Medina et al., 2008). miR-221 and miR-222 
were found to target CDK inhibitors- p27 and p57 and prevent quiescence when elevated 
during growth factor deprivation and induced cell death by causing precocious S-phase 
entry. Further, the inhibition of the expression of these miRNAs in glioma cell lines led to 
the increased apoptosis (Zhang et al.). The effect of the miRNA on apoptosis was also 
attributed to its ability to target pro-apoptotic gene PUMA. The over expression of PUMA 
reversed the phenotypes caused by the over expression of the miRNAs. In tumour xenograft 
model, inhibition of miR-221/222 reduced the tumour volume compared to the scramble 
control along with increased apoptosis, reduced Ki-67 staining, increased PUMA and Bax 
and reduced Bcl-2 expression. In human glioma tissue samples, the down regulation of 
PUMA negatively correlated with the upregulation of miR-221/222 suggesting the 
importance of the regulation in the clinical samples.  
4.2.4 miR-296 
The profiling of miRNAs upon co-culturing human brain endothelial cells (HBMVECs) 
with human glioma cell line U87 identified that miR-296 is the only upregulated miRNA 
(Wurdinger et al., 2008). The miR-296 expression also increased in HBMVECs upon 
treatment with angiogenic factors like EGM, VEGF and EGF. Treatment of HBMVECs 
with VEGF resulted in the tubule formation, increased the migration distance and also 
increased the miR-296 level in dose dependent manner. Treatment of cells with miR-296 
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the increased apoptosis (Zhang et al.). The effect of the miRNA on apoptosis was also 
attributed to its ability to target pro-apoptotic gene PUMA. The over expression of PUMA 
reversed the phenotypes caused by the over expression of the miRNAs. In tumour xenograft 
model, inhibition of miR-221/222 reduced the tumour volume compared to the scramble 
control along with increased apoptosis, reduced Ki-67 staining, increased PUMA and Bax 
and reduced Bcl-2 expression. In human glioma tissue samples, the down regulation of 
PUMA negatively correlated with the upregulation of miR-221/222 suggesting the 
importance of the regulation in the clinical samples.  
4.2.4 miR-296 
The profiling of miRNAs upon co-culturing human brain endothelial cells (HBMVECs) 
with human glioma cell line U87 identified that miR-296 is the only upregulated miRNA 
(Wurdinger et al., 2008). The miR-296 expression also increased in HBMVECs upon 
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with VEGF resulted in the tubule formation, increased the migration distance and also 
increased the miR-296 level in dose dependent manner. Treatment of cells with miR-296 
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inhibitors led to decreased tubule formation and migration distance. On the other hand, 
the overexpression of the miRNA led to increased tubule formation. The target prediction 
algorithms and subsequently, experimental evidences suggested that HGS, hepatocyte 
growth factor regulated receptor kinase substrate, to be the target of the miR-296. HGS 
was previously known to regulate the levels of VEGFR2 and PDGFRβ receptors. These 
studies suggested that the miR-296 in HBMVECs target HGS with the resultant 
upregulation of VEGFR2 and PDGFRβ receptors thereby promoting angiogenesis. To 
understand the in vivo role of miR-296 in tumour angiogenesis, nude mice-bearing 
subcutaneous U87 xenografts were injected with cholesterol-conjugated miR-296 antisense 
oligonucleotide. The quantification of tumour neovascularization revealed that the mice 
injected with antisense miR-296 showed reduced tumour neovascularization as compared 
to the mice injected with the mismatch control. The endothelial cells derived from human 
glioma showed upregulation of miR-296 compared to the normal brain with concomitant 
downregulation of HGS and the upregulation of the receptors-VEGFR2 and PDGFRβ. 
These observations demonstrate the importance of miR-296 in the angiogenesis of 
malignant glioma. 
4.2.5 miR-7 
miR-7 was found to be a tumour suppressor miRNA and was downregulated in glioma 
compared to the normal brain. The in vivo experiments suggested that re-expression of miR-
7 into glioma cells decreased the cell count, invasion and increased apoptosis (Kefas et al., 
2008). Oncogenic proteins, EGFR, IRS-1 and IRS-2 were identified as the targets of miR-7. 
The miR-7 inhibited the Akt pathway but this inhibition could not be rescued by the over 
expression of wild type or the mutant EGFR. Further investigation revealed that the 
impaired processing as the mechanism of downregulation of miR-7 in glioma. 
This study unraveled the tumour suppressor property of the miR-7 by targeting the 
receptors-EGFR, IRS1 and IRS2, thereby counteracting the pro-proliferative effect of the 
pathway.  
4.2.6 miR-34a 
miR-34a was found to act as a tumour suppressor in glioma by targeting multiple oncogenes 
like c-Met, Notch1, Notch2 and CDK6 (Li et al., 2009a). The miR-34a expression in glioma 
tissues was downregulated compared to the normal brain. As the earlier reports suggested 
that miR-34a is a target of p53, authors analyzed the expression of the miRNA in cell lines 
with wild type p53 and with mutant p53 and found that the expression of miR-34a in 
mutant p53 is lower compared to that in those cell lines bearing wild type p53. In the glioma 
tissues, the c-Met and the miR-34a expression negatively correlated suggesting the miRNA 
mediated regulation of c-Met in glioma. To assess the effect of the miRNA on cell 
proliferation, cell cycle and apoptosis, the miR-34a was over expressed in different cell lines, 
along with human astrocytes. The miR-34a over expression reduced the proliferation, the 
increased G1/G0 population only in cancer cell lines, but not in normal human astrocytes. 
The invasion of the cells also decreased with miR-34a over expression. The over expression 
of c-met partially but significantly rescued the effect of miR-34a over expression on cell cycle 
where as the over expression of Notch1 and Notch2 rescued miR-34a effect on apoptosis. In 
vivo studies suggested that the miR-34a over expression in U87 cells led to the development 
of much smaller tumours compared to the control U87 cells. 
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4.2.7 miR-124 and miR-137 
Expression profiling revealed that the levels of miR-124 and miR-137 were significantly 
decreased in AA and GBM relative to non-neoplastic brain tissue (Silber et al., 2008). During 
the differentiation of cultured mouse neural stem cells following growth factor withdrawal, 
the levels of these miRNAs were increased. The re-expression of these miRNAs with the 
DNA methylation inhibitor treatment suggested a possible regulation of these miRNAs by 
epigenetic phenomenon like methylation. The over expression of miR-124 or miR-137 
induced morphological changes and also induced differentiation marker profile. Further 
studies identified that miR-124 and miR-137 target CDK6 resulting in reduced 
phosphorylated RB and G1 cell cycle arrest. 
4.2.8 miR-128  
The expression analysis revealed that miR-128 was downregulated miRNAs in glioma 
(Godlewski et al., 2008; Zhang et al., 2009). Over expression of the miRNA led to the 
decreased cell proliferation and tumour growth in vivo (Godlewski et al., 2008) suggesting 
the tumour suppressor nature of the miRNA. miR-128 was shown to target Bmi1 (B 
lymphoma mouse Moloney leukemia virus insertion region) oncogene. In the GBM 
tumours, the downregulation of miR-128 correlated with the corresponding upregulation of 
Bmi1 oncogene. The miR-128 over expression caused the reduction of H3K trimethylation 
and pAkt and also increased p21 suggesting that the cellular pathways regulated by Bmi1 
were altered with miRNA over expression leading to the decreased neurosphere formation. 
miR-128 was also shown to directly target E2F3a transcription factor generally upregulated 
in glioma. The over expression of E2F3a rescued the cell growth inhibition caused by the 
over expression of the miR-128 (Zhang et al., 2009).  
4.2.9 miR-218 
miR-218 had reduced expression in glioma cell lines compared to the normal brain (Song et 
al.). The over expression of the miRNA in glioma cell lines resulted in the decreased 
migration and invasion of the glioma cells with concomitant decreased MMP-9 activity. The 
over expression of miR-218 in glioma cell lines also resulted in the downregulation of the 
targets of NF-kB pathway suggesting the role of the miRNA in regulating the pathway. 
Using the target prediction algorithms, authors identified that miR-218 targeted IKK-β 
thereby regulating NF-κB pathway (Song et al.). 
4.2.10 miR-125b 
The expression of miR-125, a previously identified brain-specific miRNA, was found to be 
reduced when glioma cells were treated with all trans retinoic acid (ATRA) (Xia et al., 2009c). 
The over expression of miR-125b increased the cell viability in the presence or in the absence 
of ATRA along with the decrease in the apoptosis. The authors identified Bmf (Bcl-2 
modifying factor) as the direct target of miR-125b. In contrast to this report, another study 
reported that the over expression of miR-125b in glioma cells led to the decreased cell 
growth and caused the reduced progression of the cells through cell cycle by 
downregulating the levels of CDK6 and CDC25 (Shi et al.). The study also reported that 
miR-125b was expressed at a higher level in CD133 positive glioma stem cells compared to 
the CD133 negative non-stem cell population.   
 
Molecular Targets of CNS Tumors 
 
354 
inhibitors led to decreased tubule formation and migration distance. On the other hand, 
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of c-met partially but significantly rescued the effect of miR-34a over expression on cell cycle 
where as the over expression of Notch1 and Notch2 rescued miR-34a effect on apoptosis. In 
vivo studies suggested that the miR-34a over expression in U87 cells led to the development 
of much smaller tumours compared to the control U87 cells. 
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miR-451 is one of the significantly downregulated miRNA in glioma compared to the 
normal brain (Nan et al.). The over expression of miR-451 in glioma cell lines led to 
decreased proliferation and invasion, in addition to Go/G1 arrest and apoptosis induction. 
The over expression of miR-451 reduced Akt, cyclinD1, MMP2, MMP9 and Bcl-2 also 
increased p27/kip levels suggesting the tumour suppressor nature of the miRNA. However, 
the above identified miR-451 targets have not been experimentally validated (Nan et al.).  
4.2.12 miR-15b 
The modulation of miR-15b in U87 and U118 glioma cell lines demonstrated that miR-15b 
affects the cell growth and the cell cycle progression (Xia et al., 2009a). The bioinformatics 
prediction identified cyclins- cyclin E1 and cyclin D to be the targets of miR-15b. The 
authors further demonstrated that cyclin E1 was indeed a direct target of miR-15b.   
4.2.13 miR-181a and miR-181b 
The miRNAs- miR-181a and miR-181b were found to be downregulated in glioma by 
multiple studies (Ciafre et al., 2005; Conti et al., 2009; Malzkorn et al.). The overexpression of 
these miRNAs in glioma cell lines resulted in the reduction of cell growth in vivo, anchorage 
independent growth, invasion and apoptosis (Shi et al., 2008).  
4.2.14 miR-146b  
The modulation of miR-146b in glioma cell line revealed that the migration and invasion 
were inhibited by miR-146b (Katakowski et al., ; Xia et al., 2009b). miR-146 was found to 
target MMP-16 which could potentially mediate the reduced migration and invasion seen 
upon miR-146b overexpression (Xia et al., 2009b). miR-146b was also shown to directly 
target EGFR (Katakowski et al).  
5. Applications of miRNA in glioma: accurate grading, better prognosis and 
novel therapeutic approaches 
The rationale for using miRNAs in glioma diagnosis and therapeutic modalities is as 
follows. The identification of differences in the genetic alterations in miRNA genes and 
miRNA transcript levels in tumour samples compared to normal tissues provides an 
automatic basis for their utility for glioma diagnosis, classification and prognosis. In fact, 
classification of multiple cancers based on the expression pattern of couple of hundred 
miRNAs was found to be more accurate than using expression of approximately 16,000 
protein coding genes (Lu et al., 2005). Even though several miRNAs have been shown to be 
regulated in different grades of glioma, variation in the expression of individual miRNAs 
within a glioma grade suggests that distinct subgroups within each grade of glioma could 
be identified. It is likely that these subgroups may have different prognosis. miRNAs also 
appear to be an attractive target for therapeutic intervention because the aberrantly 
expressed miRNAs seem to play key role in the development of cancer and that correcting 
the miRNA deficiencies either by antagonizing or restoring miRNA function may offer a 
therapeutic gain (Bader et al.).   
Although several miRNAs have been identified to be either upregulated or down regulated 
in glioblastoma, there were only few studies which particularly investigated the differential 
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regulation of miRNAs between different grades of glioma. Real time RT-PCR analysis of 
several miRNAs in WHO grade II and grade IV samples which spontaneously progressed 
from the same set of patients identified twelve miRNAs (miR-9, miR-15a, miR-16, miR-17, 
miR-19a, miR-20a, miR-21, miR-25, miR-28, miR-130b, miR-140 and miR-210) to be 
upregulated and two miRNAs (miR-184 and miR-328) to be downregulated in grade IV 
tumours thus characterizing their role in progression (Malzkorn et al.). Analysis of miRNA 
microarray data by prediction analysis of microarrays (PAM), a 23 miRNA expression 
signature was identified that could distinguish GBM (grade IV) from AA (grade III) with an 
accuracy of  95% (Rao et al.). 
While many studies identifying an individual miRNA or miRNA expression signatures 
predicting patient survival in several cancers like lung cancer, lymphocytic leukemia; lung 
adenocarcinoma, breast and pancreas cancers have been published, there are only a few 
reports with respect to glioblastoma.  Expression profiling of 84 astrocytoma samples 
belonging to different grades and 20 normal adjacent tissue samples and subsequent 
multivariate Cox proportional hazard regression analysis and Kaplan-Meier survival 
analysis identified low expression of miR-181b or miR-106a or high expression of miR-21 to 
be associated with poor patient survival (Zhi et al.). Another recent study analysed the 
miRNA (n=304) expression data from a total of 222 GBM patients derived from The Cancer 
Genome Atlas (TCGA) data set using Cox proportional hazard regression analysis and 
identified a 10 miRNA expression signature that predicted survival (Srinivasan et al.). More 
importantly, using multivariate analysis along with patient age, the 10 miRNA expression 
signature was found to be an independent predictor of patient survival. In addition, the 
authors developed a risk score for each patient based on the expression of each of these ten 
miRNAs and subsequently showed that the risk score could segregate the patients into high 
and low risk groups with significantly different survival times. It was also interesting to 
note that the miRNA set included three miRNAs (miR-20a, miR-106a and miR-17-5p) that 
were protective and seven miRNAs (hsa-miR-31, hsa-miR-222, hsa-miR-148a, hsa-miR-221, 
hsa-miR-146b, hsa-miR-200b and hsa-miR-193a) that were risky with respect to their 
association between their expression and patient survival. The protective miRNAs were 
expressed at an elevated level in the low risk group compared to the high risk group and the 
risky miRNAs were expressed at a higher level in the high risk group than in the low risk 
group. It was suggested that the protective and risky nature of these miRNAs is indicative 
of their functions being either inhibitory or promoting, respectively, of various properties of 
cancer cells like proliferation, migration, invasion etc.   
The use of miRNAs in cancer therapy involves two approaches.  The first approach, which is 
rather more commonly followed, is to inhibit oncogenic miRNAs with a gain of function 
using miRNA antagonists.  The second approach involves reintroduction of a tumour 
suppressor miRNA with the resultant restoration of loss of function.  An interesting view of 
the potential use of miRNA based cancer therapy is that targets that are considered to be 
undruggable could be targeted using miRNA approach.  It was estimated that 
approximately only 20% of all human proteins are targetable by small molecules and 
inhibitory antibodies with the remaining 80% of genes coming under the category that are 
currently considered undruggable (Verdine, 2006). Since the RNA interference based 
approach using miRNAs can essentially target any human gene, this approach opens up a 
large number of potential targets.   
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approach using miRNAs can essentially target any human gene, this approach opens up a 
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Several reports have shown the potential use of miRNA-based approach in glioma therapy 
as a proof-of-principle. miR-21 being one of the most upregulated miRNAs in gliomas, with 
anti-apoptotic and pro-invasive functions, appears to be an automatic choice for therapeutic 
interventions. Corsten et al studied the combined effect of inhibiting miR-21 and neural 
precursor cells (NPC)-mediated secretable variant of the cytotoxic agent tumour necrosis 
factor–related apoptosis inducing ligand (S-TRAIL) on glioma (U87) tumour growth using 
an intra-cranial glioma model using athymic mice (Corsten et al., 2007). The ability of U87 
glioma cells to form tumour reduced significantly upon introduction of locked nucleic acid 
(LNA) antimiR-21 oligonucleotides. Further, simultaneous injection of NPCs expressing S-
TRAIL along with miR-21 anti-miR treated U87 cells led to synergistic cytotoxicity with the 
complete elimination of tumour growth. In another study involving a tumour suppressor 
miRNA - miR-34a, its reintroduction into U87 glioma cells led to strong inhibition of tumour 
growth in xenograft models (Li et al., 2009a). miR-296, which belongs to the new family of 
angiomirs, which are proangiogenic, was found to be elevated in human primary brain 
microvascular endothelial cells upon co-culturing with U87 glioma cells (Wurdinger et al., 
2008).  Intravenous administration of miR-296 antagomirs into mice bearing subcutaneous 
U87 tumours resulted in significant reduction of angiogenesis in tumour xenografts 
suggesting the potential utility in glioma therapy. 
6. Conclusions 
miRNAs have generated a huge excitement in the field of cancer biology. During the last six 
years, several studies have established the regulation of miRNAs in glioma development, 
identified their targets and demonstrated their role in cell proliferation, apoptosis, cell cycle 
regulation, migration, invasion and angiogenesis. This indicates that defects in miRNA 
regulatory network appear to play a key role in glioblastoma pathogenesis. Many of these 
studies have clearly showed as a proof-of-concept, the utility of miRNA based approach in 
glioma diagnosis, grading, prognosis and therapy. However, additional studies are needed 
to confirm these findings for the eventual application in clinics. With total number of known 
human miRNAs is 1040 (Release 16, miRBase), one of important needs is to carry out more 
comprehensive analysis of all known miRNAs in large number of tumour tissue samples.  
Efforts towards identifying targets, their experimental validation and establishing the 
relationships with various altered molecular pathways in cancer are also very important. In 
addition to improved understanding of biology of glioma development and progression, 
miRNA study appears to provide newer improved methods useful for variety of purposes 
in clinical medicine. Like with other biomarkers, the use of miRNAs in glioma classification 
and prognosis requires more studies in large cohorts at independent laboratories. The use of 
miRNA based glioma therapy appears to be very highly promising. The development of 
better methods of in vivo delivery of miRNAs is likely to harness the utility of miRNA in 
glioma therapy.  
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Efforts towards identifying targets, their experimental validation and establishing the 
relationships with various altered molecular pathways in cancer are also very important. In 
addition to improved understanding of biology of glioma development and progression, 
miRNA study appears to provide newer improved methods useful for variety of purposes 
in clinical medicine. Like with other biomarkers, the use of miRNAs in glioma classification 
and prognosis requires more studies in large cohorts at independent laboratories. The use of 
miRNA based glioma therapy appears to be very highly promising. The development of 
better methods of in vivo delivery of miRNAs is likely to harness the utility of miRNA in 
glioma therapy.  
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1. Introduction 
Glioblastoma multiforme (GBM) is the most common primitive malignant brain tumor. The 
GBM rapidly proliferates, invades and destroys surrounding brain tissues being nearly 
universally fatal in few months. Actual treatment options include surgery, radiotherapy, 
and chemotherapy using temozolomide (Stupp et al., 2005). As soon as the disease recurs, 
repeated surgery or administration of modified chemotherapy schemes give small chances 
of tumor growth control. Even with the most sophisticated treatments, the median overall 
survival for patients with GBM is actually estimated in approximately 15 months from 
diagnosis (Stupp et al., 2005). 
Within the last few years, a more detailed knowledge of the genetic and molecular patterns 
of this cancer has led to laboratory’s attempts in developing more targeted and effective 
therapies aiming to positively reverse its high mortality. While many important genetic 
features of GBM have been known for years or even decades through traditional methods, 
incremental technologies have allowed dramatic advances. New frontiers have been 
explored: the relatively recent discovery of microRNAs (miRNAs) has opened up a major 
new front in the war against GBM and other human tumors. A growing body of work is 
demonstrating key roles for them in GBM (Chan et al., 2005; Ciafre et al., 2005; Gillies & 
Lorimer, 2007;  Godlewski et al., 2008; Kefas et al., 2008; Kefas et al., 2009; Li et al., 2009; 
Silber et al., 2008; Würdinger et al., 2008). 
Noteworthy is the cancer genome atlas (TCGA), a joint comprehensive and coordinated 
effort of the National Cancer Institute (NCI) and the National Human Genome Research 
Institute (NHGRI), funded by the National Institutes of Health (NIH) in 2006 to thoroughly 
initially profile three cancer types systematically assessing the molecular basis and the entire 
spectrum of genomic changes involved in human tumors through the application of 
innovative genome analysis technologies, including large-scale genome sequencing 
(http://cancergenome.nih.gov). After the success of the pilot project, TCGA is now 
expanding its efforts to more than 20 different human tumors in order to yield accessible 
data set that will improve diagnosis, treatment, prognosis, and even prevention. TCGA has 
also included studies on miRNA expression with microarrays, copy number analysis with 
array comparative genomic hybridization (CGH), and sequencing of over 600 genes of 
banked high-quality tumor specimens.  
We here reviewed current literature on the role of miRNAs in GBM emphasizing the 
potential implications of these molecules as biomarkers and targets for therapy. 
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2. Biogenesis and functions of microRNAs 
The discovery of miRNAs dates back to 1993 when Lee et al. described a small RNA, 
lineage-deficient-4 (lin-4), with antisense complementarity to lin-14 involved in the 
regulation of developmental timing in Caenorhabditis elegans  (Lee et al., 1993). At that time 
most investigators considered this small RNA as an oddity in worm genetics, but hundreds 
of these miRNAs were soon discovered in C. elegans and other animals by different 
laboratories (Lee & Ambros, 2001; Pasquinelli et al., 2000). 
miRNAs consist of 18 to 25 nucleotides and represent a class of endogenous ribo-regulators 
that modulate gene expression via the RNA interference (RNAi) pathway. RNAi is a post-
transcriptional silencing mechanism, present in most eukaryotic organisms, in which 
exposure to double-stranded RNA induces the sequence specific degradation of 
homologous messenger RNAs (mRNA). miRNAs act by base-pairing with their target 
mRNAs through perfect or nearly perfect complementarity particularly at the 3′ 
untranslated regions (UTRs) of the target mRNAs (Lai, 2002; Robins & Press, 2005) leading 
to their translational repression and/or direct cleavage (Meltzer, 2005).  
To understand the mechanism of miRNA-mediated silencing, the basic steps of their 
biogenesis have to be summarized (Fig. 1). miRNAs originate from long primary miRNAs 
(pri-miRNAs) that are transcribed in the nucleus by the RNA polymerase II complex. 
miRNAs are then processed by a complex of the RNase III enzyme DROSHA and a double-
stranded RNA binding domain possessing the protein DGCR8 (DiGeorge syndrome critical 
region gene 8), to 60-70 nucleotides precursor miRNA (pre-miRNA) intermediates. These 
hairpin-shaped pre-miRNAs are transported to the cytoplasm by Exportin-5 (Exp5) (a 
member of the Ran transport receptor family).  Once in the cytoplasm, they are cleaved by 
DICER to generate 20 to 22 nucleotide duplexes bearing two nucleotide single-stranded 3’ 
extensions. Finally, the miRNA: miRNA* duplex is unwound into a mature miRNA and 
miRNA* by a helicase. Single strand miRNA is incorporated into a ribonucleoprotein 
effector complex, known as the RNA-induced silencing complex (RISC), whereas miRNA* is 
degraded. RISC identifies target messages based on complementarities between the “guide” 
miRNA and the mRNA and results in either endonucleolytic cleavage of targeted mRNA or 
translational repression. 
There are estimates, in part based on computational methods, that mammalian genomes 
encode up to 1,000 unique miRNAs (http://www.microrna.org/microrna/home.do), which 
are predicted to regulate the expression of as much as 60% of gene (Friedmann et al., 2009). 
Though more than 600 miRNAs have been identified in humans, much remains to be 
understood about their precise cellular function and role in the development of diseases. 
miRNAs are implicated in the control of many fundamental cellular and biological 
processes such as the developmental timing, stem cell division, and apoptosis (Brennecke et 
al., 2003; Chen et al., 2004; Cuellar & McManus 2005; Harfe et al., 2005; Lim et al., 2005; Poy 
et al., 2004; Wilfred et al., 2007). Therefore changes in their expression may play a role in the 
development of diseases and cancer. 
Calin and Croce first established a connection between microRNAs and cancer by showing 
that miR-15 and miR-16 are located on chromosome 13q14, a region deleted in more than 
half of B-cell chronic lymphocytic leukemia (CLL) (Calin & Croce, 2006). Cimmino et al. then 
demonstrated that expression of miR-15a and miR-16-1was inversely correlated with Bcl-2 
expression in CLL and that both miRNAs negatively regulated Bcl-2 at a posttranscriptional 
level, so explaining the exact role of those miRNAs in CLL. Furthermore, Bcl-2 repression by 
these miRNAs induced apoptosis in a leukemic cell line model (Cimmino et al., 2005).  
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how an overexpression of mir-21 could protect cultured human cells of GBM from 
temozolomide and taxol-induced apoptosis, suggesting a role in resistance to 
chemotherapeutic treatments (Ren et al., 2010; Shi et al., 2010). Even though an antiapoptotic 
role is likely for miR-21 in gliomas, other mechanisms are possible, because in Hela cells its 
down-regulation determines, instead, an increase in cell proliferation without affecting 
apoptosis. Meng et al. demonstrated that knock-down of miR-21 may render 
cholangiocarcinoma cells sensitive to gemcitabine whereas transfection of non-malignant 
cholangiocytes with the precursor of miR-21 renders them more resistant to this drug (Meng 
et al., 2007). This may be the result of downregulation of PTEN, the phosphatase that 
antagonizes the growth-promoting activity of the PI-3 kinase-Akt signaling pathway. It is 
noteworthy that PTEN was originally cloned as a oncosuppressor for brain tumors with 
point mutations occurring in 25% of cases. Further work by Frankel et al. on breast cancer 
cells (Frankel et al., 2008) and by Asangani et al. (Asangani et al., 2008) on colon cancer cells 
found that miR-21 overexpression leads to PDCD4 (programmed cell death 4) reduction, by 
direct interaction with its 3’ UTR, and that anti-miR-21 treatment is followed by an increase 
in endogenous PDCD4 protein levels. PDCD4 is a tumor suppressor known to be up-
regulated during apoptosis and reduced in different tumors, and evidence demonstrates 
that miR-21 overexpression effects are at least in part due to PDCD4 down-regulation. 
Although this target has not been proven in brain tumors, it is possible that it may be 
relevant also in these tumor types, as a recent study demonstrated that most of the glioma 
samples analyzed lacked PDCD4 protein expression whereas adjacent normal glial tissues 
expressed high levels of it. An additional molecular mechanism, proving the oncogenic 
properties of miR-21 in an in-vivo xenograft breast cancer model, consists in targeting of the 
tumor suppressor protein tropomyosin 1 (TPM1) at the translational level. Tropomyosin is 
able per se to reduce tumor cell proliferation and anchorage independence, therefore 
explaining the effects on tumor growth exerted by miR-21 (Zhu et al., 2007). 
miR-221 and miR-222 are two oncogenic miRNA overexpressed in GBM which enhance cell 
proliferation and survival (Ciafre et al., 2005; Felicetti et al., 2008; Galardi et al., 2007; Lee et 
al., 2007) targeting cell cycle inhibitors.  
Gillies and Lorimer defined a specific function of miRNA 221 and 222 in GBM, showing that 
they repress expression of the cell cycle regulatory protein p27Kip1  (Gillies & Lorimer, 
2007). The p27Kip1  gene is a member of the Cip/Kip family of cyclin-dependent kinase 
(CDK) inhibitors whose function is to negatively control cell cycle progression. The protein 
binds to CDK2 and cyclin E complexes to prevent cell cycle progression from G1 to S phase. 
p27Kip1  also acts as a tumor suppressor and its expression is often disrupted in human 
cancers. Analysis of the 3’ UTR of p27Kip1 suggests that repression of this protein is a 
consequence of direct binding of miRNA 221 and 222 to sites in the 3’ UTR. This mechanism 
was suggested contemporaneously and independently by le Sage et al. who demonstrated, 
using miRNA inhibitors, that some GBM cell lines require high activity of miR-221 and 222 
to maintain low p27Kip1 levels and continuous proliferation, and that high levels of miR-
221 and 222 seem to correlate with low levels of p27Kip1 protein in GBM (le Sage et al., 
2007). Gonzalez et al. have previously shown that inhibition of cdk4 activity enhances 
translation of p27Kip1, providing a link between these two cell-cycle regulators (Gonzalez et 
al., 2003). This effect was shown to be mediated by the 3’ UTR of p27Kip1. The GBM cells 
used in that study were mutated at the INK4A/ARF locus and did not express the cdk4 
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inhibitor p16Ink4a (Ishii et al., 1999). This suggested the possibility that loss of cdk4 
inhibition through INK4a/ARF mutations causes an increase in miR-221 levels, and a 
consequent decrease in p27Kip1. p27Kip1 is a well-known tumor suppressor down-
regulated in many human tumors, and its expression in primary cancers is highly correlated 
with reduced patient survival.  
Other oncomiR clusters affecting different targets that have been shown to be up-regulated 
in both GBM and other tumors are miR-10b (Ciafre et al., 2005; Ma et al., 2007; Silber et al., 
2008) and the recently discovered miR-26a (Kim et al., 2010). miR-10b might play some role 
in the invasion of glioma cells by a positive regulation of RhoC (Sasayama et al., 2009) and 
urokinase-type plasminogen activator receptor (uPAR) and MMP-14 (Sun et al., 2011). miR-
26a is a direct regulator of PTEN expression and is frequently amplified at the DNA level in 
human glioma, most often in association with monoallelic loss of PTEN (Huse et al., 2009). 
3.2 Oncosuppressors 
miR-34a is a well-characterized molecule playing a role as tumor suppressor. It has been 
found to be an important downstream mediator of p53 (He et al., 2007; Luan et al., 2010; Sun 
et al., 2008). Recent reports suggested a role for miR-34a in GBM (Li et al., 2009) and in vitro 
studies described that its overexpression results in inhibition of neoplastic cell growth and 
apoptosis (Luan et al., 2010). 
Other studies identified miR-124 and miR-137 as potential oncosuppressors (Silber et al., 
2008). miR-124 seems to be the most down-regulated miRNA in GBM as compared with 
low-grade gliomas and healthy brain tissue. Down-regulation of miR-124 allows cell cycle 
progression and increases tumorigenic power by preventing neuronal differentiation 
(Godlewski et al., 2008; Silber et al., 2008). In vitro, the expression of miR-137 was found to 
be increased up to 12-fold (Silber et al., 2008). Moreover, transfection of miRNA-124 or 
miRNA-137 induced morphological changes and enhanced marker expression consistent 
with neuronal differentiation in mouse and human GBM-derived neural stem cells, also 
inducing G1 cell cycle arrest in GBM cells (Silber et al., 2008). These results led to 
hypothesize that targeted delivery of miRNA-124 and/or miRNA-137 to GBM tumor cells 
may be therapeutically employed. 
Also miRNA-128 is significantly down-regulated in vivo and in GBM cell lines resulting in 
proliferation of undifferentiated cells. Moreover, in human glioma cell cultures the 
overexpression of miR-128 specifically blocks glioma self-renewal factors. This implicates 
that miR-128 may be used against the ‘‘stem cell-like’’ characteristics of glioma cells 
(Godlewski et al., 2008). In addition, the down-regulation of miRNA-128 was found to 
inversely correlate with tumor grade (Cui et al., 2010). 
miRNA-181 may also play a role in glioma development. Shi et al. reported the 
downregulation of miR-181 and 181b in both human gliomas and glioma cell lines (Shi et al., 
2008), confirming the data of Ciafre et al. (Ciafre et al., 2005). Those authors showed that 
transfection of those miRNAs triggered growth inhibition and apoptosis, and inhibited 
invasion. Furthermore, miR-181a expression turned out to be inversely correlated with 
tumor grading whereas miR-181b was uniformly downregulated in gliomas with different 
grades of malignancy. 
miR-184 is another putative suppressor of glioma progression. The expression of miR-184 is 
down-regulated during progression from low-grade to GBM. Furthermore, its over-
expression significantly decreases cell viability and proliferation of neoplastic cells, 
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suggesting an anti-proliferative tumor-suppressive role of this miRNA, through a possible 
regulation of c-Myc (Würdinger et al., 2008). Interestingly, miR-184 is able to increase and 
reduce apoptotic activity and invasive growth in different subset of cultured cells (Malzkorn 
et al., 2010). 
3.3 Metabolism, angiogenesis, immunosuppression, treatment resistance 
MicroRNAs have been linked specifically with a number of key features affecting the 
viability of GBM cells including metabolism, angiogenesis, immunosuppression, radio- and 
chemoresistance. 
Aberrant metabolism is increasingly recognized as critical issue in GBM biology. A report 
recently showed how miRNAs are involved in its regulation. miR-451, a miRNA with a role 
in cell proliferation and migration, is influenced by glucose levels and metabolic stress 
typically presented in GBM (Godlewski et al., 2010). It has been demonstrated that an 
increased expression of mirR-451 inhibits cell growth, inducing G0/G1 phase transition 
arrest, and predisposes to apoptosis. Furthermore, it diminishes the invasive capacity of 
GBM cells (Nan et al., 2010). 
Angiogenesis plays a pivotal role in the progression of most solid tumors, and miR-296 is 
up-regulated in GBM-associated endothelial cells promoting tumor angiogenesis 
(Würdinger et al., 2008). 
Immunosuppression is another trait allowing tumors to grow, and miRNAs have been 
shown to play a role here as well: miR-222 and miR-339 were found to promote GBM 
immune evasion by down-regulating the immunologic molecule ICAM-1 (Ueda et al., 2009). 
Treatment resistance is one of the principal challenges in GBM therapy, and early results of 
modern laboratory researches hint at a possible miRNAs involvement. In recent studies, a 
temozolomide-resistant GBM cell line was found to have several up-regulated miRNAs 
versus the parental line, including miR-21, miR-195, miR-455-3p, and miR-10a* (Shi et al., 
2010; Ujifuku et al., 2010). Also during radiotherapy, miR-181a and miR-181b, usually 
down-regulated in GBM (Conti et al., 2009), may influence the sensitivity of this tumor to 
radiation (Slaby et al., 2010).  
3.4 Prognosis and grading 
A role for miRNAs as prognostic biomarkers as been suggested as well. Real-time PCR 
quantitative analysis revealed increased expression levels of miR-196 in GBM cells in 
comparison with both anaplastic astrocytomas and normal brain. Furthermore, this subset 
of neoplastic patients showed significantly poorer survival. The expression level of miR-196 
was an independent predictor of overall survival (Guan et al., 2010). 
miR-182 was markedly up-regulated both in glioma cell lines and in human tumor 
specimens. Quantitative PCR analysis showed that its expression was significantly 
upregulated in GBM compared with the adjacent healthy brain tissue. Furthermore, 
statistical analysis revealed a significant correlation between miR-182 expression and tumor 
grading placing miR-182 as independent prognostic indicator for disease progression and 
survival (Jiang et al., 2010). 
Promising reliable biomarkers of GBM thoroughly studied so far are miR-21, miR-124 and 
miR-128. 
As abovementioned, miR-21 acts as an oncogene whose inhibition in GBM cells induce 
apoptosis (Chan et al., 2005) and reduce tumor cells invasiveness (Gabriely et al., 2008). 
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Recent studies also identified as miR-21 targets some tumor suppressors 
(Papagiannakopoulos & Kosik, 2008) and inhibitors of matrix metalloproteinase (Gabriely et 
al., 2008). Moreover, its expression increases 5- to 100-fold during human glioma 
progression from lower grades to GBM (Chan et al., 2005), making miR-21 a consistent both 
diagnostic and prognostic marker. 
miR-124 is downregulated in GBM. miR-124 has been identified as a suppressor of proteins 
that drive neural precursors toward non-neuronal fat (Makeyev et al., 2007). These data, 
together with the finding that one of the miR-124 targets is the oncogenic cyclin dependent 
kinase 6 (Pierson et al., 2008), support the role for miR-124 as a tumor suppressor and a 
potentially relevant biomarker in early diagnosis. 
miR-128 is another neuron-specific miRNA involved in neural tissue differentiation. It acts 
as a tumor-suppressor gene and is downregulated in GBM (Ciafre et al., 2005; Godlewski et 
al., 2008). Recent studies have shown that it inhibits the cell cycle progression and GBM 
proliferation targeting a transcription factor (Zhang et al., 2009). 
The study of epigenetics in GBM is another important frontier at a relatively early stage, and 
there are major discoveries yet to be made. Powerful input from this field has come during 
the last several years with the discovery of frequent methylation in GBM of the promoter of 
the MGMT gene (Gonzalez-Gomez et al., 2003). Found in about 30% of GBMs, MGMT 
promoter methylation appears to sensitize this subset to the effects of temozolomide and 
confers improved prognosis (Hegi et al., 2005). A recent survey addresses miR-181 as a 
predictive marker for the responsiveness to the combination of radiotherapy and 
temozolomide, founding it downregulated in this cohort of patients (Slaby et al., 2010).  
Despite the abovementioned evidence, it is quite clear that the use of a single miRNA as 
biomarker presently lacks of sufficient sensitivity and specificity, whereas the study of 
multiple miRNAs expression will possibly be used as a cluster to increase accuracy (Kong, 
et al., 2009). 
4. miRNAs: a future scenario 
There is a desperate need for developing innovative therapies for GBM. The clinical 
potential of delivering tumor-suppressive miRNAs or inhibitors of oncogenic miRNAs has 
been recently advocated (Brown et al., 2007; Edge et al., 2008; Gomez-Manzano & Fueyo, 
2010; Wu et al., 2009). The ability of individual miRNAs to target multiple genes/pathways 
and, at the same time, the capacity of multiple miRNAs in addressing the same 3’ UTR of a 
single gene, could be a major advantage, especially given the therapeutic necessity of 
simultaneously targeting multiple pathways in a multifaceted disease such as GBM. 
Furthermore, small-molecule drugs can have advantages like oral bioavailability and ability 
to penetrate the blood-brain barrier. 
miRNAs are all expressed endogenously and are supposed to be safe for normal cells; 
nonetheless, their off-target effects would likely be much higher than other gene therapies 
targeted on a single gene/protein. Despite promising in vitro results, the use of miRNAs for 
the treatment of brain tumors poses great difficulties.  A lot of interrogatives still remain 
under debate, but the main question rounds on how many molecules can be delivered and 
what kind of vehicle should be used to achieve therapeutic effects. So far, there are no 
studies to answer those questions. 
More interestingly, with recent advances in detecting and quantifying miRNAs in tissue, 
serum, and cerebrospinal fluid it appears increasingly likely that they would be clinically 
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suggesting an anti-proliferative tumor-suppressive role of this miRNA, through a possible 
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miRNAs are all expressed endogenously and are supposed to be safe for normal cells; 
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targeted on a single gene/protein. Despite promising in vitro results, the use of miRNAs for 
the treatment of brain tumors poses great difficulties.  A lot of interrogatives still remain 
under debate, but the main question rounds on how many molecules can be delivered and 
what kind of vehicle should be used to achieve therapeutic effects. So far, there are no 
studies to answer those questions. 
More interestingly, with recent advances in detecting and quantifying miRNAs in tissue, 
serum, and cerebrospinal fluid it appears increasingly likely that they would be clinically 
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useful as specific and reliable biomarkers patterns for brain tumors and other cancer 
diseases (De Smaele et al., 2010). Actually, miRNAs possess tissue specific expression in 
different regions of CNS (Bak et al., 2008; Cao et al., 2006; Trivedi & Ramakrishna, 2009) and 
some of them have been found typically expressed in the human brain with low variability 
(Smirnova et al., 2005); moreover, they have also been demonstrated to be relevant for 
neural differentiation of embryonic stem cells (Smirnova et al., 2005) and in tumorigenesis. 
The feature conferring them this putative role in early diagnosis of malignant brain tumors 
is their scarce susceptibility to protease degradation. This aspect allows their detection not 
only from fresh specimens, but also from plasma and serum (Cortez & Calin, 2009) and even 
after formalin fixation (Hasemeier et al., 2008). As for blood samples, miRNAs have been 
found in a more stable form, compared to mRNA, that is protected from endogenous RNase 
denaturation, either free (Mitchell et al., 2008) or enveloped in exosomes (Simpson et al., 
2009). Glioblastoma derived exosomes founded in blood samples contain specific miRNAs 
(Skog et al., 2008). Hence the possibility to detect non-invasively miRNA in patients affected 
by GBM by the use of real time PCR has made them ideal candidates as biomarkers. 
Therefore, there is a possibility that they may be used as early diagnostic tools or markers of 
treatment response. 
In conclusion, the uncovering of miRNAs has added a new level of complexity to our 
understanding in genetics of tumors. At the same time, it revealed a new category of 
therapeutic targets. There are huge amounts of data from researches that are still to be 
systematized, and new findings on miRNAs involved in GBM are expected from further 
analysis.  
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Gliomas are the most common primary brain tumors and accounts for about 1.7% of all 
human neoplasms and 77% of all brain tumors. Gliomas have an annual incidence of 5-10 
cases per 100,000 in western population and are a leading cause of death among children 
and adults diagnosed with a neoplasia of the brain. Gliomas are the heterogeneous group of 
tumors that are broadly classified into oligodendrogliomas, ependymomas, astrocytomas 
and mixed oligoastrocytomas based on the specific type of cell to which they closely 
resemble. According to World Health Organization (WHO) astrocytomas are divided into 
four clinical grades on the basis of analysis of the most malignant tumor region, number of 
mitoses, nuclear atypia, microvascular proliferation and presence of necrosis. These includes 
pilocytic astrocytoma (WHO grade I), diffuse astrocytoma (WHO grade II) anaplastic 
astrocytoma (WHO grade III) and glioblastoma multiforme (WHO grade IV). Glioblastoma 
multiforme (GBM) is most malignant, aggressive and devastating form with a worse 
prognosis. Patients with GBM have a mean survival of about 1 year, whereas patients with 
anaplastic astrocytomas survive for 2-3 years, and those with diffuse astrocytomas can 
survive for as long as 10-15 years (Ohgaki and Kleihues., 2009; Louis et al., 2007).  
Grade I tumors, also known as pilocytic astrocytomas are childhood brain tumors, benign in 
nature with circumscribed and well differentiated tumor margins. These tumors are curable 
by surgery and might represent a separate disease from the astrocytomas of other grades. 
Diffuse astrocytomas (grade II) are well differentiated and slow-growing tumors, 
predominantly manifested in young adults (~34 years). They exhibit consistent tendency to 
diffusely infiltrate surrounding brain structures and tends to progress to anaplastic 
astrocytoma and eventually to GBM. Characteristic molecular genetic features of diffuse 
astrocytomas are point mutations in the TP53 tumor suppressor gene (50-80%) and 
overexpression of PDGF-A and PDGFR-α is observed in astrocytic tumors of all stages 
(60%), but gene amplification was only detected in a small subset (<10%) of secondary GBM 
(Nupponen et al., 2006). Anaplastic astrocytoma (grade III) arise de novo or from less 
malignant diffuse astrocytoma and shows tendency for malignant progression to GBM. 
Males are frequently affected and the mean age is 41 years. Anaplastic astrocytoma 
possesses higher frequency of TP53 mutations and other genetic changes include p16 and 
p19 deletion, RB alterations, and LOH on chromosome 19q (50%) (Nupponen et al., 2006). 
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Glioblastomas are the heterogeneous intraparenchymal masses and the most common 
malignant primary brain tumors in adults. These tumors show the histological evidences of 
cellular polymorphism, nuclear atypia, mitotic activity, microvascular proliferation, vascular 
thrombosis and necrosis. Microscopically, they consists of several cell types: the glioma cell 
proper, hyper proliferative endothelial cells, macrophages and trapped cells of normal brain 
structures that are overrun by the invading glioma cells. Several histological characteristics 
are used to grade and define gliomas. These include regions of necrosis, in which necrotic 
areas are surrounded by densely packed tumor cell nuclei and are referred as 
“pseudopalisading” necrosis. In addition, the blood vessels both within and adjacent to the 
tumor are hypertrophied. Furthermore, the nuclei of tumor cells are extremely variable in 
size and shape, a characteristic called nuclear polymorphism. Tumor cells characteristically 
invade the adjacent normal brain parenchyma, migrating through the white matter tracts to 
collect around blood vessels, neurons and at the edge of the brain parenchyma in the 
subpial region (Kleihues and Ohgaki., 1999).  
GBM may develop de novo (primary GBM) or from less malignant precursor lesion 
(secondary GBM). However, the majority of develop de novo with short clinical history 
usually less than 3 months. They may manifest at any age, but are more common in adults 
(~55 years) and males are more frequently affected. The secondary GBM occur in younger 
age group (~39 years), show a slightly more favorable outcome and develop far less often 
than primary GBM. The time interval for progression from diffuse low-grade astrocytoma to 
secondary GBM varies considerably (~4-5 years). However, with regard to histopathological 
and immunohistochemical features there are no differences between primary and secondary 
GBM (Kleihues and Ohgaki., 1999). Comparative gene expression analysis showed that 
primary and secondary GBM have distinct expression profiles, however, half of the 
clinically determined primary GBM has a similar pattern to the secondary GBM. These 
suggest that primary GBM may originate from a clinically undiagnosed lower grade lesion. 
1.2 Genetic alterations associated with primary and secondary GBM 
Primary and secondary GBM are distinct in their molecular features. Chromosomal 
aberrations of gliomas have been studied using karyotyping, comparative genomic 
hybridization (CGH), or chromosome painting. The chromosomal aberrations identified in 
primary GBM are distinct from those of secondary GBM. However, there are also 
chromosomal aberrations that are shared by both primary and secondary GBM. The most 
chromosomal aberrations associated with primary GBM are amplifications and gains of 7p, 
12q13-21, and chromosome 19. The main chromosomal regions showing losses are 10q, 9p, 
13q, and 22q. In addition primary GBM may harbors additional aberrations such as losses of 
18q, 16p, and 19q, and gains of 20q, and 12q. Anaplastic astrocytomas associated with losses 
of 9p, 10q, 13q and gains of 1q, 7p, 11q, and Xq. Diffuse astrocytomas associated with gains 
of 3q, 4q, 7q, 12p, and 19p, and losses of Xp, 1p, and 19q. 
The genetic hallmark of primary GBM that typically lack a TP53 mutation is MDM2 
amplification/overexpression (50%). Additional genetic changes in primary GBM includes 
EGFR amplification (40% of cases) and/or overexpression (60%), CDKN2-A, CDKN2-B and 
PTEN mutations (30%), RB alteration, p16 deletion (30-40%) LOH on the entire chromosome 
10 (50-80%). The sequence in which gene alterations are acquired is not known since these 
neoplasms develop very rapidly, without a clinically or histopathologically identifiable 
precursor lesion. The TP53 mutations are less common in primary GBM (<10%). Secondary 
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GBM frequently associate with mutations of gene TP53. These mutations in more than 90% 
cases are already present in the first biopsy of diffuse low grade or anaplastic astrocytoma. 
Most likely, the TP53 mutation is the initial gatekeeper lesion in astrocytic tumors, which 
then, through genetic instability undergoes malignant progression. The pathway to 
secondary glioblastoma is further characterized by LOH on chromosomes 19q and 10q (but 
not on the entire chromosome 10 as it is seen in primary GBM). Recently it was pointed out 
that genomic alterations of LOH 1p and 19q, which are observed in the majority of 
oligodendroglioma, may be observed in GBM. However, in contrast to oligodendroglioma, 
in GBM loss of 19q is more likely to be partial than complete and loss of 1p is uncommon 
(~10%). It was suggested that combined losses of chromosome arms 1p and 19q may 
indicate better prognosis and potential sensitivity to chemotherapy in GBM patients, while 
isolated loss of either 1p or 19q is of no prognostic significance. The IDH1 gene at 2q33 
encodes isocitrate dehydrogenase 1 (IDH1) catalyzes the oxidative carboxylation of 
isocitrate to α-ketoglutarate, predominantly located in the cytosol. Recent studies 
demonstrated that IDH1 mutations are very early and frequent genetic alteration in low 
grade astrocytomas (80%), anaplastic astrocytomas and secondary glioblastomas. In 
contrast, IDH1 mutations are very rare (<5%) or absent in pilocytic astrocytomas and 
primary glioblastomas. Almost 60% of the low grade astrocytomas have both TP53 and 
IDH1 mutations (Ohgaki and Kleihues., 2009). 
The progression of astrocytomas to more malignant forms results from the stepwise 
accumulation of genetic alterations and the consequent disruption of apoptotic pathway and 
augmentation of survival signaling. These genetic alterations in astrocytomas ultimately 
result in the abnormal activation of signal transduction pathways, downstream of receptor 
tyrosine kinases or disruption of cell cycle arrest pathways. For example, amplification or 
activating mutations of EGFR, over-expression of FGF, FGFR, PDGF and PDGFR due to 
either gene amplification or other epigenetic mechanisms, all lead to constitutive activation 
of corresponding receptor tyrosine kinase signaling. Subsequently, a number of downstream 
signal transduction pathways are activated, including the PI3K/AKT pathway, RAS/MAP 
kinase pathway, C-MYC pathway, protein kinase C pathway, and STAT pathways (Ohgaki 
and Kleihues., 2007). 
1.3 Wnt signaling pathway 
The Wnt proteins (the name derived from mouse Int-1 and Drosophila wingless) comprise a 
large family of protein ligands that affect diverse processes such as embryonic induction, 
generation of cell polarity, and the specification of cell fate (Logan et al., 2004), tissue 
homeostasis and cancer. A number of Wnt genes, including Wnt2, Wnt7b and Wnt 5a, have 
been associated with abnormal proliferation of human breast tissue and other tumors. The 
Wnt receptor complex that activates the canonical pathway contains two components: a 
member of the Frizzled family and either one of two single-span transmembrane proteins, 
low density-lipoprotein receptor related proteins (LRP5 and LRP6). Once bound by their 
cognate ligands, the Fzd/LRP receptor complex activates the canonical signaling pathway. 
The central player of the canonical signaling pathway is β-catenin, a cytoplasmic protein 
whose stability is regulated by the “destruction complex”. Within this complex the Axin and 
APC proteins form a scaffold that facilitates β-catenin phosphorylation by CK1α and 
GSK3β. Phosphorylated β-catenin is subsequently recognized and ubiquitinylated, and 
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degrades in proteasomes. The resulting low levels of β-catenin allow the DNA binding 
Tcf/Lef proteins to interact with transcriptional co-repressors to block target genes 
expression. Interaction of Wnt ligand with its specific receptor complex containing a 
Frizzled family member and LRP5 or LRP6 triggers the formation of Dvl-Fzd complexes and 
the phosphorylation of LRP by CK1γ facilitating relocation of Axin to the membrane and 
inactivation of the destruction box. This allows β-catenin to accumulate and enter the 
nucleus, where it interacts with members of the Tcf/Lef family and converts them into 
potent transcriptional activators by displacing groucho/TLE proteins and recruiting an 
array of co-activator proteins including CBP, TBP, BRG1, BCL9/PYG, Legless, Mediator and 
Hyrax. This ensures efficient activation of Tcf target genes such as c-myc, n-myc, cyclinD1, 
c-jun, MMP7, VEGF, IL-8 etc (Moon et al., 2004. The overview of Wnt signaling pathway is 
illustrated in figure 1. 
1.4 Wnt signaling-neural stem cells-gliomas 
During the development of nervous system neural precursor or progenitor cells (NPC) act 
as a source of various types of specialized cells in the brain. Several studies have suggested 
that these cells are able to self-renew, a hall mark of stem cells. Wnt signaling is a candidate 
pathway in controlling neural stem cells self-renewal and differentiation. Wnt signaling is 
required at several stages of central nervous system development. The neural stem cells and 
progenitor cells in the brain are at a risk of malignant transformation, presumably because 
of the fact that most of the oncogenic and developmental pathways that responsible for 
tumor formation are critical for the functions like cell survival, self renewal, proliferation 
and differentiation and neural stem cells exhibit least resistance in tumorigenesis, since they 
already have the ability to bypass apoptosis and senescence. The developmental pathways 
in particular Wnt signaling pathway critically regulate the self-renewal, proliferation and 
differentiation of neural stem cells and other progenitor cells in the brain. Deregulation 
of/or abnormal operation of this pathway potentially leads to the development of brain 
tumors.  
2. Wnt/β-catenin/Tcf signaling pathway components in gliomas 
The progression of low grade astrocytomas to higher grades results from the stepwise 
accumulation of genetic alterations and the consequent disruption of the apoptotic 
pathways and augmentation of survival signaling. Here investigations on the possible role 
of Wnt signaling pathway components were described in detail. 
2.1 Extracellular Wnt signaling inhibitors 
Wnt signaling pathway is inhibited by extracellular Wnt antagonists which are divided into 
two functional classes, the sFRP (secreted Frizzled Related Protein) class and the Dickkopf 
class. sFRP class includes sFRP family (sFRP1, sFRP2, sFRP3, sFRP4, and sFRP5), sizzled, 
sizzled2, crescent, WIF-1 (Wnt inhibitory factor-1) and cerebrus, which directly binds to 
Wnts, thereby altering their ability to bind to the receptor complex. Roth et al. (2000) 
investigated the role of sFRPs in glioma cell growth and motility. sFRP-1 and sFRP-2 are 
produced by the majority of malignant glioma cell lines and ectopic expression of sFRPs 
increased clonogenecity and enhanced resistance to serum starvation. In contrast, sFRPs do 
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not modulate glioma cell susceptibility to apoptosis induced by the cytotoxic cytokines and 
cytotoxic drugs. sFRP-2 strongly promotes the growth of intracranial glioma xenografts in 
nude mice. In contrast, enhanced expression of sFRPs inhibits the motility of glioma cells in 
vitro. sFRP-mediated effects on glioma cells are accompanied by decreased expression and 
activity of matrix metalloproteinase-2 (MMP-2) and decreased tyrosine phosphorylation of 
β-catenin. This suggested that sFRPs promote survival under non-supportive conditions and 
inhibit the migration of glioma cells. Dickkopf family comprises four members (Dkk-1 to 
Dkk-4) and a unique Dkk-3-related protein named Soggy (sgy). The DKK family of 
glycoproteins curtails Wnt induced signals by binding to co-receptors LRP 5 and LRP 6. The 
human Dkk-1 (hDkk-1) gene, a transcriptional target of the p53 tumor suppressor, encodes a 
potent inhibitor of the Wnt signaling pathway and regulates the spatial 
patterning/morphogenesis of the mammalian central nervous system. Its induction was 
greatly enhanced following DNA damage and in response to other chemotherapeutic agents 
through p53 dependent mechanism. Shou et al. (2002) reported that over expression of DKK-
1 significantly reduced the Wnt2 dependent β-catenin expression and sensitizes the 
glioblastoma cell lines to apoptosis in response to various chemotherapeutic agents that 
cause DNA alkylation and DNA damage. Muller et al. (2005) analyzed the DKK1 in series of 
73 brain tumors for structural alterations in the entire coding sequence by single-strand 
conformation polymorphism and direct sequencing. They detected several sequence 
variants but no obvious mutations that affecting DKK1. REIC/Dkk-3 acts as a suppressor in 
various human cancers. Studies by Mizobuchi et al. (2007) showed that the expression levels 
of Dkk-3 were lower in human malignant glioma tissues compared to normal brain tissues 
and inversely correlated with the degree of malignancy. Dkk-3 expression levels were lower 
in glioma cell lines compared to normal human astrocytes. Knockdown of Dkk-3 using si-
RNA resulted in increased survival cell index compared to control cells.  Further, ectopic 
expression of Dkk-3 in glioblastoma cell lines showed the decreased survival index in a time 
dependent manner. In contrast forced expression of Dkk-3 does not alter the survival cell 
index in normal astrocytes. Overexpression of Dkk-3 induced the apoptosis in GBM cell 
lines through the activation of phosphor-JUN, caspase-9 and caspase-3 and also resulted in 
the reduction and degradation of β-catenin. 
Wnt inhibitory factor-1 (WIF-1) is one of the secreted antagonists that can directly bind to 
Wnt proteins and inhibits the Wnt/β-catenin signaling. Down-regulation and promoter 
hypermethylation of WIF-1 have been reported in several human malignancies. Yang et al. 
(2010) reported that expression levels of WIF-1 mRNA and protein were significantly 
decreased in human astrocytomas compared to normal brain tissues and expression levels 
were negatively correlated with the histological malignancy astrocytomas. Further this 
reduced WIF-1 gene expression was associated with the hypermethylation of WIF-1 gene 
promoter. In contrast, no hypermethylation was observed in normal brain tissues. 
Hypermethylation was observed in 54.72% of astrocytoma samples, especially in 70% of 
high grade astrocytomas. Gotze et al., (2009) investigated gliomas of different malignancy 
grades for promoter hypermethylation in members of the secreted frizzled-related protein 
(SFRP1, SFRP2, SFRP4, SFRP5), dickkopf (DKK1, DKK3) and naked (NKD1, NKD2) families 
of Wnt pathway inhibitors. They found that frequent promoter hypermethylation of Wnt 
pathway inhibitor genes in astrocytomas of varying grades. Hypermethylation of SFRP1, 
SFRP2 and NKD2 each occurred in more than 40% of the primary glioblastomas, while 
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degrades in proteasomes. The resulting low levels of β-catenin allow the DNA binding 
Tcf/Lef proteins to interact with transcriptional co-repressors to block target genes 
expression. Interaction of Wnt ligand with its specific receptor complex containing a 
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the phosphorylation of LRP by CK1γ facilitating relocation of Axin to the membrane and 
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nucleus, where it interacts with members of the Tcf/Lef family and converts them into 
potent transcriptional activators by displacing groucho/TLE proteins and recruiting an 
array of co-activator proteins including CBP, TBP, BRG1, BCL9/PYG, Legless, Mediator and 
Hyrax. This ensures efficient activation of Tcf target genes such as c-myc, n-myc, cyclinD1, 
c-jun, MMP7, VEGF, IL-8 etc (Moon et al., 2004. The overview of Wnt signaling pathway is 
illustrated in figure 1. 
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progenitor cells in the brain are at a risk of malignant transformation, presumably because 
of the fact that most of the oncogenic and developmental pathways that responsible for 
tumor formation are critical for the functions like cell survival, self renewal, proliferation 
and differentiation and neural stem cells exhibit least resistance in tumorigenesis, since they 
already have the ability to bypass apoptosis and senescence. The developmental pathways 
in particular Wnt signaling pathway critically regulate the self-renewal, proliferation and 
differentiation of neural stem cells and other progenitor cells in the brain. Deregulation 
of/or abnormal operation of this pathway potentially leads to the development of brain 
tumors.  
2. Wnt/β-catenin/Tcf signaling pathway components in gliomas 
The progression of low grade astrocytomas to higher grades results from the stepwise 
accumulation of genetic alterations and the consequent disruption of the apoptotic 
pathways and augmentation of survival signaling. Here investigations on the possible role 
of Wnt signaling pathway components were described in detail. 
2.1 Extracellular Wnt signaling inhibitors 
Wnt signaling pathway is inhibited by extracellular Wnt antagonists which are divided into 
two functional classes, the sFRP (secreted Frizzled Related Protein) class and the Dickkopf 
class. sFRP class includes sFRP family (sFRP1, sFRP2, sFRP3, sFRP4, and sFRP5), sizzled, 
sizzled2, crescent, WIF-1 (Wnt inhibitory factor-1) and cerebrus, which directly binds to 
Wnts, thereby altering their ability to bind to the receptor complex. Roth et al. (2000) 
investigated the role of sFRPs in glioma cell growth and motility. sFRP-1 and sFRP-2 are 
produced by the majority of malignant glioma cell lines and ectopic expression of sFRPs 
increased clonogenecity and enhanced resistance to serum starvation. In contrast, sFRPs do 
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not modulate glioma cell susceptibility to apoptosis induced by the cytotoxic cytokines and 
cytotoxic drugs. sFRP-2 strongly promotes the growth of intracranial glioma xenografts in 
nude mice. In contrast, enhanced expression of sFRPs inhibits the motility of glioma cells in 
vitro. sFRP-mediated effects on glioma cells are accompanied by decreased expression and 
activity of matrix metalloproteinase-2 (MMP-2) and decreased tyrosine phosphorylation of 
β-catenin. This suggested that sFRPs promote survival under non-supportive conditions and 
inhibit the migration of glioma cells. Dickkopf family comprises four members (Dkk-1 to 
Dkk-4) and a unique Dkk-3-related protein named Soggy (sgy). The DKK family of 
glycoproteins curtails Wnt induced signals by binding to co-receptors LRP 5 and LRP 6. The 
human Dkk-1 (hDkk-1) gene, a transcriptional target of the p53 tumor suppressor, encodes a 
potent inhibitor of the Wnt signaling pathway and regulates the spatial 
patterning/morphogenesis of the mammalian central nervous system. Its induction was 
greatly enhanced following DNA damage and in response to other chemotherapeutic agents 
through p53 dependent mechanism. Shou et al. (2002) reported that over expression of DKK-
1 significantly reduced the Wnt2 dependent β-catenin expression and sensitizes the 
glioblastoma cell lines to apoptosis in response to various chemotherapeutic agents that 
cause DNA alkylation and DNA damage. Muller et al. (2005) analyzed the DKK1 in series of 
73 brain tumors for structural alterations in the entire coding sequence by single-strand 
conformation polymorphism and direct sequencing. They detected several sequence 
variants but no obvious mutations that affecting DKK1. REIC/Dkk-3 acts as a suppressor in 
various human cancers. Studies by Mizobuchi et al. (2007) showed that the expression levels 
of Dkk-3 were lower in human malignant glioma tissues compared to normal brain tissues 
and inversely correlated with the degree of malignancy. Dkk-3 expression levels were lower 
in glioma cell lines compared to normal human astrocytes. Knockdown of Dkk-3 using si-
RNA resulted in increased survival cell index compared to control cells.  Further, ectopic 
expression of Dkk-3 in glioblastoma cell lines showed the decreased survival index in a time 
dependent manner. In contrast forced expression of Dkk-3 does not alter the survival cell 
index in normal astrocytes. Overexpression of Dkk-3 induced the apoptosis in GBM cell 
lines through the activation of phosphor-JUN, caspase-9 and caspase-3 and also resulted in 
the reduction and degradation of β-catenin. 
Wnt inhibitory factor-1 (WIF-1) is one of the secreted antagonists that can directly bind to 
Wnt proteins and inhibits the Wnt/β-catenin signaling. Down-regulation and promoter 
hypermethylation of WIF-1 have been reported in several human malignancies. Yang et al. 
(2010) reported that expression levels of WIF-1 mRNA and protein were significantly 
decreased in human astrocytomas compared to normal brain tissues and expression levels 
were negatively correlated with the histological malignancy astrocytomas. Further this 
reduced WIF-1 gene expression was associated with the hypermethylation of WIF-1 gene 
promoter. In contrast, no hypermethylation was observed in normal brain tissues. 
Hypermethylation was observed in 54.72% of astrocytoma samples, especially in 70% of 
high grade astrocytomas. Gotze et al., (2009) investigated gliomas of different malignancy 
grades for promoter hypermethylation in members of the secreted frizzled-related protein 
(SFRP1, SFRP2, SFRP4, SFRP5), dickkopf (DKK1, DKK3) and naked (NKD1, NKD2) families 
of Wnt pathway inhibitors. They found that frequent promoter hypermethylation of Wnt 
pathway inhibitor genes in astrocytomas of varying grades. Hypermethylation of SFRP1, 
SFRP2 and NKD2 each occurred in more than 40% of the primary glioblastomas, while 
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DKK1 hypermethylation was found in 50% of secondary glioblastomas. Further, treatment 
of SFRP1-, SFRP5-, DKK1-, DKK3-, NKD1- and NKD2-hypermethylated U87-MG 
glioblastoma cells with demethylating agent 5-aza-2-deoxycytidine and with histone 
deacetylase inhibitor Trichostatin A resulted in increased expression of each gene. 
Furthermore, SFRP1-hypermethylated gliomas showed significantly lower expression of the 
respective transcripts when compared with unmethylated tumors. Similarly, Foltz et al., 
(2010) studied epigenetic inactivation of Wnt pathway inhibitors in glioblastomas using a 
large-scale whole-genome approach. They found that three genes DKK1, SFRP1, and WIF1 
were epigenetically silenced in glioblastomas and confirmed the decreased expression of 
these genes in GBM tumor tissue samples relative to normal brain tissue samples. Further, 
the expression of these genes is restored in T98G GBM cells by treatment Trichostatin A, but 
only DKK1 expression is restored by treatment with the 5-azacytidine. Ectopic expression of 
DKK1 significantly reduces colony formation and increases chemotherapy-induced 
apoptosis in T98G glioblastoma cells. While, ectopic expression of WIF1 and SFRP1 shows a 
relative lack of response. Chronic Wnt3a stimulation only partially reverses growth 
suppression after DKK1 reexpression, whereas a specific inhibitor of the JNK pathway 
significantly reversed the effect of DKK1 reexpression on colony formation and apoptosis in 
T98G cells. This support the potential growth-suppressive function for epigenetically 
silenced DKK1 in GBM and suggests that DKK1 restoration could modulate Wnt signaling 
through both canonical and noncanonical pathways. These investigations suggest an 
important role of epigenetic silencing of Wnt pathway inhibitor genes in gliomas, 
particularly in glioblastomas, with distinct patterns of hypermethylated genes 
distinguishing primary from secondary glioblastomas. 
2.2 Wnt ligands and frizzled receptors 
Wnt proteins are secreted glycoproteins which are modified through post-translational 
modifications such as palmitoylation, required for correct secretion and N-linked 
glycosylation which increases the stability of Wnts. These are categorized according to 
canonical and noncanonical based on the pathway activated by Wnts. It was reported that a 
number of Wnt genes, including Wnt1, Wnt2, Wnt3a, Wnt5a, Wnt7a, Wnt7b, Wnt 10b and 
Wnt13, have been associated with tumor development. There were several studies 
investigated the expression of Wnts in gliomas. Howng et al. (2002) studied the mRNA 
expression of Wnt1, Wnt5a, Wnt10b and Wnt13 in brain tumors. It was observed that Wnt 
5a, Wnt10b, Wnt13 were expressed in most of the brain tumors, whereas Wnt1 was less 
expressed. Further no correlations were observed between Wnts expression and 
histopathological grading. Yu et al. (2007) showed that Wnt5a was upregulated in 
glioblastomas than that of lowgrade tumors and normal brain samples and overexpression 
of Wnt5a in glioblastoma cell lines increased the proliferation. Knockdown of Wnt5a using 
siRNA resulted in the reduction of proliferation of glioblastoma cell lines and also reduced 
the tumor growth in vivo. Pu et al. (2009) studied the mRNA expression of Wnt1, Wnt2, 
Wnt3, Wnt4, Wnt5a, Wnt10b and Wnt13 and frizzled receptors Fzd2 and Fzd5. The 
expression levels of Wnt2, Wnt5a and Fzd2 mRNA and protein were overexpressed in 
astrocytomas but not expressed in normal brain tissues and exhibited significant positive 
correlation with the degree of malignancy. Whereas, Wnt1 and Fzd5 were not expressed in 
gliomas and Wnt3, Wnt4, Wnt10b, Wnt13 expression were almost equally expressed in 
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tumor and normal brain tissues. Knockdown of Wnt2 in glioma cell lines significantly 
downregulated the expression of Wnt2, β-catenin as well as expression of Fzd2, p-GSK3β, 
cyclin D1, PI3K, and p-Akt. Further, Wnt2 knockdown also resulted in the reduced cell 
viability, cell cycle arrest in Go/G1 phase with lowered S phase proportion, increase in 
apoptotic cell population and reduced invasive ability. In nude mice experiments of 
xenograft tumors, Wnt2 siRNA treatment slowdown the tumor growth and the tumor size 
was significantly lower than control treated. Also in this subcutaneous model the 
expression levels of Wnt2, fzd2, β-catenin and p-GSK3β were decreased following Wnt2 
siRNA treatment and induce tumor cell apoptosis. Zhang et al. (2006) studied the role of 
Frizzled 9 in astrocytoma samples and reported that Frizzled 9 was upregulated in 
astrocytomas.  
2.3 Dishevelled and FRAT-1 
Dishevelled (Dvl) identified as positive regulator of Wnt signaling pathway positioning 
downstream of the frizzled receptor and upstream of β-catenin. Overexpression or 
constitutive activation of dishevelled promotes neoplastic transformation and its 
involvement has been reported in various human cancers. Dvl performs dual functions, on 
one hand it transduces Wnt signals to stabilize the β-catenin and on the other hand it relays 
the signals for the activation of Jun kinases. Three variants of Dvls were identified to date 
and their prominent role in tumor progression was reported in several human cancers. In 
canonical Wnt signaling Dvl interacts with Axin and dissociates the destruction complex by 
relocating the Axin to the cytoplasmic tail of LRP. Also by interaction with FRAT1/GBP it 
inhibits the GSK3β activity. These mechanisms lead to the stabilization of β-catenin levels in 
the cytoplasm. We studied (Sareddy et al., 2009a) the expression status of Dvl variants in 
astrocytoma tissues and found that Dvl-3 was upregulated in tumor tissues while very low 
expression was observed in normal brain sample. The expression levels were progressively 
increased from low grade to high grade astrocytomas and showed significant positive 
correlation with the pathological grade of astrocytomas.  
FRAT1 (frequently arranged in advanced T-cell lymphomas-1) is an inhibitor of GSK-3β and 
was identified as a positive regulator of Wnt/β-catenin pathway by inhibiting the GSK-3β 
activity there by stabilizing β-catenin. Its oncogenic role was established in several human 
cancers. In response to Wnt signaling activation Dishevelled protein recruits FRAT1 into the 
destruction complex which facilitates the dissociation of GSK3β from destruction complex, 
leading to the stabilization of β-catenin. Guo et al. (2010) found that FRAT1 was 
overexpressed in several human astrocytoma samples and showed the significant positive 
correlation with the pathological grading of astrocytomas. In normal brain samples FRAT1 
expression was very low compared to tumor samples. FRAT1 immunoreactivity was also 
positively correlated with the β-catenin immunoreactivity. 
2.4 AXIN-APC-GSK3β 
Axin, a tumor suppressor was originally identified as an inhibitor of Wnt signaling and is 
central to the down regulation of β-catenin. Axin acts as a scaffolding protein which 
facilitates the phosphorylation of β-catenin by GSK3β and CK1α and subsequent 
proteasomal degradation. It is a core component of destruction complex and binds directly 
to β-catenin, APC, GSK3 β, CK1α and Dvl. It is often mutated in several human 
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DKK1 hypermethylation was found in 50% of secondary glioblastomas. Further, treatment 
of SFRP1-, SFRP5-, DKK1-, DKK3-, NKD1- and NKD2-hypermethylated U87-MG 
glioblastoma cells with demethylating agent 5-aza-2-deoxycytidine and with histone 
deacetylase inhibitor Trichostatin A resulted in increased expression of each gene. 
Furthermore, SFRP1-hypermethylated gliomas showed significantly lower expression of the 
respective transcripts when compared with unmethylated tumors. Similarly, Foltz et al., 
(2010) studied epigenetic inactivation of Wnt pathway inhibitors in glioblastomas using a 
large-scale whole-genome approach. They found that three genes DKK1, SFRP1, and WIF1 
were epigenetically silenced in glioblastomas and confirmed the decreased expression of 
these genes in GBM tumor tissue samples relative to normal brain tissue samples. Further, 
the expression of these genes is restored in T98G GBM cells by treatment Trichostatin A, but 
only DKK1 expression is restored by treatment with the 5-azacytidine. Ectopic expression of 
DKK1 significantly reduces colony formation and increases chemotherapy-induced 
apoptosis in T98G glioblastoma cells. While, ectopic expression of WIF1 and SFRP1 shows a 
relative lack of response. Chronic Wnt3a stimulation only partially reverses growth 
suppression after DKK1 reexpression, whereas a specific inhibitor of the JNK pathway 
significantly reversed the effect of DKK1 reexpression on colony formation and apoptosis in 
T98G cells. This support the potential growth-suppressive function for epigenetically 
silenced DKK1 in GBM and suggests that DKK1 restoration could modulate Wnt signaling 
through both canonical and noncanonical pathways. These investigations suggest an 
important role of epigenetic silencing of Wnt pathway inhibitor genes in gliomas, 
particularly in glioblastomas, with distinct patterns of hypermethylated genes 
distinguishing primary from secondary glioblastomas. 
2.2 Wnt ligands and frizzled receptors 
Wnt proteins are secreted glycoproteins which are modified through post-translational 
modifications such as palmitoylation, required for correct secretion and N-linked 
glycosylation which increases the stability of Wnts. These are categorized according to 
canonical and noncanonical based on the pathway activated by Wnts. It was reported that a 
number of Wnt genes, including Wnt1, Wnt2, Wnt3a, Wnt5a, Wnt7a, Wnt7b, Wnt 10b and 
Wnt13, have been associated with tumor development. There were several studies 
investigated the expression of Wnts in gliomas. Howng et al. (2002) studied the mRNA 
expression of Wnt1, Wnt5a, Wnt10b and Wnt13 in brain tumors. It was observed that Wnt 
5a, Wnt10b, Wnt13 were expressed in most of the brain tumors, whereas Wnt1 was less 
expressed. Further no correlations were observed between Wnts expression and 
histopathological grading. Yu et al. (2007) showed that Wnt5a was upregulated in 
glioblastomas than that of lowgrade tumors and normal brain samples and overexpression 
of Wnt5a in glioblastoma cell lines increased the proliferation. Knockdown of Wnt5a using 
siRNA resulted in the reduction of proliferation of glioblastoma cell lines and also reduced 
the tumor growth in vivo. Pu et al. (2009) studied the mRNA expression of Wnt1, Wnt2, 
Wnt3, Wnt4, Wnt5a, Wnt10b and Wnt13 and frizzled receptors Fzd2 and Fzd5. The 
expression levels of Wnt2, Wnt5a and Fzd2 mRNA and protein were overexpressed in 
astrocytomas but not expressed in normal brain tissues and exhibited significant positive 
correlation with the degree of malignancy. Whereas, Wnt1 and Fzd5 were not expressed in 
gliomas and Wnt3, Wnt4, Wnt10b, Wnt13 expression were almost equally expressed in 
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tumor and normal brain tissues. Knockdown of Wnt2 in glioma cell lines significantly 
downregulated the expression of Wnt2, β-catenin as well as expression of Fzd2, p-GSK3β, 
cyclin D1, PI3K, and p-Akt. Further, Wnt2 knockdown also resulted in the reduced cell 
viability, cell cycle arrest in Go/G1 phase with lowered S phase proportion, increase in 
apoptotic cell population and reduced invasive ability. In nude mice experiments of 
xenograft tumors, Wnt2 siRNA treatment slowdown the tumor growth and the tumor size 
was significantly lower than control treated. Also in this subcutaneous model the 
expression levels of Wnt2, fzd2, β-catenin and p-GSK3β were decreased following Wnt2 
siRNA treatment and induce tumor cell apoptosis. Zhang et al. (2006) studied the role of 
Frizzled 9 in astrocytoma samples and reported that Frizzled 9 was upregulated in 
astrocytomas.  
2.3 Dishevelled and FRAT-1 
Dishevelled (Dvl) identified as positive regulator of Wnt signaling pathway positioning 
downstream of the frizzled receptor and upstream of β-catenin. Overexpression or 
constitutive activation of dishevelled promotes neoplastic transformation and its 
involvement has been reported in various human cancers. Dvl performs dual functions, on 
one hand it transduces Wnt signals to stabilize the β-catenin and on the other hand it relays 
the signals for the activation of Jun kinases. Three variants of Dvls were identified to date 
and their prominent role in tumor progression was reported in several human cancers. In 
canonical Wnt signaling Dvl interacts with Axin and dissociates the destruction complex by 
relocating the Axin to the cytoplasmic tail of LRP. Also by interaction with FRAT1/GBP it 
inhibits the GSK3β activity. These mechanisms lead to the stabilization of β-catenin levels in 
the cytoplasm. We studied (Sareddy et al., 2009a) the expression status of Dvl variants in 
astrocytoma tissues and found that Dvl-3 was upregulated in tumor tissues while very low 
expression was observed in normal brain sample. The expression levels were progressively 
increased from low grade to high grade astrocytomas and showed significant positive 
correlation with the pathological grade of astrocytomas.  
FRAT1 (frequently arranged in advanced T-cell lymphomas-1) is an inhibitor of GSK-3β and 
was identified as a positive regulator of Wnt/β-catenin pathway by inhibiting the GSK-3β 
activity there by stabilizing β-catenin. Its oncogenic role was established in several human 
cancers. In response to Wnt signaling activation Dishevelled protein recruits FRAT1 into the 
destruction complex which facilitates the dissociation of GSK3β from destruction complex, 
leading to the stabilization of β-catenin. Guo et al. (2010) found that FRAT1 was 
overexpressed in several human astrocytoma samples and showed the significant positive 
correlation with the pathological grading of astrocytomas. In normal brain samples FRAT1 
expression was very low compared to tumor samples. FRAT1 immunoreactivity was also 
positively correlated with the β-catenin immunoreactivity. 
2.4 AXIN-APC-GSK3β 
Axin, a tumor suppressor was originally identified as an inhibitor of Wnt signaling and is 
central to the down regulation of β-catenin. Axin acts as a scaffolding protein which 
facilitates the phosphorylation of β-catenin by GSK3β and CK1α and subsequent 
proteasomal degradation. It is a core component of destruction complex and binds directly 
to β-catenin, APC, GSK3 β, CK1α and Dvl. It is often mutated in several human 
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malignancies. Nikuseva Martic et al. (2010) examined the changes of Axin1 in 72 
neuroepithelial brain tumors. LOH experiments showed the LOH of AXIN1 in 11.1% of 
brain tumors and majority proportion was distributed to glioblastomas (6.3%). Compared to 
healthy brain tissues Axin1 expression was down regulated in 65.5% of brain tumors, of 
which majority of them are astrocytomas. In most of the samples Axin was localized in the 
cytoplasm. It was also observed that β-catenin was localized mainly in nucleus or cytoplasm 
and nucleus. They also demonstrated that there was no difference in Axin protein levels in 
patients with AXIN1 LOH and patients without it. In contrast, relative β-catenin levels were 
significantly higher in patients with AXIN LOH in comparison to without it. Comparison of 
relative levels of β-catenin and AXIN1 revealed that they were significantly reversely 
proportional.  
Adenomatous polyposis coli gene (APC) is a tumor suppressor and is often mutated in wide 
variety of human cancers. It was demonstrated that most of the colon and other human 
malignancies having highly constitutive β-catenin due to mutations in APC or β-catenin 
itself. Mutations in APC and β-catenin genes were noticed in the childhood brain tumor 
medulloblastoma but till to date no mutations were found in gliomas. However, recent 
reports provided the evidence that the APC mutations are in secondary brain metastasis 
rather than in primary tumors. Pecina-Slaus et al. (2010) analyzed exon 15 of the APC in a 
49-year-old male patient with brain metastasis and its primary site was lung carcinoma. 
PCR method and direct DNA sequencing of the metastasis and autologous lymphocyte 
samples identified the presence of a somatic mutation at position 5883 G–A in the metastasis 
tissue. Interestingly, these authors observed that the lack of protein expression of APC, 
however, β-catenin localization was observed in the nucleus. The mutation is a silent 
mutation that might have consequences in the creation of a new splice site. To date no 
prominent mutations were observed in β-catenin but it was reported that β-catenin is 
mutated at S33 as sporadic event in a brain metastasis (Lee et al., 2009). Further, this mutated 
β-catenin enhances the Tcf dependent promoter activity. 
Glycogen synthase kinase 3 is a serine/threonine kinase regulates diverse signaling 
pathways involved in proliferation, apoptosis and cell cycle control. GSK3 has two isoforms 
include GSK3α, GSK3β which are functionally independent. It performs independent 
functions based on the cell type, and it described as a prosurvival factor in pancreatic cancer 
and as a pro-apoptotic factor in colon cancer and interconnects several pathways which 
plays major role in several human disorders. Korur et al. (2009) analyzed the role of GSK3β 
in malignant gliomas and reported that mRNA and protein levels of GSK-3β were 
overexpressed in human glioblastoma tissues compared to normal brain tissues. Direct 
inhibition of GSK3β activity by siRNA, the specific inhibitor SB216763, or lithium chloride 
(LiCl) induced tumor cell differentiation, tumor cell apoptosis and reduced the 
clonogenecity. 
2.5 β-Catenin 
β-Catenin was first identified as a member of Wnt signaling pathway. The β-catenin gene 
CTNNb1 was localized at 3p2.1. β-catenin existed in two pools: one is located in the 
cytomembrane which involved in cell adhesion and other is in the cytoplasm or/and 
nucleus which is mainly involved in the regulation of Wnt pathway. It was identified that 
mutations in the β-catenin gene that affect specific serine and threonine residues abrogates 
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the phosphorylation dependent degradation of β-catenin. These regulatory sequences are 
often mutated in wide variety of human cancers. It was noticed that colorectal tumors that 
contain APC mutations harbors low β-catenin mutations where as in tumors lacking APC, 
mutations in CTNNb1 was greatly increased.  Dissociation of cytoplasmic inhibitory 
complex owing to the upstream activity of Wnt signals or mutations in APC and Axin leads 
to the cytosolic accumulation of β-catenin. The Oncogenic potential of β-catenin was 
extensively studied in wide variety of human cancers. We studied the expression levels of β-
catenin mRNA and protein in 32 human astrocytoma samples and found that the mRNA 
and protein levels of β-catenin were elevated in astrocytoma samples while very low levels 
were observed in normal brain tissues. The expression levels of β-catenin were 
progressively increased form low grade astrocytomas to higher grades and positively 
correlated with the histological grading of astrocytomas. In most of the tumor sections β-
catenin was accumulated in the nucleus and cytosol which is crucial in mediating Wnt 
pathway activity (Sareddy et al. 2009a). Moreover, we examined the β-catenin levels in the 
progression of ENU-induced gliomas in rat model. In this study, we identified that the 
levels of β-catenin were increased as tumor grows and correlated with malignant 
progression of gliomas (Sareddy et al. 2009b). Pu et al. (2009) also showed that knockdown of 
β-catenin using siRNA downregulated the expression of β-catenin, p-GSK3β, cyclin D1, 
PI3K, and pAKT and reduced the cell viability, arrest the cell cycle at G0/G1 phase with 
lowered S phase cells, increased the apoptotic cell population and inhibited the invasion of 
glioma cell lines. Further, treatment with β-catenin siRNA in subcutaneous xenograft model 
reduced and slowed down the tumor size and growth respectively. In these tumors β-
catenin siRNA treatment caused the reduction in the levels of β-catenin, pGSK3β, PI3K, 
Wnt2 and Fzd2 and induced the apoptosis. Similar results were also observed by Liu et al. 
(2010), stating that expression levels of β-catenin mRNA and protein were elevated in 
astrocytomas in comparison with normal brain tissues and showed the positive correlation 
with the grade of the astrocytomas. β-catenin siRNA transfection into glioma cell lines 
inhibited the cell proliferation, induced the apoptosis, arrested the cell cycle in G0/G1 phase 
and downregulated the expression of β-catenin targets such as cyclin D1, c-jun and c-Myc. 
Zhang et al. (2009) studied the correlation between β-catenin distribution, tumor grade and 
patient 2 year survival. They found that there was no correlation between grade of the 
tumor and distribution of β-catenin. However, significant positive correlation was observed 
between levels of β-catenin and 2-year patient survival. The expression of β-catenin was not 
correlated with other clinicopathological characteristics such as tumor age, tumor size, and 
sex and tumor location. Further, survival analysis showed that patients with astrocytoma 
showing less expression of β-catenin tend to be associated with good prognosis, whereas, 
astrocytoma patients with high β-catenin expression associated with poor prognosis. 
2.6 Lef-1 and Tcf-4 
Lef/Tcf family transcription factors consist of four members: Lef-1, Tcf-1, Tcf-3 and Tcf-4. 
Lef/Tcf transcription factors belong to high mobility group (HMG) domain proteins that 
recognize the same DNA consensus motif through HMG box DNA-binding domain. Tcf-1 is 
predominantly expressed in cells of T cell lineage and Lef-1 is expressed in pre-B and T cells. 
Lack of Tcf-1 and Lef-1 augment the T cell development and arrest the development at 
earlier stages. Tcf-3 is expressed in somatic epithelium, keratinocytes of the skin. Tcf-4 is 
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correlated with the histological grading of astrocytomas. In most of the tumor sections β-
catenin was accumulated in the nucleus and cytosol which is crucial in mediating Wnt 
pathway activity (Sareddy et al. 2009a). Moreover, we examined the β-catenin levels in the 
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predominantly expressed in cells of T cell lineage and Lef-1 is expressed in pre-B and T cells. 
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Molecular Targets of CNS Tumors 
 
388 
expressed in midbrain and in epithelium of intestine and mammary glands. Constitutive 
expression of Tcf-4 is essential for maintenance of gut epithelium, however, constitutive 
active β-catenin-Tcf-4 complexes were observed in colon carcinoma. In the absence of β-
catenin, Tcf/Lef factors suppress the Wnt target gene expression by binding with members 
of the Groucho (Grg/TLE) family of transcriptional co-repressors. Translocation of β-catenin 
converts Tcf family proteins into potent transcriptional activators by displacing 
Groucho/TLE proteins and recruiting an array of co-activator proteins including CBP, TBP, 
BRG1, BCL9/PYG, Legless, Mediator and Hyrax (Barker and Clevers., 2006). β-catenin does 
not have a DNA binding domain, but it has a potent transcription activation domain. In 
general, Lef/Tcf transcription factors do not have a strong transcription activation domain, 
but they have a good DNA binding/bending domain. Thus, when β-catenin binds to 
Lef/Tcf proteins, a potent transcription regulatory complex is formed. We examined the 
expression levels of Lef1 and Tcf4 in human astrocytic samples and found that compared to 
normal brain tissues Lef1 and Tcf-4 expression levels were significantly elevated in 
astrocytomas and in most of the tumors these proteins were localized in the nucleus. The 
increased Tcf4 and Lef1 levels were significantly correlating with the pathological grade of 
astrocytomas. We also demonstrated the interaction of β-catenin with Tcf4 in the nuclear 
fractions of GBM tissues and in cell lines. In addition, we also found that the Lef-1 and tcf-4 
levels were elevated in ENU-induced rat gliomas compared to control rats and protein 
levels were progressively increased form initial stage to advanced stages. Oncogenic activity 
of Wnt signaling is mediated through overexpression of their target genes cyclin D1, c-Myc, 
c-Jun, MMP2, N-Myc etc. These proteins play essential roles in the cell cycle progression, 
cell proliferation and survival. In our study we observed the elevated levels of cyclin D1, c-
Myc, c-jun, N-Myc in astrocytomas of different clinical grade in comparison with normal 
brain samples. The protein levels were significantly correlating with the histological grading 
of astrocytomas and similar results were also observed in ENU-induced gliomas. 
2.7 Pygopus 2 
When β-catenin is accumulated and translocated to nucleus, β-catenin relieves the action of 
corepressors and recruits the array of coactivators to Tcf/Lef factors such as CBP, TBP, 
BRG1, Legless, Mediator, Hyrax, Bcl-9 (B-cell lymphoma-9), and pygopus. These 
coactivators are essential for β-catenin/Tcf dependent transcription. Wang et al. (2010) 
examined the pygopus 2 expression in human astrocytoma samples. Pygopus 2 levels were 
overexpressed in astrocytoma samples compared to controls and exhibited a positive 
correlation with tumor grade. Knockdown of pygopus with small hairpin RNA (shRNA) 
resulted in inhibition of cell proliferation, colony forming ability, BrdU incorporation and 
invasiveness of human and rat glioma cell lines. Knockdown of pygopus 2 also resulted in 
the arrest of cell cycle at G1 stage and this was associated with reduction of S phase cell 
population. Knockdown of pygopus 2 also leads to the decreased expression of Wnt target 
gene cyclin D1 without altering the β-catenin levels and its nuclear translocation. Further, 
Chen et al. (2010) examined the pygopus 2 role in rat glioma cell lines. Overexpression of 
pygopus significantly enhances the cell proliferation and cell cycle progression from G1 to S 
and this was associated with the elevation of cyclin D1 levels without altering the β-catenin 
levels. Moreover, pygo2 expression levels were significantly correlated with the expression 
of cyclin D1 in human glioma samples. 
 




Fig. 1. An overview of the Wnt signaling pathway. (a) In the absence of a Wnt signal, β-
catenin is captured by APC and axin within the destruction complex, facilitating its 
phosphorylation by the kinases CK1α and GSK3β. CK1α and GSK3β then sequentially 
phosphorylate a conserved set of serine and threonine residues at the amino terminus of β-
catenin. This facilitates binding of the β-TRCP, which subsequently mediates the 
ubiquitinylation and efficient proteasomal degradation of β-catenin. The resulting β-catenin 
‘drought’ ensures that nuclear DNA-binding proteins of the Tcf/Lef transcription factor family 
(TCF1, TCF3, TCF4 and LEF1) actively repress target genes by recruiting transcriptional co-
repressors (Groucho/TLE) to their promoters and/or enhancers. (b) Interaction of a Wnt 
ligand with its specific receptor complex containing a Frizzled family member and LRP5 or 
LRP6 triggers the formation of Dvl–Fzd complexes and the phosphorylation of LRP by CK1γ, 
facilitating relocation of axin to the membrane and inactivation of the destruction box. This 
allows β-catenin to accumulate and enter the nucleus, where it interacts with members of the 
Tcf/Lef family. In the nucleus, β-catenin converts the Tcf proteins into potent transcriptional 
activators by displacing Groucho/TLE proteins and recruiting an array of coactivator proteins 
including CBP, TBP, BRG1, BCL9/PYG, Legless, Mediator and Hyrax. This ensures efficient 
activation of Tcf target genes such as c-MYC, which instruct the cell to actively proliferate and 
remain in an undifferentiated state. Following dissipation of the Wnt signal, β-catenin is 
evicted from the nucleus by the APC protein and Tcf proteins revert to actively repressing the 
target gene program. β-TRCP, β-transducin repeat-containing protein; APC, adenomatous 
polyposis coli; BCL9, B-cell lymphoma 9; CK1α, casein kinase 1α; CK1γ, casein kinase 1γ; CBP, 
CREB-binding protein; Fzd, Frizzled; Lef, lymphoid enhancer factor; LRP, low-density 
lipoprotein receptor-related protein; PYG, Pygopus; Tcf, T-cell factor. (This illustration is 
reproduced from Barker et al., 2006). 
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not have a DNA binding domain, but it has a potent transcription activation domain. In 
general, Lef/Tcf transcription factors do not have a strong transcription activation domain, 
but they have a good DNA binding/bending domain. Thus, when β-catenin binds to 
Lef/Tcf proteins, a potent transcription regulatory complex is formed. We examined the 
expression levels of Lef1 and Tcf4 in human astrocytic samples and found that compared to 
normal brain tissues Lef1 and Tcf-4 expression levels were significantly elevated in 
astrocytomas and in most of the tumors these proteins were localized in the nucleus. The 
increased Tcf4 and Lef1 levels were significantly correlating with the pathological grade of 
astrocytomas. We also demonstrated the interaction of β-catenin with Tcf4 in the nuclear 
fractions of GBM tissues and in cell lines. In addition, we also found that the Lef-1 and tcf-4 
levels were elevated in ENU-induced rat gliomas compared to control rats and protein 
levels were progressively increased form initial stage to advanced stages. Oncogenic activity 
of Wnt signaling is mediated through overexpression of their target genes cyclin D1, c-Myc, 
c-Jun, MMP2, N-Myc etc. These proteins play essential roles in the cell cycle progression, 
cell proliferation and survival. In our study we observed the elevated levels of cyclin D1, c-
Myc, c-jun, N-Myc in astrocytomas of different clinical grade in comparison with normal 
brain samples. The protein levels were significantly correlating with the histological grading 
of astrocytomas and similar results were also observed in ENU-induced gliomas. 
2.7 Pygopus 2 
When β-catenin is accumulated and translocated to nucleus, β-catenin relieves the action of 
corepressors and recruits the array of coactivators to Tcf/Lef factors such as CBP, TBP, 
BRG1, Legless, Mediator, Hyrax, Bcl-9 (B-cell lymphoma-9), and pygopus. These 
coactivators are essential for β-catenin/Tcf dependent transcription. Wang et al. (2010) 
examined the pygopus 2 expression in human astrocytoma samples. Pygopus 2 levels were 
overexpressed in astrocytoma samples compared to controls and exhibited a positive 
correlation with tumor grade. Knockdown of pygopus with small hairpin RNA (shRNA) 
resulted in inhibition of cell proliferation, colony forming ability, BrdU incorporation and 
invasiveness of human and rat glioma cell lines. Knockdown of pygopus 2 also resulted in 
the arrest of cell cycle at G1 stage and this was associated with reduction of S phase cell 
population. Knockdown of pygopus 2 also leads to the decreased expression of Wnt target 
gene cyclin D1 without altering the β-catenin levels and its nuclear translocation. Further, 
Chen et al. (2010) examined the pygopus 2 role in rat glioma cell lines. Overexpression of 
pygopus significantly enhances the cell proliferation and cell cycle progression from G1 to S 
and this was associated with the elevation of cyclin D1 levels without altering the β-catenin 
levels. Moreover, pygo2 expression levels were significantly correlated with the expression 
of cyclin D1 in human glioma samples. 
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Molecular Targets of CNS Tumors 
 
390 
3. Conclusion  
In summary, recent activities that deal with the study of Wnt/β-catenin/Tcf signaling 
pathway in gliomas insist that this pathway is activated in human gliomas and involved in 
the malignant progression of gliomas. This pathway attracted as candidate therapeutic 
target and inhibition of this pathway may curtail the malignant progression of gliomas. 
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1. Introduction 
Glioblastoma is the most common malignant brain tumor and has an extremely lethal 
course (Clark et al., 2010).  Although genetic abnormalities in p53, Akt, phosphatase and 
tensin homolog deleted from chromosome 10 (PTEN), and epidermal growth factor receptor 
that are common to various cancers are also found in glioblastoma, the prime cause of 
glioblastoma’s malignant features and conclusive treatment targets have yet to be 
determined.  Better understanding of non-major signal pathways involved in glioblastoma 
could thus provide breakthroughs in treatment strategies.  Insulin-like growth factor 
binding protein-2 (IGFBP2) was originally reported to be a modulator of the action of 
insulin-like growth factors (IGFs), but IGF-independent effects of IGFBP2 on cellular 
proliferation, apoptosis, metabolism, and mobility have since been reported in pathological 
conditions, including cancers.  Recent studies of gene expression microarray revealed that 
elevated expression of IGFBP2 occurs in gliomas, and is associated with increasing grades of 
malignancy with significant overexpression in glioblastomas (Fuller et al., 1999; Sallinen et 
al., 2000).  Subsequent studies have suggested that IGFBP2 may be one of the proteins that 
play an important role in malignant phenotypes of glioblastoma cells (Fukushima & 
Kataoka, 2007). 
This chapter highlights key examples of recent biological and epidemiological research 
focusing on IGFBP2 in brain tumors and reviews more specialized studies on the 
fundamental role of IGFBP2 in glioma progression. 
2. Structure and physiological functions of IGFBP2 
2.1 Human insulin-like growth factor binding proteins (IGFBPs) 
IGFBPs are a family of six proteins present in plasma and bodily fluids that bind insulin-like 
growth factor-I (IGF-I) and IGF-II with high affinity (Table 1) (Hwa et al., 1999; Firth & 
Baxter, 2002; Fukushima & Kataoka, 2007).  By interacting with IGFs, the IGFBPs modulate 
distribution and activity of IGFs in various tissues and bodily fluids, thereby controlling 
their biological function in vivo (Clemmons 1998; Kelley et al., 2002). IGFBPs in IGFBP/IGF 
complexes can be cleaved at specific sites by various proteinases (Bunn et al., 2003).  This 
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IGFBP cleavage might be an important regulatory mechanism of pericellular IGF function, 
as IGFBP proteolysis releases IGF from the IGFBP/IGF complexes (Lee et al., 1996; Bunn et 
al., 2003; Fowlkes et al., 2004; Mark et al., 2005; Nakamura et al., 2005).  Therefore, IGFBPs 
both positively and negatively regulate IGF function. 
 
 IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5 IGFBP6 
Gene location 7p13-p12 2q33-q34 7p13-p12 17q12-q21.1 2q33-q36 12q13 
mRNA (kbp) 1.6 1.4 2.6 2.2 6.3 1 
MW (kDa) 25 31 43-45 24 29 28-30 
RGD motif (+) (+)     
Heparin 
binding (+) (+) (+) (+) (+) (+) 
Phospho. site (+)  (+)  (+)  
NLS   (+)  (+)  
N-
Glycosylation   (+) (+)   
O-
Glycosylation     (+) (+) 
Table 1. Summary of IGFBP family.  MW, molecular weight of mature protein.  Phosopho. 
site, presumed phosphorylation site.  NLS, nuclear localization signal. 
2.2 Molecular properties and physiological functions of IGFBP2 
2.2.1 Synthesis, structure and distribution of IGFBP2 
The IGFBP2 precursor is 36-kDa (328 amino acid residues) in size and consists of a signal 
peptide and three distinct regions: the highly conserved N-terminal region (IGFBP homolog 
domain, amino acid residues 43-136); the highly conserved C-terminal region with a 
thyroglobulin type 1 repeat (amino acid residues 229-309); and an intervening region with 
four major cleavage sites (Bunn et al., 2003; Mark et al., 2005) (Figure 1).  The N-terminal and 
C-terminal domains are cysteine-rich and globular, both of which have IGF-binding 
property.  Mature IGFBP2 is a 31.4-kDa protein and is the second most abundant IGFBP 
found in serum. 
 
 
Fig. 1. Molecular structure of human IGFBP2.  Amino acid positions of mature IGFBP2 
protein are indicated.  Integrin binding RGD motif is also shown. 
Although IGFBP1, IGFBP3, and IGFBP5 each have phosphorylation sites, IGFBP2 does not.  
IGFBP2 does, however, have an arginine-glycine-aspartic acid (RGD) motif, which binds to 
cell surface integrins, and a heparin-binding domain, which facilitates association with 
extracellular matrices (Figure 1).  Both regions are able to localize IGFBP2 and IGFBP2/IGF 
complexes on/around the cell surface (Schutt et al., 2004; Russo et al., 2005; Wang et al., 
2006).  Among the six IGFBPs, only IGFBP1 and IGFBP2 possess a RGD motif (Table 1). 
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IGFBP2 is widely expressed in the fetus where its expression is reported to closely parallel 
that of IGF-II (Wood et al, 1992, 1993; Lee et al., 1993).  IGFBP2 is predominantly expressed in 
the early post-implantation epiblast, the apical ectodermal ridge, the progenitors of spleen 
and liver, and fetal astroglial cells (Wood et al., 1992; Lee et al., 1993).  Fetal epithelial cells 
and epidermal progenitor cells abundantly express IGFBP2, which also participates in the 
regulation of hair follicle development (Harris et al., 2010).  The expression of IGFBP2 
decreases significantly after birth, but gradually increases again, especially after the age of 
sixty, and found in plasma, seminal plasma, milk and cerebrospinal fluid (Blum et al., 1993; 
Schwander & Mary, 1993; van den Beld et al., 2003). 
2.2.2 Regulation of IGFBP2 expression 
The IGFBP2 gene is located on chromosome 2q33-q34 near that of IGFBP5 (Garner et al., 
2008).  The promoter region lacks TATA box and CAAT boxes, but contains GC-rich 
sequences and therefore putative Sp1 binding sites.  Portions of the promoter responsible for 
dexamethasone-induced transcriptional activity and IGF-induced stimulation of 
transcription have also been reported (Mouhieddine et al., 1996).  Other possibly important 
promoter regions contain binding sites for AP-4 and nuclear factor κB (NF-κB) (Cazals et al., 
1999).  The relationship between IGFBP2 expression and loss of tumor suppressor gene 
function has been recently elucidated (Perks et al., 2007; Moore et al., 2009) and hypoxic 
microenvironment may also upregulate IGFBP2 gene expression (Feldser et al., 1999).  These 
lines of evidence indicate that upregulated IGFBP2 gene expression should occur in injured 
tissue and particularly in tumors. 
2.2.3 Proposed physiological functions of IGFBP2 
By virtue of its IGF binding capacity, IGFBP2 was initially considered to be an inhibitory 
factor of IGFs, particularly of IGF-II with KD values for IGF-I and IGF-II to be 1.14 and 0.37, 
espectively (Hwa et al., 1999; Russo et al., 2005).  However, it was subsequently found to 
prolong the half-life of IGFs.  The binding between IGFs and IGFBP2 is reversible, and IGFs 
are released when IGFBP2 is processed at its central region cleavage sites by serine 
proteinases including thrombin and prostate specific antigen (human tissue kallikrein 3) 
(Clemmons et al., 1998; Cohen et al., 1992, Zheng et al., 1998) or matrix metalloproteinase 
(MMP) (Nakamura et al., 2005).  As IGFBP2 can associate with cell surface integrins via its 
RGD motif, IGFBP2 could in theory not only be an IGF inhibitor but also provide an IGF 
reservoir at the cell surface to maintain efficient IGF activity in the pericellular 
microenvironment.  Therefore, interaction between integrins and IGFBP2, cleavage of 
IGFBPs by proteases, and other factors that could influence the affinity of IGFBP2 for IGFs 
may be important regulatory mechanisms of pericellular IGF function.  On the other hand, 
IGFBP2 has also been reported in several studies to have a cytosolic or perinuclear 
localization, suggesting that IGFBP2 may also have IGF-independent functions (Hoeflich et 
al., 2004; Fukushima & Kataoka, 2007; Migita et al., 2010). 
IGFBP2 knockout mice are both viable and fertile, and do not show significant differences in 
prenatal or postnatal body growth (Wood et al., 1993, 2000).  However, detailed analyses of 
the knockout mice revealed decreased spleen weight and increased liver weight (Wood et 
al., 2000).  Interestingly, male IGFBP2 knockout mice have shorter femurs than their control 
mouse counterparts, and also have significantly enhanced levels of PTEN in their 
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osteoblasts and osteoclasts (DeMambro et al., 2008).  Recent studies also revealed that 
IGFBP2 likely has a crucial regulatory role in glucose metabolism as might be expected since 
IGFBP2 is regulated by leptin, secreted by visceral white adipocytes, and contributes to the 
prevention of diet-induced obesity as well as having anti-diabetic effects (Hedbacker et al., 
2010; Li & Picard, 2010).  
3. Roles of IGFBP2 in progression of gliomas 
3.1 Expression of IGFBP2 in tumors 
3.1.1 Enhanced expression of IGFBP2 in malignancies of various organs 
To date, there is accumulating evidence to suggest that IGFBP2 is involved in tumor 
progression.  Increased serum/plasma levels of IGFBP2 are associated with many malignant 
tumors of various organs, including prostate (Cohen et al., 1993), ovary (Lancaster et al., 
2006), colon (Mishra et al., 1998), breast (Busund et al., 2005), lung (Lee et al., 1999), skin 
(Harris et al., 2010) and the central nervous system (Lin et al., 2009).  Upregulated IGFBP2 
expression levels have been reported for various tumor tissues as well, and in many 
instances, these expression levels correlate with the grade of malignancy (Mishira et al., 1998; 
Pekonen et al., 1992; Fuller et al., 1999; Rickman et al., 2001; Sallinen et al., 2000).  Moreover, 
an inverse correlation between IGFBP2 and tumor suppressor genes, such as PTEN and 
p16/INK4, whose loss-of-function is frequently observed in malignant tumors, has also been 
reported (Perks et al., 2007; Moore et al., 2009).  Indeed, induction of PTEN downregulates 
IGFBP2 expression in glioblastoma and prostate cancer cells (Levitt et al., 2005; Mehrian-Shai 
et al., 2007).  On the other hand, the p53 tumor suppressor is suggested to be a transcription 
factor that stimulates IGFBP2 expression (Grimberg et al., 2006).  Hypoxia-induced 
expression of IGFBP2 mediated by hypoxia inducible factor 1α (HIF1α), has also been 
demonstrated (Feldser et al., 1999).  In sum, the expression of IGFBP2 can be significantly 
influenced by oncogenic genetic alteration and by a hypoxic tumor microenvironment, and 
many clinicopathological analyses strongly suggest that IGFBP2 participates in tumor 
progression. 
3.1.2 Expression of IGFBP2 in gliomas and its correlation with histological grade 
A consistent overexpression of IGFBP2 in glioblastoma was initially reported by Fuller et al. 
(1999) based on a gene expression profiling analysis.  This finding has since been confirmed 
by many researchers and it is now well established that IGFBP2 expression in gliomas 
increases with tumor grade (Sallinen et al., 2000; Rickman et al., 2001; Elminger et al., 2001; 
Fukushima & Kataoka, 2007).  Indeed, IGFBP2 is one of the most powerful discriminators to 
distinguish glioblastomas from low-grade gliomas in proteomic analyses (Jiang et al, 2006).  
Regarding a possible mechanism for IGFBP2 overexpression in glioblastoma, Mehrian-Shai 
et al. (2007) have identified IGFBP2 as the most significant molecular signature for loss of 
PTEN and activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway.  Notably, 
glioblastoma is one of the cancers most commonly affected by PTEN abnormalities (Sulis & 
Parsons, 2003).  Enhanced activation of NF-κB signaling pathway in glioblastoma cells 
(Wang et al., 2004) may also be involved in the upregulation of IGFBP-2 transcription (Cazals 
et al., 1999). 
The prognostic impact of IGFBPs expression in patients with newly diagnosed glioblastoma 
was recently reported (Santosh et al., 2010), with protein expression of IGFBP2, IGFBP 3 and 
Insulin-Like Growth Factor Binding Protein-2: 
A Possible Regulator of Invasive Growth in Glioblastoma 
 
399 
IGFBP5 being significantly associated with shorter survival by univariate Cox regression 
analysis.  However, multivariate Cox proportional hazards model showed that only IGFBP3 
had independent prognostic impact.  Plasma levels of IGFBP2 can also predict clinical 
outcomes of patients with glioblastoma (Lin et al., 2009).  In that study, preoperative plasma 
IGFBP2 levels were significantly higher in high-grade glioma patients compared to low-
grade glioma patients, and are significantly correlated with recurrence and disease-free 
survival in glioblastoma patients. 
3.1.3 Expression of IGFBP2 in other brain tumors 
Analysis of tissue mRNA levels revealed that IGFBP2 expression is indicative of poor 
prognosis in patients with medulloblastoma (de Bont et al., 2008).   IGFBP2 is also expressed 
by meningiomas, and a high IGF-II/IGFBP2 mRNA ratio is a sign of biologically aggressive 
behavior in meningiomas (Nordqvist et al., 1997).  However, a subsequent study by the same 
group revealed that IGFBP6 mRNA is more informative than IGFBP2 for the evaluation of 
meningioma invasiveness (Nordqvist et al., 2002). 
3.2 Role of IGFBP2 in malignant progression of gliomas 
3.2.1 Role for IGFBP2 in glioma development 
As mentioned above, analyses of clinical samples revealed that IGFBP2 expression 
significantly correlates with disease progression of gliomas, suggesting a role for IGFBP2 in 
malignant progression.  Furthermore, a recent study using a glial-specific transgenic 
(RCAS/Ntv-a) mouse system indicated that IGFBP2 in combination with platelet-derived 
growth factor-β (PDGFB) is also an oncogenic factor in glioma development (Dunlap et al., 
2007).  In this model, the expression of oncogenic IGFBP2 is negatively regulated by Ink4a-
Arf, and consequently, loss of Ink4a-Arf results in enhanced IGFBP2 expression (Moore et al., 
2009).  Indeed, the Ink4a-Arf locus is frequently deleted in human gliomas and IGFBP2 
expression is inversely correlated with p16INK4a status (Moore et al., 2009). 
Evidence regarding a role for IGFBP2 in glioma development also arose from a recent study 
of glioma stem cell (GSC) that was found to overexpress IGFBP2, which subsequently 
promoted GSC expansion and survival (Hsieh et al., 2010).  Notably Hedgehog-GLI1 
signaling regulates human glioma growth, GSC self-renewal, and tumorigenicity (Clement 
et al., 2007) and gene expression of IGFs and IGFBPs is upregulated by GLI transcription 
factors (Villani et al., 2010).  Therefore, an autocrine circuit of IGF/IGFBP2- or IGFBP2-
induced signaling may be established in GSCs via activation of Hedgehog-GLI1 signaling, 
which may contribute to the stemness of GSCs. 
3.2.2 Roles for IGFBP2 in malignant phenotypes of glioblastoma cells 
Glioblastoma is a devastating brain tumor with extremely poor prognosis (Clarke et al., 
2010). Significant invasiveness into surrounding brain parenchyma, increased mitotic 
activity, sustained angiogenesis and necrosis surrounded by palisaded atypical tumor cells 
are histological hallmarks of this untreatable tumor.  The major impediment to successful 
therapeutic intervention for glioblastomas is their diffuse invasive nature.  An in vitro study 
using a human glioblastoma cell line engineered to overexpress IGFBP2 revealed that 
IGFBP2 enhances glioblastoma cell invasiveness (Wang et al., 2003).  Similarly, a study using 
human glioblastoma cell lines in which IGFBP2 expression was knocked down by consistent 
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osteoblasts and osteoclasts (DeMambro et al., 2008).  Recent studies also revealed that 
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IGFBP5 being significantly associated with shorter survival by univariate Cox regression 
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retroviral expression of IGFBP2 short hairpin RNA (shRNA) revealed that silencing of the 
IGFBP2 gene reduces in vitro invasiveness and in vivo aggressiveness of the cells (Fukushima 
et al., 2007).  Consistent with these studies, high levels of IGFBP2 expression were detected 
within the infiltrating tumor cells of human glioblastomas in vivo (de Groot et al., 2010).  
Therefore, IGFBP2 has a crucial role in glioblastoma invasion. 
IGFBP2 may also be implicated in glioblastoma angiogenesis.  In a cDNA-array analysis of 
53 patient biopsies, IGFBP2 was included in a prominent gene cluster that allowed 
discrimination between primary (de novo) and non-primary (secondary) glioblastomas 
(Godard et al., 2003).  This gene cluster is composed mostly of angiogenesis-related genes, 
including vascular endothelial growth factor (VEGF) and fms-related tyrosine kinase 1.  
Notably, in situ hybridization demonstrates coexpression of IGFBP2 and VEGF in 
pseudopalisading cells surrounding tumor necrosis, providing evidence for a possible 
involvement of IGFBP2 in angiogenesis (Godard et al., 2003).  It is reasonable to postulate 
that HIF1α is responsible for the concomitant expression of VEGF and IGFBP2 (Carmeliet et 
al., 1998; Feldser et al., 1999).  In addition, an anti-apoptotic function of intracellular IGFBP2 
was recently reported in lung cancer cells (Migita et al., 2010), which may also have 
implications for the enhanced expression of IGFBP2 within glioblastoma cells around 
necrosis. 
Taken together, these results strongly indicate that IGFBP2 has significant roles in the 
development of the malignant phenotypes of glioblastoma. 
3.2.3 Potential mechanisms of IGFBP2 action in the invasive growth of glioblastoma 
cells 
Interaction of IGFBP2 with components of the pericellular matrices results in local 
sequestration of IGFs and then in an enhancement of cellular IGF-induced signaling (Schutt 
et al., 2004).  Experiments using a cultured neuroblastoma cell line showed that the heparin 
binding domain of IGFBP2 is required for IGFBP2 association to pericellular matrices and 
for IGFBP2 to promote invasive growth via efficient pericellular localization of IGF-1 (Russo 
et al., 2005). 
However, IGF-independent actions of IGFBP2 may be equally or more important in 
glioblastoma biology, as has been amply demonstrated by recent research.  Interaction of 
IGFBP2 RGD domain with integrin α5 induces outside-in signaling and may be essential for 
IGFBP2-induced glioma cell mobility (Wang et al., 2006).  Moreover, intracellular 
localization of IGFBP2 has been shown in glioblastoma cells and other tumor cells such as 
lung carcinoma, which appears to influence the cellular gene expression signature 
(Fukushima & Kataoka, 2007; Migita et al., 2010).  Overexpression of IGFBP2 in the SNB19 
human glioblastoma cell line revealed that IGFBP2 enhances the invasiveness of these cells 
by up-regulating expression of invasion-associated gene products, such as extracellular 
matrix-degrading protease, MMP-2 (Wang et al., 2003).  We compared the expression 
profiles of two human glioblastoma cell lines, U251 and YKG-1, in the presence and absence 
of shRNA-induced silencing of IGFBP2 expression (Fukushima et al., 2007).  In both cell 
lines, expression levels of various genes were altered by IGFBP2 knockdown without 
apparent alteration of IGF signaling, suggesting that IGFBP2 influences transcriptional 
regulation of many genes in glioblastoma cells independent of IGF signaling.  Among the 
genes influenced by IGFBP2 silencing, the CD24 gene was identified as a candidate 
downstream target of IGFBP2-induced signaling, and subsequent analysis revealed that 
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CD24 is critically involved in the invasiveness of U251 and YKG-1 cells (Fukushima et al., 
2007).  CD24 is a heavily glycosylated, cell surface, glycosylphosphatidylinositol-anchored 
protein (Kristiansen et al., 2004).  While the precise mechanism by which CD24 induces 
cellular invasion is unclear, CD24 has been shown to recruit adhesion molecules to lipid 
rafts, thereby contributing to tumor cell migration, dissemination, and metastasis (Baumann 
et al., 2005; Runz et al., 2008).  Of interest is a recent observation that a splice variant of GLI1, 
truncated GLI1 (tGLI1), which is highly expressed in glioblastoma cells but not in normal 
cells, induces cellular migratory and invasive capabilities via upregulaton of CD24 in U87 
glioblastoma cells (Lo et al., 2009).  As mentioned above, Hedgehog-GLI1 signaling is 
involved in glioma cell growth, expansion of GSC and induction of IGFBP2 expression 
(Clement et al., 2007; Villani et al., 2010).  Therefore, Hedgehog-GLI1/IGFBP2/CD24 
signaling may play a pivotal role in the invasive growth of glioblastoma cells. 
The NF-κB pathway is another important candidate for the signaling involved in IGFBP2-
induced phenotypes.  In fact, NF-κB signaling is activated in glioblastomas and involved in 
invasion and angiogenesis of glioma cells (Wang et al., 2004; Li et al., 2007).  While NF-κB is 
suggested to regulate IGFBP2 gene expression in response to tissue injury (Cazals et al., 
1999), intracellular IGFBP2 itself is involved in the regulation of NF-κB signaling via binding 
to invasion inhibitory protein 45 (IIp45, also named migration and invasion inhibitor protein 
MIIP), which was identified by a yeast two-hybrid assay (Song et al., 2003).  The IIp45 gene is 
located on chromosome 1p36 (Song et al., 2003), a region that is frequently deleted in 
oligodendrogliomas and occasionally deleted in astrocytomas (Smith et al., 1999).  Decreased 
IIp45/MIIP levels were also observed in 15% of glioblastoma cases (Song et al., 2003).  
IIp45/MIIP binds to the RGD motif of IGFBP2 and inhibits the interaction between IGFBP2 
and integrin, which eventually may inhibit the expression of transcriptional NF-κB and its 
downstream genes involved in invasive glioma cell growth (Song et al., 2003).  It may be 
possible that upregulated NF-κB in the absence of IIp45/MIIP also stimulates IGFBP2 
transcription and eventually establishes an autocrine stimulation circuit for invasive growth.  
Moreover, recent studies have indicated that IIp45/MIIP also interacts with intracellular 
proteins, such as Cdc20 and histon deacetylase 6 (HDAC6), and inhibits glioma cell 
proliferation and migration (Ji et al., 2010; Wu et al., 2010).  Therefore, interaction between 
IIp45/MIIP and intracellular IGFBP2 may occur in glioblastoma cells, which may attenuate 
the function of IIp45/MIIP and thereby may enhance the cellular proliferation and 
migration. 
We summarize hypothetical functions of IGFBP2 in the invasive growth of glioblastoma 
cells in Figure 2. 
3.2.4 IGFBP2 as a therapeutic target for high-grade gliomas 
We have shown above that IGFBP2 can provide crucial signaling during glioma 
development and can exhibit malignant phenotypes of glioblastoma.  As such, IGFBP2 and 
its downstream targets may reasonably serve as novel therapeutic targets for glioblastoma.  
However, there have been limited attempts to target IGFBP2 for in vivo glioblastoma 
treatments.  Moore et al. (2009) examined the effect of antisense IGFBP2 in vivo using 
PDGFB-induced glioma in Ink4a-Arf-null mice, and found that the inhibition of IGFBP2 
expression confers a survival benefit.  Therefore, IGFBP2 is a potential therapeutic target for 
Ink4a-Arf-dleted gliomas, such as anaplastic oligodendroglioma and glioblastoma (Moore et 
al., 2009). 
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As a downstream molecule of IGFBP2 involved in invasiveness of glioblastoma cells, CD24 
may also serve as a molecular target for glioblastoma treatment.  Targeting CD24 by 
monoclonal antibodies, small interfering RNA or shRNA has been reported in xenograft 
models of human colorectal cancer, pancreatic cancer and ovarian cancer cell lines (Sagiv et 
al., 2008; Su et al., 2009).  In those studies, retardation of tumorigenicity and significant 
reduction of tumor growth were observed in vivo, indicating that CD24 is a promising 
therapeutic target for treatment of cancer.  As glioblastomas abundantly express CD24 as 
well as IGFBP2 (Fukushima et al., 2007), we suggest that targeting CD24 may be a potential 




Fig. 2. Roles for IGFBP2 in the establishment of malignant phenotypes of glioblastoma cells.  
Both IGF-dependent and IGF–independent effects of IGFBP2 have been proposed.  Integrin-
mediated outside-in signaling and NF-κB signaling appear to be involved in the IGFBP2-
induced effects, which eventually result in enhanced expression of proinvasive molecules, 
such as CD24 and MMP-2.  While IIp45/MIIP may inhibit binding of IGFBP2 to integrin, it 
is possible to hypothesize that excess intracellular (intranuclear) IGFBP2 may suppress the 
inhibitory effects of IIp45/MIIP on Cdc20 and/or HDAC6-mediated cellular growth and 
migration.  The upregulated NF-κB signaling enhances the expression of IGFBP2. Hypoxic 
microenvironment, loss of PTEN function and Hedgehog-GLI1 signaling might also be 
involved in the enhanced IGFBP2 expression in glioblastoma cells.  Functions of intracellular 
and intranuclear IGFBP2 remain to be elucidated.  ECM, extracellular matrix. 
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IGFBP2 may also be an attractive marker to influence glioblastoma treatment strategy 
decisions.  Since high IGFBP2 levels serve as a marker for loss of PTEN function and 
PI3K/Akt activation, the clinical data linking IGFBP2 expression to poor prognosis may be 
due, at least in part, to the loss of PTEN function, which is well known to lead to aggressive 
behavior of gliomas (Levitt et al., 2005; Mehrian-Shai, 2007).  Therefore, measurements of 
IGFBP2 expression levels may be useful for estimating the functional PTEN status and 
PI3K/Akt activation levels in glioma, which in turn may be beneficial for organizing specific 
treatment strategies for each glioma case (Gonzalez & de Groot, 2008).  Moreover, recent 
study suggests that IGFBP2 expression level may be a marker for DNA hypermethylation 
profiles in gliomas (Zheng et al., 2011). 
4. Conclusion 
IGFBP2 is a pleiotropic protein that appears to be involved in many aspects of physiological 
and pathological processes and shows both positive and negative effects.  Even in cancers, 
opposite effects of IGFBP2 are observed.  For example, the growth of colorectal adenomas 
induced by chemical carcinogens in mice was inhibited upon crossing with IGFBP2 
transgenic mice (Diehl et al., 2008).  In contrast, IGFBP2 exerts oncogenic effects in brain-
specific transgenic mice (Dunlap et al., 2007; Moore et al., 2009).  Thus, IGFBP2 shows both 
negative and positive effects on tumor growth, and these differences are probably 
dependent on cell type and pericellular environment.  Despite the diverse effects of IGFBP2 
on the biological behaviors of cancers, it has been clearly demonstrated that IGFBP2 is 
overexpressed in a wide variety of human malignancies, and evidence is rapidly 
accumulating to indicate that IGFBP2 is significantly involved in the progression of glioma 
and confers malignant phenotypes of glioblastoma cells.  To clarify the molecular 
mechanisms underlying the effects of IGFBP2 on gliomas, not only the pericellular IGF-
dependent and IGF-independent functions but also the functions of intracellular IGFBP2 
should be defined (Figure 2).  Additional information concerning the factors that directly 
regulate IGFBP2 overexpression in gliomas and those that are critically involved in the 
IGFBP2-mediated malignant features of glioblastoma cells is required and may lead to new 
therapeutic avenues for one of the most treatment-resistant human tumors. 
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treatment strategies for each glioma case (Gonzalez & de Groot, 2008).  Moreover, recent 
study suggests that IGFBP2 expression level may be a marker for DNA hypermethylation 
profiles in gliomas (Zheng et al., 2011). 
4. Conclusion 
IGFBP2 is a pleiotropic protein that appears to be involved in many aspects of physiological 
and pathological processes and shows both positive and negative effects.  Even in cancers, 
opposite effects of IGFBP2 are observed.  For example, the growth of colorectal adenomas 
induced by chemical carcinogens in mice was inhibited upon crossing with IGFBP2 
transgenic mice (Diehl et al., 2008).  In contrast, IGFBP2 exerts oncogenic effects in brain-
specific transgenic mice (Dunlap et al., 2007; Moore et al., 2009).  Thus, IGFBP2 shows both 
negative and positive effects on tumor growth, and these differences are probably 
dependent on cell type and pericellular environment.  Despite the diverse effects of IGFBP2 
on the biological behaviors of cancers, it has been clearly demonstrated that IGFBP2 is 
overexpressed in a wide variety of human malignancies, and evidence is rapidly 
accumulating to indicate that IGFBP2 is significantly involved in the progression of glioma 
and confers malignant phenotypes of glioblastoma cells.  To clarify the molecular 
mechanisms underlying the effects of IGFBP2 on gliomas, not only the pericellular IGF-
dependent and IGF-independent functions but also the functions of intracellular IGFBP2 
should be defined (Figure 2).  Additional information concerning the factors that directly 
regulate IGFBP2 overexpression in gliomas and those that are critically involved in the 
IGFBP2-mediated malignant features of glioblastoma cells is required and may lead to new 
therapeutic avenues for one of the most treatment-resistant human tumors. 
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Isocitrate dehydrogenases (IDHs) are enzymes long known to biologists as a component of 
the tricarboxylic acid (TCA) cycle that converts isocitrate to α-ketoglutarate (α-KG) with 
production of NADH and/or NADPH. However, it was mainly viewed as a 
“housekeeping” gene by cancer biologists with no previously defined role in cancer. This 
changed in 2008 with the discovery that IDH1 was frequently mutated in glioblastoma 
multiformes (GBMs) (Parsons et al., 2008). IDH mutations have now also been found in 
lower grade gliomas as well as in acute myelocytic leukemias. The purpose of this chapter is 
to review the normal functions of the IDH isoforms and their role in glioma brain tumors 
from initial discovery of a specific mutation in IDH1 to what is currently known about the 
mechanisms of action of mutant IDHs. 
2. Normal function of isocitrate dehydrogenases 
2.1 Isocitrate dehydrogenase enzymatic activity and structure 
IDH is an enzyme whose activity is to oxidatively decarboxylate isocitrate producing α–
ketoglutarate (α-KG) and CO2 (Haselbeck & McAlister-Henn, 1993). A schematic of this 
reaction with all the family members is shown (Fig. 1). During this process, NAD+ or 
NADP+ is reduced to NADH or NADPH, respectively, depending on the isoform that is 
catalyzing this reaction. The IDH1 and IDH2 isoforms are NADP+ dependent and function 
as homodimers (Bailey & Colman, 1985; Kelly & Plaut, 1981). They are structurally related 
sharing approximately 70% sequence identity between the two isoforms (Xu et al., 2004). 
IDH1 is most highly expressed in liver while IDH2 show the greatest expression in muscle 
(Haselbeck et al., 1992; Jennings et al., 1994). However, both isoforms show moderate 
expression within a variety of other tissues including brain (Jennings et al., 1994). The IDH3 
isoform is NAD+ dependent, functions as a heterotetramer consisting of 2 α, 1 β and 1 γ 
subunits (Ramachandran & Colman, 1980), and is structurally unrelated to IDH1 and IDH2 
(Nichols et al., 1993; Nichols et al., 1995). IDH3 is the classical TCA cycle enzyme and plays 
an integral role in cellular energy metabolism. Consequently, IDH3 is found predominantly 
in the mitochondria (Haselbeck & McAlister-Henn, 1993). IDH2 also localizes to the 
mitochondria and has a mitochondrial signal peptide at its N-terminus (Nekrutenko et al., 
1998). By contrast, IDH1 is localized mainly in the cytoplasm but has a type 1 peroxisomal 
targeting sequence permitting localization in peroxisomes (Henke et al., 1998; Nekrutenko et 
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al., 1998). The reactions catalyzed by IDH1/2 are reversible while the similar reaction 
catalyzed by IDH3 is irreversible. Because only IDH1 and IDH2 mutations have been shown 
to be important in malignancies, we will not be addressing IDH3 further. 
 
 
Fig. 1. Enzymatic activity of wild type and mutant IDH isoforms.  
Structural characteristics of mammalian IDH1 and IDH2 are well-known with elucidation of 
their crystal structures (Ceccarelli et al., 2002; Xu et al., 2004). A cartoon representation of the 
IDH1 homodimer is shown (IDH2 structure is similar) (Fig. 2). These enzymes dimerize 
with two active site in an open, inactive conformation, which is maintained by an 
intramolecular interaction between a conserved serine at position 94 and aspartic acid at 
position 279 in IDH1 blocking access to the active site. The IDH homodimer shifts to the 
closed, active conformation when this serine:aspartic acid interaction is lost permitting entry 
of an isocitrate:metal ion complex into the active site. The reaction proceeds with formation 
of α-KG and NADPH which is released with either immediate reoccupation of the active site 
with another isocitrate:metal ion complex and NADP+ or reassociation of the serine:aspartic 
acid interaction returning the enzyme back to an inactive state. 
 
 
Fig. 2. Representation of wild type IDH1 homodimers shifting between the inactive and 
active conformations. 
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2.2 Normal function of isocitrate dehydrogenase in cellular metabolism 
Both IDH1 and IDH2 play key roles in various cellular metabolic functions. They are 
involved in the oxidation of polyunsaturated fatty acids within peroxisomes (IDH1) and 
mitochondria (IDH2) by using the NADPH generated by their enzymatic activity (Minard & 
McAlister-Henn, 1999; van Roermund et al., 1998). In the liver, IDH1 is regulated by sterol 
regulatory element-binding proteins and also generates NADPH for peroxisomal 
lipogenesis (Shechter et al., 2003). In pancreatic islet cells, IDH1 has an important role in 
cellular glucose sensing as evidenced by impairment of glucose-stimulated insulin secretion 
after knockdown of IDH1 expression (Ronnebaum et al., 2006). Consistent with these 
functions, IDH1 transgenic mice display fatty livers, hyperlipidemia, obesity and higher 
glucose sensitivity on glucose tolerance testing consistent with enhanced insulin secretion 
(Koh et al., 2004). Finally, IDH2 has probable roles in the TCA cycle as evidenced by the lack 
of pathology in most normal tissues of certain retinitis pigmentosa patients with a 
homozygous IDH3 subunit defect (Hartong et al., 2008). The reverse reaction (producing 
isocitrate and NADP+ from α–KG and NADPH) by IDH2 has been proposed as a way of 
limiting flux through the TCA cycle and dissipating the proton electrochemical gradient 
across the inner mitochondrial membrane with heat generation (Sazanov & Jackson, 1994). 
These various metabolic functions that have been defined to date show the central role that 
IDH1 and IDH2 play at the crossroads of lipid synthesis and carbohydrate utilization. 
2.3 The role of isocitrate dehydrogenase in response to oxidative stress 
IDH1/2 also likely plays a part in the oxidative stress response and helps limit damage from 
such insults. Consistent with this idea, Mailloux et al. found that oxidative stress enhances 
α-KG and NADPH production by IDH1/2 with a concomitant decrease in IDH3, α-KG 
dehydrogenase, and succinate dehydrogenase activities decreasing utilization of the TCA 
cycle (Mailloux et al., 2007). NADPH produced by IDH1/2 can also be used by glutathione 
reductase for converting the oxidized form of glutathione (GSSG) to the reduced form 
(GSH) that can neutralize free radicals and reactive oxygen species (Jo et al., 2001; Kehrer & 
Lund, 1994; Lee et al., 2002). While the pentose phosphate pathway is the major source of 
NADPH required for regeneration of GSH, IDH1/2 can also contribute to this NADPH pool 
(Winkler et al., 1986). In addition, Lee et al. were able to generate a series of NIH3T3 
derviatives that expressed varying levels of IDH1 and found that the ratio of GSH:GSSG 
was directly correlated with IDH1 expression level consistent with a role of this enzyme in 
the regeneration of GSH (Lee et al., 2002). Reduced expression of both IDH1 and IDH2 
results in higher levels of reactive oxygen species and greater oxidative damage in response 
to an oxidative insult (Jo et al., 2001; Lee et al., 2002). In fact, numerous reports have now 
demonstrated that overexpression of IDH1 and IDH2 can protect cells against a variety of 
insults that produce oxidative stress (Jo et al., 2002; Kim et al., 2007; Lee et al., 2004; Shin et 
al., 2004). Based on this wealth of evidence demonstrating a role in the response of IDH1/2 
to oxidative damage, the NADP+-dependent IDHs clearly have significant functions beyond 
energy metabolism and biosynthetic processes. 
3. Isocitrate dehydrogenase mutations in glial and other neoplasms 
3.1 Discovery of isocitrate dehydrogenase 1 mutations in glioblastomas 
GBMs are highly aggressive brain tumors classified by the World Health Organization 
(WHO) grading system as grade IV astrocytomas (Louis et al., 2007). While outcomes for 
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patients with this diagnosis have gradually improved with better surgical/radiation therapy 
techniques and temozolomide chemotherapy, median survival still remain only slightly 
longer than one year (Stupp et al., 2005). With recent genomic technology advances, projects 
were initiated to perform detailed genomic analysis of various malignancies including 
GBMs. This effort quickly bore fruit with the discovery by Parson et al. that IDH1 is 
frequently mutated in GBMs (Parsons et al., 2008). They performed an initial screen 
consisting of comprehensive analysis of 20,661 protein-coding genes in 22 GBM samples. 
This yielded 21 mutated genes that were further analyzed in a followup screen on 83 
additional GBMs. In addition to finding expected mutations at several genes known to be 
important in GBMs, the IDH1 gene was surprisingly found to be altered in 11% of analyzed 
GBMs. Most striking, mutations were invariably at a highly conserved arginine at position 
132 (R132) found in the isocitrate binding site and was mutated to either histidine (R132H) 
(10 of 12) or serine (R132S) (remaining 2). This unexpected finding implicated IDH1 in the 
development and/or maintenance of glial neoplasms.  
Followup studies confirmed the presence of IDH mutations in GBMs (Balss et al., 2008; 
Hartmann et al., 2009; Sanson et al., 2009; Watanabe et al., 2009; Yan et al., 2009) (Table 1). 
GBMs are classified as primary (de novo) or secondary depending on whether they arise 
spontaneously or from malignant transformation of a low grade glioma. Interestingly, the 
frequency of IDH1 mutations was significantly higher in secondary (82%) than primary (6%) 
GBMs. Thus, the incidence of IDH mutations in an undifferentiated cohort of GBMs would 
depend on the distribution of primary and secondary tumors in that group. Of note, initial 
studies suggest that pediatric GBMs only rarely harbor IDH mutations (Antonelli et al., 
2010; Balss et al., 2008; Paugh et al., 2010; Yan et al., 2009). However, a recent paper suggests 
that pediatric malignant glioma patients ≥ 14 years of age appear to harbor IDH mutations 




Tumor type Balss/ 
Hartmann1
Yan2 Watanabe3 Sanson4 Total (percent) 
IV 1o GBM 7/99 6/123 3/59 11/183 27/464 (5.8%) 
2o GBM 7/8 11/13 28/34 10/13 56/68 (82.4%) 
III AA 148/228 38/52 21/27 9/18 216/325 (66.5%) 
AOA 128/177 7/7 10/14 34/54 179/252 (71.0%) 
AO 130/174 34/36 6/8 24/49 194/267 (72.7%) 
II A 167/227 27/30 60/68 10/12 264/337 (78.3%) 
OA 63/76 3/3 16/17 26/34 108/130 (83.1%) 
O 111/128 43/51 31/39 41/54 226/272 (83.1%) 
I Pilocytic 
Astrocytoma
1/41 0/21 3/31 NT 4/93 (4.3%) 
I-III Ependymoma 0/31 0/30 0/24 NT 0/85 (0%) 
1 Combined results of Balss and Hartmann studies due to duplication of some cases (Balss et al., 2008; 
Hartmann et al., 2009), 2 (Yan et al., 2009), 3 (Watanabe et al., 2009), 4 (Sanson et al., 2009). 
Abbreviations:  WHO, World Health Organization; GBM, glioblastoma multiforme; AA, anaplastic 
astrocytoma; AOA, anaplastic oligoastrocytoma; AO, anaplastic oligodendroglioma; A, astrocytoma; 
OA, oligoastrocytoma; O, oligodendroglioma; NT, not tested. 
Table 1. Frequency of IDH mutations in various glial brain tumors. 
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gliomas in younger pediatric patients may be a different entity that those presenting in late 
adolescence with the older pediatric patients likely having a tumor that may be more similar 
to such tumors that present in young adulthood (eg. 20-40 years of age). 
3.2 Isocitrate dehydrogenase mutations in other gliomas 
Since secondary GBMs have a high incidence of IDH mutations, these mutations were 
postulated to be present in low grade gliomas as well. As predicted, pooled results found 
IDH mutations in 65% to 80% of grade II/III astrocytomas (Table 1) (Balss et al., 2008; 
Hartmann et al., 2009; Sanson et al., 2009; Watanabe et al., 2009; Yan et al., 2009). Grade 
II/III oligodendrogliomas and oligoastrocytomas also had a high incidence of IDH1 
mutations in the 70-85% range. Finally, pilocytic astrocytomas only rarely harbor IDH1 
mutations (<5%) while no IDH1 mutations were found in ependymomas of any grade (Balss 
et al., 2008; Watanabe et al., 2009; Yan et al., 2009). 
Although IDH1 and IDH2 reside largely in different subcellular compartments, they have 
the same enzymatic activity, utilize NADP+, and are believed to provide some redundant 
function(s) in the cell. Therefore, Yan et al. also sequenced IDH2 in addition to IDH1 in their 
series of brain tumors  and found that IDH2 was, in fact, mutated at a low frequency on 
arginine at position 172 (R172), the comparable residue to R132 of IDH1 (Yan et al., 2009). 
Based on pooled results from multiple studies examining glioma brain tumors, when IDH is 
mutated, IDH1 is affected 96% of the time and IDH2 is affected in only 4% of cases (Table 2) 
(Hartmann et al., 2009; Sonoda et al., 2009; Yan et al., 2009). In addition, mutation on one 
IDH isoform was always mutually exclusive for mutation on the other isoform. 
 
Type Balss1 Yan2 Hartman3 Sanson4 Sonoda5 Total (percent) 
IDH1 221 161 716 155 39 1292 
R132H 205 142 664 138 39 1188 (92.0%) 
R132C 8 7 29 5 -- 49 (3.8%) 
R132L 1 7 2 2 -- 12 (0.9%) 
R132S 4 4 11 3 -- 22 (1.7%) 
R132G 2 1 10 7 -- 20 (1.5%) 
R132V 1 -- -- -- -- 1 (0.1%) 
IDH2 NT 9 31 NT 1 41 
R172K NT 4 20 NT 1 25 (61.0%) 
R172M NT 3 6 NT -- 9 (22.0%) 
R172G NT 2 -- NT -- 2 (4.9%) 
R172W NT -- 5 NT -- 5 (12.2%) 
1 (Balss et al., 2008), 2 (Yan et al., 2009), 3 (Hartmann et al., 2009), 4 (Sanson et al., 2009), 5 (Sonoda et al., 
2009). 
Abbreviations: IDH, isocitrate dehydrogenase; NT, not tested. 
Table 2. Type and frequency of IDH1/IDH2 mutations in gliomas. 
The frequency distribution of mutations in IDH1/2 is summarized on Table 2 (Balss et al., 
2008; Hartmann et al., 2009; Sanson et al., 2009; Sonoda et al., 2009; Yan et al., 2009). The 
great majority of mutations at R132 in IDH1 and R172 in IDH2 result from single nucleotide 
changes within the codon. Possible changes at these codons are shown with the frequency 
they are observed (Fig. 3). It is interesting to note that nearly 92% of IDH1 mutations were to 
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Type Balss1 Yan2 Hartman3 Sanson4 Sonoda5 Total (percent) 
IDH1 221 161 716 155 39 1292 
R132H 205 142 664 138 39 1188 (92.0%) 
R132C 8 7 29 5 -- 49 (3.8%) 
R132L 1 7 2 2 -- 12 (0.9%) 
R132S 4 4 11 3 -- 22 (1.7%) 
R132G 2 1 10 7 -- 20 (1.5%) 
R132V 1 -- -- -- -- 1 (0.1%) 
IDH2 NT 9 31 NT 1 41 
R172K NT 4 20 NT 1 25 (61.0%) 
R172M NT 3 6 NT -- 9 (22.0%) 
R172G NT 2 -- NT -- 2 (4.9%) 
R172W NT -- 5 NT -- 5 (12.2%) 
1 (Balss et al., 2008), 2 (Yan et al., 2009), 3 (Hartmann et al., 2009), 4 (Sanson et al., 2009), 5 (Sonoda et al., 
2009). 
Abbreviations: IDH, isocitrate dehydrogenase; NT, not tested. 
Table 2. Type and frequency of IDH1/IDH2 mutations in gliomas. 
The frequency distribution of mutations in IDH1/2 is summarized on Table 2 (Balss et al., 
2008; Hartmann et al., 2009; Sanson et al., 2009; Sonoda et al., 2009; Yan et al., 2009). The 
great majority of mutations at R132 in IDH1 and R172 in IDH2 result from single nucleotide 
changes within the codon. Possible changes at these codons are shown with the frequency 
they are observed (Fig. 3). It is interesting to note that nearly 92% of IDH1 mutations were to 
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histidine. Thus, a very significant selective advantage must be at play for this particular 
point mutation. There may also be slight selection for alterations to cysteine with an 
increased incidence of between 2-4 fold higher than any of the other three observed amino 
acids although total number of cases are relatively small. Numbers for IDH2 mutations are 
also relatively small, but does suggest skewing towards mutation of R172 to lysine (R172K). 
 
 
Fig. 3. Possible mutations in codon 132 of IDH1 and codon 172 of IDH2 with observed 
frequency in glial neoplasms. 
3.3 Isocitrate dehydrogenase mutations in other malignancies 
After discovery of the specific IDH1 and IDH2 mutations in gliomas, there was significant 
interest to determine whether these mutations were also present in other malignancies. 
Despite screening of a large number of tumor specimens, very few non-glioma, solid 
malignancies were found to contain these mutations. One study found 2 of 75 (2.7%) 
prostate cancers with IDH1 mutations while a second study found a metastatic melanoma 
with an IDH1 mutant (Bleeker et al., 2009; Kang et al., 2009; Lopez et al., 2010). Kang et al. 
also found an IDH1 mutation in 1 of 60 cases of B-cell acute lymphoblastic leukemia (Kang 
et al., 2009). Mutations at both IDH1 and IDH2 have now been shown to be present in acute 
myelogenous leukemias (AMLs). Mardis et al. were the first to report that 16 of 188 (8.5%) 
primary, cytogenetically normal AMLs had mutation at R132 in IDH1 (Mardis et al., 2009). 
Likewise, Ward et al. found in their cohort that 6 of 60 (10%) karyotypically normal AMLs 
had the expected IDH1 mutation (Ward et al., 2010). They also found that these AMLs were 
actually more likely to harbor mutations in IDH2 with the previously defined R172K 
mutation seen in 5 cases and a new mutation altering arginine at position 140 to glutamine 
(R140Q). These specific mutations all resulted in elevated levels of 2-hydroxyglutarate (2-
HG), a marker of mutant IDH activity (details of this enzymatic activity will be covered in 
section 4.3). Marcucci et al. reported similar results in a Cancer and Leukemia Group B 
study where out of 358 cases of cytogenetically normal AMLs, 47 had IDH1 mutations at 
R132, 13 had IDH2 mutations at R172 and 56 had IDH2 mutations at R140 (Marcucci et al., 
2010). Based on these studies, it appears that ~30% of cytogenetically normal AMLs harbor 
mutations in IDH1/2. Also, whereas the great majority of IDH mutations found in gliomas 
involve IDH1, mutations of IDH in AML are more evenly distributed between IDH1 and 
IDH2 with a slight favoring of the latter. Unlike the case where IDH1 and IDH2 mutations 
were always mutually exclusive, rare instances of AMLs with both mutation present has 
been reported (Paschka et al., 2010). 
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3.4 Clinical outcomes in gliomas harboring isocitrate dehydrogenase mutations 
With the identification of IDH1 mutations in GBMs, Parson et al. made an intriguing 
observation that patients with this mutation had a significantly better survival (Parsons et 
al., 2008). However, since their clinical series only included 11 patients with  
IDH1 mutations, this finding required validation. At this time, multiple reports have 
confirmed that IDH1/2 mutations predict for improved outcomes in patients with GBMs as 
well as lower grade glial neoplasms (Dubbink et al., 2009; Nobusawa et al., 2009; Sanson et 
al., 2009; Sonoda et al., 2009; Yan et al., 2009). A summary of these reports is shown on  
Table 3. 
 
  Median OS1 (n = # of pts)  
Publications Glioma type wtIDH mutIDH P-value 
Parsons2 GBM 1.1 yrs (79) 3.8 yrs (11) <0.001 
Yan3 GBM 15 (115) 31 (14) 0.002 
AA 20 (14) 65 (38) < 0.001 
Sanson4 GBM, 1o 14 (172) 27.4 (11) < 0.01 
Grade 3 19.4 (54) 81.1 (67) < 0.001 
Grade 2 60.1 (23) 150.9 (77) 0.01 
Nobusawa5 GBM, all 9.9 (186) 24.0 (17) < 0.0001 
GBM, 1o 10.0 (185) 31.6 (9) < 0.0001 
Sonoda6 GBM (1o and 
2o) 17 (57) 66 (5) 0.1 
AA 22 (8) 50 (13) 0.001 
Dubbink7 Grade 2 48 (7) 98 (42) 0.003 
1 in months except when otherwise indicated, 2 (Parsons et al., 2008), 3 (Yan et al., 2009), 4 (Sanson et al., 
2009), 5 (Nobusawa et al., 2009), 6 (Sonoda et al., 2009), 7 (Dubbink et al., 2009). 
Abbreviations: OS, overall survival; wtIDH, wild type isocitrate dehydrogenase; mutIDH, mutant 
isocitrate dehydrogenase; GBM, glioblastoma multiforme; AA, anaplastic astrocytomas; yrs, years. 
Table 3. Series reporting outcomes for glioma patients with IDH mutations. 
3.5 Factors in gliomas correlating with isocitrate dehydrogenase mutations 
Certain clinical characteristics and markers have been associated with the presence of IDH1 
mutations in GBMs. Patients with tumors harboring this mutation tend to be younger with 
an average age in the 40-50 year range versus 60+ years in patients lacking this mutation 
(Nobusawa et al., 2009). Although IDH1 mutations were associated with a younger age, 
presence of this mutation was still independently prognostic. Patients with tumors 
containing IDH1 mutations were also more likely to have a longer duration of symptoms 
consistent with a slower growing, less aggressive tumor. In addition, the presence of IDH1 
mutations appears to be associated with certain genetic abnormalities including TP53 
mutation, PTEN mutation, lack of EGFR amplification, loss of heterozygosity on 19q, and 
loss of CDKN2A/B (Nobusawa et al., 2009; Yan et al., 2009). These correlations are not 
surprising given the predominance of IDH1 mutation in secondary GBMs. However, even 
when only primary GBMs are considered, correlation between IDH mutations and TP53 
mutation/lack of EGFR amplification was maintained (Nobusawa et al., 2009). 
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histidine. Thus, a very significant selective advantage must be at play for this particular 
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mutation/lack of EGFR amplification was maintained (Nobusawa et al., 2009). 
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3.6 Isocitrate dehydrogenase mutations associate with proneural glioblastomas 
Expression profiling of a series of high-grade astrocytomas have permitted subclassification 
based on a molecular signature. Phillips et al. performed one such analysis whereby 115 
grade 3 and 4 astrocytomas were evaluated (Phillips et al., 2006). Based on their analysis,  3 
distinct subgroups termed proneural, proliferative and mesenchymal could be identified 
based on similarities in gene expression pattern. The proneural group had markedly better 
prognosis and expressed genes associated with normal brain and neurogenesis. The 
proliferative group had a poor prognosis and expressed genes in a pattern that resembled 
highly proliferative cell lines. The mesenchymal group likewise had a poor prognosis and 
expressed genes that resembled tissues of mesenchymal origin. Since this report, the 
National Institutes of Health (NIH) established The Cancer Genome Atlas (TCGA) program 
that was charged with generating comprehensive multi-dimensional maps of the key 
genomic changes in major types of cancers. GBM was chosen as the pilot disease for this 
program. The expression profiling of GBMs for TCGA also permitted classification into 
subtypes (proneural, neural, classical, mesenchymal) similar to that described by Phillips et 
al. (Fig. 4) (Phillips et al., 2006; Verhaak et al., 2010). Interestingly, IDH1 was mutated in 11 
of 37 cases (30%) of proneural GBMs with only a single case of mutant IDH1 found outside 
of the proneural group with that case being classified in the neural group (Verhaak et al., 
2010). This analysis also validated an association between mutations in TP53 and the 
presence of IDH1 mutations that had previously been noted. A subsequent updated TCGA 
report continues to show a tight association between IDH1 mutation and this favorable 
GBM subtype (Noushmehr et al., 2010). 
 
 
Fig. 4. GBM subtypes with their characteristics as classified by TCGA analysis with survival 
outcomes and associations with IDH1 and TP53 mutations. 
4. Functional consequence of isocitrate dehydrogenase mutations 
4.1 Isocitrate dehydrogenase mutants lose normal enzymatic activity 
Based on modeling studies, the side chain of R132 can form three hydrogen bonds with the 
α– and β–carboxyl groups of isocitrate while other residues within the binding site forms no 
more than two such bonds (Zhao et al., 2009). Thus, replacement of R132 is likely to impair 
 
The Role of Isocitrate Dehydrogenase Mutations in Glioma Brain Tumors 
 
421 
interactions between isocitrate and this site. In fact, this residue in IDH1 has been previously 
mutated to glutamic acid (R132E) and resulted in almost complete abrogation of enzymatic 
activity (Jennings et al., 1997). Zhao et al. show that the activity of the R132H, R132C and 
R132S mutants dropped to less than 20% of the wild type IDH1 enzyme with a 
corresponding increase in the Km for isocitrate by 60 to 94-fold (Zhao et al., 2009). Porcine 
IDH2 have also been mutated at the site comparable to R172 in human IDH2 (R133Q) and 
found to have decreased activity and increased Km for isocitrate (Soundar et al., 2000). All 
of the mutations found in IDH1 at R132 and in IDH2 at R172 have now been tested and the 
normal enzymatic activity is impaired in each case (Ichimura et al., 2009; Zhao et al., 2009).  
4.2 Possible dominant negative activity of mutant isocitrate dehydrogenase 1 
Because R132 mutations were so specific and alterations in the second allele had not been 
seen, this had the profile of an activating mutation. This hypothesis appeared to be incorrect 
with the discovery that R132 mutations resulted in loss of enzymatic activity (see section 4.1) 
(Yan et al., 2009; Zhao et al., 2009). However, since homozygous deletions or other 
inactivating mutations of IDH1/2 had not been reported, the IDH1 R132 mutations (and the 
IDH2R172 mutations) were clearly acting in a more complex fashion. This was explained to 
some extent with the report that R132 IDH1 mutants can act as a dominant negative 
inhibitor (Zhao et al., 2009). To show this, His-tagged wild type IDH1 and FLAG-tagged 
R132H mutant were purified, mixed and subjected to affinity purification using nickel resin 
and anti-FLAG beads to obtain preparations of wild type homodimer, R132H homodimers 
and wild type:R132H heterodimers. The R132H homodimer was found to have no activity 
while the wild type:R132 heterodimer had 4% of the wild type homodimer activity. While 
this result partially explained how mutant IDH1 can act as a tumor suppressor in the 
absence of deletion of its second allele, this model was still not completely satisfying. In this 
model, mutant IDH1 needs to be in great excess (although amplification/overexpression has 
never been shown) or the wild type:mutant IDH1 interactions needs to be favored over wild 
type:wild type interactions (although such differential affinity has also never been 
demonstrated). In addition, the cellular metabolite profiles of cells engineered either to 
express the R132H mutant or to suppress expression of wild type IDH1 have been assessed 
and showed very little similarity again consistent with the putative dominant negative 
function of mutant IDH1 having little if any role in vivo (Reitman et al., 2011). Finally, Jin et 
al. found that the various IDH mutants did not associate with or inhibit the activity of the 
corresponding native IDH enzyme (Jin et al., 2011).  
4.3 Isocitrate dehydrogenase mutations results in a neomorphic enzyme activity 
Based on discussion in the previous section, if these mutations at R132 in IDH1 (or R172 in 
IDH2) were activating, it would better fit the available observations. Complicating this 
assertion, though, was the fact that the normal enzymatic activity of IDH1 was severely 
hampered when R132 was mutated. This hypothesis was finally proven with the report that 
2-hydroxyglutarate (2-HG) accumulates in glioma cells that express the R132H mutant 
(Dang et al., 2010). In particular, the (R) enantiomer of 2-HG (D-2-hydroxyglutarate, D-2-
HG) was detecetd with no (S) enantiomer (L-2-hydroxyglutarate, L-2-HG) found in mutant 
IDH1-expressing cells. Like previous investigators, Dang et al. found that the R132H mutant 
lost the ability to oxidative decarboxylate isocitrate to α–KG (Dang et al., 2010; Yan et al., 
2009; Zhao et al., 2009). However, this mutant now gained a new activity, namely, the 
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interactions between isocitrate and this site. In fact, this residue in IDH1 has been previously 
mutated to glutamic acid (R132E) and resulted in almost complete abrogation of enzymatic 
activity (Jennings et al., 1997). Zhao et al. show that the activity of the R132H, R132C and 
R132S mutants dropped to less than 20% of the wild type IDH1 enzyme with a 
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IDH2 have also been mutated at the site comparable to R172 in human IDH2 (R133Q) and 
found to have decreased activity and increased Km for isocitrate (Soundar et al., 2000). All 
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NADPH-dependent reduction of α–KG to 2-HG (Fig. 1) (Dang et al., 2010). Importantly, 
coexpression of wild type IDH1 and the R132H mutant did not reduce this new enzymatic 
activity but actually appear to enhance it. This has led to the suggestion that heterodimers 
can more efficiently produce 2-HG due to higher local concentrations of α–KG and NADPH 
produced by the wild type partner (Fig. 5). The x-ray structures of wild type IDH1 and the 
R132H mutant have been compared (Dang et al., 2010; Xu et al., 2004). Overall, R132 acts as 
a gate-keeper residue orchestrating the hinge movement between an open and closed 
conformation with the histidine mutation favoring a shift to the closed conformation which 
may increase binding of a new substrate (α–KG) and cofactor (NADPH) (Fig. 5). 
 
 
Fig. 5. Representation of wild type:R132H mutant IDH1 heterodimers shifting between the 
inactive and active conformations. 
Ward et al. performed a comparable analysis of the R172K IDH2 mutant found in AMLs and 
gliomas (Ward et al., 2010). Similar to the finding of Dang et al., this IDH2 mutant also 
displayed α-KG-dependent NADPH consumption and accumulation of 2-HG within 
expressing cells and surrounding media (Dang et al., 2010; Ward et al., 2010). Interestingly, 
they also found that knockdown of both wild type IDH1 and IDH2 with siRNA dramatically 
decreased proliferative capacity of a cancer cell line (Ward et al., 2010). These findings 
provide another explanation for why the corresponding normal IDH allele is not deleted 
and actually appears to always be present with the mutant IDH allele. Finally, this study 
found a new mutant IDH2 (R140Q) that also resulted in accumulation of 2-HG in 
cytogenetically normal AMLs. R140 is also a highly conserved residue and structural 
modeling puts it immediately adjacent to R172 in the isocitrate binding site, which helps 
explain acquisition of this neomorphic enzymatic activity in R140 mutants. To date, R140 
mutations in IDH2 have not been identified in gliomas. Based on previous discussions, 
IDH1 mutations at R132 and IDH2 mutations at R140 and R172 gain similar new enzymatic 
function. However, differences must still exist between these mutations due to the observed 
disparity in distribution of IDH1 and IDH2 mutations in gliomas (ratio of ~9:1) and AMLs 
(ratio of ~2:3). One factor for this difference may lie in their respective subcellular location. 
IDH1 is primarily cytosolic and peroxisomal where NADPH is more limiting while IDH2 is 
mitochondrial where NADPH is more readily available because it can be easily 
interchanged with NADH produced by IDH3 through the action of H+-transhydrogenase 
(Sazanov & Jackson, 1994). Despite this, both mutant IDH1 and IDH2 can produce 2-HG, 
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which can readily pass throughout the cell and even be secreted, and no definite functional 
differences between the two mutant enzymes have been demonstrated. 
5. The effect of mutant isocitrate dehydrogenase on normal cellular functions 
5.1 The effect of mutant isocitrate dehydrogenase on cellular metabolism 
Mutant IDHs are clearly selected for in gliomas and AMLs. While wild type IDH1/2 have 
well-defined roles in metabolism, it remains unclear in what way expression of mutant 
IDHs will alter these various processes. One consequence of mutant IDH expression is 
decreased NADPH levels, which can potentially affect cellular biosynthetic processes such 
as lipogenesis. Similarly, depletion of cytosolic NADPH may be sensed in the cell as a low 
nutrient status leading to a response marked by increasing cellular nutrient consumption 
(eg. increase glucose transporters, increase throughput in the pentose phosphate pathway, 
etc.). These responses may provide malignant cells expressing mutant IDHs with a selective 
growth advantage. Reitman et al. have now profiled >200 metabolites in human 
oligodendroglioma cells engineered to express mutant IDH1 and IDH2 (Reitman et al., 
2011). One striking finding from this study was that the profile of mutant IDH-expressing 
cells were very similar to those of corresponding cells treated with octyl-2-HG, a cell 
permeable precursor of 2-HG. This directly implicates this mutant IDH product as a key 
component of the cellular changes seen in mutant IDH-expressing cells. The main classes of 
changes found on this study include increases in free amino acids, increases in lipid 
precursors such as glycerol-phosphates and glycerophosphocholine, depletion of TCA cycle 
intermediaries and depletion of N-acetylated amino acids such as N-acetyl-aspartate and N-
acetyl-aspartyl-glutamate, two of the most abundant compounds found in brain. Such 
widespread changes are likely a consequence of global changes in gene expression that will 
be discussed in sections 5.3-5.4 on epigenetic changes associated with mutant IDHs. 
5.2 Mutant isocitrate dehydrogenase and hypoxia signaling 
In addition to its effects on cellular metabolism, mutant IDHs may alter hypoxic response. 
Zhao et al. showed that expression of the R132H mutant in U87MG and 293T cells induced 
HIF-1α expression in a response that could be mitigated by treatment of cells with octyl-α-
KG, a cell-permeable derivative of α-KG (Zhao et al., 2009). Prolyl hydroxylase utilizes α-KG 
to hydroxylate conserved prolines on HIF-1α leading to ubiquitination and subsequent 
rapid degradation (for review, see (Semenza, 2007)). Expression of the R132H mutant can 
theoretically deplete α-KG that is needed for HIF-1α proline hydroxylation or, alternatively, 
the 2-HG product of R132H may act as a competitive inhibitor of prolyl hydroxylase 
limiting HIF-1α proline hydroxylation. Since α-KG levels in mutant IDH1-expressing cells 
generally change very little while 2-HG levels rise tremendously (Dang et al., 2010), the 
latter hypothesis was more likely to be correct. Direct evidence for this have now been 
reported by Xu et al. whereby treatment of cells with octyl-2-HG induces HIF-1α in a 
process that is reversible with concomitant treatment with octyl-α-KG (Xu et al., 2011). The 
consequence of HIF-1α stabilization is induction of HIF-dependent genes such as vascular 
endothelial growth factor (VEGF), a pro-angiogenic factor, and glucose transporter 1 (glut1), 
which can alter metabolism and nutrient consumption (Zhao et al., 2009). While this HIF-1α 
response and its consequence is certainly intriguing, it still remains unclear how much of a 
role this induction actually plays in the tumorigenic process. HIF-1α and VEGF induction 
 
Molecular Targets of CNS Tumors 
 
422 
NADPH-dependent reduction of α–KG to 2-HG (Fig. 1) (Dang et al., 2010). Importantly, 
coexpression of wild type IDH1 and the R132H mutant did not reduce this new enzymatic 
activity but actually appear to enhance it. This has led to the suggestion that heterodimers 
can more efficiently produce 2-HG due to higher local concentrations of α–KG and NADPH 
produced by the wild type partner (Fig. 5). The x-ray structures of wild type IDH1 and the 
R132H mutant have been compared (Dang et al., 2010; Xu et al., 2004). Overall, R132 acts as 
a gate-keeper residue orchestrating the hinge movement between an open and closed 
conformation with the histidine mutation favoring a shift to the closed conformation which 
may increase binding of a new substrate (α–KG) and cofactor (NADPH) (Fig. 5). 
 
 
Fig. 5. Representation of wild type:R132H mutant IDH1 heterodimers shifting between the 
inactive and active conformations. 
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found a new mutant IDH2 (R140Q) that also resulted in accumulation of 2-HG in 
cytogenetically normal AMLs. R140 is also a highly conserved residue and structural 
modeling puts it immediately adjacent to R172 in the isocitrate binding site, which helps 
explain acquisition of this neomorphic enzymatic activity in R140 mutants. To date, R140 
mutations in IDH2 have not been identified in gliomas. Based on previous discussions, 
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function. However, differences must still exist between these mutations due to the observed 
disparity in distribution of IDH1 and IDH2 mutations in gliomas (ratio of ~9:1) and AMLs 
(ratio of ~2:3). One factor for this difference may lie in their respective subcellular location. 
IDH1 is primarily cytosolic and peroxisomal where NADPH is more limiting while IDH2 is 
mitochondrial where NADPH is more readily available because it can be easily 
interchanged with NADH produced by IDH3 through the action of H+-transhydrogenase 
(Sazanov & Jackson, 1994). Despite this, both mutant IDH1 and IDH2 can produce 2-HG, 
 
The Role of Isocitrate Dehydrogenase Mutations in Glioma Brain Tumors 
 
423 
which can readily pass throughout the cell and even be secreted, and no definite functional 
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nutrient status leading to a response marked by increasing cellular nutrient consumption 
(eg. increase glucose transporters, increase throughput in the pentose phosphate pathway, 
etc.). These responses may provide malignant cells expressing mutant IDHs with a selective 
growth advantage. Reitman et al. have now profiled >200 metabolites in human 
oligodendroglioma cells engineered to express mutant IDH1 and IDH2 (Reitman et al., 
2011). One striking finding from this study was that the profile of mutant IDH-expressing 
cells were very similar to those of corresponding cells treated with octyl-2-HG, a cell 
permeable precursor of 2-HG. This directly implicates this mutant IDH product as a key 
component of the cellular changes seen in mutant IDH-expressing cells. The main classes of 
changes found on this study include increases in free amino acids, increases in lipid 
precursors such as glycerol-phosphates and glycerophosphocholine, depletion of TCA cycle 
intermediaries and depletion of N-acetylated amino acids such as N-acetyl-aspartate and N-
acetyl-aspartyl-glutamate, two of the most abundant compounds found in brain. Such 
widespread changes are likely a consequence of global changes in gene expression that will 
be discussed in sections 5.3-5.4 on epigenetic changes associated with mutant IDHs. 
5.2 Mutant isocitrate dehydrogenase and hypoxia signaling 
In addition to its effects on cellular metabolism, mutant IDHs may alter hypoxic response. 
Zhao et al. showed that expression of the R132H mutant in U87MG and 293T cells induced 
HIF-1α expression in a response that could be mitigated by treatment of cells with octyl-α-
KG, a cell-permeable derivative of α-KG (Zhao et al., 2009). Prolyl hydroxylase utilizes α-KG 
to hydroxylate conserved prolines on HIF-1α leading to ubiquitination and subsequent 
rapid degradation (for review, see (Semenza, 2007)). Expression of the R132H mutant can 
theoretically deplete α-KG that is needed for HIF-1α proline hydroxylation or, alternatively, 
the 2-HG product of R132H may act as a competitive inhibitor of prolyl hydroxylase 
limiting HIF-1α proline hydroxylation. Since α-KG levels in mutant IDH1-expressing cells 
generally change very little while 2-HG levels rise tremendously (Dang et al., 2010), the 
latter hypothesis was more likely to be correct. Direct evidence for this have now been 
reported by Xu et al. whereby treatment of cells with octyl-2-HG induces HIF-1α in a 
process that is reversible with concomitant treatment with octyl-α-KG (Xu et al., 2011). The 
consequence of HIF-1α stabilization is induction of HIF-dependent genes such as vascular 
endothelial growth factor (VEGF), a pro-angiogenic factor, and glucose transporter 1 (glut1), 
which can alter metabolism and nutrient consumption (Zhao et al., 2009). While this HIF-1α 
response and its consequence is certainly intriguing, it still remains unclear how much of a 
role this induction actually plays in the tumorigenic process. HIF-1α and VEGF induction 
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may contribute to the angiogenic phenotype seen in GBMs (for review, see (Van Meir et al., 
2010)). However, since IDH mutation is a positive prognostic factor, that would suggest that 
HIF-1α induction is not a major function of IDH mutants (Nobusawa et al., 2009; Parsons et 
al., 2008; Yan et al., 2009). This is further supported by the lack of significant tumor 
angiogenesis in grade II and III gliomas of which >70% contain IDH mutations and the lack 
of HIF-1 target gene induction in AMLs with IDH mutation (Balss et al., 2008; Hartmann et 
al., 2009; Mardis et al., 2009; Yan et al., 2009). 
5.3 Mutant isocitrate dehydrogenase is associated with a hypermethylation 
phenotype in gliomas 
Association of IDH1 mutations with the proneural GBM subtype was a key finding from the 
assessment of GBMs in TCGA based mainly on expression profiling (Verhaak et al., 2010). 
Since that project acquired a host of genetic and epigenetic information about GBMs, 
investigators also looked for other factors that may associate with mutant IDH1. This 
culminated in work that found a glioma-CpG island methylator phenotype (G-CIMP) that 
defined a subgroup of GBMs that was tightly associated with IDH1 mutations (Noushmehr 
et al., 2010). Using the Illumina GoldenGate and/or Infinium methylation array platform, 
272 TCGA GBM samples were assessed. Hypermethylation in a subset of loci was seen in 24 
samples from this group that was reminiscent of the CpG island methylator phenotype 
(CIMP) previously described in colorectal cancer (Noushmehr et al., 2010; Toyota et al., 
1999). 21 of 24 G-CIMP samples were classified as a proneural subtype and this represented 
approximately 30% of all proneural tumors. A subset of this cohort (207 samples) was then 
assessed for IDH mutations with the discovery of 18 IDH1 and no IDH2 mutations. 
Interestingly, all 18 tumors that had IDH1 mutations were labeled G-CIMP+ (18/23). 
Patients with proneural GBMs have been previously shown to have a better prognosis 
(Phillips et al., 2006; Verhaak et al., 2010). This study replicated that finding but found that 
G-CIMP positivity was an even stronger predictor of better outcomes (Noushmehr et al., 
2010). Patients with G-CIMP+ proneural tumors (n=20) had a median survival of ~4 years 
while patients with G-CIMP- proneural tumors (n=49) did no better than patients with other 
subtypes (n=184) (median survivals of ~1 year). The association between mutant IDH1 and 
G-CIMP positivity also held in grade II and III gliomas and G-CIMP positivity still predicted 
for survival in the lower grade tumors. These results have now been replicated in an 
independent set of gliomas with the presence of IDH mutations correlating more strongly 
with hypermethylation than TP53 mutation or lack of EGFR alterations (Christensen et al., 
2011). Hypermethylation of the O-6-methylguanine-DNA-methyltransferase (MGMT) 
promoter is highly associated with better outcomes in patients with GBM (Hegi et al., 2005; 
Stupp et al., 2009). Given its prognostic value, MGMT methylation testing of has become 
relatively standard in the pathologic workup of GBMs. Although MGMT was not among the 
50 most differentially hypermethylated genes on the TCGA study (Noushmehr et al., 2010), 
MGMT hypermethylation is correlated with IDH1 mutations in gliomas (Christensen et al., 
2011; Laffaire et al., 2010; Sanson et al., 2009). 
5.4 Mutant isocitrate dehydrogenase is associated with hypermethylation in AMLs 
Previously, AMLs without known genetic or molecular features were found to be 
classifiable into five distinct clusters with particular epigenetic signatures (Figueroa et al., 
2010b). Similar to the association of IDH1 mutation and G-CIMP, IDH1/2 mutations were 
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also associated with certain DNA methylation patterns in AML (Figueroa et al., 2010a). In 
fact, AMLs with IDH mutations fell primarily in two epigenetically-defined clusters that 
tended toward increased DNA methylation, which was reminiscent of G-CIMP (Figueroa et 
al., 2010a; Noushmehr et al., 2010). Hypermethylation was associated with decreased 
expression of the relevant gene in the majority of cases. Unlike GBMs where >90% of IDH 
mutations were on IDH1, mutations in AMLs are more equally distributed permitting 
comparisons in the type of methylation phenotypes that arise. Despite the IDH isoforms 
localizing to different subregions of the cell, DNA methylation profile was not significantly 
different between the two IDH mutants (Figueroa et al., 2010a). Giving more support for 
IDH mutants having a causative role in increasing DNA methylation, engineered 
overexpression of mutant IDH1 or IDH2 both leads to increased 5-methylcytosine levels 
(Figueroa et al., 2010a). A mechanism for how the DNA hypermethylation phenotype arises 
in mutant IDH-expressing cells has been proposed and will be reviewed in section 6.2. 
6. The role of 2-hydroxyglutarate in human malignancies 
6.1 Genetic disorders that result in 2-hydroxyglutarate accumulation 
With the identification of 2-HG as a novel tumor-associated metabolite, or oncometabolite, its 
effect on tumor cells has received increasing scrutiny. Two genetic defects have been described 
that involves accumulation of 2-HG and have been termed L-2- and D-2-hydroxyglutaric 
aciduria (L-2-HGA and D-2-HGA) based on which enantiomer of 2-HG accumulates (for 
reviews, see (Struys, 2006; Van Schaftingen et al., 2009)). They are rare neurometabolic 
disorders characterized by elevated 2-HG in bodily fluids including urine, plasma, and 
cerebrospinal fluid. L-2-HGA is the more common of the two. It is associated with L-2-HG 
dehydrogenase loss in virtually all cases resulting in the inability to oxidize L-2-HG to α-KG 
leading to L-2-HG accumulation. D-2-HGA is associated with either D-2-HG dehydrogenase 
loss or an R140 mutation in IDH2 both of which leads to D-2-HG accumulation (Kranendijk et 
al., 2010). L-2-HGA is the more severe of the two disorders and mainly affects the central 
nervous system with symptoms of hypotonia, tremors, and epilepsy that may progress to 
spongiform leukencephalopathy, muscular choreodystonia, mental retardation and 
psychomotor regression. Symptoms associated with D-2-HGA may be mild to nearly absent 
and include developmental delay, epilepsy, hypotonia, cardiomyopathy, and dysmorphic 
features. Interestingly, while IDH mutations result in D-2-HG accumulation, patients with L-2-
HGA, and not D-2-HGA, have been reported to have a higher risk of developing malignant 
brain tumors (Aghili et al., 2009; Haliloglu et al., 2008). Thus mutant IDH likely has other 
effects beyond just production of the oncometabolite D-2-HG. 
6.2 Inhibition of hydroxylases by 2-hydroxyglutarate 
A major breakthrough in elucidating the function of 2-HG came with the discovery that this 
metabolite can inhibit the function of the TET dioxygenases (Xu et al., 2011). Members of the 
TET family have been shown to catalyze the conversion of 5-methylcytosine to 5-
hydroxymethylcytosine (5-OH-MeC) in a reaction requiring α-KG, iron and oxygen (Ito et 
al., 2010; Tahiliani et al., 2009). While the physiologic significance of 5-OH-MeC has not been 
fully defined, it is believed to be an intermediate in the pathway that demethylates 5-
methylcytosine. Thus, TET activity will result in decreased DNA methylation with potential 
widespread changes in gene expression. The first clue that 2-HG may be interacting with 
TET was the discovery that TET2 loss-of-function mutations seen in AML was mutually 
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may contribute to the angiogenic phenotype seen in GBMs (for review, see (Van Meir et al., 
2010)). However, since IDH mutation is a positive prognostic factor, that would suggest that 
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also associated with certain DNA methylation patterns in AML (Figueroa et al., 2010a). In 
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localizing to different subregions of the cell, DNA methylation profile was not significantly 
different between the two IDH mutants (Figueroa et al., 2010a). Giving more support for 
IDH mutants having a causative role in increasing DNA methylation, engineered 
overexpression of mutant IDH1 or IDH2 both leads to increased 5-methylcytosine levels 
(Figueroa et al., 2010a). A mechanism for how the DNA hypermethylation phenotype arises 
in mutant IDH-expressing cells has been proposed and will be reviewed in section 6.2. 
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With the identification of 2-HG as a novel tumor-associated metabolite, or oncometabolite, its 
effect on tumor cells has received increasing scrutiny. Two genetic defects have been described 
that involves accumulation of 2-HG and have been termed L-2- and D-2-hydroxyglutaric 
aciduria (L-2-HGA and D-2-HGA) based on which enantiomer of 2-HG accumulates (for 
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leading to L-2-HG accumulation. D-2-HGA is associated with either D-2-HG dehydrogenase 
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features. Interestingly, while IDH mutations result in D-2-HG accumulation, patients with L-2-
HGA, and not D-2-HGA, have been reported to have a higher risk of developing malignant 
brain tumors (Aghili et al., 2009; Haliloglu et al., 2008). Thus mutant IDH likely has other 
effects beyond just production of the oncometabolite D-2-HG. 
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A major breakthrough in elucidating the function of 2-HG came with the discovery that this 
metabolite can inhibit the function of the TET dioxygenases (Xu et al., 2011). Members of the 
TET family have been shown to catalyze the conversion of 5-methylcytosine to 5-
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fully defined, it is believed to be an intermediate in the pathway that demethylates 5-
methylcytosine. Thus, TET activity will result in decreased DNA methylation with potential 
widespread changes in gene expression. The first clue that 2-HG may be interacting with 
TET was the discovery that TET2 loss-of-function mutations seen in AML was mutually 
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exclusive with IDH1/2 mutations (Of 375 cases, 57 were IDH mutants, 28 were TET2 
mutants, 0 were both IDH and TET2 mutants) (Figueroa et al., 2010a). This result suggests 
that IDH1/2 mutations and TET2 mutations have overlapping roles in AML pathogenesis. 
Forced expression of TET2 also resulted in increased 5-OH-MeC levels and this could be 
blocked by cotransfection with mutant but not wild type IDH1. Xu et al. has now shown 
that 2-HG can act as a competitive inhibitor of multiple α-KG-dependent dioxygenases 
including the TET family of 5-methylcytosine hydroxylases, histone demethylases and even 
prolyl hydroxylases (see section 5.2)  (Xu et al., 2011). Using an in vitro enzymatic assay, D-2-
HG could inhibit the activity of TET1 and TET2 reducing 5-OH-MeC in a dose-dependent 
fashion. Interestingly, L-2-HG, which is not produced by mutant IDH, was actually even 
more effective at inhibiting the TET enzymes than the (D) enantiomer (Xu et al., 2011). This 
result may partially explain why malignant brain tumors were associated with the L-2-HGA 
but not the D-2-HGA genetic disorder. 
6.3 Metabolic consequence of 2-hydroxyglutarate accumulation 
As reviewed in section 5.1, direct treatment of cells with D-2-HG results in a metabolite 
profile, or metabolome that was similar to that found with mutant IDH1/2-expressing cells 
(Reitman et al., 2011). Of the 204 assessed biochemicals, from 107 to 130 were altered either 
up or down in the R132H-expressing or 2-HG-treated cells. Of these, 64 biochemical changes 
were shared between these cells. This number was much greater than the biochemical 
changes seen when comparing the R132H-expressing and the IDH1 knockdown cells where 
only 28 biochemicals were altered similarly. Likewise, mutant IDH2 (R172K) gave a profile 
similar to the R132H mutant. While these results suggest that D-2-HG is mediating some of 
the downstream effects of mutant IDH1/2, significant differences still exist thus 
highlighting 2-HG-independent effects of the mutant IDHs. One potential difference 
between these cells is that mutant IDH1 expression leads to glutamate depletion due to its 
conversion to α-KG and 2-HG while simply treating cells with 2-HG will not deplete 
glutamate. Some of the observed differences is consistent with this explanation as decreases 
in glutamate and several metabolites that are directly or indirectly derived from glutamate 
including glutathiones, N-acetylglutamate, N-acetyl-aspartyl-glutamate, α-KG, malate and 
fumarate are seen uniquely in mutant IDH1-expressing cells (Reitman et al., 2011). 
However, this explanation does not account for all the differences seen and mutant IDH 
expression is still likely to be causing some changes in the metabolite profile that is 2-HG-
independent. These exact changes remain to be defined. The overall implication of these 
metabolite shifts on gliomagenesis is currently still largely unknown. However, there is an 
increasing recognition that changes in metabolism can have effects on tumorigenesis (for 
review, see (Vander Heiden et al., 2009)) and further research will likely begin to unravel the 
answers to these questions in the near future. 
7. Diagnostic and therapeutic considerations with isocitrate dehydrogenase 
status in gliomas 
7.1  Should routine testing for isocitrate dehydrogenase be performed? 
Currently, determining the mutation status of IDH1/2 is not part of the standard molecular 
pathologic workup of gliomas. However, this is likely to change in the near future given the 
significant prognostic information the mutation status provides. With the high incidence of 
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these IDH1/2 mutations in grade II and III gliomas (range from 66-83%) including 
astrocytomas, oligodendrogliomas and mixed oligoastrocytomas (Table 1), we would 
propose that all such tumors be assessed for these mutations. The incidence of these 
mutations is lower with GBMs so the decision to assess for such mutations remains an open 
question. Clearly, the incidence of IDH mutations in secondary GBMs is quite high, similar 
to that seen in lower grade gliomas. However, primary GBMs probably only contain IDH 
mutations in ~6% of cases (Table 1). Given this yield, we favor routine testing for IDH 
mutations in secondary but not primary GBMs. This view is based on the low potential yield 
of positive results in this GBM patient population and the fact that knowing the mutation 
status, while prognostic, will not alter the current therapeutic approach for these patients. 
However, if therapies that exploit the presence of these mutations are developed in the 
future, more comprehensive testing among all GBMs would be warranted. 
7.2 Diagnostic tests used to detect mutant isocitrate dehydrogenase status 
Determining the mutation status of IDH can be accomplished in a number of different ways. 
One standard approach is to detect for the mutant IDH protein. Currently, antibodies that 
recognize the mutant-specific epitope of the R132H IDH1 mutant have been reported 
(Capper et al., 2009; Kato et al., 2009). These antibodies have utility for western blotting of 
tumor cell lysates or immunohistochemical (IHC) staining of tumor tissue. While these 
methods utilize standard techniques familiar to pathology and molecular biology 
laboratories, they are limited by the fact that only the R132H mutant, which represents ~85% 
of IDH mutations in gliomas, can be identified (Table 2). Recently, an antibody specific for 
the altered epitope in the R132S IDH1 mutant was generated and found to be useful for 
western blotting and IHC staining (Kaneko et al., 2010). As more mutant-specific IDH1/2 
antibodies become available, these antibodies and western blotting/IHC staining may be 
used to identify almost all potential cases with IDH1/2 mutations. 
Alternatively, direct sequencing of the relevant regions in IDH1/2, or even the entire 
IDH1/2 genes, can be accomplished either from RNA or DNA harvested from the tumor. 
Improved genomic technologies have made these approaches very accessible both 
technically and costwise. Direct sequencing should theoretically provide 100% yield of 
mutations at the R132 residue of IDH1 and R140/R172 residues of IDH2. However, in 
practice, this may not be the case. Takano et al. reported their experience in comparing 
positive staining for IMab-1, an R132H-specific antibody, with results from routine direct 
sequencing of tumor DNA (Takano et al., 2010). In their study, only 9 of 12 cases detected as 
positive for expressing the R132H mutant on IHC staining turned out to be positive on 
initial screening with direct DNA sequencing. However, when the initial PCR product was 
subcloned, the IDH1-R132H could finally be detected in the three negative cases. This result 
indicates that tumor DNA was likely contaminated with a large amount of normal brain 
DNA making it difficult to detect the mutation on their initial screen. They conclude that 
IHC staining with the R132H antibody may be more sensitive than routine DNA sequencing 
for the detection of the IDH1-R132H mutant. 
Finally, a mass spectrometry approach may be taken to detect for elevated D-2-HG in tumor 
lysate. This approach should permit detection of nearly all cases of mutant IDH1/2 since the 
neomorphic enzyme activity producing D-2-HG results with every mutation detected on 
R132 of IDH1 and R140/R172 of IDH2. Techniques for the detection both enantiomers of 
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exclusive with IDH1/2 mutations (Of 375 cases, 57 were IDH mutants, 28 were TET2 
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2HG from urine or plasma using gas chromatography/mass spectrometry (GC/MS) or 
liquid chromatography/mass spectrometry (LC/MS) have been published and are routinely 
used by molecular genetics labs for the diagnosis of 2-hydroxyglutaric aciduria (Nyhan et 
al., 1995; Rashed et al., 2000). GC/MS and LC/MS have also been used by mutiple groups in 
the detection of 2-HG from media and lysates of cells grown in culture as well as of tumor 
tissue (Dang et al., 2010; Ward et al., 2010; Xu et al., 2011). These techniques should be 
rapidly adaptable for clinical use in the detection of the 2-HG metabolite in tumor lysates. 
7.3 Future directions for mutant isocitrate dehydrogenase diagnostic testing 
Because 2-HG is produced in the media of cells expressing mutant IDH1/2, this  
metabolite may be a good biomarker for detection of disease, response to therapy, and, 
potentially, long-term followup assessing for disease control. Although there are no current 
reports of this approach, mass spectrometry analysis of cerebrospinal fluid (CSF) may 
potentially be utilized for detecting 2-HG produced by gliomas of varying grades. 
Examining CSF for 2-HG have been proposed as a reliable screen for the detection of this 
tumor-specific metabolite and plans are in place to investigate this in more detail (Van Meir, 
2011). Similarly, 2-HG elevations may be detected by mass spectrometry in other bodily 
fluids such as serum or urine as alternative means of detecting for tumors that express 
mutant IDH1/2. Finally, others have proposed using magnetic resonance spectroscopic 
imaging (MRSI) as a potential approach for noninvasive detection of 2-HG within  
tumors seen on MRI (Mao, 2011). Again, while interesting, significant research on the use of 
MRSI for detection of 2-HG will need to be accomplished before clinical use can be 
contemplated. 
7.4 Therapeutic targeting of mutant isocitrate dehydrogenase status 
The specific IDH mutations is a very attractive target for therapeutic manipulations. A 
variety of therapeutics approaches can be realistically taken to target this mutation. One 
obvious approach would be to directly target the mutant enzyme. This can potentially be 
accomplished by utilizing approaches that alter the expression of the mutant enzyme or 
developing therapeutic inhibitors of its neomorphic enzyme activity. Alternatively, 
approaches that target some of the downstream effects of this enzyme activity can be taken. 
This might include counteracting the pseudohypoxic state that results from 2-HG inhibition 
of prolyl hydroxylases that induces HIF-1α, reversing partially or fully the 
hypermethylation phenotype that results from 2-HG inhibition of the 5-methylcytosine 
hydroxylases, etc. However, caution must be taken with approaches that target these 
changes since such patients have been shown to have a better prognosis than their 
counterparts without IDH mutations (Nobusawa et al., 2009; Sanson et al., 2009; Yan et al., 
2009). The main concern is that cellular changes that result from IDH mutations is actually 
driving increased sensitivity to current therapies and reversing some effects of these 
mutations may decrease response to such therapies potentially worsening patient outcomes. 
In addition, since mutant IDH1/2 is thought to mainly have a role in tumor initiation  
and not necessarily in tumor maintenance, blocking mutant IDH1/2 activity or its 
downstream consequences may not be a particularly effective therapy. Therefore, any 
potential therapeutic regimen that targets mutant IDH1/2 and/or its downstream effects 
needs to be carefully evaluated to assure that such therapies are not detrimentally affecting 
outcomes. 
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7.5 Therapeutic targeting of a metabolic dependency seen in tumors that express 
mutant isocitrate dehydrogenase 
An alternative therapeutic approach might be to target a “weakness” that results from the 
adaptation of the cell to the presence of IDH mutations. Seltzer et al. recently proposed an 
interesting idea along this line whereby they sought to target a specific metabolic 
dependency found in mutant IDH1-expressing tumors (Seltzer et al., 2010). Previous work 
had demonstrated that the predominant source of cytoplasmic α-KG for mutant IDH1 is 
glutamine (Dang et al., 2010), which is converted to glutamate by glutaminase and then to α-
KG by either glutamate oxaloacetate transaminase or glutamate dehydrogenase. They 
reasoned that inhibition of glutaminase (GLS) could severely limit the availability of α-KG 
for production of 2-HG by mutant IDH1, which could potentially have anti-tumor effects in 
mutant IDH1-expressing tumors. Exactly as predicted, inhibition of GLS either genetically 
with siRNA targeting GLS or chemically with bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-
yl)ethyl sulfide (BPTES) resulted in growth inhibition of mutant but not wild type IDH1-
expressing cells (Seltzer et al., 2010). However, this explanation does not fully resolve all 
their data since they also found that inhibition of glutamine uptake by glutamine 
deprivation did not have a similar selective effect on mutant IDH1-expressing cells. They 
speculate that the growth inhibitory effect mediated by glutaminase inhibition may be 
dictated by alteration in the balance of specific metabolites that are not altered when 
glutamine is simply limited. Overall, this novel approach provides an example of a therapy 
that can be developed to specifically target the growth of mutant IDH1-expressing tumors 
by exploiting a metabolic dependency found in these tumors. 
8. Conclusion 
Even though IDH mutations were discovered less than 3 years ago, researchers have  
already gained a wealth of knowledge about how they are functioning. It is clear that IDH 
mutants lose their normal enzymatic activity and gain a new one that results in production 
of 2-HG. As we reviewed in this chapter, 2-HG appears to inhibit a number of α–KG-
dependent hydroxylases which can have broad-ranging effects on a host of cellular 
functions. These include epigenetic changes with implications for having global effects on 
gene expression and changes in the stability of factors such as HIF-1α which can also change 
gene expression for hypoxia-related genes producing a pseudohypoxic state that may 
detrimentally affect treatment response. Researchers are probably just scratching the surface 
about the potential cellular effects of 2-HG. It is also apparent that mutant IDHs probably 
have cellular effects beyond just producing 2-HG. Many of these 2-HG-independent effects 
still remain to be determined. Currently, assessing for IDH1/2 mutations can be readily 
done in a number of ways but still only provides prognostic information. As we gain a 
greater understanding of the many cellular effects of mutant IDHs and start to link them 
with mechanisms involved in the initiation and maintenance of glial neoplasms, then more 
novel therapeutic approaches that exploit the presence of these mutations may be developed 
for these tumors.  
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1. Introduction 
1.1 Glioma 
Malignant gliomas are the most common types of brain tumors in adults. These tumors are 
highly invasive and despite multi- modality treatment, the mean survival time of patients is 
still less than a year (Machado et al., 2005). Gliomas, a cancer of glial cells constitute more 
than 90% of all primary malignant central nervous system (CNS) tumors. Although gliomas 
are the most common major subgroup of primary nervous systems tumors, their etiology is 
less well understood than is the etiology of the other two major subgroups: meningiomas 
and neuromas. The development of glioma is a complex process with the involvement of 
both oncogenes and tumor suppressor genes in the accumulation of genetic lesions (Zhang 
et al., 2005). Brain tumors arise as a result of gradual accumulation of several genetic 
aberrations in precursor cells which can occur either at the chromosomal level or at the gene 
expression level (Furnari et al. 1995). Despite considerable efforts to unravel the etiologic 
basis for this cancer and attempts to find a cure, gliomas largely remain refractory to 
treatment. Except for a small percentage of cases, the tumors continue to show high 
morbidity and mortality (Wrensch et al. 2005). The identification and evaluation of the 
cellular sites in which such genes and their encoded proteins are expressed, could help us to 
determine how those cellular expression sites are linked to the convoluted circuits of 
neurons that control brain function. To date, there is major technological challenge in the 
capability to detect and map genes whose expression is altered either by the disease’s 
process or by the cells adaptations to resist the disease’s process (Bloom et al., 2004). 
1.2 Primary culture 
Primary culture is the initial culture established from an individual which represents the 
environment most closely related to the original cell. The availability of unlimited number 
of cells and the possibility of performing multiple,  repetitive experiments over long period 
of time renders cultured tumor cells a valuable mean for preliminary assessments of new 
therapeutic agents (Bakir et al., 1998). Development of biotechnology methods including 
primary culture technique gives us the opportunity to study the malignant glioma in depth 
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in order to understand the etiology of the brain tumor especially on gene regulations and 
cellular pathway mechanisms.   
1.2.1 Primary culture: explant technique 
Primary explant technique is one of the primary culture techniques. It was the original 
method developed by Harrison (1907) and Carrel (1912), and others for initiating a tissue 
culture. As originally performed, a fragment of tissue was embedded in blood plasma or 
lymph, mixed with heterologous serum and embryo extract, and placed on a coverslip that 
was inverted over a concative slide. The clotted plasma held the tissue in place, and the 
explant could be examined with a conventional microscope. The heterologous serum 
induced clotting of the plasma, the embryo extract and serum, together with the plasma, 
supplied nutrients and growth factors will stimulate cell migration from the explant. This 
technique is still being used but has been largely replaced by the simplified method. First of 
all, the tissue is chopped finely and rinsed, the pieces are seeded onto the surface of a 
culture flask or petri dish in a small volume of medium with a high concentration of serum, 
such that surface tension holds the pieces in place until they adhere spontaneously to the 
surface. Once this is archieved, outgrowth of cells usually follows. 
1.3 Glioma primary culture 
The established glioma primary culture gives us permanent material to examine the 
expression of proteins of interest and their functional characterization in vivo and in vitro. 
For that reason, we developed our very own primary culture of the cancerous glioma from 
local clinical tumor sample so as to understand better its genetic background and cellular 
development.  Establishing primary glioma cell line in culture, the malignant cells will 
represent an excellent permanent representative material for molecular and cellular 
characterization of tumor supported with specific antigenic identification and biochemical 
characterization of cellular proliferation (Tomaso et al., 2000; Halfter et al., 1998; Pohl et al., 
1999; Grippo et al., 2001; Machado et al., 2005).  In this study, we used four well known 
antigens such as GFAP (Glial Fibrillary Acidic Protein), which has been shown to be a 
marker of glial cell origin (Zhang et al., 2005), S-100 protein which was originally identified 
as a brain specific marker (Machado et al., 2005), Vimentin which has been detected in a few 
primary cultured glioma (Bakir et al., 1998) and positive expression of BORIS protein in 
glioma (D’Arcy et al., 2006).   
1.4 Transcription factor in cancer development 
Cancer is known to be a pathophysiological condition with many different genes involved 
including transcription factor as a main. Transcription factor is a molecule that participates, 
alone or as part of a complex, in the binding to a gene’s enhancer response element or 
promoter. Transcription factors also known as regulatory proteins which have an ability to 
bind to specific DNA sequences (Nebert, 2002). Transcription factor have two separate 
protein domains called a DNA binding domain and a regulatory domain. DNA binding 
domain binds to their specific DNA binding sites and the regulatory domain modulates 
transcription. The DNA binding domain interacts with the promoters and the regulatory 
domain allows interaction with other transcription factors. The binding of the transcription 
factors activates (or  in some cases, to inhibits) transcription of the specific DNA  with the 
ultimate outcome being the up- or down-regulation of expression of that gene (Nebert, 2002, 
Theresa Phillips, 2008) which leads to the production of the gene’s end product; mainly in 
protein form or in certain circumstances without production of functional end product.  
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1.4.1 BORIS as a transcription factor and cancer testis antigen (CTA) family 
BORIS is one of the transcription factors which believed to play role in cancer development. 
Human BORIS (Brother of the Regulator of Imprinted Sites) gene maps to chromosome 
20q13.2 (Loukinov et al, 2002). This chromosome region is often amplified in many cancers 




Fig. 1. BORIS map to cancer-associated ‘hot spots’ on HUMAN CHROMOSOME 20q13. 
(Modified from Klenova et al., 2002) 
BORIS is a conserved, ubiquitous, and highly versatile 11-zinc-finger transcription factor 
involved in various aspects of gene regulation, forms methylation-sensitive insulators that 
regulate X chromosome inactivation and expression of imprinted genes. It is a multivalent 
Zinc Finger transcription factor which present only in the testis and expressed in a mutually 
exclusive manner with CTCF (CCCTC- binding factor) Zinc Finger transcription factor 
during spermatogenesis. BORIS is paralogous to CTCF and thus has the same DNA-binding 
potential, but with distinct amino and carboxy termini (Loukinov et al., 2002). Under normal 
physiologic conditions, BORIS is predominantly expressed during embryonic male germ 
cell development. However, BORIS is also expressed in tumors and cancer cell lines 
including glioma and it has been classified as a cancer-germ line or cancer-testis gene 
(Nguyen et al., 2008). Since BORIS bears the same DNA-binding domain that CTCF employs 
for recognition of methylation marks in the soma, it was identified as a candidate protein for 
the elusive epigenetic reprogramming factor acting in the male germ line (Loukinov et al., 
2002). Other than glioma, recent studies reported that BORIS is aberrantly expressed in 
various cancer cell lines including uterine cancer and breast cancer (Klenova et al. 2002; 
Loukinov et al. 2002;Hoffmann et al., 2006; Risinger et al.; 2007, D'Arcy et al., 2008).  
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Fig. 2. Exon- Intron structure of BORIS is shown. The 11 Zn fingers are positioned in exons 
E3 through E8, with several individual fingers being separated between neighbouring 
exons.  Exon 10 harbours the stop codon and a long 3'- UTR. (Klenova et al., 2002) 
BORIS has been implicated in the initiation of a series of methylation events at the 
imprinting control regions, in the vicinity of the CTCF-/BORIS-binding sites which may be 
significant for cancer development (Jelinic and Shaw, 2007). However, recent study by 
Renaud et al. (2007) reveal that the regulation of BORIS activity is complex and being both 
promoter- and cell type-dependent. Varying promoter usage driving multiple BORIS 
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the C2H2-ZF structures are shown by outlined letters in a bigger font. The near-identical 
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similar to those in the H3 and H4 histones, are highlighted in green. The experimentally 
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homologous site in BORIS, are underlined in addition to green background that shows 
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single-strand DNA and RNA (Ladomery & Dellaire, 2002). It is remarkable that the 11 ZF 
DBD regions in BORIS and CTCF are encoded by genomic sequences, which present an 
accurate duplication of a region containing all ZF-coding exons of the CTCF gene from an 
early mammal. The accuracy of this duplication in the human genome was maintained to 
the extent that genomic nucleotide similarities between CTCF and BORIS at individual 
intron–exon junctions approach 100% identity at the single nucleotide level (Loukinov et al. 
2002). Due to this shared DNA-recognition domain, BORIS can bind specifically to the same 
DNA target sequences that interact with CTCF. However, the consequences of BORIS or 
CTCF bound to the same site would be different because the amino- and carboxy-termini of 
BORIS and CTCF are totally unrelated (Klenova et al, 2002; Loukinov et al, 2002;  Campbell 
et al., 2010). And the different functional outcomes depending on which one of the two 
paralogs occupies a CTCF/BORIS-11ZF binding site (Vatolin et al., 2005). 
2. Materials and methods 
2.1 Patient and tumor 
Malignant glioma was obtained directly from the operation theater , Hospital Universiti 
Sains Malaysia Kubang Kerian, Malaysia with the permission from the Human Ethical 
Committee, Universiti Sains Malaysia (Reference number: USM/ PPSP/Ethics Com/ 2006 
(179.5(2). The sample was derived from an adult male patient with recurrent glioblastoma 
multiforme. After surgery, the sample was immediately transferred into sterile falcon tube 
and transported in ice to the laboratory for subsequent culture. The cell line has been 
successfully cryopreserved and passaged up to 32 times.  
2.2 Primary culture work 
2.2.1 Preparation of sterile complete media RPMI 1640 (50mL) 
10mL pre- warmed Fetal Bovine Serum (Sigma, USA) was poured into a sterile falcon tube 
(50mL). 1mL of penicillin-streptomycin and 100µL antibiotic cocktail (kanamycin, 
gentamycin, streptomycin, ampicillin, penicillin and chloramphenicol with total working 
concentration 50µg/ mL) (Sigma, USA) were added into the same falcon tube. Finally, RPMI 
1640 with L-Glutamine and NaHCO3 (HyClone, A Perbio Science Company) was added 
until the mixture volume became 50mL. Then, the completed media was dispensed into 
another sterile 50mL falcon tubes after filtering it through 0.22 micron (μm) membrane filter. 
The media was kept in 40C refrigerator until use. 
2.2.2 Glioma culture 
As for the primary culture technique, we chose the explant method developed by Harrison 
(1907) and Carrel (1912) for initiating the culture of clinically derived glioma tissue since it 
was a type of soft tissue and in most cases, we only managed to take out a very small 
amount. Based on local adaptation to our operation theatre (OT), we added a few extra steps 
to modify the standard explant method to reduce or to eliminate possible contamination at 
the early stage. For that purpose, the addition of antibiotic cocktail in the complete culture 
media and the pre-rinsing of the collected tissue with 70% ethanol before culturing in the 
flasks help us in achieving that goal. In addition, full cooperation from the neurosurgeons 
and OT staffs in avoiding cross contamination between surgical procedure, careful retrieval 
of the clinical sample from the patient’s brain and careful transportation of collected sample 
from the OT to our culture laboratory also helped to reduce and eliminate contamination. 
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The tumor was given a quick rinse in 70% ethanol to disinfect all the possible 
microorganisms, followed by a brief rinse in sterile 1x PBS (Sigma, USA) to wash out the 
ethanol and also the blood. The tumor was then placed in a sterile petri dish filled with 
complete culture media and minced into fragments sized 1-2 mm by using a sterile blade in 
sterile complete medium RPMI 1640 with L-Glutamine and NaHCO3 (refer to 2.2.1). The 
fragments were then layered on the bottom of plastic flasks (25 cm2) and 3mL of the 
complete medium was poured gently into the flask to avoid detachment of the tissue 
fragments. The culture was incubated at 37oC in a humidified atmosphere of 5% CO2 for 
about 5-7 days (Figure 1). Once the cells had migrated out and attached to the bottom of the 





Fig. 4. Primary cell culture; steps in processing the clinical samples. (A) Materials used to 
culture clinical tissues   (        ); i- 70% ethanol to disinfect the tissues; ii- sterile PBS to rinse 
the tissues; iii- complete media RPMI 1640 wherein tissues been minced  to small pieces. (B) 
Minced tissues transferred into cell culture flask with complete media RPMI 1640. (C) 
Volume of the complete media RPMI 1640 sufficient for the minced tissue contact to the 
bottom of the inner flask surface. (D) Labeled flask is ready to be placed in humid CO2 
incubator 
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When the primary culture reached confluence the cells were sub-cultured by treatment with 
0.05% trypsin and 0.02% EDTA and maintained in the same medium. Subsequently the 
cultures were serially sub-cultured using the same procedure. Large quantities of this 
glioma cells were routinely frozen at various passage levels in 95% fetal bovine serum plus 
5% DMSO (v/v) for future use. 
2.3 Image analysis work: phase contrast microscopy  
The cellular glioma cultured cells at various passages were grown in sterile cell culture 
flasks. The cultured cells were observed and photographed using an inverted microscope 
fitted with a camera (Axiovert 25 ZEISS with 0.5 X magnifier software evolution LC Kit and 
Image Pro- Express software). 
2.4 Confirmation of cell line establishment based on marker antigen 
2.4.1 ProteinExpression: SDS-PAGE & western blotting 
The human malignant glioma cells were cultured in 75cm2 flasks. Subconfluent tumor cells 
were collected after incubation with 0.25% trypsin and 0.02% EDTA, and washed once with 
pre- cooled PBS. The neutralization of the trypsin was done by the addition of pre-cooled 
complete medium. The detached cells suspension was spun down by centrifugation at 
1500rpm for 5 minutes. The supernatant was discarded and the pellet was washed with pre-
cooled sterile 1x PBS. Following centrifugation, the supernatant was discarded and the 
pellet was lyzed with pre- cooled radioimmunoprecipitation assay (RIPA) buffer (0.4 M 
NaCl, 50 mM Tris pH 7.5 (by HEPES), 1% NP- 40, 0.1% SDS, 0.1% Na deoxycholate, 1mM 
EDTA, 1mM PMSF ) overnight at 4oC . The next day, the suspension was spun at 10, 000 
rpm for 20 minutes at 4oC and the supernatant was then extracted. Protein samples with 
concentration of approximately 0.72 mg/mL were mixed with an equal volume of 2x 
loading dye/ treatment buffer and then heated at 950C for 5 minutes. Samples were 
electrophoresed in gradient (12.5% and 10%) SDS-PAGE. Once electrophoresis was 
completed, the proteins were visualized either by staining with commasie blue or by 
western blotting. SDS- PAGE used in this study was a modified of Laemmli system 
(Laemmli, 1970).  
After electrophoresis, gels were electroblotted onto the PVDF membrane (MILLIPORE 
Immobilon P- Transfer membrane). The membrane was treated with 5% skim milk for 1 
hour. After washing with the washing buffer, the membrane was then incubated with 
primary antibody; GFAP (abcam), Vimentin (abcam) or BORIS (Santa Cruz) for 1 hour at 
room temperature. Following three times (5 minutes each) washes in washing buffer, the 
membrane was treated with anti- mouse or anti- rabbit immunoglobulin antibody 
conjugated with Horse-Radish Peroxidase (HRP) for 1 hour at room temperature. A final 
wash was performed, and the membrane was equilibrated with detection buffer ECL 
solution (Immobilon Western Chemiluminescent HRP Substrate) for about 3 minutes and 
the membrane was placed in developing folder on the hypercassette (Amersham Life 
Science). In the dark room, the film (Kodak X- Omat LS Film Sigma- Aldrich) was exposed 
to the membrane for about 10 minutes before it was developed accordingly. 
2.4.2 Immunocytochemistry 
Immunocytochemical analysis of neuron- glial markers ( Beta III- Tubulin, MAP2, 
Oligodendrocytes and GFAP) were performed using specific antibodies purchased ; neuron- 
glial cell marker sampler kit from Millipore, Chemicon whereas the other glial markers (S-
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100 and vimentin) and BORIS were performed using specific antibodies purchased from 
Abcam and Santa Cruz respectively. IHC Select HRP/ DAB (Millipore, Chemicon) kit was 
used as the secondary antibody system in this analysis.  
Briefly, cultured glioma cells were harvested at a specific passage, trypsinized and cultured 
in new chambered slides. When the cells in each chamber reached semi confluent, the 
medium was discarded, washed with sterile 1X PBS plus 0.05% tween 20. The slides were 
then fixed in cold methanol for 20 minutes at 4o C. After a thorough wash with  0.05% tween 
20 in 1X PBS, the cells were treated with all of the above primary antibodies according to the 
manufacture's instructions. The bound primary antibody was detected using peroxidase 
labeled polymer conjugated to either mouse or rabbit secondary antibodies. Subsequently, 
the slides were incubated with a substrate mixture of 3, 3- diaminobenzidine (DAB) and 
0.02% H2O2. Cells were then counterstained with haematoxylin. Negative control slide was 
also included by omission of the primary antibody. 
2.5 Growth curve 
Glioma cells were collected from the 16th passage for determination of growth curves. 
Briefly, semi confluent cultures were trypsinized and cells resuspended in complete 
medium for counting. Cells (1 × 104) were plated into each well of a 12-well plate and counts 
from triplicate wells were made daily for 8 days. Trypsinized cells were counted in 
haemocytometer chamber and numbers were averaged for each time interval. Cell 
population doubling time was calculated from the linear phase of the growth curve, and the 
saturation density was the plateau point on the growth curve after the linear growth phase. 
2.6 Real-time PCR analysis 
Total RNA from cell lines (~1x107 cells) were extracted using RNeasy Mini Kit (Qiagen, 
Germany) and checked for concentration, integrity and purity.  Two microgram of total 
RNA was reverse transcribed into cDNA using Revert Aid H Minus First Strand cDNA 
Synthesis Kit (Fermentas, USA). The BORIS primers and probe were the same as previously 
published by D’Arcy et al., (2006); the sequences (64bp) were as follows, forward: 5’-
CCCATTGTGCCACCATCA-3’, reverse: AGCATGCAAGTTGCGCATAT--3’, and probe: 
6FAM-ACGGAAAAGCGACCTAC-MGB; they were purchased from Applied Biosystems, 
USA.  Real-time PCR analysis with optimal condition was performed using Taqman probe 
Master Mix (ABI, USA) via Applied Biosystems 7500 Real-Time PCR System (USA). The 
Real-time PCR products were also subsequently subjected to 2% agarose gel electrophoresis 
for the confirmation of PCR amplicons. 
3. Results and discussion 
Working in a high humidity and tropical condition exposed our clinical sample to bacterial 
and fungal contamination. Indeed, it is one of the constraints in the establishments of any 
primary tumor culture taken from a clinical source. We established an antibiotic cocktail that 
we used in our initial complete media which consists of amphotericin B (fungizone), 
gentamycin, chloramphenicol, kanamycin and ampicilin. The concentration of the cocktail 
used in this study varies depending on the severity of contamination in the initial condition 
of our clinical samples. A referral to a comprehensive pharmacology guide for antibiotic-
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cellular incompatibilities information was very important when we were using two or more 
antibiotics in the same culture system because combined antibiotics frequently exert 
cytotoxic effects at lower concentrations than those indicated as appropriate for the 
individual antibiotics (Sigma-Aldrich.inc). In this case, we have started the cocktail addition 













Fig. 5. Morphology of the clinical derived glioblastoma multiforme primary cell line at the 
initial stage; Attached tissue fragment (          ). (A) 10 X magnification; (B) 20 X 
magnification; and (C) 40 X magnification. 
 




















Fig. 6. Morphology of the clinical derived glioblastoma multiforme primary cell line at passage 1; 
rounded cells and dendritic-like cells with extensive cytoplasmatic prolongations (        ).  
(A) 10 X magnification; (B) 20 X magnification; and (C) 40 X magnification. 
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cytotoxic effects at lower concentrations than those indicated as appropriate for the 
individual antibiotics (Sigma-Aldrich.inc). In this case, we have started the cocktail addition 













Fig. 5. Morphology of the clinical derived glioblastoma multiforme primary cell line at the 
initial stage; Attached tissue fragment (          ). (A) 10 X magnification; (B) 20 X 
magnification; and (C) 40 X magnification. 
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Fig. 7. Confluent monolayer of the clinical derived glioblastoma multiforme primary cell 
line with rounded and dendritic-like cells. (A) 10 X magnification; (B) 20 X magnification; 
and (C) 40 X magnification. 
Variable morphological features could be found in the glioblastoma multiforme cells i.e 
small rounded cells and dendritic- like cells with extensive cytoplasmatic prolongations 
(figure 2, figure 3 and figure 4). Our finding was in agreement with other works in literature 
that showed evidences suggesting that some types of cancers, notably solid tumors,were not 
homogeneous in their cell composition but are composed of heterogeneous cell types 
(Bigner et al.,1979, 1981; Perzelova et al., 1998; Grippo et al., 2001; Machado et al., 2005). 
Similar morphological features were observed throughout serial passages, as described. This 
tumor cell line presented features of malignant glioma characterized by cell pleomorphism, 
necrosis and aggressive growth (Machado et al. 2005; Grippo MC et al. 2001). Low passage 
cultures grew slower than high passage cultures. This fact could indicated a perfect 
adaptation of cells to the culture conditions. This cell line would be useful for testing 
potential anticancer agents either in vitro or in vivo.  
 





Fig. 8. Western Blotting of the clinical derived glioblastoma multiforme (rGBM) primary cell 
line. 
Western blotting of total lysate of DBTRG-05MG (ATCC derived glioma) and primary 
culture cell glioblastoma multiforme (rGBM) separated in SDS-PAGE and probed with: 
(A) α-BORIS  polyclonal  (dilution 1:500). The presence of BORIS  is indicated by red 
arrow at ~76 kDa for both  DBTRG-05MG and rGBM. 
(B)  α-GFAP monoclonal  (dilution 1:500). The presence of GFAP is indicated by red 
arrow at ~50 kDa to  ~57kDa for  both  DBTRG-05MG and rGBM. 
(C)  α-Vimentin monoclonal  (dilution 1:500). The presence of vimentin  is indicated 
by red arrow at ~50 to ~57 kDa for both DBTRG-05MG and rGBM. 
Western blot analyses showed strong expression for BORIS protein (figure 8, A). BORIS is a 
CTCF paralog, which contains all eleven zinc fingers of CTCF, and has been shown to 
promote cell growth leading to transformation (Loukinov et al., 2002). One mechanism of 
action by which BORIS is thought to cause cancer through interference is the maintenance of 
an appropriate methylation pattern in the genome (Klenova et al., 2002). The detection of 
BORIS protein in glioblastoma multiforme suggested its potential as an early marker of this 
type of glioma since BORIS has been reported as an early tumor marker in breast cancer 
(D’Arcy et al., 2006). Western blot analysis also showed that the glioblastoma multiforme 
cell line retains the expression of GFAP (figure 5, B) which is a reliable marker of astrocytic 
cells (Moore 1965; Machado et al., 2005). However,literature has shown a negative 
correlation between the degree of malignancy and the expression of GFAP protein in the 
majority of human gliomas (Machado et al., 2005). We also showed that vimentin which has 
been identified in some human glioma cell lines (Roessmann et al., 1983; Rutka et al., 1998) 
was also detectable in this glioma cell line (figure 8, C). Machado et al., 2005 claimed that the 
effect of vimentin filaments on the invaginations or folding in the nucleus is not absolute 
and raised the possibility that this nuclear configuration could be an indirect effect of a 
metabolic difference between cells that contain or lack organized vimentin filaments. To all 
appearances, ours and previous study results indicated that the absence or presence of an 
organized vimentin filament network do not affect the shape of the cell. However, 
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interestingly S100 protein that was originally identified as brain specific (Moore, 1965) and 
believed to be expressed in a few types of gliomas was not identified in this cell line. But 
still, literature has shown a negative correlation between the degree of malignancy and the 
expression of GFAP and S100 protein in the majority of human gliomas (Jacques et al., 1981; 
Duffy et al., 1982).  
 
 
Fig. 9. Immunocytochemical staining in glioma cell line (glioblastoma multiforme) at 
passage 6 to passage 17 at 5 x magnification. Note the immunopositive staining for (A) 
BORIS, (B) GFAP and (C) B- tubulin. On the other hand, cells were S-100- negative stained 
(D). The negative control is the slide that stained with secondary antibody only. 
Immunopositive (figure 9) and western blotting results for BORIS indicates that the tumor-
antigenic polypeptide is expressed in the glioma cell lines. These results suggest that BORIS 
might play an important role in regulating the tumorigenesis pathway. And if that persists, 
BORIS can be manipulated as a biomarker in detecting the presence of tumoric condition in 
glial cells in an uninvasive way and at the very early stage. Deeper understanding of the 
place and the role of BORIS in that exact molecular pathway, gave us a good chance in 
preventing or disrupting the tumorigenesis pathway. This could lead to the application of 
genetic therapy in treating glioma patients. Understanding and moving towards that goal, 
require us to study deeper and not just stop at this preliminary study. This cell line showed 
negative expression of MAP-2, a neuron-marker which suggests that the tumor cell line is 
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not originated from neuron cell and the negative expression of oligodendrocytes suggested 
that the cells absolutely not oligodendrocytes.  
The newly established cells entered into an exponential growth phase at the 16th passage, 
when the cells grew aggressively in the culture. The high growth rate was observed for 
these successive passages when the population doubling time of the glioblastoma 
multiforme cell line was about 6 hrs at 37°C and the saturation cell density was reached at 
3.3 × 105 cells/cm2 (graph 1). The cells showed continuous progressive growth until day 7 
without showing any sign of senescence. On the other hand, the growth kinetic of the 
DBTRG-05MG cells, used as a reference cells in this study, achieved population doubling 
time of approximately 34 to 41 hours. The saturation density of the cells reached 8.3 X 105 
cells/ well (Kruise et al., 1992). 
In comparison, DBTRG-05MG the well known established glioma cell line, introduced by 
Kruse et al. in 1992, showed rounded and spindle shape cells with fibroblast-like cells 
(figure 7).This is exactly different with our newly established clinically derived glioma but 
the heterogeneity of the morphology was in parallel with most studies done in glioma 
cells. 
The study of characterization of the ATCC derived cell line also revealed positive expression 
of BORIS, GFAP, Vimentin (figure 8) and S100 proteins (Kruise et al., 1992). This profiling 
was in parallel with our newly established glioma cells with the exclusion of S100 protein. 
Figure 9 (D) showed our newly established cells immunonegative for S100 protein. The 
comparison of protein expression in both DBTRG-05MG the ATCC derived glioma cell line 

























Graph 1. Growth kinetic of glioblastoma multiforme cell line for passage 16 (linear graph) 
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Fig. 10. Morphology of DBTRG-05MG (ATCC derived glioma cell line) under phase contrast 







Fig. 11. Immunopositive of BORIS in DBTRG-05MG ATCC derived cell line. The negative 
control is the slide that stained with secondary antibody only (not shown). 
 





Clinically derived glioma 
(this study) 
ATCC derived glioma 
(DBTRG-05MG) 
BORIS + +    (Kruise et al., 1992) 
GFAP + +   (this study) 
Vimentin + +   (Kruise et al., 1992) 
S100 - +   (Kruise et al., 1992) 
Table 1. The summary of protein studies based on immunocytochemistry and western 
blotting assay for established glioma cell line in comparison with the ATCC derived glioma 
cell line (adapted from Kruise et al., 1992). 
 
 
Fig. 12. Amplification plots of BORIS mRNA expression using Taqman probe master mix. 
The result showed that BORIS mRNA was unexpressed in DBTRG-05MG (ATCC derived 
glioma), ATCC derived normal osteoblast, ATCC derived normal glial cell lines and in no 
template controls (A). BORIS mRNA was expressed in positive control osteosarcoma U2OS 
cells (ATCC derived) detected at ~38 cycles (B). 
The expression of BORIS mRNA was not found in DBTRG-05MG ATCC derived glioma cell 
line (Figure 12) although we observed the positive expression of BORIS protein in the same 
sample. Recently Hines et al., 2010 has reported that BORIS mRNA was not expressed in 
most human breast cancer cell lines and tumors.  Furthermore expression of BORIS mRNA 
showed no significant difference between normal and prostate cancer tissues overall and no 
relationship was seen to clinical parameters (D’Arcy et al., 2006). This strengthened the 
study done by Renaud et al., in 2007 that BORIS involved in complex mechanism and it is 
promoter dependent gene. Therefore, at this stage we expected the undetected expression of 
BORIS mRNA in our newly established clinically derived glioma primary cell line with 
positive expression of BORIS protein in the same clinical derived sample.   
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We established our glioblastoma multiforme cell line with the basic characteristics including 
the morphology study, surface antigen profile, protein study and also the growth analysis. 
This cell line which was derived from our clinical sample would be useful for studies on the 
molecular basis of malignancy and progression of glioma as well as in studies of glioma 
treatment. BORIS has been shown to be expressed in our glioma primary cell line. This 
study has strengthened the suggestion of a previous study (D’ Arcy et al., 2001) where 
BORIS could play an important role in the early diagnosis of glioma which requires further 
study with consideration of its complex behaviour in cancer development as well as the 
splice variants in promoter dependent gene. 
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1. Introduction  
MicroRNAs (miRNAs or miRs) are a class of small noncoding RNAs of 19~22 nucleotides, 
and repress protein expression at the posttranscriptional level through imperfect or perfect 
base pairing with 3`untranslated region of the target mRNA in mammalian cells, leading to 
its reduced translation or mRNA degradation. Although miRs are thought to be involved in 
various biological processes, including development, differentiation, cell proliferation, cell 
death, and so on, accumulating evidence suggests that alterations of their expression may 
play a role in the development of human cancers(1-4). Specific miRNAs have been 
demonstrated to be deregulated in diverse cancer subtypes including lymphoma, colorectal 
cancer, lung cancer, breast cancer, papillary thyroid carcinoma, hepatocellular carcinoma, 
and glioblastoma(5-13). Ciafre et al. used microarray method to compare the global 
expression levels of 245 miRNAs in glioblastoma tissue with normal brain tissue and found 
that the expression of miR-221 was strongly upregulated in glioblastoma cells. They 
identified nine overexpression miRNAs including miR-221 and miR-222(miR-221/222) 
cluster (13). This chapter review how miR-221/222 cluster regulated glioma cell phenotype 
and it`s mechanism. 
2. miR-221 and miR-222 cluster regulated glioma cell phenotype and it`s 
mechanism 
In Ciafre study, they found that miR-221 and miR-222 overexpress in glioma tumor tissue 
and glioma cell line compare to normal brain tissue, as well as our microarray results. So, 
we question what biogenesis of miR-221 and miR-222 and this cluster miRs function. 
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2.1 Biogenesis of miR-221 and miR-222 and this tow miRs location 
MiR-221, miR-222 genes are clustered chromosome Xp11.3 in tandem. When zhanglilei 
research retinitis pigmentosa, they discover miR-221 and miR-222 genes. Two miR genes are 
located near the telomeric end of deletion ~700bp apart(mir-221：45,361,839-45,361,948 and 
mir-222：45,362,675-45,362,784) (14). Like some other clustered miRNA genes, two miRNA 
genes is high similariry in sequence and they might be transcribed as polycistrons (Fig 1). 
 
 
Fig. 1. A schematic representation defines the miR-221 and miR-222 sequences (arrow 
indicates identical seed sequences AGCUACAU as shown in GeneDoc, 
www.psc.edu/biomed /genedoc). 
As well as the other miRs, biogenesis of miR-221 and miR-222 are a multi-step process 
beginning with transcription by RNA polymerase Ⅱ of a primary transcript, called pri-
miRNA. This precursor is cleaved to form a 70nt long stem-loop precursor RNA(pre- 
miRNA) by an RNAse Ⅲ type endonuclease called Drosha inside the nucleus. RanGTP 
exportin 5 transports pre- miRNA to the cytoplasm, where another RNAse Ⅲ, Dicer, cleaves 
the stem-loop structure to produce 19~23 nucleotide miRNA duplexes. That one of the two 
RNA strands is then included into the RNA-induced silencing complex(RISC) form 
asymmetric RISC assembley. Asymmetric RISC assembley is also called miRNP. It inhibit 
translation or mRNA degradation by miRNA complete pairing or incomplete pairing with 
mRNA 3`UTRs.(15-17) 
2.2 miR-221 and miR-222 cluster regulated glioma cell phenotype in vitro 
We already proved that miR-221 and miR-222 upregulted in glioma compared to normal 
brain tissue, and knowed this two miRs biogenesis and location in chromosome. 
Furthermore, we ready to research how the cluster miRs affect glioma cell phenotype, 
including proliferation, cell cycle, apoptosis, invasion and radiosensitivity, in vitro. 
Our previous work identified that a functional overlap between miR-221/222 in modulating 
glioma cell phenotype. So, we knocked down or ectopic express miR-221/222 to study their 
function. Firstly, by northern blot, it is identified that pMSCV-miR-221/222 increased miR-221 
and miR-222 level and anti-miR-221/222(AS-miR-221/222 or As-miR-221/222) knocked down 
miR-221 and miR-222 level (not show).By MTT assay, the glioma U251 cell proliferation rate in 
different transfected cells was measured. It was shown that the cells transfected with anti-miR-
221/222 were proliferated at a significantly lower rate than the other three groups (Figure 2). 
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Moreover, the cells transfected with pMSCV-miR-221/222 proliferated at a significantly higher 
rate than the control and the scramble groups (Figure 2). These data demonstrated that the 
growth rate of glioma cell could be co-modulated by miR-221 and miR-222. The result were 
also proved in the other tumors. Agami R et al found that miR-221 and miR-222 promote 
cancer cell proliferation(18). Frenquelli M et al also identified that miR-221 and miR-222 
promote cancer cell proliferation in chronic lymphocytic leukemia(19). The same result were 
also proved in human prostate carcinoma cell lines, human thyroid papillary carcinomas, 
human colorectal carcinoma, and so on(20-22).  
 


































Fig. 2. As-miR-221/222 decrease cell proliferation. MTT assay show that the cells transfected 
with As-miR-221/222 were proliferated at a significantly lower rate than the other four 
groups. The latitudinal axis represented days after cell implantation in the 96-well plate. The 
cell proliferation rate in parental U251 glioma cells was presented as 100%.  
The cell cycle distribution and cell apoptosis were analyzed by flow cytometry. The cell 
cycle distribution showed that the G0/G1 phase percentage of control, scramble treated cells 
was 28.6%, 26.0%, respectively; while the fraction of anti-miR-221/222 treated cells was 
46.2% and the fraction of pMSCV-miR-221/222 treated cells was 22.3%. The S phase fraction 
in control, scramble treated cells, anti-miR-221/222 treated cells, pMSCV-miR-221/222 
treated cells was 56.8%, 57.2%, 26.8%, 60%, respectively. No statistical significance of G2/M 
phase percentage was detected among the four groups (Fig. 3). Frenquelli M et al also 
identified that miR-221/222 promote cancer cell into S phase in chronic lymphocytic 
leukemia. They synchronized cells in the G1 phase and analyzed by flow cytometry the cell-
cycle distribution at 4, 6, and 24 hours after cell-cycle block release. The result document that 
miR-221– and miR-222–transduced cells progressed more quickly through the cell-cycle 
phases (19). The same result was also proved in human prostate carcinoma cell lines, human 
thyroid papillary carcinomas, human colorectal carcinoma, and so on (20-22). 
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Fig. 3. Co-suppression of miR-221/222 expression by as-miR-221/222 induce G1 arrest in 
U251 cell. Transfected and control cells were harvested by trypsinization, washed and fixed 
overnight. Nuclei of cells were stained with propidium iodide, a total of 10,000 nuclei were 
examined. By flow cytometry analysis, the rate of cell in G1 in anti-miR-221/222 group was 
higher significantly than the other four groups. 
Moreover, miR-221 and miR-222 inhibit glioma cell apoptosis. To examine biological 
significance of miR-221 and miR-222 in glioma, glioma U251 cells were treated with anti-
miR-221 /222. Interestingly, annexin V-labeling revealed that knockdown of miR-221 and 
miR-222 significantly increased cell apoptosis compared to the cells treated with scramble 
oligonucleotide (Fig. 4). In addition, caspase 3/7 activity was also considerably elevated in 
miR-221 and miR-222 knocked down cells (Fig. 5). Since collapse of the mitochondrial 
membrane potential is one of the early events in apoptosis (23), we next examined whether 
miR-221 and miR-222 regulate mitochondrial membrane potential. The cells with depletion 
of miR-221 and miR-222 were stained with cationic dye JC-1. FACSCalibur analysis showed 
that the mitochondrial membrane potential was largely damaged when miR-221 and miR-
222 were depleted (Fig. 6). These findings indicate that miR-221 and miR-222 play an 
important role in initiation of cell apoptosis(24). 
 






Fig. 4. Annexin V analysis showed that U251 cells transfected with As-miR-221/222 








































Fig. 5. Caspase 3/7 activity was considerably elevated in miR-221 and miR-222 knocked 
down cells compared to the other three group. 
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Fig. 5. Caspase 3/7 activity was considerably elevated in miR-221 and miR-222 knocked 
down cells compared to the other three group. 
 




Fig. 6. U251 cells transfected with As-miR-221/222 showed a significantly greater collapse in 
mitochondrial membrane potential compared with the other four groups. 
Furthermore, Garofalo M et al proved that miR-221/222 modulated TIMP3 expression by 
binding it`s 3`UTR (25). Whether miR-221/222 modulated TIMP3 expression to affect 
glioma cell invasion or not. To further explore the role of miR-221/222 in cell invasion, we 
performed gain-of-function and loss-of-function analyses by over-expressing or suppressing 
miR-221/222 with anti-miR-221/222 or pMSCV-miR-221/222, respectively. Interestingly, 
the transwell assay revealed that knockdown of miR-221/222 significantly decreased cell 
invasion potential compared with cells treated with scrambled oligonucleotide, whereas 
over-expression of miR-221/222 increased cell invasion (Fig. 7). Consistent with the results 
of the transwell assay, in the wound healing assay, repression of miR-221/222 significantly 
inhibited cell migration, while over-expression of miR-221/222 increased migration in U251 
cells (Fig. 8). Therefore, miR-221 and miR-222 are required for glioma cell invasion. 
In addition to modulating proliferation, cell cycle, apoptosis and invasion, whether miR-221 
and miR-222 regulated glioma cell radiosensitivity or not. To test this hypothesis, we 
transfected AS-miR-221/-222 into U251 cells, then preformed the colony formation assay to 
elevated radiosensitivity. Figure 9 shows the survival curves for U251 cells transfected with 
control, anti-miR-221/-222, and scrambled oligonucleotides and then exposed to IR over a 
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transfected with AS-miR-221/-222 was 1.97 (Table 1) (p < 0.01 compared to the controls), 
indicating a radiosensitization potential for targeting miR-221/-222. Collectively, these 
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Fig. 9. miR-221/-222 knockdown leads to an increase of radiosensitivity. U251 cells stably 
transfected with control, AS-miR-221/-222, or scrambled ODN were exposed to 0 to 6 Gy IR 
and incubated for 2 weeks prior to fixation, staining, and assessment of colony formation. 
The clonogenic survival assays were performed in triplicate. Standard errors of the mean are 
shown by error bars. 
 
 
Abbreviations: D0 = dose to reduce survival to 37% of its value; SF2 = surviving fraction at 2 
Gy; SER10 = sensitizer enhancement ratio at 10% survival.* p<0.01. 
Table 1. Radiosensitizing effects of respective cell lines 
 
 
Fig. 10. SLDT assay showed that the functional GJIC in AS-miR-221/222 treated U251 cells 
were re-established, lucifer yellow was transferred to multiple rows of cells nearby the 
scrape border. 
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In addition, by Scrape loading and dye transfer (SLDT) assay, we found that miR-221 and 
miR-222 also regulated gap junction intercellular communication (GJIC) of glioma cell. 
2.3 miR-221 and miR-222 cluster promote glioma growth in vivo 
In vitro, miR-221/222 modulated glioma cell growth by regulating cell cycle, apoptosis, and 
invasion, and so on. Whether these results are right or not in vivo. Ciafre et al firstly proved 
that the anti-miR-221/222 antagomir treatment of established subcutaneous tumors derived 
from the highly aggressive PC3 cell line, naturally expressing high levels of miR-221/222, 
reduces tumor growth by increasing intratumoral p27 amount; this effect is long lasting, as 
it is detectable as long as 25 days after the treatment(26). We used 5-week-old female 
immune-deficient nude mice (BALB/C-nu) to perform related experiment. It were housed 
in microisolator individually ventilated cages with water and food. All experimental 
procedures were carried out according to the regulations and internal biosafety and 
bioethics guidelines of Tianjin Medical University and the Tianjin Municipal Science and 
Technology Commission. U251 glioma subcutaneous model was established as previously 
described (27). When the volumer of the subcutaneous tumor reached 50 mm3, the mice 
were randomly divided into four groups (ten mice/group). A mixture of 5 μl 
oligonucleotides containing Scr, AS-miR-221, AS-miR-222 or equal mount of AS-miR-
221/222 cluster and 10 μl Lipofectamine was injected into the xenograft tumor model using 
a multi-site injection manner. Mice in U251 control group received 10 μl of PBS only. 
Treatment was conducted one time every three days and five times in all (Please confirm if it 
is correct). The tumor volume was measured with a caliper every two days, using the 
formula volume = length × width2/2. 
Fluorescence in situ hybridization proved that As-miR-221 and As-miR-222 efficiently and 
specifically silenced endogenous miR-221 and miR-222, respectively, in xenograft tumor in 
vivo (Figure 11).Moveover, we have found that transfection of U251 cells with As-miR-
221/222 mediated significant inhibition of tumor growth in a xenograft tumor mouse model 
(Figure 12). Tumor pathological examination of xenograft tumors demonstrated that, in 
control and scramble group, more neonatal micro-vessels, bigger tumor cell nucleus, deeper 





Fig. 11. Tumor pathological section of xenograft tumors show that miR-221 and miR-222 
expression were knocked down by As-miR-221/222 in vivo by fluorescence in situ 
hybridization . 
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observed than in As-miR-221/222 treatment group (Figure13). All these morphological 
changes among the three different treated groups indicate that the xenograft tumor without 
effective As-miR-221/222 therapy can perform relative more malignant pathological 
manifestation. TUNEL assay analysis of xenograft tumor taken at 28 days after treatment 
revealed much more apoptosis in As-miR221/222 group when compared to tumors from 
scramble and control groups (Figure14). Also, the As-miR-221/222 treated tumors had a 
lower level of Ki-67 expression compared to the other four groups group. Tumor 
immunochemistry examination of xenograft tumors demonstrated that some protein 
expression level in As-miR-221/222 group was up-regulated significantly than the other 
four groups, such as p27, puma, PTEN, TIMP3, and so on. Some protein expression levels in 
As-miR-221/222 group was down-regulated significantly than the other four groups, such 












Fig. 12. Transfection of U251 cells with As-miR-221/222 mediated significant inhibition of 
tumor growth in a xenograft tumor mouse model. 
 












Fig. 13. Tumor pathological examination of xenograft tumors demonstrated that, in control 
and scramble group, more neonatal micro-vessels, bigger tumor cell nucleus, deeper blue 
staining chromosome, more mitotic tumor cells and lesser necrosis focuses were observed 











Fig. 14. TUNEL assay revealed much more apoptosis in As-miR221/222 group when 
compared to tumors from scramble and control groups. 
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Fig. 15. Tumor immunochemistry examination of xenograft tumors demonstrated that some 
protein expression level in As-miR-221/222 group was up-regulated significantly than the 
other four groups and the other proteins expression level in As-miR-221/222 group was 
down-regulated. 
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2.4 The mechanism on miR-221 and miR-222 cluster modulate glioma cell malignant 
phenotype  
MiRs repress protein expression at the posttranscriptional level through imperfect base 
pairing with 3`untranslated region of the target mRNA in mammalian cells, leading to its 
reduced translation in order to affect cell function. That is, function of miRs depend on 
function of it target. So, it is necessary to identify targets of miRs. Bioinformatic analysis is 
the most effective approach to study miRNAs. We search some target by miRs target 
database, such as PicTar, TargetScan, and so on. Then, by luciferase assay, these targets were 
identified. As for miR-221 and miR-222, we proved that p27, PUMA, PTEN, TIMP3 and 
Cx43 were some targets of miR-221 and miR-222 in glioma. 
2.4.1 p27Kip1 
The p27Kip1 gene is a member of the cip/kip family of cyclin-dependent kinase (CDK) 
inhibitors that negatively control the cell cycle progression. The p27Kip1 binds to CDK2 and 
cyclin E complexes to prevent cell cycle progression from G1 to S phase (28,29). The p27Kip1 
does not follow Knudson's classic ‘two-hit hypothesis’ of tumor suppression. The 
inactivation of p27Kip1 is not caused by direct mutations in the gene encoding p27Kip1. The 
homozygous loss or silencing of the locus in human tumors is extremely rare (30). A recent 
study demonstrated that the miR-221/222 cluster is an endogenous regulator of p27Kip1, 
confirming the miRNA modulation may play a key role in the inactivation of p27Kip1 (31-34). 
However, that the miR-221/222 cluster affects tumor cell proliferation by regulating p27Kip1 
in vivo has not been well documented. 
2.4.2 PUMA 
Puma was originally identified during large-scale analysis for novel p53-inducible genes 
and Bcl-2-interacting proteins. Puma is an extremely potent BH3-only protein, having the 
capacity to bind with high affinity to all known anti-apoptotic Bcl-2 proteins. In addition, 
Puma may also directly interact with and activate Bax/Bak, for example, through an 
interaction with the first α-helix of Bax. In keeping with its highly pro-apoptotic nature, 
Puma has been shown to have an essential role in the induction of apoptosis in numerous in 
vitro and in vivo systems and cell types including neurons, lymphocytes, thymocytes, 
fibroblasts and cardiomyocytes. Puma expression is regulated by transcription, and factors 
regulating Puma ranscription include p53, p73, E2F and FOXO3a (24,35). 
2.4.3 PTEN 
The PTEN (phosphatase and tensin homology) gene, located at 10q23.3, encodes a central 
domain with homology to the catalytic region of protein tyrosine phosphatases. It is 
important in the function of protein phosphatases and 3’ -phosphoinositol phosphatase 
acivities. It dephosphorylates phosphatidylinositol-3,4,5-triphosphate(PIP3), the second 
messenger produced by PI3K. In do so, PTEN negatively regulates the activity of the 
serine/threonine protein kinase, AKt(36-37). PTEN is inactivated  in some malignant 
tumors, including glioblastoma 、prostate cancer、melanoma、endometrial carcinoma and 
lung carcinoma. To restore PTEN expression become an approach which enhances cancer 
radiosensitivity instead of suppressing Akt activity in PTEN-deficient tumor cells(38). 
2.4.4 TIMP3 
Malignant glioma cells express certain known proteinases such as matrix metalloproteinases 
(MMPs), which have been implicated as important factors in regulating cell invasiveness in 
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gliomas(39). MMPs are a family of at least 20 zinc-dependent endopeptidases collectively 
capable of degrading essentially all extracellular matrix(ECM) components, including 
collagents, fibronectin, laminin and basement membrance proteoglycans (40). Among the 
MMPs, attention has focused on gelatinases(MMP-2 and MMP-9) in human gliomas. A high 
level of MMP-2 expression was observed in the higher-grade gliomas, which correlated well 
with the malignant potential of human gliomas (41). A major mechanism for controlling 
MMPs activity in the pericellular space is mediated by the action of tissue inhibitors of 
metalloproteinases (TIMPs), which bind to active MMPs in a 1:1 molar stoichiometry (42). 
There are four family member, including TIMP-1, TIMP-2, TIMP-3, TIMP-4 (43). TIMP-3 is 
unique within the TIMP family as it remains closely associated to the extracellular matrix 
after being secreted by the cell (40, 44). In human gliomas, TIMP expression is reported to be 
down-regulated with increasing malignancy, including TIMP-3 (44). 
2.4.5 Cx43 
Cx genes have been demonstrated as tumor suppressor genes. Up to date, twenty members of 
Cx genes have been identified in mammalian tissues and they are expressed in tissue specific 
manner. Cx43 is the predominant form of Cxs expressed in astrocytes and also the constituent 
of connexons which compose the gap junction intercellular communication(GJIC) in brain (45, 
46). Our previous study and other studies showed that Cx 43 expression was inversely 
correlated with the degree of malignancy of astrocytomas (47). In most malignant gliomas, 
Cx43 expression was reduced or deleted and GJIC was deficient (47). 
In addition these target above, c-kit, p57, ERα,Bmf are also is some target of miR-221 and 
miR-222, but they are not proved in glioma until now (48-51). 
2.5 Inter-relationship between miR-221 and miR-222 expression and global mRNA 
expression 
Studies above have identified some targets of miR-221 and miR-222, such as p27, p57, and so 
on. Inter-relationship between miR-221 and miR-222 expression and global mRNA 
expression remains important as well. Here we knocked down miR-221 and miR-222 
expression and found 158 differentially expressed genes with 2-fold changes in U251 glioma 
cells by microarray analysis. Using the KEGG pathway databases and BioCarta, we found 
that the IFN-α signaling pathway was the most significant pathway modulated by 
differentially expressed genes. STAT1 and STAT2 are core proteins in the IFN-α signaling 
pathway. By Western blotting and immunofluorescence, we found that STAT1 and STAT2 
expression and phosphorylation were upregulated in U251 cells with knocked-down miR-
221/222. Furthermore, tyrosine phosphorylation of STAT1 and STAT2 was present in the 
nucleus after repression of miR-221/222 expression in U251 cells. These data indicate for the 
first time a mechanism involving STAT1/2 upregulation under the transcriptional control of 
INF-αsignaling after knockdown of miR-221/222 cluster in U251 glioma cells. 
2.6 Transcription factor modulate miR-221 and miR-222 expression  
MiRNAs finely modulate virtually all physiological pathways in metazoans, and are deeply 
implicated in all main pathologies by regulating their taregets. But who regulate them 
expression. Ciafrè et al report that the ectopic modulation of NF-kB modifies miR-221/222 
expression in prostate carcinoma and glioblastoma cell lines, where we had previously 
shown their oncogenic activity. We identify two separate distal regions upstream of miR-
221/222 promoter which are bound by the NF-kB subunit p65 and drive efficient 
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transcription in luciferase reporter assays; consistently, the site-directed mutagenesis 
disrupting p65 binding sites or the ectopical inhibition of NF-kB activity significantly reduce 
luciferase activity. In the most distal enhancer region, we also define a binding site for c-Jun, 
and we show that the binding of this factor cooperates with that of p65, fully accounting for 
the observed upregulation of miR-221/222. Thus, our work uncovers an additional 
mechanism through which NF-kB and c-Jun, two transcription factors deeply involved in 
cancer onset and progression, contribute to oncogenesis, by inducing miR-221/222 
transcription (52).Moreover, Garofalo et al also identified that c-jun regulated miR-221 and 
miR-222 expression level. 
 
 
Fig. 16. Constructed network of miR-221/222-TFs-STAT1/2-gene expression. Genes 
involved in TF-gene expression in glioma U251 cells after repression of the miR-221/222 
cluster, determining the cell death or survival through the INF-α pathway. Genes 
associated with eight TFs (FOS, ESR1,ETS2, IRF2, ARNT, ETS1, HOXC1, FOXN2) were 
manually identified via literature mining. IRF-1, STAT1 and STAT2 regulate the balance 
between miR-221/222-TFs and TF-gene expression, determining the cell death or survival 
through the INF-α pathway in glioma U251 cells. The INF-α pathway regulates cell 
survival negatively, via processes occurring in multiple intracellular compartments. 
Regulatory relationships are denoted by line colors, including the 28 genes and 64 verified 
modulation nodes. 
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In summary, We first identified that miR-221 and miR-222 play an role in malignant 
phenotype of glioma by increasing or knocking down miR-221 and miR-222. It was found 
that miR-221/222 increased cell proliferation, increased S phase proportionality, inhibited 
cell apoptosis, increased cell invasion and migration, enhanced radioresistance and reduced 
gap junction intercellular communication (GJIC) in glioma U251 cell. Furthermore, 
knockeddown miR-221/222 considerably decreases tumor growth in U251 cell xenograft 
model. Then, we identified that p27kip1, PUMA, PTEN, TIMP3 and Cx43 are some targets 
of miR-221 and miR-222. We also found that knocked down miR-221/222 changed some 
proteins expression. Taken together, our studies provide evidence that miR-221/222 
regulate its target genes and its related transduction signal way to promote the growth of 
malignant glioma cells. So, we thought that miR-221 and miR-222 may serve as a novel 
therapeutic target for malignant gliomas.  
4. Acknowledgment 
Supported by China National Natural Scientific Found (30772231, 30901772), Tianjin Science 
and Technology Committee (07ZCGHHZ01000), and Program for New Century Excellent 
Talents in University (NCET-07-0615). The authors wish to thank Dr. R. Agami, Division of 
Tumor Biology, The Netherlands Cancer Institute, Amsterdam, Netherlands, for kindly 
providing the constructs of pGL3-p27-3’UTR and pGL3-p27-3’UTR-DM; and Dr. J.Q. Cheng, 
Molecular Oncology, H. Lee Moffitt Cancer Center, Tampa, USA, for kindly providing the 
protocol of miRNA Northern blotting. PH.D. Xu B, Department of Radiation Oncology, The 
Methodist Hospital Research Institute, Houston, TX, USA, for help in studying glioma cell 
radiosensitivity. 
5. References 
[1] Osada H, Takahashi T. MicroRNAs in biological processes and carcinogenesis. 
Carcinogenesis 2007,28:2-12. 
[2] Zhang BH, Pan XP, Cobb GP, Anderson TA. MicroRNA as oncogenes and tumor 
suppressors. Developmental Biology. 2007,302:1-12. 
[3] Dalmay T, Edwards DR. MicroRNAs and the hallmarks of cancer. Oncogene. 
2006,25:6170-6175. 
[4] Chen CZ. MicroRNAs as Oncogenes and Tumor Suppressors. New England Med, 2005, 
353:1768-1771. 
[5] George A .Calin, Carlo M.Croce, MicroRNA signatures in human cancers, Nature 
Reviews Cancer 6(2006)857-866. 
[6] Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A, High expression of precursor 
microRNA-155/BIC RNA in children with Burkitt lymphoma, Genes Chromosomes 
Cancer 39(2004)167-169  
[7] Michael MZ, O' Connor SM, van Holst Pellekaan NG, Young GP, James RJ, Reduced 
accumulation of specific microRNAs in colorectal neoplasia, Mol Cancer Res 1(2003) 
882- 891. 
 
MiR-221/222 Promote the Growth of Malignant Glioma Cells by Regulating Its Target Genes  
 
479 
[8] Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano 
T,Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T, Reduced expression of 
the let-7 microRNAs in human lung cancers in association with shortened 
postoperative survival, Cancer Res 64(2004) 3753-3756. 
[9] Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E,Pedriali M, 
Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, 
Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM, MicroRNA gene expression 
deregulation in human breast cancer, Cancer Res 65(2005)7065-7070. 
[10] He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, 
Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A, The role of microRNA 
genes in papillary thyroid carcinoma, Proc Natl Acad Sci U S A 102(2005)19075-19080 
[11] Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K, 
Comprehensive analysis of microRNA expression patterns in hepatocellular 
carcinoma and non-tumorous tissues, Oncogene 25(2006)2537-2545. 
[12] Chan JA, Krichevsky AM, Kosik KS, MicroRNA-21 is an antiapoptotic factor in human 
glioblastoma cells, Cancer Res 65(2005)6029-6033. 
[13] Ciafrè SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M,Maira G, 
Croce CM, Farace MG, Extensive modulation of a set of microRNAs in primary 
glioblastoma, Biochem Biophys Res Commun 334(2005)1351-1358. 
[14] Zhang lilei, Wang tao, Wright AF, et al. A microdeletion in Xp11.3 accounts for co-
segregation of retinitis pigmentosa  and mental retardation in a large kindred. 
American Journal of Medical Genetics.2006,140A:349-357. 
[15] Branislav Kusenda, Marek Mraz, Jiri Mayer, et al. MicroRNA biogenesis, functionality 
and cancer relevance. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 
2006, 150:205-215.  
[16] Mishima T, Mizuguchi Y, Kawahigashi Y, et al. RT-PCR-based analysis of microRNA 
(miR-1 and -124) expression in mouse CNS. Brain Res, 2007,1131:37-43. 
[17] Berezikov E, Thuemmler F, Van Laake LW, et al. Diversity of microRNAs in human 
and chimpanzee brain. Nat Genet,2006 ,38:1375-1377. 
[18] le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Anile C, Maira G, 
Mercatelli N, Ciafrè SA, Farace MG, Agami R, Regulation of the p27(Kip1) tumor 
suppressor by miR-221 and miR-222 promotes cancer cell proliferation, EMBO J 
26(2007)3699-3708. 
[19] Frenquelli M, Muzio M, Scielzo C, Fazi C, Scarfo` L, Rossi L, Ferrari G, Ghia P, 
Caligaris-Cappio F. MicroRNA and proliferation control in chronic lymphocytic 
leukemia: functional relationship between miR-221/222 cluster and p27. Blood.2010, 
115: 3949-3959. 
[20] Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA, Farace MG, miR-
221 and miR-222 expression affects the proliferation potential of human prostate 
carcinoma cell lines by targeting p27Kip1, J Biol Chem 282( 2007)23716-23724.  
[21] Visone R, Russo L, Pallante P, Martino ID, Ferraro A, Leone V, Borbone E, Petrocca 
F,Alder H, Croce2 CM, Fusco A. MicroRNAs (miR)-221 and miR-222, both 
overexpressed in human thyroid papillarycarcinomas, regulate p27Kip1 protein 
levels and cell cycle. Endocrine-Related Cancer.2007,14:791–798. 
 




In summary, We first identified that miR-221 and miR-222 play an role in malignant 
phenotype of glioma by increasing or knocking down miR-221 and miR-222. It was found 
that miR-221/222 increased cell proliferation, increased S phase proportionality, inhibited 
cell apoptosis, increased cell invasion and migration, enhanced radioresistance and reduced 
gap junction intercellular communication (GJIC) in glioma U251 cell. Furthermore, 
knockeddown miR-221/222 considerably decreases tumor growth in U251 cell xenograft 
model. Then, we identified that p27kip1, PUMA, PTEN, TIMP3 and Cx43 are some targets 
of miR-221 and miR-222. We also found that knocked down miR-221/222 changed some 
proteins expression. Taken together, our studies provide evidence that miR-221/222 
regulate its target genes and its related transduction signal way to promote the growth of 
malignant glioma cells. So, we thought that miR-221 and miR-222 may serve as a novel 
therapeutic target for malignant gliomas.  
4. Acknowledgment 
Supported by China National Natural Scientific Found (30772231, 30901772), Tianjin Science 
and Technology Committee (07ZCGHHZ01000), and Program for New Century Excellent 
Talents in University (NCET-07-0615). The authors wish to thank Dr. R. Agami, Division of 
Tumor Biology, The Netherlands Cancer Institute, Amsterdam, Netherlands, for kindly 
providing the constructs of pGL3-p27-3’UTR and pGL3-p27-3’UTR-DM; and Dr. J.Q. Cheng, 
Molecular Oncology, H. Lee Moffitt Cancer Center, Tampa, USA, for kindly providing the 
protocol of miRNA Northern blotting. PH.D. Xu B, Department of Radiation Oncology, The 
Methodist Hospital Research Institute, Houston, TX, USA, for help in studying glioma cell 
radiosensitivity. 
5. References 
[1] Osada H, Takahashi T. MicroRNAs in biological processes and carcinogenesis. 
Carcinogenesis 2007,28:2-12. 
[2] Zhang BH, Pan XP, Cobb GP, Anderson TA. MicroRNA as oncogenes and tumor 
suppressors. Developmental Biology. 2007,302:1-12. 
[3] Dalmay T, Edwards DR. MicroRNAs and the hallmarks of cancer. Oncogene. 
2006,25:6170-6175. 
[4] Chen CZ. MicroRNAs as Oncogenes and Tumor Suppressors. New England Med, 2005, 
353:1768-1771. 
[5] George A .Calin, Carlo M.Croce, MicroRNA signatures in human cancers, Nature 
Reviews Cancer 6(2006)857-866. 
[6] Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A, High expression of precursor 
microRNA-155/BIC RNA in children with Burkitt lymphoma, Genes Chromosomes 
Cancer 39(2004)167-169  
[7] Michael MZ, O' Connor SM, van Holst Pellekaan NG, Young GP, James RJ, Reduced 
accumulation of specific microRNAs in colorectal neoplasia, Mol Cancer Res 1(2003) 
882- 891. 
 
MiR-221/222 Promote the Growth of Malignant Glioma Cells by Regulating Its Target Genes  
 
479 
[8] Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano 
T,Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T, Reduced expression of 
the let-7 microRNAs in human lung cancers in association with shortened 
postoperative survival, Cancer Res 64(2004) 3753-3756. 
[9] Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E,Pedriali M, 
Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, 
Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM, MicroRNA gene expression 
deregulation in human breast cancer, Cancer Res 65(2005)7065-7070. 
[10] He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, 
Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A, The role of microRNA 
genes in papillary thyroid carcinoma, Proc Natl Acad Sci U S A 102(2005)19075-19080 
[11] Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K, 
Comprehensive analysis of microRNA expression patterns in hepatocellular 
carcinoma and non-tumorous tissues, Oncogene 25(2006)2537-2545. 
[12] Chan JA, Krichevsky AM, Kosik KS, MicroRNA-21 is an antiapoptotic factor in human 
glioblastoma cells, Cancer Res 65(2005)6029-6033. 
[13] Ciafrè SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M,Maira G, 
Croce CM, Farace MG, Extensive modulation of a set of microRNAs in primary 
glioblastoma, Biochem Biophys Res Commun 334(2005)1351-1358. 
[14] Zhang lilei, Wang tao, Wright AF, et al. A microdeletion in Xp11.3 accounts for co-
segregation of retinitis pigmentosa  and mental retardation in a large kindred. 
American Journal of Medical Genetics.2006,140A:349-357. 
[15] Branislav Kusenda, Marek Mraz, Jiri Mayer, et al. MicroRNA biogenesis, functionality 
and cancer relevance. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 
2006, 150:205-215.  
[16] Mishima T, Mizuguchi Y, Kawahigashi Y, et al. RT-PCR-based analysis of microRNA 
(miR-1 and -124) expression in mouse CNS. Brain Res, 2007,1131:37-43. 
[17] Berezikov E, Thuemmler F, Van Laake LW, et al. Diversity of microRNAs in human 
and chimpanzee brain. Nat Genet,2006 ,38:1375-1377. 
[18] le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Anile C, Maira G, 
Mercatelli N, Ciafrè SA, Farace MG, Agami R, Regulation of the p27(Kip1) tumor 
suppressor by miR-221 and miR-222 promotes cancer cell proliferation, EMBO J 
26(2007)3699-3708. 
[19] Frenquelli M, Muzio M, Scielzo C, Fazi C, Scarfo` L, Rossi L, Ferrari G, Ghia P, 
Caligaris-Cappio F. MicroRNA and proliferation control in chronic lymphocytic 
leukemia: functional relationship between miR-221/222 cluster and p27. Blood.2010, 
115: 3949-3959. 
[20] Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA, Farace MG, miR-
221 and miR-222 expression affects the proliferation potential of human prostate 
carcinoma cell lines by targeting p27Kip1, J Biol Chem 282( 2007)23716-23724.  
[21] Visone R, Russo L, Pallante P, Martino ID, Ferraro A, Leone V, Borbone E, Petrocca 
F,Alder H, Croce2 CM, Fusco A. MicroRNAs (miR)-221 and miR-222, both 
overexpressed in human thyroid papillarycarcinomas, regulate p27Kip1 protein 
levels and cell cycle. Endocrine-Related Cancer.2007,14:791–798. 
 
Molecular Targets of CNS Tumors 
 
480 
[22] Sun K, Wang W, Zeng J, Wu C, Lei S, Li G. MicroRNA-221 inhibits CDKN1C/p57 
expression in human colorectal carcinoma. Acta Pharmacologica Sinica (2011) 32: 
375–384. 
[23] Yee KS, Wilkinson S, James J, Ryan KM, Vousden KH: PUMA- and Baxinduced 
autophagy contributes to apoptosis. Cell Death Differ. 2009,16:1135-1145. 
[24] Zhang C, Zhang J, Zhang A, Han L, Jia Z, Yang W, Wang G, You Y, Pu P, Cheng J, 
Kang C. MiR-221 and miR-222 target PUMA to induce Cell suvivalI in glioblastoma. 
Molecular Cancer. 2010,9:229. 
[25] Garofalo M, Leva GD, Romano G, Nuovo G, Suh SS, Ngankeu A, Taccioli C, Pichiorri F, 
Alder H, Secchiero P, Gasparini P, Gonelli A, Costinean S, Acunzo M, Condorelli G, 
Croce CM. MiR-221&222 regulate TRAIL-resistance and enhance tumorigenicity 
through PTEN and TIMP3 down-regulation. Cancer Cell. 2009 , 16: 498–509. 
[26] Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M, Bonanno E, 
Muto G, Frajese GV, Maria RD, Spagnoli LG, Farace MG, Ciafre SA. The Inhibition of 
the Highly Expressed Mir-221 and Mir-222 Impairs the Growth of Prostate 
Carcinoma Xenografts in Mice. PLoS one. 2008,3: e4029. 
[27] Kang CS, Zhang ZY, Jia ZF, Wang GX, Qiu MZ, Zhou HX, Yu SZ, Chang J, Jiang H, Pu 
PY. Suppression of EGFR expression by antisense or small interference RNA inhibits 
U251 glioma cell growth in vitro and in vivo, Cancer Gene Ther.2006, 13:530-538. 
[28] Blain SW, Scher HI, Cordon-Cardo C and Koff A. p27 as a target for cancer 
therapeutics. Cancer Cell.2003,3: 111-115. 
[29] Chu IM, Hengst L and Slingerland JM. The Cdk inhibitor p27 in human cancer: 
prognostic potential andrelevance to anticancer therapy. Nat Rev. 2008, 8: 253-267. 
[30] Philipp-Staheli J, Payne SR and Kemp CJ. p27Kip1: regulation and function of a 
haploin-sufficient tumor suppressor and its misregulation in cancer. Exp Cell 
Res.2001,264: 148-168. 
[31] Le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Anile C, Maira G, 
Mercatelli N, Ciafre SA, Farace MG and Agami R. Regulation of the p27 (Kip1) tumor 
suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO 
J.2007,26: 3699-3708. 
[32] Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA and Farace MG. 
miR-221 and miR-222 expression affects the proliferation potential of human prostate 
carcinoma cell lines by targeting p27Kip1. J Biol Chem.2007,282: 23716-23724. 
[33] Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C, Liu CG, Croce 
CM and Condorelli G. MicroRNA signatures of TRAIL resistance in human non-
small cell lung cancer. Oncogene . 2008 , 27:3845-3855. 
[34] Chunzhi Zhang, Chunsheng Kang, Yongping You , Peiyu Pu, Weidong Yang, Peng 
Zhao, Guangxiu Wang, Anling Zhang, Zhifan Jia, Lei Han, Hao Jiang. Co-
suppression of miR-221/222 cluster suppresses human glioma cells growth by 
targeting p27kip1 in vitro and in vivo. International Journal of Oncology. 2009, 
34:1653-1660. 
[35] Fricker M, O’Prey J, Tolkovsky AM and Ryan KM. Phosphorylation of Puma 
modulates its apoptotic function by regulating protein stability. Cell Death and 
Disease.2010, 1: e59 
 
MiR-221/222 Promote the Growth of Malignant Glioma Cells by Regulating Its Target Genes  
 
481 
[36] Sun YL, LK.St.Clair D, Fang F, Warren GW, Rangnekar VM, Crooks PA, St.Clair WH. 
The radiosensitization effect of parthenolide in prostate cancer cells is mediated by 
nuclear factor-κB inhibition and enhanced by the presence of PTEN. Mol Cancer 
Ther. 2007,6:2477-2486. 
[37] Jiang ZB, Pore N, Cerniglia GJ, Mick R, Georgescu MM, Bernhard EJ, Hahn SM, Gupta 
AK, Maity A. Phosphatase and tensin homologye deficiency in glioblastoma confers 
resistance to radiation and temozolomide that is reversed by the protease inhibitor 
nelfinavir. Cancer Res.2007,67:4467-4473. 
[38] Pappas G, Zumstrin LA, Munshi A, Hobbs M, Meyn RE. Adenoviral-mediated PTEN 
expression radiosensitizes non-small cell lung cancer cells by suppressing DNA 
repair capacity. Cancer Gene Therapy.2007,14:543-549. 
[39] Hsun-Jin Jan, Chin-Cheng Lee, Yung-Luen Shih, Dueng-Yuan Hueng, Hsin-I Ma, Jing-
Huei Lai, Hen-Wei Wei and Horng-Mo Lee. Osteopontin regulates human glioma cell 
invasiveness and tumor growth in mice. Neuro-Oncology.2010,12:58-70. 
[40] Paula Lam, Kar Sian Lim, Suk Mei Wang, Kam M.Hui. A mictoarry study to charaterize 
the molecular mechanism to TIMP-3-mediated tumor rejection. Molecular Therapy. 
2005,12:144-152. 
[41] Levicar N, Nuttall RK, Lah TT. Proteases in brain tumor progression. Acta 
Neurochir(Wien). 2003,145:825-838. 
[42] Jiang Y, Goldberg I.D, Shi Y.E. Complex role of tissue inhibitor of metalloproteinases in 
cancer. Oncogene.2002,21:2245-2252. 
[43] Brew.K, Dinakarpandian.D, Nagase.H. Tissue inhibitors of metalloproteinase: 
evolution, structure and function. Biochim. Biophys. Acta.2000,1477:267-283. 
[44] Martine LM, Gianni D, Tung CH, Idema S, Schagen HE, Carette JE, Quax HA, 
Beusechem WV, Vandertop WP, Dirven MF, Chiocca EA, Gerritsen WR. Tissue 
inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits 
matrix metalloproteinase activity in vivo without affecting antitumoral efficacy in 
malignant glioma. Cancer Res.2005,65:9398-9405. 
[45] Yamasaki, H, Naus, CC. Role of connexin genes in growth control. Carcinogenesis 
1996, 17: 1199–1213. 
[46] Medina R, Zaidi SK, Liu CG, Stein JL, van Wijnen AJ, Croce CM, Stein GS. MicroRNAs 
221 and 222 bypass quiescence and compromise cell survival. Cancer Res. 2008, 68: 
2773-2780. 
[47] Pu PY, Xia ZB, Yu SZ, Huang Q. Altered expression of Cx43 in astrocytic tumors. Clin 
Neurol Neurosurg 2004, 107: 49-54. 
[48] Mayoral RJ, Monticelli S. Stable overexpression of miRNAs in bone marrow-derived 
murine mast cells using lentiviral expression vectors. Methods Mol Biol. 2010;667:205-
14. 
[49] Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, 
Giovannini C, Croce CM, Bolondi L, Negrini M. MiR-221 controls CDKN1C/p57 and 
CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 2008 , 
27:5651-5661. 
 
Molecular Targets of CNS Tumors 
 
480 
[22] Sun K, Wang W, Zeng J, Wu C, Lei S, Li G. MicroRNA-221 inhibits CDKN1C/p57 
expression in human colorectal carcinoma. Acta Pharmacologica Sinica (2011) 32: 
375–384. 
[23] Yee KS, Wilkinson S, James J, Ryan KM, Vousden KH: PUMA- and Baxinduced 
autophagy contributes to apoptosis. Cell Death Differ. 2009,16:1135-1145. 
[24] Zhang C, Zhang J, Zhang A, Han L, Jia Z, Yang W, Wang G, You Y, Pu P, Cheng J, 
Kang C. MiR-221 and miR-222 target PUMA to induce Cell suvivalI in glioblastoma. 
Molecular Cancer. 2010,9:229. 
[25] Garofalo M, Leva GD, Romano G, Nuovo G, Suh SS, Ngankeu A, Taccioli C, Pichiorri F, 
Alder H, Secchiero P, Gasparini P, Gonelli A, Costinean S, Acunzo M, Condorelli G, 
Croce CM. MiR-221&222 regulate TRAIL-resistance and enhance tumorigenicity 
through PTEN and TIMP3 down-regulation. Cancer Cell. 2009 , 16: 498–509. 
[26] Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M, Bonanno E, 
Muto G, Frajese GV, Maria RD, Spagnoli LG, Farace MG, Ciafre SA. The Inhibition of 
the Highly Expressed Mir-221 and Mir-222 Impairs the Growth of Prostate 
Carcinoma Xenografts in Mice. PLoS one. 2008,3: e4029. 
[27] Kang CS, Zhang ZY, Jia ZF, Wang GX, Qiu MZ, Zhou HX, Yu SZ, Chang J, Jiang H, Pu 
PY. Suppression of EGFR expression by antisense or small interference RNA inhibits 
U251 glioma cell growth in vitro and in vivo, Cancer Gene Ther.2006, 13:530-538. 
[28] Blain SW, Scher HI, Cordon-Cardo C and Koff A. p27 as a target for cancer 
therapeutics. Cancer Cell.2003,3: 111-115. 
[29] Chu IM, Hengst L and Slingerland JM. The Cdk inhibitor p27 in human cancer: 
prognostic potential andrelevance to anticancer therapy. Nat Rev. 2008, 8: 253-267. 
[30] Philipp-Staheli J, Payne SR and Kemp CJ. p27Kip1: regulation and function of a 
haploin-sufficient tumor suppressor and its misregulation in cancer. Exp Cell 
Res.2001,264: 148-168. 
[31] Le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Anile C, Maira G, 
Mercatelli N, Ciafre SA, Farace MG and Agami R. Regulation of the p27 (Kip1) tumor 
suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO 
J.2007,26: 3699-3708. 
[32] Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA and Farace MG. 
miR-221 and miR-222 expression affects the proliferation potential of human prostate 
carcinoma cell lines by targeting p27Kip1. J Biol Chem.2007,282: 23716-23724. 
[33] Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C, Liu CG, Croce 
CM and Condorelli G. MicroRNA signatures of TRAIL resistance in human non-
small cell lung cancer. Oncogene . 2008 , 27:3845-3855. 
[34] Chunzhi Zhang, Chunsheng Kang, Yongping You , Peiyu Pu, Weidong Yang, Peng 
Zhao, Guangxiu Wang, Anling Zhang, Zhifan Jia, Lei Han, Hao Jiang. Co-
suppression of miR-221/222 cluster suppresses human glioma cells growth by 
targeting p27kip1 in vitro and in vivo. International Journal of Oncology. 2009, 
34:1653-1660. 
[35] Fricker M, O’Prey J, Tolkovsky AM and Ryan KM. Phosphorylation of Puma 
modulates its apoptotic function by regulating protein stability. Cell Death and 
Disease.2010, 1: e59 
 
MiR-221/222 Promote the Growth of Malignant Glioma Cells by Regulating Its Target Genes  
 
481 
[36] Sun YL, LK.St.Clair D, Fang F, Warren GW, Rangnekar VM, Crooks PA, St.Clair WH. 
The radiosensitization effect of parthenolide in prostate cancer cells is mediated by 
nuclear factor-κB inhibition and enhanced by the presence of PTEN. Mol Cancer 
Ther. 2007,6:2477-2486. 
[37] Jiang ZB, Pore N, Cerniglia GJ, Mick R, Georgescu MM, Bernhard EJ, Hahn SM, Gupta 
AK, Maity A. Phosphatase and tensin homologye deficiency in glioblastoma confers 
resistance to radiation and temozolomide that is reversed by the protease inhibitor 
nelfinavir. Cancer Res.2007,67:4467-4473. 
[38] Pappas G, Zumstrin LA, Munshi A, Hobbs M, Meyn RE. Adenoviral-mediated PTEN 
expression radiosensitizes non-small cell lung cancer cells by suppressing DNA 
repair capacity. Cancer Gene Therapy.2007,14:543-549. 
[39] Hsun-Jin Jan, Chin-Cheng Lee, Yung-Luen Shih, Dueng-Yuan Hueng, Hsin-I Ma, Jing-
Huei Lai, Hen-Wei Wei and Horng-Mo Lee. Osteopontin regulates human glioma cell 
invasiveness and tumor growth in mice. Neuro-Oncology.2010,12:58-70. 
[40] Paula Lam, Kar Sian Lim, Suk Mei Wang, Kam M.Hui. A mictoarry study to charaterize 
the molecular mechanism to TIMP-3-mediated tumor rejection. Molecular Therapy. 
2005,12:144-152. 
[41] Levicar N, Nuttall RK, Lah TT. Proteases in brain tumor progression. Acta 
Neurochir(Wien). 2003,145:825-838. 
[42] Jiang Y, Goldberg I.D, Shi Y.E. Complex role of tissue inhibitor of metalloproteinases in 
cancer. Oncogene.2002,21:2245-2252. 
[43] Brew.K, Dinakarpandian.D, Nagase.H. Tissue inhibitors of metalloproteinase: 
evolution, structure and function. Biochim. Biophys. Acta.2000,1477:267-283. 
[44] Martine LM, Gianni D, Tung CH, Idema S, Schagen HE, Carette JE, Quax HA, 
Beusechem WV, Vandertop WP, Dirven MF, Chiocca EA, Gerritsen WR. Tissue 
inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits 
matrix metalloproteinase activity in vivo without affecting antitumoral efficacy in 
malignant glioma. Cancer Res.2005,65:9398-9405. 
[45] Yamasaki, H, Naus, CC. Role of connexin genes in growth control. Carcinogenesis 
1996, 17: 1199–1213. 
[46] Medina R, Zaidi SK, Liu CG, Stein JL, van Wijnen AJ, Croce CM, Stein GS. MicroRNAs 
221 and 222 bypass quiescence and compromise cell survival. Cancer Res. 2008, 68: 
2773-2780. 
[47] Pu PY, Xia ZB, Yu SZ, Huang Q. Altered expression of Cx43 in astrocytic tumors. Clin 
Neurol Neurosurg 2004, 107: 49-54. 
[48] Mayoral RJ, Monticelli S. Stable overexpression of miRNAs in bone marrow-derived 
murine mast cells using lentiviral expression vectors. Methods Mol Biol. 2010;667:205-
14. 
[49] Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, 
Giovannini C, Croce CM, Bolondi L, Negrini M. MiR-221 controls CDKN1C/p57 and 
CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 2008 , 
27:5651-5661. 
 
Molecular Targets of CNS Tumors 
 
482 
[50] Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ. MicroRNA-
221/222 negatively regulates estrogen receptor alpha and is associated with 
tamoxifen resistance in breast cancer.J Biol Chem. 2008 ,283:31079-1086. 
[51] Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, 
Croce CM, Bolondi L, Negrini M.MicroRNA-221 targets Bmf in hepatocellular 
carcinoma and correlates with tumor multifocality. Clin Cancer Res. 2009 Aug 
15;15(16):5073-81. 
[52] Galardi S, Mercatelli N, Farace MG, Ciafrè SA. NF-kB and c-Jun induce the expression 
of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. 
Nucleic Acids Research, 2011, doi:10.1093/nar/gkr006 
Part 11 
EGFR /EGFRvIII Amplification - Glioblastoma 
 
Molecular Targets of CNS Tumors 
 
482 
[50] Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ. MicroRNA-
221/222 negatively regulates estrogen receptor alpha and is associated with 
tamoxifen resistance in breast cancer.J Biol Chem. 2008 ,283:31079-1086. 
[51] Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, 
Croce CM, Bolondi L, Negrini M.MicroRNA-221 targets Bmf in hepatocellular 
carcinoma and correlates with tumor multifocality. Clin Cancer Res. 2009 Aug 
15;15(16):5073-81. 
[52] Galardi S, Mercatelli N, Farace MG, Ciafrè SA. NF-kB and c-Jun induce the expression 
of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. 
Nucleic Acids Research, 2011, doi:10.1093/nar/gkr006 
Part 11 
EGFR /EGFRvIII Amplification - Glioblastoma 
 23 
Primary Glioblastoma with Different Patterns of 
EGFR Amplification and the Relationship with 
Gene Expression Profile 
Concha Lopez-Gines, Rosario Gil-Benso, Daniel Monleon, 
 Jose Gonzalez-Darder and Miguel Cerda-Nicolas 
Department of Pathology, University of Valencia. Fundación HCU, Labim, 
 Department of Neurosurgery. Hospital Clínico Universitario, 
Spain  
1. Introduction 
Glioblastoma multiforme (GBM) is the most common intracranial tumor and the most 
aggressive of all gliomas. These tumors are very heterogeneous both histopathological and 
genetic. There is no consistent theory today that can explain the etiology of glioblastoma. A 
number of factors, both environmental and genetic, have been suggested as potential causes 
of the tumor. It is possibly a combination of both which initiates and triggers the 
pathogenesis of tumor and the sequence of genetic alterations that lead to the genesis of 
neoplasia. They represent 60% of all astrocytic tumors and between 12-15% of all 
intracranial tumors. Three new patients per 100,000 people are diagnosed every year. 
Among its clinical features, age is particularly important for their development and 
survival. Although the tumor may arise at any age, most cases occur in adults (45-75 years). 
The average onset is between 53 and 62 years depending on the series (Kleihues et al., 2002, 
Ohgaki et al., 2004). The presence of tumor is much less frequent at earlier ages. Only 22% of 
cases involved patients younger than 45 years. It has been reported that cases between 0 and 
20 years old only represent 3-8% of the total (Dohrmann et al., 1976). This frequency of cases 
in the late adulthood may indicate the need for a relatively important period of time before 
the accumulation of genetic damage leading to tumor formation. As for the sex of the 
patients there is a preference for males, about 1.5 men for every woman (Kleihues et al., 
2002). 
Glioblastoma is an almost exclusively supratentorial tumor, affecting both cerebral 
hemispheres, with a similar spatial distribution to low-grade astrocytoma and anaplastic 
astrocytoma, being the most affected regions the frontal, temporal and parietal lobes 
(Dohrmann and et al., 1976; Russell & Rubinstein, 1989). The symptoms usually develop 
through a short history and in most cases do not exceed 3 months. The literature reflects that 
50% of cases are under the threshold of 3 months (Russell & Rubinstein, 1989). The speed of 
onset of symptoms can be explained by the rapid growth and by the high invasiveness and 
infiltration of the tumor. 
The three types of treatment (surgery, radiotherapy and chemotherapy) commonly used in 
the treatment of other malignancies, are also used as therapeutic strategies for glioblastoma. 
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Metastases are rarely found, probably due to the short survival time of these patients. The 
removal of a tumor produces large symptomatic relief and a slight increase in survival, but 
practically no cure. The high infiltration capacity of the tumor and the proximity of 
functionally important brain regions make surgical resection unable to eliminate all tumor 
cells, which produce relapses in short periods of time. Radiation therapy has also shown 
some efficacy in improving survival time. Likewise, chemotherapy strategies active in other 
tumors, have shown a relative efficacy in glioblastoma (Walker et al.., 1978, Walker et al., 
1980, Yung et al., 2000; Balañá et al., 2004). 
The biological aggressiveness of glioblastoma multiforme makes the survival of patients 
short, about a year, this being significantly lower than that observed for grade II and grade 
III astrocytomas (5 and 3 years respectively) (Jelsma & Bucy, 1969, Sant et al., 1988, Kallio et 
al., 1991, Ohgaki et al., 2004). 
From a histopathological point of view, glioblastoma is considered in the group of astrocytic 
gliomas and is the most malignant tumor in this group. According to the latest ranking of 
the World Health Organization (Louis et al., 2007), the tumor is classified as grade IV. It may 
show up as a lesion with high heterogeneity both intratumoral and intertumoral. This 
heterogeneity is represented by the variability of cell populations and their degree of 
differentiation. 
Glioblastoma may be the final stage of a progression that can result from less malignant 
lesions (Scherer, 1940). Low-grade astrocytoma, classified as grade II, is the first step on the 
scale of malignancy of astrocytomas, which already makes clear the invasive nature of the 
tumor. This tumor shows a slight increase in cellularity and diffuse compared to normal 
surrounding tissue. Vascularization in these cases becomes slightly hyperplasic in any of the 
three variants: fibrillary, protoplasmic and gemistocytic. Microscopically, despite the 
invasive nature, has low destructive power and distorts little the adjacent brain structures 
(Russell & Rubinstein, 2006).  
Although sharing some common ground with low-grade astrocytoma, anaplastic 
astrocytoma represents a further step in the progressive increase in cellularity,  reflected in 
the degree of anaplasia, the cellular and nuclear pleomorphism and increased proliferative 
rates, and already considered as malignant astrocytoma, grade III in the WHO classification 
(Louis et al., 2007). 
Finally, a last step in the malignant progression of the lesion, which reflects the changes 
with respect anaplastic astrocytoma, is morphologically expressed in a predominance of 
anaplastic cells and vascular proliferation with vascular hyperplasia and glomerular 
formations, besides the presence of necrosis 
 
 
Fig. 1. Histopathological features of glioblastoma with HE techniques. A) Anaplastic 
histological pattern. B) Pseudoglomerular vascular hyperplasia. C) Pseudoempalizada 
necrosis 
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The glioblastoma tumor cells differentially express glial fibrillary acidic protein (GFAP). 
GFAP is an antigen protein that is present in astroglial cells and is part of the structure of 
gliofilaments. The intensity and extent of GFAP expression is highly variable (Kleihues and 
Cavanee, 2000). Tumor cells usually retain some astrocytic differentiation and are strongly 
positive, especially gemistocytic. Undifferentiated small cells stain more weakly or are 
clearly negative. Multinucleated giant cells are the most variable in their expression of 
GFAP. Within a tumor, there may also coexist regions with no GFAP expression. As the 
tumor progresses, there is a tendency towards the lack of GFAP expression, but this fact is 
not considered to have prognostic value (Schmitt, 1983).  
In these tumors, Ki-67 rates are high ranging between 15-20% (Burger et al., 1986, 
Karamitopoulou et al., 1994). Both the number of mitosis and the proliferative rates vary 
depending on the tumor region studied. The spindle-like cells and the undifferentiated 
small cells seem to show a marked proliferative activity and may therefore have a more 
aggressive behavior. However, gemistocytic tumors show a lesser degree of proliferation. 
The determination of proliferative activity may be indicative of tumor behavior and provide 
additional information on the morphological diagnosis (Watanabe et al., 1997).  
 
 
Fig. 2. Morphological and immunohistochemical features of glioblastomas. A) Mitosis in 
tumor cells. B) Positive expression Ki-67/MIB-1. C) GFAP positive expression. 
According to the clinical concepts of Scherer (1940) with respect primary and secondary 
glioblastoma, most cases develop rapidly without clinical, radiological or morphological 
evidence of a less malignant precursor. This type of glioblastoma is considered primary or 
de novo glioblastoma, if also the diagnosis of glioblastoma was obtained in the first biopsy. 
In these cases, the tumor rapidly develops after a short history of less than 3 months in most 
cases. The diagnosis of secondary glioblastoma is performed only in cases with 
histopathological evidence of an earlier low-grade astrocytoma or anaplastic astrocytoma. In 
these cases, the tumor develops slowly and is considered to have arisen from the 
glioblastoma tumor progression of lower primary malignancy. Using these criteria, 
secondary glioblastomas are much less common than primary, reaching only 5% of the total 
(Dropcho & Soong, 1996, Ohgaki & Kleihues, 2005).  
Besides the difference in the diagnosis and progression of primary and secondary 
glioblastoma, there are also differences in the distribution of age and sex in the two types of 
tumors. Primary glioblastoma affects older patients with a mean age of 62, while secondary 
glioblastoma affects middle-aged patients with a mean of 45 years. The distribution between 
the sexes is also different, dominated by men in cases of primary glioblastoma (M:F 1.5), and 
women in secondary (F:M 0.65) (Ohgaki & Kleihues, 2005).  
A difference between the two subtypes is also observed in terms of survival. Primary 
glioblastoma has a median survival time shorter (4.7 months) than secondary glioblastoma 
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(7.8 months). This difference in survival may be due to the difference in the age at which 
they occur. In fact, there is no significant difference after an adjustment for age (Ohgaki & 
Kleihues, 2005).  
Primary and secondary glioblastomas are two tumor subtypes indistinguishable from a 
histopathological point of view.  
Taking these differences and clinical presentation, the group of Kleihues et al (1997), studied 
the distribution of molecular features known for glioblastomas, in each of these two 
subtypes. These authors performed a separation of primary and secondary glioblastomas 
based on two different histogenetic pathways. Amplification / overexpression of EGFR and 
TP53 mutation are considered the pillars of the two proposed genetic pathways for the 
formation of the two subtypes of glioblastomas. In principle, they were also considered 
mutually exclusive.  
Further studies were to define more precisely the presence of these molecular alterations. 
Amplification in primary glioblastomas and / or overexpression of EGFR occurred in about 
40% of cases. Mutations in TP53, however, are features of secondary glioblastomas and 
appeared in 65% of cases, being much less frequent in primary glioblastomas (28% of cases) 
(Ohgaki et al., 2004, Ohgaki & Kleihues, 2005). 
This chapter is organized as follow: In the 2nd section, we have realised a description on 
cytogenetic and molecular characteristics of glioblastoma. We analyzed the presence of 
numerical chromosomal aberrations by applying cytogenetic methods in cultured cells and 
centromeric DNA probes specific for chromosomes 7 and 10 in material proceeding from 
smear preparations; and we have studied the association between these parameters. Then, in 
the 3rd section, characteristics of epidermal growth factor receptor gene (EGFR) and its 
implication in the pathways of signalization are illustrated. We have investigated the 
expression of activated ERK1/2 in glioblastomas using western blot analysis and 
immunohistochemistry, and assessed the relationship between activated ERK1/2 and genetic 
factors such as EGFR amplification, TP53 mutation and alteration of 9p21 locus genes, as well 
as clinicopathological parameters. In section 4, we presented the histopathological and genetic 
findings of primary glioblastomas. The association between cases with EGFR gene 
amplification and cases without EGFR amplification with cytogenetic parameters, TP53 
mutations, MDM2 and CDK4 amplification, and cell cycle regulatory genes located at 9p21, 
was evaluated. A second aim of this study was to investigate the relationship between such 
genetic variations and clinical and pathological data. For last, in section 5, we investigated 
differences in the pattern of EGFR amplification in the glioblastoma. We performed FISH 
analysis with an EGFR probe in metaphases of primary cultured cells and in paraffin sections 
from 60 cases of primary glioblastomas. We also aimed to compare the EGFR copy number 
alterations, mRNA level and protein expression status and to correlate the FISH data with the 
clinical and histopathological parameters in the glioblastoma multiforme.        
2. Genetic hallmarks in glioblastomas  
The glioblastoma is characterized by intratumoral heterogeneity with regard to both 
histomorphology and genetic changes. Cytogenetically, the GBM displays highly complex 
karyotypes, with numerous structural and numerical aberrations, the presence of double 
minutes, as well as differences in ploidy level. The most common numerical chromosome 
aberrations are +7, +8, -9, -10, -13, -14, -22 and loss of a sex chromosome. Structural changes 
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involve predominantly the following chromosome arms: 1q, 2q, 6q, 7p, 7q, 9p, 14q, 17p and 
18p (Jenkins et al., 1989, Bigner et al., 1990, Mitelman et al., 2004, Lopez-Gines et al., 2006). 
However, in vitro tissue culturing for karyotype analysis may result in the selective growth 
of cells with the highest proliferative activity, and these cells may not be representative of 
the primary tissue (Heim et al., 1989, Moertel et al., 1993). 
 
 
Fig. 3. Cytogenetic alterations in glioblastomas   
By minimizing any in vitro culture artefact, fluorescence in situ hybridization (FISH) may 
more accurately depict the chromosome aberrations in tissues, like the brain, in which 
cellular turnover is low. These studies showed different aneuploidy for chromosomes 1, 7, 
10, 17, X, and Y in astrocytomas, and in all of them the over-representation of chromosome 7 
and the under-representation of chromosome 10 are the most common in GBM (Arnoldus et 
al., 1992, Wernicke et al., 1997, Amalfitano et al., 2000, Koschny et al., 2002, Lopez-Gines et 
al., 2005). FISH on interphase cells is a powerful tool for detecting different chromosome 
aberrations, because it can detect chromosomal changes on a cell-by-cell basis. The FISH 
studies of GBM have also found, that trisomy for chromosome 7 and/or monosomy for 
chromosome 10 are the principal anomalies, but very few of them have been carried out on 
about smear preparations; this is a good material and a rapid method for to detection 
aneuploidy, with control by hematoxilyin-eosin for the presence of tumoral cells in the 
preparation. According to a few publications, the association between trisomy/polisomy 7 
and monosomy 10 is very different, 35-80% depending on the methods used (Steilen-Gimbel 
et al., 1996, Nishizaki et al., 2002, Lopez-Gines et al., 2005). The studies using karyotype 
analysis consider trisomy/polisomy 7 to be an early change and monosomy 10 as a 
progression-associated aberration (Rey et al., 1987, Bigner et al., 1990). On the contrary, 
other studies with FISH have suggested that in tumorigenesis, monosomy 10 may be an 
earlier change than the abnormalities in chromosome 7, because cases with monosomy 10 
but without trisomy 7 were observed (Steilen-Gimbel et al., 1996, Amalfitano et al., 2000). It 
is possible that the association of both is necessary in tumorigenesis of GBM.  
At the molecular level the glioblastoma multiforme has been studied extensively and the 
most commonly affected genes are the following:  
• Loss of heterozygosity (LOH): LOH on chromosome arm 10q is the most frequent gene 
alteration for both primary and secondary glioblastomas; it occurs in 60-90% of cases. 
This mutation appears to be specific for glioblastoma multiforme and is found rarely in 
other tumor grades. This mutation is associated with poor survival (Fujisawa et al., 
1999, Tada et al., 2001). 
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At the molecular level the glioblastoma multiforme has been studied extensively and the 
most commonly affected genes are the following:  
• Loss of heterozygosity (LOH): LOH on chromosome arm 10q is the most frequent gene 
alteration for both primary and secondary glioblastomas; it occurs in 60-90% of cases. 
This mutation appears to be specific for glioblastoma multiforme and is found rarely in 
other tumor grades. This mutation is associated with poor survival (Fujisawa et al., 
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• Epidermal growth factor receptor (EGFR) gene: This oncogene is frequently 
amplified/overexpressed and mutated in glioblastoma. This alteration is observed in 
40-50% of these tumors (Wong et al., 1992, Ekstrand et al., 1994, Wang et al., 1994).  
• TP53 tumor suppressor gene: Appears to be deleted or altered in approximately 25-40% 
of all glioblastoma multiformes, more commonly in secondary glioblastoma (Yoon et 
al., 2001, Houiller et al.., 2006). 
• PTEN: Also known as MMAC and TEP1, encodes a tyrosine phosphatase located at 
band 10q23.3. PTEN mutations have been found in as many as 30% of glioblastomas, 
more commonly in primary glioblastoma (Karlbom et al., 1993, Lin et al., 1998). 
• MDM2: Amplification or overexpression of MDM2 is the second most common gene 
amplification in glioblastoma and is observed in 10-15% of patients. Some studies show 
that this mutation has been associated with a poor prognosis (Reifenberger et al., 1994). 
• Platelet-derived growth factor–alpha (PDGF-alpha) gene: The PDGF gene acts as a major 
mitogen for glial cells by binding to the PDGF receptor (PDGFR). Amplification or 
overexpression of PDGFR is typical (60%) in the pathway leading to secondary 
glioblastomas (Hermanson et al., 1992; Varela et al., 2004). 
• Additional genetic alterations in primary glioblastomas include INK4A deletions (30-
40%), and retinoblastoma (RB) gene protein alterations (Quelle et al., 1995, Stott et al., 
1998, Ichimura et al., 1996).  
 
 
Fig. 4. FISH analysis. A) Metaphase with trisomy 7 (painting probe). B) Metaphase with 
trisomy 7 (probe centromere of chromosome 7). C) Interphase nuclei with polysomy of 
chromosome 7. 
3. Epidermal growth factor receptor gene and pathways of signalization in 
glioblastoma multiforme 
The EGFR receptor is encoded by the gene c-erbB-1 or Her-1, located on chromosome 7 in 
the 7p12 region (Kondo et al., 1983). EGFR was the first receptor in which the ability to 
phosphorylate tyrosine residues in a portion of the molecule was detected. Their activation 
by the ligand leads to an increase in DNA synthesis, and consequently to an increase in cell 
proliferation and a decrease in apoptotic activity. This stimulation of cell division begins in 
the actions of its tyrosine kinase activity (Carpenter & Cohen, 1990). 
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The oncogenic properties of EGFR receptor are associated with a constitutive and 
uncontrolled increase in its phosphorylation catalytic activity. The reversible 
phosphorylation of proteins is one of the major mechanisms for protein regulation and for 
control of cell physiology. The phosphorylation of certain residues of a protein can regulate 
its activity, its interaction with other proteins, its structure and its location. Hence, protein 
kinases and phosphatases are an important part in its control. 
The kinases that phosphorylate tyrosine are involved in the initial steps of transmitting 
signals within the cell, resulting from ligand binding to the receptor (Ullrich & Schlessinger, 
1990).  
Phosphorylated tyrosine residues serve to the receptor as recruitment and association site 
for cytosolic proteins, which are activated in turn by new phosphorylations. The association 
of a protein to the receptor also produces the approximation of soluble proteins from the 
cytoplasm and thus facilitates this interaction. This will initiate the signaling pathways 
mediated by these molecules. 
Transduction pathways that are activated in this way include the route PI3 kinase/AKT, the 
Ras/MAP kinase, route c-myc, protein kinase C route and route STAT. All these paths 
induce the cell to activate transcription of specific genes that produce cell proliferation, 
apoptosis resistance, invasion, metastasis and angiogenesis, ultimately leading to malignant 
transformation (Dai et al., 2001; Arteaga, 2002, Rao & James, 2004). Therefore, the 
intracellular domain of the receptor has an extracellular signal transmitted to the cell 
nucleus via phosphorylation cascades.  
The signaling pathway RAS/RAF is altered in many tumor types, including glioblastomas. 
This signaling pathway through MAP kinases is involved in cell proliferation. ERK1 and 
ERK2 are the best studied kinases in solid tumors. ERK1/2 are activated by phosphorylation 
of tyrosine and threonine residues. Dual phosphorylation is necessary for full activation of 
ERK1/2. When ERK1/2 is activated migrates into the nucleus and phosphorylates 
transcription factors which affect the expression of certain genes and ultimately cell growth 
(Canagarajah et al., 1997, Jelinek et al., 1996). In our work we have observed that in many 
cases the amplification of EGFR is related to the dual activation of ERK1/2. Additionally, if 
the amplification of EGFR is linked to deletions or p16 gene methylation, the relationship 
with activation of ERK1/2 is more significant (Lopez-Gines et al., 2008). 
Major intracellular signaling pathways related to aging and apoptosis involve the enzyme 
phosphatidylinositol 3-kinase PI3-K. This kinase phosphorylates inositol phospholipids 
instead of proteins, and also acts on Akt by phosphorylation. Akt itself phosphorylates 
MDM2, which enters the nucleus where it accumulates, causing inhibition of TP53 (Honda 
et al., 1997; Roth et al., 1998). 
Nuclear factor NFkB is an important mediator in the regulation of TP53 and in the Akt 
signaling pathway. This regulation is achieved through an essential component of NFkB 
activation cascade, the protein RIP1 (death domain-containing receptor kinase interacting 
protein 1). RIP1 activates NFkB which causes an increase in MDM2 gene expression by 
inhibiting the action of TP53 (Park et al., 2009). 
Conversely, in the P13-K/PTEN/AKT pathway, PTEN tumor suppressor plays also an 
important role. This tumor gene encodes a phosphatase that dephosphorylates PI3-K, thus 
preventing the phosphorylation of Akt, and thus favoring TP53 action. PTEN produces a 
negative control on Akt kinase pathway, by its action opposite to PI3-K. Therefore, alterations 
in this gene have a negative effect on TP53 and therefore influence the aging processes and 
apoptosis, and the cell migration and tumor invasion (Li et al., 1997; Knobbe et al., 2002). 
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The genetic pathway TP53/MDM2 is also regulated by p14/ARF. p14 is a repressor of 
MDM2. If p14 does not exert its proper function, it will trigger an excess of free MDM2 and 
consequently inactivation of TP53. The alterations of these genes are diverse. p14, which acts 
as a suppressor gene, typically exhibits some deletions. MDM2, on the other hand, with 
oncogenic activity is often amplified whereas TP53 can show different types of mutations 
(Stott et al., 1998, Ichimura et al., 2000). 
Finally, another pathway affected in glioblastomas is p16/Rb/CDK4, which controls the G1-
S transition in the cell cycle and hence proliferation. In glioblastomas this pathway is 
impaired because p16, which normally acts as a tumor suppressor gene, has deletions. 
Additionally, CDK4 amplifications are also present, giving the cells oncogenic activity. The 
disturbance causes Rb to be continuously phosphorylated, and as a result there is an 
uncontrolled cell division (Reifenberger et al., 1994, Rollbrocker et al., 1996). 




Fig. 5. Pathways of signalization in glioblastoma multiforme 
Most gene amplification events in astrocytoma in general and in glioblastoma specifically, 
involve the EGFR gene. These gene amplification phenomena involve the duplication of 
certain regions of DNA that leads to the existence of multiple copies of a gene. EGFR 
amplification was an early genetic alteration involved in tumorigenesis of glioblastoma 
(Márquez et al., 2004). 
The vast majority of authors place the percentage of glioblastomas with EGFR amplification 
around 40-50% (Ekstrand et al., 1992, Diedrich et al., 1995, Shinojima et al., 2003). However, 
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some studies extend this range up to 73% (Márquez et al., 2004). These differences have been 
attributed to the different methodologies used (PCR, FISH, Southern blot). EGFR 
amplification has been observed in association with the increase in the number of copies of 
chromosome 7, both total or partial, which is the most common karyotypic abnormality 
found in glioblastoma (Hurtt et al., 1992, Rao & James, 2004). 
An increase in EGF receptor expression and its natural ligands has been observed using 
immunohistochemical techniques. This expression is not limited to the membrane, but also 
observed in the nucleus of tumor cells (Libermann et al., 1985, Ekstrand et al., 1991; 
Shinojima et al., 2003, Márquez et al., 2004). 
This increase coincides with the amplification of the gene encoding the receptor (Shinojima 
et al., 2003, Varela et al., 2004, Márquez et al., 2004, Lopez-Gines et al., 2005). On the 
contrary, no expression of this marker is present in normal tissue (Márquez et al., 2004). 
The combined increase in the expression of ligands and receptors has led to the assumption 
that there is a loop autocrine/paracrine growth which stimulates neoplasic growth. Thus, by 
the autocrine stimulation the cell induces autoproliferation in response to their own growth 
factors and by the paracrine stimulation there is induction of proliferation in response to 
factors secreted by neighboring cells and adjacent. In any case, there is an activation of the 
machinery of the cell cycle and uncontrolled cell proliferation. In fact there are several 
studies that support the importance of the system EGF/EGFR in the tumorigenesis of 
glioblastoma, due to the strong coexpression of EGF receptor and its respective ligands EGF 
and TGF-α (Ekstrand et al , 1991; Shinojima et al., 2003).  
Half of the glioblastoma cases with EGFR amplification also exhibit rearrangements of the 
gene, which results in a considerable variety of qualitative and structural alterations of the 
receptor, prompted by different mutations that can undergo the gene (Ekstrand et al., 1992, 
Shinojima et al., 2003, Rao & James, 2004). 
The gene sequences which are amplified in glioblastoma are frequently mutated and code 
protein variants shorter than the native protein (Frederick et al., 2000; Shinojima et al., 2003). 
These mutations can affect both the 5 'region and the 3' region of the gene. Thus, the mutant 
protein can be affected at both the extracellular and the intracellular domain. On the other 
hand, the reading frame is not usually affected by these mutations (Eley et al., 1998, 
Frederick et al., 2000). 
The most common rearrangement is a variant called EGFRvIII, a receptor with a molecular 
weight of 140-155 kDa that is expressed together with the normal 170 kDa protein (Sugawa 
et al., 1990, Sugawa et al., 1998; Wikstrand et al., 1998). This rearrangement has also been 
seen in other tumors where EGFR is also overexpressed (Eley et al., 1998; Arteaga, 2002). 
This mutation lacks a portion of the ligand binding extracellular domain as a result of 
genomic deletions that eliminate exons 2-7 in the EGFR mRNA (Frederick et al., 2000; 
Collins, 2002; Shinojima et al., 2003). This gives this form of the receptor a number of 
features distinct to those of the normal EGFR (Collins, 2002; Shinojima et al., 2003). 
4. Primary glioblastomas with and without EGFR amplification 
The pathogenic mechanisms leading to the development and progression of glioblastoma 
are still unclear. EGFR amplification has been identified as a genetic hallmark of primary 
glioblastoma and occurs in approximately 40-60% of primary glioblastomas, but rarely in 
secondary glioblastomas (Houiller et al., 2006, TCGA, 2008). Generally, primary 
glioblastomas with EGFR amplification show EGFR overexpression, and 70% to 90% of 
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those with EGFR overexpression have EGFR amplification (Liu et al., 2004). This 
oncogenetic pathway, is heavily involved in this variant of glioblastoma. However, there 
exist primary glioblastomas with no amplification/overexpression of the EGFR.   
In our previous works, EGFR amplification was observed in 53% of the tumors, and 80% of 
them presented EGFR overexpression. On the other hand, 47% of our primary glioblastomas 
showed no EGFR amplification and 67% of them showed no overexpression. We studied the 
association between cases with EGFR gene amplification and cases without EGFR 
amplification with cytogenetic parameters, TP53 mutations, MDM2 and CDK4 
amplification, and cell cycle regulatory genes located at 9p21. Furthermore, we investigated 
the relationship between such genetic variations and clinical and pathological data (Benito 
et al., 2009).  
At clinipathological level, the age distribution of cases with EGFR amplification closely 
follows that of patients with primary glioblastomas (60 years), and patients of less than 35 
years of age are more infrequent. In our results, the mean age of the group with EGFR 
amplification was 57.2 years and only one patient was under 35 years of age. However, the 
mean age for the group of cases without EGFR amplification was 49.8 years and four 
patients were under 35 years of age. The rest of the clinicopathological findings on primary 
glioblastomas with and without EGFR amplification did not show any significant 
differences, although, interestingly, patients with EGFR amplification survived for the 
shortest time.  
Cytogenetically, glioblastomas have shown many numerical and structural anomalies 
(Bigner et al., 1990, Lopez-Gines et al., 2006). In our study, the number of karyotypes with 
anomalies was greater in the group without EGFR amplification. Trisomy 7, monosomy 10 
and monosomy 22 were observed in both groups, and the structural alterations of 
chromosomes 1, 7 and 9 were more frequent in the first group. Every case with dmin had 
EGFR amplification.  
FISH on interphase cells is a powerful tool for detecting different chromosome aberrations, 
because it can detect chromosome changes on cell-by-cell bases. The FISH studies into 
primary glioblastomas have also found that trisomy for chromosome 7 and/or monosomy 
for chromosome 10 are the principal anomalies. In our cases, we found a high percentage 
(85%) of trisomy/polisomy and 70% of monosomy 10, higher in fact than those found by 
conventional cytogenetic analysis. Likewise, the association of both trisomy/polisomy 7 and 
monosomy 10 were present in 59% of the cases. In our study, both amplified and non-
amplified tumors showed trisomy/polysomy of chromosome 7 and monosomy of 
chromosome 10. This fact suggests that these alterations could be an initial event in the 
tumorigenesis of glioblastoma. 
At a molecular level, a close association between EGFR amplification and CDKN2A 
(INK4a/ARF) deletions is a frequent alteration in glioblastomas. Homozygous INK4a/ARF 
deletions were more frequent in primary than in secondary glioblastomas, but there was no 
significant difference in the overall frequency of these alterations (homozygous deletion and 
promoter methylation) between primary and secondary glioblastomas (Ohgaki & Kleihues, 
2007). In our results on primary glioblastomas, both  cases with and without EGFR 
amplification showed similar percentages of INK4a/ARF deletions, but the promoter 
methylation of INK4a was more frequent  in the group of cases with EGFR amplification.  As 
a consequence of CDKN2A deletions, there is a disruption of both RB1/CDK4/P16 and 
P53/MDM2/p14 pathways. MDM2 facilitates the ubiquitin-mediated degradation of p53, 
which is inhibited by p14/ARF. This fact probably explains why both MDM2 amplification 
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and INK4a/ARF are mutually exclusive. The amplification of MDM2 is present in less than 
10% of glioblastomas, exclusively in primary glioblastomas that lack a TP53 mutation 
(Houiller et al., 2006, Ohgaki & Kleihues, 2007). In our series, MDM2 amplification was 
present in 11% of the cases, all of them with EGFR amplification and without deletions of 
INK4a/ARF. CDK4 promotes the phosphorylation of the Rb protein and is inhibited by p16 
protein, a product of the INK4a tumor suppressor gene. Again, both alterations result in a 
redundant effect. In our cases, CDK4 amplification and INK4a/ARF deletions were mutually 
exclusive, and all cases except one were present with EGFR amplification. We also found 
tightly associated MDM2 and CDK4 amplifications, suggesting that both genes, which map 
close together to the same region on 12q13, are frequently included in the same amplicon. 
 
 
Table 1. Co-presence of genetic alterations in glioblastomas (expressed in %). 
Finally, the TP53 pathway plays a crucial role in the development of secondary 
glioblastomas, TP53 mutations being the first detectable genetic alteration. However, 
although this event also occurs in primary glioblastomas, it does so at a lower frequency 
(<30% of the cases). In our study, 18% of primary glioblastomas showed TP53 mutations. 
Furthermore, we have been found two glioblastomas showing both concurrent EGFR 
amplification and TP53 mutation. 
The first case, arising de novo in a 51-years old woman, expressed GFAP, S100, vimentin, and 
had p53_LI of 27%. EGFR was overexpressed. The cytogenetic analysis showed a 
hypertriploid complex karyotype with rearrangements of chromosomes 1, 7, 8, and 11, and 
dmin. FISH studies using centromeric DNA probes for chromosomes 7 and 10 showed 
trisomy 7 and monosomy 10 in the majority of the cells. Molecular biology showed EGFR 
amplification, and a C176R TP53 mutation; furthermore, aberrant hypermehylation in the 
promoter region of p14 gene was demonstrated. 
The second case arising three years later than a previous anaplastic astrocytoma in a 38-year 
old man, expressed GFAP, S-100, vimentin, and had p53_LI of 26%. EGFR was 
overexpressed. The karyotype was hypodiploid, with a t(9;18) and rearrangements of 
chromosomes 2, 13, and 14. Disomy 7/monosomy 10 was confirmed by FISH. At molecular 
level the tumor showed EGFR amplification and a R282W TP53 mutation. 
 
Molecular Targets of CNS Tumors 
 
494 
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showed no EGFR amplification and 67% of them showed no overexpression. We studied the 
association between cases with EGFR gene amplification and cases without EGFR 
amplification with cytogenetic parameters, TP53 mutations, MDM2 and CDK4 
amplification, and cell cycle regulatory genes located at 9p21. Furthermore, we investigated 
the relationship between such genetic variations and clinical and pathological data (Benito 
et al., 2009).  
At clinipathological level, the age distribution of cases with EGFR amplification closely 
follows that of patients with primary glioblastomas (60 years), and patients of less than 35 
years of age are more infrequent. In our results, the mean age of the group with EGFR 
amplification was 57.2 years and only one patient was under 35 years of age. However, the 
mean age for the group of cases without EGFR amplification was 49.8 years and four 
patients were under 35 years of age. The rest of the clinicopathological findings on primary 
glioblastomas with and without EGFR amplification did not show any significant 
differences, although, interestingly, patients with EGFR amplification survived for the 
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(Bigner et al., 1990, Lopez-Gines et al., 2006). In our study, the number of karyotypes with 
anomalies was greater in the group without EGFR amplification. Trisomy 7, monosomy 10 
and monosomy 22 were observed in both groups, and the structural alterations of 
chromosomes 1, 7 and 9 were more frequent in the first group. Every case with dmin had 
EGFR amplification.  
FISH on interphase cells is a powerful tool for detecting different chromosome aberrations, 
because it can detect chromosome changes on cell-by-cell bases. The FISH studies into 
primary glioblastomas have also found that trisomy for chromosome 7 and/or monosomy 
for chromosome 10 are the principal anomalies. In our cases, we found a high percentage 
(85%) of trisomy/polisomy and 70% of monosomy 10, higher in fact than those found by 
conventional cytogenetic analysis. Likewise, the association of both trisomy/polisomy 7 and 
monosomy 10 were present in 59% of the cases. In our study, both amplified and non-
amplified tumors showed trisomy/polysomy of chromosome 7 and monosomy of 
chromosome 10. This fact suggests that these alterations could be an initial event in the 
tumorigenesis of glioblastoma. 
At a molecular level, a close association between EGFR amplification and CDKN2A 
(INK4a/ARF) deletions is a frequent alteration in glioblastomas. Homozygous INK4a/ARF 
deletions were more frequent in primary than in secondary glioblastomas, but there was no 
significant difference in the overall frequency of these alterations (homozygous deletion and 
promoter methylation) between primary and secondary glioblastomas (Ohgaki & Kleihues, 
2007). In our results on primary glioblastomas, both  cases with and without EGFR 
amplification showed similar percentages of INK4a/ARF deletions, but the promoter 
methylation of INK4a was more frequent  in the group of cases with EGFR amplification.  As 
a consequence of CDKN2A deletions, there is a disruption of both RB1/CDK4/P16 and 
P53/MDM2/p14 pathways. MDM2 facilitates the ubiquitin-mediated degradation of p53, 
which is inhibited by p14/ARF. This fact probably explains why both MDM2 amplification 
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and INK4a/ARF are mutually exclusive. The amplification of MDM2 is present in less than 
10% of glioblastomas, exclusively in primary glioblastomas that lack a TP53 mutation 
(Houiller et al., 2006, Ohgaki & Kleihues, 2007). In our series, MDM2 amplification was 
present in 11% of the cases, all of them with EGFR amplification and without deletions of 
INK4a/ARF. CDK4 promotes the phosphorylation of the Rb protein and is inhibited by p16 
protein, a product of the INK4a tumor suppressor gene. Again, both alterations result in a 
redundant effect. In our cases, CDK4 amplification and INK4a/ARF deletions were mutually 
exclusive, and all cases except one were present with EGFR amplification. We also found 
tightly associated MDM2 and CDK4 amplifications, suggesting that both genes, which map 
close together to the same region on 12q13, are frequently included in the same amplicon. 
 
 
Table 1. Co-presence of genetic alterations in glioblastomas (expressed in %). 
Finally, the TP53 pathway plays a crucial role in the development of secondary 
glioblastomas, TP53 mutations being the first detectable genetic alteration. However, 
although this event also occurs in primary glioblastomas, it does so at a lower frequency 
(<30% of the cases). In our study, 18% of primary glioblastomas showed TP53 mutations. 
Furthermore, we have been found two glioblastomas showing both concurrent EGFR 
amplification and TP53 mutation. 
The first case, arising de novo in a 51-years old woman, expressed GFAP, S100, vimentin, and 
had p53_LI of 27%. EGFR was overexpressed. The cytogenetic analysis showed a 
hypertriploid complex karyotype with rearrangements of chromosomes 1, 7, 8, and 11, and 
dmin. FISH studies using centromeric DNA probes for chromosomes 7 and 10 showed 
trisomy 7 and monosomy 10 in the majority of the cells. Molecular biology showed EGFR 
amplification, and a C176R TP53 mutation; furthermore, aberrant hypermehylation in the 
promoter region of p14 gene was demonstrated. 
The second case arising three years later than a previous anaplastic astrocytoma in a 38-year 
old man, expressed GFAP, S-100, vimentin, and had p53_LI of 26%. EGFR was 
overexpressed. The karyotype was hypodiploid, with a t(9;18) and rearrangements of 
chromosomes 2, 13, and 14. Disomy 7/monosomy 10 was confirmed by FISH. At molecular 
level the tumor showed EGFR amplification and a R282W TP53 mutation. 
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Hypermethylation of promoter region of p16 gene was also observed. These cases showed, 
in common, monosomy of chromosome 10, hypermethylation in the INK4A locus, EGFR 
amplification and TP53 mutation (Gil-Benso et al., 2007). 
Our results suggest that, in primary glioblastomas, there exists a subgroup of cases closely 
linked with EGFR amplification. However, there is another subgroup of cases without EGFR 
amplification with some different clinical and genetic characteristics. This second group 
might include the increased activation or expression of other growth factor receptors 
observed in these tumors such as PDGFR or IGFR, although they are only amplified in a low 
percentage of cases. 
 
 
Table 2. Characteristics of glioblastomas with and without EGFR amplification 
5. Patterns of EGFR amplification and gene expression profile 
Amplifications are mutations that result in multiple copies of genes in chromosomal regions 
(amplicons) and induce overexpression in cancer cells. The amount of overexpressed genes 
in amplified regions varies between different types of cancers, and gene expression in 
general was significantly regulated by DNA copy number alterations (Schwab, 1998, 
Myllykangas & Knuutila, 2006). Chromosomal abnormalities associated with DNA 
amplification can be organized as extrachromosomal copies, called double minutes (dmin);  
in tandem arrays as head-to-tail or inverted repeats within a chromosome, often forming a 
cytologically visible, homogeneously staining region (HSR); or distributed at various 
locations in the genome (distributed insertions) (Schwab,1998, Kuwahara et al., 2004, 
Albertson, 2006). MYCN, ERBB2 and EGFR are the most frequently amplified genes in 
cancers. 
According to the breakage-fusion-bridge (BFB) model of amplification, the initiating event 
in HSR formation is double chromatid breakage at a fragile site or telomere erosion 
(Coquelle et al., 1997, Murnane & Sabatier, 2004), fused sister chromatids and breaking of 
the anaphase bridges (Shimizu et al., 2005). BFB cycles could then result in inverted 
amplified structures (Toledo et al., 1992), and the mutated sister chromatids are distributed 
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to the daughter cells giving rise to intra-tumor heterogeneity (Gisselsson et al., 2000). Gene 
amplifications are also acquired by selection and unequal segregation of circular 
extrachromosomal chromatin (dmin and episomes). These elements are formed by looping 
out from the chromosomes. Dmin and episomes may also relocate in the genome after DNA 
double-stranded breaks to form HSR or distributed insertions (Schwab, 1999, Kuwahara et 
al., 2004). Instead of these above-mentioned mechanisms, N-myc duplication located at 2p24 
has been described in neuroblastoma cell lines, as studied by FISH (Corvi et al., 1995). Large 
direct duplications may arise by unequal sister-chromatid exchange and appear to play a 
role during the initial stages in amplification. It is unclear whether duplication represents a 
prelude to amplification or an alternative pathway for activating the oncogenic potential of 
MYC. (Corvi et al., 1995, Schwab, 2004).  
 
 
Fig. 6. Patterns of gene amplification: dmin, hsr and genomic insertion. 
The first evidence of gene amplification in glioblastoma was provided by cytogenetic 
analyses which exhibited the presence of dmin, found in up to 50% of tumors (Bigner & 
Volgelstein, 1990; Thiel et al., 1992).  
Molecular studies demonstrated the amplification of several genes in these tumors, 
especially of the EGFR gene; the amplified sequences were found located on dmin in a small 
number of cases, by in situ hybridization of tumor metaphases (Muleris et al., 1994, Vogt et 
al., 2004). However, studies by FISH in interphase nuclei are more frequent, displaying a 
considerable heterogeneity of EGFR copy number (Sauter et al., 1996, Vogt et al., 2004, 
Layfield et al., 2006, Mizoguchi et al., 2006). The large fraction of cases presenting a diffuse 
rather than a clustered pattern of amplification within single cells supports the notion that 
the most common pattern of EGFR amplification in glioblastoma biopsies is as double 
minutes, which ranged in size from 0.7 to 2.1 Mb and in level of amplification from 8-to-63-
fold (Vogt et al., 2004). The FISH signals differed from case to case, intense and multiple, 
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double, faint and single. This suggests the complexity of dmin formation since both their 
size and the number of EGFR copies they contain, vary. Cell to cell variations are also likely 
to exist for a given tumor (Sauter et al., 1996). 
Molecular screening for gene amplification revealed the frequent amplification of the EGFR, 
observed in about 35%-70% of glioblastomas (Sauter et al., 1996, Okada et al., 2003, Ohgaki 
and Kleihues, 2007). Differences in the frequency of EGFR amplification are most likely due 
to the different methods used, such as Southern blot, polymerase chain reaction (PCR), and 
fluorescent in situ hybridization. 
EGFR protein overexpresssion is usually associated with gene amplification in 
glioblastomas and these two parameters have been studied as a potential prognostic 
indicator (Shinojima et al., 2003, Layfield et al., 2006). The majority of GBMs with EGFR 
amplification also contain the mutant EGFR gene, EGFRvIII, which is characterized by the 
deletion of exons 2–7, resulting in an in frame deletion variant that has a truncated 
extracellular domain with ligand-independent constitutive activity.  
Overexpression of wild-type EGFR was not found to be an independent prognostic 
indicator of survival in several studies, and one study was inconclusive (Simmons et al., 
2001, Shinojima et al., 2003). Four studies identified EGFR as a negative prognostic indicator 
of survival, one of which showed the effect only in patients younger than 45. In some of 
these studies, analysis was limited by small sample size, uncharacterized extent of surgical 
resection, and variable postoperative treatment. The prognostic impact of EGFRvIII has not 
been as extensively studied, but in the study that addressed this variable, the presence of 
EGFRvIII was found to be an independent and significant unfavorable prognosticator of 
survival (Ekstrand et al., 1991, Simmons et al., Smith et al., 2001, Arteaga et al., 2002, 
Marquez et al., 2004). EGFR amplification and EGFRvIII have been shown to increase glioma 
proliferation and invasion in vitro; therefore logically EGFR and/or EGFRvIII expression 
could exhibit a proclivity towards the development of multifocal disease, gliomatosis cerebri 
or ependymal seeding.  
In our study we performed FISH analysis with an EGFR specific probe in metaphases of 
primary cultured cells and in paraffin sections from 60 cases of primary glioblastomas, in 
order to investigate differences in the pattern of EGFR amplification in this tumor. We 
compared the EGFR copy number alterations and gene expression with the clinical and 
histopathological parameters in this subset of tumors.   
5.1 Methodology 
5.1.1 Histopathological study 
Tissue removed from the patient during the surgical resection was divided into three 
fragments, one for histopathological and immunohistochemical study, one for culture, and 
the other was frozen and stored at -80ºC until molecular analysis and DNA extraction were 
performed. 
The tumoral tissue was fixed in neutral-buffered formalin during the first 48h, embedded in 
paraffin, sectioned and stained with HE. The samples were categorized according to the 
WHO classification and diagnosed as glioblastoma multiforme (Louis et al., 2007). Mitotic 
index values were obtained by counting the total number of mitotic figures in the tumor 
cells in 20 high-power fields (HPF) and in two different sections. The values are the mean 
number of mitoses per 10 HPF. 
The immunohistochemical study was performed on paraffin-embedded sections using the 
avidin-biotin peroxidase method. The study was carried out with antibodies against glial 
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fibrillary acidic protein (GFAP) (Dako, Glostrup, Denmark), Ki-67 (MIB-1, Dako, Glostrup, 
Denmark), p53 (Dako, Glostrup, Denmark), and monoclonal mouse antihuman EGFR (clone 
H11, Dako, Glostrup, Denmark) that recognizes the wild-type EGFR and the deletion 
mutant form of the receptor (EGFRvIII). 
Proliferation index was evaluated using MIB-1 antibody staining, and was calculated by 
determining the percentage of immunopositive nuclei. EGFR expression was scored 
according to the intensity of staining and number of staining cells, as: 0 (no staining), 1 (light 
or focal), 2 (moderate) and 3 (strong). Scores of 0 or 1 were defined as no overexpression; 
scores of 2 and 3 as overexpression (Shinojima et al., 2003).  
5.1.2 Cytogenetic analysis and fluorescence in situ hybridization 
Cytogenetic analyses were performed by short-term culture of the tumors. Fresh tumor 
samples were disaggregated with 2mg/mL of collagenase II. The cells were seeded in flasks 
using RPMI-1640 medium supplemented with 20% foetal bovine serum, L- glutamine, and 
antibiotics. The cells were processed after 72 h of culture by a standard technique. Air dried 




Fig. 7. Cultured cells of glioblastoma 
To evaluate EGFR gene status, dual-color FISH was performed on cultured cells and on 
paraffin sections. FISH was carried out using the LSR EGFR Spectrum Orange/CEP 7 





Fig. 8. LSR EGFR Spectrum Orange/CEP 7 Spectrum Green Probe (Vysis). 
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Cultured cells were treated with Colcemid (0.02 µg/mL) (Gibco BRL, Grand Island, NY, 
USA) for 80 minutes, and chromosomes were prepared by conventional fixation. The 
paraffin embedded tissues were cut at 5-μm and mounted on Superfrost/Plus microscope 
slides. Hybridizations were performed according to the instructions that accompany the 
probe. Counterstaining of nuclei was carried out using DAPI. The fluorescent signal was 
detected using a photomicroscope Axioplan 2 and Axiophot 2 (Zeiss) equipped with a set of 
the appropriate filters. Signals were counted in 100-200 cultured cell nuclei, in all the 
possible metaphases and in 100 non-overlapping tumor cell nuclei in the paraffin sections. 
The mean signal number for the EGFR gene and CEP 7 was calculated for each case, as well 
as the EGFR gene/CEP 7 ratio. The EGFR gene was scored as amplified in individual cells 
when the EGFR/control signal ratio was greater than 2 (Layfield et al., 2006). 
5.1.3 Real-time quantitative PCR 
Tumor DNA was extracted from 10-15 mg using DNeasy kit extraction (Qiagen, Valencia, 
CA). Quantitative PCR was performed using an ABI Prism 7900 HT Fast Real-Time PCR 
System (Applied Biosystem, Foster City, CA) to analyze EGFR copy number. Primer 
sequences for EGFR were: forward GTGCAGATCGCAAAGGTAATCAG; reverse 
GCAGACCGCATGT GAGGAT; and probe FAM-CCCCTCCCCGTATCTC-MGB. Primer 
sequences for RNase P and GAPDH used as references genes were purchased to TaqMan 
RNase P and GAPDH Detection Reagents  (P/N: 4316831).  
Target and reference genes were amplified in separate wells. Each 20 µl assay contained 20 
ng of genomic DNA, 900 nM each of forward and reverse primers for the gene (RNasa P, and 
GAPDH as reference gene, and EGFR as target gene), and 250 nM of labelled gene specific 
probe in 1x TaqMan Universal PCR Master Mix. The TaqMan universal PCR Master Mix 
(Applied Biosystems) contained AmpliTaq Gold DNA polymerase, AmpErase uracyl-N-
Glycosylase, deoxynucleotide triphospates with dUTP that replace dTTP, and optimized 
buffers.  
Individual samples were run in triplicate. PCR conditions were: 2 min at 50ºC (initial 
incubation for activate AmpErase), 10 min at 95ºC (Activation of AmpliTaq Gold DNA 
Polymerase) followed by 40 cycles of 15 sec at 95ºC (melt) and 1 min at 60ºC 
(anneal/extend). Real Time data was collected by the SDS 2.1 software. Each replicate was 
normalized to reference gene (RNasa P and GAPDH) to obtain ΔCt, and average ΔCt for each 
sample (from the 3 replicates) was calculated. All samples were normalized to a calibrator 
sample to determine ΔΔCt. Relative quantity is 2 –ΔΔCt , and copy number is 2x (Relative 
quantity) (Livak & Schmittgen, 2001). 
Theoretically, a normal sample has two copies for each gene. Such an assumption is right in 
cell lines, but taking into consideration that human tumor tissue samples may be 
contaminated by normal cells, we use a copy number range approach and consider: 
Homozigous Deletion (HD) 0 - 0.4; Borderline HD-Loss of Heterozigosity (LOH) > 0.4 - 0.6; 
LOH > 0.6 – 1.4; Borderline LOH-Normal > 1.4 – 1.6; Normal > 1.6 - 2.4; Borderline 
Amplification > 2.4 – 2.6; and Amplification > 2.6. 
5.1.4 Single nucleotide polymorphism (SNPs) array analysis for assessment of EGFR 
copy number status 
Nucleic Acid Isolation and microarray experiment: Fresh frozen tumor tissues (10-20 mg) 
from patients with glioblastoma were used to extract high molecular weight, genomic DNA 
using DNeasy kit extraction (Qiagen, Valencia, CA). DNA quality was assessed by 
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electrophoresis in 1% of agarose gel. Two hundred and fifty DNA nanograms were used for 
hybridization on Genechip Human Mapping 100K as recommended by the manufacturer 
(Affymetrix, Santa Clara, CA). The mapping 100K set provides a broad coverage of the 
human genome (92%), with an average distance between SNPs of 23.6 Kb. This set includes 
two arrays, each with more than 50,000 SNPs. The processing was performed following the 
manufacturer’s guidelines. Arrays were scanned by means of a GeneChip Scanner 3000, and 
GeneChip Operating software was used to define Absent or Present Call and generate CEL 
files. 
Data Analysis: CEL files were imported into dChipSNP arrays analysis software (Lin et al., 
2004). Arrays were normalized against the array with median overall intensity (Baseline 
array) employing the Invariant set normalization method (Li & Wong 2001a). Probe set signal 
intensity was obtained by using a model based on expression index (PM/MM) method (Li & 
Wong, 2001b). Average array call rate was > 95 %. We employ a Hidden-Markov model to 
identify LOH regions from unpaired tumor samples, taking into account SNP intermarker 
distance, SNP heterozigosity rates, and the haplotype structure of the genome (Beroukhim 
et al., 2006). We used 60 CEPH parents as normal reference genotype and we removed 
inferred LOH regions consistent with 95% of homozygous markers in normal reference 
samples. Copy number alterations at each SNP locus were determined using the probe level 
signal intensity data. Reference signal distribution was obtained using a trimmed analysis 
with 80 % of the samples.  
5.1.5 EGFR mRNA expression 
Nucleic acid isolation: RNA was extracted from 19 glioblastoma samples. Five pilocytic 
astrocytomas without EGFR amplification were used as reference. For total RNA extraction, 
10-20 mg of frozen tumor samples were homogenized with Ultra Turrax and total RNA was 
isolated using mirVANA kit (Ambion Inc, Austin, TX) following the manufacturer’s 
instructions. Purified RNA was quantified by UV absorbance at 260 and 280 nm and RNA 
quality was assessed using a spectrophotometer and Agilent 2100 Bioanalyzer (Agilent 
Technologies, Palo Alto, CA). Samples with 28S/18S ratio of ≥ 1.1 and no evidence of 
ribosomal peak degradation were included. 
Microarray experiments: Total RNA (1-15µg) was used to generate double-stranded cDNA. 
cDNA synthesis and cRNA labelling were performed using the protocol for one-cycle cDNA 
synthesis. Biotin-labeled cRNA (20 µg) was fragmented and hybridized overnight to 
Affymetrix HU133plus2.0 genechip. Protocols were performed as recommended by 
Affymetrix. Arrays were washed, stained with streptavidin phycoerythrin and scanned to 
generate an image file. Scan quality was assessed by the inspection of visible microarray 
artifacts, grid placement, background intensity, and housekeeping gene expression. 
GeneChip operating software (GCOS) was used to define Absent or Present Call and 
generate CEL files. Arrays with < 30% “Present” call for the 47,000 probe sets and signal 
3´/5´ratio of GDAPH control 0.5 ≤ ratio ≤ 4.5 were omitted.  
Data analysis: CEL files were imported into dCHIP program. Arrays were normalized 
against the array with median overall intensity (Baseline array) employing the Invariant set 
normalization method (Li & Wong 2001a).  Probeset signal intensity was obtained by using 
a model based on expression index (PM/MM) method (Li & Wong, 2001b). EGFR probesets 
with Present Call and expression level ≥10 in ≥ 45 % samples were selected. Probesets that 
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211607_x_at. 
 
Molecular Targets of CNS Tumors 
 
500 
Cultured cells were treated with Colcemid (0.02 µg/mL) (Gibco BRL, Grand Island, NY, 
USA) for 80 minutes, and chromosomes were prepared by conventional fixation. The 
paraffin embedded tissues were cut at 5-μm and mounted on Superfrost/Plus microscope 
slides. Hybridizations were performed according to the instructions that accompany the 
probe. Counterstaining of nuclei was carried out using DAPI. The fluorescent signal was 
detected using a photomicroscope Axioplan 2 and Axiophot 2 (Zeiss) equipped with a set of 
the appropriate filters. Signals were counted in 100-200 cultured cell nuclei, in all the 
possible metaphases and in 100 non-overlapping tumor cell nuclei in the paraffin sections. 
The mean signal number for the EGFR gene and CEP 7 was calculated for each case, as well 
as the EGFR gene/CEP 7 ratio. The EGFR gene was scored as amplified in individual cells 
when the EGFR/control signal ratio was greater than 2 (Layfield et al., 2006). 
5.1.3 Real-time quantitative PCR 
Tumor DNA was extracted from 10-15 mg using DNeasy kit extraction (Qiagen, Valencia, 
CA). Quantitative PCR was performed using an ABI Prism 7900 HT Fast Real-Time PCR 
System (Applied Biosystem, Foster City, CA) to analyze EGFR copy number. Primer 
sequences for EGFR were: forward GTGCAGATCGCAAAGGTAATCAG; reverse 
GCAGACCGCATGT GAGGAT; and probe FAM-CCCCTCCCCGTATCTC-MGB. Primer 
sequences for RNase P and GAPDH used as references genes were purchased to TaqMan 
RNase P and GAPDH Detection Reagents  (P/N: 4316831).  
Target and reference genes were amplified in separate wells. Each 20 µl assay contained 20 
ng of genomic DNA, 900 nM each of forward and reverse primers for the gene (RNasa P, and 
GAPDH as reference gene, and EGFR as target gene), and 250 nM of labelled gene specific 
probe in 1x TaqMan Universal PCR Master Mix. The TaqMan universal PCR Master Mix 
(Applied Biosystems) contained AmpliTaq Gold DNA polymerase, AmpErase uracyl-N-
Glycosylase, deoxynucleotide triphospates with dUTP that replace dTTP, and optimized 
buffers.  
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Polymerase) followed by 40 cycles of 15 sec at 95ºC (melt) and 1 min at 60ºC 
(anneal/extend). Real Time data was collected by the SDS 2.1 software. Each replicate was 
normalized to reference gene (RNasa P and GAPDH) to obtain ΔCt, and average ΔCt for each 
sample (from the 3 replicates) was calculated. All samples were normalized to a calibrator 
sample to determine ΔΔCt. Relative quantity is 2 –ΔΔCt , and copy number is 2x (Relative 
quantity) (Livak & Schmittgen, 2001). 
Theoretically, a normal sample has two copies for each gene. Such an assumption is right in 
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contaminated by normal cells, we use a copy number range approach and consider: 
Homozigous Deletion (HD) 0 - 0.4; Borderline HD-Loss of Heterozigosity (LOH) > 0.4 - 0.6; 
LOH > 0.6 – 1.4; Borderline LOH-Normal > 1.4 – 1.6; Normal > 1.6 - 2.4; Borderline 
Amplification > 2.4 – 2.6; and Amplification > 2.6. 
5.1.4 Single nucleotide polymorphism (SNPs) array analysis for assessment of EGFR 
copy number status 
Nucleic Acid Isolation and microarray experiment: Fresh frozen tumor tissues (10-20 mg) 
from patients with glioblastoma were used to extract high molecular weight, genomic DNA 
using DNeasy kit extraction (Qiagen, Valencia, CA). DNA quality was assessed by 
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electrophoresis in 1% of agarose gel. Two hundred and fifty DNA nanograms were used for 
hybridization on Genechip Human Mapping 100K as recommended by the manufacturer 
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2004). Arrays were normalized against the array with median overall intensity (Baseline 
array) employing the Invariant set normalization method (Li & Wong 2001a). Probe set signal 
intensity was obtained by using a model based on expression index (PM/MM) method (Li & 
Wong, 2001b). Average array call rate was > 95 %. We employ a Hidden-Markov model to 
identify LOH regions from unpaired tumor samples, taking into account SNP intermarker 
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with 80 % of the samples.  
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5.1.6 Statistical analysis 
In this study we used no parametric test for Ki67 levels, EGFR copy number, EGFR 
transcript expression, and percentage of cells found to be EGFR amplification by FISH. First, 
the Kruskal-Wallis test was used to assess significant differences among established groups, 
and then the comparisons among the pairs of groups were assessed by means of the Mann-
Whitney U test. We used the Bonferroni method to correct the p-values in order to avoid 
type I error. 
Pearson´s coefficient was used to assess the significant correlation between: EGFR copy 
number measured by qPCR, EGFR transcript expression and percentage of EGFR positive 
cells measured by FISH. The significance of the differential protein expression was 
contrasted by comparing the EGFR amplification type using Fischer´s exact test (one-tailed). 
Survival curves for amplification types, KPS groups (≤80, >80), and age (<55, ≥55 years) 
were evaluated by the Kaplan-Meier method and were compared with the log-rank test. The 
statistical tests significance was determined at p-value ≤ 0.05. The analysis was performed 
with SPSS 15.0 software (SPSS Inc., Chicago, IL). 
5.2 Levels of EGFR amplification in glioblastoma 
Sixty glioblastomas were analyzed successfully by FISH in cultured cells and paraffin 
sections. We have analyzed the type of EGFR amplification, the fraction of amplified cells, 
and the number of signals of EGFR in each tumor. 
 On basis of the EGFR status, the gene copy number and the type of amplification, the cases 
were categorized into three groups: GBM-h: high level EGFR gene amplification and dmin, 
GBM-l: low level EGFR gene amplification and insertions, and GBM-n: no EGFR gene 
amplification (Lopez-Gines et al., 2010).  
GBM-h: The 47% of the cases was included in this group. The 50% of patients were male 
and 50% female. Patient age ranged from 38 to 72, with a mean age of 56 years. Survival 
ranged from 1 to 24 months, with a mean of 9 months. 
Histologically, all tumors demonstrated features of glioblastoma with pleomorphic, 
astrocytic tumor cells, prominent microvascular proliferation, and necrosis. In every case, 
the expression of GFAP was confirmed in the neoplastic cells. The number of mitoses 
ranged between 1 and 20, with a mean of 7. The mean Ki-67 of the tumors was 38%; range: 
10-80%.  
The type of amplification was dmin with a variable number of copies affecting over 25% of 
the cells in most cases. Only two cases contained less than 10% of amplified cells in paraffin 
sections. 
By using SNP arrays, we inferred the presence of frequent copy number gains in the region 
of the EGFR locus. In tumor samples, an excess of EGFR gene copies was identified by copy 
number variation from the reference set and from the copy number of the control samples. 
Gene copy numbers at 7p12.1 were validated by quantitative PCR. Every case showed a 
strong correlation of these values with the copies demonstrated by FISH (Pearson’s 
correlation coefficient= 0.77; p-value≤ 0.01).  
Gene expression have a significant, positive correlation between the EGFR copy number and 
the transcript gene expression (Pearson’s correlation coefficient = 0.75; p-value≤ 0.01). The 
higher percentage of cases of amplified EGFR detected by FISH was correlated with a higher 
gene expression (Pearson’s correlation coefficient = 0.85; p-value≤ 0.01). 
The EGFR protein expression was evaluated by immunohistochemistry. Cases with a high 
level of amplification, manifested EGFR overexpression (except in two cases). 
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Fig. 9. High-level of amplification of the EGFR present in GBM-h group. Probe for EGFR and 
centromere 7 were labelled with red and green respectively.  A) Interphase nuclei of 
cultured cells. B) Metaphase showing trisomy 7 and EGFR amplification as dmin C) Nuclei 
in paraffin sections showing high level of amplification. Probe for EGFR and centromere 7 
were labelled with red and green respectively. D) Immunoreactivity for EGFR: Strong 
staining.  
    
Fig. 10. Low-level of amplification of the EGFR present in GBM-l group. A) Different 
interphase nuclei of cultured cells showing low-level (arrow) of amplification. B) Metaphase 
spread with extra copies of EGFR inserted in p and q arms of chromosomes 7. C) Tumoral 
cells in paraffin section with low-level amplification/copy number gains with other cells 
exhibiting a normal copy number of the EGFR gene. D) Immunoreactivity for EGFR with 
focal staining. 
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GBM-l: The 21% of the cases was included in this group. The 69% of patients were male and 
31% female. Patient age ranged from 24 to 73, with a mean age of 48 years. Survival ranged 
from 3 to 23 months, with a mean of 12 months. 
Histologically, all tumors demonstrated features of glioblastoma with pleomorphic, 
astrocytic tumor cells, prominent microvascular proliferation, and necrosis. In every case, 
the expression of GFAP was confirmed in the neoplastic cells. The number of mitoses 
ranged between 0 and 20, with a mean of 4. The mean Ki-67 of the tumors was 24%; range: 
5-50%. The type of amplification showed extra copies of EGFR inserted in different locus of 
chromosome 7, both in p and q arms. In this form of amplification, the number of copies was 
small, and the percentage of cells with  EGFR amplification, rarely affects more than 15% of 
the cells. These cases presented low values validated by quantitative PCR.  The increase in 
mRNA caused by amplification is not always proportional to the number of gene copies. 
Non increase of RNA expression was found in this group. The EGFR protein expression was 
variable, only one third of the cases scored EGFR overexpression. 
GBM-n: The 32% of the cases was included in this group. The 63% of patients were male 
and 37% female. Patient age ranged from 22 to 76, with a mean age of 49 years. Survival 
ranged from 3 to 24 months, with a mean of 11 months. 
Histologically, all tumors demonstrated features of glioblastoma with pleomorphic, 
astrocytic tumor cells, prominent microvascular proliferation, and necrosis. In every case, 
the expression of GFAP was confirmed in the neoplastic cells. The number of mitoses 
ranged between 0 and 10, with a mean of 3.The mean Ki-67 of the tumors was 23%; range: 5-
50%. 
These cases without EGFR amplification presented the values of quantitave PCR nearly 2, 
and non increase of RNA expression was found. The immunohistochemistry analysis 
showed no overexpression in 79% of cases and overexpression in 21% of cases. 
 
 
Fig. 11. No amplification of the EGFR present in GBM-n group. A) Different interphase 
nuclei of cultured cells showing no amplification. B) Metaphases spread with three 
centromeres of chromosome 7 and three copies of EGFR. C) Non-amplified tumoral cells of 
paraffin sections. D) No immunoexpression for EGFR 
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On the basis of these results, the model of amplification of group GBM-l could correspond to 
a variant of the distributed insertion mechanism, or a consequence of a process of 
duplication like the one demonstrated in neuroblastoma cell lines (Corvi et al., 1995), and 
we suggest that this mechanism could be considered as an early stage of amplification in 
glioblastoma. This hypothesis is corroborated by the findings of both status of amplification, 
dmin, and extra copies located in chromosome 7, in two cases. In glioblastomas, the cut-
points that define amplification are controversial (Smith et al., 2001, Layfield et al., 2006), 
although the most commonly accepted criteria is that EGFR amplification exists when the 
EGFR gene/chromosome per cell ratio was ≥2, or ≥15 copies of EGFR per cell in ≥10% of 
analyzed cells (Capuzzo et al., 2005, Nagasaka et al., 2007).  
 
 
Fig. 12. Model of amplification of EGFR correspond to a variant of the distributed insertion 
mechanism. 
In addition, there was considerable heterogeneity in the centromere 7 (CEP7) copy number 
in these tumors. The relationship between trisomy/polysomy of chromosome 7 and EGFR 
gene amplification has been analyzed. In our study, both amplified and non-amplified 
tumors showed trisomy/polysomy of chromosome 7. This fact suggests that this alteration 
could be an initial event in the tumorigenesis of glioblastoma. 
 
 
Table 3. Characterization of the three types of EGFR amplification found in glioblastoma 
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5.3 Statistical correlation of EGFR copy alterations with clinicopathological 
parameters 
The Kruskal Wallis test was used to assess the differences among the three amplification 
groups and it showed significant differences in the percentage of cells with positive EGFR 
amplification detected by FISH, the EGFR copy number quantified by PCR, and the EGFR 
transcript expression assessed by microarrays (p-value ≤ 0.01). In the percentage of EGFR 
positive cells and EGFR copy number, all bilateral comparisons of the  three amplification 
groups showed statistically significant differences, after the Bonferroni correction (GBM-h 
vs GBM-l, GBM-h vs GBM-n, GBM-l vs GBM-n) (p-value ≤ 0.01). The EGFR expression 
values of amplification types GBM-h and GBM-l were statistically significant after the 
Bonferroni correction (p-value ≤ 0.01). No significant differences were found between types 
GBM-l and GBM-n. The mean Ki-67 value of group GBM-h exhibited statistically significant 
differences with respect the rest (p-value < 0.05). Ki-67 mean values for the different groups 
were 38% for the GBM-h group, 24% for the GBM-l group and 23% for the GBM-n group. 
None of the survival curves showed any significant differences in established groups 
according to EGFR amplification type, and age (<55, ≥55 years). As we expected, younger 
patients (<55 years) showed a slightly higher survival rate. Interestingly, patients with EGFR 
amplification type GBM-h survived for the shortest time, a mean of 9 months. 
Amplification in general and amplicons in particular are important for both prognosis and 
targeted therapies. Specific amplicons, such as MYCN in neuroblastomas, and MYC and 
ERBB2 in breast cancer, also have prognostic significance (Albertson, 2006). EGFR 
amplification status has been studied as a potential prognostic indicator. The majority of the 
early reports showed that amplification of the EGFR was associated with a poorer prognosis 
than that associated with non-amplified glioblastomas (Simmons et al., 2001, Shinojima et 
al., 2003). Other studies failed to confirm this relationship. Our study did not show that the 
type of EGFR amplification led to significant differences in survival rates; although, 
interestingly, patients of group GBM-h, with EGFR amplification type dmin survived for the 
shortest time.  
6. Conclusion 
Glioblastoma multiforme is characterized by intratumoral heterogeneity in both 
histomorphological and genetic changes, displaying a wide variety of numerical 
chromosome aberrations, the most common of which are trisomy 7 and monosomy 10. The 
amplification of the epidermal growth factor receptor (EGFR) gene is the most frequently 
reported genetic abnormality. 
Our studies about histopathological and genetical characterization of glioblastoma 
multiforme suggest that, in primary glioblastomas, there exists a subgroup of cases closely 
linked with EGFR amplification. However, there is another subgroup of cases without EGFR 
amplification with some different clinical and genetic characteristics. This second group 
might include the increased activation or expression of other growth factor receptors 
observed in these tumors such as PDGFR or IGFR, although they are only amplified in a low 
percentage of cases.  
Furthermore, we proposed that EGFR amplification is an important and frequent pathway 
in glioblastomas. This amplification is expressed as dmin in a subset of glioblastoma, but we 
have observed another type of amplification of the EGFR gene. This is seen at chromosome 
level as distributed insertions of this gene in chromosome 7 itself. Detection of this pattern 
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of amplification of EGFR may further improve the prognostic value of genomic diagnosis of 
this disease.  
Since amplification is often associated with poor prognosis and is a mechanism of resistance 
to therapies, it will be important to identify the genes or pathways (or both) that promote 
amplification in tumors, so that they might be targeted as part of a combination therapy to 
prevent the evolution of resistance to drugs designed to arrest or eradicate the tumor.  
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5.3 Statistical correlation of EGFR copy alterations with clinicopathological 
parameters 
The Kruskal Wallis test was used to assess the differences among the three amplification 
groups and it showed significant differences in the percentage of cells with positive EGFR 
amplification detected by FISH, the EGFR copy number quantified by PCR, and the EGFR 
transcript expression assessed by microarrays (p-value ≤ 0.01). In the percentage of EGFR 
positive cells and EGFR copy number, all bilateral comparisons of the  three amplification 
groups showed statistically significant differences, after the Bonferroni correction (GBM-h 
vs GBM-l, GBM-h vs GBM-n, GBM-l vs GBM-n) (p-value ≤ 0.01). The EGFR expression 
values of amplification types GBM-h and GBM-l were statistically significant after the 
Bonferroni correction (p-value ≤ 0.01). No significant differences were found between types 
GBM-l and GBM-n. The mean Ki-67 value of group GBM-h exhibited statistically significant 
differences with respect the rest (p-value < 0.05). Ki-67 mean values for the different groups 
were 38% for the GBM-h group, 24% for the GBM-l group and 23% for the GBM-n group. 
None of the survival curves showed any significant differences in established groups 
according to EGFR amplification type, and age (<55, ≥55 years). As we expected, younger 
patients (<55 years) showed a slightly higher survival rate. Interestingly, patients with EGFR 
amplification type GBM-h survived for the shortest time, a mean of 9 months. 
Amplification in general and amplicons in particular are important for both prognosis and 
targeted therapies. Specific amplicons, such as MYCN in neuroblastomas, and MYC and 
ERBB2 in breast cancer, also have prognostic significance (Albertson, 2006). EGFR 
amplification status has been studied as a potential prognostic indicator. The majority of the 
early reports showed that amplification of the EGFR was associated with a poorer prognosis 
than that associated with non-amplified glioblastomas (Simmons et al., 2001, Shinojima et 
al., 2003). Other studies failed to confirm this relationship. Our study did not show that the 
type of EGFR amplification led to significant differences in survival rates; although, 
interestingly, patients of group GBM-h, with EGFR amplification type dmin survived for the 
shortest time.  
6. Conclusion 
Glioblastoma multiforme is characterized by intratumoral heterogeneity in both 
histomorphological and genetic changes, displaying a wide variety of numerical 
chromosome aberrations, the most common of which are trisomy 7 and monosomy 10. The 
amplification of the epidermal growth factor receptor (EGFR) gene is the most frequently 
reported genetic abnormality. 
Our studies about histopathological and genetical characterization of glioblastoma 
multiforme suggest that, in primary glioblastomas, there exists a subgroup of cases closely 
linked with EGFR amplification. However, there is another subgroup of cases without EGFR 
amplification with some different clinical and genetic characteristics. This second group 
might include the increased activation or expression of other growth factor receptors 
observed in these tumors such as PDGFR or IGFR, although they are only amplified in a low 
percentage of cases.  
Furthermore, we proposed that EGFR amplification is an important and frequent pathway 
in glioblastomas. This amplification is expressed as dmin in a subset of glioblastoma, but we 
have observed another type of amplification of the EGFR gene. This is seen at chromosome 
level as distributed insertions of this gene in chromosome 7 itself. Detection of this pattern 
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of amplification of EGFR may further improve the prognostic value of genomic diagnosis of 
this disease.  
Since amplification is often associated with poor prognosis and is a mechanism of resistance 
to therapies, it will be important to identify the genes or pathways (or both) that promote 
amplification in tumors, so that they might be targeted as part of a combination therapy to 
prevent the evolution of resistance to drugs designed to arrest or eradicate the tumor.  
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1. Introduction  
The pivotal role of kinases in signal transduction and cellular regulation has lent them 
considerable appeal as therapeutic targets across a broad spectrum of cancers. The 
epidermal growth factor receptor (EGFR) was the first receptor tyrosine kinase to be 
discovered and remains the most investigated. Most of the mechanistic principles of 
receptor tyrosine kinases were first established with the EGFR family as a model. EGFR is a 
single pass transmembrane receptor with two extracellular, cysteine-rich regions involved in 
ligand binding, and intervening region important for receptor dimerization, an intracellular 
tyrosine kinase domain, and a number of intracellular sites for autophosphorylation, 
phosphorylation by other kinases, and docking of signaling components. Three additional 
EGFR family members have been identified, human epidermal growth factor receptor (erbB 
or HER) 2, 3 and 4. In many cell types, including those of epithelial and mesenchymal 
lineages, receptors of the HER family transduce signals from the cell surface to the 
intracellular domain, regulating normal cell growth, lineage determination, repair and 
functional differentiation. A range of growth factors serves as ligands for these receptors, 
although none have been identified for the HER2 receptor. Ligands for HER1/EGFR include 
epidermal growth factor (EGF) and transforming growth factor-α (TGF-α), and heregulins 
serve as ligands for both HER3 and HER4. Binding of a ligand to a HER family member 
leads to receptor homodimerization, or heterodimerization with another HER receptor, 
bringing about receptor phosphorylation. Ligand binding to HER1, HER3 or HER4 induces 
rapid receptor dimerization, with a marked preference for HER2 as a partner(Graus-Porta et 
al., 1997). Moreover, HER2-containing heterodimers generate intracellular signals that are 
significantly more potent than signals emanating from other HER combinations. Of the 
receptor dimers, HER3 homodimers cannot initiate signal transduction.The differing 
signaling characteristics of the HER family members are thought to be due to their different 
ligand-binding affinities and the type of phosphorylated homo- or heterodimer formed, and 
the resulting intracellular signaling events. Two of the key pathways involved in this 
cascade are the ras-raf-mitogen-activated protein kinase (MAPK) pathway, which affects 
DNA synthesis and cell proliferation, and the phosphatidylinositol 3-kinase (PI3-K)/Akt 
pathway, which plays a role in cell metabolism and survival (Yarden and Sliwkowski, 2001; 
Bange et al., 2001). 
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Functional dysregulation of the EGFR family is frequently observed in human cancers, 
suggesting that its signal modulates processes that play a pivotal role in tumorigenesis and 
disease progression. Activating mutations, gene amplification and overexpression of HER 
family kinases have been implicated as integral contributors to a variety of epithelial 
cancers, including breast, colon, pancreas, lung, and squamous cancers and also 
glioblastomas(Yarden, 2001; Foley et al., 2010; Yarom and Jonker, 2011; Wheeler et al., 2010; 
Dobashi et al., 2011; Machiels and Schmitz, 2011; Hwang, 2008). This is highlighted by 
HER1/EGFR overexpression or activation by autocrine or paracrine growth factor loops in 
at least 50% of epithelial malignancies, HER2 amplification and overexpression in 
approximately 20–25% of breast cancers and variable HER3 and HER4 expression in breast 
and other cancers. Overexpression and/or activation of HER1/EGFR, HER2/neu and HER3 
have been correlated with poor prognosis. In contrast, it is unclear whether HER4 induces 
cell division or differentiation, and there is controversy regarding its role in breast cancer, 
with conflicting reports associating overexpression with shorter or prolonged survival 
(Normanno et al., 2006). Therefore, attenuation of HER family signaling is a developing 
strategy for the management of human malignancies and is the subject of a number of 
ongoing clinical trials. 
Signaling from the plasma membrane by receptor tyrosine kinases (RTKs) to initiate 
downstream events that bring about their biological effects is well established.  In the past 
decade, it has become increasingly apparent that several RTKs also move to several 
intracellular compartments, with nuclear localization in many cases being necessary for full 
function of the receptors. Access to the inside of the cell by the RTKs has in fact been shown 
to contribute to genesis and progression of a variety of human tumors (Carpenter, 2003). 
Accruing evidence points to a scenario where nuclear localization of EGFR in different 
tumor types has impact on not only the tumor grade but also on the resistance of tumors to 
therapies (Lo et al., 2006b; Wang and Hung, 2009). Here we critically evaluate the existing 
literature regarding intracellular localization of EGFR and its importance to cancer, and 
discuss future directions for the field. Further, the opportunity for targeting nuclear 
translocation of EGFR to develop therapeutics for intervention during critical stages of 
development and progression of neoplasms should be evaluated. There are numerous 
excellent recent reviews of HER family biology, signaling and therapeutic targeting (Yarden, 
2001; Yarden and Sliwkowski, 2001; Foley et al., 2010; Yarom and Jonker, 2011; Wheeler et 
al., 2010; Hwang, 2008). This chapter will provide an overview of aberrant EGFR signaling 
in the biology of gliomas highlighting several key developments in the rapidly evolving 
area of HER family biology with specific reference to new localization of EGFR and the 
integral role of these receptors in malignant transformation and as targets of cancer therapy 
specifically in glioblastomas. 
2. EGFR in glioma 
Although a large number of other genetic alterations also occur in GBM, EGFR represents 
the most frequently amplified gene (2008; Hatanpaa et al., 2010). In fact, in primary GBM, it 
has been noted for about two decades and confirmed recently with two large-scale cancer 
genomics studies that EGFR amplification and mutation is a recurrent occurrence, being 
detected in about 40% of the samples (2008; Parsons et al., 2008). However, this is a rare 
event in low-grade gliomas (Ohgaki and Kleihues, 2007), suggesting a causal role for 
aberrant EGFR signaling in the pathogenesis of primary GBM. The resulting dysregulation 
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of the signal transduction process affects gene transcription and protein translation, 
stimulating tumor cell proliferation, tumorigenesis, migration, adhesion and angiogenesis, 
and inhibiting apoptosis (Huang et al., 2009). Recent research has shown an unfavorable 
prognostic relationship between EGFR amplification and overall survival in patients with 
GBM (Aldape et al., 2004; Heimberger et al., 2005; Pelloski et al., 2007). EGFR expression is 
also associated with enhanced resistance to radiation in malignant GBM cells in vitro and is 
correlated with poor radiographic response to radiation therapy in some patients with GBM 
(Nakamura, 2007; Hatanpaa et al., 2010). EGFR dysregulation in GBM result from a number 
of different mechanisms. Primarily, gene amplification causes EGFR overexpression, which 
correlates with disease progression, poor prognosis and reduced sensitivity to 
chemotherapy. In addition, overproduction of EGFR ligands, such as TGF-α and EGF can 
cause autocrine receptor activation, enhancing transformation and leading to independent 
tumor cell growth. Further, activating mutations in EGFR generates EGFR mutants that 
demonstrate constitutive activity resulting in activation of the downstream intracellular 
cascade without ligand binding and insensitivity to regulation by normal cellular controls 
(Hwang, 2008). 
While there are various mutant forms of EGFR in GBM, the most prevalent and well studied 
EGFR mutation is EGFRvIII (Hwang, 2008). EGFRvIII is detected in about half of all  
tumors with EGFR amplification (Aldape et al., 2004; Heimberger et al., 2005). 
Immunohistochemical and quantitative PCR studies of human GBM biopsies suggest that in 
most tumors the overexpression or amplification of EGFRvIII occurs concurrently with that 
of EGFR. Only in about 10% of glioblastomas does overexpression or amplification of 
EGFRvIII exceed that of the wild-type receptor (Sugawa et al., 1990; Furnari et al., 2007). In 
addition to GBM, EGFRvIII has been detected in several human cancers including NSCLC 
and breast carcinomas (Moscatello et al., 1995; Ge et al., 2002; Ji et al., 2006; Sasaki et al., 
2007). Structurally, EGFRvIII exhibits a large inframe deletion of the extracellular ligand 
binding domain which results from the elimination of a 801 base pair (nucleotide positions 
275–1075) DNA fragment containing exons 2–7 of the gene (Sugawa et al., 1990; Ekstrand et 
al., 1991; Wong et al., 1992; Frederick et al., 2000). This partial deletion of the ligand-binding 
domain renders EGFRvIII ligand insensitive and also constitutively activated. The ability of 
this variant to ‘switch on’ cell signaling without ligand stimulation, albeit at low levels, 
results in increased oncogenic signaling and aggressive behavior in tumors that express it 
(Huang et al., 1997; Nishikawa et al., 1994; Chu et al., 1997). Further, it has a low rate of 
receptor endocytosis, so is not readily attenuated and/or down-regulated (Chu et al., 1997; 
Huang et al., 1997). EGFRvIII correlates with advanced disease and resistance to therapy 
(Hwang, 2008). Several studies have found that it enhances tumorigenicity in human glioma 
xenografts in mice. The introduction of EGFRvIII into glioma cells enhances tumorigenicity, 
proliferation, migration, and inhibits apoptosis (Huang et al., 1997; Nagane et al., 1996; 
Nagane et al., 2001). In a transgenic mouse model, EGFRvIII was found to contribute to 
glioma progression in the presence of other predisposing genetic changes, such as mutated 
RAS, but failed to initiate tumors on its own (Holland et al., 1998; Bachoo et al., 2002; Ding et 
al., 2003). Furthermore, there is growing evidence from in vitro studies in human 
glioblastoma cells, human tumor xenografts in animal models, and in patients with GBM, to 
suggest that EGFRvIII promotes tumor growth and progression in part via constitutive 
activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway (Choe et al., 2003; 
Aldape et al., 2004; Mizoguchi et al., 2006; Pedersen et al., 2005; Huang et al., 2007). The role 
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of the mitogen-activated protein kinase (MAPK)/ERK 1/2 signal transduction pathway 
downstream of EGFRvIII is still unclear. Constitutive activity as well as impaired 
attenuation has been implicated as mechanisms for the enhancement of human glioblastoma 
cell tumorigenicity by EGFRvIII as compared to wild-type EGFR. Further, it has been 
recently demonstrated that EGFRvIII overexpression results in secretion of IL-6 and other 
cytokines to potentiate tumorigenesis in a paracrine manner (Inda et al., 2010). These data 
may explain the observation that patients with EGFRvIII-expressing tumors have a shorter 
interval to clinical relapse and poorer survival than patients with EGFRvIII-negative tumors. 
For GBM patients who survive 1 year or longer after diagnosis, the expression of EGFRvIII 
is also an independent negative prognostic indicator of survival (Aldape et al., 2004; 
Heimberger et al., 2005; Pelloski et al., 2007), which makes EGFRvIII an ideal target for 
antitumor therapy. 
Signaling pathways are complex, multidimensional events that frequently converge, 
diverge, and cross talk with one another. The traditional cellular functions of EGFR and 
EGFRvIII has been reviewed elsewhere; this review focuses specifically on the role played 
by EGFR and EGFRvIII in the nuclear compartment as well as its nuclear downstream 
effectors in a number of human malignancies, and the possible novel therapeutic 
opportunities provided for development of anti-tumor agents. 
3. EGFR/EGFRvIII in mitochondria 
In the past decade, it has become increasingly apparent that several RTKs, including EGFR 
act also from intracellular organelles wherein they elicit biological effects that are uniquely 
distinct from their cell-surface functions. In addition to translocation to the nucleus (which is 
described in detail in the next sections), EGFR also localizes to the mitochondria, where it 
interacts with COXII and regulates cell survival in an EGFR Tyr845-dependent manner 
(Boerner et al., 2004). Src can activate EGFR by phosphorylating it on the Tyr845 and 
interestingly, the kinetics of mitochrondrial localization of both EGFR and Src (which also 
undergoes mitochondrial import) seem to be similar suggesting that they might translocate  
in the same complex (Demory et al., 2009). While the complete mechanism by which EGFR 
translocates to the mitochondria has not yet been defined, a recent investigation revealed 
that both EGFR and Src kinase activity was essential for mitochondrial translocation. 
Further, the same group identified that a mitochondrial localization signal in the 
juxtamembrane region of EGFR (residues 645 to 666) as well as the endocytic pathway are 
important for the movement of EGFR to the mitochondrion (Demory et al., 2009).  Since the 
fusion of endosomes with mitochondria has not been demonstrated, the actual process by 
which endosomal EGFR moves to the mitochondria is still open to investigation. However, 
it was also shown that EGFR interacted with Tom40 (Demory et al., 2009), the pore 
component of the TOM complex and an outer mitochondrial membrane transport protein 
that is necessary for transport of newly synthesized mitochondrial proteins encoded by 
nuclear DNA. This suggests that EGFR could utilize the TOM complex to enter the 
mitochondria.  Further, a report also demonstrated that EGFR translocates to the 
mitochondrion during autophagy where it again promoted cell survival (Yue et al., 2008), 
implying that mitochondrial localization of EGFR could potentially be an important survival 
strategy for cells. The same study showed that EGFR mitochondrial translocation can be 
increased by the mTOR inhibitor, rapamycin, and decreased by the topoisomerase inhibitor, 
etoposide, and by 3'-methyladenine, an inhibitor of autophagy. The reported link between 
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autophagy and mitochondrial EGFR is particularly interesting due to the recent observation 
that apoptotic stress induces EGFR mitochondrial transport. Given the pivotal role that 
mitochondria plays in intrinsic apoptosis, a study by Cao et al (Cao et al., 2011) show that 
not only EGFR but EGFRvIII can also translocate to the mitochondria when induced by 
apoptosis-inducing agents and EGFR kinase inhibitors(Iressa) and that tumor cells with 
accumulated mitochondrial EGFRvIII are resistant to apoptosis induced by these 
agents. These results implicate mitochondrial EGFR/EGFRvIII in the modulation of 
mitochondria-mediated apoptosis. Taken together these studies suggest that tumor cells re-
program their intracellular trafficking of EGFR/EGFRvIII  by increasing its mitochondrial 
accumulation, as a mechanism for escape from therapy- and stress-induced apoptosis and 
growth suppression. 
4. EGFR in the nuclear compartment 
In addition to ligand recognition, binding, and initiation of intracellular signaling cascades, 
receptor tyrosine kinases such as the EGFR family have newly emerging roles in the 
regulation of nuclear functions through their direct translocation to the cell nucleus. Broadly 
speaking two kinds of nuclear translocation have been identified: EGFR, HER2 and HER3 
have been found as full-length proteins in the nuclear compartment and this will be our 
focus here; in contrast HER4 nuclear translocation and transactivation functions occur 
through a separate mechanism involving cleavage by matrix metalloprotease of the 
extracellular domain upon receptor activation, and cleavage of the intracellular domain by 
gamma secretase, releasing a protein fragment that translocates to the nucleus (Carpenter, 
2003). This carboxyl-terminal HER4 fragment then associates with the WW-domain-
containing transcriptional regulatory protein YAP (Yes-associated protein) and acts as a co-
transcriptional activator (Ni et al., 2001). The physiological and clinical importance of 
nuclear EGFR has been underscored by the observation that presence of EGFR in the nuclear 
compartment in tumor biopsies correlates strongly with poor prognosis and resistance to 
standard treatment modalities (Wang and Hung, 2009).  
4.1 Nuclear localization and function 
Almost two decades of research have documented the presence of EGFR and its ligand EGF 
in the nucleus. Early studies focused on EGF localization and demonstrated that nuclear 
presence of intact EGF was dependent on the expression of EGFR (Rakowicz-Szulczynska et 
al., 1986; Rakowicz-Szulczynska et al., 1989). The use of labeled EGF enabled definitive 
documentation that nuclear EGF was derived from extracellularly added ligand (Rakowicz-
Szulczynska et al., 1989). The same studies demonstrated that the nuclear membranes and 
isolated chromatin contained EGFR which was indistinguishable from plasma membrane 
localized EGFR both biochemically and immunologically (Rakowicz-Szulczynska et al., 
1989; Oksvold et al., 2002; Cao et al., 1995; Marti et al., 1991; Marti and Wells, 2000). Further, 
EGF could stimulate phosphorylation of nuclear EGFR and other nuclear proteins in 
isolated nuclei and nuclear membranes, and could be specifically inhibited by monoclonal 
antibodies directed against the extracellular domain of cell surface EGFR (Holt et al., 1994). 
In normal tissues, nuclear expression of EGFR has been shown to be associated with the 
acquisition of proliferative capabilities of the cell. In hepatocytes which start proliferating 
after hepatectomy, nuclear EGFR was detected. In contrast, quiescent hepatocytes did not 
show nuclear EGFR (Marti et al., 1991). EGFR was also identified in the nucleus of mouse 
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autophagy and mitochondrial EGFR is particularly interesting due to the recent observation 
that apoptotic stress induces EGFR mitochondrial transport. Given the pivotal role that 
mitochondria plays in intrinsic apoptosis, a study by Cao et al (Cao et al., 2011) show that 
not only EGFR but EGFRvIII can also translocate to the mitochondria when induced by 
apoptosis-inducing agents and EGFR kinase inhibitors(Iressa) and that tumor cells with 
accumulated mitochondrial EGFRvIII are resistant to apoptosis induced by these 
agents. These results implicate mitochondrial EGFR/EGFRvIII in the modulation of 
mitochondria-mediated apoptosis. Taken together these studies suggest that tumor cells re-
program their intracellular trafficking of EGFR/EGFRvIII  by increasing its mitochondrial 
accumulation, as a mechanism for escape from therapy- and stress-induced apoptosis and 
growth suppression. 
4. EGFR in the nuclear compartment 
In addition to ligand recognition, binding, and initiation of intracellular signaling cascades, 
receptor tyrosine kinases such as the EGFR family have newly emerging roles in the 
regulation of nuclear functions through their direct translocation to the cell nucleus. Broadly 
speaking two kinds of nuclear translocation have been identified: EGFR, HER2 and HER3 
have been found as full-length proteins in the nuclear compartment and this will be our 
focus here; in contrast HER4 nuclear translocation and transactivation functions occur 
through a separate mechanism involving cleavage by matrix metalloprotease of the 
extracellular domain upon receptor activation, and cleavage of the intracellular domain by 
gamma secretase, releasing a protein fragment that translocates to the nucleus (Carpenter, 
2003). This carboxyl-terminal HER4 fragment then associates with the WW-domain-
containing transcriptional regulatory protein YAP (Yes-associated protein) and acts as a co-
transcriptional activator (Ni et al., 2001). The physiological and clinical importance of 
nuclear EGFR has been underscored by the observation that presence of EGFR in the nuclear 
compartment in tumor biopsies correlates strongly with poor prognosis and resistance to 
standard treatment modalities (Wang and Hung, 2009).  
4.1 Nuclear localization and function 
Almost two decades of research have documented the presence of EGFR and its ligand EGF 
in the nucleus. Early studies focused on EGF localization and demonstrated that nuclear 
presence of intact EGF was dependent on the expression of EGFR (Rakowicz-Szulczynska et 
al., 1986; Rakowicz-Szulczynska et al., 1989). The use of labeled EGF enabled definitive 
documentation that nuclear EGF was derived from extracellularly added ligand (Rakowicz-
Szulczynska et al., 1989). The same studies demonstrated that the nuclear membranes and 
isolated chromatin contained EGFR which was indistinguishable from plasma membrane 
localized EGFR both biochemically and immunologically (Rakowicz-Szulczynska et al., 
1989; Oksvold et al., 2002; Cao et al., 1995; Marti et al., 1991; Marti and Wells, 2000). Further, 
EGF could stimulate phosphorylation of nuclear EGFR and other nuclear proteins in 
isolated nuclei and nuclear membranes, and could be specifically inhibited by monoclonal 
antibodies directed against the extracellular domain of cell surface EGFR (Holt et al., 1994). 
In normal tissues, nuclear expression of EGFR has been shown to be associated with the 
acquisition of proliferative capabilities of the cell. In hepatocytes which start proliferating 
after hepatectomy, nuclear EGFR was detected. In contrast, quiescent hepatocytes did not 
show nuclear EGFR (Marti et al., 1991). EGFR was also identified in the nucleus of mouse 
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lung epithelial cells where it was shown to respond to neuregulin stimulation(Zscheppang 
et al., 2006). Additionally, functional nuclear EGFR was demonstrated in human placenta 
where its role as a transcription factor was put forth (Cao et al., 1995). Further, nuclear 
localization of EGFR was demonstrated in primary human umbilical venous endothelial 
cells (HUVEC) and arterial endothelial cells (HUAEC) derived from early fetal gestation 
(Bueter et al., 2006). 
Three basic functions of nuclear EGFR have been defined thus far (Figure 1). They are 
1. gene regulation/transactivation, 
2. tyrosine phosphorylation of target proteins and  
3. protein-protein interactions leading to DNA repair  
 
 
Fig. 1. Schematic representation of nuclear functions of EGFR. The cartoon shows both 
traditional cytoplasmic signaling eliciting nuclear effects as well as the more recently 
identified nuclear translocation and direct nuclear effects. Adapted from (Lo et al., 2006c) 
4.1.1 Regulation of transcription 
Although nuclear localization and potential transcriptional activity of EGFR had been noted 
in previous publications, Lin et al. demonstrated for the first time the presence of a strong 
transactivation domain in the C-terminal Pro-rich domain of EGFR, which mediated nuclear 
transactivation functions in a sequence-specific fashion (Lin et al., 2001). Although an EGFR 
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mutant which lacked the transmembrane domain could also translocate to the nucleus, this 
movement required both wild type EGFR and active ligand signaling (Marti and Wells, 
2000). Upon ligand stimulation, EGFR translocated to the nucleus and associated with an 
A/T-rich sequence (ATRS) in the cyclin D1 promoter, resulting in transcriptional activation 
of cyclin D1. This study thus defined a direct link between nuclear EGFR function and cell 
proliferation specifically in tumors (Lin et al., 2001). Interestingly, it had been shown about a 
decade earlier that for induction of a mitogenic response, amphiregulin, one of the ligands 
of EGFR, had to undergo nuclear translocation where it bound to AT-rich DNA sequences 
(Kimura, 1993). Since EGFR lacks a putative DNA-binding domain, the wide-held idea in 
the field is that EGFR first associates with DNA-binding transcription factors and then 
enhances target gene transcription via their intrinsic transactivational activity. Another 
mechanism underlying nuclear EGFR-mediated gene regulation could be attributed to its 
interaction with mucin 1 (MUC1) wherein there is increased accumulation of chromatin-
bound EGFR on cyclin D1 promoter and significant co-localization with phosphorylated 
RNA polymerase II, a marker of active transcription (Bitler et al., 2010). A recent study 
showed that EGFR was also able to associate with ATRS sites on DNA by association with 
RNA helicase A (RHA), a DNA and RNA binding protein (Huo et al., 2010). This association 
was found to be absolutely necessary for EGFR recruitment to the ATRS site of cyclin D1 
promoter and partially necessary for recruitment onto another ATRS-containing promoter 
of inducible nitric oxide synthase (iNOS) gene (Huo et al., 2010). The partial role of RHA in 
EGFR regulation of iNOS could be because nuclear EGFR has been shown to get recruited to 
iNOS promoter via physical protein-protein interaction with the well characterized 
transcription factor, signal transducer and activator of transcription 3 (STAT3) (Lo et al., 
2005a). Physical interaction and functional cooperation of EGFR with STAT3 at the 
cytoplasmic level is very well characterized. According to this classical model, active EGFR 
at the plasma membrane binds to the SH2 domain of STAT3, via the two docking 
autophosphorylated tyrosines (Tyr1068 and Tyr1086)(Shao et al., 2003). This interaction 
leads to the phosphorylation of STAT3 at Tyr705 and its activation. The dimeric STAT 
complex translocates to the nucleus, where it binds to specific DNA promoter sequences, 
recruits other transcriptional regulators, and activates the transcription of multiple genes 
important for cell survival (Shao et al., 2003). However, data now show that EGFR can 
interact with STAT3 in the nucleus where they form a complex that functions as a 
transcriptional activator for the iNOS gene (Lo et al., 2005a) and the Cox-2 gene (Lo et al., 
2010), allowing for the possibility that STAT activation is not an exclusively plasma 
membrane/cytosolic event. Further, iNOS gene expression was also induced by nuclear 
EGFR in reactive astrocytes of human glaucomatous optic nerve head, implying an 
important role for nuclear EGFR in other diseases besides cancers (Liu and Neufeld, 2003). 
Furthermore, cooperation of nuclear EGFR with the transcription factor E2F1 activates 
expression of B-Myb, a positive regulator of G1/S cell-cycle progression (Hanada et al., 
2006). Thus, B-Myb joins cyclin D1 as another transcriptional target of nuclear EGFR that 
promotes cell proliferation. 
Another member of the STAT family that associates with EGFR in both the cytoplasmic and 
nuclear compartment is STAT5. There are two STAT5 proteins, STAT5A and STAT5B, which 
are encoded by two distinct but closely related genes. STAT5A has a higher DNA-binding 
affinity than STAT5B, and it is mostly involved in prolactin-directed mammary gland 
maturation (Grimley et al., 1999), whereas STAT5B is believed to be involved in the response 
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to the growth hormone. Similar to STAT3, unphosphorylated STAT5 is present in the 
nucleus and cytoplasm, and it constitutively shuttles in and out of the nucleus (Zheng et al., 
2002). The N terminus is required for the constitutive nuclear import of STAT5, although the 
precise nature of its nuclear import domain remains to be determined. Following tyrosine 
phosphorylation, STAT5 accumulates in the nucleus where it induces its biological effects by 
transcriptional control of target genes (Debierre-Grockiego, 2004). As observed with STAT3, 
EGFR interacts with STAT5 on the ATRS motif to transactivate the Aurora-A promoter . 
Increased expression of the Aurora-A gene induced centrosome amplification and 
microtubule disorder (Hung et al., 2008). Further, studies from our laboratory have shown 
that EGFR can also associate with STAT5b to regulate Bcl-XL expression (Latha et. al., 
manuscript in preparation). Our study also showed a significant correlation between 
phosphoSTAT5b and EGFR expression in human GBMs. Furthermore, semi-quantitative 
scoring showed that patients whose tumors had detectable phosphoSTAT5 had a worse 
clinical outcome when compared to patients whose tumors had no detectable 
phosphoSTAT5 (Latha et. al., manuscript in preparation).  
4.1.2 Nuclear substrates of EGFR  
That the nucleus is an important site of direct action on the part of EGFR is supported by 
studies showing that exogenously added EGF can stimulate autophosphorylation of the 
EGFR, along with stimulation of phosphorylation of other non-EGF-binding proteins in 
isolated nuclei and nuclear membranes (Holt et al., 1994). Further, use of monoclonal 
antibody directed against the extracellular domain of EGFR inhibited the phosphorylation 
induced by EGF in isolated nuclei (Holt et al., 1994; Cao et al., 1995). Thus, apart from 
functioning as a transcriptional coregulator to modulate gene expression, the regulated 
kinase activity of EGFR in the nucleus can control the activation state of nuclear factors and 
thereby gene expression as well as other functions of such nuclear factors. The only direct 
nuclear substrate identified thus far is proliferating cell nuclear antigen (PCNA) (Wang et 
al., 2006).   Wang et al. showed that nuclear EGFR phoshorylates chromatin-bound PCNA 
on Tyr211, and this phosphorylation is required for maintaining PCNA function on 
chromatin.  Inhibition of the phosphorylation led to degradation of the chromatin-bound, 
but not the unbound, form of PCNA in a proteasome-dependent manner and consequently 
suppressed its function in DNA synthesis and DNA damage repair (Wang et al., 2006). This 
important finding raised the possibility that additional nuclear proteins may be 
phosphorylated by nuclear EGFR and their functions, stability, and/or subcellular 
localization altered as a consequence of tyrosine phosphorylation. Future efforts are needed 
to explore this possibility. 
4.1.3 Regulation of DNA repair by nuclear EGFR 
In addition to ligand-induced accumulation of EGFR in the nucleus, EGFR has been 
demonstrated to escape receptor degradation after internalization and translocate to the 
nucleus in response to stress signals such as ionizing radiation, heat shock, H2O2, and 
cisplatin (Rodemann et al., 2007).  Specifically, ionizing radiation causes nuclear transport of 
EGFR via caveolin and protein kinase C dependent mechanisms (Khan et al., 2006). Further, 
radiation has also been shown to drive EGFR translocation from the perinuclear region to 
the nucleoplasm via a process involving generation of free radicals (Dittmann et al., 2005a). 
Also, ultraviolet irradiation has been shown to induce EGFR nuclear translocation in human 
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keratinocytes (Xu et al., 2009). In addition, Bandyopadhyay et al. reported that nuclear 
EGFR can influence DNA repair directly via physical interaction with DNA-dependent 
kinase (DNA-PK). They showed that cetuximab, an EGFR neutralizing antibody could 
decrease nuclear DNA-PK protein and kinase activity (Bandyopadhyay et al., 1998). 
Cetuximab treatment was also shown to block nuclear shuttling of EGFR and increased 
sensitivity to radiation-induced cell death in these cells (Dittmann et al., 2005b). It was also 
shown that the presence of EGFR in the nucleus resulted in activation of DNA-PK as shown 
by its phosphorylation on Thr2609. In the same study, it was again demonstrated that 
nuclear EGFR binds to the catalytic subunit DNA-PKs, and the regulatory subunit Ku70 of 
DNA-PK (Dittmann et al., 2005b). Nuclear EGFR has been shown to associate with p53 and 
MDC1 protein, an essential protein for the recruitment of DNA repair foci, following 
irradiation and treatment with the radioprotector Bowman-Birk proteinase inhibitor 
(Gueven et al., 1998; Dittmann et al., 2008a). Another radioprotector O-phospho-l-tyrosine 
(P-Tyr) has been shown to activate PKCepsilon, which triggers nuclear EGFR accumulation 
and concurrent phosphorylation of DNA-PK at amino acid residue Thr2609, and leads to 
repair of DNA double-strand breaks (Dittmann et al., 2007). Together these observations 
suggest an important role of nuclear EGFR for regulation of DNA repair following 
treatment with genotoxic substances. 
4.2 Mechanism of nuclear transport 
The intact EGFR protein containing both intracellular and extracellular domains moves to 
the nucleus in a ligand-bound form and the mechanism of this translocation is still 
incompletely understood.  A seminal study very clearly demonstrated that intact EGFR 
bound by monoclonal antibodies directed against extracellular residues can accumulate 
specifically in the nucleus only in EGFR-expressing cells (Holt et al., 1994). This provided 
the first clue that endocytic events associated with the plasma membrane receptor could 
lead to intracellular trafficking and the delivery of EGFR to the nucleus. Further studies 
have convincingly demonstrated that a novel pathway exists by which internalized EGFR in 
the early endosomes is transferred into the nucleus instead of lysosomes or being recycled to 
the cell surface.  Inhibition of receptor endocytosis using a dominant-negative dynamin 
mutant, which abrogates the formation of clathrin-coated pits from the cell surface, blocks 
the nuclear transport of EGFR (Lo et al., 2006a). Further, EGFR has been shown to colocalize 
with EEA1, an early endosomal marker in the nuclear compartment (Giri et al., 2005; Lo et 
al., 2006a). Thus, it seems clear that EGFR utilizes the endocytic pathway for its translocation 
into the nucleus, though additional routes cannot be excluded. 
Nuclear localization requires recognition by the cellular nuclear import machinery and, in 
particular, by members of the nuclear localization sequence (NLS)-recognizing IMP 
superfamily. The best-understood NLS dependent nuclear import pathway is that mediated 
by the IMPα/β heterodimer. After irradiation, it was demonstrated that EGFR is found in 
complex with Importin α and RAN-GTP. It was also shown that EGFR-dependent activation 
of the PI3K/AKT signaling pathway was important for this association (Dittmann et al., 
2005a). A prerequisite for Importin binding is the presence of an NLS within the cargo 
protein. EGFR has been shown to contain a tripartite NLS in its juxtamembrane region that 
mediates the nuclear translocation. EGFR has also been demonstrated to interact with 
importins α1/β1 for which the NLS appears to be indispensable (Lo et al., 2006a; Lin et al., 
2001; Hsu and Hung, 2007). Interestingly, another group studying nuclear transport of 
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EGFR following irradiation observed phosphorylation of EGFR at residue T654, which is 
located within the EGFR NLS. Furthermore, the same group identified PKCepsilon as the 
kinase responsible for this modification (Wanner et al., 2008). Nuclear EGFR accumulation 
results from a balance of import and export processes. Recent evidence also showed that the 
CRM1 is involved in nuclear–cytoplasmic shuttling of EGFR (Lo et al., 2006a). Existence of 
nuclear export sequences within EGFR sequence, however, has not yet been demonstrated.  
While the above delineated mechanisms shed light on the mechanics of nuclear 
translocation of EGFR, it still is unclear how a transmembrane receptor is processed into a 
nuclear non-membrane-bound receptor. A protein translocon mediates the trafficking of 
protein complexes into and out of lipid bilayers.  It was first suggested by Liao & Carpenter 
that the Sec61 translocon could mediate nuclear transport of EGFR (Liao and Carpenter, 
2007). The Sec61 translocon is located in the endoplasmic reticulum and mediates the 
trafficking of secretory and transmembrane proteins into the ER during protein sythesis. 
This translocon is bidirectional and functions also, as part of the ERAD pathway, to 
retrotranslocate malfolded transmembrane proteins from the ER to the cytoplasm. Studies 
showed that radiation and EGF induced trafficking of EGFR to the ER membrane 
presumably via membrane fusion of the late edosomes to the golgi apparatus where it 
interacted with the Sec61 translocon. The data showed that knock-down of a Sec61 subunit 
abrogates both EGFR nuclear localization and EGF induction of cyclin D1 (Liao and 
Carpenter, 2007).  While it has been proposed that Sec61 associated EGFR is 
retrotranslocated to the cytoplasm and subsequently imported into the nucleus via 
Importinβ and the nuclear pore complex (NPC), a recent study showed that Sec61β present 
in the inner nuclear membrane (INM) mediates retrotranslocation of EGFR from the INM 
into the nucleus (Wang et al., 2010b). Since the ER membrane system is contiguous with the 
outer nuclear membrane (ONM) and it is known that the ONM connects to the INM at the 
NPCs, it presents a model where EGFR is traficked first to ER via the endocytic machinery, 
then to the INM and then released into the nucleus by retrograde translocation at the NPC 
(Figure 2). 
4.3 Nuclear EGFR in the clinical setting 
Over the last 20 years, multiple reports have demonstrated beyond doubt that EGFR can 
translocate into the nuclear compartment where it has specific functions as outlined above. 
Concurrent studies have also identified that nuclear localization of EGFR is a common 
component of numerous cancer types. In addition to rapidly proliferating cells, nuclear 
EGFR has been detected in glioma as well as cancers of the breast, epidermoid, bladder, 
ovary, and oral cavity (Wang and Hung, 2009). 
Increased nuclear EGFR expression is a prognostic feature in multiple tumor types 
correlating with parameters of known prognostic significance, such as tumor grade, stage 
and metastasis and is also associated with resistance to standard therapy such as radiation 
and cisplatin (Wang and Hung, 2009; Hwang, 2008). Analysis of nuclear localization of 
EGFR in human breast carcinoma biopsy samples demonstrated that nuclear EGFR levels 
inversely correlated with survival and correlation existed between nuclear localization of 
EGFR and markers of proliferation such as Cyclin D1 (that was shown to be a transcriptional 
target of EGFR in the same study) and Ki-67 (Lin et al., 2001). A follow up study also 
showed positive correlation between nuclear EGFR, Cyclin D1 and RHA expression in 
breast tumors (Huo et al., 2010). Early investigations revealed that cases with high nuclear 
EGFR demonstrated a trend towards poor survival in oral carcinomas (Lo et al., 2005b). This 
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was later corroborated by studies that showed that nuclear EGFR was associated with 
increased local recurrence rate and inversely correlated with disease free survival (Psyrri et 
al., 2005). A study in esophageal squamous cell carcinoma using antibodies specific for 
phosphorylated EGFR showed that pEGFR not only localized to the nucleus but also 
correlated with higher TNM stage, nodal metastasis, and poor patient outcome (Hoshino et 
al., 2007). A follow up analysis by the same group showed that there was a strong 
correlation between nuclear EGFR and PCNA as well as nuclear ERK2 and non-nuclear 
EGFR (Psyrri et al., 2008). The above study was in line with earlier findings that PCNA is a 
substrate for EGFR in the nucleus and PCNA Tyr211 phosphorylation was associated with 
pronounced increase in cell proliferation and worse survival of breast cancer patients (Wang 
et al., 2006). A recent study also demonstrated that an inverse correlation exists between 
increased nuclear localization of EGFR and overall survival in ovarian tumor samples (Xia et 




Fig. 2. A cartoon depicting the transport of EGFR from the plasma membrane to the nucleus. 
The current model shows the role of endocytosis for movement of EGFR to the early 
endosome, Golgi and thereafter, to the ER. From the ER, it is assumed that EGFR moves to 
the ONM and then via the NPC and Importinβ to the INM. On INM, it associates with 
Sec61β and through retrograde transport is released into the nucleoplasm. Nuclear export 
occurs via CRM1. The dotted lines represent potential pathways while solid lines depict 
pathways that have been experimentally proved. After (Wang et al., 2010a) 
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These clinical correlations of nuclear EGFR expression underscore the importance of 
examining the role of nuclear EGFR in other cancers especially those of epithelial origin as 
well as other human diseases. In this context, interestingly in addition to cancers, 
localization of EGFR in the nuclear compartment has also been implicated in glaucoma and 
neuropathy of the optic nerve (Liu and Neufeld, 2003). While the above studies indicate that 
nuclear EGFR is a prognostic indicator for poor clinical outcome and nuclear expression of 
EGFR is associated with cancer development, all the studies have been correlative studies. 
Mechanistic investigations delineating oncogenic capacity of nuclear EGFR are still limited 
and need to be further addressed. Further, a systematic approach has, yet to be conducted to 
identify nuclear EGFR target genes. Knowledge of the target genes will advance our 
understanding of the nature and effect of nuclear EGFR on cell physiology, provide novel 
insights into the role of nuclear EGFR in human cancers, and help clarify some of the 
molecular mechanisms underlying the observed association between nuclear EGFR and 
poor clinical outcome.  
5. Role of EGFRvIII in the nucleus 
A substantial body of evidence suggests that the EGFRvIII contributes a strong oncogenic 
signal in GBM while simultaneously protecting them from conventional therapy (Hwang, 
2008; Gan et al., 2009). Two recent reports briefly described the nuclear localization of 
EGFRvIII in glial cells as well as glioblastoma (de, I et al., 2008; Lo et al., 2010). In 
glioblastoma, nuclear EGFRvIII was found to form a complex with STAT3 as was observed 
for EGFR. The EGFRvIII-STAT3 oncogenic complex was found to be essential for EGFRvIII 
induced transformation of astrocytes (de, I et al., 2008). Further, the second report of 
EGFRvIII nuclear localization showed that the EGFRvIII-STAT3 transcriptional complex 
could get recruited onto the promoter of Cox2 gene in glioma cells and increase 
transcription of Cox2 (Lo et al., 2010). Likewise, our finding that EGFRvIII binds STAT5b 
and positively regulates the transcription of Aurora A and Bcl-XL is the first demonstration 
of a role for EGFR/STAT5 pathway in the nucleus. Importantly, we show that nuclear 
EGFRvIII cooperates with STAT5b to regulate the Bcl-XL promoter and its expression in 
gliomas (Latha et. al., manuscript in preparation). This suggests that nuclear EGFR and 
EGFRvIII may be acting in concert with several members of the STAT family to generate a 
specific facet of its oncogenic signal in the nucleus and they also provide a potential role for 
combination therapy targeting EGFR/EGFRvIII and STAT5.The above studies suggest that 
the EGFRvIII-STAT family axis is important in gliomas. Although the above studies have 
shown nuclear translocation of EGFRvIII, the mechanism of translocation as well as the 
oncogenic role of EGFR in the nucleus remains unkown. Our recent investigation has shown 
that in gliomas, nuclear EGFRvIII as well as EGFR is membrane-derived and cycling of 
EGFRvIII and EGFR between the cytoplasm and nucleus is dependent on Importinβ and 
CRM1. Moreover, by manipulating EGFRvIII such that it is restricted to either the nucleus or 
the cytoplasm followed by functional studies, we show that nuclear EGFRvIII drives tumor 
formation. There is dramatic attenuation in the tumorigenic capacity of EGFRvIII upon 
blockade of its nuclear translocation in glioma cells (Gururaj et. al., manuscript in 
preparation). This suggests that while only a fraction of EGFRvIII or EGFR is in the nucleus, 
signaling here may be particularly important as it offers direct access to transcriptional 
regulators such as members of the STAT family. Taken together, these data provide an 
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important insight into a new signaling node that may make a unique and key contribution 
to the oncogenic signal from overactive and mutant EGFR. 
Nuclear expression EGFRvIII has also been described in prostate cancer (Edwards et al., 
2006) and invasive breast cancer. In hormone-refractory prostate cancer, nuclear expression 
of EGFRvIII was associated with decreased time to death from relapse and decreased overall 
survival (Edwards et al., 2006). EGFRvIII is associated with radioresistance as well as 
chemoresistance (Huang et al., 2009; Schmidt and Lichtner, 2002; Chakravarti et al., 2004), 
which may be related to nuclear localization, in light of the finding that EGFR’s association 
with nuclear targets is key to its ability to protect cells from DNA damaging agents, 
discussed above. In vitro studies using established glioma cell lines have shown that 
EGFRvIII confers resistance to cisplatin (Nagane et al., 1998; Nagane et al., 2000; Lammering 
et al., 2001; Lammering et al., 2003; Stea et al., 2003) and IR . Further, xenograft studies have 
shown that EGFR-specific inhibitors (small-molecule as well as α-EGFR antibodies) 
significantly enhance the efficacy of radiotherapy (Chakravarti et al., 2004; Harari and 
Huang, 2000). Also, EGFRvIII expression has been shown to enhance radioresistance by 
promoting the rapid repair of radiation-induced DNA double-strand breaks (Mukherjee et 
al., 2009). In line with this, a recent study showed that as with EGFR, EGFRvIII associates 
with DNA-PKcs after radiation and cisplatin treatment. They also showed that EGFRvIII not 
only conferred resistance to the two treatment modules but also significantly increased the 
activity of DNA-PKcs in cells (Liccardi et al., 2011). Recently, two independent studies 
showed that nuclear EGFR contributes to resistance to cisplatin treatment and cetuximab 
treatment (Hsu et al., 2009; Li et al., 2009). One of the studies also demonstrated that nuclear 
EGFR is required for DNA repair (Hsu et al., 2009). However, the role of nuclear EGFRvIII 
in either chemo- or radiation resistance in GBM is yet to be explored. 
6. Nuclear EGFR/EGFRvIII and therapeutics 
Since EGFR function is aberrantly regulated in a majority of the different epithelial cancers, 
attenuation of EGFR signaling is one of the key strategies for the management of human 
malignancies. Various therapeutic strategies have been developed to block EGFR signaling, 
with the most frequent strategies involving humanized monoclonal antibodies directed 
against EGFR, and small molecule tyrosine kinase inhibitors that target the enzymatic 
activity of the tyrosine kinase domain.  
Anti-receptor antibodies including cetuximab bind to the receptor extracellular domain and 
induce internalization and degradation, thus effectively blocking receptor activation of 
subsequent cellular signaling cascades. Cetuximab is currently used in combination with 
chemotherapy for treatment of metastatic colorectal cancers with EGFR expression and wt-
KRAS genotype as well as recurrent or metastatic head and neck squamous cell carcinoma 
(HNSCC). It is also indicated in treatment along with radiation for locally advanced 
HNSCC. As monotherapy, it is used in treatment of patients who have failed platinum 
based therapy of metastatic colorectal cancers. With respect to nuclear translocation of EGFR 
and cetuximab, there are conflicting data. In the context of radiation induced nuclear 
translocation, it was shown that cetuximab treatments results in accumulation of 
cytoplasmic EGFR and blockade of EGFR transport into the nucleus following radiation 
(Dittmann et al., 2005b). In contrast, a more recent study showed that cetuximab, like EGF, 
can induce nuclear localization of EGFR (Liao and Carpenter, 2009). However, it is to be 
noted that in this study, it was also shown that while EGF induced translocation required 
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glioblastoma, nuclear EGFRvIII was found to form a complex with STAT3 as was observed 
for EGFR. The EGFRvIII-STAT3 oncogenic complex was found to be essential for EGFRvIII 
induced transformation of astrocytes (de, I et al., 2008). Further, the second report of 
EGFRvIII nuclear localization showed that the EGFRvIII-STAT3 transcriptional complex 
could get recruited onto the promoter of Cox2 gene in glioma cells and increase 
transcription of Cox2 (Lo et al., 2010). Likewise, our finding that EGFRvIII binds STAT5b 
and positively regulates the transcription of Aurora A and Bcl-XL is the first demonstration 
of a role for EGFR/STAT5 pathway in the nucleus. Importantly, we show that nuclear 
EGFRvIII cooperates with STAT5b to regulate the Bcl-XL promoter and its expression in 
gliomas (Latha et. al., manuscript in preparation). This suggests that nuclear EGFR and 
EGFRvIII may be acting in concert with several members of the STAT family to generate a 
specific facet of its oncogenic signal in the nucleus and they also provide a potential role for 
combination therapy targeting EGFR/EGFRvIII and STAT5.The above studies suggest that 
the EGFRvIII-STAT family axis is important in gliomas. Although the above studies have 
shown nuclear translocation of EGFRvIII, the mechanism of translocation as well as the 
oncogenic role of EGFR in the nucleus remains unkown. Our recent investigation has shown 
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EGFRvIII and EGFR between the cytoplasm and nucleus is dependent on Importinβ and 
CRM1. Moreover, by manipulating EGFRvIII such that it is restricted to either the nucleus or 
the cytoplasm followed by functional studies, we show that nuclear EGFRvIII drives tumor 
formation. There is dramatic attenuation in the tumorigenic capacity of EGFRvIII upon 
blockade of its nuclear translocation in glioma cells (Gururaj et. al., manuscript in 
preparation). This suggests that while only a fraction of EGFRvIII or EGFR is in the nucleus, 
signaling here may be particularly important as it offers direct access to transcriptional 
regulators such as members of the STAT family. Taken together, these data provide an 
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important insight into a new signaling node that may make a unique and key contribution 
to the oncogenic signal from overactive and mutant EGFR. 
Nuclear expression EGFRvIII has also been described in prostate cancer (Edwards et al., 
2006) and invasive breast cancer. In hormone-refractory prostate cancer, nuclear expression 
of EGFRvIII was associated with decreased time to death from relapse and decreased overall 
survival (Edwards et al., 2006). EGFRvIII is associated with radioresistance as well as 
chemoresistance (Huang et al., 2009; Schmidt and Lichtner, 2002; Chakravarti et al., 2004), 
which may be related to nuclear localization, in light of the finding that EGFR’s association 
with nuclear targets is key to its ability to protect cells from DNA damaging agents, 
discussed above. In vitro studies using established glioma cell lines have shown that 
EGFRvIII confers resistance to cisplatin (Nagane et al., 1998; Nagane et al., 2000; Lammering 
et al., 2001; Lammering et al., 2003; Stea et al., 2003) and IR . Further, xenograft studies have 
shown that EGFR-specific inhibitors (small-molecule as well as α-EGFR antibodies) 
significantly enhance the efficacy of radiotherapy (Chakravarti et al., 2004; Harari and 
Huang, 2000). Also, EGFRvIII expression has been shown to enhance radioresistance by 
promoting the rapid repair of radiation-induced DNA double-strand breaks (Mukherjee et 
al., 2009). In line with this, a recent study showed that as with EGFR, EGFRvIII associates 
with DNA-PKcs after radiation and cisplatin treatment. They also showed that EGFRvIII not 
only conferred resistance to the two treatment modules but also significantly increased the 
activity of DNA-PKcs in cells (Liccardi et al., 2011). Recently, two independent studies 
showed that nuclear EGFR contributes to resistance to cisplatin treatment and cetuximab 
treatment (Hsu et al., 2009; Li et al., 2009). One of the studies also demonstrated that nuclear 
EGFR is required for DNA repair (Hsu et al., 2009). However, the role of nuclear EGFRvIII 
in either chemo- or radiation resistance in GBM is yet to be explored. 
6. Nuclear EGFR/EGFRvIII and therapeutics 
Since EGFR function is aberrantly regulated in a majority of the different epithelial cancers, 
attenuation of EGFR signaling is one of the key strategies for the management of human 
malignancies. Various therapeutic strategies have been developed to block EGFR signaling, 
with the most frequent strategies involving humanized monoclonal antibodies directed 
against EGFR, and small molecule tyrosine kinase inhibitors that target the enzymatic 
activity of the tyrosine kinase domain.  
Anti-receptor antibodies including cetuximab bind to the receptor extracellular domain and 
induce internalization and degradation, thus effectively blocking receptor activation of 
subsequent cellular signaling cascades. Cetuximab is currently used in combination with 
chemotherapy for treatment of metastatic colorectal cancers with EGFR expression and wt-
KRAS genotype as well as recurrent or metastatic head and neck squamous cell carcinoma 
(HNSCC). It is also indicated in treatment along with radiation for locally advanced 
HNSCC. As monotherapy, it is used in treatment of patients who have failed platinum 
based therapy of metastatic colorectal cancers. With respect to nuclear translocation of EGFR 
and cetuximab, there are conflicting data. In the context of radiation induced nuclear 
translocation, it was shown that cetuximab treatments results in accumulation of 
cytoplasmic EGFR and blockade of EGFR transport into the nucleus following radiation 
(Dittmann et al., 2005b). In contrast, a more recent study showed that cetuximab, like EGF, 
can induce nuclear localization of EGFR (Liao and Carpenter, 2009). However, it is to be 
noted that in this study, it was also shown that while EGF induced translocation required 
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kinase activity, cetuximab induced translocation was kinase independent (Liao and 
Carpenter, 2009). This could be due to a fundamental difference either in the trafficking or 
conformation of EGF- and cetuximab- bound EGFR and warrants further investigation. Of 
interest is another study demonstrating that cells which acquire resistance to cetuximab 
show increased localization of EGFR in the nuclear compartment (Li et al., 2009). Further, 
expression of EGFR tagged with NLS that show increased nuclear localization render cells 
resistant to cetuximab treatment both in vitro and in xenograft studies (Li et al., 2009). 
Collectively, these data suggest that the mechanisms of the effect of cetuximab on EGFR 
nuclear transport are likely to be complex and dependent on cellular context. Further 
research is necessary to clarify the role and effect of cetuximab in nuclear translocation of 
EGFR. Interestingly, a recent study also showed that a monoclonal antibody which 
recognizes EGFRvIII and activated EGFR, Mab 806, and which has been demonstrated to 
inhibit the growth of tumors expressing EGFRvIII or overexpressing EGFR, can sensitize 
radioresistant glioma cells expressing EGFRvIII (Johns et al., 2010). These findings provide a 
strong rationale for the study of nuclear EGFRvIII in resistance to therapy which has not 
been addressed thus far. 
Small molecule inhibitors such as erlotinib act against the cytoplasmic tyrosine kinase 
domain and inhibit the enzymatic activity of EGFR and so cytoplasmic signaling. Erlotinib is 
used as monotherapy for locally advanced or metastatic non-small cell lung cancer patients 
who have failed chemotherapy regimen and also for pancreatic cancer patients who have 
advanced local disease, metastasis or non-resectable tumors. However, there is insufficient 
evidence for using combinations of erlotinib with either chemotherapy or radiotherapy in 
patients and needs to be further investigated. Lapatinib, a dual EGFR and HER2 tyrosine 
kinase inhibitor, can sensitize cells to fluoropyrimidines possibly by inhibiting nuclear 
translocation of both EGFR and HER2 (Kim et al., 2009). Also, a recent study showed that 
nuclear EGFR is required for tumor resistance to DNA damage induced by the DNA 
alkylator, cisplatin (Hsu et al., 2009). Interestingly, a COX2 inhibitor, celecoxib has been 
shown to radiosensitize tumor cells by inhibiting radiation-induced nuclear EGFR 
translocation and DNA repair. Since this action of celecoxib did not correlate with COX2 
expression, it is suggested that it could be a COX2 independent mechanism (Dittmann et al., 
2008b). Another investigation demonstrated that the Src family kinase inhibitor, dasatinib 
could resensitize cells that were cetuximab resistant by inhibiting nuclear transport of EGFR 
(Li et al., 2009). While the above studies encourage the use of combination therapy to 
address treatment resistance by keeping EGFR out of the nucleus, we must proceed with 
caution since we are yet to understand the nuclear functions of EGFR in a comprehensive 
manner. Furthermore, such knowledge holds out the hope of leading to new targets that 
could be exploited in new combinations in the future. 
7. Conclusion 
Recent research has further strengthened the case for an important role of the EGFR family 
in a variety of cancers. It has also broadened our understanding of where these proteins may 
be active, by showing that in addition to propagating cytoplasmic signaling events, EGFR 
can also control other functions directly by translocating into the nuclear or mitochondrial 
compartment. Direct action within the nucleus could be a means by which the receptor 
achieves selectivity, specificity, and efficiency of gene activation not possible through shared 
transcription factors and second messenger/phosphorylation cascade systems. It may also 
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represent an ancient signaling connection between the limiting membrane and the genetic 
material and other vital cellular complexes that predate the evolution of intracellular, 
membrane bound organelles. Understanding the nuclear functions of EGFR as well as the 
mechanisms of its nuclear trafficking provides the hope of novel avenues for therapeutic 
interventions in various tumor types. Further, nuclear EGFR itself could be a new clinically 
relevant target with the potential to find application specifically in chemo- and radio-
resistant tumors. However, to evaluate the fitness of nuclear EGFR as a target, a selective 
inhibitor of EGFR transport needs to be identified. Thus, the current challenge in the field is 
to gain substantial knowledge about the functions as well as translocation of EGFR and 
define its role in cancer prognosis, targeting, and therapeutic sensitization. 
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kinase activity, cetuximab induced translocation was kinase independent (Liao and 
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recognizes EGFRvIII and activated EGFR, Mab 806, and which has been demonstrated to 
inhibit the growth of tumors expressing EGFRvIII or overexpressing EGFR, can sensitize 
radioresistant glioma cells expressing EGFRvIII (Johns et al., 2010). These findings provide a 
strong rationale for the study of nuclear EGFRvIII in resistance to therapy which has not 
been addressed thus far. 
Small molecule inhibitors such as erlotinib act against the cytoplasmic tyrosine kinase 
domain and inhibit the enzymatic activity of EGFR and so cytoplasmic signaling. Erlotinib is 
used as monotherapy for locally advanced or metastatic non-small cell lung cancer patients 
who have failed chemotherapy regimen and also for pancreatic cancer patients who have 
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expression, it is suggested that it could be a COX2 independent mechanism (Dittmann et al., 
2008b). Another investigation demonstrated that the Src family kinase inhibitor, dasatinib 
could resensitize cells that were cetuximab resistant by inhibiting nuclear transport of EGFR 
(Li et al., 2009). While the above studies encourage the use of combination therapy to 
address treatment resistance by keeping EGFR out of the nucleus, we must proceed with 
caution since we are yet to understand the nuclear functions of EGFR in a comprehensive 
manner. Furthermore, such knowledge holds out the hope of leading to new targets that 
could be exploited in new combinations in the future. 
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Recent research has further strengthened the case for an important role of the EGFR family 
in a variety of cancers. It has also broadened our understanding of where these proteins may 
be active, by showing that in addition to propagating cytoplasmic signaling events, EGFR 
can also control other functions directly by translocating into the nuclear or mitochondrial 
compartment. Direct action within the nucleus could be a means by which the receptor 
achieves selectivity, specificity, and efficiency of gene activation not possible through shared 
transcription factors and second messenger/phosphorylation cascade systems. It may also 
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represent an ancient signaling connection between the limiting membrane and the genetic 
material and other vital cellular complexes that predate the evolution of intracellular, 
membrane bound organelles. Understanding the nuclear functions of EGFR as well as the 
mechanisms of its nuclear trafficking provides the hope of novel avenues for therapeutic 
interventions in various tumor types. Further, nuclear EGFR itself could be a new clinically 
relevant target with the potential to find application specifically in chemo- and radio-
resistant tumors. However, to evaluate the fitness of nuclear EGFR as a target, a selective 
inhibitor of EGFR transport needs to be identified. Thus, the current challenge in the field is 
to gain substantial knowledge about the functions as well as translocation of EGFR and 
define its role in cancer prognosis, targeting, and therapeutic sensitization. 
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1. Introduction 
Although the origins of cancer can be exceptionally complex due to the range of genes that 
may be involved it is also apparent that there are “consensus” genes, ones that are 
frequently mutated. The AP-1 family of transcription factors represent a set of proteins that 
are commonly involved in cancers as well as other developmental and pathological 
conditions including heart development, apoptosis, and hepatogenesis (reviewed in (1). 
Although defined as a protein that can bind to a consensus sequence in a variety of 
promoters, AP-1 is in fact a series of heterodimmers that are created between at least 7 
distinct proteins including c-jun, junB, Fos, FosB, Fra1,Fra2 and the Maf family of proteins 
(2). Each of these proteins is the product of distinct genes and although they are different at 
the amino acid level they share homology and structural similarities including a leucine 
zipper, transactivation domain and a basic region. Expression of these different proteins is 
tightly controlled and they may be expressed at different times of development and in 
different tissues. Control of AP-1 activity revolves around the control of these protein’s 
transcription, translation and post-translation modification 
There have been several reports that have detailed the role that some of the family members 
may play in several tumors. Through the use of dominant negative mutants for c-jun it has 
been demonstrated that this protein is necessary for tumor survival while inhibition of jun-B 
may enhance tumor survival (3-5). In all of these experiments it is not clear if any of the 
other family members that comprise AP-1 are actually present in the cell and if they might 
play roles as well. Instead of developing dominant negative mutants that could mask the 
role that the other family members play in tumorigenesis we have taken the approach of 
creating a series of either siRNAs or shRNAs to investigate the role that each of these family 
members play in a glioblastoma cell line. Our results demonstrate that in the U87-MG cell 
line all family members are expressed. However the necessity of each these members varies 
greatly for cell proliferation and survival.  
2. Materials and methods 
Cells and transfections: Cell lines U87-MG, U118-MG and U373-MG were obtained from the 
American Type Culture Collection and maintained according to their instructions. Cells 
transfections, selections in geneticin sulfate and secreted alkaline phosphatase assays were 
performed as essentially as  described (6) 
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shRNA: siRNAs were developed by Elbashir using the methods described by (7, 8). At 63-
190 nucletoides downstream of the start codon a 19 nucleotide sequence was chosen. This 
sequence began with an adenine dimer and had a 47-80% GC content. Controls were 
created from these sequences by randomizing the order of the bases. Both the selected 
shRNA sequence and its cognate control were compared to the nucleotide databases at the 
National Institute for Biotechnoilogy using the BLAST program (9). Only those sequences 
that were unique were used for oligonucleotides synthesis. These sequences were then 
used to direct the synthesis of oligonucleotides. In addition to the shRNA sequences these 
oligonucleoitides contained a short region that resulted in a hairpin region. 
Oligonucleotides were ligated into pBluescript that contained an H1 promoter (10) and 
pSuperiorneo (Oligoengines). Clones were verified by sequence analysis. 
Cell growth assays. Cells were seeded into 96 well plates. On day 0 cells were dosed with 
media that contained the control solvent or media that contained 2μg/ml doxycycline . 
Medium was replenished every 2 days thereafter with the appropriate additions. Cell 
division was determined using the 10 μl per well of CCK8 (Dojindo) a formazan dye based 
assay. After 1 hour of incubation with the dye the amount of dye converted was measured 
by spectrophotometry at a wavelength of 459 nm.  
Western blots. Western blots were performed essentially as described (6). Protein amounts 
in each sample were determined using the BCA assay (Pierce) with bovine serum albumin 
as a standard. Antibodies to c-jun, c-fos (Upstate Biotechnologies) JunB, JunD, FosB, Fra-1 
and Fra-2 (Santa Cruz), and cleaved PARP (Cell Signalling Technologies) were purchased. 
Caspase assays. Assays for activated caspase 3 and 7 were performed using the Apo-ONE 
kit (Promega). Lysates from induced cells were compared to cells that were not induced 
with 2μg/ml of doxycyclin. Assays were read on a Perkin Elmer LS-50B fluorometer with an 
excitation wavelength of 485nm and an emission wavelength of 530nm according to 
manufacturer’s recommendations. 
3. Results 
To determine if the transcription factor AP-1 was present at elevated levels in glioblastomas 
we transfected a reporter plasmid, pAP-1SEAP, or a control plasmid pTal into the 
glioblastoma cell lines U87-MG, U118-MG and U373-MG. After 24 hour cells were 
harvested, the amounts of protein and β-galactosidase measured. Identical amounts of 
protein were then used for a secreted alkaline phosphatase assay and the assay results 
normalized to the specific activity of β-galactosidase. The results are presented in Fig.1 and 
demonstrate that the levels of AP-1 were significantly elevated in both U87-Mg and U118-
MG cells. U373-MG cells did not have elevated levels of SEAP indicating that they did not 
have activated Ap-1 (data not shown). The AP-1 activity was sensitive to genistein 
indicating the possible involvement of a tyrosine kinase in activating the AP-1 pathway. We 
have obtained similar results with NF-κB activation (6). When compared to a control cell 
line, MCF-10A, which is a cell line derived from normal breast epithelium, U87-MG and 
U118-MG Ap-1 levels also appeared elevated (data not shown). 
Although it was clear that AP-1 levels were elevated at least in the two glioblastomas cell 
lines it was not clear which of the family members of AP-1 might be present and the 
contribution that each family member was making. To determine what roles each individual  
 



















































Fig. 1. AP-1 is elevated in the glioblastoma cell lines U87-MG and U118-MG. Cells were co-
transfected with either the pTAL (black bars), or pAP1SEAP (diagonal striped bars), or 
pAP1SEAP in the presence of genistein (horizontal striped bars) and a plasmid that 
constitutively expressed the β-galactosidase protein. Media was assayed for the presence of 
secreted alkaline phosphatase and the values were normalized to the specific activity of β− 
galactosidase levels from cell lysates. Levels of SEAP in pAP1SEAP transfected cells were 
statistically significantly different from either the pTAL control or the cells treated with  
genistein (p0.05). 
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shRNA: siRNAs were developed by Elbashir using the methods described by (7, 8). At 63-
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shRNA sequences. Sequences for the shRNAs are given in table 1.  
 
Table 1. Sequences of the siRNAs that were synthesized. The designation of c indicates 
control oligonucleotides that are scrambled. Note that the overhanging ends are compatible 
with HindII and BglII sites in the vectors that were used. 
family member might be playing in the increased levels of AP-1 we designed a series of 
shRNAs that were directed specifically to each individual family member (Table 1). We then 
tested these constructs in both transient expression and in stable expression assays. Western 
blotting demonstrated that all of the family members were present in the U87-MG cells that 
there were no family members that were expressed. Furthermore, levels of these proteins 
could be reduced with either transient or stable expression studies as compared to cognate 
controls (Fig. 2). 
To determine what effect, if any, this reduction in protein might have on AP-1 activity we 
transfected into cells the pAP1-SEAP reporter plasmid or its control pTAL. From this assay 
it became apparent that the contributions that the different AP-1 family members had on 
AP-1 levels were quite variable and ranged from a low of 7% for JunB to 84% for c-Fos.  
We were interested what the affect was of inhibiting these proteins would have on the cells 
in stable assays. Transient transfections could only allow us to assay the affects of the 
shRNA constructs on a potentially minor proportion of the population of cells. By creating 
stable transfectants we could investigate the role of some of these proteins consistently 
within a population. The shRNAs for c-Jun and c-Fos were cloned into a modified pSuperior 
neo vector that we created so that it expressed the hygromycin resistance gene in place of  
 
 








Fig. 2. Expression of AP-1 family members transiently transfected with plasmids that either 
expressed shRNA or the scrambled control shRNA. Cels were transfected with indicated 
plasmids and lysates were tested for expression of the various family members by western 
blot analysis of whole cell lysates. Cells were also transfected with the pAP1SEAP reporter 
plasmid and the media assayed for SEAP. 
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Reduction in AP-1 activity 
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Fig. 3. Stable transfection and inhibition of cell doubling with c-Jun and c-Fos shRNAs. U87-
MG cells that expressed the pTET-ON plasmid were transfected with the pSuperior 
constructs of the shRNAs for c-Jun and c-fos shRNAs or their cognate controls. Cells 
selected in hygromycin were then tested for their ability to replicate in the presence or 
absence of the inducer for shRNA, doxtcyclin. In both cases day 6 values are statistically 
significantly different between the control and shRNA expressing cells (p<0.05). 
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the neo resistance gene. The promoter in this vector that drives the expression of the 
shRNAs is an H1 promoter that has additional sequences that make is responsive to the Tet 
repressor. Cell lines of U87-MG were created that expressed the Tet repressor and these 
were transfected and selected so that they also carried either the c-Fos or c-Jun shRNAs that 
were used in the transient assays described above. As expected induction of the shRNA 
expression with doxycycline resulted in depression of c-Jun (90%) and c-Fos (98%) protein 
levels as compared to their uninduced controls (Fig. 3a). To determine what effect this type 
of reduction would have on the ability of the cells to divide cells were treated with 
doxycycline and their division measured over a period of several days using a formazan dye 
derivative. The results (Fig. 3b) demonstrate that a reduction in c-Fos and c-Jun did have a 
modest but statistically significant suppressive affect on cell division which was not seen in 
the cells that were transfected with the scrambled control oligonucleotides. If doxycycline 
was removed part way through the assay this effect was not seen indicating that the effect 
could be cytostatic as opposed to resulting in apoptosis or cell death. However, western 
blots of the cell lines demonstrated that they had increased levels of cleaved PARP and 
caspase 3,7 activity indicating that at least some of the cells were undergoing apoptosis in 
response to expression of the shRNAs. 
4. Discussion 
AP-1 is a transcription factor that is frequently up regulated in a variety of tumors. In this 
study we determined that AP-1 is up regulated in some glioblastoma cell lines. 
Transcription factors are typically defined by the sequences that they are capable of binding  
even though the transcription factor itself may be composed of several different but related 
polypeptides. The purpose of this study was to determine if the cell lines that expressed 
higher levels of activated AP-1 only expressed certain family members. Similar to what we 
previously found with the NF-κB family of transcription factors (6), most if not all of the 
family members of AP-1 were present in these cells and they appeared to play a role in the 
level of AP-1 that was found within the cell. Although inhibition of c-Jun, JunD, c-Fos, FosB, 
Fra-1 and 2 all had similar effects on the levels of AP-1, inhibition of JunB did not have a 
substantial impact on AP-1 levels indicating that certain family members were not as 
important for the AP-1 effect on the cells. This is in contrast to previous findings that JunB 
had an antagonistic effect to c-Jun on cells (4). Whether our results differ due to the fact that 
we used established cell lines as opposed to fresh tumor tissue is unclear.   
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1. Introduction 
Musashi1 (Msi1) is an evolutionary conserved RNA-binding protein that plays important 
roles in neural stem cell maintenance, nervous system development, and tumorigenesis. In 
glioblastoma, Msi1 is found to be highly expressed and to control a network of cancer-
related genes. In this chapter, we will review the participation of RNA-binding proteins in 
tumorigenesis and the role of Msi1 in stem cells and in glioblastoma. Furthermore, we will 
discuss the results of a study done with The Cancer Genome Atlas (TCGA) dataset to map 
genes highly correlated in expression with Msi1 as an avenue to understand its function in 
gliomagenesis.  
2. Musashi1 and RNA-binding proteins 
2.1 RNA-binding proteins 
RNA-binding proteins (RBPs) are instrumental in RNA metabolism, from biogenesis to 
degradation affecting molecular processes associated with mRNA capping, 3’ end 
formation, splicing, transport, localization, stability, and translation (Figure 1). RNA-
binding proteins associate with target RNA ligands forming the so-called ribonucleoprotein 
complexes (RNPs). Changes that affect RBP expression and/or function, either temporally 
or spatially, can have a profound impact on the fate of their target RNAs. 
Recent genomic analyses suggest that RNA-binding proteins target mRNAs that code for 
proteins of similar function, forming the so-called RNA operon (Keene, 2007). In this 
scenario, RNA-binding proteins coordinate the expression of newly synthesized transcripts 
in order to ensure the needs of the cells are met. This relationship is not linear and any 
particularly mRNA may be bound by many different RNA-binding proteins thus forming a 
higher order of regulation termed the RNA regulon. Since RNA-binding proteins regulate 
large subsets of mRNA, it is conceivable that changes in expression or function can have a 
profound impact on human disease.    
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Fig. 1. RNA-binding proteins have diverse functions in RNA metabolism. A schematic of the 
life cycle of an mRNA and various functions, in black boxes, where RNA-binding proteins 
participate is shown. m7G denotes the 7-methylguanosine cap and poly(A) denotes the 
poly(A) tail of mRNAs.  
2.2 RNA-binding proteins and cancer 
 
RNA-binding proteins can regulate operons formed by mRNAs involved in cell 
proliferation, apoptosis, growth, angiogenesis, and invasion/metastasis, processes which, if 
dysregulated can lead to or potentiate cancer (Lukong et al., 2008). In recent times, the 
recognition of the impact RNA-binding proteins have on tumorigenesis has been emerging. 
For example, eIF4E is an important RNA-binding protein that acts downstream of the 
mTOR pathway (Wendel et al., 2007). This protein functions normally as a component of the 
translation initiation complex. When elevated, eIF4e contributes to tumor formation by 
increasing the translation of oncogenes and genes involved in cell proliferation.  
It is estimated that the human genome encodes ~1000 different RNA-binding proteins. A 
recent study from our lab utilized a comprehensive in silico approach to analyze the 
expression pattern of RNA-binding proteins in normal and tumor tissues (Galante et al., 
2009). In this study, we analyzed 383 RNA-binding proteins in 12 different tissue/tumor 
types. 53 proteins have been shown to be aberrantly expressed in at least two tumor types, 
with the majority of them being upregulated, suggesting that RNA-binding proteins may be 
oncogenic or potentiate certain characteristics in cancer. One example is Musashi1, whose 
increased expression pattern has been shown in malignancies such as glioblastoma, 
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medulloblastoma, breast, and colon cancer (Kanemura et al., 2001; Toda et al., 2001; Sureban 
et al., 2008; Wang et al., 2010).  
2.3 The Musashi1 RNA-binding protein 
Musashi (Msi) is an evolutionarily conserved RNA-binding protein (RBP) that controls 
translation through its interaction with specific motifs located in the 3’ untranslated region 
of target messenger mRNAs (Okano et al., 2005). Msi1 represses the translation of Numb 
(Imai et al., 2001), a negative regulator of Notch, p21Cip1, an inhibitor of cyclin-dependent 
kinases (Battelli et al., 2006), and doublecortin (Dcx), a microtubule-binding protein 
involved in neural stem cell migration (Horisawa et al., 2009), but promotes the translation 
of Robo3, a receptor involved in axonal guidance (Kuwako et al., 2010). Additional targets 
for Msi1, many of which pertain to the cell cycle, apoptosis, proliferation and differentiation 
were identified by RIP-chip analysis (de Sousa Abreu et al., 2009). The ability of Msi1 to 
either positively or negatively control protein expression suggests the duality of its function 
in translation. Musashi1 inhibits translation through its interaction with poly (A)-binding 
protein (PABP), thus disrupting the formation of an active translation complex (Kawahara et 
al., 2008). The mechanism by which Msi1 activates translation is not yet known.  
Msi1 was identified in Drosophila as a protein involved in sensory organ development and 
asymmetric cell division (Nakamura et al., 1994). In Drosophila, mutations in Musashi results 
in a double sensory shaft. The name Musashi is a tribute to the famous 17th century samurai, 
Miyamoto Musashi, who developed the two sword technique. In metazoans, Musashi has 
two paralogs, Msi1 and Msi2, which have similar RNA-binding properties (Sakakibara et al., 
1996; Sakakibara et al., 2001; Sakakibara et al., 2002). Although Msi1 and Msi2 have differing 
patterns of expression and roles within the cell (Aubert et al., 2003; Chan et al., 2006; Siddall 
et al., 2006; Sugiyama-Nakagiri et al., 2006; Sgubin et al., 2007; Kharas et al., 2010), both Msi1 
and Msi2 are required for brain stem cell self-renewal (Sakakibara et al., 2002). In 
mammalian cells, Msi1 denotes multipotent stem cells in the brain (Sakakibara et al., 1996; 
Keyoung et al., 2001; McGuckin et al., 2004; Uchida et al., 2004), intestine (Kayahara et al., 
2003; Nishimura et al., 2003; Sakatani et al., 2005) , breast (Clarke, 2005; Wang et al., 2008), 
and hair follicles (Sugiyama-Nakagiri et al., 2006). 
2.4 Function of Musashi1 in normal and cancer stem cells 
In breast cancer cells, Musashi1 maintains the expression of the embryonic stem cell (ESC) 
markers c-Myc, Nanog, Sox2, Bmi1 and Oct4 (Wang et al., 2010). These markers when 
collectively expressed in differentiated cells were able to reprogram cells, conferring them 
stem-like characteristics (Yu et al., 2007; Gonzalez et al., 2009; Yu et al., 2009; Stadtfeld et al., 
2010). An embryonic stem cell signature in breast cancer is associated with a lower five-year 
survival rate (Wang et al., 2010). The expression of embryonic stem cell markers are usually 
found in other malignant tumors such as cervical cancer, retinoblastoma, poorly 
differentiated lung cancer, medulloblastoma, glioblastoma, bladder cancer, and basal-type 
breast cancer, and predicts lower overall survival (Ben-Porath et al., 2008; Hassan et al., 
2009; Hemmati et al., 2003; Seigel et al., 2007; Stevenson et al., 2009; Ye et al., 2008).  
Msi1 expression is particularly important for the proper development of the brain as 
suggested by a genetically engineered msi1-/- in a C57BL6 background which results in a 
mouse with obstructive hydrocephalus and ependymal abnormalities (Sakakibara et al., 
2002). Additionally, Msi1 is known as a neural stem cell marker useful for studying the 
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migration and biology of neural stem/progenitor cells during development (Kaneko et al., 
2000; Chan et al., 2006). In a recent study, Msi1 was shown to be required for neuronal 
migration of precerebellar neurons via its target gene, Robo3 (Kuwako et al., 2010). Robo3 is 
a receptor found on astrocytes and is required to receive signals from migrating neurons 
through the secretion of the Slit1 diffusable protein. Slit1 signals the change of astrocyte 
morphology to create astrocytic tunnels, allowing migrating neurons to navigate through 
the dense meshwork of the adult brain (Kaneko et al., 2010).   
Consistent with its role in self-renewal, Msi1 expression is positively correlated with a label-
retaining and side population human breast epithelial cells enriched in ERα, p21Cip1, CK19 
and double-positive CK14/CK18 progenitor cells (Smalley and Clarke, 2005; Clarke et al., 
2005). When Msi1 is overexpressed in murine mammary epithelial cells, CD24hi/Sca-1+, 
CD24hi/CD29+, CK14+/CK18+ and CK6+ and CK19+ expression is enhanced in mammary 
stem and progenitor cells (Glazer et al., 2008; Wang et al., 2008). Msi1 acts in a unique 
autocrine pathway which consists of increased secretion of the growth factor Proliferin, loss 
of the Wnt inhibitor DKK3, activation of Wnt and Notch signaling (Glazer et al., 2008; Wang 
et al., 2008). This results in a gene expression profile indicative of the cell cycle, growth 
factor signaling, invasion, adhesion, survival and embryonic stem cells. In addition, 
CD24+/CD29hi mouse mammary cells contain multipotent self-renewing mammary stem 
cells which can reconstitute a complete mammary gland from a single mammary stem cell 
and represent a cancer stem cell population in tumors from MMTV-Wnt1 and p53-null in 
murine breast cancer models (Shackleton et al., 2006; Zhang et al., 2008). CD24 expression is 
controlled through the IGF2 receptor which binds to Proliferin and coexpressed in Msi1-
positive cells (Glazer et al., 2008; Wang et al., 2008). In colon cancer, high expression of Msi1 
is observed as a result of increased IGF2 expression in intestinal crypt cells due to loss of 
imprinting, thus predisposing the crypt cells to become malignant (Sakatani et al., 2005; Cui 
et al., 2006). Loss of imprinting of IGF2 is observed in other cancers such as 
medulloblastoma (Corcoran et al., 2008). In studies done in our lab using the cross-linked 
and immunoprecipitation, or CLIP analysis in U251 glioblastoma cells, IGF2 was identified 
as a potential target of Musashi1 (Penalva lab, unpublished results), suggesting a potential 
mechanism by which Msi1 may control tumor progression. 
3. Musashi1 as a critical regulator in brain tumors 
Musashi1 expression has been seen to be elevated in brain tumors such as glioma and 
medulloblastoma. In gliomas, high Msi1 expression was identified as a poor prognostic 
factor (Kanemura et al., 2001). In in vivo xenograft models, silencing of Musashi1 by small 
interfering RNAs caused a reduction in tumor growth of both glioblastoma and 
medulloblastoma cells (Penalva lab, unpublished results). We summarized below the 
connections between Msi1 and brain tumor-related pathways. 
3.1 Notch pathway 
Musashi1 and Notch 1 expression correlate in areas of tumor proliferation and infiltration 
(Kanemura et al., 2001). Furthermore, suppression subtractive hybridization experiments 
established an association between Msi1 and Notch pathway activation in medulloblastoma 
cells (Yokota et al., 2004). Notch is a well-conserved signaling pathway that regulates cell 
fate, cell proliferation, and cell death during development (Artavanis-Tsakonas et al., 1999).  
Upon binding, cleavage of the Notch receptor occurs in two separate events. The first event 
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is catalyzed by the ADAM-family of metalloproteinases. The second event is catalyzed by 
the γ-secretase protein complex; this complex consists of four proteins, presenilin, nicastrin, 
PEN2, and APH2 (Fortini, 2002). Cleavage by the γ-secretase protein complex releases the 
Notch intracellular domain, or NICD, which then localizes in the nucleus and transactivates 
transcription (Schweisguth, 2004). Musashi1 interacts with the Notch pathway via post-
transcriptional regulation of the negative Notch regulator, Numb. Upon binding to the 3’ 
untranslated region of Numb, Musashi1 causes translational repression, thus effectively 
releasing Notch inhibition (Imai et al., 2001). 
3.2 Wnt pathway 
Wnt is an essential signaling pathway required for developmental processes such as body 
axis specification and morphogenic signaling (Cadigan and Nusse, 1997). Wnt is a family of 
secreted cysteine-rich glycoproteins that act in a paracrine-like fashion over short distances 
to activate signaling pathways. Msi1 influences Wnt pathway activation by repressing the 
translation of p21, a cyclin-dependent kinase inhibitor, required for the transition between 
the G1 and S phase of the cell cycle (Battelli et al., 2006). Additionally, p21 negatively 
regulates Wnt4 transcription, thus connecting cell cycle regulation with the Wnt signaling 
pathway (Devgan et al., 2005).  
3.3 Hedgehog pathway 
The Hedgehog pathway initiates with the secretion of Hedgehog ligand from different 
tissues during development (Ingham and McMahon, 2001). Upon binding, the Hedgehog 
ligand inactivates the Patched-1 Hedgehog receptor, leading to the release of the catalytic 
inhibition on the Smoothened G-protein-coupled receptor signal transduction molecule 
(Villavicencio et al., 2000; Chen et al., 2002). This event activates the Hedgehog signal 
transduction cascade with the subsequent activation of transcription by the glioma-
associated oncogene zinc finger transcription factor GLI2 and GLI3 of Hedgehog target 
genes (Dahmane et al., 2001). Msi1 interacts with the Hedgehog pathway by interfering with 
the expression of several key Hedgehog components such as SMO and GLI1. Morover, 
inhibition of Msi1 causes increased sensitivity to cyclopamine, a Hedgehog pathway 
inhibitor, resulting in a decrease in cell proliferation (Sanchez-Diaz et al., 2008).   
3.4 Mining through the cancer genome atlas 
To better understand the participation of Msi1 in glioblastoma, we conducted an expression 
correlation study to identify genes closely associated with Msi1. Glioblastoma (GBM) data 
from The Cancer Genome Atlas (TCGA) consortium was collected representing microarrays 
performed on GBM in nearly 500 patients (The Cancer Genome Atlas Research Network, 
2008). The microarray results were downloaded from 7 distinct batches of experiments and 
then filtered for only those tumors assayed by the Agilent 244K platform and then combined 
to form a single dataset comprising expression results for 17815 genes across all patients. 
Due to data access restrictions patients could not be stratified by age, gender, or race. The 
data were re-normalized using quantile normalization, and the correlation with Msi1 and all 
other genes was computed for each batch stratum. The mean correlation across batches was 
computed for each gene, and the absolute value of the correlation was used to sort the genes 
from most correlated to least correlated with MSI1. 
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The genes with significant expression correlation with Musahi1 (~250 genes) were then 
analyzed for ontological information pertaining to disease states (Figure 2 and 3), biological 
processes (Figure 4), and functional association using Ariadne Genomics Pathway Studio 
(Figure 5). Identified genes were not found to have significant change in correlation levels 
across the four known subtypes of glioblastoma tumors (Classical, Mesenchymal, Proneural, 
and Neural) as defined by the TCGA (Parsons et al., 2008). Approximately 10% of the genes 
were shown to have interactions with other genes within the group (Figure 5). Major nodes 
in this network include CSF3 (Granulocyte colony stimulating factor), GnRH 
(Gonadotropin-releasing hormone), RARA (Retinoic acid receptor alpha), and RELB. All of 





Fig. 2. Msi1-correlated genes are involved in disease processes. The table above shows the 
incidence of genes from the TCGA data set shown to be correlated with MSI1 in various 
diseases. Genes in red were positively correlated with MSI1 expression while genes in green 
were negatively correlated with MSI1 expression. 
 





Fig. 3. Msi1-correlated genes have implication in important disease states. Genes and 
Disease were sorted by incidence count which is also given adjacent to or bellow each group 
respectively. Genes in red were positively correlated with MSI1 expression while genes in 
green were negatively correlated with MSI1 expression. 
3.5 Genes that correlate with Msi1 expression are important players in glioblastoma 
Among the genes identified in the TCGA analysis, a few should be highlighted based on its 
importance and role in gliomagenesis. We will summarize the functions of granulocyte 
colony stimulating factor 3 (CSF3), gonadotropin-releasing hormone (GnRH), retinoic acid 
receptor alpha (RARA), Notch3/4, DNA ligase IV (LIG4), excision repair cross-
complementing rodent repair deficiency, complementation group 2 (ERCC2), and (C-X3-C 
motif) ligand 1 (CX3CL1).  
3.5.1 Granulocyte colony stimulating factor 3 
Granulocyte colony stimulating factor (CSF3) is a cytokine that controls the production, 
differentiation, and function of granulocytes. In the central nervous system, CSF3 plays an 
important role by inducing neurogenesis, maintain neuroplasticity, halting tissue 
degradation through inhibition of apoptosis and promoting cell survival through the 
MAPK, PI3K, and Akt pathways (Schneider et al., 2005).  
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Fig. 4. Msi1-correlated genes are involved in many cancer-related processes. The table above 
shows the incidence of genes correlated with MSI1 in various pathways. Genes in red were 
positively correlated with MSI1 expression while genes in green were negatively correlated 
with MSI1 expression. 
3.5.2 Gonadotropin-releasing hormone 
Gonadotropin-releasing hormone (GnRH) is a tropic peptide hormone that facilitates the 
release of follicle-stimulating hormone and luteinizing hormone from the anterior pituitary. 
GnRH-mediated signaling may be important for the growth and maintenance of gliomas. 
The use of the GnRH agonist Zoladex results in inhibition of cell proliferation in two 
glioblastoma cell lines (U87MG and U373) thus presenting GnRH signaling as a potential 
therapeutic target (Marelli et al., 2009).   
3.5.3 Retinoic acid receptor alpha 
Retinoic acid receptor alpha (RARA) is a ligand-dependent nuclear receptor that upon 
binding to retinoic acid, can affect processes such as development, differentiation, apoptosis, 
and transcription of clock genes. Glioblastoma is extremely sensitive to retinoic acid, which 
flattens cell morphology, forming intercellular cross-bridges, and reduces anchorage-
independent growth (Mukherjee and Das, 1995). Treatment of glioblastoma cells in vitro 
results in growth arrest and induces differentiation through the Notch pathway (Ying et al., 
2011).    
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Fig. 5. Msi1-correlated genes interact in a wide network in glioblastoma. The image above 
shows the interactions amongst genes from the TCGA data set shown to be correlated with 
Msi1. Genes in red were positively correlated with Msi1 expression while genes in green 
were negatively correlated with Msi1 expression. The mitochondria, nucleus, and cell 
membrane are shown and genes are placed accordingly. Connections that involved positive 
changes in expression / up regulation are drawn with a "plus" symbol while those involving 
negative changes in expression / down regulation are shown with a bar. If no information 
was present or the effect was unclear only the direction of the connection was shown with 
an arrow. 
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3.5.4 Notch receptors  
Notch3 and Notch4 receptors have been previously implicated in association with Msi1. 
Msi1 has been previously demonstrated to negatively affect Numb expression, a negative 
effector of the Notch pathway. Notch3 and Notch4 have previously been demonstrated to 
play important roles in the tumorigenesis and glioblastoma biology. Enhanced Notch3/4 
expression is observed in astrocytomas and medulloblastomas in part due to the loss of the 
FBXW7, a Skp1-Cul1-F-box E2 ubiquitin ligase (Hagedorn et al., 2007; Xu et al., 2009). 
Notch3 activation has been implicated in gliomagenesis (Pierfelice et al., 2011).  
3.5.5 DNA repair enzymes 
A hurdle in treatment of glioblastoma with adjuvant chemotherapy or radiation therapy is 
the enhanced ability for the cell to repair DNA resultant of damage induced by the 
chemotherapeutic or radiation. Two genes, LIG4 and ERCC2, are found to be correlated 
with Msi1. LIG4, or DNA ligase IV, expression causes cells to be resistant to treatment by the 
nitrosourea chloroethylating agent, nimustine (ACNU) through the role of DNA ligase IV in 
nonhomologous end joining and siRNA silencing of LIG4 results in increased cell death 
when induced with ACNU (Kondo et al., 2010). In human genetic studies, polymorphisms 
of LIG4, particularly SNP2 rs3093739:T>C, was associated with increased risk for 
developing gliomas, probably due to increased DNA damage and the inability for the cell to 
repair the damage effectively, thus leading to tumor formation (Liu et al., 2008). ERCC2, or 
excision repair cross-complementing rodent repair deficiency, complementation group 2, is 
another DNA repair gene whose expression is associated with Msi1. ERCC2 is involved in 
transcription-coupled nucleotide excision repair through its binding to the basal 
transcription factor BTF2/TFIIH complex. Allelic loss of ERCC2 is associated with a 
younger age of diagnosis of glioma; however, the loss of the ERCC2 gene is not associated 
with a difference in response to therapy or survival (Liang et al., 1995). More recently, 
polymorphisms in the ERCC2 gene have been revealed. Particularly, homozygosity at codon 
156 for the silent AA allele results in high incidences of glioma (odds ratio 2.3), probably 
through an alteration in relationship with a currently unidentified gene and ERCC2 
(Caggana et al., 2001). In a follow up study, it was seen that a single nucleotide 
polymorphism, rs13181, for ERCC2 confers a significant, protective effect (McKean-Cowdin 
et al., 2009). 
3.5.6 Chemokine (C-X3-C motif) ligand 1 
Glioblastoma also have an enhanced ability to invade adjacent normal brain tissue; one gene 
that has been implicated in invasion is the chemokine ligand, CX3CL1 chemokine (C-X3-C 
motif) ligand 1 gene mediating the cross-talk between neurons and microglia. The 
chemokine receptor CX3CR1 and the ligand, CX3CL1, expression is increased in human 
glioblastoma samples and neural cancer stem cells at the mRNA and protein level (Erreni et 
al., 2010; Locatelli et al., 2010). The high expression levels are inversely correlated with 
patient overall survival (Erreni et al., 2010). CX3CL1 is localized in the outer layer of cells of 
glioblastoma tumorspheres, suggesting the involvement of the chemokine system in 
intracellular adhesion (Erreni et al., 2010). The high levels of CX3CL1/CX3CR1 results in the 
recruitment of glioma-infiltrating microglia, which displays high levels of adhesion and 
migration in vitro; this suggests an important role for the chemokine system in tumor 
promotion (Held-Feindt et al., 2010). 
 




Musashi1 plays a role in glioblastoma and other tumor types by affecting a complex 
network of genes implicated in numerous cancer-related processes and biological pathways. 
This is evident from the TCGA study we discussed in this chapter. Further wet-lab 
experimentation is required to understand the different branches of Musashi1 regulation 
and hopefully to provide insight for the development of novel glioblastoma therapeutics.  
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3.5.4 Notch receptors  
Notch3 and Notch4 receptors have been previously implicated in association with Msi1. 
Msi1 has been previously demonstrated to negatively affect Numb expression, a negative 
effector of the Notch pathway. Notch3 and Notch4 have previously been demonstrated to 
play important roles in the tumorigenesis and glioblastoma biology. Enhanced Notch3/4 
expression is observed in astrocytomas and medulloblastomas in part due to the loss of the 
FBXW7, a Skp1-Cul1-F-box E2 ubiquitin ligase (Hagedorn et al., 2007; Xu et al., 2009). 
Notch3 activation has been implicated in gliomagenesis (Pierfelice et al., 2011).  
3.5.5 DNA repair enzymes 
A hurdle in treatment of glioblastoma with adjuvant chemotherapy or radiation therapy is 
the enhanced ability for the cell to repair DNA resultant of damage induced by the 
chemotherapeutic or radiation. Two genes, LIG4 and ERCC2, are found to be correlated 
with Msi1. LIG4, or DNA ligase IV, expression causes cells to be resistant to treatment by the 
nitrosourea chloroethylating agent, nimustine (ACNU) through the role of DNA ligase IV in 
nonhomologous end joining and siRNA silencing of LIG4 results in increased cell death 
when induced with ACNU (Kondo et al., 2010). In human genetic studies, polymorphisms 
of LIG4, particularly SNP2 rs3093739:T>C, was associated with increased risk for 
developing gliomas, probably due to increased DNA damage and the inability for the cell to 
repair the damage effectively, thus leading to tumor formation (Liu et al., 2008). ERCC2, or 
excision repair cross-complementing rodent repair deficiency, complementation group 2, is 
another DNA repair gene whose expression is associated with Msi1. ERCC2 is involved in 
transcription-coupled nucleotide excision repair through its binding to the basal 
transcription factor BTF2/TFIIH complex. Allelic loss of ERCC2 is associated with a 
younger age of diagnosis of glioma; however, the loss of the ERCC2 gene is not associated 
with a difference in response to therapy or survival (Liang et al., 1995). More recently, 
polymorphisms in the ERCC2 gene have been revealed. Particularly, homozygosity at codon 
156 for the silent AA allele results in high incidences of glioma (odds ratio 2.3), probably 
through an alteration in relationship with a currently unidentified gene and ERCC2 
(Caggana et al., 2001). In a follow up study, it was seen that a single nucleotide 
polymorphism, rs13181, for ERCC2 confers a significant, protective effect (McKean-Cowdin 
et al., 2009). 
3.5.6 Chemokine (C-X3-C motif) ligand 1 
Glioblastoma also have an enhanced ability to invade adjacent normal brain tissue; one gene 
that has been implicated in invasion is the chemokine ligand, CX3CL1 chemokine (C-X3-C 
motif) ligand 1 gene mediating the cross-talk between neurons and microglia. The 
chemokine receptor CX3CR1 and the ligand, CX3CL1, expression is increased in human 
glioblastoma samples and neural cancer stem cells at the mRNA and protein level (Erreni et 
al., 2010; Locatelli et al., 2010). The high expression levels are inversely correlated with 
patient overall survival (Erreni et al., 2010). CX3CL1 is localized in the outer layer of cells of 
glioblastoma tumorspheres, suggesting the involvement of the chemokine system in 
intracellular adhesion (Erreni et al., 2010). The high levels of CX3CL1/CX3CR1 results in the 
recruitment of glioma-infiltrating microglia, which displays high levels of adhesion and 
migration in vitro; this suggests an important role for the chemokine system in tumor 
promotion (Held-Feindt et al., 2010). 
 




Musashi1 plays a role in glioblastoma and other tumor types by affecting a complex 
network of genes implicated in numerous cancer-related processes and biological pathways. 
This is evident from the TCGA study we discussed in this chapter. Further wet-lab 
experimentation is required to understand the different branches of Musashi1 regulation 
and hopefully to provide insight for the development of novel glioblastoma therapeutics.  
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1. Introduction  
Glioblastoma (GBM) is the most common malignant primary brain tumor in adults and one 
of the most lethal of all human cancers. Despite substantial advances in surgical intervention 
and combining radiotherapy regimens with new generation chemotherapies, the median 
survival for these patients is still about 15 months (Nagane, 2011). In recent years, cancer 
treatments using molecularly targeted drugs that act against the respective molecules have 
been successful, although successful molecular targeted therapies for glioma have yet to be 
established. Because the mechanisms underlying glioma formation and progression are 
complex, many candidate target molecules are identified as potential therapeutic targets 
(Nakada M et al., 2011). To date, the benefit of molecularly targeted therapies is limited, 
although there are many completed and on-going clinical trials (Quant & Wen, 2010). Thus, 
promising molecular targets should be identified to establish innovative molecularly 
targeted therapies against GBM. 
Glycogen synthase kinase 3β (GSK3β) is a serine-threonine protein kinase originally 
identified for its inhibitory role in the conversion of glucose to glycogen via phosphorylation 
and inactivation of glycogen synthase. Recent studies suggest a conflicting role of GSK3β in 
various human cancers, either as a tumor suppressor or tumor promoter. Emerging 
evidence suggests that GSK3β is a tumor promoter in glioma, acting to regulate and link key 
players that control proliferation, resistance to radiochemotherapy, activation of invasion, 
and anti-apoptosis (Kotliarova et al., 2008; Miyashita et al., 2009a; Nowicki et al., 2008). The 
combined anti-proliferative and anti-invasive properties of small molecule GSK3β 
inhibitors make them an attractive treatment modality for controlling GBM. 
The aim of this chapter is to highlight important aspects of the biology of GSK3β, focusing 
on the pathological role, signal transduction, and possibility of being a molecular target for 
GBM.  
2. General knowledge of GSK3β 
GSK3 was discovered in 1980 as a kinase that phosphorylates glycogen synthase, a key 
enzyme involved in glycogen synthesis (Embi et al., 1980). GSK3 is evolutionarily conserved 
and consists of 2 distinct isoforms encoded by 2 different genes, GSK3α and GSK3β, in 
mammals (Woodgett, 1991). GSK3 is ubiquitously expressed, and is highly enriched in the 
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brain. Compared with GSK3α, the GSK3β protein lacks 60 amino acid residues at the N 
terminus, resulting in a lower molecular weight for GSK3β (46.7 kDa). The 2 isoforms share 
extensive homology, most notably in the kinase domain (ATP binding site), which shares 
97% homology. Initially, the primary function attributed to GSK3 was negative regulation of 
glycogen synthesis through phosphorylation and inactivation of glycogen synthase. 
However, further studies have uncovered additional functions of GSK3, such as cell cycle 
regulation, proliferation, differentiation, apoptosis, and migration. Despite high homology, 
the 2 isoforms are not functionally redundant, as demonstrated by gene knockout studies 
(Hoeflich et al., 2000). 
2.1 Biological characteristics of GSK3β 
Although the differences in functional roles of the 2 isoforms are not fully elucidated, 
research thus far has primarily focused on GSK3β. GSK3β is subject to multiple levels of 
regulation mediated by its phosphorylation, subcellular localization, and protein–protein 
interactions. GSK3β protein itself undergoes multiple phosphorylation events, which impact 
its activity depending on the amino acid being modified (Doble & Woodgett, 2003). Tyrosine 
phosphorylation of the GSK3β kinase domain at Tyr216 leads to its activation (Dajani et al., 
2001), whereas phosphorylation of the N-terminal Ser9 results in inhibition of its activity 
and plays an important role in the regulation of GSK3β function (Stambolic & Woodgett, 
1994) (Figure 1).  
 
 
Fig. 1. Phosphorylation and activation of GSK3β. Akt and MAPKAP-K1 phosphorylate Ser9 
of GSK3β, resulting in inhibition of activity. The inhibition of GSK3β decreases the 
phosphorylation of glycogen synthase, leading to an increase in the active form, since 
phosphorylated glycogen synthase is less active. As a result, glycogen synthesis is 
promoted. MAPK: mitogen-activated protein kinase, MAPKAP-K1: MAPK-activated protein 
kinase-1 (also called RSK), Circled P: phosphorylation. 
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One of the main regulators of GSK3β activity is the phosphoinositide 3-kinase (PI3-
kinase)/Akt pathway. PI3-kinase–induced activation of Akt mediates Ser9 phosphorylation 
of GSK3β (Cross et al., 1995; Pap & Cooper, 1998), resulting in the inhibition of GSK3β 
activity. GSK3β can also be phosphorylated at Ser9 by the most downstream kinase of the 
classical mitogen-activated protein kinase (MAPK) cascade, called MAPK-activated protein 
kinase-1 (MAPKAP-K1, also called RSK) (Frame & Cohen, 2001). Apart from this, GSK3β 
functions as a suppressor protein in the Wnt signaling pathway, which is the protein 
network associated with embryo development and cancer progression (Cook et al., 1996; 
Manoukian & Woodgett, 2002; Fuchs et al., 2005). The Wnt pathway was found to have 
essential roles in promoting the survival, proliferation, differentiation, and migration of cells 
in many different tissues, including nervous tissue, as well as in synapse formation in the 
nervous system. Briefly, the Wnt pathway involves the inhibition of an inhibitor, leading to 
activation of a transcription factor. When Wnt signal is absent, GSK3β associates with other 
proteins (e.g., axin, adenomatous polyposis coli [APC]) and functions as a critical mediator 
of the pathway. In this situation, the proto-oncoprotein β-catenin is constitutively 
phosphorylated, rapidly removed by degradation, and thus, will not build up in the cell to a 
significant level (Hagen & Vidal-Puig, 2002). In contrast, when Wnt binds to frizzled (Frz), 
its receptor, dishevelled (Dsh) is recruited to the cell membrane. GSK3β is inhibited by the 
activation of Dsh. Consequently, β-catenin, having escaped ubiquitination-dependent 
proteasomal degradation mediated by GSK3β phosphorylation, accumulates in the 
cytoplasm. It is subsequently shifted to the nucleus, where it assembles with other proteins 
(e.g., T-cell factor [Tcf]/lymphoid enhancer factor [Lef]) to switch on transcription of specific 
target genes, leading to its function as an oncoprotein. In this mechanism, GSK3β is thought 
of as a tumor suppressor protein (Figure 2). 
GSK3β acts as a downstream regulatory switch that determines the output of numerous 
signaling pathways initiated by diverse stimuli (Frame & Cohen, 2001). Phosphorylation of 
GSK3β (Ser9) leads to the dephosphorylation of substrates, including glycogen synthase and 
translation factor eukaryotic protein synthesis initiation factor-2B (eIF-2B) (Welsh et al., 
1998), resulting in their functional activation and consequent increase in glycogen synthesis, 
release of a number of transcription factors from tonic inhibition, and protein synthesis 
(Cohen & Frame, 2001). Thus, GSK3β affects both key components of the response to 
stimuli, reprogramming of gene expression, and activation of protein synthesis. 
Additionally, GSK3β phosphorylates a broad range of substrates: c-myc (Gregory et al., 
2003), c-Jun (Boyle et al., 1991), c-Myb (Kitagawa et al., 2010), cyclin D1 (Diehl et al., 1998), 
Cdc25A (Kang et al., 2008), nuclear factor of activated T-cells (Beals et al., 1997), heat shock 
factor-1 (He et al., 1998; Xavier et al., 2000), Mcl-1 (Ding et al., 2007), cAMP response 
element-binding protein (Bullock & Habener, 1998), and so on. GSK3β can target these 
substrates for degradation or inactivation, resulting in inhibition of cell proliferation and 
self-renewal. GSK3β also regulates nuclear factor (NF)-κB stability and activity (Demarchi et 
al., 2003; Hoeflich et al., 2000). These findings identified GSK3β as a key determinant in both 
physiological and pathological conditions, such as glycogen metabolism, insulin signaling, 
cell fate, neuronal function, and oncogenesis. 
2.2 Physiological function 
GSK3β participates in a number of different cellular pathways in a context-dependent 
manner and is implicated in the regulation of a wide range of cellular processes, including 
apoptosis, cell proliferation, and migration. Multiple lines of evidence indicate that the 
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apoptosis, cell proliferation, and migration. Multiple lines of evidence indicate that the 
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function of GSK3β is opposing in different cell types. This functional dichotomy suggests 
that the function of GSK3β seems to be dependent on cell-types and/or cell conditions, 




Fig. 2. Role of GSK3β in the Wnt pathway. When Wnt signal is absent, GSK3β promotes the 
proteasomal degradation of β-catenin. In contrast, when Wnt binds to frizzled (Frz), its 
receptor, dishevelled (Dsh) is recruited to the cell membrane. GSK3β is inhibited by the 
activation of Dsh. Consequently, β-catenin accumulates in the cytoplasm and is 
subsequently translocated into the nucleus to switch on Tcf/Lef-dependent transcription of 
specific target genes, leading it to act as an oncoprotein. Note that there are other regulatory 
components of each pathway; this schema was simplified for clarity. 
2.2.1 Apoptosis 
GSK3β is a component of signaling cascades involved in the process of apoptosis  (Iqbal & 
Grundke-Iqbal, 2008) and is a critical downstream element of the PI3-kinase/Akt cell survival 
pathway (Pap & Cooper, 1998). Transient overexpression of GSK3β was found to induce 
spontaneous apoptosis in PC12 cells, used as a model system for neuronal differentiation, in a 
caspase-3-dependent manner (Pap & Cooper, 1998). Inhibition of GSK3β activity prevented 
cell death by blocking mitochondrial membrane potential changes and subsequent caspase-9 
and caspase-3 activation in murine TSM1 neuronal cells (Petit-Paitel et al., 2009).  
 




GSK3β is involved in cell proliferation through the canonical Wnt/β-catenin signaling 
pathway. GSK3β inhibition promotes translocation of dephosphorylated and stabilized β-
catenin to the nucleus and its interaction with transcription factors, resulting in the 
induction of genes responsible for cell proliferation. Lithium chloride (LiCl), a chemical 
GSK3β inhibitor, significantly increased the proliferative potency of thyrocytes that 
appeared to be mediated by β-catenin (Rao et al., 2005). Similarly, the small molecule 6-
bromoindirubin-3′-oxime (BIO), a specific inhibitor for GSK3, promotes proliferation in 
mammalian cardiomyocytes by elevated β-catenin activity (Tseng et al., 2006). In addition, it 
is known that inhibition of GSK3β promotes vascular cell proliferation, suggesting that 
active GSK3β inhibits angiogenesis (Hou et al., 2010). GSK3β signaling also plays an 
essential role in regulating the differentiation and proliferation of adult neural stem cells. 
Inhibition of GSK3β results in transcriptional activation of distinct target genes via β-
catenin, leading to an increase in the number of neurons that differentiated from 
neurospheres (Maurer et al., 2007).  
2.2.3 Migration 
It has also been shown that, during cell migration, GSK3β plays a positive role in activating 
Rac, a Rho family member, and ADP-ribosylation factor 6 (Arf6), a related small GTPase, in 
adherent cells. Rac is responsible for forming lamellipodia during cell migration. Arf6 is also 
involved in vesicle trafficking, membrane ruffling, as well as lamellipodia formation (Turner 
& Brown, 2001). It has been shown that GSK3β activity is required for keratinocytes to form 
lamellipodia and migrate directionally in response to wound signaling (Koivisto et al., 
2003). Similarly, GSK3β activates Rac in response to wound signaling in intestinal epithelial 
cells. When GSK3β is inhibited, and thus Rac activation prevented, these cells stop moving 
(Vaidya et al., 2006). Although the mechanisms by which guanine nucleotide exchange 
factor (GEF) and GTPase-activating protein (GAP) regulate Rac or Arf6 have been 
extensively studied, no direct evidence has demonstrated that GSK3β modifies these GEFs 
and GAPs. 
Focal adhesion kinase (FAK) is another candidate that contributes to the regulation of cell 
migration by GSK3β. FAK tyrosine phosphorylation and Rac activation were suppressed in 
GSK3β knocked-down HeLa S3 (human cervical carcinoma cell line) cells, suggesting that 
GSK3β mediates the disassembly of focal adhesions to promote cell migration (Kobayashi et 
al., 2006). In contrast, Bianchi et al. showed that GSK3β reduces FAK kinase activity and cell 
motility in rat fibroblasts and HEK-293 (human embryonic kidney 293) cells. The influence 
of GSK3β on migration of various types of cells (e.g., neoplastic and non-neoplastic) appears 
to be complex. Further identification of additional GSK3β targets and more detailed studies 
of the pathways affecting cell migration will be necessary to clarify the function of GSK3β in 
cell migration (Sun et al., 2009). 
2.3 Pathological function 
GSK3β is ubiquitously expressed at high levels in the brain. Numerous studies have 
indicated that GSK3β is involved in key functions of the brain and is associated with a 
variety of neurological disorders like Alzheimer, Parkinson, and Huntington diseases, as 
well as affective disorders and other neurodegenerative disorders (Grimes & Jope, 2001; 
Jope & Roh, 2006). Additionally, it is not surprising that GSK3β has been implicated in 
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glucose intolerance, considering its primary role is as a negative regulator of insulin-
mediated glycogen synthesis and glucose homeostasis. Indeed, the activity of GSK3β has 
been reported in type II diabetes mellitus and obese animal models (Eldar-Finkelman et al., 
1999; Nikoulina et al., 2000). GSK3β is also involved in inflammation that accompanies 
various kinds of diseases (reviewed in Jope et al., 2007). GSK3β inhibition attenuates 
activation of the pro-inflammatory transcription factor NF-κB and activates the 
immunomodulatory transcription factor β-catenin (Gong et al., 2008). GSK3β inhibition also 
induces secretion of the anti-inflammatory cytokine IL-10 (Hu et al., 2006).  
More recent studies indicate a role for GSK3β in the control of neoplastic transformation and 
tumor development (reviewd in Miyashita et al., 2009b). Overexpression and activation of 
GSK3β was confirmed in various kinds of cancers such as colorectal, stomach, pancreatic, 
and liver cancers, as well as leukemia and GBM (Shakoori et al., 2005; Shakoori et al., 2007; 
Wang et al., 2008; Miyashita et al., 2009a; Mai et al., 2009). Previous studies have shown that 
inhibition of GSK3β suppresses cancer cell proliferation and induces apoptosis (Ougolkov et 
al., 2005; Ougolkov et al., 2007). In these cancers, the function of GSK3β is critical for 
malignant phenotype with respect to proliferation and invasion. Accumulated evidence 
supports the role of GSK3β in the regulation of apoptosis and proliferation appears to be 
diverse between physiological and pathological conditions. 
However, the exact role of GSK3β in malignancies remains highly controversial due to the 
conflicting results from different tumor models. It has been shown that GSK3β is a tumor 
suppressor protein that controls cellular fate determination and stem cell maintenance 
through inhibition of the Wnt, Hedgehog, and Notch pathways. These pathways are 
aberrantly activated in several cancers (Saldanha, 2001; Waaler et al., 2011). This suggests 
that GSK3β inhibitors could exert a therapeutically negative, pro-survival effect on tumor 
cells. In addition, some studies found that GSK3β is part of a tumor suppressor complex 
consisting of axin and APC that phosphorylates the oncoprotein β-catenin and that, when 
GSK3β is inactivated, could possibly lead to tumor promotion (Hinoi et al., 2000; Rask et al., 
2003). Available evidence indicates that GSK3β may function as a “tumor suppressor” for 
certain types of tumors such as skin and mammary tumors (Farago et al., 2005; Ma et al., 
2007). These findings suggest that the mechanisms underlying the function of GSK3β as a 
tumor promoter or suppressor might depend on cell type and tissue context.  
3. GSK3β biology in glioma 
Recently, 3 independent research groups, including our group, simultaneously reported that 
GSK3β is a key promoter of malignant GBM phenotypes and is thus a promising candidate 
for molecular-targeted therapy (Kotliarova et al., 2008; Nowicki et al., 2008; Miyashita et al., 
2009a).  
3.1 Expression and activation 
GSK3β is consistently expressed in primary GBM (Korur et al., 2009; Li et al., 2010). High 
expression levels of GSK3β and phosphorylated GSK3β (Tyr216) were detected in GBM 
compared with non-neoplastic brain tissues (Miyashita et al., 2009a). This finding identified 
GSK3β as an important regulator of malignant phenotype in GBM cells. GSK3β is 
constitutively active in GBM cells, despite the fact that PI3K/Akt, which can inhibit GSK3β 
activity, is a major signaling pathway in GBM. It is possible that an undetermined pathway 
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other than that mediated by Akt prevents GSK3β Ser9 phosphorylation (Shakoori et al., 
2005), allowing GSK3β to be constitutively active in GBM cells.  
3.2 Localization in tumor cells 
Overexpression of GSK3β was observed in the cytoplasm of neoplastic cells in GBM, 
whereas only weak expression was observed in the cytoplasm of neurons from non-
neoplastic tissue (Miyashita et al., 2009a).  
3.3 Function 
GSK3β function in glioma has been investigated by inhibiting GSK3β using small interfering 
RNA (siRNA), the small-molecule inhibitors LiCl or thiazolidinediones (TZD), and a small 
heterocyclic compound first described as a non-ATP competitive inhibitor of GSK3β. 
Inhibition of GSK3β activity attenuated proliferation, inhibited cell survival, enhanced 
tumor cell apoptosis, induced tumor cell differentiation, impaired formation of 
neurospheres, and reduced clonogenicity of GBM cells in a dose-dependent manner 
(Aguilar-Morante et al., 2010; Korur et al., 2009; Kotliarova et al., 2008; Miyashita et al., 
2009a) (Table 1). The cytotoxic effects are directly correlated with decreased enzyme-
activating phosphorylation of GSK3β (Tyr216) (Kotliarova et al., 2008). Furthermore, specific 
pharmacologic GSK3β inhibitors and siRNA knockdown of GSK3β reduced glioma cell 
motility (Nowicki et al., 2008). Importantly, administration of a highly specific GSK3β 
inhibitor, AR-A014418 (Bhat et al., 2003), at a low dose sensitized GBM cells to 
chemotherapeutic agents such as temozolomide and ionizing radiation, resulting in reduced 
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4. GSK3β-mediated signaling in glioma 
4.1 Apoptosis 
The molecules associated with GSK3β were also assessed by GSK3β inhibition. Several 
signaling pathways are associated with the decreased cell survival related to GSK3β 
inhibition. Inhibition of GSK3β activates the oncogenic transcription factor c-myc, leading to 
the induction of apoptosis promoting factors such as Bax, Bim, DR4/DR5, and tumor 
necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), as well as subsequent 
cytotoxicity (Kotliarova et al., 2008). In addition, inhibition of GSK3β was associated with 
increased expression of p53 and p21 in GBM cells with wild-type p53. Simultaneously, the 
phosphorylated fraction of retinoblastoma protein (Rb) (inactive form) decreased, which 
associated with down-regulation of cyclin-dependent kinase 6 (CDK6) (Miyashita et al., 
2009a). It has been reported that decreased phosphorylation of Rb (activation of Rb) could 
be attributed to the down-regulation of CDK6 (Classon & Harlow, 2002). These signaling 
pathways probably induce apoptosis by inhibition of GSK3β in GBM cells. In contrast to the 
GSK3β phosphorylates the Thr366 residue of PTEN that negatively regulates PI3K and then 
reduces Akt activity. Blocking phosphorylation of PTEN by either mutating or inhibiting 
GSK3β in GBM cell lines leads to stabilization of the PTEN protein (Maccario et al., 2007). In 
this situation, PTEN can work stably as a suppressor for PI3K/Akt, leading to apoptosis 
(Figure 3).  
4.2 Proliferation 
One of the major targets of GSK3β is NF-κB, which is an intracellular protein complex that 
controls DNA transcription and is a pro-survival factor in glioma (Kasuga et al., 2004; Robe 
et al., 2004). Inhibition of GSK3β activity by GSK3β-specific inhibitors such as LiCl and by 
GSK3β siRNA caused a dramatic decrease in intracellular NF-κB activity in U251, T98, and 
U87 GBM cell lines (Kotliarova et al., 2008). NF-κB inhibition then resulted in decreased 
glioma cell survival in vitro and inhibition of tumor growth in vivo (Kotliarova et al., 2008) 
(Figure 3). TZD-8 can inhibit GSK3β activity not only by directly interacting with this 
enzyme, but also by phosphorylating the Ser9 residue of GSK3β via MAPK pathway 
activation. TZD-8 suppresses the growth of glioma cells in vivo and exerts anti-proliferative 
and pro-apoptotic activities in glioma cells in vitro (Aguilar-Morante et al., 2010). These 
effects were accompanied by an activation of the MAPK signaling pathway, concomitant 
phosphorylation of Ser9, inactivation of GSK3β, and an inhibition of NF-κB activity. These 
results are consistent with previously published data, showing that an activation of MAPK 
is associated with a reduction in cell survival in different tumor cell lines, including GBM 
cell lines (Tewari et al., 2008). In contrast, GSK3β inhibition promotes entrance of β-catenin 
to the nucleus and the interaction of β-catenin with transcription factors. While this could 
promote cell proliferation, it does not take place, presumably, because of the simultaneous 
action of other pathways, which inhibit glioma cell proliferation (Kotliarova, 2008). 
4.3 Migration/invasion 
Specific inhibitors and siRNA knockdown of GSK3β both reduced glioma cell motility. The 
effects are dose dependent and reversible (Nowicki et al., 2008). However, the mechanisms 
underlying the effect of GSK3β on glioma cell migration and invasion required further 
study. Migration of GBM cells requires the formation of lamellipodia at the cell front and 
stress fibers consisting of actomyosin at the rear; contraction of these stress fibers causes the 
cell to reacquire front-rear symmetry. The migrating morphology of GBM cells is dependent  
 





Fig. 3. GSK3β-mediated signaling in glioma. The signaling pathways associated with 
apoptosis, proliferation, angiogenesis, cell stemness, and glycogen synthesis are depicted. 
Apoptosis: GSK3β activity results in c-myc inhibition that consequently decreases 
expression of Bax, Bim, DR4/DR5, and TRAIL, preventing subsequent cytotoxicity. GSK3β 
increases the levels of Rb phosphorylation, resulting in Rb inactivation. Decreased Rb 
phosphorylation is associated with down-regulation of CDK6. GSK3β destabilizes PTEN, 
which negatively regulates PI3K and reduces Akt activity. Proliferation: siRNA targeting 
GSK3β causes a dramatic decrease in intracellular NF-κB activity. NF-κB inhibition results in 
decreased glioma cell survival. Angiogenesis: Hypoxia activates RhoB. HIF-1α may be 
regulated by RhoB through the Akt/GSK3β pathway under hypoxic conditions, although 
there is no data proving direct inhibition of HIF-1α by GSK3β. Stemness: Expression of 
GSK3β is reduced by down-regulation of polycomb group protein Bmi1. Inhibition of Bmi1 
induces a differentiation phenotype and reduces expression of Nestin and Sox2 in glioma 
cells. Glycogen synthesis: GSK3β stabilizes HKII on the outer mitochondrial membrane, 
thereby supporting glycolysis. Bax: BCL2-associated X protein, Bim: BCL2 interacting 
protein, DR4/DR5: death receptor 4/death receptor 5, HIF-1α: hypoxia-inducible factor 1α, 
HKII: hexokinase-II, NF-κB: nuclear factor-kappa B, PI3K: phosphatidylinositol 3-kinases, 
PTEN: phosphatase and tensin homolog, Rb: retinoblastoma protein, RhoB: Ras homolog 
gene family member B, Sox2: SRY (sex determining region Y)-box 2, TRAIL: tumor necrosis 
factor (TNF)-related apoptosis-inducing ligand, Circled P, phosphorylation. 
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Fig. 3. GSK3β-mediated signaling in glioma. The signaling pathways associated with 
apoptosis, proliferation, angiogenesis, cell stemness, and glycogen synthesis are depicted. 
Apoptosis: GSK3β activity results in c-myc inhibition that consequently decreases 
expression of Bax, Bim, DR4/DR5, and TRAIL, preventing subsequent cytotoxicity. GSK3β 
increases the levels of Rb phosphorylation, resulting in Rb inactivation. Decreased Rb 
phosphorylation is associated with down-regulation of CDK6. GSK3β destabilizes PTEN, 
which negatively regulates PI3K and reduces Akt activity. Proliferation: siRNA targeting 
GSK3β causes a dramatic decrease in intracellular NF-κB activity. NF-κB inhibition results in 
decreased glioma cell survival. Angiogenesis: Hypoxia activates RhoB. HIF-1α may be 
regulated by RhoB through the Akt/GSK3β pathway under hypoxic conditions, although 
there is no data proving direct inhibition of HIF-1α by GSK3β. Stemness: Expression of 
GSK3β is reduced by down-regulation of polycomb group protein Bmi1. Inhibition of Bmi1 
induces a differentiation phenotype and reduces expression of Nestin and Sox2 in glioma 
cells. Glycogen synthesis: GSK3β stabilizes HKII on the outer mitochondrial membrane, 
thereby supporting glycolysis. Bax: BCL2-associated X protein, Bim: BCL2 interacting 
protein, DR4/DR5: death receptor 4/death receptor 5, HIF-1α: hypoxia-inducible factor 1α, 
HKII: hexokinase-II, NF-κB: nuclear factor-kappa B, PI3K: phosphatidylinositol 3-kinases, 
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gene family member B, Sox2: SRY (sex determining region Y)-box 2, TRAIL: tumor necrosis 
factor (TNF)-related apoptosis-inducing ligand, Circled P, phosphorylation. 
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on the balance between Rac1, whose activity is largely responsible for lamellipodia 
formation, and RhoA, which is related to stress fiber formation. Interference with 
lamellipodia by the inhibition of Rac1 reduces migration. This also causes GBM cells to 
acquire a relatively round shape without extending cell processes (Chuang et al., 2004). In 
contrast, collapse of actin stress fiber formation by the inhibition of RhoA promotes 
migration (Salhia et al., 2005). As LiCl treatment is associated with a marked change in GBM 
cell morphology, with cells retracting their long extensions at their leading edge and losing 
lamellipodia formation (Nowicki et al., 2008), GSK3β signaling may involve small GTPases 
such as Rac1 and RhoA. 
4.4 Angiogenesis (signal induced by hypoxia) 
A hypoxic microenvironment is a striking characteristic of GBM that is the collective 
consequence of morphologically and functionally immature neovascularization, irregular 
blood flow, anemia, and high oxygen consumption due to rapidly proliferating malignant 
cells (Jensen, 2009). The hypoxic microenvironment is a powerful stimulus for the 
expression of genes involved in tumor cell proliferation and angiogenesis (Carmeliet et al., 
1998). Hypoxia markedly increases the inactive GSK3β fraction and decreases the active 
GSK3β fraction in U87 GBM cells. In U87 cells under hypoxia, depletion of Ras homolog 
gene family member B (RhoB) by siRNA decreases the inactive form of GSK3β and increases 
active GSK3β. At the same time, RhoB inhibition induces degradation of hypoxia-inducible 
factor 1α (HIF-1α) in the proteasome (Skuli et al., 2006). These experimental data suggest 
that GSK3β controls RhoB-dependent HIF-1α stabilization under hypoxic conditions (Figure 
3). The transcription factor, HIF-1, is an essential regulator of oxygen homeostasis by 
controlling a battery of target genes involved in angiogenesis, glycolysis, proliferation, and 
pH regulation (Semenza, 2009). According to this mechanism, it was shown that inhibition 
of RhoB in GBM xenografts leads to a decrease in vessel density (Ader et al., 2003). 
Considering the role of RhoB in the stimulation of angiogenesis, as well as the presumed 
connection between RhoB expression and GSK3β activity, it is reasonable to speculate that 
GSK3β activity in hypoxic conditions can regulate angiogenesis in GBM. However, the 
precise effect of GSK3β inhibition on angiogenesis has yet to be identified. 
4.5 Cell stemness 
GSK3β activity appears to regulate glioma stem cell populations. GSK3β protein, as well as 
stem cell markers Nestin and Notch2, are highly expressed in CD133+ populations, which 
was identified as a surface marker of cancer stem cells in brain tumors (Singh et al., 2004). 
Down-regulating GSK3β specifically decreased the subpopulation of cancer cells, with a 50–
60% depletion of CD133+ cells that possessed a cancer stem cell-like signature. This 
depletion was attributed to the differentiation of the cell subtype. Additionally, reduction of 
Nestin in GBM stem cell cultures treated with GSK3β inhibitor at the molecular level 
indicated loss of cell stemness (Aguilar-Morante, 2010). Indeed, inhibition of GSK3β reduces 
the GBM stem cell pool and induces phenotypic switch towards differentiation in GBM cell 
cultures. This increases the expression of differentiation markers such as neuronal marker β-
tubulin III, oligodendrocyte-specific marker CNPase, and astrocytic marker GFAP (Korur et 
al., 2009). One explanation for this mechanism is as follows. shRNA-mediated depletion of 
Bmi1, a polycomb group protein that is required for neural stem cell self-renewal, reduced 
expression of GSK3β in glioma. This decreased expression of Sox2 and Nestin in glioma cells 
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and induced cell differentiation, suggesting a putative functional link between GSK3β and 
Bmi1 in glioma cell stemness (Figure 3). 
Neurosphere formation is a representative feature of glioma stem cells. GSK3β inhibition 
significantly reduced the number and volume of neurospheres in glioma cells (Korur et al., 
2009). Primary neurosphere cultures treated with TZD-8 failed to give rise to secondary 
neurospheres, indicating that self-renewing stem cells are lost under TZD-8 treatment 
(Aguilar-Morante et al., 2010). TZD-8 inhibits the proliferation and expansion of these 
neurospheres and hampered their capacity for self-renewal, suggesting that TZD-8 could 
reduce the tumor-initiating cells (Aguilar-Morante et al., 2010). Furthermore, reduction in 
the levels of Nestin protein in GBM stem cell cultures treated with TZD-8 indicated a loss of 
cell stemness induced by GSK3β inhibition (Aguilar-Morante et al., 2010). Taken together, 
GSK3β activation is identified as a key element in maintaining stem cell-like characteristics 
in a subset of glioma cells, providing these cells with a higher self-renewal capacity. 
In contrast, there is a recent contradictory report showing that forced expression of GSK3β 
induces cellular differentiation of malignant glioma cells to normal astrocytes. Conversely, 
GSK3β suppression inhibits differentiation and is accompanied by the interruption of cyclin 
D1 proteolysis, which is necessary for the astrocytic differentiation of malignant glioma cells 
(Li et al., 2010). The exact mechanisms underlying the effect of GSK3β on glioma cell 
differentiation require more detailed study. 
4.6 Metabolism 
Increased glycolysis is characteristic of malignancy. Glioma cell growth is closely associated 
with glucose metabolism. Down-regulation of GSK3β activity results in changes of 
intracellular glucose metabolism (Kotliarova et al., 2008). The activity of mitochondrial 
hexokinase, an enzyme that localizes at the outer mitochondrial membrane and metabolizes 
glucose in rapidly-growing glioma cells, is about 3 times higher than that in slow-growing 
cells. Consistently, the intracellular glucose concentration is undetectable in rapidly-
growing glioma cells, suggesting that glucose catabolism is activated in these cells 
(Nagamatsu et al., 1996). The dissociation of hexokinase from the outer mitochondrial 
membrane by GSK3β inhibition is partially responsible for the reduction in intracellular 
glucose concentration (Kotliarova et al., 2008). However, the reduction of intracellular 
glucose after GSK3β inhibition is mainly due to decreased GSK3β-dependent glycogen 
synthase phosphorylation. This leads to glycogen synthase activation and consequently to 
the increased intracellular glycogen (Figure 1). Further studies are necessary to examine 
whether the forced glucose consumption and subsequent accumulation of glycogen by 
GSK3β inhibition affects the glioma phenotype. However, it may be possible that GBM cells 
cannot use glucose effectively for cell proliferation and survival due to the lack of glucose 
under the condition induced by GSK3β inhibition. 
4.7 Chemosensitivity 
One of the potential molecules involved in the chemosensitization associated with GSK3β 
inhibition in GBM cells is O6-methylguanine-DNA methyltransferase (MGMT), a DNA 
repair enzyme and major determinant of temozolomide cytotoxicity. Recently, clinical 
research has revealed that the methylation status of the MGMT promoter is associated with 
the prognostic outcome of GBM patients treated with temozolomide (Hegi et al., 2005). 
Reduction of MGMT expression induced by p53 in GBM cells renders them sensitive to 
 
Molecular Targets of CNS Tumors  
 
576 
on the balance between Rac1, whose activity is largely responsible for lamellipodia 
formation, and RhoA, which is related to stress fiber formation. Interference with 
lamellipodia by the inhibition of Rac1 reduces migration. This also causes GBM cells to 
acquire a relatively round shape without extending cell processes (Chuang et al., 2004). In 
contrast, collapse of actin stress fiber formation by the inhibition of RhoA promotes 
migration (Salhia et al., 2005). As LiCl treatment is associated with a marked change in GBM 
cell morphology, with cells retracting their long extensions at their leading edge and losing 
lamellipodia formation (Nowicki et al., 2008), GSK3β signaling may involve small GTPases 
such as Rac1 and RhoA. 
4.4 Angiogenesis (signal induced by hypoxia) 
A hypoxic microenvironment is a striking characteristic of GBM that is the collective 
consequence of morphologically and functionally immature neovascularization, irregular 
blood flow, anemia, and high oxygen consumption due to rapidly proliferating malignant 
cells (Jensen, 2009). The hypoxic microenvironment is a powerful stimulus for the 
expression of genes involved in tumor cell proliferation and angiogenesis (Carmeliet et al., 
1998). Hypoxia markedly increases the inactive GSK3β fraction and decreases the active 
GSK3β fraction in U87 GBM cells. In U87 cells under hypoxia, depletion of Ras homolog 
gene family member B (RhoB) by siRNA decreases the inactive form of GSK3β and increases 
active GSK3β. At the same time, RhoB inhibition induces degradation of hypoxia-inducible 
factor 1α (HIF-1α) in the proteasome (Skuli et al., 2006). These experimental data suggest 
that GSK3β controls RhoB-dependent HIF-1α stabilization under hypoxic conditions (Figure 
3). The transcription factor, HIF-1, is an essential regulator of oxygen homeostasis by 
controlling a battery of target genes involved in angiogenesis, glycolysis, proliferation, and 
pH regulation (Semenza, 2009). According to this mechanism, it was shown that inhibition 
of RhoB in GBM xenografts leads to a decrease in vessel density (Ader et al., 2003). 
Considering the role of RhoB in the stimulation of angiogenesis, as well as the presumed 
connection between RhoB expression and GSK3β activity, it is reasonable to speculate that 
GSK3β activity in hypoxic conditions can regulate angiogenesis in GBM. However, the 
precise effect of GSK3β inhibition on angiogenesis has yet to be identified. 
4.5 Cell stemness 
GSK3β activity appears to regulate glioma stem cell populations. GSK3β protein, as well as 
stem cell markers Nestin and Notch2, are highly expressed in CD133+ populations, which 
was identified as a surface marker of cancer stem cells in brain tumors (Singh et al., 2004). 
Down-regulating GSK3β specifically decreased the subpopulation of cancer cells, with a 50–
60% depletion of CD133+ cells that possessed a cancer stem cell-like signature. This 
depletion was attributed to the differentiation of the cell subtype. Additionally, reduction of 
Nestin in GBM stem cell cultures treated with GSK3β inhibitor at the molecular level 
indicated loss of cell stemness (Aguilar-Morante, 2010). Indeed, inhibition of GSK3β reduces 
the GBM stem cell pool and induces phenotypic switch towards differentiation in GBM cell 
cultures. This increases the expression of differentiation markers such as neuronal marker β-
tubulin III, oligodendrocyte-specific marker CNPase, and astrocytic marker GFAP (Korur et 
al., 2009). One explanation for this mechanism is as follows. shRNA-mediated depletion of 
Bmi1, a polycomb group protein that is required for neural stem cell self-renewal, reduced 
expression of GSK3β in glioma. This decreased expression of Sox2 and Nestin in glioma cells 
 
The Pivotal Roles of GSK3β in Glioma Biology 
 
577 
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temozolomide (Natsume et al., 2005). It is reasonable to speculate that increased expression 
of p53 by GSK3β inhibition enhances temozolomide chemosensitivity through the reduction 
of MGMT (Miyashita et al, 2009a).  
4.8 Neuroprotection 
Radiation is a standard post-operative therapy for patients with GBM. Intellectual 
impairment, reduction in performance IQ, memory loss, and dementia have been reported 
after exposure of the brain to radiation. However, the exact mechanisms of radiation-
induced brain injury remain unknown and prevention of cranial radiation-induced 
morbidity remains challenging. Recent studies indicate that inhibition of GSK3β protects 
hippocampal neurons from radiation–induced apoptosis and attenuation of neurocognitive 
dysfunction resulting from cranial radiation (Thotala et al., 2008; Yang et al., 2011). 
Inhibition of GSK3β accelerated double strand-break repair efficiency in irradiated mouse 
hippocampal neurons, whereas, none of these effects were observed in GBM cells, 
suggesting potential clinical application of neuroprotection with GSK3β inhibitors during 
cranial radiation. 
5. GSK3β as a therapeutic target 
In the field of medicinal chemistry, GSK3β has recently emerged as one of the most 
attractive therapeutic targets for the development of selective inhibitors as promising new 
drugs for diabetes. Several potent GSK3 inhibitors have been developed by pharmaceutical 
companies in preclinical models for diabetes treatment. Apart from this, inhibitors of GSK3β 
have enormous potential as therapeutics for a number of serious pathologies, including 
Alzheimer's disease, bipolar disorders, chronic inflammatory processes, and cancer. GSK3β 
inhibitors are being actively developed as drugs for the treatment of these various disorders. 
The therapeutic effect of GSK3β inhibition has been confirmed to inhibit inflammation in 
several studies (Jope et al., 2007). Concerns for the therapeutic use of GSK3β inhibitors 
remain because they may activate oncogenic (e.g., Wnt) signaling, thus promoting cell 
proliferation. Certainly, however, this concern has not deterred preclinical studies of GSK3β 
inhibitors in the treatment of many types of cancers, as discussed above, or Phase II clinical 
trials for the treatment of neurological diseases (Chico et al., 2009).  
5.1 GSK3β-targeted therapy for cancers in clinic  
The need for accurate determination of GSK3β status is illustrated by the excellent results of 
therapies targeting GSK3β in clinic. These strategies have been shown to benefit only tumors 
overexpressing the GSK3β protein. In other words, tumors that do not express GSK3β do 
not benefit from GSK3β-targeted therapies. To date, there are no clinical trial reports 
describing the use of specific GSK3β inhibitors for cancers, although many basic research 
results identified GSK3β as a tumor promoter and suitable candidate for targeted treatment. 
Chemical drugs already prescribed for other diseases were shown to have an inhibitory 
effect on GSK3β.  
5.1.1 Lithium chloride (LiCl) 
LiCl is highly effective in the treatment of bipolar disorder (Bowden et al., 2005). Results 
from an epidemiological study indicated that cancer prevalence in psychiatric patients on 
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long-term LiCl medication was lower than in the general population (Cohen et al., 1998), 
suggesting that administration of LiCl induces cell differentiation and inhibits proliferation 
and, therefore, might effectively inhibit tumor formation and progression. GSK3β has 
emerged as a key target that is central to the effects of LiCl treatment. There are 2 
mechanisms by which LiCl inhibits GSK3β (Figure 4). Firstly, LiCl promotes Ser9 
phosphorylation in GSK3β, resulting in a less active form of GSK3β (Jope, 2003). Secondly, 
LiCl blocks the function of activated GSK3β by competing with magnesium ions (Mg2+) 
(Jope, 2003). Mg2+ is required for activated GSK3β to phosphorylate its substrates, which are 
involved in the propagation of chemical signals required for cell survival, proliferation, and 
differentiation. As a consequence of these inhibitory effects, GSK3β can no longer regulate 
many important biological processes. It is notable that LiCl protects hippocampal neurons 
from radiation–induced apoptosis by promoting the DNA repair pathway, probably a result 
of the effect of GSK3β inhibition (Yang et al., 2009; Yang et al., 2011). 
 
 
Fig. 4. Therapeutic mechanism of GSK3β inhibition in clinic. Lithium chloride (LiCl) inhibits 
phosphorylation of GSK3β substrates by competing with Mg2+, which is required for 
GSK3β-dependent substrate phosphorylation. Simultaneously, LiCl and olanzapine increase 
the phosphorylation of the Ser9 residue. Valproic acid (VPA) inhibits GSK3β by direct 
interaction. LiCl and VPA show additive effects on GSK3β inhibition. Like a 
pharmacological GSK3β inhibitor AR-A014418, olanzapine can be successfully docked 
within the adenosine triphosphate (ATP)-binding pocket of GSK3β. Cimetidine, 
gemifloxacin, and hydroxychloroquine are potent GSK3β inhibitors with at least 2 distinct 
binding modes accessible to ligands within the GSK3β binding pocket. Circled P, 
phosphorylation. 
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5.1.2 Valproic acid (VPA)  
VPA is now an established drug for the treatment of epileptic seizures (absence, tonic-clonic, 
and complex partial seizures) and mania in bipolar disorder (Kostrouchova & Kostrouch, 
2007). VPA affects multiple cell regulatory pathways. The best substantiated molecular 
mechanism of VPA action is its inhibitory effect on histone deacetylase (HDAC) activity, a 
key regulator in the dynamics of chromatin structure and function. It was proposed that 
VPA activates Wnt-dependent gene expression through inhibition of HDAC, which 
generated interest for its use in cancer therapy (Phiel et al., 2001). Apart from this, VPA, like 
LiCl, exerts significant inhibitory effects on the activity of GSK3β both directly in vitro and 
also on endogenous GSK3β in intact human neuroblastoma SY5Y cells (Chen et al., 1999) 
(Figure 4). The dual inhibition of HDAC and GSK3β by VPA may provide a basis for its 
anticancer activity. As expected, clinical trials using VPA for cancer showed some effects 
(Chateauvieux et al., 2010). 
Significant inhibitory effects for GSK3β are clearly observed at VPA concentrations 
approximating those attained clinically during treatment. Furthermore, addition of LiCl at 
therapeutic concentrations results in additive inhibitory effects to that of VPA. These 
additive effects of LiCl and VPA on GSK3β suggest that the 2 drugs may exert their effects at 
different sites, but additional studies will be necessary to establish this definitively (Chen et 
al., 1999). 
5.1.3 Olanzapine 
Olanzapine is broadly used for patients with schizophrenia. Recently, olanzapine was 
identified as a GSK3β inhibitor by a docking simulation experiment, which validates the 
interaction between the drug and its target molecule. Olanzapine, as well as the well-known 
GSK3β inhibitor AR-A014418, were found to readily fit within the adenosine triphosphate 
(ATP)-binding pocket of GSK3β and to inhibit its activity (Mohammad et al., 2008). 
Additionally, the administration of olanzapine, similar to LiCl, increased phospho-Ser9-
GSK3β in brain (Li et al., 2007) (Figure 4). The inhibition of GSK3β by olanzapine was 
accompanied by a decrease in the blood glucose level and accumulation of glycogen in the 
liver in a dose-dependent manner. This is consistent with the effect of GSK3β inhibition 
(Mohammad et al., 2008). Olanzapine-induced low blood glucose level is also consistent 
with clinical reports (Budman & Gayer, 2001). This result contrasts that of a previous report, 
where olanzapine induced hyperglycemia as a major side effect (Fertig et al., 1998). The 
molecular mechanism of these contradictory findings is currently unknown. 
On the basis of the reported reduced cancer risk in schizophrenic patients (Catts et al., 2008), 
a recent study demonstrated the anti-tumor effect of a number of antipsychotic drugs, 
including olanzapine, except for risperidone (Wiklund et al., 2010). The effect of these drugs 
against cancer cells was associated with changes in the expression of genes acting on 
cholesterol homeostasis and the biophysical properties of the cellular membrane. Inhibition 
of GSK3β activity might be an alternate mechanism by which olanzapine acts against cancer. 
5.1.4 Cimetidine 
Cimetidine was the first registered histamine H2 receptor antagonist, and its frequent 
prescription was based on its clinical effectiveness in healing gastrointestinal ulcers by 
inhibiting gastric acid secretion (Somogyi & Gugler, 1983). Cimetidine has been 
demonstrated to possess anti-tumor activity against colon, gastric, and kidney cancers and 
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melanomas. This activity involves a number of different mechanisms of action, including 
blocking the cell growth-promoting activity of histamine (Lefranc et al., 2006). With respect 
to GBM, cimetidine combined with temozolomide was superior to temozolomide alone in 
extending the survival of nude mice with human GBM cells orthotopically xenografted into 
their brain (Lefranc et al., 2005).  
In silico screening is a powerful method to analyze large chemical databases in order to 
identify possible new drug candidates. Recently, in silico screening revealed that cimetidine, 
as well as hydroxychlorquine (an antimalarial and anti-lupus erythematosus agent) and 
gemifloxacin (a new quinolone antibiotic), have an inhibitory effect on GSK3β (Taha et al., 
2008) (Figure 4).  
5.1.5 Enzastaurin 
Enzastaurin, a selective serine/threonine protein kinase inhibitor already under clinical 
evaluation to treat recurrent GBM, potently inhibits GSK3β in addition to its primary target, 
protein kinase C (PKC) β. In phase I/II clinical trials, enzastaurin showed potentially 
encouraging efficacy in a subset of patients with recurrent malignant glioma, but does not 
appear to have enough single-agent activity to be useful as a monotherapy (Kreisl et al., 
2009; Kreisl et al., 2010). In this trial, phosphorylation of GSK3β in peripheral blood 
mononuclear cells was identified as a potential biomarker of drug activity. 
6. Perspective 
GSK3β has been recognized as a key component in a wide range of cellular functions and is 
involved in the vast number of signaling pathways that converge on this enzyme, and 
subsequently, an even greater number of biological targets. GSK3β is undoubtedly a 
promising target not only for diabetes, bipolar disorder, Alzheimer’s, and several other 
neurological disorders, but also for human cancers, including GBM, on the basis of the 
accumulated evidence. Inhibitors of GSK3β have enormous therapeutic potential. Of great 
importance is understanding the precise molecular mechanisms of GSK3β-mediated signal 
transduction, including signaling elements involved in proliferation, apoptosis, invasion, 
differentiation, chemosensitivity, radiosensitivity, and neuroprotection, as well as the 
precise functions of GSK3β proteins in cellular responses induced in human normal and 
malignant cell types. The emerging understanding of GSK3β function would also give rise 
to new insights in tumor biology. In the future, it is hoped that increasing knowledge of 
GSK3β will be translated into molecularly targeted therapies against intractable cancers 
represented by glioblastoma multiforme. 
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5.1.2 Valproic acid (VPA)  
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liver in a dose-dependent manner. This is consistent with the effect of GSK3β inhibition 
(Mohammad et al., 2008). Olanzapine-induced low blood glucose level is also consistent 
with clinical reports (Budman & Gayer, 2001). This result contrasts that of a previous report, 
where olanzapine induced hyperglycemia as a major side effect (Fertig et al., 1998). The 
molecular mechanism of these contradictory findings is currently unknown. 
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a recent study demonstrated the anti-tumor effect of a number of antipsychotic drugs, 
including olanzapine, except for risperidone (Wiklund et al., 2010). The effect of these drugs 
against cancer cells was associated with changes in the expression of genes acting on 
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melanomas. This activity involves a number of different mechanisms of action, including 
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identify possible new drug candidates. Recently, in silico screening revealed that cimetidine, 
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gemifloxacin (a new quinolone antibiotic), have an inhibitory effect on GSK3β (Taha et al., 
2008) (Figure 4).  
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Enzastaurin, a selective serine/threonine protein kinase inhibitor already under clinical 
evaluation to treat recurrent GBM, potently inhibits GSK3β in addition to its primary target, 
protein kinase C (PKC) β. In phase I/II clinical trials, enzastaurin showed potentially 
encouraging efficacy in a subset of patients with recurrent malignant glioma, but does not 
appear to have enough single-agent activity to be useful as a monotherapy (Kreisl et al., 
2009; Kreisl et al., 2010). In this trial, phosphorylation of GSK3β in peripheral blood 
mononuclear cells was identified as a potential biomarker of drug activity. 
6. Perspective 
GSK3β has been recognized as a key component in a wide range of cellular functions and is 
involved in the vast number of signaling pathways that converge on this enzyme, and 
subsequently, an even greater number of biological targets. GSK3β is undoubtedly a 
promising target not only for diabetes, bipolar disorder, Alzheimer’s, and several other 
neurological disorders, but also for human cancers, including GBM, on the basis of the 
accumulated evidence. Inhibitors of GSK3β have enormous therapeutic potential. Of great 
importance is understanding the precise molecular mechanisms of GSK3β-mediated signal 
transduction, including signaling elements involved in proliferation, apoptosis, invasion, 
differentiation, chemosensitivity, radiosensitivity, and neuroprotection, as well as the 
precise functions of GSK3β proteins in cellular responses induced in human normal and 
malignant cell types. The emerging understanding of GSK3β function would also give rise 
to new insights in tumor biology. In the future, it is hoped that increasing knowledge of 
GSK3β will be translated into molecularly targeted therapies against intractable cancers 
represented by glioblastoma multiforme. 
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1. Introduction 
Neoplasms of the central nervous system (CNS) constitute a group of tumors that are 
heterogeneous in epidemiology, biological behavior, genetic alterations, histological type, 
tumor location, pattern of spread, clinical presentation, natural history, age of occurrence, 
and prognosis (Behin et al., 2003; Louis, 2006; Stroher et al., 2000). According to the 2010 
Surveillance Epidemiology and End Results [SEER] data, there were approximately 22,020 
deaths from cancers of the brain and nervous system in the U.S. As reported by Binder et al., 
(2003) and Wrensch et al., (2002), some 7 to 16 cases of primary CNS tumors per 100,000 
person-years are diagnosed in adults; approximately 50% of these cases are metastatic 
tumors, according to Hill et al. 1999.   
CNS tumors are the third leading cause of cancer deaths in middle-aged adults, the second 
most common cause of death in children, and the most common solid tumor in children 
(Giles, 1995; Heuer et al., 2007). The incidence of CNS tumors in children and adolescents is 
approximately 2.7 cases per 100,000 patients per year. This figure accounts for 16% of the 
neoplasms within this group, making CNS tumors the second most frequent type of cancer 
(after leukemia) in young patients (20 years old and younger). The mortality rate observed 
with CNS tumors is one of the highest among childhood cancers. Diagnosis and treatment 
improvements, however, has contributed to the survival of these patients (Potter et al., 
1998). 
Epidemiological studies have shown a slight increase in the incidence of CNS tumors during 
the 1980s and 1990s in children and the elderly (Fisher et al. 2007; Swensen & Bushouse 
1998). The apparent increase in the number of cases of CNS cancers is directly linked to the 
implementation of high-resolution neuroimaging tools, such as Magnetic Resonance 
Imaging (MRI) and Computed Tomography (CT), which have impacted the clinical 
diagnosis of neurological diseases (Cristensen et al., 2003; Fisher et al., 2007). Another 
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important cause for the apparent increase in the incidence of brain tumors is the recent 
inclusion of low-grade neoplasms, which were not previously counted in the population-
based registries (Linet et al., 1999). 
Brain tumors have different incidence rates in different populations, with the highest rates 
in developed countries. Some  factors have influenced the increased incidence in these 
countries, such as the  increased accessibility of medical care and the implementation of 
cutting-edge technologies in health.However, cultural influences and ethnic or geographical 
differences cannot be disregarded as risk factors (Davis, 2007; Ohgaki & Kleihues, 2005). The 
incidence of brain tumors in Japan, for example, is less than half that of the northern 
European countries. In the U.S., neuroepithelial tumors are found more frequently in 
Caucasians than in blacks, Hispanics and Asians (SEER, 2010; Wrensch et al., 2002). 
The etiologic factors of CNS tumors are not well established, and several studies have 
sought to elucidate the risk factors for these cancers. Some of the possible factors are shown 
in Table 1. Among the numerous associations that have been studied, the ones that 
definitely cause primary CNS tumors are the hereditary syndromes (tuberous sclerosis and 
neurofibromatosis Types 1 and 2) and ionizing radiation used for therapeutic purposes 
(Davis, 2007; Guney et al. 2001; Skalr, 2002) 
 
Hereditary syndromes** 
Family history of brain tumors 
Constitutive polymorphisms  
Lymphocyte mutagen sensitivity  
Prior cancers 
Infectious agents or immunological response 
Allergies 
Head trauma 
Epilepsy, seizures, or convulsions 
Drugs and medications 
Diet and vitamins  
Tobacco smoke exposure 
Alcohol 
Hair dyes and sprays 
Traffic-related air pollution 
Occupational and industrial exposures 
Ionizing radiation**  
Cellular telephones 
Other radio frequency exposures 
Power frequency electromagnetic fields 
Table 1. Factors that have been studied in relation to the risk of primary tumors of the 
neuroepithelial tissue or meninges (adapted from Wrensh et al., 2002). **These factors have 
been shown to cause primary brain tumors.  
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The anatomical and pathological classifications of clinical brain tumors are complex and 
controversial, especially with regard to mixed tumors. As a result, the histological 
classification of brain tumors has been subject to constant review from the first attempt at 
histological classification proposed by Bailey & Cushing until today (Louis et al. 2007; 
Wrensh et al., 2002). 
The histological classification of brain tumors currently adopted by the World Health 
Organization (WHO) divides these entities according to the predominant cell type in the 
lesions. This classification extends the concept of the degree of malignancy by incorporating 
data from phenotypic and molecular changes observed in these tumors. The WHO 
classification organizes brain tumors into neuroepithelial tumors of peripheral nerves, 
tumors of the meninges, lymphomas and hematological malignancies, germ cell tumors and 
metastatic tumors of the sellar region, with a total of over 100 distinct histological entities 
(Louis et al. 2007; Kleihues et al., 2002). 
CNS tumors that originate from neuroepithelial tissue, generically called gliomas, are the 
CNS neoplasms that are most frequently encountered in children and adults. The subtypes 
have different biological behaviors and are distinguished by their histological 
characteristics, such as nuclear atypia, mitotic index, blood microvessel formation and 
necrosis. Such peculiarities are also used to assess the degree of malignancy according to the 
standards adopted by the WHO (Louis, 2006;  Kleihues et al., 2002). Table 2 shows the WHO 
classification for neuroepithelial tumors in simplified form. 
 
Neuroepithelial tumors 
Astrocytic tumors  
Pilocytic astrocytoma  9421/1* 
Diffuse astrocytoma  9420/3 
Anaplastic astrocytoma  9401/3 
Glioblastoma  
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Anaplastic  oligodendroglioma   
9382/3 
Ependymal tumors  
Ependymoma   
9391/3 
 
Anaplastic ependymoma  9392/3 
Myxopapillary ependymoma 9394/1 
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important cause for the apparent increase in the incidence of brain tumors is the recent 
inclusion of low-grade neoplasms, which were not previously counted in the population-
based registries (Linet et al., 1999). 
Brain tumors have different incidence rates in different populations, with the highest rates 
in developed countries. Some  factors have influenced the increased incidence in these 
countries, such as the  increased accessibility of medical care and the implementation of 
cutting-edge technologies in health.However, cultural influences and ethnic or geographical 
differences cannot be disregarded as risk factors (Davis, 2007; Ohgaki & Kleihues, 2005). The 
incidence of brain tumors in Japan, for example, is less than half that of the northern 
European countries. In the U.S., neuroepithelial tumors are found more frequently in 
Caucasians than in blacks, Hispanics and Asians (SEER, 2010; Wrensch et al., 2002). 
The etiologic factors of CNS tumors are not well established, and several studies have 
sought to elucidate the risk factors for these cancers. Some of the possible factors are shown 
in Table 1. Among the numerous associations that have been studied, the ones that 
definitely cause primary CNS tumors are the hereditary syndromes (tuberous sclerosis and 
neurofibromatosis Types 1 and 2) and ionizing radiation used for therapeutic purposes 
(Davis, 2007; Guney et al. 2001; Skalr, 2002) 
 
Hereditary syndromes** 
Family history of brain tumors 
Constitutive polymorphisms  
Lymphocyte mutagen sensitivity  
Prior cancers 
Infectious agents or immunological response 
Allergies 
Head trauma 
Epilepsy, seizures, or convulsions 
Drugs and medications 
Diet and vitamins  
Tobacco smoke exposure 
Alcohol 
Hair dyes and sprays 
Traffic-related air pollution 
Occupational and industrial exposures 
Ionizing radiation**  
Cellular telephones 
Other radio frequency exposures 
Power frequency electromagnetic fields 
Table 1. Factors that have been studied in relation to the risk of primary tumors of the 
neuroepithelial tissue or meninges (adapted from Wrensh et al., 2002). **These factors have 
been shown to cause primary brain tumors.  
The Role of Matrix Metalloproteinases and 
Tissue Inhibitors of Metalloproteinases in the Progression of Astrocytomas 595 
The anatomical and pathological classifications of clinical brain tumors are complex and 
controversial, especially with regard to mixed tumors. As a result, the histological 
classification of brain tumors has been subject to constant review from the first attempt at 
histological classification proposed by Bailey & Cushing until today (Louis et al. 2007; 
Wrensh et al., 2002). 
The histological classification of brain tumors currently adopted by the World Health 
Organization (WHO) divides these entities according to the predominant cell type in the 
lesions. This classification extends the concept of the degree of malignancy by incorporating 
data from phenotypic and molecular changes observed in these tumors. The WHO 
classification organizes brain tumors into neuroepithelial tumors of peripheral nerves, 
tumors of the meninges, lymphomas and hematological malignancies, germ cell tumors and 
metastatic tumors of the sellar region, with a total of over 100 distinct histological entities 
(Louis et al. 2007; Kleihues et al., 2002). 
CNS tumors that originate from neuroepithelial tissue, generically called gliomas, are the 
CNS neoplasms that are most frequently encountered in children and adults. The subtypes 
have different biological behaviors and are distinguished by their histological 
characteristics, such as nuclear atypia, mitotic index, blood microvessel formation and 
necrosis. Such peculiarities are also used to assess the degree of malignancy according to the 
standards adopted by the WHO (Louis, 2006;  Kleihues et al., 2002). Table 2 shows the WHO 
classification for neuroepithelial tumors in simplified form. 
 
Neuroepithelial tumors 
Astrocytic tumors  
Pilocytic astrocytoma  9421/1* 
Diffuse astrocytoma  9420/3 
Anaplastic astrocytoma  9401/3 
Glioblastoma  
 




Oligodendroglial tumors  
Oligodendroglioma 9450/3 
Anaplastic  oligodendroglioma   
9382/3 
Ependymal tumors  
Ependymoma   
9391/3 
 
Anaplastic ependymoma  9392/3 
Myxopapillary ependymoma 9394/1 
 
Molecular Targets of CNS Tumors 596 
Neuroepithelial tumors 
 
Subependymoma                                                                               
 
9383/1 
Choroid plexus tumors  
Choroid plexus papilloma 
 
Atypical choroid plexus papilloma 
 











Angiocentric glioma 9431/1 
Chordoid gliomas of the third ventricle 9444/1 







Central neurocytoma  9506/1 
Embryonal tumors  




Atypical teratoid/rhabdoid tumor 9508/3 
Table 2. WHO classification for neuroepithelial tumors. * International Classification of 
Diseases - Oncology (ICD-O) (adapted from Louis et al., 2007). 
1.1 Astrocytic tumors 
The astrocytic tumors are derived from astrocytes, the principal glial support cells. These 
tumors are the most common primary brain tumors. They present extensive heterogeneity, 
differing in the location, age, extent, invasive potential, clinical course and tendency to 
progress (Khatua et al., 2003; Wang et al., 2003). Classically, astrocytomas are divided 
according to the degree of malignancy: pilocytic astrocytoma (Grade I), fibrillar diffuse 
astrocytoma (Grade II), anaplastic astrocytoma (Grade III) and glioblastoma multiforme 
(Grade IV). 
The pilocytic astrocytomas are rare neoplasms, with an estimated incidence of less than 1 
case per 100.000 person-years. They are predominantly pediatric tumors and are usually 
located in the cerebral hemispheres, with no infiltrative and circumscribed lesions. They are 
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slow-growing and rarely lead to malignant transformation. Thus, these diffuse astrocytoma 
tumors are considered to be low-grade malignant neoplasms (Evren-Keles, et al., 2004). 
Although these neoplasms display benign behavior when located in the cerebral 
hemispheres, the same cannot be said when the lesions occur in the visual pathways or 
hypothalamus. 
Histologically, pilocytic astrocytomas are presented as tumors of low to moderate 
cellularity. They consist of astrocytes with regular, uniform nuclei and little atypia. They are 
characterized by the presence of numerous Rosenthal fibers, which are protein inclusions 
within their astrocytic prolongations (Strother et al., 2000). Surgery is the recommended 
treatment for these lesions and is curative in most cases. 
Chemotherapy has been used in specific cases, especially in children, with tumors of the 
optic tracts who experience progression after an initial period of observation and potential 
deterioration of vision (Packer et al., 1997). 
Diffuse or fibrillary astrocytomas (Grade II) are less frequent in children, and commonly 
affecting young adults. Histologically, these tumors have increased cellularity, often do not 
exhibit microcysts or Rosenthal fibers, tend to undergo anaplastic transformation more 
frequently and they are more infiltrative (Behin et al., 2003). 
Anaplastic astrocytomas (Grade III) are infiltrative, have a high proliferative potential and 
affect mainly adults. This type of tumor is associated with a shorter survival time than the 
two previously mentioned; presenting the three- or four-year survival in 70% of the cases. 
Surgery remains the best treatment option and this should target as wide an area as possible 
(Behin et al., 2003). 
Grade IV astrocytoma, more commonly called glioblastoma multiforme, is most frequent in 
adults and is the most aggressive tumor of this lineage; it corresponds to approximately 50% 
of the malignant tumors of the CNS. It is clinically aggressive, highly invasive and capable 
of invading extra-axially. This neoplasm often appears in adulthood, after 40 years of age, 
which does not mean it is  exclusive to this age group (Binder et al., 2003). 
The histological features of glioblastoma multiforme are hypercellularity, cellular atypia and 
anaplasia, frequent nuclear mitotic figures, necrosis and endothelial proliferation. (Behin et 
al., 2003; Strother et al., 2000). 
The optimal treatment is surgery, but many patients with neurological problems, the very 
elderly (over 80 years), and those at high risk of complications from anesthesia should be 
carefully evaluated; in many cases, biopsy is most suitable. Local radiotherapy is also 
indicated, even in cases where there is no indication for surgery. 
Glioblastomas may arise from the transformation of low-grade or anaplastic tumors (in 
which case they are called secondary glioblastomas), or they can be primary (in which case 
they are called primary glioblastomas) (Kleihues et al., 2000). Although this classification is 
widely accepted in clinical practice, the designation of primary or secondary glioblastomas 
is more conceptual than diagnostic and has no pratical impact on treatment. The molecular 
analysis of these tumors has led to a classification based on the genetic alterations 
commonly found in them, which can distinguish primary from secondary glioblastomas 
(Figure 1) (Kleihues & Ohgaki, 2007). 
2. The Extracellular Matrix (ECM) 
The ECM consists of a complex network of proteins and proteoglycans, secreted by the 
connective tissue, whose purpose is to support the tissues that make up an organism. This 
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they are called primary glioblastomas) (Kleihues et al., 2000). Although this classification is 
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Molecular Targets of CNS Tumors 598 
network of proteins has a decisive influence on various biological activities (Giancotti et al. 
1999; Matrisian, 1990). 
The degradation of the ECM is a physiological process that is strictly controlled by the 
dynamic equilibrium between the activity of matrix metalloproteinases (MMPs) and tissue 
inhibitors of metalloproteinases (TIMPs). The cell–ECM interactions send signals promoting 
cell differentiation, migration and mobility that are necessary for cell homeostasis (Chang & 
Werb, 2001). MMPs degrade the ECM proteins and pericellular microenvironment, 
activating growth factors and adhesion molecules. These events are essential for a variety of 
physiological processes, such as embryonic development, remodeling, tissue repair and 
angiogenesis (Chakraborti et al. 2003; Löffek et al. 2010; Matrisian, 1990). 
The disordered destruction of the ECM plays a crucial role in the development of various 
pathologies, such as liver fibrosis, aneurysms, periodontosis, rheumatoid arthritis, multiple 
sclerosis, cystic fibrosis and tumor formation. The development of tumors is highly 
dependent on the microenvironment because the production and/or uncontrolled activation 
of proteolytic enzymes involved in the degradation and remodeling of the ECM are the 





Fig. 1. The genetic pathways involved in the development of primary and secondary 
glioblastomas (adapted from Ohgaki & Kleihues, 2007).  
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2.1 Matrix metalloproteinases  
The metalloproteinases are divided according to their biochemical characteristics as follows: 
MMPs; a disintegrin and metalloproteinases (ADAMs); and ADAMs with thrombospondin 
domains (ADAMS-TS) (Malemud, 2006; Werb, 1997). 
MMPs are zinc-dependent (Zn+2) peptidases with highly conserved substrate specificity that 
are capable of degrading proteoglycans, laminin, fibronectin, gelatin and fibrillar collagen 
(Types I, II, III, V and XI) on the basal membrane and in the ECM (Curran & Murray, 2000, 
Yong et al., 1998). There are more than 20 known members of this family of proteases. 
Mammalian MMPs are classified into soluble (secreted) and membrane (MT-MMPs) 
(Amalinei et al. 2007; Pei et al. 2000; Seiki, 1999). 
Soluble MMPs are synthesized as pro-enzymes, while the MT-MMPs are activated in the 
intracellular space and expressed on the cell surface as active enzymes. These MMPs are 
divided into four subclasses according to their structural and functional characteristics: 
collagenases, gelatinases, stromelysins, and matrilysins (Nabeshima et al., 2002; Nagase & 
Woessner, 1999; Visse & Nagase, 2003).  
The degradation of ECM is a physiological process that is strictly controlled by the dynamic 
equilibrium between the activity of matrix metalloproteinases (MMPs) and tissue inhibitors 
of metalloproteinases (TIMPs). The cell–ECM interactions send signals that promote cell 
differentiation, migration and mobility, which are necessary for cell homeostasis (Chang & 
Werb, 2001). MMPs degrade ECM proteins and the pericellular microenvironment, 
activating growth factors and adhesion molecules. These events are essential for a variety of 
physiological processes, such as embryonic development, remodeling, tissue repair and 
angiogenesis (Chakraborti et al. 2003; Löffek et al. 2010; Matrisian, 1990). 
The general structure of MMPs consists of three domains that are highly conserved among 
this family but still distinct: a pro-N-terminal domain, a catalytic domain, and a C-terminal 
domain that contains the conserved hemopexin (HEXGHXXGXXH) motif (the matrilysins 
subfamilies do not have this motif). The histidine residues (H) contained in the hemopexin 
domain are involved in binding to Zn+2, which is required for its proteolytic activity. The 
pro-domain of MMPs also contains a highly conserved PRCGVDP motif that bonds 
covalently to Zn+2, keeping the protein in its non-activated zymogen form. Gelatinases have 
a binding site for fibronectin in the catalytic domain that confers specificity to the substrate 
(Figure 2) (Nakada et al. 1999; Pollet et al. 2004; Vihinen & Kalahari, 2002). 
The collagenase subfamily includes MMP-1, MMP-8, MMP-13 and MMP-18, which exhibit 
biochemical characteristics that allow them to cleave interstitial collagen I, II and III in a site-
specific N-terminal domain. Interstitial collagen I is one of the most abundant substances in 
the human body, so collagenases play an important role in the process of remodeling and 
degrading the ECM (Curran & Murray, 2000; Visse & Nagase, 2003). 
The gelatinases include gelatinase A (MMP-2) and gelatinase B (MMP-9). These enzymes are 
specialized in degrading Type IV collagen, the main constituent of the basement membrane 
of cerebral blood vessels. As previously mentioned, these enzymes have three repeats of a 
fibronectin domain in their catalytic domains, which allows the gelatinases to bind to 
laminins and gelatin (Yong et al., 1998). 
MMP-2, is a 72-kDa gelatinase, encoded on human chromosome 16q13 and constitutively 
expressed in variety of  cell types. This enzyme has the ability to degrade collagen V, VII, XI 
and fibronectin. MMP-2 also mediates proliferation, adhesion and cell migration. This 
enzyme is secreted in its inactive form and gains catalytic activity by interacting with the 
complex formed by membrane metalloproteinase 1 (MT1-MMP, or MMP-14) and TIMP-2 
(Chintala et al., 1999). 
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Fig. 2. The general structure of MMPs and their subfamilies (Vihinen & Kalahari, 2002). 
MMP-9 is a 90–110-kDa protein encoded in the region 20q11.2-13.1. This enzyme is also 
secreted as a zymogen that can be stored in an active or latent form in the cytosol. The 
expression of MMP-9 is not constitutive and may be influenced by many factors, such as cell 
growth, cytokine signaling, cell–cell adhesion and cell–ECM interactions. The mechanism of 
protease activation thus involves a complex web of interactions with other MMPs and 
TIMPs (Amalinei et al. 2007; Chintala et al. 1999). 
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The stromelysins group is composed of the following proteases: MMP-3 (stromelysin-1), 
MMP-10 (stromelysin-2); and MMP-11 (stromelysis-3). These proteases have similar 
substrates, but MMP-3 has higher proteolytic activity than the other stromelysins. MMP-3 is 
expressed in several cell types and acts on the following ECM components: collagen, gelatin, 
elastin, fibronectin, and vitronectin. In addition to digesting the ECM components, MMP-3 
participates in the activation of pro-MMP-1 and pro-MMP-9 (Egeblad & Werb, 2002). 
The membrane-MMP subfamily consists of six MT-MMPs (MT1-MMP through MT6-MMP) 
and two glycosylphosphatidylinositol (GPI)-anchored MMPs (MMP-17 and MMP-25). One 
of the most prominent members of this subfamily is MT1-MMP (MMP-14), whose substrates 
are collagen Types I, II and III, gelatin, fibronectin and laminin (Koshikawa et al., 2000). 
MT1-MMP is considered a multifunctional molecule. It is directly involved in cell growth, 
inflammation, the formation of new vessels, and the processes of cell adhesion and 
migration. Consequently, it plays a role in the formation of metastases (Shiomi & Okada, 
2003; Yana & Seiki, 2002). 
Its interactions with MT1-MMP cause TIMP-2 to play a crucial role in the activation of pro-
MMP-2. The catalytic domain of MT1-MMP binds to the N-terminal domain of TIMP-2, 
causing the C-terminal region of TIMP-2 to become capable of connecting to the hemopexin 
domain of pro-MMP-2. The location of this protease in the membrane plays a role in 
pericellular proteolysis because this molecule activates pro-MMP-2, enabling it to use 
exogenous substrates to mediate the processes of invasion and metastasis. (Sternlicht & 
Werb, 2001; Sounni et al., 2003). 
The expressions of MMPs are under the control of a sophisticated genetic mechanism. 
Under basal circumstances, levels of MMPs are relatively low; however, the expression of 
MMPs is increased by the processes of ECM remodeling that result from physiological or 
pathological conditions. The expression of some subfamilies of MMPs is tissue-specific. The 
regulation of the expressions of MMPs occurs by three main routes:  transcriptional 
regulation of MMPs; activation of pro-enzymes, and inhibition by the action of TIMPs 
(Nagase et al., 2006; Yong et al. 1998). 
2.1.1 Transcriptional regulation of MMP genes 
The transcription factors that regulate MMP gene expression include activating protein-1 
(AP-1), polyoma enhancer activator 3 (PEA3), SP1, β-catenin/Tcf-4 and NF-κB, these factors 
seem to have synergistic effects on MMP gene regulation. Based on the composition of their 
regulatory elements, the promoters of these genes can be divided into Classes I, II and III 
(Yan & Bold, 2007). 
The Class I promoters contain a TATA box at position -30 (relative to the transcription start 
site) and an AP1-binding site at position -70. Many of these promoters also contain a binding 
site for PEA3 that is adjacent to the AP1 site. The Class II promoters also have a TATA box 
but without the proximal AP1 site. The regulation of these promoters is relatively simple 
and it is distinct from the regulation of the Class I promoters (Benbow & Brinckerhoff, 1997; 
Chakraborti et al., 2003). 
The third and final group of promoters does not have a TATA box, meaning that 
transcription begins at multiple sites. However, the SP1 family of transcription factors, 
which bind close to the GC box, . controls the regulation of this group. The FOS and JUN 
proteins actively participate in the transcription regulatory mechanism by forming a 
heterodimer that binds to the AP1 sites and stimulates the transcription of MMPs in 
response to inflammatory cytokines (Matrisian, 1990). The structural differences between 
the MMP promoters are shown in Figure 3. 
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Fig. 2. The general structure of MMPs and their subfamilies (Vihinen & Kalahari, 2002). 
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The stromelysins group is composed of the following proteases: MMP-3 (stromelysin-1), 
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expressed in several cell types and acts on the following ECM components: collagen, gelatin, 
elastin, fibronectin, and vitronectin. In addition to digesting the ECM components, MMP-3 
participates in the activation of pro-MMP-1 and pro-MMP-9 (Egeblad & Werb, 2002). 
The membrane-MMP subfamily consists of six MT-MMPs (MT1-MMP through MT6-MMP) 
and two glycosylphosphatidylinositol (GPI)-anchored MMPs (MMP-17 and MMP-25). One 
of the most prominent members of this subfamily is MT1-MMP (MMP-14), whose substrates 
are collagen Types I, II and III, gelatin, fibronectin and laminin (Koshikawa et al., 2000). 
MT1-MMP is considered a multifunctional molecule. It is directly involved in cell growth, 
inflammation, the formation of new vessels, and the processes of cell adhesion and 
migration. Consequently, it plays a role in the formation of metastases (Shiomi & Okada, 
2003; Yana & Seiki, 2002). 
Its interactions with MT1-MMP cause TIMP-2 to play a crucial role in the activation of pro-
MMP-2. The catalytic domain of MT1-MMP binds to the N-terminal domain of TIMP-2, 
causing the C-terminal region of TIMP-2 to become capable of connecting to the hemopexin 
domain of pro-MMP-2. The location of this protease in the membrane plays a role in 
pericellular proteolysis because this molecule activates pro-MMP-2, enabling it to use 
exogenous substrates to mediate the processes of invasion and metastasis. (Sternlicht & 
Werb, 2001; Sounni et al., 2003). 
The expressions of MMPs are under the control of a sophisticated genetic mechanism. 
Under basal circumstances, levels of MMPs are relatively low; however, the expression of 
MMPs is increased by the processes of ECM remodeling that result from physiological or 
pathological conditions. The expression of some subfamilies of MMPs is tissue-specific. The 
regulation of the expressions of MMPs occurs by three main routes:  transcriptional 
regulation of MMPs; activation of pro-enzymes, and inhibition by the action of TIMPs 
(Nagase et al., 2006; Yong et al. 1998). 
2.1.1 Transcriptional regulation of MMP genes 
The transcription factors that regulate MMP gene expression include activating protein-1 
(AP-1), polyoma enhancer activator 3 (PEA3), SP1, β-catenin/Tcf-4 and NF-κB, these factors 
seem to have synergistic effects on MMP gene regulation. Based on the composition of their 
regulatory elements, the promoters of these genes can be divided into Classes I, II and III 
(Yan & Bold, 2007). 
The Class I promoters contain a TATA box at position -30 (relative to the transcription start 
site) and an AP1-binding site at position -70. Many of these promoters also contain a binding 
site for PEA3 that is adjacent to the AP1 site. The Class II promoters also have a TATA box 
but without the proximal AP1 site. The regulation of these promoters is relatively simple 
and it is distinct from the regulation of the Class I promoters (Benbow & Brinckerhoff, 1997; 
Chakraborti et al., 2003). 
The third and final group of promoters does not have a TATA box, meaning that 
transcription begins at multiple sites. However, the SP1 family of transcription factors, 
which bind close to the GC box, . controls the regulation of this group. The FOS and JUN 
proteins actively participate in the transcription regulatory mechanism by forming a 
heterodimer that binds to the AP1 sites and stimulates the transcription of MMPs in 
response to inflammatory cytokines (Matrisian, 1990). The structural differences between 
the MMP promoters are shown in Figure 3. 
 
Molecular Targets of CNS Tumors 602 
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2.1.2 Activation of proenzymes 
MMPs are synthesized as zymogens. These enzymes can be activated by proteases in vivo or 
in vitro after exposure to chemical agents, such as thiol compounds (HgCl2 and N-
ethylmaleimide), SDS, reactive oxygen species, and exposure to heat or acidic pH. 
Activation in vivo occurs in the extracellular space and requires breaking the zinc–cysteine 
complex to expose its catalytic site. The cysteine residue (C) of the PRCGVPD sequence in 
the pro-domain interacts with the catalytic portion of the Zn2+ while maintaining the pro-
MMPs in latent form. The disruption of this C–Zn2+ interaction results in a partial activation 
of the intermediate form of the enzyme, leading to the autocatalysis of the pro-peptide 
region that provides full activity to the enzyme. This mechanism allows the pro-MMPs to be 
activated by multiple agents, as mentioned above (Ra & Parks, 2007; Van Wart & Birkedal-
Hansen, 1990). 
The plasminogen/urokinase system is also an important physiological activator of pro-
MMPs. The plasminogen activator of urokinase is associated with the membrane, thus 
creating an activation site for pro-MMPs and the subsequent renewal of the ECM. Plasmin 
can activate pro-MMP-1, pro-MMP-3, pro-MMP-7, pro-MMP-9, pro-MMP-10 and pro-MMP-
13 (Nagase et al., 2006). 
Most pro-MMPs that are secreted into the extracellular space are activated. Some pro-MMPs 
have a furin domain (KCKR) that allows them to be activated by furin in the intracellular 
space. These pro-enzymes include pro-MMP-11, MT-MMPs, pro-MMP-23 and pro-MMP-28 
(Amalinei et al., 2007; Satmenkovic, 2003). 
The activation of pro-MMP-2 is mediated by the MT-MMPs, with the exception of MT4-
MMP, and it depends on the participation of TIMP-2. Pro-MMP-2 forms a complex with 
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TIMP-2 through its C-terminal domain, allowing the N-terminal domain of TIMP-2 to bind 
to MT1-MMP on the cell surface. The complex containing MT1-MMP, TIMP-2, and pro-
MMP-2 is then presented to an adjacent free MT1-MMP, which activates the pro-MMP-2. 
The hemopexin domain seems to facilitate this activation process (Jo et al., 2000). 
2.2 Tissue inhibitors of metalloproteinases 
The TIMPs constitute the third regulatory level of MMP expression. These proteins are 
major physiological inhibitors of MMPs. The TIMPs are low-molecular-weight, 21–30 kDa, 
molecules that have approximately 12 cysteine residues that are involved in disulfide 
bridges, six of which are responsible for the formation of two domains that are essential for 
the interaction of these molecules with MMPs. The C-terminal domain is responsible for the 
interaction with and activation of pro-MMPs and for the subcellular localization of these 
proteins. The N-terminal domain acts as an independent unit that inhibits the activity of 
MMPs (Baker et al., 2002; Brew et al. 2000). 
Blocking the proteolytic activity of both soluble and membrane-bound MMPs is 
accomplished by TIMPs through the formation of monocovalent complexes at a 1:1 ratio 
between the catalytic site of MMPs and the N-terminus of TIMPs. The amino groups and 
carbonyl groups of the cysteine residues in the N-terminus of TIMPs act together to chelate 
the Zn2+ in the catalytic domain of MMPs, making Zn2+ unavailable to activate the MMPs 
(Nagase et al., 2006; Visse & Nagase, 2003). 
Four TIMPs, designated as TIMP-1 through TIMP-4, have been characterized in humans. 
They are resistant to heat denaturation and proteolytic degradation. These proteins are 
expressed in a variety of cell types and fluids (Gómez et al., 1997). Although all TIMPs are 
capable of inhibiting all the MMPs that have been studied, they differ in many aspects, such 
as solubility, the complementary nature of the pro-enzymes and the regulation of 
expression. TIMP-1, TIMP-2 and TIMP-4 are present in the soluble form, while TIMP-3 is 
connected to the ECM (Lamfers et al., 2005). The expression of TIMP-1 is inducible. This 
molecule has weak inhibitory action against MMP-19 and MT-MMPs (MT-MMP1, MT-
MMP-2, MT-MMP-3 and MT-MMP-5) and even inhibits ADAM -10. The expression of 
TIMP-2 is constitutive, and it has strong inhibitory action against the MT-MMPs. TIMP-3 
may also inhibit other members of the ADAM family, such as ADAM-17, ADAMTS-4 and 
ADAMTS-5, and the inhibitory effects of this molecule on MMP-9 are greater than those 
observed for TIMP-1 and TIMP-2. TIMP-4 expression is inducible, and it appears to inhibit 
the activities of MMPs constitutively. Table 3 presents some of the molecular characteristics 
and biological properties of TIMPs. 
The TIMPs have also the ability to form complexes with pro-MMPs, thus regulating their 
activation. TIMP-1 preferentially forms complexes with pro-MMP-9, and TIMP-2 binds 
preferentially to pro-MMP-2 to facilitate its activation (Baker et al., 2002). TIMP-3 binds to 
both pro-MMP-2 and pro-MMP-9 (Bigg et al., 1997), and TIMP-4 can bind to the C-terminal 
domain of pro-MMP-2 (Butler et al., 1999). 
The inhibition of MMPs is not unique to TIMPs. Molecules such as α-macroglobulin, general 
protease inhibitors, β-amyloid precursors linked to the cell membrane, and the membrane 
protein RECK play the same. RECK is a GPI-type, membrane-anchored protein that 
decreases the catalytic activity of MMP-2, MMP-9 and MT1-MMP and can overcome the 
angiogenic activity in neoplastic processes, leading to the death of tumor cells (Oh et al., 
2001). A scheme for the interaction between the activation and inhibition of MMPs by TIMPs 
is presented in Figure 4. 
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the interaction of these molecules with MMPs. The C-terminal domain is responsible for the 
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proteins. The N-terminal domain acts as an independent unit that inhibits the activity of 
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the Zn2+ in the catalytic domain of MMPs, making Zn2+ unavailable to activate the MMPs 
(Nagase et al., 2006; Visse & Nagase, 2003). 
Four TIMPs, designated as TIMP-1 through TIMP-4, have been characterized in humans. 
They are resistant to heat denaturation and proteolytic degradation. These proteins are 
expressed in a variety of cell types and fluids (Gómez et al., 1997). Although all TIMPs are 
capable of inhibiting all the MMPs that have been studied, they differ in many aspects, such 
as solubility, the complementary nature of the pro-enzymes and the regulation of 
expression. TIMP-1, TIMP-2 and TIMP-4 are present in the soluble form, while TIMP-3 is 
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may also inhibit other members of the ADAM family, such as ADAM-17, ADAMTS-4 and 
ADAMTS-5, and the inhibitory effects of this molecule on MMP-9 are greater than those 
observed for TIMP-1 and TIMP-2. TIMP-4 expression is inducible, and it appears to inhibit 
the activities of MMPs constitutively. Table 3 presents some of the molecular characteristics 
and biological properties of TIMPs. 
The TIMPs have also the ability to form complexes with pro-MMPs, thus regulating their 
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protease inhibitors, β-amyloid precursors linked to the cell membrane, and the membrane 
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decreases the catalytic activity of MMP-2, MMP-9 and MT1-MMP and can overcome the 
angiogenic activity in neoplastic processes, leading to the death of tumor cells (Oh et al., 
2001). A scheme for the interaction between the activation and inhibition of MMPs by TIMPs 
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Fig. 4. MMPs are a class of proteases secreted by tumor cells. RECK is a membrane-anchored 
inhibitor of MMPs. It inhibits MMP-2, MMP-9 and MT1-MMP. Soluble, secreted MMP 
inhibitors, TIMPs, have also been identified. They appear to be less active at inhibiting 
MMPs and are perhaps even essential for MMP maturation. The inhibition of MMPs by 
RECK inhibits invasion of tissues, metastasis and tumor angiogenesis and is essential for 
normal development. (www.biocarta.com). 
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The main function of TIMPs is to act as natural receptor inhibitors of metalloproteinases. 
However, some studies have attributed other functions to TIMPs. Some of these functions 
are related to inhibiting MMPs and others are independent of it, such as promoting cell 
proliferation, anti-apoptosis activity and anti-angiogenesis (Chang & Werb, 2001; Chirco et 
al., 2006). 
The induction of cell proliferation by TIMPs was first described for TIMP-1 and TIMP-2; 
they enhance the effect of erythropoietin in the proliferation and differentiation of erythroid 
progenitors. This property was observed not only in this cell type but also in keratinocytes, 
chondrocytes, epithelial cells and cancer cells (Hayakawa et al. 1992; Murat et al., 1993). In 
addition to promoting cell proliferation, the TIMPs may also modulate apoptosis in various 
ways, including opposing effects. TIMP-1 and TIMP-2 are involved in resistance to 
apoptosis in normal and cancer cells. The effect of TIMP-3 is different because it promotes 
apoptosis in smooth muscle cells, inducing the shedding of the ECM from transformed cells 
(Baker et al., 1998). 
The effects of TIMP-4 in modulating apoptosis are contradictory; fibroblast-transformed 
heart tissue appear to be induced to apoptosis by TIMP-4, and the protein seems to have an 
inhibiting effect on apoptosis when hyperexpressed in breast-tumor cell lines (Baker et al., 
2002). 
Angiogenesis is described as the biological process of new capillary formation from existing 
vessels, which occurs in normal and pathological events. The TIMPs have anti-angiogenic 
activity, as was first demonstrated for TIMP-1 and TIMP-2. When hyperexpressed, they 
reduce angiogenic activity in pancreatic adenocarcinomas (Bloomston et al., 2002). TIMP-3 
also has anti-angiogenesis and anti-invasion activities. For example, it reduces the 
invasiveness of the HT1080 cell line derived from fibrosarcoma and the expression of MMP-
9, a molecule with known angiogenic activity (Lamfers et al., 2005). These observations 
corroborate the notion that the imbalance between the expressions of MMPs and TIMPs has 
a decisive role in the initiation and development of neoplastic processes. 
2.3 The role of MMPs in progression of astrocytic tumors 
Since the discovery of MMPs in 1962 by Gross and LaPierre, these enzymes have attracted 
great interest among researchers for their involvement in various physiological and 
pathological events. However, only in the 1980s, MMPs were discovered to be involved in 
the development and progression of tumors, a function that is widely studied to this day 
(Bourboulia & Stetler-Stevenson, 2010; Matrisian  et al., 1986). 
The invasive properties of CNS tumors are of great clinical importance because they 
contribute to the aggressive behavior of these tumors (Rao, 2003). For reasons still not well 
clarified yet , most primary neuroepithelial tumors do not evolve into metastatic disease. 
However, these tumors invade surrounding tissues, infiltrate their cells into normal tissue 
and (more rarely) spread along the neuro-axis into the cerebrospinal fluid. 
The mechanism of astrocytic-tumor invasion is a complex process in which tumor cells 
separate from the parental tumor and rejoin the ECM. This process is associated with an 
increase in cell motility and with the ability of tumor cells to hydrolyze proteins, 
carbohydrates and proteoglycans in the ECM. These cells perform this task through the 
excessive production of proteases that modify the ECM, thus creating access to the 
surrounding tissues and promoting migration to other parts of the brain (Levicar et al., 
2003). 
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vessels, which occurs in normal and pathological events. The TIMPs have anti-angiogenic 
activity, as was first demonstrated for TIMP-1 and TIMP-2. When hyperexpressed, they 
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MMPs are among the proteases that can degrade the ECM in brain tissue. The integrity of 
the ECM depends on a dynamic balance between MMP and TIMP activities. The loss of this 
balance can lead to the creation of a permissive environment for the initiation and 
development of a neoplastic process in brain tissue. MMPs, TIMPs and cell adhesion 
molecules are involved in the development of CNS malignancies (Forsyth et al. 1999; 
Mohana et al. 1995; Nakada et al. 2001; Rooprai et al., 1998). Changes in the expression of 
these proteins appear to be directly linked to the invasiveness of tumor cells. Classically, 
MMPs are considered to be responsible for promoting tumor growth, while TIMPs are 
thought to block the invasive ability of tumors (Amalinei et al. 2010; Deryugina & Quinley, 
2006). 
High-grade astrocytomas and medulloblastomas are neuroepithelial tumors of different 
cellular origins and are highly invasive. The degradation of the ECM is a prerequisite for 
invasion by these tumors. Among the MMPs that are commonly associated with the 
progression of astrocytic tumors are the gelatinases and the membrane MMPs, especially 
MT1-MMP1. Gelatinases A (MMP-2) and B (MMP-9) are undoubtedly the most well-studied 
MMPs in CNS tumors, and they have been identified as important factors in the 
development of high-grade gliomas (Munaut et al. 2003; Pagenstecher et al. 2001; Zhao, et 
al., 2007). This observation is directly linked to the invasive nature of these tumors because 
the expression levels of these gelatinases are generally low in normal brain tissue (Van 
Meter et al., 2001). 
A study by Jäälinojä et al. (2000) demonstrated that the high expression of MMP-2 is a 
characteristic of highly malignant tumors and is associated with poor patient survival,  
similar data were also observed by Kunishio et al. (2003), who used immunohistochemistry 
analysis to show that MMP-2 and MMP-9 are not associated with increased aggressiveness 
in astrocytic tumors. 
Komatsu et al. (2004) studied the expression of MMP-2 and MMP-9 in human gliomas by 
using two different techniques, RQ-PCR and immunohistochemistry, the results revealed no 
correlation between the expression of MMP-2 protein and the degree of malignancy. 
However, quantitative analysis of the mRNA showed that tumors of the highest grade, such 
as glioblastomas, express much higher levels of the MMP-2 and MMP-9 genes than do low-
grade tumors. This study clearly demonstrated that methodological differences may explain 
some of the conflicting results found in the literature. 
Increased levels of MMP-2 and MMP-9 and their relationships with astrocytic tumors of 
greater aggressiveness and invasiveness have also been reported by a number of authors, 
such as Forsyth et al. (1999), Lampert et al. (1998), Munaut et al. (2003), Pagenstecher et al. 
(2001) and Wang et al. (2003). Wild-Bode et al. (2001) reported that the overexpression of 
MMP-2 and MMP-9 is the best predictor of cell invasion by high-grade gliomas.  
Another important result that highlights the prognostic significance of elevated MMP-9 
expression was discovered by Hormigo et al. (2006), who found elevated MMP-9 protein in 
the serum of patients suffering from high-grade astrocytomas, which was not observed in 
low-grade tumors or in non-neoplastic tissue. These authors also suggested that MMP-9 can 
be used as a biomarker in the management of glioblastoma patients. 
The analysis of MMP-9  expression conducted by our group revealed that this gene is 
expressed more highly in astrocytic tumors than in non-tumor tissue. The expression is 
much greater in tumors with the highest degree of malignancy, especially glioblastomas, 
than in low-grade astrocytomas. Our study also revealed that pilocytic astrocytomas arising 
in the optic tracts, hypothalamus and pituitary gland, which appear to exhibit more 
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aggressive behavior, show higher expressions of MMP-9 than do the tumors that originate 
in the cerebral hemispheres (unpublished data). These observations suggest that 
overexpression of MMP-9 is one of the main mechanisms necessary to increase the 
invasiveness and aggressiveness of CNS tumors. Our data also show that overexpression of 
MMP-9 in patients suffering from glioblastomas is significantly associated with decreased 
overall survival, as shown in Figure 5 (unpublished data). A multivariate analysis suggested 
that overexpression of MMP-9 is an independent prognostic factor of paramount 
importance in the management of glioblastoma patients. These observations support the 




Fig. 5. The Overall survival of glioblastoma patients. The patients who overexpress the 
MMP-9 gene have significantly lower survival than patients with no marked upregulation 
of this gene (unpublished data). 
Our observations suggest that overexpression of MMP-9 increases the invasiveness of 
astrocytic tumors, making it a potential target for combating these neoplasms. Other 
authors, such as Vince et al. (2001), have found higher levels of expression of this gelatinase 
in medulloblastomas than in glioblastomas. They also observed that MMP-2 is more 
commonly found in areas of intense proliferative activity, while MMP-9 is associated with 
sites of angiogenesis, a typical feature of the invasive capacity of these tumors. Angiogenesis 
is highly dependent on the migration and invasion of endothelial cells into tissues. The ECM 
sequesters and stores angiogenesis-promoting factors, such as VEGF, bFGF and TGF1, 
which are released during the proteolytic degradation of the ECM. Accordingly, MMPs play 
a critical role in the process of angiogenesis. MMPs both promote and inhibit angiogenesis 
(Jain et al. 2007; Rundhaug, 2005; Zhao et al., 2008). 
Gelatinases are the main promoters of the invasion of endothelial cells in the CNS (Lakka et 
al., 2005). MMP-2 is constitutively expressed by endothelial cells and interacts with 
thrombin, which is present at high levels in angiogenic sites. This interaction leads to 
activation of protein C on the surface of the endothelium. Activated protein C interacts with 
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balance can lead to the creation of a permissive environment for the initiation and 
development of a neoplastic process in brain tissue. MMPs, TIMPs and cell adhesion 
molecules are involved in the development of CNS malignancies (Forsyth et al. 1999; 
Mohana et al. 1995; Nakada et al. 2001; Rooprai et al., 1998). Changes in the expression of 
these proteins appear to be directly linked to the invasiveness of tumor cells. Classically, 
MMPs are considered to be responsible for promoting tumor growth, while TIMPs are 
thought to block the invasive ability of tumors (Amalinei et al. 2010; Deryugina & Quinley, 
2006). 
High-grade astrocytomas and medulloblastomas are neuroepithelial tumors of different 
cellular origins and are highly invasive. The degradation of the ECM is a prerequisite for 
invasion by these tumors. Among the MMPs that are commonly associated with the 
progression of astrocytic tumors are the gelatinases and the membrane MMPs, especially 
MT1-MMP1. Gelatinases A (MMP-2) and B (MMP-9) are undoubtedly the most well-studied 
MMPs in CNS tumors, and they have been identified as important factors in the 
development of high-grade gliomas (Munaut et al. 2003; Pagenstecher et al. 2001; Zhao, et 
al., 2007). This observation is directly linked to the invasive nature of these tumors because 
the expression levels of these gelatinases are generally low in normal brain tissue (Van 
Meter et al., 2001). 
A study by Jäälinojä et al. (2000) demonstrated that the high expression of MMP-2 is a 
characteristic of highly malignant tumors and is associated with poor patient survival,  
similar data were also observed by Kunishio et al. (2003), who used immunohistochemistry 
analysis to show that MMP-2 and MMP-9 are not associated with increased aggressiveness 
in astrocytic tumors. 
Komatsu et al. (2004) studied the expression of MMP-2 and MMP-9 in human gliomas by 
using two different techniques, RQ-PCR and immunohistochemistry, the results revealed no 
correlation between the expression of MMP-2 protein and the degree of malignancy. 
However, quantitative analysis of the mRNA showed that tumors of the highest grade, such 
as glioblastomas, express much higher levels of the MMP-2 and MMP-9 genes than do low-
grade tumors. This study clearly demonstrated that methodological differences may explain 
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MMP-9 in patients suffering from glioblastomas is significantly associated with decreased 
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importance in the management of glioblastoma patients. These observations support the 
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latent MMP-2 to increase its protease activity, thus allowing the endothelial cells to degrade 
the basement membrane. MMP-9 is then activated by intracellular vesicles secreted from 
endothelial cells to enhance the degradation of basement membrane. When the basement 
membrane reaches the interstice, the abundant collagen Type I contributes to the prolonged 
activation of MMP-2, thus consolidating the process of angiogenesis (Nguyen et al., 2001). 
Glioblastomas are astrocytic tumors with increased invasive behavior, this property is 
closely related to their high vascularization. In vivo and in vitro, MMP-2 and MMP-9 are 
hyperexpressed in endothelial cells of glioblastomas (Vince et al., 2001; Zhao et al., 2010). 
The direct involvement of these proteins in angiogenesis may explain our observation of 
increased expression of MMP-2 and MMP-9 mRNA in highly malignant tumors 
(unpublished data). Similar results were found by Munaut et al. (2003), who also observed 
that overexpression of MMP-2 and MMP-9 is correlated with overexpression of VEGF in 
glioblastomas, a key mediator of angiogenesis.  
Elevated expression of MMP-2 and MMP-9 and its clinical and biological implications for 
other cancers have been reported in several studies. Cho et al. (2007) reported that 
overexpression of MMP-9 is associated with poor prognosis in colorectal tumors. Similar 
observations were obtained by Kawata et al. (2007) for renal tumors and Iniesta et al. (2007) 
for non–small cell lung cancer. 
Like the gelatinases, MT1-MMP is considered to be a promoter of tumor cell invasion and a 
facilitator of metastasis. MT1-MMP promotes the acquisition of invasive capacity in both 
normal and neoplastic cells through its ability to degrade pericellular collagen. It also 
facilitates angiogenesis by activating endothelial cells. This activity has been documented 
both in vivo and in vitro (Martin & Matrisian, 2007). The pro-invasive activity of MT1-MMP 
has been associated by some authors with invasion and progression in other tumors, such as 
neck tumors by Zhai et al. (2005) and astrocytic tumors by Forsyth et al. (1999); Nakada et al. 
(1999, 2001) and Kong et al. (2007). 
Among the studies that have found a direct relationship between the increased expression 
of MT1-MMP and the evolution of gliomas, that of Nuttall et al. (2003) stands out because it 
found a greater than 21-fold increase in the level of MT1-MMP mRNA in glioblastomas 
relative to non-tumor brain tissue. The overexpression of MT1-MMP was also reported in a 
glioblastoma cell line (U251), the most invasive of the strains tested by the authors. This 
increase in the level of MT1-MMP was accompanied by the overexpression of MMP-2 and 
MMP-9 and of genes related to angiogenesis, such as VEGF. Munaut et al. (2003) also 
reported that strong expression of VEGF is accompanied by overexpression of MMP-2, 
MMP-9 and MT1-MMP and that these proteins act synergistically to create a permissive 
environment for glioblastoma cell invasion. Pagenstecher et al. (1999) also observed that the 
levels of MMP expression in pilocytic astrocytomas are comparable to those observed in 
anaplastic astrocytomas and glioblastomas, suggesting that this molecule is a major player 
in the progression of astrocytic tumors.  
Arroyo et al. (2007) and Basile et al. (2007) demonstrated that MT1-MMP plays a crucial role 
in angiogenesis and that this protein is usually hyperexpressed at sites of neoangiogenesis. 
We believe that our observations are related to the level of vascularization of these tumors, 
and high-grade pilocytic astrocytomas have a significant level of vascularization. The 
overexpression of MT1-MMP and its relationship with the aggressive behavior of tumors 
have also been described in soft tissue cancers Roebuck et al. (2005) and more recently by 
Sroka et al. (2008) in prostate tumors. 
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2.4 The role of TIMPs in the progression of astrocytic tumors. 
A high level of TIMP expression may occur in two distinct contexts: (1) as part of the 
defense mechanisms of the host tissue against the invasion; and (2) as promoter, either 
directly or indirectly, of cell growth in the tumor mass that helps the tumor progress and 
invade adjacent structures (Brand, 2002). The latter property directly promotes the evolution 
of these lesions to higher-malignancy tumors.  
TIMP-1 is involved in a series of biological and pathological processes, including growth-
promoting activity, inhibition of angiogenesis and changes in cell morphology. In the CNS, 
this molecule seems to possess the neuroprotective effect of maintaining the blood–brain 
barrier by its inherent inhibitory action on MMPs. TIMP-1 also has the distinguishing 
characteristic of not being able to inhibit MT1-MMP, in contrast to other TIMPs (Duffy et al., 
2008). TIMP-1 is also involved in the development of neuroepithelial tumors (Gardner & 
Ghorpade, 2003; Lampert et al. 1998; Kakagawa et al. 1994; Pagentecher et al. 1999). Groft et 
al. (2001) showed that overexpression of TIMP-1 is associated with malignancy in gliomas 
and that TIMP-1 is detected mainly near the sites of blood vessel formation. These 
observations could be a result of interactions with pro-MMP-9 and the angiogenesis-
promoting ability of this MMP. Huang et al (2005) and Pagentecher et al. (1999) found 
higher levels of TIMP-1 expression in pilocytic astrocytomas and glioblastomas. This result 
seems contradictory, but it may act to offset the simultaneous increases in the expression of 
MMP-9 and TIMP-1 because TIMP-1 preferentially inhibits MMP-9. The results of 
Pagentecher et al. (1999) also showed that this overexpression is linked to sites of 
neoangiogenesis. 
Overexpression of TIMP-1 appears to be an important prognostic factor for patients with 
breast cancer, since those patients with greater expression of this gene have higher survival 
rates (Nakopoulou et al., 2003). However, we found no similar reports for astrocytic tumors. 
TIMP-2 preferentially inhibits MMP-2 and activates pro-MMP-2 by forming complexes with 
MT1-MMP. Béliveau et al. (1999), Huang et al. (2005) and Nakada et al. (2001) suggests that 
there is an inverse correlation between the expression of TIMP-2 and the degree of 
malignancy in CNS tumors. This result may be related to the antagonistic effects of these 
genes in the classical biological behavior of astrocytic tumors, in which MMPs act as 
promoters of invasion and TIMPs as blockers of tumor growth. Nuttal et al. (2003) has also 
detected high levels of TIMP-2 mRNA and protein expression in non-neoplastic brain-tissue 
samples. The in vitro protective effects of TIMP-2 were also described by Papi et al. (2007) in 
experiments using cells derived from gliomas. Moreover, Saxena et al. (1999) found a 
positive correlation between the expressions of TIMP-2 and MMP-2 and the degree of 
malignancy of CNS tumors, in which the highest levels of expression of these genes are 
primarily found in recurrent tumors. The increased expression of TIMP-2 in these tumors 
may be related to defense against invasion or, more precisely, to the attempt to block the 
proteolytic activity of MMP-2, which facilitates tumor invasion. Other associations between 
the expression of TIMP-2 and survival in patients affected by CNS tumors have not been 
found. Curran et al. (2004) observed that the loss of TIMP-2 expression contributes 
significantly to the low survival rate of patients suffering from colorectal tumors. 
The loss of TIMP-3 expression is related to cancer development, and normal brain tissue has 
high levels of TIMP-3. This physiological inhibitor of MMPs antagonizes the activity of most 
metalloproteinases, thereby leading to the inhibition of tumor growth, angiogenesis, 
invasion and metastasis formation. The overexpression of this gene in tumor cells seems to 
promote apoptosis and suppress early tumor growth (Hoe et al., 2007). 
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Arroyo et al. (2007) and Basile et al. (2007) demonstrated that MT1-MMP plays a crucial role 
in angiogenesis and that this protein is usually hyperexpressed at sites of neoangiogenesis. 
We believe that our observations are related to the level of vascularization of these tumors, 
and high-grade pilocytic astrocytomas have a significant level of vascularization. The 
overexpression of MT1-MMP and its relationship with the aggressive behavior of tumors 
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invasion and metastasis formation. The overexpression of this gene in tumor cells seems to 
promote apoptosis and suppress early tumor growth (Hoe et al., 2007). 
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A study using microarray analysis that was conducted by Bozinov et al. (2008) showed that 
TIMP-3 is one of the genes preferentially expressed in less-malignant CNS tumors. Huang et 
al. (2003) also observed that non-neoplastic tissue has low expression of TIMP-3. 
Furthermore, Lampert et al. (1998) and Pangestecher et al. (1999) found no variation in the 
gene expression levels between gliomas and suggested that this observation is consistent 
with constitutive expression. The protective effect of TIMPs against invasion by glioma cells 
was demonstrated by Lamfers et al. (2005), who used an adenovirus to transfer the gene for 
TIMP-3 into cultured cells, which resulted in increased expression of the gene and a 
reduction in the invasive capacity of the cells. The main cause of the decreased expression of 
TIMP-3 is the hypermethylation of its promoter region. Gonzalez-Gomez et al. (2003a, 
2003b) have shown that the promoter region of this gene is hypermethylated in 
glioblastomas, especially in secondary glioblastomas, and in medulloblastomas. Nakamura 
et al. (2005) have also found that the loss of heterozygosity in region 22q12.3, the region 
containing the TIMP- gene, is a frequent event in glioblastomas. These authors also 
suggested that these molecular alterations may be the primary cause of decreased 
expression of TIMP-3 in high-grade astrocytic tumors. Nakamura et al. (2005) have shown 
that hypermethylation of TIMP-3, and the consequent reduced expression of the gene, is an 
important factor in the poor survival of patients affected by highly malignant tumors. 
Correlations between decreased expression of this gene and low survival rates have also 
been observed in colorectal cancer (Hilska et al., 2007), non–small cell lung cancer (Mino et 
al., 2007) and bladder carcinomas (Hoque et al., 2008). 
TIMP-4 has been studied less than the other TIMPs. It was discovered by Greene et al. 
(1996), who identified an expressed sequence tag (EST) with that was closely related to that 
of other TIMPs. This EST was identified and cloned in cDNA libraries from the human 
heart. They identified low levels of this transcript in a variety of tissues and organs, such as 
kidney and placenta, and did not observe expression of the gene in tissues derived from 
brain, lung, thymus or liver. These authors suggested that the contribution of TIMP-4 to 
maintaining the homeostasis of the ECM is tissue-specific. Bigg et al. (1997) also showed that 
TIMP-4 has a strong affinity for pro-MMP-2 and that, together with TIMP-2, it participates 
in the activation of pro-gelatinase A. The literature addressing the involvement of TIMP-4 in 
the development and progression of CNS tumors is sparse. Groft et al. (2001) have identified 
an inverse relationship between the expression of TIMP-4 and malignant CNS tumors. 
Microarray data obtained by Rorive et al. (2006) also show that TIMP-4 is preferentially 
expressed in pilocytic astrocytomas relative to normal brain tissue, Grade II astrocytomas 
and high-grade astrocytomas (Grades III and IV).The elevated expression of TIMP-4 in 
samples with low invasive potential compared to more aggressive tumors is not unique to 
CNS tumors. Similar findings have also been observed in studies of cells derived from 
breast tumors (Wang et al., 1997), prostate tumors (Lee et al., 2006) and rectal tumors (Hilska 
et al., 2007), in which the authors also observed that patients with higher expressions of 
TIMP-4 showed increased survival. However, our data revealed no relationship between the 
expression of TIMP-4 and patient survival. These findings suggest that the supposed 
protection afforded by the overexpression of TIMP-4 is directly related to the ability of this 
molecule to promote the apoptosis of tumor cells (Guo et al., 2004). 
The inherent properties of TIMPs can be exploited to achieve therapeutic benefits in various 
diseases. The role of the MMP/TIMP balance in blocking or even reversing tumor 
progression has led to the development of synthetic inhibitors of MMPs (ISMPs). Clinical 
trials evaluating the ISMPs, like batimastat and marimastat for cancer treatment have shown 
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encouraging results, although they are less effective in advanced cancers and do have some 
side effects (Baker et al., 2002). 
However, the results observed in animal models have shown that the use of Chantix 
prevented tumor growth and vascularization of pre-malignant tumors (Bergers et al. 1999; 
Mucha et al., 2007). TIMP gene therapy has also emerged as an important therapy for certain 
cancers, such as prostate (Deng et al., 2008) and hepatocellular carcinoma (Xia et al., 2006). 
3. Conclusion 
Recent advances in genetics and molecular biology have provided a great leap in 
understanding the molecular events responsible for the development and progression of 
brain tumors. The assessment of the level of expression of genes involved in the creation and 
maintenance of tumors of the nervous system can provide accurate information as which 
genes are involved in the development of a specific type of CNS tumor and to determine the 
molecular pathways that may become targets for therapy. Thereby, improving the prognosis 
of patients affected by this neoplasia, and their chances of cure. In this scenario the 
imbalance in the expression of MMPs and TIMPs seems to be an important clue to  the 
progression, and therefore the aggressiveness, of astrocytic tumors. The invasive nature of 
these tumors is a major constraint on the efficacy of available therapies, especially for highly 
malignant astrocytomas. Therefore, a complete understanding of the interaction between the 
molecules that promote and block the migration routes of tumor cells will contribute 
significantly to developing new therapies to combat the progression of CNS tumors. 
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Furthermore, Lampert et al. (1998) and Pangestecher et al. (1999) found no variation in the 
gene expression levels between gliomas and suggested that this observation is consistent 
with constitutive expression. The protective effect of TIMPs against invasion by glioma cells 
was demonstrated by Lamfers et al. (2005), who used an adenovirus to transfer the gene for 
TIMP-3 into cultured cells, which resulted in increased expression of the gene and a 
reduction in the invasive capacity of the cells. The main cause of the decreased expression of 
TIMP-3 is the hypermethylation of its promoter region. Gonzalez-Gomez et al. (2003a, 
2003b) have shown that the promoter region of this gene is hypermethylated in 
glioblastomas, especially in secondary glioblastomas, and in medulloblastomas. Nakamura 
et al. (2005) have also found that the loss of heterozygosity in region 22q12.3, the region 
containing the TIMP- gene, is a frequent event in glioblastomas. These authors also 
suggested that these molecular alterations may be the primary cause of decreased 
expression of TIMP-3 in high-grade astrocytic tumors. Nakamura et al. (2005) have shown 
that hypermethylation of TIMP-3, and the consequent reduced expression of the gene, is an 
important factor in the poor survival of patients affected by highly malignant tumors. 
Correlations between decreased expression of this gene and low survival rates have also 
been observed in colorectal cancer (Hilska et al., 2007), non–small cell lung cancer (Mino et 
al., 2007) and bladder carcinomas (Hoque et al., 2008). 
TIMP-4 has been studied less than the other TIMPs. It was discovered by Greene et al. 
(1996), who identified an expressed sequence tag (EST) with that was closely related to that 
of other TIMPs. This EST was identified and cloned in cDNA libraries from the human 
heart. They identified low levels of this transcript in a variety of tissues and organs, such as 
kidney and placenta, and did not observe expression of the gene in tissues derived from 
brain, lung, thymus or liver. These authors suggested that the contribution of TIMP-4 to 
maintaining the homeostasis of the ECM is tissue-specific. Bigg et al. (1997) also showed that 
TIMP-4 has a strong affinity for pro-MMP-2 and that, together with TIMP-2, it participates 
in the activation of pro-gelatinase A. The literature addressing the involvement of TIMP-4 in 
the development and progression of CNS tumors is sparse. Groft et al. (2001) have identified 
an inverse relationship between the expression of TIMP-4 and malignant CNS tumors. 
Microarray data obtained by Rorive et al. (2006) also show that TIMP-4 is preferentially 
expressed in pilocytic astrocytomas relative to normal brain tissue, Grade II astrocytomas 
and high-grade astrocytomas (Grades III and IV).The elevated expression of TIMP-4 in 
samples with low invasive potential compared to more aggressive tumors is not unique to 
CNS tumors. Similar findings have also been observed in studies of cells derived from 
breast tumors (Wang et al., 1997), prostate tumors (Lee et al., 2006) and rectal tumors (Hilska 
et al., 2007), in which the authors also observed that patients with higher expressions of 
TIMP-4 showed increased survival. However, our data revealed no relationship between the 
expression of TIMP-4 and patient survival. These findings suggest that the supposed 
protection afforded by the overexpression of TIMP-4 is directly related to the ability of this 
molecule to promote the apoptosis of tumor cells (Guo et al., 2004). 
The inherent properties of TIMPs can be exploited to achieve therapeutic benefits in various 
diseases. The role of the MMP/TIMP balance in blocking or even reversing tumor 
progression has led to the development of synthetic inhibitors of MMPs (ISMPs). Clinical 
trials evaluating the ISMPs, like batimastat and marimastat for cancer treatment have shown 
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encouraging results, although they are less effective in advanced cancers and do have some 
side effects (Baker et al., 2002). 
However, the results observed in animal models have shown that the use of Chantix 
prevented tumor growth and vascularization of pre-malignant tumors (Bergers et al. 1999; 
Mucha et al., 2007). TIMP gene therapy has also emerged as an important therapy for certain 
cancers, such as prostate (Deng et al., 2008) and hepatocellular carcinoma (Xia et al., 2006). 
3. Conclusion 
Recent advances in genetics and molecular biology have provided a great leap in 
understanding the molecular events responsible for the development and progression of 
brain tumors. The assessment of the level of expression of genes involved in the creation and 
maintenance of tumors of the nervous system can provide accurate information as which 
genes are involved in the development of a specific type of CNS tumor and to determine the 
molecular pathways that may become targets for therapy. Thereby, improving the prognosis 
of patients affected by this neoplasia, and their chances of cure. In this scenario the 
imbalance in the expression of MMPs and TIMPs seems to be an important clue to  the 
progression, and therefore the aggressiveness, of astrocytic tumors. The invasive nature of 
these tumors is a major constraint on the efficacy of available therapies, especially for highly 
malignant astrocytomas. Therefore, a complete understanding of the interaction between the 
molecules that promote and block the migration routes of tumor cells will contribute 
significantly to developing new therapies to combat the progression of CNS tumors. 
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1. Introduction   
Medulloblastoma (MB) is an embryonal brain tumor of the cerebellum. MB accounts for 4- 
6% of all primary intracranial tumors. It is the most common malignant brain tumor in 
children it represents 15-30% of all pediatric brain tumors, with 85% of MBs being 
diagnosed in patients younger then 18 years of age. The peak incidence occurs between the 
ages 3-9 years, with about  35% metastasis disease(Crawford et al., 2007; Polkinghorn and 
Tarbell 2007; Rossi et al., 2008).  
In contrast, medulloblastoma is rare in adults and accounts for less than1% of primary 
intracranial malignancies in this age group (Brandes et al 2009; Louis 2007; Padovani  et al 
2007).  
Based on histopathological features, the 2007 WHO classification of CNS tumors (Louis et 
al.,2007; Gilbertson and Ellison 2008), has separated  MB into five recognizable subtypes:  
the classic tumor which is the most common subtype of MB in general and in children in 
particular. The other four variants are: 1. desmoplastic/nodular which is the second most 
common (10-20% of the cases) in very young patients and adults, 2. MB with extensive 
nodularity is predominantly observed in infants (less then 3 years old), 3. anaplastic MB,  4. 
large cell MB  is rare in infants, both of  which account for 5-10% of the cases 
The histological classification and clinical staging have proven to be less then ideal methods 
for stratification. Histological subtypes are often quite heterogeneous and exhibit highly 
variable clinical behavior, with anaplastic subtype typically associated with the worst 
prognosis, followed by classic and desmoplastic\nodular MB, which correlate with 
improved overall survival.  
MB with extensive nodularity and desmoplastic/nodular MB in infants have a better 
outcome than the classic MB tumors, while large cell and anaplastic MB behave 
aggressively. Thus infants with desmoplastic MB should be stratified into a low risk 
therapeutic group while the large cell MB is rare but points to a poor prognosis that often 
presents with metastatic disease (Gilbertson and Ellison 2008).  
The increasing recognition of MB as a heterogeneous disease, with histological and 
molecular variants that have distinct biological behavior, affected the disease classification 
and treatment.  
In spite of current aggressive therapies, approximately one third of the patients eventually 
succumb to the disease due to metastasis. Furthermore the post- treatment squeal, which 
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includes neurological, vascular and long-term neurocognitive impairments, can be 
devastating for survivors of the disease (Ribi et al., 2005).  
It is imperative to gain a better understanding of the molecular alterations and other 
biological squeal in medulloblastom for future targeted therapies that are more effective and 
less toxic. 
A combination of clinicopathological evaluation and assays based on molecular subgroups 
of the disease allow stratification of patients into risk groups and more tailored approach to 
therapy which should prevent the significant adverse effects among survivors.  
Studies in the last 5 years have helped to build a consensus on the value and means of using 
molecular markers in the therapeutic stratification of childhood medulloblastoma 
(Gilbertson 2004 ; Packer and Vezina 2008 ; Pizer and Clifford 2009). 
These studies have revealed the genetic heterogeneity within MB including dysregulation of 
several signaling pathways. The genetic heterogeneity appears to be the basis for differential 
response to treatment and give a new impact to the traditional histological subtyping and 
improve to some extend the accuracy of diagnosis and prognosis and as a consequence the 
stratification to risk groups (Packer and Vezina 2008). 
Although, adult MB is considered different from their childhood counterparts in terms of 
tumor biology and clinical variables, yet, because of the high incidence of MB in childhood 
and low incidence in adults most of the studies have been done on the MB of childhood. 
Some studies documented differences between childhood and adults tumors with regards to 
localization, cell of origin, histopathologic features, tumor cell differentiation, and treatment 
outcome. The adult's MB found to be also genetically distinct from the pediatric MB 
(Korshunov et al 2010).  
Here we focused on the genetic alteration reported so far in MB and their significance in 
sub-typing, stratification, and medical care.  
2. Heritability of medulloblastoma  
Neither familial cases of MB, nor MB's cases affected by defined environmental factors have 
been described so far. Also, no specific chromosomal aberration has been described in more 
then about 40% of the MB cases. Unlike Ewing sarcoma, where t(11;21) can be found in 
about 90% of the cases, in MB no main specific gene alteration can be detected. Yet, there is a 
wide basis to believe that inheritable factors play a significant role in MB pathogenesis and 
prevalence. Some of the evidence that support this point of view are:   
A. Age of onset- MB is most prevalent in childhood including about 3% in infancy, mainly 
medulloblastoma with extensive nodularity, while it is rare in adults. MB is mostly a 
childhood brain tumor with a peak in 3-9 years age. Inheritable markers are most probably 
expressed phenotypically at the early ages of life. The younger the patient is, the higher 
chance that the genetic part is more pronounced, and so in the adults, the latter the age of 
tumor appearance the higher chance for multi-factorial environmental cause. About 85% of 
the primary intracranial tumors diagnosed as MB in patients younger then 18 years of age 
while in adults about 1% of the primary intracranial tumors diagnosed as MB. It is well 
known that infants are the more vulnerable group with 25-60% rate of cure, while the over 
all 5-year survival rate in childhood is about 80%. Although, the environmental factors 
could not be totally excluded, yet the younger age of MB appearance with 35% metastatic, 
points toward a more pronounced genetic background rather then environmental (Rossi et 
al 2008, Bar and Stearns 2008).  
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B. Severity of the disease- the most prevalent MB sub-type in infancy is the desmoplastic 
which is considered the most aggressive sub-type especially when it also appear with 
metastasis , 35% of the childhood MB are metastatic at presentation. Metastatic phenotype 
considered as a high risk group with the worst prognosis. Cure rates are lower for infants 
than for older children. This might point either to the more significant-effective role of the 
inheritage genetics predisposition in infants then in elderly or adults MB. Also most 
probably radiotherapy can be particularly more adverse in the immature infant brain (Grill 
et al 2005; Packer and Vezina 2008; Rutkowski et al., 2009). The main consequence of 
carniospinal irradiation (CSI) is notably cognitive problems children's IQ can decrease by as 
much as 30 points in the standard risk group. The high risk group (metastasis, significant 
post operative residual tumor) remains poor 5-years event free survival (EFS) being 25-40% 
the worse prognosis is particularly in younger children 
Although 5-years overall survival rates have reached 60-80% , survivors often face a variety 
of long term neurological , neuroendocrine , and social squeal as a result of conventional 
treatment regimens (surgery, radiotherapy, and chemotherapy (Pizer and Clifford 2009)  
(Packer and Vezina 2008; Rossi et al 2008, Bar and Stearns 2008). It is imperative to gain a 
better understanding of the molecular alterations in MB for future targeted therapies that 
are more effective and less toxic.  
C. Predisposition- Predisposition to develop MB due to known genetic alterations- some 
MB cases are associated with known hereditary syndromes such as Gorlin,  Turcot and Li-
Fraumeni. (Reviewed by Ellison 2010, Northcott, 2011; Onvani 2010) will be discussed in the 
gene alteration part. All the above points support the suggestion that genetic factors cause 
predisposition for MB's development.  
Most studies on MB have focused on genes that are already known to be involved in the 
pathogenesis of tumors, such as Wnt, SHH, Notch TP53. The specific genetic pathway/s in 
MB is/are still unknown.  
Studying the different MB's subtypes with the most advanced technologies will significantly 
contribute to the overall understanding of  MB pathogenesis in general and in particular  in 
MB genetic knowledge. 
3. Chromosomal aberration and its corroletion to clinicohistopatological 
classification 
Cytogenetics and molecular genetics are two different levels of genetic studies. Both of them 
are in use for characterization of tumors in general and MB in particular. Nowadays, these 
tests in combination with other standard methods such immunohistochemistry, significantly 
improved the diagnosis, prognosis  and consequently the treatment modalities and survival of 
the patients with malignant diseases. Cytogenetics, molecular cytogenetics (FISH, CGH ) and 
molecular genetics are three methods that supplement each other, and their combination leads 
to the identification of the genes that are involved in tumorigenesis (tumor suppressor genes 
and oncogenes) and thus can give complete information for prognostic and diagnostic 
purposes. Although, impressive progress has been achieved in the nano molecular genetics, 
next generation sequencing, proteomics and transcriptomics, in the last decade, yet, we can not 
give up the "macro-tests":  the old gold standard methods such as cytogenetics and histology. 
The nano tests are still new and very expensive to implicate to routine work up, they are in a 
developing stage and the accumulated experience with their use is still limited. There is still 
missing information regarding the whole range of polymorphism and how to differentiate it 
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includes neurological, vascular and long-term neurocognitive impairments, can be 
devastating for survivors of the disease (Ribi et al., 2005).  
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A. Age of onset- MB is most prevalent in childhood including about 3% in infancy, mainly 
medulloblastoma with extensive nodularity, while it is rare in adults. MB is mostly a 
childhood brain tumor with a peak in 3-9 years age. Inheritable markers are most probably 
expressed phenotypically at the early ages of life. The younger the patient is, the higher 
chance that the genetic part is more pronounced, and so in the adults, the latter the age of 
tumor appearance the higher chance for multi-factorial environmental cause. About 85% of 
the primary intracranial tumors diagnosed as MB in patients younger then 18 years of age 
while in adults about 1% of the primary intracranial tumors diagnosed as MB. It is well 
known that infants are the more vulnerable group with 25-60% rate of cure, while the over 
all 5-year survival rate in childhood is about 80%. Although, the environmental factors 
could not be totally excluded, yet the younger age of MB appearance with 35% metastatic, 
points toward a more pronounced genetic background rather then environmental (Rossi et 
al 2008, Bar and Stearns 2008).  
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are more effective and less toxic.  
C. Predisposition- Predisposition to develop MB due to known genetic alterations- some 
MB cases are associated with known hereditary syndromes such as Gorlin,  Turcot and Li-
Fraumeni. (Reviewed by Ellison 2010, Northcott, 2011; Onvani 2010) will be discussed in the 
gene alteration part. All the above points support the suggestion that genetic factors cause 
predisposition for MB's development.  
Most studies on MB have focused on genes that are already known to be involved in the 
pathogenesis of tumors, such as Wnt, SHH, Notch TP53. The specific genetic pathway/s in 
MB is/are still unknown.  
Studying the different MB's subtypes with the most advanced technologies will significantly 
contribute to the overall understanding of  MB pathogenesis in general and in particular  in 
MB genetic knowledge. 
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Cytogenetics and molecular genetics are two different levels of genetic studies. Both of them 
are in use for characterization of tumors in general and MB in particular. Nowadays, these 
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molecular genetics are three methods that supplement each other, and their combination leads 
to the identification of the genes that are involved in tumorigenesis (tumor suppressor genes 
and oncogenes) and thus can give complete information for prognostic and diagnostic 
purposes. Although, impressive progress has been achieved in the nano molecular genetics, 
next generation sequencing, proteomics and transcriptomics, in the last decade, yet, we can not 
give up the "macro-tests":  the old gold standard methods such as cytogenetics and histology. 
The nano tests are still new and very expensive to implicate to routine work up, they are in a 
developing stage and the accumulated experience with their use is still limited. There is still 
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from significant changes. Also the exact interactions between all the nano tests (molecular 
genetics, proteomics and transcriptomics) are only partially understood so far. Moreover the 
significance and the importance of the immerging field of epigenetics is still not clear. The field 
of epigenetics is dealing with changes that do not affect the molecular genetics itself but rather 
the changes in the expression of the gene/s by changing mythlation, acetylation, 
phosphorilation and ubiquitination (Bernstein et al. 2007; Kouzarides 2007). Its effects include 
the most delicate interactions of all the living levels, starting from biochemical reaction and the 
interactions inside the cell compartments, cell to cell, in the organ, in the host and between the 
host and the environment.  
Chromosome analysis of tumor cells plays an important role in the diagnosis, prognosis and 
follow up of many malignancies. It is a standard of care in hemato-oncology. Culturing solid 
tumor cells in vitro is essential for cytogenetic analysis. The success in getting specific 
chromosomal aberrations in solid tumors after in vitro culturing is limited because of 
technical problems such as: an overgrowth of cells from healthy part of the tissue mostly 
fibroblasts, limited growth of the abnormal tumor cells and low quality of the tumor cell 
metaphases and also the need for special and well trained cytogeneticists. These are 
probably the main reasons for the limited and what seems like a non specific chromosomal 
aberration in medulloblastoma. Only about 40% of the medulloblastomas demonstrate 
chromosomal aberrations. Presently, advanced technologies such as microarray CGH and 
next generation sequencing enable us to better evaluate chromosomal aberrations in 
medulloblastoma. It will take some time for the accumulation of new data regarding 
chromosomal aberrations using the new methods, mainly because reliable results should be 
done on a large cohort which include sufficient size group of all MB subtypes.  
Copy number abnormalities of chromosome 17 isodicentric, isochromosome of chromosome 
17q, loss of 17p, or gain of 17q  are the most frequent chromosomal abnormality in 
medulloblastomas (Mitelman database 2011, Aldosari et al 2002;  McCabe et al 2006)  it is 
found in 30-50% of the studied cases (Reardon et al 1997). Isochromosome –isodicentric 
chromosome 17 is present in approximately one third of the tumors and in some cases is the 
only chromosomal aberration (Mitelman database 2011; Pfister et al 2009; Ricket and Paulus 
2004). It has been observed in 25-30% of childhood MB. In fact there is a loss of 17p and a 
gain of 17q which is the most common isochromosome in cancer in general (Mitelman 
database 2011). This might point toward the fact that i(17q) is a general marker of neoplastic 
process rather then a specific marker of MB. Its role as an indicator for a poor outcome in 
MB stratification is controversial. The controversial evidence based mainly on the findings 
of i(17q) also in Wnt pathway subgroup which in consensus considered as a favorable 
outcome. The question whether to consider copy number abnormality of chromosome 17 as 
a marker for poor prognosis and to exclude those found to be Wnt  pathway, is still in 
debate (Pan et al 2005; Pfister et al 2009).  
Using more sophisticated and advanced techniques such as CGH to profile a panel of 27 
primary MB (Reardon et al 1997) revealed frequent loss of 10q, 11, 16q, 17p, and 8p as well 
as recurrent gains of  chromosomes 7, and 17q. These losses and gains were also confirmed 
by other techniques, such as G-banding, SKY and FISH (Aldosari et al 2002; Avet-Loiseau et 
al 1999 ; Bayani et al 2000; Eberhart et al 2002; Gilhuis et al 2000). Array CGH of 47 MB 
(Speicher and Carter 2005) showed gain of 17q, 7, and 1q and loss of 17p, 11p,10q and 8.  
There have also been reports, although less frequently of losses on chromosomes 10q, 11, 
17p qnd 22 as well as gains on chromosomes 1q, 7 and 7q (Mitelman database 2011; Bayani 
et al 2000).  
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SKY analysis of 19 primary MB revealed structural aberrations involving chromosomes 7, 
17, 3, 14, 10 and 22.(Bayani et al 2009).  
 Monosomy 6 is strongly associated with Wnt profile in MB (Clifford et al 2006). 
Chromosomal abnormalities including loss of chromosome X in females and loss of 
chromosome 8, have been found mainly in non SHH/Wnt subgroups.  
4. Genetic alterations and its correlation with clinicohistopatological 
classification 
Tumorigenesis is a process in which one of the pathways leading to normal cell 
development has lost its control and its normal function. In addition, the neovasculization, 
cell proliferation, differentiation, motility and apoptosis (death) are also altered.  
There are two possible categories in tumor specific genetic alteration; one is inheritable or 
germ cells mutation and the other is acquired alteration. Also there is a difference between 
general tumorigenesis pathways and tumor specific pathway and general chromosomal 
aberration and tumor specific chromosomal aberration.  
Usually, the tumor specific pathway is a part of the general tumorigenesis pathways but still 
it is predominant in one specific tumor subgroup, for example RB gene that causes mainly 
retinoblastoma, WT gene that causes mainly Willm's tumor, both are also causing 
predisposition to other tumors. Similarly, the acquired gene alteration occurring during the 
life time, such as BCR/ABL is causing chronic myeloid leukemia and EWSR1-FLI1 is 
causing Ewing sarcoma. Specific acquired aberration found in addition to the cancer they 
caused, also in other cancers ,  there its significance and  its prognostic value is different, for 
instance BCR/ABL points to a favorable prognosis in CML and points  to a poor prognosis 
in acute lymphocytic leukemia (ALL).  
Among the life time acquired mutation, one should differentiate between the first event, 
such as alteration of a gene that causes the disease and has a diagnostic value and those 
mutations that are considered as the latter (the second or the third) events for example 
KRAS and TP53 mutation in adenomatose polyposis coli (APC) and MNP1 or FLT1 
mutation in acute leukemia. Those gene alterations have mainly prognostic value and may 
play as a general event seen in other tumors as well.   
Unfortunately, neither MB specific chromosomal changes nor MB specific gene were found 
to be a clear evidence for the possible pathogenesis of MB, neither in MB general nor in one 
of its subtypes. The understanding of MB pathogenesis is still limited, mainly because most 
of the MB studies are associated with genes that are already known to be involved in other 
tumors or syndromes, rather then studying the MB specific gene alterations as the first goal.  
Indeed, MB is associated with other (tumor's) syndromes such as Gorlin,Turcot and Li 
Fraumeni, in which several important developmental signal transduction pathways, 
including sonic hedgehog (SHH), Wingless (Wnt) and Notch signaling cascades. SHH, Wnt, 
TP53  and Notch signaling cascades are implicated in the cells migration and localization in 
the cerebrum,  and their proliferation and differentiation. The alterations in these pathways 
by any component of each signaling pathway may lead to tumorigenesis (Marino 2005; 
Ingham and Placzek 2006). For example, Gorlin's syndrome characterized by a germ line 
mutation in the patched homologue 1 (PTCH1) located on 9q22 ( Frandon et al 1992 ) that 
served as a negative regulator of SHH gene during normal cerebella development. Mutation 
in PTCH1 gene can cause predisposition to different tumor development including MB with 
incidence of 5-20% (Friedrich 2007). 
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from significant changes. Also the exact interactions between all the nano tests (molecular 
genetics, proteomics and transcriptomics) are only partially understood so far. Moreover the 
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tumor cells in vitro is essential for cytogenetic analysis. The success in getting specific 
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done on a large cohort which include sufficient size group of all MB subtypes.  
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medulloblastomas (Mitelman database 2011, Aldosari et al 2002;  McCabe et al 2006)  it is 
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2004). It has been observed in 25-30% of childhood MB. In fact there is a loss of 17p and a 
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database 2011). This might point toward the fact that i(17q) is a general marker of neoplastic 
process rather then a specific marker of MB. Its role as an indicator for a poor outcome in 
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SKY analysis of 19 primary MB revealed structural aberrations involving chromosomes 7, 
17, 3, 14, 10 and 22.(Bayani et al 2009).  
 Monosomy 6 is strongly associated with Wnt profile in MB (Clifford et al 2006). 
Chromosomal abnormalities including loss of chromosome X in females and loss of 
chromosome 8, have been found mainly in non SHH/Wnt subgroups.  
4. Genetic alterations and its correlation with clinicohistopatological 
classification 
Tumorigenesis is a process in which one of the pathways leading to normal cell 
development has lost its control and its normal function. In addition, the neovasculization, 
cell proliferation, differentiation, motility and apoptosis (death) are also altered.  
There are two possible categories in tumor specific genetic alteration; one is inheritable or 
germ cells mutation and the other is acquired alteration. Also there is a difference between 
general tumorigenesis pathways and tumor specific pathway and general chromosomal 
aberration and tumor specific chromosomal aberration.  
Usually, the tumor specific pathway is a part of the general tumorigenesis pathways but still 
it is predominant in one specific tumor subgroup, for example RB gene that causes mainly 
retinoblastoma, WT gene that causes mainly Willm's tumor, both are also causing 
predisposition to other tumors. Similarly, the acquired gene alteration occurring during the 
life time, such as BCR/ABL is causing chronic myeloid leukemia and EWSR1-FLI1 is 
causing Ewing sarcoma. Specific acquired aberration found in addition to the cancer they 
caused, also in other cancers ,  there its significance and  its prognostic value is different, for 
instance BCR/ABL points to a favorable prognosis in CML and points  to a poor prognosis 
in acute lymphocytic leukemia (ALL).  
Among the life time acquired mutation, one should differentiate between the first event, 
such as alteration of a gene that causes the disease and has a diagnostic value and those 
mutations that are considered as the latter (the second or the third) events for example 
KRAS and TP53 mutation in adenomatose polyposis coli (APC) and MNP1 or FLT1 
mutation in acute leukemia. Those gene alterations have mainly prognostic value and may 
play as a general event seen in other tumors as well.   
Unfortunately, neither MB specific chromosomal changes nor MB specific gene were found 
to be a clear evidence for the possible pathogenesis of MB, neither in MB general nor in one 
of its subtypes. The understanding of MB pathogenesis is still limited, mainly because most 
of the MB studies are associated with genes that are already known to be involved in other 
tumors or syndromes, rather then studying the MB specific gene alterations as the first goal.  
Indeed, MB is associated with other (tumor's) syndromes such as Gorlin,Turcot and Li 
Fraumeni, in which several important developmental signal transduction pathways, 
including sonic hedgehog (SHH), Wingless (Wnt) and Notch signaling cascades. SHH, Wnt, 
TP53  and Notch signaling cascades are implicated in the cells migration and localization in 
the cerebrum,  and their proliferation and differentiation. The alterations in these pathways 
by any component of each signaling pathway may lead to tumorigenesis (Marino 2005; 
Ingham and Placzek 2006). For example, Gorlin's syndrome characterized by a germ line 
mutation in the patched homologue 1 (PTCH1) located on 9q22 ( Frandon et al 1992 ) that 
served as a negative regulator of SHH gene during normal cerebella development. Mutation 
in PTCH1 gene can cause predisposition to different tumor development including MB with 
incidence of 5-20% (Friedrich 2007). 
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Turcot syndrome is characterized by the mutation in the APC a tumor suppressor gene that 
is predisposed mainly (about 90% during life time) to colon cancer adenomatous polyposis 
coli (APC), (Hamilton et al 1995) but also predisposed to a lesser extend  to other tumors 
including MB (Huang et al 2000). The APC gene regulates the Wnt signaling pathway.  
Recent advances in gene expression profiling techniques have led to the generation of 
several molecular classification schemes in MB (Thompson et al 2006; Kool et al 2008; 
Northcott et al 2010 epub). 
In general, based on the molecular studies done so far, three main subgroups were defined: 
SHH, Wnt and non SHH/Wnt pathways which include another 2 subgroups which are less 
distinct (Thompson et al 2006; Kool et al 2008; Onvani et al 2010; Ellison 2010; Northcott et al 
2011). SHH pathway subgroup accounts for 15-25% cases of MB and have a poor 
prognosis,Wnt pathway subgroup accounts for 15-20% cases of MB and mostly has 
favorable prognosis, and non SHH/Wnt subgroups account for 60% cases of MB.  
According to the Thompson's (2006) classification based on molecular and FISH 
examination 5 distinct subtypes identified (A to E) including subgroup B in which Wnt 
pathway and monosomy 6 have been found and subgroup D in which SHH pathway has 
been found. Kool et al (2008) further corroborated Thompson's classification using CGH and 
defined 5 subgroups: (A)-Wnt signaling subgroup, (B)-SHH signaling pathway, C and D 
expression of neural differentiation genes, D and E expression of photoreceptor genes. 
Subgroups C, D and E are genetically closely related and most often associated with 
metastatic appearance mainly subgroup E.   
SHH pathway MB associated with desmoplastic phenotype (Behesti 2009) and also  with large cell 
and anaplastic MB. They are both reported mainly in infancy and childhood. Metastatic 
disease at presentation characterizes some SHH pathway mostly large cells and anaplastic MB. 
Less then half of the SHH pathway MB have PTCH1 mutations or show copy number loss at 
the PTCH1 locus, 9q22, mutations in SMOH and SUFU are rare thus there must be other 
undiscovered SHH pathway/s (Thompson et al 2006; Kool et al 2008; Northcott et al 2011).  
In contrast Wnt pathway is mostly associated with classic MB (Fattet et al 2009) it has a 
favorable outcome it tends to be present in childhood in the pre-teen years (6-13 years) but 
almost do not present in infancy. Most of the children with this tumor survived ( Thompson 
et al 2006). Metastatic disease at presentation is rare in Wnt pathway. There is no report on 
desmopastic medulloblastoma with Wnt pathway and also large cell and anaplastic MB 
with Wnt is rare. The APC protein is a regulator of Wnt signaling that function in a complex 
with other components to regulate several important developmental processes, including 
proliferation and specification of neural progenitor cells during early cerebellar 
development (Sillitoe and Joyner 2007). APC function as a tumor suppressor through 
CTNNB1 (β-catenin) of sporadic cases of MB, a downstream component of the Wnt 
signaling pathway (Hamilton et al 1995) this account for 15% of the cases. β-catenin  by itself 
also activates transcription of several oncogenes such as MYC and CCND1 resulting in 
enhanced cell proliferation (Ellison et al 2005). 
Only a small part of the Wnt pathway MBs are found to be carrying mutations in CTNNB1 
gene-captured by identification of the nuclear activity of β-catenin in the MB. Mutations in 
APC and AX1N1/2 are rare, thus there are still undiscovered components also in Wnt 
pathway (Ellison et al 2005; Fattet et al 2009; Norhcott et al 2011).  
Most of non SHH/Wnt MBs have a classic pathology and present in infancy and childhood. 
About half of the large cell and anplastic MBs are non SHH/Wnt. Metastatic disease at 
presentation also falls into the non SHH\Wnt tumor subgroup.  
 
Medulloblastoma – Genetic Alterations 
 
629 
Other molecular markers beside the above three identified groups is the amplification of 
MYC family (MYC and MYCN proto-oncogenes), that account for 4-15% of MBs (Rossi et al 
2008; McCabe et al 2006). MYCN is an early transcriptional target of the SHH pathway and 
activation by SHH promotes the expression of the cell cycle proteins cyclinD1 and CyclinD2 
leading to GCP proliferation (Behesti amd Marino 2009). A high expression level of MYC is 
reported to cause progression of MB to an anaplastic phenotype and has been linked to a 
poor prognosis while even though MYCN shows some association with large cells and 
anaplastic MB yet it is less established as a marker for an adverse outcome (Aldosari et al 
2002; Pfister et al 2009). 
Both SHH and Wnt subgroups rarely show copy number abnormalities of chromosome 17, 
amplification of MYC and MYCN or any other widespread ploidy changes. MB occurred 
also in 5% of the Li Fraumeni syndrome's patients carrying mutation in the suppressor gene 
TP53 (Northcott 2009). Other known pathways are involved in the normal cerebellar 
development found also to be aberrant in some of the MB. For example a disturbance of the 
RAS-MAP upregulation through downstream components such a MAP2K1,MAP2K2, and 
MAPK1/3. It is found to be correlated with metastatic behavior (Gilbertson and Clifford 
2003). Also, overexpression of the EGF receptor family member ERBB2 is linked to 
metastatic behavior. A number of proto-oncogenes in MB such as CDK6, PDGFRA, KIT and 
MYCL1 have been found to be amplified by array CGH. A single copy numbers gains of 
MET locus on chromosome 7q in 38.5% of the cases in 13 MBs (MacBabe 2006; Tong et al 
2004). 
The Notch pathway was found to be implicated in MBs pathogenesis in a number of studies. 
Notch promote granule cell precursor (GCP) proliferation and prevents their differentiation 
( Behesti and Marino 2009). Increased copy number of Notch2 has been found in 15% of the 
studied MBs. Also, mutated  Hes1 gene that unregulated the Notch  pathway have been 
found in a small study group, although it has been associated with poor prognosis and 
outcome, its role and  implication should be carefully considered and further examined (Fan 
et al 2004; Thompson et al 2006; Kool et al 2008; Northcott et al 2009).  
Due to technology limitations and the availability research strategies most molecular studies 
of MBs , we are still missing the  MB specific molecular markers. Hopefully, MB subtypes 
specific markers will be discovered by using the advanced technologies which enables us to 
study MB at different levels: DNA by next generation sequencing, gene expression by 
transcriptomic and protienomic, epigenomic and miRs.  
An accurate classification and the stratification will implicate the medical care. An optimal 
classification will differentiate between MB in each age interval (infancy, childhood and 
adult) and between the subgroups in each age.  
There is a general consensus that a better understanding of the disease biology should allow 
us to develop more effective and less harmful treatments of MB. 
Northcott et al (2011) generated a class prediction algorithm, an 8-gene classification model 
which successfully predicted the survival status for 47 out of the 60 patients profiled. The 
markers of the cerebellar differentiation (β-NAP, NSCLI, TRKC) and component of the 
extracellular matrix (lysyl hydroxylase[PLOD], collagen TypeVai and elastin) predict  
favorable prognosis. While genes involved in cell proliferation and metabolism (MYBL2, 
enolas 1, LDH, HMGI[y], and cytochrome C oxidase) as well as ribosomal protein coding 
genes predict poor prognosis.  
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5. MicroRNA (miR) and its corroletion with clinicohistopatological 
classification 
The field on miRNA emerged in the last few years, concentrates on small non coding, single 
strand RNA molecules that are found to play a regulatory role on gene expression.  
Differential microRNA (miR) expression analysis has also contributed to our knowledge on 
MB pathogenesis. The miRs are the short fragments of endogenous noncoding RNA that 
play an important role in the developmental processes by regulating gene expression. Target 
mRNAs are either degraded or translationed by specific miRNAs. Ferretti et al (2008) 
performed one of the earliest expression profiles on MB. Northcott et al (2009) identified 
amplification of miR17/92 polycistron proto-oncogen in 6% of pediatric MBs and showed 
upregulation of miR17/92 expression in a large percentage of primary cases. Similarly, 
Pierson et al. (2008) demonstrated decreased expression of miR-124a in primary MB as well 
as in MB cell line. Onvani et al (2010) have reported that miR124a as a negative regulator of 
CDK6 which are found to be overexpressed in MB (Mendrzyk et al 2005). Additional 
oncogenic targets, such as miR-30b and miR-30d have also been proposed through miRNA 
profiling ( Lu et al 2009 )   
Northcott et al (2009) have described subgroup classification based on transcription profile, 
using mRNA and miRNA examination. They identified 4 distinct subgroups including the 
well known Wnt and SHH and another two independent subgroup C and D. It has been 
found that mir17/92, cluster of oncogenic miRNAs, was highly expressed in SHH tumors in 
association with MYCN expression, while group C was found to be correlated with MYC.  
High–resolution SNP array profiling on a group of >200 MB revealed high–level 
amplification of miR-17/92 on 13q31 (Northcott et al 2009).  
It has been found that miR-17/92 and related paralogs (miR-106a/363 and miR-106b/25) 
were identified as the most highly upregulated miRNAs in MB when compared with 
normal cerebellum in this analysis. The combination of miR 17/92 amplification and 
consistent overexpression suggested miR-17/92 as a key player in MB pathogenesis. There 
is evidence that miR17/92 might cooperate with SHH in MB, as it showed preferential 
upregulation in SHH subtype. 
Recently the role of miRNA  in MB has been studied on 14 primary cases using profile of 248 
miRNAs showing a general biased downregulation in MB cells as compared to the control 
cells . A subset of 86 miRNAs which were previously reported to be expressed in neuronal 
tissues and/or cancer studied in cohort of 34 among them two neuronal candidates miR-9 
and miR-125a were chosen for functional analysis. Induction of their expression resulted in 
the decrease in tumorigenic features: promoted apoptosis, inhibited cell proliferation and 
impaired anchorage-independent growth. Moreover loss of miR9 and miR125a correlated 
well with upregulation of truncated trkC which was identified as a target for 
posttranscriptional repression (Northcott 2009). 
In order to discriminate between miRs deregulation in SHH–driven MB from non SHH-
cases, 31 MBs studied using a set of 250 miRs. Two groups were defined GLI1-high and 
GIL1-low. A set of 34 miRs was found with a significant differential expression between the 
two classes. For functional analysis of the GLI1-high class three candidates (miR-125b, miR-
324-5p, and miR-326) exhibiting reduced expression were chosen based on their predicted 
capacity to target the SHH family members, Smo and Gil1. They were proven to repress 
Smo mRNA level in the MB cell line (Ferretti et al 2008).  
SNPs array profiling of more then 200 MB revealed copy number aberration of multiple 
unreported regions including high level amplification of miR17/92  
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Another miRNAome study of 90 MB revealed that four distinct molecular subgroups can be 
described. These subtypes include the well characterized Wnt and SHH subgroups and 
another 2 subgroup designated C and D (Northcott et al 2009).  
The miR-17/92 was the most highly expressed in SHH-driven MB but also in tumors 
exhibiting high MYCN (SHH) and MYC (group C,Wnt) expression. MiR-17/92 
transcriptional upregulation by N-Myc and Myc and confirming miR-17/92 aberrancy in a 
large percentage of the MBs (� about 60%). Based on experiments on mice it was suggested 
by Northcott et al (2009) that miR 17/92 cooperate with SHH signaling to promote and/or 
enhance CGNP proliferation.  
The miRs studies are still in their initial stage and we are still far from understanding their 
exact role and how they affect processes in MB pathogenesis. 
6. Epigenomic and its corroletion with clinicohistopatological classification 
Until recently the thought was that genetic alteration is the main cause of each tumor 
development and progress. Researchers invest their efforts in finding a tumor specific 
pattern of genetic alteration. Over the past few years another aspect has arisen which is the 
deregulation of epigenetics to malignancy (Jones and Baylin 2002;Bernstein et al 2007; 
Kouzarides 2007; Kongham et al 2008; Esteller 2008). 
Epigenetics involves nongenetic DNA modifications that result in changes in gene expression. 
These changes include gene promoter mythylation on cytocine residues, most frequently of the 
CpG islands of the promoter, as well as their histone code. These changes are found to be 
involved in pathogenesis of tumors including MB, through hypermethylation of promoter of 
tumor suppressor genes and consequently silencing them (Kongham et al 2008).  
Fruhwald et al (2001) showed methylation of up to 1% of all CpG island in 17 primary 
medulloblastoms, it was linked to poor prognosis.  
Epigenetics is defined as "mitotically heritable changes in gene expression that are not 
accompanied by modifications in primary DNA sequence". It is highly correlated with the 
MB class were ZIC and NSCL1 , encoding transcription factors that are specific for cerebellar 
granule cells point to the MB arised from cerebellar granule cells. 
Anderton et al(2008) have identified tumor –specific methylation of COL1A2 in 77% of the 
studied primary MBs (46 out of 60) and showed an age-dependent methylation pattern for 
this gene in desmoplastic tumors, which presented COL1A2 as a potential MB subtype 
biomarker. Kongkham et al. (2008) identified serin protease inhibitor kuntiz-type2 
(SPINT2/HAI-2), an HGF/cMET signaling inhibitor, as a novel tumor suppressor gene that 
is frequently silenced by promoter hypermethylation in MBs (Kongham et al 2008). Also 
Waha et al (2007) found promoter hypermethylation-induced reduction of SCG5 expression 
in primary 16 out of  23 primary cases compared to normal cerebellar controls ( Waha 2007), 
points to its possible role in pathogenesis of MB. Furthermore, promoter hypermethylation-
mediated silencing of CASP8, HICI and RASSF1A tumor suppressor genes has also been 
discovered in more than 30% of MBs by various groups (Lindsey et al 2004).  
Pfister et al (2007) showed a striking association between samples classified as either "low 
methylators" or "high methylators" and patient outcome, where the "high methylators" 
group exhibited reduced overall survival.  
Also the GLI C2H2-type zing-finger protein family member ZIC2 was identified as 
hypermethylated and thus it has been silenced (Pfister et al 2007).  
It has been found that EHMTI  function as part of a transcriptional repressor complex that 
mediates gene silencing by promoting dimethylation of H3K9 (Tachibana et al 2005), a 
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repressive epigenic modification (Bernstein et al 2007; Kouzarides 2007) in the promoter 
regions of target genes. An obvious correlation between loss of EHMTI leads to H3K9 
hypomethyelation. 
Another study using microarray-based differential methylation hybridization (Waha et al 
2007) identified hypermethylation of the SCG5 (secretory granule, neuroendocrine protein 
1[7B2 protein] gene) in 16 out of 23 (70%) primary MB. Expression of SCG5 found to be 
downregulated in the MB in comparison with normal cerebral controls. Another gene that 
found to be down regulated is SPINT2 that was found in 41 out of 56 primary MB. Stable 
expression of SPINT2 resulted in attenuation of the malignant phenotype: inhibiting cell 
proliferation, anchorage-independent growth in soft agar and cell motility, of cell lines 
(Kongham et al 2008). This study suggested that SPINT2 is a suppressor gene. Treatment of 
MB cell lines suggesting that SCG5 is a suppressor gene (Fruhwald et al 2001) or increased 
gene with demethylation agent (5-aza-2'deoxycytidine) reduced colony formation 
expression (Anderton et al 2008; Kongham et al 2008).  
The MB epigenomic studies demonstrate that not only the genetic alteration can cause loss 
of control in a cell and transformation to a malignant cell but also other mechanism can 
cause malignancy, implicated epigenetic gene silencing as important mechanism of the 
tumor suppressor gene inactivation in MB. 
7. Summary 
The reported genetic alterations of MB, either chromosomal or molecular, are so far not 
specific.The main distinct subgroups are the Wnt and the SHH both account for 30-40% of 
MB. These pathways are common in many other tumors, suggesting they are not exclusive 
to MB. There are some other pathways involved in MB pathogenesis that might be more 
specific to MB. Similarly, the chromosomal aberration i(17q) which is found in about 40% of 
MBs, as well as in many other tumors including in chronic myelocytic leukemia (CML) can 
possibly be a secondary chromosomal aberration. Some of the features found in different 
subtypes but not in an equal distribution, for instance i(17q) were found in 34% ,36%,12%  in 
classic ,large cell and desmoplastic MB respectively and are associate with poor prognosis 
(Gillbertson & Ellison 2008). Another example NOTCH and PDGF, they both have been 
found in A and B Kool's subtypes and also subtypes C, D and E  share increased expression 
of neural differentiation genes. Another example is the Wnt-β catenin, found in all subtypes 
defined in Northcott's classification. This overlapping between the different subtypes, points 
toward the fact that some of the alterations are not, necessarily, a specific prognostic marker.  
Studies have been done on a mice model and on cell lines in order to learn more about 
pathogenesis of MB are important; however the data learned from these experimental 
systems should be first corroborated with the data learned from human primary MBs, 
before going to conclusions on the pathogenesis of human MB. This is the reason for 
focusing in this chapter mainly on the studies done on primary human MBs studies.   
Due to the variable results, the exact and specific chromosomal changes in MB which is a 
crucial event in pathogenesis, is still unknown.  
Gilberston and Ellison (2008) wrote in their review: "Genomic-seeing the wood and the 
trees". The literature is full of studies (over 200 papers) on genetic alteration in MB trying to 
understand the MB pathogenesis, some of them corroborate with each other. Most of the 
studies have been done from different research points of view and emphasis, using different 
technologies. Presently, there are at least 5 different suggestions for classification and 
 
Medulloblastoma – Genetic Alterations 
 
633 
stratification of MB: Thompson's (2006), WHO (2007), Kool's (2008), Pefister's (2008) and 




















































































E classic metastases Photoreceptor 
genes 


















6%/4%/10%  13% 
 
Molecular Targets of CNS Tumors 
 
632 
repressive epigenic modification (Bernstein et al 2007; Kouzarides 2007) in the promoter 
regions of target genes. An obvious correlation between loss of EHMTI leads to H3K9 
hypomethyelation. 
Another study using microarray-based differential methylation hybridization (Waha et al 
2007) identified hypermethylation of the SCG5 (secretory granule, neuroendocrine protein 
1[7B2 protein] gene) in 16 out of 23 (70%) primary MB. Expression of SCG5 found to be 
downregulated in the MB in comparison with normal cerebral controls. Another gene that 
found to be down regulated is SPINT2 that was found in 41 out of 56 primary MB. Stable 
expression of SPINT2 resulted in attenuation of the malignant phenotype: inhibiting cell 
proliferation, anchorage-independent growth in soft agar and cell motility, of cell lines 
(Kongham et al 2008). This study suggested that SPINT2 is a suppressor gene. Treatment of 
MB cell lines suggesting that SCG5 is a suppressor gene (Fruhwald et al 2001) or increased 
gene with demethylation agent (5-aza-2'deoxycytidine) reduced colony formation 
expression (Anderton et al 2008; Kongham et al 2008).  
The MB epigenomic studies demonstrate that not only the genetic alteration can cause loss 
of control in a cell and transformation to a malignant cell but also other mechanism can 
cause malignancy, implicated epigenetic gene silencing as important mechanism of the 
tumor suppressor gene inactivation in MB. 
7. Summary 
The reported genetic alterations of MB, either chromosomal or molecular, are so far not 
specific.The main distinct subgroups are the Wnt and the SHH both account for 30-40% of 
MB. These pathways are common in many other tumors, suggesting they are not exclusive 
to MB. There are some other pathways involved in MB pathogenesis that might be more 
specific to MB. Similarly, the chromosomal aberration i(17q) which is found in about 40% of 
MBs, as well as in many other tumors including in chronic myelocytic leukemia (CML) can 
possibly be a secondary chromosomal aberration. Some of the features found in different 
subtypes but not in an equal distribution, for instance i(17q) were found in 34% ,36%,12%  in 
classic ,large cell and desmoplastic MB respectively and are associate with poor prognosis 
(Gillbertson & Ellison 2008). Another example NOTCH and PDGF, they both have been 
found in A and B Kool's subtypes and also subtypes C, D and E  share increased expression 
of neural differentiation genes. Another example is the Wnt-β catenin, found in all subtypes 
defined in Northcott's classification. This overlapping between the different subtypes, points 
toward the fact that some of the alterations are not, necessarily, a specific prognostic marker.  
Studies have been done on a mice model and on cell lines in order to learn more about 
pathogenesis of MB are important; however the data learned from these experimental 
systems should be first corroborated with the data learned from human primary MBs, 
before going to conclusions on the pathogenesis of human MB. This is the reason for 
focusing in this chapter mainly on the studies done on primary human MBs studies.   
Due to the variable results, the exact and specific chromosomal changes in MB which is a 
crucial event in pathogenesis, is still unknown.  
Gilberston and Ellison (2008) wrote in their review: "Genomic-seeing the wood and the 
trees". The literature is full of studies (over 200 papers) on genetic alteration in MB trying to 
understand the MB pathogenesis, some of them corroborate with each other. Most of the 
studies have been done from different research points of view and emphasis, using different 
technologies. Presently, there are at least 5 different suggestions for classification and 
 
Medulloblastoma – Genetic Alterations 
 
633 
stratification of MB: Thompson's (2006), WHO (2007), Kool's (2008), Pefister's (2008) and 




















































































E classic metastases Photoreceptor 
genes 


















6%/4%/10%  13% 
 



































Wnt   MYC↑ 
Wnt-β catenin
 































































WHO (2007): Classic, desmoplastic, MB with extensive nodularity, anaplastic, Large cell 
*For more details see: Louis 2007, Thompson et al 2006, Kool et al 2008, Pifster et al 2009, Northcott et al 
2010 J. Clin.Oncol., Parenthesis-Year of publication.  
** See table 2 in Ellison 2010, Table 2 in Huse and Holland 2010, Table 1-Northcott 2010 J. Clin.Oncol. 
Parenthesis –Number of samples 
Table 1. Medulloblastoma classification according to: WHO- Louis et al 2007, Thompson et al 
2006, Kool et al 2008, Pifster et al 2009, Northcott  et al 2011. 
There is also early evidences that epigenetics and miRs might play a role in MB pathogenesis 
and can be used as a prognostic tool. However , the data regarded to epigenetics and miRs  in 
MB is still limited and uncompleted, as part of the studies done on MB cell line which might 
point to a candidate involved genes with no assurance for there role in the MB tumor. There 
are few studies on primary MBs, thus any conclusion from this data is still immature. This 
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emphasized the need for further studying the MB pathogenesis for either specific germ line 
mutation or other specific level of alteration (transcriptome, proteome, epigenome levels). 
These should be done as a multi-center study , on a large size of cohort including sufficient 
number of samples of each MB subtype including adult and childhood MBs. The study should 
be performed uniformly using different levels of examinations: histologic, cytogenetic, 
molecular, transcriptome, proteome, epigennetics, and miRs. Hopefully such a study will 
provide us with more personalized medical care with less adverse side effects.   
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1. Introduction 
Medulloblastoma is the most common malignant brain tumor in childhood and represents 
around 10% of all pediatric cancer deaths. It arises in the cerebellum and originates from 
aberrant proliferation of neural progenitor cells during development. It has a high tendency 
to disseminate throughout the central nervous system with as many as 30% of children with 
metastatic spread at the time of diagnosis. Dissemination is the most important factor 
associated with poor survival and the leading cause of treatment failure. The current 
therapies include surgery, radiation and chemotherapy with 5-year survival rates ranging 
between 50 and 80%. Among long-term survivors, a major concern is the sequelae induced 
by treatment including endocrinologic, neurocognitive and behavioral dysfunction. 
The genetic heterogeneity of medulloblastoma appears to be the basis for differential 
response to treatment, which leads to the conclusion that current tumor classification 
systems based solely on histological or clinical criteria are clearly insufficient and limited. 
Recent studies have identified distinct molecular variants of medulloblastoma that 
correspond with different clinical presentations, transcriptional profiles, genetic 
abnormalities and clinical outcomes (Eberhart, 2011; Ellison et al., 2011; Northcott et al., 
2010; Pfister et al., 2010). Thus, a better understanding of the molecular biology of this tumor 
will have significant diagnostic, prognostic and therapeutic value. 
Medulloblastoma is associated with dysregulation of the pathways that normally lead to 
cerebellum development. Over the past few years, different signaling pathways have been 
shown to play a critical role in medulloblastoma formation and progression. The hepatocyte 
growth factor (HGF)/c-Met signaling pathway has been implicated in different processes 
including development and tumorigenesis but only recently has it been demonstrated in 
medulloblastoma pathogenesis. The receptor tyrosine kinase c-Met is normally activated 
following engagement with HGF ligand, secreted as a precursor that is proteolytically 
cleaved in an active form by the serine protease hepatocyte growth factor activator. HGF is a 
member of the plasminogen-related growth factor family and was originally identified as a 
growth factor for hepatocytes and as a fibroblast-derived cell motility or scatter factor. The 
interplay between c-Met and its ligand mediate downstream events that, in the central 
nervous system, play a critical role in cerebellar granule cell precursors proliferation and 
survival. Dysregulation of this pathway can promote tumorigenesis through cell migration, 
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invasion and metastasis, angiogenesis and prevention of apoptosis. Met has been found to 
be overexpressed in a variety of malignancies where its activation can occur by HGF ligation 
or through ligand independent mechanisms, including mutations and amplifications. 
It was shown that medulloblastoma tumor cell lines and surgical tumor samples express 
HGF and c-Met. Furthermore, overexpression of c-Met is associated with poor clinical 
outcome. Treatment of medulloblastoma cell lines with HGF induced tumor cell 
proliferation, anchorage-independent growth and reduced apoptosis in response to 
chemotherapy. Recently, Serine protease inhibitor kunitz-type 2 (SPINT2), a tumor supressor 
gene silenced by promoter methylation in medulloblastoma, was identified by our group as 
a key regulator of HGF/c-Met pathway (Kongkham et al., 2008). Several therapeutic 
strategies aiming to target and limit the signaling cascade of HGF/c-Met were examined 
with the c-Met inhibitors being the most promising. Targeting the HGF/c-Met pathway, 
alone or in combination with standard therapies is likely to improve present treatments in 
Met-dependent malignancies such as medulloblastoma. 
In this chapter we examine the role of the HGF/c-Met pathway in normal cerebellar 
development and in medulloblastoma formation and progression. We also highlight the 
most recent advances in targeted therapies to the HGF/c-Met axis in cancer. 
2. HGF/c-Met pathway signaling 
The HGF/c-Met pathway has been associated with normal development, organ 
regeneration and cancer. Met is a high affinity tyrosine kinase receptor for hepatocyte 
growth factor (also known as scatter factor, capable of inducing dissociation and motility). 
Met is generally expressed in epithelial cells and is activated by HGF produced in 
surrounding mesenchymal cells or released into the circulation.  
During embryogenesis HGF/c-Met signaling is necessary for the development of the 
placenta, liver, kidney and neuronal tissue but also for the directional migration of skeletal 
muscle cells (Birchmeier & Gherardi, 1998). In adult tissues, this pathway has been 
implicated in regeneration and wound healing (Chmielowiec et al., 2007; Huh et al., 2004). 
Therefore, the HGF/c-Met axis is a key player in cell proliferation, survival and migration 
and, when dysregulated, can give origin to a variety of cancers. 
2.1 Structure of HGF and Met 
HGF is a multidomain protein similar to plasminogen, a circulating proenzyme that 
promotes the lysis of fibrin blood clots in its active form as plasmin. HGF is synthesized as a 
single-chain inactive precursor and it is converted by serine proteases into an active form 
with two chains (α and β chain) linked by a disulfide bond. HGF consists of six domains: an 
amino-terminal hairpin loop domain (HL), four kringle domains (K1-K4) and a serine 
protease homology (SPH) domain which lacks enzymatic activity (Figure 1). 
Met, the HGF receptor, is a disulfide-linked heterodimer which results from cleavage of a 
precursor into an extracellular α chain and a transmembrane β chain. The extracellular 
region of Met is composed of three domains: the Sema domain (homologous to the Sema 
domain of the semaphorins and plexins) that includes the entire α chain and part of the β 
chain; the PSI domain (also present in the plexins, semaphorins and integrins); and four IPT 
domains (immunoglobulin-like also found in plexins and transcriptional factors). The 
intracellular region of Met consists of three portions: a juxtamembrane sequence that has the 
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role to downregulate kinase activity upon phosphorylation of Ser975; a catalytic region that 
activates kinase activity following phosphorylation of Tyr1234 and Tyr1235; and a carboxy-
terminal multifunctional docking site that contains two docking tyrosines (Tyr1349 and 
Tyr1356) essential for downstream signaling (Trusolino et al., 2010). 
 
 
Fig. 1. HGF and Met structures 
2.2 Met signal transduction 
To activate the Met receptor, the single chain HGF precursor is cleaved into a heterodimeric 
active form by a protease called HGF activator (HGFA) (Miyazawa et al., 1993). This process 
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is regulated by a protein family of serine protease inhibitors called SPINT1 and SPINT2 
(Kawaguchi et al., 1997; Shimomura et al., 1997). Inhibiting the activation of HGF by HGFA, 
SPINT1 and -2 limit signaling through the HGF/c-Met pathway. 
Following HGF binding, the kinase activity of Met is switched on. This process starts with 
receptor dimerization and trans-phosphorylation of two tyrosine residues in the catalytic 
region (Tyr1234 and Tyr1235) and is followed by phosphorylation of two additional 
tyrosines in the carboxy-terminal tail (Tyr1349 and Tyr1356). These tyrosines create docking 
sites for a variety of adaptor proteins and direct kinase substrates including the growth 
factor receptor-bound protein 2 (Grb2), Grb2-associated adaptor protein (Gab1), son of 
sevenless (SOS), SRC homology protein tyrosine phosphatase 3 (Shp2), 
phosphatidylinositol-3-kinase (PI3K) and signal transducer and activator of transcription 3 
(STAT3). This leads to the activation of downstream signaling pathways that include the 
mitogen-activated protein kinase (MAPK), PI3K/AKT and STAT pathways, which mediate 
Met-dependent cell proliferation, survival, migration and invasion (Figure 2). 
 
 
Fig. 2. The HGF/c-Met signaling pathway 
The activation of MAPK cascade will sequentially activate different protein kinases whose 
terminal effectors include extracellular signal-regulated kinases (Erk1 and Erk2), Jun amino-
terminal kinases (JNK1, JNK2 and JNK3) and p38. These downstream elements will activate 
cell cycle regulators leading to cell proliferation and will promote alterations in cytoskeletal 
functions that control cell migration and invasion. PI3K/AKT activation mediates cell 
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survival and resistance to apoptosis through inactivation of the pro-apoptotic protein BCL-2 
antagonist of cell death (BAD) and degradation of the pro-apoptotic protein p53 (Birchmeier 
et al., 2003). Upon activation of STAT3 by the Met receptor at the plasma membrane, it 
translocates to the nucleus to operate as a transcription factor regulating the expression of 
genes implicated in cell proliferation and differentiation (Y. W. Zhang et al., 2002). 
Other molecules that interact with the Met receptor include the epidermal growth factor 
receptor (EGFR), the α6β4 integrin, the semaphoring receptors of the plexin B family and the 
variant of the hyaluronan receptor CD44 (that links the extracellular matrix and the 
intracellular cytoskeleton) (Bertotti et al., 2006; Guo et al., 2008; Orian-Rousseau et al., 2002). 
This crosstalk of Met with different surface proteins highlights the dynamic environment at 
the plasma membrane and contributes to Met associated biological responses (Lai et al., 
2009).  
2.3 Regulation of Met signaling 
It has been shown that the signaling network around the tyrosine kinase receptor Met is 
more complex than the known process of recruiting signaling effectors at the plasma 
membrane and subsequently stimulating intermediates in the cytosol. In fact, this view has 
been expanded by the finding that Met signals can also originate from endosomal 
compartments and by a series of other events. 
Upon HGF binding, Met is internalized by clathrin-mediated endocytosis and recruited into 
peripheral early endosomes. This process is mediated by protein kinase Cε (PKCε) that 
promotes the transfer of active Erk to focal adhesions and, subsequently, the HGF-induced 
cell migration. From the peripheral endosomes, Met travels along the microtubule network 
to late perinuclear compartments in a process mediated by PKCα. This juxtanuclear 
accumulation of Met is a determinant step for activation and nuclear translocation of STAT3 
(Kermorgant & Parker, 2005, 2008). 
Downregulation of Met signaling involves trafficking and degradation of ligand-activated 
receptors in the lysosomes. This process is initiated by the association of Met with casitas B-
lineage lymphoma (CBL) and endocytic adaptors. Following endocytosis, Met accumulates 
in multivesicular bodies that later fuse with lysosomes and leads to protein degradation. 
Met can also undergo sequential proteolytic cleavage at two juxtamembrane sites. The first 
cleavage occurs in the extracellular domain and is mediated by a disintegrin and 
metalloprotease (ADAM) originating a ‘decoy’ fragment that sequesters the ligand and 
interferes with the receptor’s activity. The second cleavage is performed in the intracellular 
domain, by a γ-secretase and yields a fragment that is destroyed in the proteasome 
(Hammond et al., 2001)(Figure 3). 
3. HGF, Met and cancer 
The dysregulation of HGF/c-Met signaling has emerged as a key player in several human 
malignancies, particularly in invasion and metastasis. Human cell lines overexpressing 
either HGF and/or Met become tumorigenic and metastatic when implanted into nude mice 
(Rong et al., 1994). Moreover, transgenic mice expressing the receptor or the ligand develop 
metastatic tumors (Takayama et al., 1997). On the contrary, downregulation of HGF or Met 
expression in human tumor xenografts decreases tumor growth (Abounader et al., 2002). 
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metastatic tumors (Takayama et al., 1997). On the contrary, downregulation of HGF or Met 
expression in human tumor xenografts decreases tumor growth (Abounader et al., 2002). 
 
Molecular Targets of CNS Tumors  646 
 
Fig. 3. Mechanisms of Met signaling regulation 
There are three biological mechanisms underlying the tumorigenicity of Met: a) the 
establishment of HGF/c-Met autocrine loops; b) the overexpression of HGF or Met; and c) 
the presence of activating mutations in the Met receptor (Benvenuti & Comoglio, 2007). 
An autocrine mechanism of Met activation is found in some human tumors. For example, 
osteosarcomas and rabdomyosarcomas are derived from mesenchymal cells which 
physiologically produce HGF. Glioblastomas and breast carcinomas are derived from 
ectodermal tissues that normally express Met but not HGF. Experimental models of HGF/c-
Met autocrine loops were also able to generate invasive tumors in vitro and in transgenic 
mice (Boccaccio & Comoglio, 2006). 
The most frequent mechanism of Met dysregulation found in human tumors is the 
overexpression of the receptor or its ligand. A large number of studies showed that HGF 
and Met are expressed in a wide variety of human tumors and in their metastasis. These 
include carcinomas of the breast, colon, lung, ovary, liver, kidney, upper gastrointestinal 
tract, pancreas and prostate but also sarcomas, haematopoietic malignancies, melanomas 
and glioblastomas (Birchmeier et al., 2003). 
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It has also been shown that high expression levels of Met and its ligand correlate with 
increased aggressiveness of tumors and patients poor prognosis (Birchmeier et al., 2003). For 
example, in colorectal cancer patients Met is a powerful prognostic factor for early stage 
invasion and metastasis (Kammula et al., 2007). Moreover, in a study including 74 clinical 
samples of low-grade and high-grade gliomas the authors described a correlation of HGF 
and Met expression levels with tumor grade (Abounader & Laterra, 2005).  
The compelling evidence that links Met with human cancer lies in the MET-activating 
mutations found in hereditary renal papillary carcinoma. These mutations were also found 
in sporadic tumors such as renal carcinoma, gastric cancer, childhood hepatocellular 
carcinoma and in head and neck squamous cell carcinomas (Boccaccio & Comoglio, 2006; 
Lai et al., 2009).  
The association between cancer and blood coagulation disorders has been known for many 
years. In fact, approximately 50% of all patients with malignant tumors and up to 90% of 
those with metastasis have coagulopathies (Wojtukiewicz et al., 2001). Interestingly, 
Boccaccio et al. showed in a mouse model that activation of the oncogene Met induced 
cancer and a thrombohemorrhagic syndrome through transcriptional upregulation of the 
procoagulation factors plasminogen activator inhibitor type 1 (PAI-1) and cyclooxygenase-2 
(COX-2). Upon a first phase characterized by a hypercoagulation state due to Met signaling 
activation, the mice developed a hemorrhagic diathesis due to exhaustion of the 
hyperactivated hemostatic system (Boccaccio et al., 2005). At the early step of this process, 
hypoxia induces transcription of Met that, subsequently, activates the transcription of genes 
involved in hemostasis, such as PAI-1 and COX-2. The activation of the coagulation cascade 
will lead to fibrin deposition around cells forming an extracellular matrix that will promote 
angiogenesis and cell migration (Boccaccio & Comoglio, 2005). 
HGF/c-Met signaling also has a role in angiogenesis either by direct influence of c-Met 
activation in vascular endothelial cells, or by regulation of the expression levels of other 
angiogenic factors in tumor cells. It was previously shown that the HGF/c-Met interaction 
stimulates proliferation and migration of endothelial cells in vitro and induces blood vessel 
formation in vivo (Bussolino et al., 1992). Zhang et al. described the “angiogenic switch” in 
tumor cells upon HGF stimulation by simultaneous upregulation of the proangiogenic 
vascular endothelial growth factor (VEGF) and downregulation of thrombospondin 1 (TSP-
1), an angiogenesis inhibitor (Y. W. Zhang et al., 2003). This process has distinct mediators: 
while VEGF is modulated by MAPK, PI3K and STAT3, TSP-1 is targeted only by MAPK. An 
interesting example of this regulation was found in human glioma cells where stimulation 
with HGF increased the expression levels of VEGF and tumor-associated angiogenesis. The 
use of HGF and Met inhibitors in experimental tumor models significantly reduced tumor 
growth and tumor vessel formation (Abounader & Laterra, 2005).  
Recently, a new key player of the HGF/c-Met pathway was described. Metastasis-associated 
in colon cancer-1 (MACC1) was identified by genome-wide expression analysis in primary 
and metastatic colon carcinomas. Its expression in human tumor samples was found to be 
an independent prognostic factor for metastasis formation and metastasis-free survival. The 
experimental studies showed that MACC1 promotes proliferation, invasion and HGF-
induced scattering in vitro and tumor growth and metastasis in xenograft models (Stein et 
al., 2009). The authors proposed a positive feedback mechanism where MACC1 acts as a 
transcriptional regulator of the Met gene. The stimulation of the Met receptor with HGF 
causes the translocation of MACC1 from the cytoplasm into the nucleus. There, MACC1 
activates the transcription of the Met gene by binding to its promoter (Arlt & Stein, 2009). 
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The increased amounts of Met receptor will be able to bind more HGF molecules thereby 
enhancing the pathway signaling and promoting cell proliferation, migration and 
metastasis. 
4. HGF/c-Met signaling in medulloblastoma 
4.1 Medulloblastoma overview 
Medulloblastoma is the most common malignant childhood brain tumor, comprising 20% of 
all primary brain tumors in the pediatric population (Crawford et al., 2007). It is an 
embryonal tumor that arises in the cerebellum from primitive pluripotent precursor cells of 
the ventricular zone and the external granular layer (Hatten & Roussel, 2011).  
The 2007 World Health Organization (WHO) classified medulloblastoma in five variants: 
classic, desmoplastic, anaplastic, large cell and medulloblastoma with extensive 
nodularity. Clinical data suggests a favorable prognosis for desmoplastic 
medulloblastoma and a significant worst outcome for the anaplastic subtype (Gilbertson 
& Ellison, 2008).  
Medulloblastoma formation is strongly associated with dysregulation of the pathways 
involved in the normal development of the cerebellum. The best characterized pathways in 
medulloblastoma tumorigenesis are the Sonic hedgehog (Shh), Wingless (Wnt) and Notch 
pathways (Hatten & Roussel, 2011).  
Traditionally, patients are stratified into standard risk and high-risk groups according to 
age, residual tumor and metastatic disease at diagnosis. High-risk patients include those 
younger than 3 years of age or having a residual tumor or disseminated disease at diagnosis 
(Packer et al., 2003). In fact, one third of the patients will have metastasis at the time of 
diagnosis and two thirds will have leptomeningeal spread by the time of relapse 
(MacDonald, 2008). Moreover, dissemination is the leading cause of treatment failure and 
the most powerful factor associated with poor survival (Zeltzer et al., 1999). 
Recently, Northcott and co-workers described four molecular subtypes of 
medulloblastoma using gene expression profiling and some genomic features (Northcott 
et al., 2010). These medulloblastoma subtypes are distinct with respect to the underlying 
signaling pathway that is dysregulated and the clinical outcome. The Wnt subgroup 
includes classic medulloblastomas and has a better prognosis. Most tumors in the Shh 
subgroup are desmoplastic medulloblastomas and also have good prognosis. The other 
two subgroups, group C and D, are non-Shh/Wnt, and demonstrate Myc overexpression 
as the main feature of group C, and isochromosome 17q as the main feature of group D. 
Interestingly, group C patients showed a significantly reduced survival, regardless of 
their metastatic status.      
The treatment for standard risk patients includes surgery, craniospinal irradiation and 
chemotherapy with reported 5-year overall survival of 80%. For patients with metastatic 
disease the intensified treatment regimens, including high-dose chemotherapy with 
autologous stem-cell transplantation and non-conventional radiotherapy, have improved 
prognosis, with 5-year overall survival rates between 50 and 70% (Gajjar et al., 2006; Sanders 
et al., 2008). Among survivors, a major concern is the long-term sequelae induced by 
treatments which include endocrinological, neurocognitive, behavioral, motor and sensitive 
deficits (Armstrong et al., 2009). Therefore, there is a critical need to identify new molecular 
targets that improve tumor growth suppression while minimizing the side effects of 
therapy. 
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4.2 HGF/c-Met pathway in cerebellar development 
During embryonic development, the progenitor cells localized in the ventricular zone of the 
cerebellum (also called primary germinal zone), along the IVth ventricle, migrate radially to 
give rise to Purkinje cells, neurons of the cerebellar nuclei and different types of cerebellar 
interneurons. Simultaneously, the progenitor cells in the rombic lip migrate dorsally to 
originate the external granule layer (EGL or secondary germinal zone). The peak of 
proliferation of these cells occurs between postnatal day (P) P5 and P8 in the mouse. 
Through a tightly regulated mechanism, the progenitor cells in the EGL become postmitotic, 
differentiate and migrate inwards to give origin to the internal granule layer (IGL), a process 
that is complete by P20 in the mouse (Marino, 2005). 
During the early postnatal period, multiple mitogenic pathways, such as Shh, Wnt and 
Notch, promote the rapid expansion of progenitor cells in the EGL. It is believed that this 
vast population of cells includes subgroups of progenitors with distinct genetic properties, 
that give origin to the different medulloblastoma subtypes (Hatten & Roussel, 2011).     
The HGF/c-Met pathway also plays a critical role in cerebellar development. The knockout 
mice for HGF, Met and SPINT2 are all embryonic lethal (Bladt et al., 1995; Mitchell et al., 2001; 
Uehara et al., 1995). Comparing the regional expression of HGF and Met in both developing 
and adult rat brains, Achim and co-workers found expression of HGF in the parietal cortex, 
striatum and cerebellar deep gray matter in developing but not in adult brain. Abundant 
expression of Met was also detected in the newborn cortex, thalamus and brainstem (Achim et 
al., 1997). The analysis of HGF and Met expression in the central nervous system of different 
mammalian species showed that their neuronal expression is highly conserved during 
evolution, a sign that they mediate important functions (Jung et al., 1994). 
Leraci et al. described the expression of Met in the proliferating cells of the external granule 
layer of the cerebellum and increased proliferation after stimulation of primary cultures of 
granule cells with HGF. In addition, transgenic mice with partial loss of Met function had a 
smaller cerebellum with abnormal foliation and balance impairment (Ieraci et al., 2002).  
HGF has also been proposed to mediate neurotrophic functions during neurogenesis both in 
the central and peripheral nervous systems. In fact, it was shown that HGF is a 
chemoattractant and promotes survival of motor neurons in the embryo. Furthermore, 
stimulation of sensory and sympathetic neurons with HGF enhances survival, 
differentiation and axonal growth (Maina & Klein, 1999). Exploring the neuroprotective role 
of HGF, different groups showed that HGF treatment of primary cerebellar granule neurons 
prevents apoptotic cell death through activation of the PI3K/AKT pathway signaling 
(Honda et al., 1995; Hossain et al., 2002; L. Zhang et al., 2000). 
To further investigate the influence of aberrant HGF/c-Met pathway signaling on cerebellar 
development and medulloblastoma initiation and progression, our group genetically 
engineered a transgenic mouse that expresses a constitutively active mutant of human Met, 
specifically within the cerebellum. We are in the process of characterizing the cerebellar 
development in the transgenic line as compared to the wild type, and determine the effects 
of constitutive Met activation in medulloblastoma pathogenesis.  
4.3 HGF/c-Met pathway in medulloblastoma formation 
HGF/c-Met signaling has an important role in tumorigenesis and metastatic behavior in 
several human malignancies but its role in medulloblastoma pathogenesis was only recently 
described.  
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Studying a series of 14 human medulloblastoma samples by comparative genomic 
hybridization Tong et al. found amplification of the Met oncogene on chromosome 7q in 38.5% 
of cases (Tong et al., 2004). A separate group showed a correlation between the expression of 
HGF and Met in human medulloblastoma samples and patient clinical outcome (Li et al., 
2005). When they stimulated medulloblastoma cells with HGF there was an activation of 
downstream effectors, evidenced by Met, MAPK and AKT phosphorylation. Up-regulation of 
the pathway was also able to induce cell proliferation, cell cycle progression, anchorage-
independent growth and resistance to chemotherapy-induced apoptosis in medulloblastoma 
cell lines. In vivo models overexpressing HGF also had increased tumor growth and invasion 
(Li et al., 2005). More recently, the same group identified an association between HGF/c-Met 
signaling and c-Myc in medulloblastoma. They found that HGF induced c-Myc expression 
both at transcriptional and post-transcriptional levels, leading to cell cycle progression, cell 
proliferation and increased apoptosis (Li et al., 2008b). 
Although the anti-apoptotic functions of HGF/c-Met pathway seem to be predominant, Li et 
al. described enhanced cell death in Daoy cell lines after Met activation. Apoptotic cell death 
can be induced by two different pathways: the intrinsic mitochondrial pathway and the 
extrinsic death receptor pathway. In malignant tissues, the tumor necrosis factor-related 
apoptosis–inducing ligand (TRAIL) has the potential to activate the death receptor pathway 
upon binding of death receptors DR4 and DR5, which leads to downstream caspase 
activation and apoptosis (Suliman et al., 2001). Li and co-workers found that increased 
apoptosis of medulloblastoma cell lines after stimulation with HGF was induced by TRAIL 
and mediated by DR5 overexpression (Li et al., 2008a). Moreover, the treatment of those 
cells with a specific c-Met inhibitor (PHA665752) reduced apoptosis indicating that it 
requires activation of the canonical receptor tyrosine kinase (Li et al., 2008a). 
Using an epigenome-wide screening our group identified an inhibitor of HGF/c-Met 
signaling. SPINT2, a tumor suppressor gene, was downregulated in 73.2% of primary 
medulloblastoma samples while Met was upregulated in 45% of cases. SPINT2 was silenced 
by promoter hypermethylation in 34.4% of primary tumor samples (Kongkham et al., 2008). 
A single nucleotide polymorphism (SNP) array analysis identified hemizygous deletions in 
the SPINT2 locus on chromosome 19q13.2 and gains in the HGF and MET loci on 
chromosome 7q. The experimental studies using medulloblastoma cells transfected with 
SPINT2 showed decreased proliferation, migration and anchorage-independent growth in 
vitro and increased survival times in mouse xenografts (Kongkham et al., 2008). Although 
SPINT2 downregulation has already been implicated in other human cancers (Dong et al., 
2010; Morris et al., 2005; Parr et al., 2004) this was the first report to establish its role in 
medulloblastoma pathogenesis.  
Binning et al. showed that HGF and Shh cooperate to transform cerebellar neural 
progenitors in transgenic mice, leading to medulloblastoma initiation and growth (Binning 
et al., 2008). Furthermore, the treatment of mice bearing Shh+HGF induced tumors with a 
monoclonal antibody against HGF (L2G7) prolonged survival by increasing apoptosis 
(Binning et al., 2008). Previous studies had already shown that systemic administration of 
L2G7 to mouse xenografts of human HGF+/c-Met+ glioblastomas improved survival and 
reduced tumor growth (Kim et al., 2006). 
Knowing that a procoagulant state is often the first manifestation of a malignancy and that it 
is due to the expression of specific proteins such as tissue factor (TF), Provencal and 
colleagues analyzed the expression of this protein in human medulloblastoma samples and 
observed a strong correlation between Met and TF expression levels. Furthermore, the 
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stimulation of Daoy cells with HGF increased the expression of TF and the treatment of 
those cells with physiological amounts of TF activator (factor VIIa) increased their migratory 
potential (Provencal et al., 2009). It was hypothesized that the acquisition of a procoagulant 
phenotype by medulloblastoma favors its dissemination because the enrichment of the 
tumor environment with fibrin protects the cancer cells from the immune system and forms 
a matrix for cell migration (Provencal et al., 2009). The same group found that upregulation 
of TF upon Met pathway activation was associated with increased resistance to the 
chemotherapeutic drug etoposide (Provencal et al., 2010). This observation suggested that 
the combination of anticoagulant drugs and chemotherapy could improve the efficacy of 
chemotherapeutic agents. In fact, this regimen was already tested in metastatic breast cancer 
with encouraging results (Falanga et al., 1998). 
These findings show the importance of the HGF/c-Met pathway signaling in 
medulloblastoma malignancy. Furthermore, they also provide validation of this pathway as 
a target for new and promising therapies using small molecular inhibitors and antibodies, 
some of them already in clinical trials for other cancers. 
5. Inhibitors of HGF/c-Met pathway in cancer therapy 
The evidence that the HGF/c-Met pathway is involved in the progression and 
dissemination of several malignancies has generated considerable interest in HGF and Met 
as major targets in cancer therapy and drug development. Different strategies are being 
explored and some of them are already being tested in clinical trials. We can consider three 
main groups of drugs: a) HGF and Met antagonists or competitors; b) Monoclonal 
antibodies directed against HGF and Met; and c) Small molecule tyrosine kinase inhibitors. 
The use of molecular targeted therapies against HGF and Met in medulloblastoma was only 
recently reported. Our group demonstrated the efficacy of a highly specific small molecular 
inhibitor (PHA665752) in the treatment of medulloblastoma cell lines by reducing cell 
proliferation, migration and anchorage-independent growth (Kongkham et al. 2010). 
Another group used an orally available small molecule inhibitor of Met (SGX523) in 
medulloblastoma cells and human glioblastoma xenografts. They reported decreased cell 
proliferation, migration and invasion in the in vitro studies and significant reduction of in 
vivo tumor growth (Guessous et al., 2010). The HGF-neutralizing monoclonal antibody, 
L2G7, was also tested in monotherapy and in combination therapy in genetically engineered 
mice with medulloblastomas induced by Shh and HGF. The authors reported tumor growth 
inhibition and increased survival with L2G7 monotherapy (Coon et al., 2010). 
Strategies using combined regimens targeting multiple receptor tyrosine kinases are 
currently under study. This can be achieved in two different ways either by a combination 
of highly selective agents or by using a single agent that targets multiple specific members 
of the Met pathway. The use of broad-spectrum agents may have the advantage of reducing 
drug interactions, but it may also affect other unintended kinases. Stommel et al., studying 
glioma cell lines, xenografts and human primary glioblastomas, showed simultaneous 
activation of multiple receptor tyrosine kinases and better responses to combined treatment 
when compared to monotherapy (Stommel et al., 2007). 
We provide a brief summary of the latest advances in HGF/c-Met targeted therapy (Table 1). 
5.1 HGF and Met antagonists 
HGF and Met antagonists or decoys are molecules that bind to the receptor with high 
affinity without activation of downstream signaling. The activation of Met by HGF involves 
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the dimerization of the receptor upon binding of the two chains of the ligand. HGF has a 
high affinity site located in the α–chain and a low affinity site in the β–chain, which only 
becomes accessible after pro-HGF activation (Comoglio et al., 2008). This means that the 
inactive form of HGF or HGF fragments can interact with Met by binding to the high affinity 
site but they cannot induce Met signaling because they are unable to promote receptor 
dimerization.  
Examples of HGF competitors are NK2, NK4 and uncleavable HGF. NK2 is a naturally 
occurring HGF fragment and NK4 is a synthetic truncated form of HGF that contains only 
the α–chain. This is by far the best studied HGF antagonist and it was shown that it inhibits 
cell invasion and angiogenesis in vitro and in xenografts (Kuba et al., 2000). Uncleavable pro-
HGF is an unprocessable form of HGF that competes with active HGF for Met binding and 
with pro-HGF proteases for HGF proteolytic activation. 
Decoy Met is an enzymatically inactive molecule that corresponds to the extracellular 
domain of the receptor. It interacts with HGF and full-length Met, sequestering the ligand 
and interfering with the receptor dimerization. 
5.2 Monoclonal antibodies directed against HGF and Met 
The use of monoclonal antibodies has the following advantages:  Specificity against HGF 
and Met; a relatively longer half-life when compared to other inhibitors; and the potential to 
induce a host immune response against the tumor cells (Eder et al., 2009). 
AMG102 is a fully human IgG2 antibody against HGF that was found to enhance the effects 
of temozolomide and docetaxel in vitro and in xenograft models of gliomas (Jun et al., 2007). 
A Phase I study used a combination of AMG102 and the antiangiogenic drugs bevacizumab 
and motesanib in the treatment of patients with advanced solid tumors, showing a stable 
disease in most patients (Rosen et al., 2008). This molecule has also been tested in Phase II 
clinical trials for advanced glioblastomas and renal cell carcinomas and a preliminary 
analysis in glioma patients suggested that AMG102 has limited efficacy as monotherapy 
(Reardon et al., 2008). Therefore, the most recent clinical trials will use AMG102 in 
combination therapy (http://clinicaltrials.gov). L2G7 is another anti-HGF antibody that 
proved to be effective reducing subcutaneous and intracranial glioma xenografts and to 
increase survival (Kim et al., 2006). 
The initial efforts to develop antibodies against Met were unsuccessful because they tended 
to behave as agonists rather than antagonists, due to its bivalent structure that acts as a 
natural dimerizing agent. To circumvent this problem a ‘one-armed’ antibody (OA-5D5; 
MetMAb), consisting of a monovalent Fab fragment, was developed. It binds to Met with 
high affinity preventing HGF interaction and subsequent downstream signaling. Martens et 
al. infused MetMAb intratumorally, reporting almost complete inhibition of tumor growth 
in a glioblastoma mouse model (Martens et al., 2006). Phase II clinical trials using MetMAb 
in combination with bevacizumav and paclitaxel for metastatic breast cancer and with 
erlotinib for advanced non-small cell lung cancer have been initiated 
(http://clinicaltrials.gov). 
5.3 Small molecule tyrosine kinase inhibitors  
Small molecule inhibitors target the ATP-binding site of the Met receptor, blocking its 
transphosphorylation. These molecules can also be classified according to their specificity 
for Met. Highly selective drugs may not be desirable as inhibition of multiple kinases may 
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transphosphorylation. These molecules can also be classified according to their specificity 
for Met. Highly selective drugs may not be desirable as inhibition of multiple kinases may 
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be more efficient and reduce the development of resistance. On the other hand, off-target 
inhibition of essential kinases may also be deleterious. With the recent advances in research 
and the ongoing clinical trials the small molecule inhibitors have emerged as promising 
drugs (Naran et al., 2009). 
PHA665752 is a Met selective inhibitor that was found to be effective in tumor cell lines and 
xenografts, particularly in a subset of cancers with amplification of the Met gene 
(Kongkham et al., 2010; Smolen et al., 2006). Due to its low oral bioavailability another drug 
(PF2341066) with identical structure but more favorable pharmacokinetic properties was 
designed. PF2341066 selectively targets Met and anaplastic lymphoma kinase (ALK) and 
was shown to have antitumor cytoreductive activity and antiangiogenic activity in several 
cancer models (Christensen et al., 2007; Zillhardt et al., 2010; Zou et al., 2007). A Phase II 
study in non-small-cell lung cancer reported encouraging results with a disease control rate 
of 87% (Mayor, 2011). The drug is now in Phase III trials. Interestingly, PF2341066 is also 
being tested in Phase I/II studies in children with recurrent solid tumors, primary central 
nervous system tumors and anaplastic large cell lymphoma (http://clinicaltrials.gov).     
ARQ197 is a highly selective, non-ATP competitive drug with reported clinical activity in 
several types of solid tumors. A Phase II trial in patients with non-small-cell lung cancer 
reported improved survival in patients treated with ARQ197 and erlotinib when compared 
to erlotinib monotherapy (Mayor, 2011). 
SGX523 is an orally available ATP-competitive molecule with high selectivity for Met. 
Although the initial results with in vitro and in vivo models of medulloblastomas and 
gliomas looked promising because of its efficacy in reducing tumor growth, the drug was 
discontinued from a Phase I trial due to renal toxicity (Diamond et al., 2010). 
XL184 and XL880 are orally available, non-selective inhibitors, with high binding affinity to 
both Met and VEGFR and to a lesser extent to other receptor tyrosine kinases such as 
PDGFR, Ret, Kit, Flt-3 and Tie-2 (Liu et al., 2010). XL184 is being evaluated in a Phase III 
study in patients with advanced medullary thyroid cancer and in Phase II studies in patients 
with glioblastoma multiforme and non-small-cell lung cancer that has progressed after 
previous benefit with erlotinib. XL880 has been tested in Phase II clinical trials in metastatic 
gastric cancer, papillary renal cell carcinoma and head and neck squamous cell cancer 
(http://clinicaltrials.gov). 
MP470 is a multi-kinase inhibitor, orally available, that was reported to radiosensitize 
glioblastoma cell lines, through the suppression of RAD51, a DNA repair related protein 
(Welsh et al., 2009). Additional Phase I clinical studies, currently underway, use MP470 in 
monotherapy or in combination with standard chemotherapies in patients with metastatic 
solid tumors and lymphoma (http://clinicaltrials.gov). 
6. Conclusion and future directions 
The HGF/c-Met signaling pathway plays a significant role in cancer and has emerged 
recently as a promising target in the treatment of several malignancies. It was shown that 
HGF and Met are key players in cerebellum development and that their dysregulation is 
involved in medulloblastoma formation and progression.  
Advances in understanding the molecular mechanisms and genetic profiles underlying the 
different subtypes of medulloblastoma created an urgent need for new and less toxic 
targeted therapies. HGF/c-Met inhibitors used in the treatment of gliomas in vitro and in 
 
The Role of HGF/c-Met Pathway Signaling in Human Medulloblastoma 655 
vivo showed efficient reduction in tumor growth and are, therefore, being evaluated in 
clinical trials. Our preliminary data using a Met selective inhibitor in medulloblastoma cell 
lines showed that the HGF/c-Met pathway is a novel and promising therapeutic target in 
this disease. 
In the future we will test a panel of available HGF and Met inhibitors using orthotopic 
xenograft models and our transgenic medulloblastoma mouse model. We hope that the 
results of our pre-clinical studies will provide the basis for future clinical trials where the 
HGF and Met inhibitors could synergize with current therapies to increase survival and 
improve the quality of life of children with brain tumors. 
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1. Introduction   
In a normal cell, there exists a balance between the free radical generation and the 
antioxidant defense (Devi et al., 2000). It has long been documented that cancer cells are 
under increased and persistent oxidative stress due to increased reactive oxygen species. 
Oxidative stress describes the state of a cell whose antioxidant mechanisms can not manage 
its content of free radicals (Figure 1). As a consequence, cellular constituents are disrupted, 
and free radical reactions become less controllable since endogenous antioxidants are 
themselves injured by oxidative insults. Oxidative stress induces a cellular redox imbalance 
which has been found to be present in various cancer cells compared with normal cells; the 
redox imbalance thus may be related to oncogenic stimulation (Valko et al., 2006). Increased 
intrinsic reactive oxygen species (ROS) stress in cancer cells has been speculated to be due to 
a number of factors such as oncogenic stimulation, increased metabolic activity, and 
mitochondrial malfunction (Pelicano et al., 2004).The cellular redox state has important 
effects on the control of cell survival, apoptosis, and expression of tumor suppressor genes. 
A high cell redox state would encourage tumor formation by creating an enhanced cell 
proliferative environment. In opposition to this, a high cell redox state would also support 
increased apoptosis, which would inhibit tumor formation by eliminating partially 
transformed cells. In addition to ROS, various redox metals, due to their ability to generate 
free radicals, or non-redox metals, due to their ability to bind to critical thiols, have been 
implicated in the mechanisms of carcinogenesis. (Leonard et al., 2004; Valko et al., 2005). 
Cancer cells can generate large amounts of hydrogen peroxide and this, if it occurs in vivo, 
may contribute to their ability to mutate and damage normal tissues, and, moreover, 
facilitate tumour growth and invasion (Burdon, 1995). Indeed, it has been suggested that 
persistent oxidative stress in tumour cells could partly explain some important 
characteristics of cancer. A wide variety of normal and malignant cell types generate and 
release superoxide or hydrogen peroxide in vitro either in response to specific cytokine and 
growth factor stimulus or constitutively in the case of tumour cells (Szatrowski at al., 1991). 
Tumors of the nervous system are among the most common and pharmacologically 
intractable neoplastic disorders. Malignant peripheral nervous system tumors include 
neuroblastoma, the most common extracranial solid tumor. Because of the frequency with 
which neuroblastoma is metastatic or otherwise surgically incurable at the time of diagnosis, 
treatment of this tumor often involves chemotherapy. Malignant gliomas comprise the 
majority of primary brain tumors. (Louis et al., 2002). Of these, glioblastoma multiforme 
(GBM) is the most common and has the poorest prognosis. It is therefore apparent that a 
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more complete understanding of malignant gliomas and the pathophysiologic mechanisms 
responsible for tumor growth, invasion, and resistance to therapy is needed. Meningiomas 






Fig. 1. Oxidative stress balance 
2. Oxidative stress and neuronal redox countenance in the brain 
Redox balance in neural tissue has an important role in the pathophysiology of 
neurotoxicity from free radical generation, but also in the pathophysiology of neurotoxicity 
from free radical generation. The concept of redox status includes both physiological and 
pathological effects of redox phenomena. ROS are particularly active in the brain and 
neuronal tissue and aggressive to glial cells and neurons. In-built endogenous antioxidant 
system plays its decisive role in prevention of any loss due to free radicals. However, 
imbalanced defense mechanism of antioxidants, overproduction or incorporation of free 
radicals from environment to living system leads to serious penalty and therefore to 
neuronal death (Halliwell, 2001). The brain has high content of peroxidizable unsaturated 
fatty acids, high oxygen consumption per unit weight, high content of iron which is a key in 
lipid peroxidation and a shortage of antioxidant defense systems (Floyd, 1999) so is more 
susceptible to oxidative stress compared to other tissues and is unique as a target organ for 
metastatic growth being surrounded by the blood-brain barrier.  The generation of ROS, or 
free radicals, can exceed the scavenging ability of endogenous antioxidants, resulting in a 
shift of the redox state of the brain to the oxidative state.  
The concentrations of free heavy metals are also tightly controlled in the nervous system by 
transport proteins such as ferritin (Sies, 1993), thus limiting the non-enzymatic catalysis of 
hydroxyl radical formation. The nervous system contains some antioxidant enzymes; 
including Cu/Zn- and Mn dependent superoxide dismutase (SOD), and glutathione 
peroxidase (GPx) which are expressed in higher quantities than catalase (Shivakumar et al., 
1991; Hussain et al., 1995). This spectrum of enzymatic defences suggests that the brain may 
efficiently metabolize superoxide but may have difficulties in eliminating the hydrogen 
peroxide produced by the reaction. The accumulation of hydrogen peroxide is of major 
concern since the brain contains large quantities of iron and copper (Moos, 1995), which may 
catalyse the formation of the hydroxyl radical and induce lipid peroxidation (Oubidar et al., 
1996)(Fig.1). Exogenous antioxidants are nowadays considered a promising therapeutic 
approach since they could play an important role in preventing and/or minimizing 
neuronal oxidative damage (Halliwell, 2001; Uttara et al., 2009). 
 




Fig. 2. Reactions of oxygen and nitrogen species 
3. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are products of normal 
cellular metabolism. The interest in the role of oxygen-free radicals, more generally known 
as ROS and of RNS in experimental and clinical medicine is consequential (Halliwell, 1999). 
ROS/RNS are known to play a dual role since they can be either harmful or beneficial 
(Valko et al., 2004). Utile effects of ROS are having physiological roles in cellular responses 
to noxa and in the function of a number of cellular signalling systems. The harmful effects of 
ROS are balanced by the antioxidant action of nonenzymatic antioxidants in addition to 
antioxidant enzymes (Halliwell, 1996). ROS/RNS are known to act as secondary messengers 
controlling various normal physiological functions of the organism. In addition, ROS and 
RNS participate in various redox-regulatory mechanisms of cells in order to protect cells 
against oxidative stress and maintenance of cellular redox homeostasis. The cumulative 
production of ROS through either endogenous or exogenous insults is common for many 
types of cancer cell that are linked with altered redox regulation of cellular signaling 
pathways.  ROS are not only toxicants to the cell, but also second messengers in intracellular 
signal transduction, and control the action of several signaling pathways. RNS include a 
series of metabolites which are nitric oxide, nitrite, peroxynitrite with functional implication 
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mainly in vascular stability. Overproduction of reactive nitrogen species is called nitrosative 
stress (Klatt & Lamas, 2000).  This may occur when the generation of reactive nitrogen 
species in a system exceeds the system’s ability to neutralise and eliminate them. Nitrosative 
stress may lead to nitrosylation reactions that can alter the structure of proteins and so 
inhibit their normal function and there has been much interest in the roles nitric oxide may 
play in the pathogenesis of GBM. When ROS/RNS levels exceed a certain threshold, 
deleterious effects are apparent and became dangerous for cell integrity  (Panayiotidis et al., 
1999; Barbouti et al., 2002). Oxidative stress can be defined as a deterioration of redox 
signaling and control (Jones, 2006). Overproduction of reactive oxygen species (ROS) and 
reactive nitrogen species (RNS), a decreased antioxidant defense system, or both typically 
results in significant protein oxidation (Hensley et al., 1995; Stadtman & Berlett, 1997), lipid 
peroxidation (Markesbery & Lovell, 1998; Butterfield & Lauderback, 2002), and DNA/RNA 
oxidation (Butterfield et al., 2001). Increased formation of ROS and RNS in the cells can 
contribute to the process of carcinogenesis through either direct genotoxic effects or indirect 
via modification of signaling pathways that lead to altered expression of numerous genes. 
Modulations of cell signaling pathways can activate transcriptional factors, like AP-1, NF-jB, 
HIF-1, and p53 among others (Arrigo, 1999; Bensaad, 2005). These transcriptional factors 
control the expression of genes the protein products of which participate in complex signal 
transduction pathways that can lead to cell transformation.The effect of reactive oxygen and 
nitrogen species is balanced by the antioxidant action of nonenzymatic antioxidants, as well 
as by antioxidant enzymes. Such antioxidant defences are extremely important as they 
represent the direct removal of free radicals, thus providing maximal protection for 
biological sites. As key mediators of cellular oxidative stress and redox state, ROS and RNS 
also provide plausible platforms for drug design. In fact, the efficacy of a number of 
established anticancer drugs.   
4. Redox status and apoptosis 
The intracellular redox state which is directly related to the production of intracellular 
reactive oxygen species in cancer cells has also been indicated to control the aggressiveness 
of cancer cells. Cancer development represents a multistage process in which at least three 
distinct stages which are; initiation, promotion and progression are involved (Klaunig, 2004) 
and is characterized with increased cell growth and/or decreased capacity for apoptosis. 
Apoptosis is potentially a protective mechanism against both exogenous carcinogens and 
inflammatory states and is regulated in part by the cellular redox state. Since apoptosis is 
caused by elevated levels of free radicals, decreased concentrations of free radicals due to 
the excessive administration of antioxidants might actually stimulate survival of damaged 
cells and proliferation into neoplastic state and thus rather promote process of 
carcinogenesis than interrupt it. Mitochondrial driven apoptosis is most interesting when 
ROS mediated mechanisms are being considered. Typical features in apoptosis include 
permeabilization of the mitochondrial membrane in a process associated with ROS 
generation. Some of the physiological effects of free radicals may be mediated through their 
influuence on redox sensitive transcription factors (Suzuki et al., 1997) and consequently 
modulation of gene expression (Cimino et al., 1997). Although care should be taken before 
concluding that free radicals are intracellular second messengers, there is growing 
agreement that they act as modulators of cell signaling and messenger systems. Therefore, it 
seems that the cellular redox status, defined as the balance between intracellular oxidants 
and antioxidants, is regulated so as to lie within an optimal range for cell survival. The 
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importance of cellular antioxidant capacity as the result of a complex cell program involves 
enhanced motility and a profound change in energy metabolism so avoiding oxidative 
damage and escaping excess ROS in the primary tumor site in cancer cells explain why 
redox signaling pathways are important. 
5. Antioxidant defence 
Cells have numerous protective mechanisms that maintain the concentrations of ROS   
within a range compatible with survival. The most efficient enzymatic antioxidants involve 
superoxide dismutase, catalase and glutathione peroxidase (Mates et al., 1999). Non 
enzymatic antioxidants involve vitamin C, vitamin E, carotenoids, thiol antioxidants 
(glutathione, thioredoxin and lipoic acid), natural flavonoids, melatonin and other 
compounds (McCall & Frei, 1999). Some antioxidants act in a hydrophilic environment, 
others in a hydrophobic environment, and some act in both environments of the cell.  
Glutathione (GSH), a thiol-containing tripeptide, is a major antioxidant and a cofactor of 
glutathione peroxidases (Meister, 1995); it is present in large quantities in the developing 
nervous system It has been hypothesized that some trophic factors may upregulate neuronal 
antioxidant capacities (Mattson and Furukawa, 1996). If neuronal death involves an 
imbalance of the redox status towards oxidation, antioxidants should be protective.  
GSH is a major intracellular antioxidant present ubiquitously in the brain in millimolar 
amounts.  GSH detoxifies intracellular H2O2 to H2O and O2 via oxidation to glutathione 
disulfide (GSSG) by the enzyme GPx. GSSG is recycled to GSH via glutathione reductase 
(GR). The GSH/GSSG ratio is critical to maintaining the intracellular redox balance (Smith 
et al., 1996). A decrease in total GSH levels, or an imbalance in the ratio of reduced to 
oxidized GSH may cause oxidative stress (Stadtman & Berlett, 1997) and lipid peroxidation 
(Markesbery & Lovell, 1998). So, the brain is heavily dependent on GSH as a primary 
endogenous neuroprotectant. It has been reported that elevation of intracellular GSH in 
tumour cells is associated with mitogenic stimulation (Shaw & Chou, 1986), that GSH 
controls the onset of tumour-cell proliferation by regulating protein kinase C activity and 
intracellular pH (Terradez et al., 1993). GSH and its dependent enzymes work in concert 
with other antioxidants and antioxidant enzymes to protect cells against reactive oxygen 
intermediates (Sies, 1986). So, it can be said that reduced GSH plays a role in the rescue of 
cells from apoptosis. GPx and GR decrease and protein oxidation increases in patients with 
glioblastoma multiforme and transitional meningioma and clear different oxidative status 
was found in the two kinds of tumors which represent specially one of the most malignant 
and most benign tumors respectively (Tanriverdi et al., 2007) and it was shown that there is 
a complex relationship between pro- and anti-apoptotic molecules in glioblastoma 
multiforme pathogenesis, thus targeting multiple pathways with advanced 
chemotherapeutic agents or radiotheraupetic regimens following total resections might be 
helpful in patients with glioblastoma multiforme (Atukeren et al., 2010). So the development 
of chemopreventive strategies would be desirably based on an association between a 
particular beneficial effect and a redox condition, as for example, with antioxidant 
protection against oxidative stress.  
6. Mitochondrial redox status 
One of the important sources for ROS generation is the mitochondria where some of the 
oxygen  is reduced by single steps of one electron reduction, thus releasing superoxide 
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6. Mitochondrial redox status 
One of the important sources for ROS generation is the mitochondria where some of the 
oxygen  is reduced by single steps of one electron reduction, thus releasing superoxide 
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radical and other ROS (Giorgio et al., 2007). However, it is difficult to detect the occurrence 
of the superoxide radical in intact mitochondria, most probably in consequence of the 
presence of high SOD activity therein. Mitochondria have long been known to generate 
significant quantities of hydrogen peroxide as mitochondrial generation of superoxide to 
that of hydrogen peroxide is known. Since mitochondria are the major site of free radical 
generation, they are highly enriched with antioxidants including GSH and enzymes, such as 
SOD and GPx, which are present on both sides of their membranes in order to minimise 
oxidative stress in the organelle (Cadenas & Davies, 2000).  Superoxide radicals are 
efficiently detoxified initially to hydrogen peroxide and then to water by Cu/ZnSOD and 
MnSOD. The redox components of the cell consists of interlinked mitochondrial redox 
indicators: glutathione (GSH/GSSG), thioredoxin (Trx/TrxR), glutaredoxin (Grx), 
peroxiredoxins (Prx), systems dependent solely on steady flux of NADPH generated 
through reduction of  NADP+ by NADH by the energetic component of mitochondria 
(Figure 3). Trx/TrxR system reverses protein disulfide linkages that occur in thiols of 
oxidized cysteine residues (Holmgren, 1985). Upregulation in the activity of the Trx/TrxR 
system seen in many tumors is thought to be a result of increased ROS production 
associated with oncogenic transformation and correlates with resistance to apoptosis and 
tumor cell proliferation (Baker et al., 1997; Lincoln et al., 2003). Disruption of the cellular 
redox state via inhibition of TrxR, either in the cytosol or the mitochondria has been shown 
to increase the ratio of oxidized/reduced Trx, increase ROS, modulate cell signaling, 
sensitize cancer cell lines to chemotherapeutic agents, and induce cell cycle arrest, 
senescence and apoptosis of cancer cells (Urig &vBecker, 2006; Mukherjee & Martin, 2008) 
so decrease in mitochondrial bioenergetic capacity and altered redox status should be  
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viewed as a concerted process. Prx are a family of proteins that function in antioxidant 
defense and in redox signaling cascades by reaction with peroxides. During their catalytic 
cycle, oxidized species of Prx are reduced and reactivated by thioredoxin or glutathione 
(Immenschuh & Baumgart-Vogt, 2005; Winterbourn & Hampton, 2008) and GSH is 
important for a wide range of cellular redox active proteins and pathways, including 
glutaredoxin (Grx), glutathione S-transferase (GST), glutathione peroxidase (GPx) and more 
(Meister & Anderson, 1983; Go et al., 2009). 
7. Prospects of antioxidant therapy  
Several antioxidant defense mechanisms have evolved to protect cell components from the 
harmful effects of ROS and RNS. As is known two major groups of endogenous antioxidants 
are low molecular weight antioxidant compounds such as vitamin C and vitamin E, lipoic 
acid and ubiquinones and antioxidant enzymes (Gilgun-Sherki et al., 2001). Antioxidant 
enzymes activity and concentration of nonenzymatic antioxidants in human brain tumours 
were evaluated and significant increases in all enzyme activities and decreases in GSH and 
ascorbate levels were observed in brain tumors (Dudek et al., 2004) and consistent 
differences in the levels of antioxidants in different types of brain tumors were emphasized 
in different studies (Hanimoglu et al., 2007; Tanriverdi et al., 2007; Tuzgen et al., 2007; 
Zengin et al., 2009). The relationship between oxidative gene polymorphism and the risk of 
brain tumors is investigated and it was seen that; the increased risk of glioma and 
meningioma type brain tumors is related with variants in some antioxidant enzyme genes 
(Rajaraman et al., 2008) and in a study, tissue expression of MnSOD is suggested to be a 
prognostic marker for glioblastoma (Park et al., 2009). The importance of daily intake of 
antioxidants among people with malignant glioma was shown in various studies (Il'yasova 
et al., 2009; DeLorenze et al., 2010). Recently, exogenous antioxidants are considered a 
promising therapeutic approach in preventing or minimizing neuronal oxidative damage 
(Halliwell, 2001; Uttara et al., 2009). Recent interest has been focused on dietary phenolic 
antioxidants, such as carotenoids, cinnamic acids and flavonoids, as potentially useful 
agents (Fresco et al., 2006; Uttara et al., 2009). In a study, the effects of flavonoids which are 
natural polyphenolic antioxidant compounds in brain development, neuroprotection and 
glial tumor formation are discussed and suggested to develop new therapeutic approaches 
(Nones et al.; 2010). Curcumin as a polyphenol gets attention in blocking brain tumor 
formation in a study. The chemopreventive and anticarcinogenic action of curcumin is 
shown and suggested as this might be due to its ability to inhibit proteins that initiate 
protective signals (Sudarshana et al., 2009). Also, Gynostemma pentaphyllum extract 
selectively shifted H2O2 concentration in glioma tumor cells to toxic levels due to increased 
SOD activity so can be suggested for cancer therapy (Schild et al., 2010) and the apoptotic 
effect of γ-Mangostin in Garcinia mangostana fruit was investigated and it was suggested as 
a potential in developing an anti brain tumor agent (Chang et al., 2010). In another study, 
the potential therapeutic effect of resveratrol being a dietary phytochemical antioxidant, is 
investigated in glioma type brain tumors (Gangliano et al., 2010). Also another study implies 
the importance of using nutritional antioxidants such as lycopene for their potential 
therapeutic benefit in the adjuvant management of high-grade gliomas (Puri et al., 2010). So 
antioxidants are incontestably implicated in brain cancer treatment and they may protect 
against side effects from conventional therapies, as well as enhance chemotherapy and 
support anticancer activities. Obviously, antioxidants must be chosen based on their ability 
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acid and ubiquinones and antioxidant enzymes (Gilgun-Sherki et al., 2001). Antioxidant 
enzymes activity and concentration of nonenzymatic antioxidants in human brain tumours 
were evaluated and significant increases in all enzyme activities and decreases in GSH and 
ascorbate levels were observed in brain tumors (Dudek et al., 2004) and consistent 
differences in the levels of antioxidants in different types of brain tumors were emphasized 
in different studies (Hanimoglu et al., 2007; Tanriverdi et al., 2007; Tuzgen et al., 2007; 
Zengin et al., 2009). The relationship between oxidative gene polymorphism and the risk of 
brain tumors is investigated and it was seen that; the increased risk of glioma and 
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(Rajaraman et al., 2008) and in a study, tissue expression of MnSOD is suggested to be a 
prognostic marker for glioblastoma (Park et al., 2009). The importance of daily intake of 
antioxidants among people with malignant glioma was shown in various studies (Il'yasova 
et al., 2009; DeLorenze et al., 2010). Recently, exogenous antioxidants are considered a 
promising therapeutic approach in preventing or minimizing neuronal oxidative damage 
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agents (Fresco et al., 2006; Uttara et al., 2009). In a study, the effects of flavonoids which are 
natural polyphenolic antioxidant compounds in brain development, neuroprotection and 
glial tumor formation are discussed and suggested to develop new therapeutic approaches 
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formation in a study. The chemopreventive and anticarcinogenic action of curcumin is 
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effect of γ-Mangostin in Garcinia mangostana fruit was investigated and it was suggested as 
a potential in developing an anti brain tumor agent (Chang et al., 2010). In another study, 
the potential therapeutic effect of resveratrol being a dietary phytochemical antioxidant, is 
investigated in glioma type brain tumors (Gangliano et al., 2010). Also another study implies 
the importance of using nutritional antioxidants such as lycopene for their potential 
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against side effects from conventional therapies, as well as enhance chemotherapy and 
support anticancer activities. Obviously, antioxidants must be chosen based on their ability 
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to treat a particular redox event or they must act contextually and evolve with the redox 
conditions to restore balance. 
8. Conclusion  
Various studies showed that not only oxidants but the redox status as a whole modulates 
mechanisms regulating neuronal fate. The deleterious effects of high concentrations of 
antioxidants and the protective actions of sublethal oxidative challenges suggest that 
neuronal survival depends on the maintenance of an adequate redox status between the two 
extremes of oxidative and reductive stress, respectively. In addition to its widespread 
consequences for our understanding of fundamental aspects of neuronal death, the concept 
of neuronal redox status as opposed to oxidative stress may have clinical implications. 
Neuronal survival thus seems to be associated with an optimal redox status; an imbalance 
towards oxidation leads to oxidative stress, whereas high doses of antioxidants may induce 
a reductive stress. Maintenance of intracellular redox state is critical to cellular homeostasis 
therefore tumor selectivity in targeting at the cellular and enzymatic levels are of great 
interest to the rational design of treating compounds. Targeting the mitochondrial apoptotic 
regulatory machinery is also a promising anticancer approach and in many studies thiol 
redox platforms were used to discover and develop drugs. Strategies for redox balance 
analysis rely on different  assumption and this approach gives a dynamic idea of  what is the 
general oxidative status in a given condition and evaluation of redox potential of molecules 
gives idea of what really happened in a period that is a function of half life of a given 
molecule so this maybe utilized in parallel to gain a more representative picture of a clinical 
conditioning evolution. Hence, chemotherapeutic outcomes are not compromised, 
administration of antioxidants capable of maintaining the antioxidant defense system in 
brain may protect cancer patients from the apparent cognitive rigors of chemotherapy and 
these redox manipulating compounds could be used in conjunction with existing treatments 
to beneficial effect. So, it can be said that, as a preliminary approach, to determine optimal 
doses of antioxidants in order to design treatment protocols respecting the redox 
homeostasis would be useful. 
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